{"dd6ea267b78d8d150be8ad645b74dd13a8c08ac2": [["BackgroundPandemic COVID-19, caused by a beta-coronavirus named SARS-CoV-2 first identified in Wuhan, China [1] , has spread rapidly, particularly in temperate regions in the northern hemisphere [2] .", [["beta-coronavirus", "ORGANISM", 41, 57], ["SARS-CoV-2", "ORGANISM", 64, 74], ["BackgroundPandemic COVID-19", "SPECIES", 0, 27], ["BackgroundPandemic COVID", "TEST", 0, 24], ["a beta-coronavirus", "PROBLEM", 39, 57], ["northern hemisphere", "ANATOMY", 175, 194]]], ["The number of cases reported in countries in tropical regions, most of which are low-and middle-income countries (LMICs) with weaker detection and response capacity [3] , is lower [2] .", [["response capacity", "TEST", 147, 164], ["tropical", "ANATOMY_MODIFIER", 45, 53], ["regions", "ANATOMY_MODIFIER", 54, 61], ["low", "OBSERVATION_MODIFIER", 81, 84], ["middle", "ANATOMY_MODIFIER", 89, 95]]], ["There has been much speculation about whether warming temperatures with the onset of spring and summer will contribute to decreased transmission in the northern hemisphere, as is observed for many viral respiratory infections [4] .", [["respiratory", "ANATOMY", 203, 214], ["decreased transmission in the northern hemisphere", "DISEASE", 122, 171], ["viral respiratory infections", "DISEASE", 197, 225], ["warming temperatures", "PROBLEM", 46, 66], ["decreased transmission in the northern hemisphere", "PROBLEM", 122, 171], ["many viral respiratory infections", "PROBLEM", 192, 225], ["northern hemisphere", "ANATOMY", 152, 171], ["viral", "OBSERVATION_MODIFIER", 197, 202], ["respiratory infections", "OBSERVATION", 203, 225]]], ["This would also have implications for the risk of spread in temperate regions in the southern hemisphere at the onset of winter, and for tropical regions where the vast majority of LMICs are located.", [["tropical regions", "PROBLEM", 137, 153], ["spread", "OBSERVATION", 50, 56], ["southern hemisphere", "ANATOMY", 85, 104]]], ["Higher temperatures were shown to have a protective effect against transmission of severe acute respiratory syndrome (SARS) in 2002-2003 [5] , possibly due to the decreased survival of the SARS-CoV on surfaces at higher temperatures [6] .", [["acute respiratory syndrome", "DISEASE", 90, 116], ["SARS", "DISEASE", 118, 122], ["SARS", "DISEASE", 189, 193], ["CoV", "ORGANISM", 194, 197], ["SARS-CoV", "SPECIES", 189, 197], ["Higher temperatures", "PROBLEM", 0, 19], ["severe acute respiratory syndrome", "PROBLEM", 83, 116], ["the SARS", "PROBLEM", 185, 193], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["acute", "OBSERVATION_MODIFIER", 90, 95], ["respiratory syndrome", "OBSERVATION", 96, 116]]], ["Decreased aerosol spread at higher temperatures is another possible mechanism, as observed for human influenza viruses [7] .", [["influenza viruses", "DISEASE", 101, 118], ["human influenza viruses", "ORGANISM", 95, 118], ["human", "SPECIES", 95, 100], ["human influenza viruses", "SPECIES", 95, 118], ["Decreased aerosol spread", "PROBLEM", 0, 24], ["human influenza viruses", "PROBLEM", 95, 118], ["aerosol spread", "OBSERVATION", 10, 24]]], ["This study aimed to provide preliminary data on whether there may be seasonal variation in COVID-19 incidence, in sub-national regions that have reported at least one confirmed COVID-19 case.MethodsAn open-source line list of confirmed COVID-19 cases was downloaded on March 2 nd 2020 [8] .", [["COVID", "DNA", 236, 241], ["This study", "TEST", 0, 10], ["preliminary data", "TEST", 28, 44], ["seasonal variation", "PROBLEM", 69, 87], ["COVID", "TEST", 91, 96], ["COVID", "TEST", 177, 182], ["COVID", "TEST", 236, 241], ["may be", "UNCERTAINTY", 62, 68], ["seasonal variation", "OBSERVATION", 69, 87]]], ["The reported coordinates of the case (variably a point location, city centroid, or different subnational administrative levels) were used to determine the ADM1 in which the case occurred.", [["ADM1", "DNA", 155, 159]]], ["For each ADM1, an observation period was defined as period from the date of onset of symptoms of the first reported case for that ADM1 to February 29 th 2020.", [["ADM1", "DNA", 9, 13], ["symptoms", "PROBLEM", 85, 93]]], ["When information regarding onset of symptoms of the first reported case was missing, the confirmation date of the first reported case was used instead.MethodsDaily gridded temperature data at 0.5-degree spatial resolution were obtained from the Climate Prediction Centre (NOAA/OAR/ESRL PSD, Boulder, Colorado, USA, https://www.esrl.noaa.gov/psd/, accessed March 4 th 2020).", [["symptoms", "PROBLEM", 36, 44], ["gridded temperature data", "TEST", 164, 188], ["NOAA/OAR/ESRL PSD", "TREATMENT", 272, 289], ["Boulder", "ANATOMY", 291, 298]]], ["The average temperature at the ADM1 centroid was calculated by taking the average of the maximum and minimum temperatures over the observation period at the centroid coordinates, using packages {ncdf4} [9] and {rgdal} [10] .", [["{ncdf4", "CHEMICAL", 194, 200], ["{rgdal}", "CHEMICAL", 210, 217], ["{ncdf4} [9]", "SIMPLE_CHEMICAL", 194, 205]]], ["All the analyses were implemented in the R environment [11] .MethodsAll ADM1 associated with at least one confirmed case of COVID-19 in the source dataset were included in the analysis, excluding Hubei province in China where the outbreak emerged.", [["ADM1", "DNA", 72, 76], ["COVID-19", "DNA", 124, 132], ["COVID", "TEST", 124, 129], ["the analysis", "TEST", 172, 184]]], ["We modelled the cumulative number of COVID-19 cases classified as local cases in each ADM1 during the observation period.", [["COVID", "TEST", 37, 42]]], ["The statistical model was based on the generalized linear regression framework [12] .", [["the generalized linear regression framework", "PROBLEM", 35, 78]]], ["We used a negative binomial distribution to account for the overdispersion of the number of local cases during the observation period.", [["a negative binomial distribution", "PROBLEM", 8, 40]]], ["Temperature was included in the model both as a linear and a quadratic term to account for the non-linearity of the association observed during initial data exploration.MethodsFour variables were included in the model as potential confounders: the cumulative number of imported cases, time since the first reported case (to account for right-censoring), the median age of the national population (United Nations database, https://ourworldindata.org/age-structure, to account for the higher incidence of severe cases in older people, which may be more readily detected), and the capacity of the country to detect an emerging infectious disease.", [["infectious disease", "DISEASE", 624, 642], ["people", "ORGANISM", 525, 531], ["people", "SPECIES", 525, 531], ["Temperature", "TEST", 0, 11], ["initial data exploration", "TEST", 144, 168], ["an emerging infectious disease", "PROBLEM", 612, 642], ["severe", "OBSERVATION_MODIFIER", 503, 509], ["infectious", "OBSERVATION", 624, 634]]], ["The Global Health Security Index (GHSI) (https://www.ghsindex.org/) publishes a country-level score (out of 100) for capacity for \"early detection and reporting for epidemics of potential concern\".", [["Global", "OBSERVATION_MODIFIER", 4, 10]]], ["This indicator is a weighted average of indicators related to laboratory systems, real-time surveillance and reporting, epidemiology workforce, and data integration between human, animal and environmental health sectors, each of which reflects a core capacity defined under the International Health Regulations (2005). is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintMethodsThe copyright holder for this this version posted March 20, 2020. .MethodsLikelihood ratio tests were used to identify variables that did not significantly improve model fit and obtain a final model specification.", [["human", "ORGANISM", 173, 178], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["laboratory systems", "TEST", 62, 80], ["a core capacity", "PROBLEM", 244, 259], ["Methods", "TREATMENT", 451, 458], ["The copyright holder", "TREATMENT", 458, 478], ["MethodsLikelihood ratio tests", "TEST", 525, 554], ["med", "ANATOMY", 357, 360]]], ["Model fit indicators (leverage, influence, residuals and fitted values) were assessed graphically.", [["residuals", "TEST", 43, 52]]], ["Pseudo R-squared values were calculated using the Nagelkerke's method [13] .Results and discussionAs of February 29 th 2020, 188 ADM1 units worldwide reported at least one imported case and were included as observations in the model.", [["Pseudo R-squared values", "TEST", 0, 23], ["the Nagelkerke's method", "TREATMENT", 46, 69]]], ["The number of presumed locally-transmitted cases ranged from 0 to 1,220 in provinces in China (excluding Hubei), and 0 to 552 in ADM1 outside China (Table 1) .", [["locally-transmitted cases", "PROBLEM", 23, 48], ["presumed", "UNCERTAINTY", 14, 22], ["locally", "OBSERVATION_MODIFIER", 23, 30]]], ["Average temperatures at ADM1 centroids in China (excluding Hubei) ranged from -16.8\u00b0C to 20.4\u00b0C, and from -18.7\u00b0C to 31.9\u00b0C outside China (Table 1) .Results and discussion.", [["Hubei", "TEST", 59, 64], ["C", "TEST", 94, 95]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Results and discussionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint Average temperature (as a linear and quadratic term combination) was strongly associated with count of local COVID-19 cases (likelihood ratio test = 19.4, df = 2, p=0.00006).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["a linear and quadratic term combination", "TREATMENT", 257, 296], ["local COVID", "TEST", 336, 347], ["likelihood ratio test", "TEST", 358, 379], ["df", "TEST", 388, 390], ["p", "TEST", 396, 397], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 138, 141]]], ["The model results indicate that there was a negative correlation in the predicted number of cases with temperature from 1\u00b0C and above ( Figure 2 ).", [["temperature", "TEST", 103, 114]]], ["For example, at mean values for the other variables, an increase in average temperature from 1\u00b0C to 9\u00b0C was associated with a decrease in predicted cases at ADM1 level from 24 cases to 19 cases, respectively.", [["ADM1", "GENE_OR_GENE_PRODUCT", 157, 161], ["ADM1", "PROTEIN", 157, 161], ["average temperature", "TEST", 68, 87], ["a decrease in predicted cases", "PROBLEM", 124, 153], ["increase", "OBSERVATION_MODIFIER", 56, 64], ["average", "OBSERVATION_MODIFIER", 68, 75], ["temperature", "OBSERVATION_MODIFIER", 76, 87], ["decrease", "OBSERVATION_MODIFIER", 126, 134]]], ["Similarly, an increase in average temperature from 10\u00b0C to 19\u00b0C was associated with a decrease from 18 to 7 predicted cases at ADM1 level, respectively.", [["ADM1", "GENE_OR_GENE_PRODUCT", 127, 131], ["ADM1", "PROTEIN", 127, 131], ["average temperature", "TEST", 26, 45], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["average", "OBSERVATION_MODIFIER", 26, 33], ["temperature", "OBSERVATION_MODIFIER", 34, 45], ["decrease", "OBSERVATION_MODIFIER", 86, 94]]], ["The pseudo R-squared values for the final model with and without temperature were 0.44 and 0.39, respectively, indicating that the inclusion of the temperature effect only provided a relatively modest improvement in model fit.Results and discussion.", [["temperature", "TEST", 65, 76], ["the temperature effect", "PROBLEM", 144, 166], ["modest", "OBSERVATION_MODIFIER", 194, 200], ["improvement", "OBSERVATION", 201, 212], ["model fit", "OBSERVATION", 216, 225]]], ["CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.Results and discussionis the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintResults and discussionThe copyright holder for this this version posted March 20, 2020. .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["ND", "PROBLEM", 9, 11], ["The copyright holder", "TREATMENT", 254, 274], ["NC", "ANATOMY", 6, 8], ["med", "ANATOMY", 138, 141]]], ["There are several important limitations to this study.", [["this study", "TEST", 43, 53]]], ["There was no data available on many characteristics that affect rate of spread within a region, especially the interventions initiated in response to the detection of imported or locally transmitted cases.", [["the interventions", "TREATMENT", 107, 124]]], ["Furthermore, the model could not be fitted with a random intercept for country to account for clustering of ADM1 units within countries, as the uneven distribution of the number of affected provinces by country led to model instability.", [["ADM1 units", "TREATMENT", 108, 118], ["model instability", "PROBLEM", 218, 235], ["uneven", "OBSERVATION_MODIFIER", 144, 150], ["distribution", "OBSERVATION_MODIFIER", 151, 163], ["instability", "OBSERVATION", 224, 235]]], ["However, the early detection score likely captures part of the country-level variance.", [["the early detection score", "TEST", 9, 34]]], ["These results need to be confirmed by repeating the analysis as the pandemic progresses, and including data on implemented interventions to contain or mitigate COVID-19 as it becomes available.Results and discussionMany LMICs had not detected a COVID-19 case as of 29 th February 2020 and therefore were not included in this analysis.", [["the analysis", "TEST", 48, 60], ["implemented interventions", "TREATMENT", 111, 136], ["COVID", "TEST", 160, 165], ["a COVID", "TEST", 243, 250], ["this analysis", "TEST", 320, 333]]], ["Caution is warranted in extrapolating the association between local COVID-19 case counts and temperature to LMICs in tropical regions.", [["local COVID", "TEST", 62, 73], ["tropical", "ANATOMY_MODIFIER", 117, 125]]], ["COVID-19 outbreaks in LMICs, even if at somewhat lower incidence due to higher temperatures, are still likely to have a substantial impact on health services that are already significantly resource constrained.Results and discussionThis study provides preliminary evidence that there may be seasonal variability in transmission of SARS-CoV-2, but this analysis does not imply that temperature alone is a primary driver of COVID-19 transmission.", [["SARS", "DISEASE", 331, 335], ["SARS-CoV-2", "ORGANISM", 331, 341], ["COVID-19", "GENE_OR_GENE_PRODUCT", 422, 430], ["SARS-CoV", "SPECIES", 331, 339], ["COVID", "TEST", 0, 5], ["higher temperatures", "PROBLEM", 72, 91], ["This study", "TEST", 232, 242], ["seasonal variability", "PROBLEM", 291, 311], ["SARS", "PROBLEM", 331, 335], ["CoV", "TEST", 336, 339], ["this analysis", "TEST", 347, 360], ["may be", "UNCERTAINTY", 284, 290], ["seasonal variability", "OBSERVATION", 291, 311]]], ["The observed association may not be due directly to temperature, but to correlated factors such as relative humidity, or human behaviours during cold weather.", [["human", "ORGANISM", 121, 126], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126]]], ["The findings present an argument for further significant scaling up of containment measures now.", [["significant", "OBSERVATION_MODIFIER", 45, 56], ["scaling", "OBSERVATION_MODIFIER", 57, 64], ["containment", "OBSERVATION_MODIFIER", 71, 82]]], ["The onset of warmer weather in the northern hemisphere may modestly reduce rate of spread, but anticipation of a substantial decline in total number infected due to warmer temperatures alone is not warranted by these findings.", [["decline in total number infected", "DISEASE", 125, 157], ["warmer weather", "PROBLEM", 13, 27], ["a substantial decline", "PROBLEM", 111, 132], ["warmer temperatures", "TREATMENT", 165, 184], ["warmer weather", "OBSERVATION", 13, 27], ["substantial", "OBSERVATION_MODIFIER", 113, 124], ["decline", "OBSERVATION_MODIFIER", 125, 132]]], ["Furthermore, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprintResults and discussionThe copyright holder for this this version posted March 20, 2020. . https://doi.org/10.1101/2020.03.18.20036731 doi: medRxiv preprint", [["The copyright holder", "TREATMENT", 167, 187], ["medRxiv", "TREATMENT", 284, 291], ["med", "ANATOMY", 51, 54]]]], "PMC7415165": [["Always on the lookout for articles from the journal Complementary Therapies in Clinical Practice one in particular has attracted a lot of attention due the eminent clinical importance of this study.", [["this study", "TEST", 187, 197]]], ["Very recent, Xu and Zhang published an excellent review article clearly demonstrating that the intervention of traditional Chinese medicine can reduce severe symptoms of patients with the new coronavirus (SARS-Cov-2) [1].", [["coronavirus", "DISEASE", 192, 203], ["SARS", "DISEASE", 205, 209], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["traditional Chinese medicine", "TREATMENT", 111, 139], ["severe symptoms", "PROBLEM", 151, 166], ["the new coronavirus", "PROBLEM", 184, 203]]], ["Considering that there is no standard therapy for SARS-Cov-2 prevention or treatment, we would like to add some thoughts that may open the debate about the possible viability of propolis in this situation.", [["SARS", "DISEASE", 50, 54], ["propolis", "CHEMICAL", 178, 186], ["propolis", "ORGANISM", 178, 186], ["standard therapy", "TREATMENT", 29, 45], ["SARS", "PROBLEM", 50, 54], ["Cov-2 prevention", "TREATMENT", 55, 71], ["treatment", "TREATMENT", 75, 84], ["propolis", "TREATMENT", 178, 186], ["no", "UNCERTAINTY", 26, 28]]]], "PMC7435512": [["INTRODUCTION TO SARS\u2010CORONAVIRUS 2Over the last 20 years, three coronaviruses (CoVs) that cause severe pulmonary infections in humans have crossed the species barrier.1,2The last of these CoVs, named SARS\u2010CoV\u20102, emerged in the Hubei province (China) in December 2019, and rapidly spread worldwide becoming a major public health threat.3In approximately 20% of patients, the disease progresses to severe pneumonia, respiratory and multi\u2010visceral failure, often leading to death of patients with comorbidity.4This worsening is associated with a deregulated immune response, including exacerbated production of pro\u2010inflammatory cytokines.5Therefore, specific and effective antiviral therapies are urgently needed, due to the absence of a vaccine.INTRODUCTION TO SARS\u2010CORONAVIRUS 2Coronaviruses belong to the Nidovirales order, a group of enveloped viruses with genomic RNA of positive polarity.", [["pulmonary", "ANATOMY", 103, 112], ["respiratory", "ANATOMY", 414, 425], ["pulmonary infections", "DISEASE", 103, 123], ["1,2", "CHEMICAL", 167, 170], ["SARS", "DISEASE", 200, 204], ["pneumonia", "DISEASE", 403, 412], ["respiratory and multi\u2010visceral failure", "DISEASE", 414, 452], ["death", "DISEASE", 471, 476], ["coronaviruses", "ORGANISM", 64, 77], ["CoVs", "CANCER", 79, 83], ["pulmonary", "ORGAN", 103, 112], ["humans", "ORGANISM", 127, 133], ["CoVs", "GENE_OR_GENE_PRODUCT", 188, 192], ["patients", "ORGANISM", 360, 368], ["patients", "ORGANISM", 480, 488], ["pro\u2010inflammatory cytokines", "PROTEIN", 608, 634], ["genomic RNA", "RNA", 858, 869], ["humans", "SPECIES", 127, 133], ["patients", "SPECIES", 360, 368], ["patients", "SPECIES", 480, 488], ["humans", "SPECIES", 127, 133], ["SARS\u2010CoV", "SPECIES", 200, 208], ["three coronaviruses (CoVs", "PROBLEM", 58, 83], ["severe pulmonary infections in humans", "PROBLEM", 96, 133], ["the disease", "PROBLEM", 370, 381], ["severe pneumonia", "PROBLEM", 396, 412], ["respiratory and multi\u2010visceral failure", "PROBLEM", 414, 452], ["comorbidity", "PROBLEM", 494, 505], ["a deregulated immune response", "PROBLEM", 541, 570], ["pro\u2010inflammatory cytokines", "PROBLEM", 608, 634], ["effective antiviral therapies", "TREATMENT", 660, 689], ["a vaccine", "TREATMENT", 733, 742], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["pulmonary", "ANATOMY", 103, 112], ["infections", "OBSERVATION", 113, 123], ["CoVs", "OBSERVATION", 188, 192], ["disease", "OBSERVATION", 374, 381], ["severe", "OBSERVATION_MODIFIER", 396, 402], ["pneumonia", "OBSERVATION", 403, 412], ["respiratory", "ANATOMY", 414, 425], ["multi\u2010visceral failure", "OBSERVATION", 430, 452], ["immune response", "OBSERVATION", 555, 570], ["pro\u2010inflammatory cytokines", "OBSERVATION", 608, 634], ["viruses", "OBSERVATION", 845, 852], ["positive polarity", "OBSERVATION", 873, 890]]], ["Their 27 to 34 kb genome encodes 16 nonstructural proteins (nsps) and 4 structural proteins (spike protein [S], envelope protein [E], membrane protein [M], and nucleoprotein [N]).6The virus life cycle, described in Figure 1, begins by the attachment of the viral particle to the angiotensin\u2010converting enzyme 2 (ACE2) cell surface receptor, mediated by the S protein.7,8Virus entry is achieved by endocytosis and/or direct fusion of the cell and viral membranes.", [["membrane", "ANATOMY", 134, 142], ["cell surface", "ANATOMY", 318, 330], ["cell", "ANATOMY", 437, 441], ["membranes", "ANATOMY", 452, 461], ["nsps", "GENE_OR_GENE_PRODUCT", 60, 64], ["spike protein [S]", "GENE_OR_GENE_PRODUCT", 93, 110], ["envelope protein [E]", "GENE_OR_GENE_PRODUCT", 112, 132], ["membrane", "CELLULAR_COMPONENT", 134, 142], ["M]", "GENE_OR_GENE_PRODUCT", 152, 154], ["angiotensin\u2010converting enzyme 2", "GENE_OR_GENE_PRODUCT", 279, 310], ["ACE2", "GENE_OR_GENE_PRODUCT", 312, 316], ["cell surface receptor", "GENE_OR_GENE_PRODUCT", 318, 339], ["7,8Virus", "ORGANISM", 367, 375], ["cell", "CELL", 437, 441], ["viral membranes", "CELLULAR_COMPONENT", 446, 461], ["27 to 34 kb genome", "DNA", 6, 24], ["nonstructural proteins", "PROTEIN", 36, 58], ["nsps", "PROTEIN", 60, 64], ["structural proteins", "PROTEIN", 72, 91], ["spike protein [S]", "PROTEIN", 93, 110], ["envelope protein", "PROTEIN", 112, 128], ["E", "PROTEIN", 130, 131], ["membrane protein", "PROTEIN", 134, 150], ["M]", "PROTEIN", 152, 154], ["nucleoprotein [N]", "PROTEIN", 160, 177], ["angiotensin\u2010converting enzyme 2 (ACE2) cell surface receptor", "PROTEIN", 279, 339], ["S protein", "PROTEIN", 357, 366], ["kb genome encodes", "TEST", 15, 32], ["nonstructural proteins", "TEST", 36, 58], ["nsps", "TEST", 60, 64], ["structural proteins", "TEST", 72, 91], ["spike protein", "TEST", 93, 106], ["S", "TEST", 108, 109], ["envelope protein", "TEST", 112, 128], ["E", "TEST", 130, 131], ["membrane protein", "TEST", 134, 150], ["the angiotensin\u2010converting enzyme", "TEST", 275, 308], ["cell surface receptor", "TEST", 318, 339], ["virus", "OBSERVATION", 184, 189], ["viral particle", "OBSERVATION", 257, 271], ["cell", "ANATOMY", 437, 441], ["viral membranes", "OBSERVATION", 446, 461]]], ["This step requires S protein activation.", [["S protein", "GENE_OR_GENE_PRODUCT", 19, 28], ["S protein", "PROTEIN", 19, 28], ["S protein activation", "TREATMENT", 19, 39]]], ["The S protein is synthesized as an inactive precursor that is inserted in the viral membrane, and requires two subsequent cleavages by cellular proteases to become functionally active.", [["membrane", "ANATOMY", 84, 92], ["cellular", "ANATOMY", 135, 143], ["membrane", "CELLULAR_COMPONENT", 84, 92], ["cellular", "CELL", 135, 143], ["S protein", "PROTEIN", 4, 13], ["cellular proteases", "PROTEIN", 135, 153], ["an inactive precursor", "PROBLEM", 32, 53], ["two subsequent cleavages", "TREATMENT", 107, 131], ["inactive", "OBSERVATION_MODIFIER", 35, 43], ["precursor", "OBSERVATION", 44, 53], ["viral membrane", "OBSERVATION", 78, 92], ["cleavages", "OBSERVATION", 122, 131], ["active", "OBSERVATION_MODIFIER", 177, 183]]], ["Different cellular proteases, such as furin\u2010like enzymes and the transmembrane protease serine 2 (TMPRSS2), may cleave the S protein in two subunits, S1 and S2, in a process called \u201cpriming.\u201d9,10A recent study showed that this furin\u2010mediated cleavage is important for virus entry in lung cells.11In addition, for virus entry, a second proteolytic cleavage is required at the S2\u2032 site localized immediately upstream of the fusion peptide,12,13and seems to involve at least TMPRSS2.14The viral genome is then released into the cytoplasm of the infected cells.", [["cellular", "ANATOMY", 10, 18], ["lung cells", "ANATOMY", 283, 293], ["cytoplasm", "ANATOMY", 525, 534], ["cells", "ANATOMY", 551, 556], ["serine", "CHEMICAL", 88, 94], ["cellular", "CELL", 10, 18], ["furin\u2010like enzymes", "GENE_OR_GENE_PRODUCT", 38, 56], ["transmembrane protease serine 2", "GENE_OR_GENE_PRODUCT", 65, 96], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 98, 105], ["S2", "GENE_OR_GENE_PRODUCT", 157, 159], ["lung cells", "CELL", 283, 293], ["11In", "SIMPLE_CHEMICAL", 294, 298], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 472, 479], ["cytoplasm", "ORGANISM_SUBSTANCE", 525, 534], ["cells", "CELL", 551, 556], ["cellular proteases", "PROTEIN", 10, 28], ["furin\u2010like enzymes", "PROTEIN", 38, 56], ["transmembrane protease serine 2", "PROTEIN", 65, 96], ["TMPRSS2", "PROTEIN", 98, 105], ["S protein", "PROTEIN", 123, 132], ["S1", "PROTEIN", 150, 152], ["S2", "PROTEIN", 157, 159], ["lung cells", "CELL_TYPE", 283, 293], ["S2\u2032 site", "DNA", 375, 383], ["TMPRSS2", "PROTEIN", 472, 479], ["viral genome", "DNA", 486, 498], ["infected cells", "CELL_TYPE", 542, 556], ["Different cellular proteases", "PROBLEM", 0, 28], ["furin\u2010like enzymes", "TEST", 38, 56], ["the transmembrane protease serine", "TEST", 61, 94], ["TMPRSS2", "TEST", 98, 105], ["A recent study", "TEST", 195, 209], ["this furin\u2010mediated cleavage", "PROBLEM", 222, 250], ["virus entry in lung cells", "PROBLEM", 268, 293], ["virus entry", "PROBLEM", 313, 324], ["a second proteolytic cleavage", "TREATMENT", 326, 355], ["the fusion peptide", "TEST", 418, 436], ["cellular proteases", "OBSERVATION", 10, 28], ["S2", "ANATOMY", 157, 159], ["lung", "ANATOMY", 283, 287], ["fusion", "OBSERVATION", 422, 428], ["viral genome", "OBSERVATION", 486, 498], ["cytoplasm", "OBSERVATION_MODIFIER", 525, 534], ["infected cells", "OBSERVATION", 542, 556]]], ["This allows the translation of the viral mRNA into two polyprotein precursors, pp1a and pp1ab, controlled by a \u22121 ribosomal frameshift.", [["ribosomal", "ANATOMY", 114, 123], ["pp1a", "GENE_OR_GENE_PRODUCT", 79, 83], ["pp1ab", "GENE_OR_GENE_PRODUCT", 88, 93], ["viral mRNA", "RNA", 35, 45], ["polyprotein precursors", "PROTEIN", 55, 77], ["pp1a", "PROTEIN", 79, 83], ["pp1ab", "PROTEIN", 88, 93], ["\u22121 ribosomal frameshift", "DNA", 111, 134], ["viral mRNA", "OBSERVATION", 35, 45], ["polyprotein precursors", "OBSERVATION", 55, 77], ["ribosomal frameshift", "OBSERVATION", 114, 134]]], ["These polyprotein precursors are then cleaved by two viral proteases, chymotrypsin\u2010like 3 (3CLpro) and papain\u2010like (PLpro), to generate the 16 nsps (nsp1 to 16).", [["chymotrypsin\u2010like 3", "GENE_OR_GENE_PRODUCT", 70, 89], ["3CLpro", "GENE_OR_GENE_PRODUCT", 91, 97], ["papain\u2010like", "GENE_OR_GENE_PRODUCT", 103, 114], ["viral proteases", "PROTEIN", 53, 68], ["chymotrypsin\u2010like 3", "PROTEIN", 70, 89], ["3CLpro", "PROTEIN", 91, 97], ["papain\u2010like", "PROTEIN", 103, 114], ["PLpro", "PROTEIN", 116, 121], ["16 nsps", "PROTEIN", 140, 147], ["nsp1 to 16", "PROTEIN", 149, 159], ["These polyprotein precursors", "TREATMENT", 0, 28], ["chymotrypsin\u2010like 3 (3CLpro)", "TREATMENT", 70, 98], ["papain\u2010like (PLpro)", "TREATMENT", 103, 122]]], ["Many of these proteins participate in the formation of the replication and transcription complex that orchestrates genome replication, mRNA synthesis and capping.", [["genome", "CELLULAR_COMPONENT", 115, 121], ["transcription complex", "PROTEIN", 75, 96], ["the replication", "TREATMENT", 55, 70], ["transcription complex", "TREATMENT", 75, 96], ["mRNA synthesis and capping", "TREATMENT", 135, 161], ["proteins", "OBSERVATION", 14, 22], ["genome replication", "OBSERVATION", 115, 133], ["capping", "OBSERVATION_MODIFIER", 154, 161]]], ["At the final stage of viral infection, the N protein assembles with the neo\u2010synthesized viral genome to form the nucleocapsid that associates with the viral structural proteins to generate new virions released by exocytosis.6", [["virions", "ANATOMY", 193, 200], ["viral infection", "DISEASE", 22, 37], ["N protein", "PROTEIN", 43, 52], ["neo\u2010synthesized viral genome", "DNA", 72, 100], ["viral structural proteins", "PROTEIN", 151, 176], ["viral infection", "PROBLEM", 22, 37], ["the N protein", "TREATMENT", 39, 52], ["the neo\u2010synthesized viral genome", "PROBLEM", 68, 100], ["the nucleocapsid", "PROBLEM", 109, 125], ["the viral structural proteins", "PROBLEM", 147, 176], ["new virions", "PROBLEM", 189, 200], ["final stage", "OBSERVATION_MODIFIER", 7, 18], ["viral", "OBSERVATION_MODIFIER", 22, 27], ["infection", "OBSERVATION", 28, 37], ["viral genome", "OBSERVATION", 88, 100]]]], "PMC7110256": [["Severe acute respiratory syndrome (SARS) is caused by a novel coronavirus (SARS-CoV) strain and is clinically similar to many other acute respiratory infections [1, 2].", [["respiratory", "ANATOMY", 138, 149], ["acute respiratory syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["SARS-CoV)", "DISEASE", 75, 84], ["respiratory infections", "DISEASE", 138, 160], ["SARS-CoV", "ORGANISM", 75, 83], ["SARS-CoV", "SPECIES", 75, 83], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["SARS", "PROBLEM", 35, 39], ["a novel coronavirus (SARS-CoV) strain", "PROBLEM", 54, 91], ["many other acute respiratory infections", "PROBLEM", 121, 160], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["coronavirus", "OBSERVATION", 62, 73], ["acute", "OBSERVATION_MODIFIER", 132, 137], ["respiratory", "ANATOMY", 138, 149], ["infections", "OBSERVATION", 150, 160]]], ["Its symptoms include high fever, chills, rigors, dyspnea, nonproductive cough, myalgias, lymphopenia, and chest infiltrates, which begin after an incubation period of 2\u201310 days.", [["chest infiltrates", "ANATOMY", 106, 123], ["fever", "DISEASE", 26, 31], ["chills", "DISEASE", 33, 39], ["rigors", "DISEASE", 41, 47], ["dyspnea", "DISEASE", 49, 56], ["cough", "DISEASE", 72, 77], ["myalgias", "DISEASE", 79, 87], ["lymphopenia", "DISEASE", 89, 100], ["chest infiltrates", "DISEASE", 106, 123], ["Its symptoms", "PROBLEM", 0, 12], ["high fever", "PROBLEM", 21, 31], ["chills", "PROBLEM", 33, 39], ["rigors", "PROBLEM", 41, 47], ["dyspnea", "PROBLEM", 49, 56], ["nonproductive cough", "PROBLEM", 58, 77], ["myalgias", "PROBLEM", 79, 87], ["lymphopenia", "PROBLEM", 89, 100], ["chest infiltrates", "PROBLEM", 106, 123], ["high", "OBSERVATION_MODIFIER", 21, 25], ["fever", "OBSERVATION", 26, 31], ["chills", "OBSERVATION", 33, 39], ["nonproductive", "OBSERVATION_MODIFIER", 58, 71], ["cough", "OBSERVATION", 72, 77], ["myalgias", "OBSERVATION", 79, 87], ["lymphopenia", "OBSERVATION", 89, 100], ["chest", "ANATOMY", 106, 111], ["infiltrates", "OBSERVATION", 112, 123]]], ["SARS initially appeared in southern China at the end of 2002 and was first recognized as a new disease entity by World Health Organization infectious-diseases expert Carlo Urbani.", [["SARS", "DISEASE", 0, 4], ["infectious-diseases", "DISEASE", 139, 158], ["SARS", "PROBLEM", 0, 4], ["a new disease entity", "PROBLEM", 89, 109]]], ["By the beginning of 2003, SARS had spread into 29 countries.", [["SARS", "DISEASE", 26, 30], ["SARS", "PROBLEM", 26, 30]]], ["The 2003 epidemic lasted >16 weeks and affected 8098 people, 774 of whom died.", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59]]], ["Nosocomial transmission of SARS-CoV was a striking feature of the epidemic.", [["SARS", "DISEASE", 27, 31], ["SARS-CoV", "ORGANISM", 27, 35], ["SARS-CoV", "SPECIES", 27, 35], ["Nosocomial transmission of SARS", "PROBLEM", 0, 31], ["CoV", "PROBLEM", 32, 35], ["the epidemic", "PROBLEM", 62, 74], ["epidemic", "OBSERVATION", 66, 74]]], ["If another SARS epidemic were to occur, surveillance efforts in containing the secondary transmission of SARS-CoV would ideally be combined with better prophylactic and therapeutic measures.", [["SARS", "DISEASE", 11, 15], ["SARS", "DISEASE", 105, 109], ["SARS-CoV", "ORGANISM", 105, 113], ["SARS-CoV", "SPECIES", 105, 113], ["another SARS epidemic", "PROBLEM", 3, 24], ["SARS", "PROBLEM", 105, 109], ["CoV", "PROBLEM", 110, 113], ["therapeutic measures", "TREATMENT", 169, 189]]], ["Despite the substantial number of cases and the intensive studies that have been conducted, the mechanism of the protective immune response against SARS-CoV remains unknown", [["SARS-CoV", "DISEASE", 148, 156], ["SARS-CoV", "ORGANISM", 148, 156], ["SARS-CoV", "SPECIES", 148, 156], ["the intensive studies", "TEST", 44, 65], ["SARS", "PROBLEM", 148, 152]]]], "385ab42188b929fca7f505049527527b640cd1cc": [["IntroductionUntil 2002, coronaviruses (HCoV-NL63, HCoV-229E, HCoV-OC43 and HKU) were first known to cause common cold in humans.", [["coronaviruses", "ORGANISM", 24, 37], ["HCoV-NL63", "ORGANISM", 39, 48], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 50, 59], ["HCoV-OC43", "GENE_OR_GENE_PRODUCT", 61, 70], ["HKU", "GENE_OR_GENE_PRODUCT", 75, 78], ["humans", "ORGANISM", 121, 127], ["HCoV", "DNA", 61, 65], ["OC43", "DNA", 66, 70], ["HKU", "DNA", 75, 78], ["humans", "SPECIES", 121, 127], ["humans", "SPECIES", 121, 127], ["IntroductionUntil", "TEST", 0, 17], ["coronaviruses", "TEST", 24, 37], ["HCoV", "TEST", 39, 43], ["HCoV", "TEST", 50, 54], ["HCoV", "TEST", 61, 65], ["HKU", "TEST", 75, 78], ["common cold in humans", "PROBLEM", 106, 127]]], ["However, in 2002 the SARS-CoV emerged, and then in 2013 the MERS-CoV.", [["SARS", "DISEASE", 21, 25], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 60, 68], ["SARS-CoV", "SPECIES", 21, 29], ["MERS-CoV", "SPECIES", 60, 68]]], ["The SARS-CoV and MERS-CoV caused severe respiratory syndrome and were highly pathogenic for humans, because of their ability to adapt to their host, notably to increase affinity for their receptor, leading to high infectivity in humans (1, 2) .IntroductionIn December 2019, a new coronavirus, first called 2019-nCov and then SARS-CoV-2 for severe acute respiratory syndrome coronavirus 2, was identified in Wuhan, China (3) .", [["SARS", "DISEASE", 4, 8], ["respiratory syndrome", "DISEASE", 40, 60], ["coronavirus", "DISEASE", 280, 291], ["acute respiratory syndrome coronavirus", "DISEASE", 347, 385], ["SARS-CoV", "ORGANISM", 4, 12], ["MERS-CoV", "ORGANISM", 17, 25], ["humans", "ORGANISM", 92, 98], ["humans", "ORGANISM", 229, 235], ["coronavirus", "ORGANISM", 280, 291], ["SARS-CoV-2", "ORGANISM", 325, 335], ["humans", "SPECIES", 92, 98], ["humans", "SPECIES", 229, 235], ["SARS-CoV", "SPECIES", 4, 12], ["MERS-CoV", "SPECIES", 17, 25], ["humans", "SPECIES", 92, 98], ["humans", "SPECIES", 229, 235], ["SARS-CoV", "SPECIES", 325, 333], ["severe acute respiratory syndrome coronavirus", "SPECIES", 340, 385], ["The SARS", "TEST", 0, 8], ["severe respiratory syndrome", "PROBLEM", 33, 60], ["high infectivity in humans", "PROBLEM", 209, 235], ["CoV", "TEST", 330, 333], ["severe acute respiratory syndrome coronavirus 2", "PROBLEM", 340, 387], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["respiratory syndrome", "OBSERVATION", 40, 60], ["high", "OBSERVATION_MODIFIER", 209, 213], ["infectivity", "OBSERVATION", 214, 225], ["severe", "OBSERVATION_MODIFIER", 340, 346], ["acute", "OBSERVATION_MODIFIER", 347, 352], ["respiratory syndrome", "OBSERVATION", 353, 373]]], ["SARS-CoV-2 spreads very efficiently, causing the current COVID-19 (Coronavirus Disease 2019) pandemic, that by mid-May 2020 has already killed more than 300,000 people all over the world.IntroductionThe highest morbi-mortality of COVID-19 is observed among older patients (4) .", [["SARS", "DISEASE", 0, 4], ["Coronavirus Disease 2019) pandemic", "DISEASE", 67, 101], ["SARS-CoV-2", "ORGANISM", 0, 10], ["people", "ORGANISM", 161, 167], ["patients", "ORGANISM", 263, 271], ["COVID-19", "DNA", 230, 238], ["people", "SPECIES", 161, 167], ["patients", "SPECIES", 263, 271], ["SARS-CoV", "SPECIES", 0, 8], ["SARS", "PROBLEM", 0, 4], ["the current COVID", "TEST", 45, 62], ["Coronavirus Disease", "PROBLEM", 67, 86], ["pandemic", "PROBLEM", 93, 101], ["COVID", "TEST", 230, 235]]], ["Patients in intensive care unit (ICU) are older than patients not requiring ICU (5) .", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 53, 61], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 53, 61]]], ["In a study using an observational database from 169 hospitals in Asia, Europe, and North America, an age of more than 65 years-old was associated with a higher risk of in-hospital death: 10.0% mortality rates for people \u2265 65 years-old vs. 4.9% for those < 65 years-old (6) .", [["death", "DISEASE", 180, 185], ["people", "ORGANISM", 213, 219], ["people", "SPECIES", 213, 219], ["a study", "TEST", 3, 10]]], ["In France, 3.6% of infected individuals needed to be hospitalized, with an average death rate of 0.7% ranging from 0.001% in individuals < 20 years-old, to 10.1% in those > 80 years-old (7) .IntroductionNot all older adults appear to be equally vulnerable to SARS-CoV-2 infection (8) .", [["death", "DISEASE", 83, 88], ["SARS-CoV-2 infection", "DISEASE", 259, 279], ["individuals", "ORGANISM", 28, 39], ["adults", "ORGANISM", 217, 223], ["SARS-CoV-2", "ORGANISM", 259, 269], ["SARS-CoV", "SPECIES", 259, 267], ["infected individuals", "PROBLEM", 19, 39], ["an average death rate", "TEST", 72, 93], ["SARS", "PROBLEM", 259, 263], ["CoV-2 infection", "PROBLEM", 264, 279], ["SARS", "OBSERVATION", 259, 263], ["infection", "OBSERVATION", 270, 279]]], ["Frailty is a clinical syndrome in older adults characterized by an increased vulnerability for adverse health outcomes and aging-associated functional declines (9) .", [["Frailty", "DISEASE", 0, 7], ["a clinical syndrome", "PROBLEM", 11, 30], ["an increased vulnerability", "PROBLEM", 64, 90], ["adverse health outcomes", "PROBLEM", 95, 118], ["increased", "OBSERVATION_MODIFIER", 67, 76], ["vulnerability", "OBSERVATION", 77, 90]]], ["Frail older adults, especially those with comorbidities (eg, hypertension, obesity, diabetes) are at higher risk of death if they get infected than younger adults (10) .", [["hypertension", "DISEASE", 61, 73], ["obesity", "DISEASE", 75, 82], ["diabetes", "DISEASE", 84, 92], ["death", "DISEASE", 116, 121], ["comorbidities (eg", "PROBLEM", 42, 59], ["hypertension", "PROBLEM", 61, 73], ["obesity", "PROBLEM", 75, 82], ["diabetes", "PROBLEM", 84, 92], ["hypertension", "OBSERVATION", 61, 73], ["obesity", "OBSERVATION", 75, 82]]], ["Prevention interventions need to be developed to reduce the impact of COVID-19 in older people.", [["people", "ORGANISM", 88, 94], ["people", "SPECIES", 88, 94], ["Prevention interventions", "TREATMENT", 0, 24], ["COVID", "TEST", 70, 75]]], ["Geroscience is an interdisciplinary field that seeks to understand the links of biological mechanisms of aging with biological mechanisms of disease and body functions (eg, mobility, cognition) to ultimately find potential interventions and promote health in older adults (11) .IntroductionIn this perspective paper, we will describe SARS-CoV-2 properties; then we will focus in the relationship between SARS-CoV-2 and aging, discussing the potential roles of comorbidities, inflammaging, immunosenescence, and immune escape.", [["body", "ANATOMY", 153, 157], ["inflammaging", "DISEASE", 475, 487], ["body", "ORGANISM_SUBDIVISION", 153, 157], ["disease", "PROBLEM", 141, 148], ["comorbidities", "PROBLEM", 460, 473]]], ["Finally, we will introduce Geroscience as a global approach to treat and prevent the onset and decrease the severity of diseases during aging, notably COVID-19.SARS-CoV-2 propertiesCoronaviruses are members of the Coronaviridae family.", [["SARS", "DISEASE", 160, 164], ["CoV-2", "ORGANISM", 165, 170], ["Coronaviruses", "GENE_OR_GENE_PRODUCT", 181, 194], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 214, 227], ["Coronaviridae family", "PROTEIN", 214, 234], ["Geroscience", "TREATMENT", 27, 38], ["a global approach", "TREATMENT", 42, 59], ["the severity of diseases", "PROBLEM", 104, 128], ["COVID", "TEST", 151, 156], ["diseases", "OBSERVATION", 120, 128]]], ["They are divided into Alphacoronavirus and Betacoronavirus that can only infect mammals, and Gammacoronavirus and Deltacoronavirus which mostly infect birds (1).", [["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 22, 38], ["Betacoronavirus", "GENE_OR_GENE_PRODUCT", 43, 58], ["Gammacoronavirus", "GENE_OR_GENE_PRODUCT", 93, 109], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 114, 130], ["Betacoronavirus", "TREATMENT", 43, 58], ["Gammacoronavirus", "PROBLEM", 93, 109], ["Deltacoronavirus", "PROBLEM", 114, 130]]], ["SARS-CoV-2 is a Betacoronavirus (subgroup B Sarbecovirus), enveloped, with a positive single-stranded large RNA that can infect animals and humans.", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["B Sarbecovirus", "ORGANISM", 42, 56], ["humans", "ORGANISM", 140, 146], ["humans", "SPECIES", 140, 146], ["SARS-CoV-2", "SPECIES", 0, 10], ["humans", "SPECIES", 140, 146], ["SARS-CoV", "TEST", 0, 8], ["a Betacoronavirus (subgroup B Sarbecovirus", "PROBLEM", 14, 56], ["a positive single-stranded large RNA", "PROBLEM", 75, 111], ["large RNA", "OBSERVATION_MODIFIER", 102, 111]]], ["As MERS-CoV and SARS-CoV, it may cause severe diseases and high fatality rate.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 3, 11], ["SARS-CoV", "ORGANISM", 16, 24], ["MERS-CoV", "SPECIES", 3, 11], ["SARS-CoV", "SPECIES", 16, 24], ["SARS", "PROBLEM", 16, 20], ["severe diseases", "PROBLEM", 39, 54], ["high fatality rate", "PROBLEM", 59, 77], ["may cause", "UNCERTAINTY", 29, 38], ["severe", "OBSERVATION_MODIFIER", 39, 45], ["diseases", "OBSERVATION", 46, 54], ["high", "OBSERVATION_MODIFIER", 59, 63]]], ["The envelope spike protein of the SARS-CoV-2 recognizes the human angiotensin-converting enzyme II (ACE2) as an entry receptor, and preferentially infects lung epithelial cells (12, 13) .", [["lung epithelial cells", "ANATOMY", 155, 176], ["angiotensin", "CHEMICAL", 66, 77], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 34, 44], ["human", "ORGANISM", 60, 65], ["angiotensin-converting enzyme II", "GENE_OR_GENE_PRODUCT", 66, 98], ["ACE2", "GENE_OR_GENE_PRODUCT", 100, 104], ["lung epithelial cells", "CELL", 155, 176], ["envelope spike protein", "PROTEIN", 4, 26], ["SARS-CoV-2", "PROTEIN", 34, 44], ["human angiotensin-converting enzyme II", "PROTEIN", 60, 98], ["ACE2", "PROTEIN", 100, 104], ["entry receptor", "PROTEIN", 112, 126], ["lung epithelial cells", "CELL_TYPE", 155, 176], ["human", "SPECIES", 60, 65], ["SARS-CoV", "SPECIES", 34, 42], ["human", "SPECIES", 60, 65], ["The envelope spike protein", "TEST", 0, 26], ["the SARS", "TEST", 30, 38], ["CoV", "TEST", 39, 42], ["the human angiotensin", "TEST", 56, 77], ["an entry receptor", "TEST", 109, 126], ["spike", "OBSERVATION_MODIFIER", 13, 18], ["infects", "OBSERVATION_MODIFIER", 147, 154], ["lung", "ANATOMY", 155, 159], ["epithelial cells", "OBSERVATION", 160, 176]]], ["The receptor binding domain of the spike protein latches onto the ACE2 receptor, and then the host TMPRSS2 protease cleaves the spike protein to expose fusion peptides able to fuse the viral and cell membranes (14) .SARS-CoV-2 propertiesThe cellular tropism of a virus is determined by the susceptibility of host cells to be infected.", [["cell membranes", "ANATOMY", 195, 209], ["cellular", "ANATOMY", 241, 249], ["cells", "ANATOMY", 313, 318], ["SARS", "DISEASE", 216, 220], ["ACE2", "GENE_OR_GENE_PRODUCT", 66, 70], ["TMPRSS2 protease", "GENE_OR_GENE_PRODUCT", 99, 115], ["cell membranes", "CELLULAR_COMPONENT", 195, 209], ["cellular", "CELL", 241, 249], ["host cells", "CELL", 308, 318], ["receptor binding domain", "PROTEIN", 4, 27], ["spike protein latches", "PROTEIN", 35, 56], ["ACE2 receptor", "PROTEIN", 66, 79], ["TMPRSS2 protease", "PROTEIN", 99, 115], ["spike protein", "PROTEIN", 128, 141], ["host cells", "CELL_TYPE", 308, 318], ["the spike protein latches", "PROBLEM", 31, 56], ["the ACE2 receptor", "TREATMENT", 62, 79], ["the host TMPRSS2 protease", "TREATMENT", 90, 115], ["the spike protein", "PROBLEM", 124, 141], ["fusion peptides", "PROBLEM", 152, 167], ["SARS", "TEST", 216, 220], ["a virus", "PROBLEM", 261, 268], ["host cells", "PROBLEM", 308, 318], ["infected", "PROBLEM", 325, 333], ["viral", "OBSERVATION", 185, 190], ["cell membranes", "OBSERVATION", 195, 209], ["cellular tropism", "OBSERVATION", 241, 257], ["virus", "OBSERVATION", 263, 268], ["host cells", "OBSERVATION", 308, 318], ["infected", "OBSERVATION", 325, 333]]], ["Common COVID-19 symptoms are fever, cough, and fatigue.", [["fever", "DISEASE", 29, 34], ["cough", "DISEASE", 36, 41], ["fatigue", "DISEASE", 47, 54], ["Common COVID", "TEST", 0, 12], ["symptoms", "PROBLEM", 16, 24], ["fever", "PROBLEM", 29, 34], ["cough", "PROBLEM", 36, 41], ["fatigue", "PROBLEM", 47, 54], ["fever", "OBSERVATION", 29, 34], ["cough", "OBSERVATION", 36, 41]]], ["Other symptoms that have also been observed include headache, diarrhea, and anosmia (17, 18) , demonstrating that SARS-CoV-2 can infect cells in other human organs (19) .", [["cells", "ANATOMY", 136, 141], ["organs", "ANATOMY", 157, 163], ["headache", "DISEASE", 52, 60], ["diarrhea", "DISEASE", 62, 70], ["anosmia", "DISEASE", 76, 83], ["SARS", "DISEASE", 114, 118], ["SARS-CoV-2", "ORGANISM", 114, 124], ["cells", "CELL", 136, 141], ["human", "ORGANISM", 151, 156], ["organs", "ORGAN", 157, 163], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 151, 156], ["Other symptoms", "PROBLEM", 0, 14], ["headache", "PROBLEM", 52, 60], ["diarrhea", "PROBLEM", 62, 70], ["anosmia", "PROBLEM", 76, 83], ["SARS", "PROBLEM", 114, 118], ["CoV", "TEST", 119, 122], ["diarrhea", "OBSERVATION", 62, 70]]], ["In some cases, however, the infection can be asymptomatic or paucisymptomatic (causing little or no clinical manifestations) (20) .COVID-19, VIROLOGY AND GEROSCIENCE: A PERSPECTIVEOnce the SARS-CoV-2 enters a human cell, the virion releases its RNA in the cytoplasm.", [["cell", "ANATOMY", 215, 219], ["virion", "ANATOMY", 225, 231], ["cytoplasm", "ANATOMY", 256, 265], ["infection", "DISEASE", 28, 37], ["SARS", "DISEASE", 189, 193], ["SARS-CoV-2", "ORGANISM", 189, 199], ["human", "ORGANISM", 209, 214], ["cell", "CELL", 215, 219], ["virion", "CELLULAR_COMPONENT", 225, 231], ["cytoplasm", "ORGANISM_SUBSTANCE", 256, 265], ["human", "SPECIES", 209, 214], ["human", "SPECIES", 209, 214], ["the infection", "PROBLEM", 24, 37], ["asymptomatic", "PROBLEM", 45, 57], ["paucisymptomatic", "PROBLEM", 61, 77], ["clinical manifestations", "PROBLEM", 100, 123], ["a human cell", "TREATMENT", 207, 219], ["the virion", "TREATMENT", 221, 231], ["infection", "OBSERVATION", 28, 37]]], ["Translation and replication occur and new virions are then released from the cell through exocytosis (21) .", [["virions", "ANATOMY", 42, 49], ["cell", "ANATOMY", 77, 81], ["cell", "CELL", 77, 81], ["replication", "TREATMENT", 16, 27], ["new virions", "TREATMENT", 38, 49]]], ["Cytokine storm, or Cytokine Release Syndrome (CRS) in peripheral blood is observed in some subjects during the second week of the COVID-19 infection.", [["peripheral blood", "ANATOMY", 54, 70], ["CRS", "DISEASE", 46, 49], ["infection", "DISEASE", 139, 148], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cytokine", "GENE_OR_GENE_PRODUCT", 19, 27], ["peripheral blood", "ORGANISM_SUBSTANCE", 54, 70], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine", "PROTEIN", 19, 27], ["COVID-19", "SPECIES", 130, 138], ["Cytokine storm", "PROBLEM", 0, 14], ["Cytokine Release Syndrome", "PROBLEM", 19, 44], ["peripheral blood", "TEST", 54, 70], ["the COVID-19 infection", "PROBLEM", 126, 148], ["peripheral", "ANATOMY_MODIFIER", 54, 64], ["blood", "ANATOMY", 65, 70], ["infection", "OBSERVATION", 139, 148]]], ["Approximately 8 days after symptom onset, when it happens in patients, the acute cytokine storm is associated with unfavorable outcomes requiring sometime ICU care and mechanical ventilation.", [["patients", "ORGANISM", 61, 69], ["cytokine", "PROTEIN", 81, 89], ["patients", "SPECIES", 61, 69], ["symptom onset", "PROBLEM", 27, 40], ["the acute cytokine storm", "PROBLEM", 71, 95], ["sometime ICU care", "TREATMENT", 146, 163], ["mechanical ventilation", "TREATMENT", 168, 190], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["cytokine storm", "OBSERVATION", 81, 95], ["mechanical ventilation", "OBSERVATION", 168, 190]]], ["Inflammatory factors elevated during this storm include IL-6 (interleukin 6), IFN\u03b3 (interferon \u03b3), TNF\u03b1 (Tumor necrosis factor \u03b1 ), IL-1\u03b2, IL-8, MCP-1 (CCL2 chemokine ligand 2), IP-10 (CXCL10) in peripheral blood as well as antiinflammatory factors such as IL-1RA and IL-10 (17, (22) (23) (24) (25) (26) (27) .", [["peripheral blood", "ANATOMY", 196, 212], ["IL-6", "GENE_OR_GENE_PRODUCT", 56, 60], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 62, 75], ["IFN\u03b3", "GENE_OR_GENE_PRODUCT", 78, 82], ["interferon \u03b3", "GENE_OR_GENE_PRODUCT", 84, 96], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 99, 103], ["Tumor necrosis factor \u03b1", "GENE_OR_GENE_PRODUCT", 105, 128], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 132, 137], ["IL-8", "GENE_OR_GENE_PRODUCT", 139, 143], ["MCP-1", "GENE_OR_GENE_PRODUCT", 145, 150], ["CCL2 chemokine ligand 2", "GENE_OR_GENE_PRODUCT", 152, 175], ["IP-10", "GENE_OR_GENE_PRODUCT", 178, 183], ["CXCL10", "GENE_OR_GENE_PRODUCT", 185, 191], ["peripheral", "ORGANISM_SUBSTANCE", 196, 206], ["blood", "ORGANISM_SUBSTANCE", 207, 212], ["IL-1RA", "GENE_OR_GENE_PRODUCT", 257, 263], ["IL-10", "SIMPLE_CHEMICAL", 268, 273], ["17, (22) (23) (24) (25) (26)", "SIMPLE_CHEMICAL", 275, 303], ["Inflammatory factors", "PROTEIN", 0, 20], ["IL-6", "PROTEIN", 56, 60], ["interleukin 6", "PROTEIN", 62, 75], ["IFN\u03b3", "PROTEIN", 78, 82], ["interferon \u03b3", "PROTEIN", 84, 96], ["TNF\u03b1", "PROTEIN", 99, 103], ["Tumor necrosis factor \u03b1", "PROTEIN", 105, 128], ["MCP-1", "PROTEIN", 145, 150], ["CCL2 chemokine ligand 2", "PROTEIN", 152, 175], ["IP-10", "PROTEIN", 178, 183], ["CXCL10", "PROTEIN", 185, 191], ["antiinflammatory factors", "PROTEIN", 224, 248], ["IL", "PROTEIN", 257, 259], ["Inflammatory factors", "PROBLEM", 0, 20], ["IL-6 (interleukin", "TREATMENT", 56, 73], ["IFN\u03b3 (interferon \u03b3", "TREATMENT", 78, 96], ["TNF", "TEST", 99, 102], ["Tumor necrosis factor", "TEST", 105, 126], ["IL", "TEST", 132, 134], ["IL", "TEST", 139, 141], ["MCP", "TEST", 145, 148], ["CCL2 chemokine ligand", "TREATMENT", 152, 173], ["IP", "TEST", 178, 180], ["peripheral blood", "TEST", 196, 212], ["antiinflammatory factors", "TREATMENT", 224, 248], ["IL", "TEST", 257, 259], ["IL", "TEST", 268, 270], ["peripheral", "ANATOMY_MODIFIER", 196, 206], ["blood", "ANATOMY", 207, 212]]], ["Elevated IL-6 serum correlates with acute respiratory distress syndrome (ARDS) and multiple-organ failure (23, 24) .", [["serum", "ANATOMY", 14, 19], ["respiratory", "ANATOMY", 42, 53], ["organ", "ANATOMY", 92, 97], ["acute respiratory distress syndrome", "DISEASE", 36, 71], ["ARDS", "DISEASE", 73, 77], ["multiple-organ failure", "DISEASE", 83, 105], ["IL-6", "GENE_OR_GENE_PRODUCT", 9, 13], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["organ", "ORGAN", 92, 97], ["IL-6", "PROTEIN", 9, 13], ["Elevated IL", "PROBLEM", 0, 11], ["acute respiratory distress syndrome", "PROBLEM", 36, 71], ["ARDS", "PROBLEM", 73, 77], ["multiple-organ failure", "PROBLEM", 83, 105], ["acute", "OBSERVATION_MODIFIER", 36, 41], ["respiratory distress", "OBSERVATION", 42, 62], ["syndrome", "OBSERVATION", 63, 71], ["ARDS", "OBSERVATION", 73, 77], ["multiple", "OBSERVATION_MODIFIER", 83, 91], ["organ", "ANATOMY", 92, 97], ["failure", "OBSERVATION", 98, 105]]], ["Severe cases of COVID-19 were older, had higher levels of proinflammatory cytokines IL-6, IFN-\u03b3 and TNF\u03b1, and lower T cell counts (CD8+ and CD4+ T lymphocytes) in the peripheral blood than mild cases (26, 28, 29) .COVID-19, VIROLOGY AND GEROSCIENCE: A PERSPECTIVEHalf of the patients hospitalized for COVID-19 had a comorbidity: hypertension, 30%; diabetes, 19%; and coronary heart disease, 8% (30) .", [["T cell", "ANATOMY", 116, 122], ["CD8+", "ANATOMY", 131, 135], ["CD4+ T lymphocytes", "ANATOMY", 140, 158], ["peripheral blood", "ANATOMY", 167, 183], ["coronary", "ANATOMY", 367, 375], ["heart", "ANATOMY", 376, 381], ["COVID", "DISEASE", 301, 306], ["hypertension", "DISEASE", 329, 341], ["diabetes", "DISEASE", 348, 356], ["coronary heart disease", "DISEASE", 367, 389], ["IL-6", "GENE_OR_GENE_PRODUCT", 84, 88], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 90, 95], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 100, 104], ["T cell", "CELL", 116, 122], ["CD8", "GENE_OR_GENE_PRODUCT", 131, 134], ["CD4", "GENE_OR_GENE_PRODUCT", 140, 143], ["peripheral blood", "ORGANISM_SUBSTANCE", 167, 183], ["patients", "ORGANISM", 275, 283], ["heart", "ORGAN", 376, 381], ["proinflammatory cytokines", "PROTEIN", 58, 83], ["IL-6", "PROTEIN", 84, 88], ["IFN", "PROTEIN", 90, 93], ["TNF\u03b1", "PROTEIN", 100, 104], ["CD8", "PROTEIN", 131, 134], ["CD4", "PROTEIN", 140, 143], ["T lymphocytes", "CELL_TYPE", 145, 158], ["patients", "SPECIES", 275, 283], ["COVID", "TEST", 16, 21], ["proinflammatory cytokines IL", "TEST", 58, 86], ["IFN", "TEST", 90, 93], ["TNF", "TEST", 100, 103], ["lower T cell counts", "TEST", 110, 129], ["CD8", "TEST", 131, 134], ["CD4", "TEST", 140, 143], ["lymphocytes", "TEST", 147, 158], ["the peripheral blood than mild cases", "PROBLEM", 163, 199], ["COVID", "TEST", 301, 306], ["hypertension", "PROBLEM", 329, 341], ["diabetes", "PROBLEM", 348, 356], ["coronary heart disease", "PROBLEM", 367, 389], ["peripheral", "ANATOMY_MODIFIER", 167, 177], ["blood", "ANATOMY", 178, 183], ["mild", "OBSERVATION_MODIFIER", 189, 193], ["cases", "OBSERVATION", 194, 199], ["hypertension", "OBSERVATION", 329, 341], ["coronary heart", "ANATOMY", 367, 381], ["disease", "OBSERVATION", 382, 389]]], ["The case-fatality rate was elevated among patients with preexisting comorbidities: cardiovascular diseases, 10.5%; diabetes, 7.3%; chronic respiratory disease, 6.3%; hypertension, 6.0%. and cancer, 5.6% (4).", [["cardiovascular", "ANATOMY", 83, 97], ["respiratory", "ANATOMY", 139, 150], ["cancer", "ANATOMY", 190, 196], ["cardiovascular diseases", "DISEASE", 83, 106], ["diabetes", "DISEASE", 115, 123], ["chronic respiratory disease", "DISEASE", 131, 158], ["hypertension", "DISEASE", 166, 178], ["cancer", "DISEASE", 190, 196], ["patients", "ORGANISM", 42, 50], ["cancer", "CANCER", 190, 196], ["patients", "SPECIES", 42, 50], ["fatality rate", "TEST", 9, 22], ["elevated", "PROBLEM", 27, 35], ["preexisting comorbidities", "PROBLEM", 56, 81], ["cardiovascular diseases", "PROBLEM", 83, 106], ["diabetes", "PROBLEM", 115, 123], ["chronic respiratory disease", "PROBLEM", 131, 158], ["hypertension", "PROBLEM", 166, 178], ["cancer", "PROBLEM", 190, 196], ["cardiovascular", "ANATOMY", 83, 97], ["diseases", "OBSERVATION", 98, 106], ["chronic", "OBSERVATION_MODIFIER", 131, 138], ["respiratory disease", "OBSERVATION", 139, 158], ["hypertension", "OBSERVATION", 166, 178], ["cancer", "OBSERVATION", 190, 196]]], ["Patients infected by SARS-CoV-2 and with diabetes had higher levels of IL-6, IL-8, and TNF\u03b1 in peripheral blood, and were older than patients without diabetes (31) .", [["peripheral blood", "ANATOMY", 95, 111], ["SARS", "DISEASE", 21, 25], ["diabetes", "DISEASE", 41, 49], ["diabetes", "DISEASE", 150, 158], ["Patients", "ORGANISM", 0, 8], ["SARS-CoV-2", "ORGANISM", 21, 31], ["IL-6", "GENE_OR_GENE_PRODUCT", 71, 75], ["IL-8", "GENE_OR_GENE_PRODUCT", 77, 81], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 87, 91], ["peripheral blood", "ORGANISM_SUBSTANCE", 95, 111], ["patients", "ORGANISM", 133, 141], ["IL-6", "PROTEIN", 71, 75], ["IL-8", "PROTEIN", 77, 81], ["TNF\u03b1", "PROTEIN", 87, 91], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 133, 141], ["SARS-CoV", "SPECIES", 21, 29], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["diabetes", "PROBLEM", 41, 49], ["IL", "TEST", 71, 73], ["IL", "TEST", 77, 79], ["TNF", "TEST", 87, 90], ["diabetes", "PROBLEM", 150, 158], ["infected", "OBSERVATION", 9, 17], ["peripheral", "ANATOMY_MODIFIER", 95, 105], ["blood", "ANATOMY", 106, 111]]], ["Most of the fatal cases of COVID-19 involved older adults and patients with comorbidities.", [["COVID", "DISEASE", 27, 32], ["adults", "ORGANISM", 51, 57], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["COVID", "TEST", 27, 32], ["comorbidities", "PROBLEM", 76, 89]]], ["Cardiovascular diseases, hypertension, cancer, diabetes are also age-related diseases (32) ; and are associated with a chronic inflammation, as aging.SARS-CoV-2 and agingDuring the current SARS-CoV-2 pandemic, patients in ICU have higher levels of inflammatory factors, and are significantly older and with comorbidities than patients who are not in ICU (5, 30) .", [["Cardiovascular", "ANATOMY", 0, 14], ["cancer", "ANATOMY", 39, 45], ["Cardiovascular diseases", "DISEASE", 0, 23], ["hypertension", "DISEASE", 25, 37], ["cancer", "DISEASE", 39, 45], ["diabetes", "DISEASE", 47, 55], ["inflammation", "DISEASE", 127, 139], ["SARS", "DISEASE", 150, 154], ["SARS-CoV-2 pandemic", "DISEASE", 189, 208], ["cancer", "CANCER", 39, 45], ["SARS-CoV-2", "ORGANISM", 189, 199], ["patients", "ORGANISM", 210, 218], ["patients", "ORGANISM", 326, 334], ["inflammatory factors", "PROTEIN", 248, 268], ["patients", "SPECIES", 210, 218], ["patients", "SPECIES", 326, 334], ["Cardiovascular diseases", "PROBLEM", 0, 23], ["hypertension", "PROBLEM", 25, 37], ["cancer", "PROBLEM", 39, 45], ["diabetes", "PROBLEM", 47, 55], ["related diseases", "PROBLEM", 69, 85], ["a chronic inflammation", "PROBLEM", 117, 139], ["SARS", "TEST", 150, 154], ["inflammatory factors", "PROBLEM", 248, 268], ["diseases", "OBSERVATION", 15, 23], ["hypertension", "OBSERVATION", 25, 37], ["cancer", "OBSERVATION", 39, 45], ["diabetes", "OBSERVATION", 47, 55], ["associated with", "UNCERTAINTY", 101, 116], ["chronic", "OBSERVATION_MODIFIER", 119, 126], ["inflammation", "OBSERVATION", 127, 139], ["inflammatory", "OBSERVATION_MODIFIER", 248, 260]]], ["Older age is also associated with a higher peak viral load in the naso-pharynx, suggesting that the virus could replicate at higher rates in older adults, or more probably that their immune system is not efficient enough to limit the infection (33-35).", [["naso-pharynx", "ANATOMY", 66, 78], ["infection", "DISEASE", 234, 243], ["naso-pharynx", "ORGAN", 66, 78], ["a higher peak viral load", "PROBLEM", 34, 58], ["the virus", "PROBLEM", 96, 105], ["the infection", "PROBLEM", 230, 243], ["viral load", "OBSERVATION", 48, 58], ["pharynx", "ANATOMY", 71, 78], ["virus", "OBSERVATION", 100, 105], ["infection", "OBSERVATION", 234, 243]]], ["Differences of ACE2 expression level between young and old adults could contribute to the higher viral loads in older adults, even though this is not established yet in the literature; whereas one study suggests that ACE2 expression in the lung increases with age (36), another investigation (16) indicates that ACE2 expression levels showed no significant difference between younger and older adults.", [["lung", "ANATOMY", 240, 244], ["ACE2", "GENE_OR_GENE_PRODUCT", 15, 19], ["adults", "ORGANISM", 59, 65], ["ACE2", "GENE_OR_GENE_PRODUCT", 217, 221], ["lung", "ORGAN", 240, 244], ["ACE2", "GENE_OR_GENE_PRODUCT", 312, 316], ["ACE2", "PROTEIN", 15, 19], ["ACE2", "PROTEIN", 217, 221], ["ACE2", "PROTEIN", 312, 316], ["ACE2 expression level", "PROBLEM", 15, 36], ["the higher viral loads", "PROBLEM", 86, 108], ["one study", "TEST", 193, 202], ["ACE2 expression", "PROBLEM", 217, 232], ["another investigation", "TEST", 270, 291], ["ACE2 expression levels", "TEST", 312, 334], ["lung", "ANATOMY", 240, 244], ["increases", "OBSERVATION_MODIFIER", 245, 254], ["no", "UNCERTAINTY", 342, 344], ["significant", "OBSERVATION_MODIFIER", 345, 356]]], ["This discrepancy deserves further studies.", [["further studies", "TEST", 26, 41]]], ["When ACE2 expression in the lungs was associated with immune signatures (genes expression of CD8+ T cells, type I IFN response, B cells and NK cells), a positive correlation was observed in the older group and a negative correlation in the younger one (16) .", [["lungs", "ANATOMY", 28, 33], ["CD8+ T cells", "ANATOMY", 93, 105], ["B cells", "ANATOMY", 128, 135], ["NK cells", "ANATOMY", 140, 148], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["lungs", "ORGAN", 28, 33], ["CD8", "GENE_OR_GENE_PRODUCT", 93, 96], ["type I IFN", "GENE_OR_GENE_PRODUCT", 107, 117], ["B cells", "CELL", 128, 135], ["NK cells", "CELL", 140, 148], ["ACE2", "PROTEIN", 5, 9], ["CD8", "PROTEIN", 93, 96], ["T cells", "CELL_TYPE", 98, 105], ["IFN", "PROTEIN", 114, 117], ["B cells", "CELL_TYPE", 128, 135], ["NK cells", "CELL_TYPE", 140, 148], ["ACE2 expression in the lungs", "PROBLEM", 5, 33], ["immune signatures", "PROBLEM", 54, 71], ["CD8", "TEST", 93, 96], ["T cells", "PROBLEM", 98, 105], ["type I IFN response", "PROBLEM", 107, 126], ["B cells and NK cells", "PROBLEM", 128, 148], ["lungs", "ANATOMY", 28, 33], ["NK cells", "OBSERVATION", 140, 148]]], ["The ability of the host immune response to combat SARS-CoV-2 infection may partially explain the difference in severity between young and old adults.", [["SARS", "DISEASE", 50, 54], ["infection", "DISEASE", 61, 70], ["SARS-CoV-2", "ORGANISM", 50, 60], ["CoV-2", "SPECIES", 55, 60], ["SARS-CoV-2", "SPECIES", 50, 60], ["combat SARS", "PROBLEM", 43, 54], ["CoV-2 infection", "PROBLEM", 55, 70], ["infection", "OBSERVATION", 61, 70]]], ["The induction of proinflammatory cytokines during sepsis (as it may occur in COVID-19 pathology) is not always adequately controlled by anti-inflammatory mechanisms, notably in older patients (37) .", [["sepsis", "DISEASE", 50, 56], ["patients", "ORGANISM", 183, 191], ["proinflammatory cytokines", "PROTEIN", 17, 42], ["patients", "SPECIES", 183, 191], ["proinflammatory cytokines", "PROBLEM", 17, 42], ["sepsis", "PROBLEM", 50, 56], ["COVID", "TEST", 77, 82], ["proinflammatory", "OBSERVATION_MODIFIER", 17, 32], ["not always", "UNCERTAINTY", 100, 110]]], ["People respond differently to the infection and older patients or those with comorbidities could more frequently have an inappropriate immune response.", [["infection", "DISEASE", 34, 43], ["People", "ORGANISM", 0, 6], ["patients", "ORGANISM", 54, 62], ["People", "SPECIES", 0, 6], ["patients", "SPECIES", 54, 62], ["the infection", "PROBLEM", 30, 43], ["comorbidities", "PROBLEM", 77, 90], ["infection", "OBSERVATION", 34, 43]]], ["We can speculate that it is not the SARS-CoV-2 itself, but the inappropriate immune response and the inflammatory process that are responsible for the higher mortality of COVID-19 among older patients (29, 38) .SARS-CoV-2 and agingIn COVID-19 clinical studies, chronological age has been used, whereas all individuals do not age in the same way and the underlying mechanisms of aging may be different.", [["SARS", "DISEASE", 211, 215], ["SARS-CoV-2", "ORGANISM", 36, 46], ["patients", "ORGANISM", 192, 200], ["patients", "SPECIES", 192, 200], ["SARS-CoV", "SPECIES", 36, 44], ["the SARS", "TEST", 32, 40], ["CoV", "TEST", 41, 44], ["the inappropriate immune response", "PROBLEM", 59, 92], ["the inflammatory process", "PROBLEM", 97, 121], ["COVID", "TEST", 171, 176], ["SARS", "TEST", 211, 215], ["CoV", "TEST", 216, 219], ["agingIn COVID", "TEST", 226, 239], ["clinical studies", "TEST", 243, 259], ["inflammatory", "OBSERVATION", 101, 113]]], ["Frailty is a clinical syndrome common in older adults.", [["Frailty", "DISEASE", 0, 7], ["a clinical syndrome", "PROBLEM", 11, 30]]], ["It has been defined by Fried et al. (9) as a clinical syndrome in which at least three of the following criteria are present: unintentional weight loss, self-reported exhaustion, weakness, slow walking speed, and low physical activity.", [["weight loss", "DISEASE", 140, 151], ["weakness", "DISEASE", 179, 187], ["low physical activity", "DISEASE", 213, 234], ["a clinical syndrome", "PROBLEM", 43, 62], ["unintentional weight loss", "PROBLEM", 126, 151], ["exhaustion", "PROBLEM", 167, 177], ["weakness", "PROBLEM", 179, 187], ["slow walking speed", "PROBLEM", 189, 207], ["weakness", "OBSERVATION", 179, 187]]], ["Aging and frailty change the clinical presentation of infections, due to alterations in temperature regulation, cognitive decline or malnutrition.", [["Aging", "DISEASE", 0, 5], ["infections", "DISEASE", 54, 64], ["cognitive decline", "DISEASE", 112, 129], ["malnutrition", "DISEASE", 133, 145], ["infections", "PROBLEM", 54, 64], ["alterations in temperature regulation", "PROBLEM", 73, 110], ["cognitive decline", "PROBLEM", 112, 129], ["malnutrition", "PROBLEM", 133, 145], ["infections", "OBSERVATION", 54, 64], ["malnutrition", "OBSERVATION", 133, 145]]], ["Fever may not be detected in older adults and we need to be aware about all the clinical manifestations of COVID-19 for an early identification of frail individuals infected by the SARS-CoV-2 (29, 39) .", [["Fever", "DISEASE", 0, 5], ["SARS", "DISEASE", 181, 185], ["SARS-CoV-2", "ORGANISM", 181, 191], ["SARS-CoV", "SPECIES", 181, 189], ["Fever", "PROBLEM", 0, 5], ["COVID", "TEST", 107, 112], ["frail individuals", "PROBLEM", 147, 164], ["the SARS", "TEST", 177, 185], ["CoV", "TEST", 186, 189], ["may not be", "UNCERTAINTY", 6, 16]]], ["There is evidence that inflammaging and immunosenescence have key roles in the pathophysiology of frailty (40) .SARS-CoV-2 and agingInflammaging is a low-grade persistent increase in inflammatory mediators (41) .", [["frailty", "DISEASE", 98, 105], ["SARS", "DISEASE", 112, 116], ["Inflammaging", "DISEASE", 132, 144], ["inflammatory mediators", "PROTEIN", 183, 205], ["inflammaging", "PROBLEM", 23, 35], ["SARS", "TEST", 112, 116], ["a low-grade persistent increase in inflammatory mediators", "PROBLEM", 148, 205], ["low-grade", "OBSERVATION_MODIFIER", 150, 159], ["persistent", "OBSERVATION_MODIFIER", 160, 170], ["increase", "OBSERVATION_MODIFIER", 171, 179], ["inflammatory", "OBSERVATION_MODIFIER", 183, 195]]], ["During aging, chronic antigenic stress (eg, chronic infection, microbiota translocation) leads to chronic low-grade inflammation, as a mechanism of defense; but the regulation by anti-inflammatory molecules is lacking in some older adults and this chronic inflammation become deleterious (42) .", [["infection", "DISEASE", 52, 61], ["inflammation", "DISEASE", 116, 128], ["inflammation", "DISEASE", 256, 268], ["anti-inflammatory molecules", "PROTEIN", 179, 206], ["chronic antigenic stress (eg", "PROBLEM", 14, 42], ["chronic infection", "PROBLEM", 44, 61], ["microbiota translocation", "PROBLEM", 63, 87], ["chronic low-grade inflammation", "PROBLEM", 98, 128], ["anti-inflammatory molecules", "TREATMENT", 179, 206], ["this chronic inflammation", "PROBLEM", 243, 268], ["chronic", "OBSERVATION_MODIFIER", 14, 21], ["antigenic stress", "OBSERVATION", 22, 38], ["chronic", "OBSERVATION_MODIFIER", 44, 51], ["infection", "OBSERVATION", 52, 61], ["chronic", "OBSERVATION_MODIFIER", 98, 105], ["low-grade", "OBSERVATION_MODIFIER", 106, 115], ["inflammation", "OBSERVATION", 116, 128], ["anti-inflammatory molecules", "OBSERVATION", 179, 206], ["chronic", "OBSERVATION_MODIFIER", 248, 255], ["inflammation", "OBSERVATION", 256, 268]]], ["Senescent cells have a Senescence-Associated-Secretory-Phenotype (SASP) and secrete high levels of inflammatory mediators such as IL-6, IL-1\u03b2, TNF\u03b1 and other molecules (IL-18, IL-8, CCL2, CCL11), growth factors and proteases (41, (43) (44) (45) (46) (47) .", [["cells", "ANATOMY", 10, 15], ["Senescent cells", "CELL", 0, 15], ["IL-6", "GENE_OR_GENE_PRODUCT", 130, 134], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 136, 141], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 143, 147], ["IL-18", "GENE_OR_GENE_PRODUCT", 169, 174], ["IL-8", "GENE_OR_GENE_PRODUCT", 176, 180], ["CCL2", "GENE_OR_GENE_PRODUCT", 182, 186], ["CCL11", "GENE_OR_GENE_PRODUCT", 188, 193], ["Senescent cells", "CELL_TYPE", 0, 15], ["inflammatory mediators", "PROTEIN", 99, 121], ["IL-6", "PROTEIN", 130, 134], ["IL-1\u03b2", "PROTEIN", 136, 141], ["TNF\u03b1", "PROTEIN", 143, 147], ["IL-18", "PROTEIN", 169, 174], ["IL", "PROTEIN", 176, 178], ["CCL2", "PROTEIN", 182, 186], ["CCL11", "PROTEIN", 188, 193], ["growth factors", "PROTEIN", 196, 210], ["proteases", "PROTEIN", 215, 224], ["Senescent cells", "PROBLEM", 0, 15], ["a Senescence", "TEST", 21, 33], ["SASP", "TEST", 66, 70], ["secrete high levels of inflammatory mediators", "PROBLEM", 76, 121], ["IL", "TEST", 130, 132], ["IL", "TEST", 136, 138], ["TNF", "TEST", 143, 146], ["other molecules", "TEST", 152, 167], ["IL", "TEST", 169, 171], ["IL", "TEST", 176, 178], ["CCL2", "TEST", 182, 186], ["CCL11", "TEST", 188, 193], ["growth factors", "TEST", 196, 210], ["proteases", "TEST", 215, 224]]], ["The SASP is a characteristic of senescent cells with arrested cell growth and resistance to apoptosis.", [["cells", "ANATOMY", 42, 47], ["cell", "ANATOMY", 62, 66], ["SASP", "SIMPLE_CHEMICAL", 4, 8], ["cells", "CELL", 42, 47], ["cell", "CELL", 62, 66], ["senescent cells", "CELL_TYPE", 32, 47], ["senescent cells", "PROBLEM", 32, 47], ["arrested cell growth", "PROBLEM", 53, 73], ["apoptosis", "PROBLEM", 92, 101], ["SASP", "OBSERVATION", 4, 8], ["characteristic of", "UNCERTAINTY", 14, 31], ["senescent cells", "OBSERVATION", 32, 47], ["arrested cell growth", "OBSERVATION", 53, 73], ["apoptosis", "OBSERVATION_MODIFIER", 92, 101]]], ["It can also be expressed by CD4+ T cells (SA-T) and senescent CD8+SARS-CoV-2 and agingT cells, associating inflammaging and immunosenescence (48, 49) .SARS-CoV-2 and agingIt is well established that the immune response decreases with aging: reduced production of B and T cells in bone marrow and thymus, diminished function of mature lymphocytes in secondary lymphoid tissues, increase in the number of memory T cells, chronic stimulation (with persistent viral infection by Cytomegalovirus and others), impaired function of B cells, and compromised communication between innate and adaptive immunity (Table 1 ) (50) (51) (52) (53) (54) (55) (56) (57) .", [["CD4+ T cells", "ANATOMY", 28, 40], ["SA-T", "ANATOMY", 42, 46], ["CD8+SARS-CoV-2", "ANATOMY", 62, 76], ["agingT cells", "ANATOMY", 81, 93], ["B", "ANATOMY", 263, 264], ["T cells", "ANATOMY", 269, 276], ["bone marrow", "ANATOMY", 280, 291], ["thymus", "ANATOMY", 296, 302], ["lymphocytes", "ANATOMY", 334, 345], ["lymphoid tissues", "ANATOMY", 359, 375], ["memory T cells", "ANATOMY", 403, 417], ["B cells", "ANATOMY", 525, 532], ["SARS", "DISEASE", 151, 155], ["infection", "DISEASE", 462, 471], ["CD4", "GENE_OR_GENE_PRODUCT", 28, 31], ["SA-T", "GENE_OR_GENE_PRODUCT", 42, 46], ["CD8", "GENE_OR_GENE_PRODUCT", 62, 65], ["agingT cells", "CELL", 81, 93], ["B", "CELL", 263, 264], ["T cells", "CELL", 269, 276], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 280, 291], ["thymus", "ORGAN", 296, 302], ["lymphocytes", "CELL", 334, 345], ["lymphoid tissues", "TISSUE", 359, 375], ["memory T cells", "CELL", 403, 417], ["Cytomegalovirus", "ORGANISM", 475, 490], ["B cells", "CELL", 525, 532], ["CD4", "PROTEIN", 28, 31], ["T cells", "CELL_TYPE", 33, 40], ["senescent CD8+SARS-CoV-2 and agingT cells", "CELL_TYPE", 52, 93], ["B and T cells", "CELL_TYPE", 263, 276], ["mature lymphocytes", "CELL_TYPE", 327, 345], ["memory T cells", "CELL_TYPE", 403, 417], ["B cells", "CELL_TYPE", 525, 532], ["CD4", "TEST", 28, 31], ["SA", "TEST", 42, 44], ["senescent CD8", "TEST", 52, 65], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["agingT cells", "PROBLEM", 81, 93], ["reduced production of B and T cells in bone marrow", "PROBLEM", 241, 291], ["mature lymphocytes", "PROBLEM", 327, 345], ["secondary lymphoid tissues", "PROBLEM", 349, 375], ["memory T cells", "PROBLEM", 403, 417], ["chronic stimulation", "PROBLEM", 419, 438], ["persistent viral infection", "PROBLEM", 445, 471], ["Cytomegalovirus", "PROBLEM", 475, 490], ["impaired function of B cells", "PROBLEM", 504, 532], ["bone marrow", "ANATOMY", 280, 291], ["thymus", "ANATOMY", 296, 302], ["diminished", "OBSERVATION_MODIFIER", 304, 314], ["mature lymphocytes", "OBSERVATION", 327, 345], ["secondary lymphoid tissues", "OBSERVATION", 349, 375], ["increase", "OBSERVATION_MODIFIER", 377, 385], ["memory T cells", "OBSERVATION", 403, 417], ["chronic", "OBSERVATION_MODIFIER", 419, 426], ["persistent", "OBSERVATION_MODIFIER", 445, 455], ["viral", "OBSERVATION_MODIFIER", 456, 461], ["infection", "OBSERVATION", 462, 471], ["B cells", "OBSERVATION", 525, 532]]], ["This series of age-related changes affecting the immune system is called \"immunosenescence\" (45) .", [["immune system", "ANATOMY", 49, 62]]], ["It affects principally the adaptive immune response.", [["immune response", "OBSERVATION", 36, 51]]], ["The consequence of immunosenescence is characterized by an increase in vulnerability, and poor resolution of homeostasis following a stress, that may lead to low resilience and frailty.", [["frailty", "DISEASE", 177, 184], ["immunosenescence", "PROBLEM", 19, 35], ["an increase in vulnerability", "PROBLEM", 56, 84], ["a stress", "PROBLEM", 131, 139], ["low resilience and frailty", "PROBLEM", 158, 184], ["immunosenescence", "OBSERVATION", 19, 35], ["increase", "OBSERVATION_MODIFIER", 59, 67], ["vulnerability", "OBSERVATION_MODIFIER", 71, 84], ["poor resolution", "OBSERVATION_MODIFIER", 90, 105]]], ["Infections in frail adults often lead to large deterioration and functional dependency which does not return to baseline homeostasis (40) .", [["Infections", "DISEASE", 0, 10], ["Infections in frail adults", "PROBLEM", 0, 26], ["large deterioration", "PROBLEM", 41, 60], ["functional dependency", "PROBLEM", 65, 86], ["large", "OBSERVATION_MODIFIER", 41, 46], ["deterioration", "OBSERVATION", 47, 60], ["functional dependency", "OBSERVATION", 65, 86]]], ["The decline immune functions of frail persons may lead to higher SARS-CoV-2 replication and more severe COVID-19.", [["SARS", "DISEASE", 65, 69], ["persons", "ORGANISM", 38, 45], ["persons", "SPECIES", 38, 45], ["frail persons", "PROBLEM", 32, 45], ["higher SARS", "PROBLEM", 58, 69], ["CoV", "TEST", 70, 73], ["more severe COVID", "PROBLEM", 92, 109]]], ["The immunosenescence is also characterized by a delayed type I interferons (IFN) response (56) .", [["type I interferons", "GENE_OR_GENE_PRODUCT", 56, 74], ["IFN", "GENE_OR_GENE_PRODUCT", 76, 79], ["I interferons", "PROTEIN", 61, 74], ["IFN", "PROTEIN", 76, 79], ["a delayed type I interferons (IFN)", "TREATMENT", 46, 80]]], ["Type I interferons (IFNs) are polypeptides secreted by infected cells.", [["cells", "ANATOMY", 64, 69], ["Type I interferons", "GENE_OR_GENE_PRODUCT", 0, 18], ["IFNs", "GENE_OR_GENE_PRODUCT", 20, 24], ["cells", "CELL", 64, 69], ["Type I interferons", "PROTEIN", 0, 18], ["IFNs", "PROTEIN", 20, 24], ["infected cells", "CELL_TYPE", 55, 69], ["Type I interferons (IFNs)", "TREATMENT", 0, 25], ["polypeptides secreted", "PROBLEM", 30, 51], ["infected cells", "PROBLEM", 55, 69], ["infected cells", "OBSERVATION", 55, 69]]], ["They induce an antimicrobial state in infected and neighboring cells to limit the spread of the virus.", [["cells", "ANATOMY", 63, 68], ["cells", "CELL", 63, 68], ["infected and neighboring cells", "CELL_TYPE", 38, 68], ["an antimicrobial state in infected and neighboring cells", "PROBLEM", 12, 68], ["the virus", "PROBLEM", 92, 101], ["antimicrobial state", "OBSERVATION", 15, 34]]], ["IFNs can also modulate innate immune responses in order to promote antigen presentation, natural killer cell functions and to restrain the production of proinflammatory mediators.", [["natural killer cell", "ANATOMY", 89, 108], ["IFNs", "GENE_OR_GENE_PRODUCT", 0, 4], ["natural killer cell", "CELL", 89, 108], ["IFNs", "PROTEIN", 0, 4], ["proinflammatory mediators", "PROTEIN", 153, 178], ["natural killer cell functions", "TREATMENT", 89, 118]]], ["Finally, IFNs activate the adaptive immune system (high-affinity antigen-specific T and B cell responses) (58) .", [["B cell", "ANATOMY", 88, 94], ["IFNs", "GENE_OR_GENE_PRODUCT", 9, 13], ["antigen", "GENE_OR_GENE_PRODUCT", 65, 72], ["T", "CELL", 82, 83], ["B cell", "CELL", 88, 94], ["IFNs", "PROTEIN", 9, 13], ["high-affinity antigen", "PROTEIN", 51, 72], ["affinity antigen", "TEST", 56, 72]]], ["The lack of type I IFN response in frail older adults leads to a low adaptive immune response (56) .", [["type I IFN", "GENE_OR_GENE_PRODUCT", 12, 22], ["IFN", "PROTEIN", 19, 22], ["type I IFN response", "PROBLEM", 12, 31]]], ["SARS-CoV-2 is a virus sensitive to type I IFN; however, it is also able to limit type I IFN induction (25, 29) .", [["SARS", "DISEASE", 0, 4], ["SARS-CoV-2", "ORGANISM", 0, 10], ["type I IFN", "GENE_OR_GENE_PRODUCT", 35, 45], ["type I IFN", "GENE_OR_GENE_PRODUCT", 81, 91], ["type I IFN", "PROTEIN", 35, 45], ["IFN", "PROTEIN", 88, 91], ["SARS-CoV", "SPECIES", 0, 8], ["a virus", "PROBLEM", 14, 21], ["type I IFN", "PROBLEM", 35, 45], ["type I IFN induction", "TREATMENT", 81, 101]]], ["With this function, the virus could escape from the human immune response.", [["human", "ORGANISM", 52, 57], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["the virus", "PROBLEM", 20, 29]]], ["Thus, the IFN-I response is limited by the immunosenescence in the host, as well as by the virus itself; explaining why frail patients could be more affected by the COVID-19 (Table 1) .", [["IFN-I", "GENE_OR_GENE_PRODUCT", 10, 15], ["patients", "ORGANISM", 126, 134], ["IFN", "PROTEIN", 10, 13], ["patients", "SPECIES", 126, 134], ["the COVID", "TEST", 161, 170]]], ["Moreover, lymphopenia during COVID-19 infection correlates with clinical severity, and occurs in 80% of critically ill patients (59) .", [["lymphopenia", "DISEASE", 10, 21], ["COVID-19", "CHEMICAL", 29, 37], ["infection", "DISEASE", 38, 47], ["critically ill", "DISEASE", 104, 118], ["COVID-19", "ORGANISM", 29, 37], ["patients", "ORGANISM", 119, 127], ["patients", "SPECIES", 119, 127], ["COVID-19", "SPECIES", 29, 37], ["lymphopenia", "PROBLEM", 10, 21], ["COVID", "TEST", 29, 34], ["infection", "PROBLEM", 38, 47], ["clinical severity", "PROBLEM", 64, 81], ["lymphopenia", "OBSERVATION", 10, 21], ["infection", "OBSERVATION", 38, 47]]], ["A recent study from Wang et al., showed that similar to MERS-CoV, the SARS-CoV-2 can infect T cells but failed to replicate in T lymphocytes (60) .", [["T cells", "ANATOMY", 92, 99], ["T lymphocytes", "ANATOMY", 127, 140], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 56, 64], ["SARS-CoV-2", "ORGANISM", 70, 80], ["T cells", "CELL", 92, 99], ["T lymphocytes", "CELL", 127, 140], ["T cells", "CELL_TYPE", 92, 99], ["T lymphocytes", "CELL_TYPE", 127, 140], ["MERS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 70, 78], ["A recent study", "TEST", 0, 14], ["the SARS", "TEST", 66, 74], ["T cells", "PROBLEM", 92, 99]]], ["If the SARS-CoV-2 could induces the apoptosis of T cells as the MERS-CoV-2, this could have a significant negative impact on frail older people with already reduced T cell production (61) .SARS-CoV-2 and agingTaken together, inflammaging and immunosenescence, observed in frail adults, can results in a decrease of the immune system ability to fight new challenges (as SARS-CoV-2 infection).", [["T cells", "ANATOMY", 49, 56], ["T cell", "ANATOMY", 165, 171], ["SARS", "DISEASE", 7, 11], ["SARS", "DISEASE", 189, 193], ["SARS-CoV-2 infection", "DISEASE", 369, 389], ["SARS-CoV-2", "ORGANISM", 7, 17], ["T cells", "CELL", 49, 56], ["MERS-CoV-2", "ORGANISM", 64, 74], ["people", "ORGANISM", 137, 143], ["T cell", "CELL", 165, 171], ["SARS-CoV-2", "ORGANISM", 369, 379], ["T cells", "CELL_TYPE", 49, 56], ["people", "SPECIES", 137, 143], ["the SARS", "TEST", 3, 11], ["the apoptosis of T cells", "PROBLEM", 32, 56], ["already reduced T cell production", "PROBLEM", 149, 182], ["a decrease of the immune system", "PROBLEM", 301, 332], ["SARS-CoV-2 infection", "PROBLEM", 369, 389], ["significant", "OBSERVATION_MODIFIER", 94, 105], ["negative", "OBSERVATION", 106, 114], ["cell production", "OBSERVATION", 167, 182]]], ["On the other hand, the SARS-CoV-2 may accentuate this immune decline, by its capacity of limiting type I IFN response and maybe infecting T cells.", [["T cells", "ANATOMY", 138, 145], ["SARS", "DISEASE", 23, 27], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 23, 33], ["type I IFN", "GENE_OR_GENE_PRODUCT", 98, 108], ["T cells", "CELL", 138, 145], ["IFN", "PROTEIN", 105, 108], ["T cells", "CELL_TYPE", 138, 145], ["the SARS", "TEST", 19, 27], ["this immune decline", "PROBLEM", 49, 68], ["type I IFN response", "PROBLEM", 98, 117], ["infecting T cells", "PROBLEM", 128, 145], ["maybe", "UNCERTAINTY", 122, 127], ["infecting T cells", "OBSERVATION", 128, 145]]], ["All of this could result in an unstopped SARS-CoV-2 infection and leads to COVID-19 complications in frail older adults.Geroscience: a global approach to treat and prevent COVID-19 or future pandemicAs of May 2020, there are no specific therapies approved for COVID-19 treatment.", [["SARS-CoV-2 infection", "DISEASE", 41, 61], ["COVID-19", "CHEMICAL", 260, 268], ["COVID-19", "CHEMICAL", 260, 268], ["COVID-19", "SIMPLE_CHEMICAL", 260, 268], ["an unstopped SARS", "PROBLEM", 28, 45], ["CoV-2 infection", "PROBLEM", 46, 61], ["a global approach", "TREATMENT", 133, 150], ["COVID", "TEST", 172, 177], ["specific therapies", "TREATMENT", 228, 246], ["COVID-19 treatment", "TREATMENT", 260, 278], ["infection", "OBSERVATION", 52, 61]]], ["One strategy is to use drugs that are already approved and known to work at different stages of viral infection and against the immune response.", [["viral infection", "DISEASE", 96, 111], ["drugs", "TREATMENT", 23, 28], ["viral infection", "PROBLEM", 96, 111], ["viral infection", "OBSERVATION", 96, 111]]], ["The use of these drugs fast-tracks a treatment plan in a global pandemic situation.", [["these drugs", "TREATMENT", 11, 22], ["a treatment plan", "TREATMENT", 35, 51]]], ["Two therapeutic strategies can be distinguished: agents that can target the virus, and agents that protect the host.", [["Two therapeutic strategies", "TREATMENT", 0, 26], ["agents", "TREATMENT", 49, 55], ["the virus", "PROBLEM", 72, 81], ["agents", "TREATMENT", 87, 93]]], ["In the former category, trials are focused on drugs that limit entry or replication (eg, Remdesivir, Lopinavir/Ritonavir, Hydroxychloroquine, IFN\u03b1, IFN\u03b2) (62) .", [["Lopinavir", "CHEMICAL", 101, 110], ["Ritonavir", "CHEMICAL", 111, 120], ["Hydroxychloroquine", "CHEMICAL", 122, 140], ["Remdesivir", "CHEMICAL", 89, 99], ["Lopinavir", "CHEMICAL", 101, 110], ["Ritonavir", "CHEMICAL", 111, 120], ["Hydroxychloroquine", "CHEMICAL", 122, 140], ["IFN\u03b1", "CHEMICAL", 142, 146], ["Lopinavir", "SIMPLE_CHEMICAL", 101, 110], ["Ritonavir", "SIMPLE_CHEMICAL", 111, 120], ["Hydroxychloroquine", "SIMPLE_CHEMICAL", 122, 140], ["IFN\u03b1", "SIMPLE_CHEMICAL", 142, 146], ["IFN\u03b2", "GENE_OR_GENE_PRODUCT", 148, 152], ["drugs", "TREATMENT", 46, 51], ["replication (eg", "TREATMENT", 72, 87], ["Remdesivir", "TREATMENT", 89, 99], ["Lopinavir", "TREATMENT", 101, 110], ["Ritonavir", "TREATMENT", 111, 120], ["Hydroxychloroquine", "TREATMENT", 122, 140]]], ["For the latter, the focus is on drugs that can limit the human inflammatory response (eg, corticosteroids, Tocilizumab which is an anti-IL-6R) or boost the innate antiviral immune response (BCG vaccine, type I IFN) (63) .Geroscience: a global approach to treat and prevent COVID-19 or future pandemicThe approaches boosting innate antiviral immune response are more interesting for older persons with a weakened immune system, but the risk is to introduce the drugs too late in the infection process.", [["immune system", "ANATOMY", 412, 425], ["Tocilizumab", "CHEMICAL", 107, 118], ["COVID", "DISEASE", 273, 278], ["infection", "DISEASE", 482, 491], ["corticosteroids", "CHEMICAL", 90, 105], ["Tocilizumab", "CHEMICAL", 107, 118], ["human", "ORGANISM", 57, 62], ["corticosteroids", "SIMPLE_CHEMICAL", 90, 105], ["Tocilizumab", "SIMPLE_CHEMICAL", 107, 118], ["anti-IL-6R", "GENE_OR_GENE_PRODUCT", 131, 141], ["type I IFN", "GENE_OR_GENE_PRODUCT", 203, 213], ["persons", "ORGANISM", 388, 395], ["immune system", "ANATOMICAL_SYSTEM", 412, 425], ["type I IFN", "PROTEIN", 203, 213], ["human", "SPECIES", 57, 62], ["persons", "SPECIES", 388, 395], ["human", "SPECIES", 57, 62], ["drugs", "TREATMENT", 32, 37], ["the human inflammatory response (eg", "TREATMENT", 53, 88], ["corticosteroids", "TREATMENT", 90, 105], ["Tocilizumab", "TREATMENT", 107, 118], ["an anti-IL-6R)", "TREATMENT", 128, 142], ["the innate antiviral immune response (BCG vaccine", "TREATMENT", 152, 201], ["a global approach", "TREATMENT", 234, 251], ["COVID", "TEST", 273, 278], ["a weakened immune system", "PROBLEM", 401, 425], ["the drugs", "TREATMENT", 456, 465], ["the infection process", "PROBLEM", 478, 499], ["infection", "OBSERVATION", 482, 491]]], ["Identifying people at-risk for COVID-19 is necessary to put in place effective and personalized preventive measures.", [["people", "ORGANISM", 12, 18], ["people", "SPECIES", 12, 18], ["COVID", "TEST", 31, 36], ["personalized preventive measures", "TREATMENT", 83, 115]]], ["To identify at-risk people, it would be interesting to determine their \"immune-age\" or \"biological age\" (64) rather than relying only on chronological age.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26]]], ["It will ensure a personalized therapeutic care, with benefits against SARS-CoV-2 infection.", [["SARS-CoV-2 infection", "DISEASE", 70, 90], ["SARS-CoV-2", "ORGANISM", 70, 80], ["SARS-CoV", "SPECIES", 70, 78], ["a personalized therapeutic care", "TREATMENT", 15, 46], ["SARS", "PROBLEM", 70, 74], ["CoV-2 infection", "PROBLEM", 75, 90], ["infection", "OBSERVATION", 81, 90]]], ["In a more global perspective, geroscience should be associated to COVID-19 prevention and treatment (64, 65) .", [["COVID", "TEST", 66, 71], ["treatment", "TREATMENT", 90, 99]]], ["Geroscience seeks to understand all biological mechanisms (genetic, molecular, and cellular) that make aging a major risk factor of chronic diseases of older adults.", [["cellular", "ANATOMY", 83, 91], ["chronic diseases", "DISEASE", 132, 148], ["cellular", "CELL", 83, 91], ["chronic diseases", "PROBLEM", 132, 148], ["chronic", "OBSERVATION_MODIFIER", 132, 139], ["diseases", "OBSERVATION", 140, 148]]], ["The aim is to target the aging process as the single most important risk factor instead of treating just the infection.", [["infection", "DISEASE", 109, 118], ["the infection", "PROBLEM", 105, 118], ["infection", "OBSERVATION", 109, 118]]], ["Treatments that target the molecular pathways of aging could decrease the development and severity of age-related disease, and more globally comorbidities.", [["Treatments", "TREATMENT", 0, 10], ["related disease", "PROBLEM", 106, 121]]], ["Among these agents, senolytics can selectively induce death of senescent cells, limiting the accumulation of SASP.", [["cells", "ANATOMY", 73, 78], ["death", "DISEASE", 54, 59], ["SASP", "CHEMICAL", 109, 113], ["senolytics", "SIMPLE_CHEMICAL", 20, 30], ["cells", "CELL", 73, 78], ["SASP", "SIMPLE_CHEMICAL", 109, 113], ["senescent cells", "CELL_TYPE", 63, 78], ["senolytics", "TREATMENT", 20, 30], ["senescent cells", "PROBLEM", 63, 78], ["SASP", "PROBLEM", 109, 113], ["senescent cells", "OBSERVATION", 63, 78], ["accumulation", "OBSERVATION_MODIFIER", 93, 105], ["SASP", "OBSERVATION", 109, 113]]], ["Senolytic drugs (eg, quercetin, dasatinib, ruxolitinib) might have a beneficial effect for the prevention or the treatment of SARS-CoV-2 infection by attenuating the cytokine storm and reducing immunosenescence (67, 68) . mTor inhibitors (eg, rapamycin, RTB101, everolimus) are approved for use in humans and are known to delay age-related diseases Circle of aging and SARS-CoV-2 infection With age, the immune system declines leading to frailty, comorbidities and high susceptibility to infections.", [["immune system", "ANATOMY", 404, 417], ["quercetin", "CHEMICAL", 21, 30], ["dasatinib", "CHEMICAL", 32, 41], ["ruxolitinib", "CHEMICAL", 43, 54], ["SARS", "DISEASE", 126, 130], ["infection", "DISEASE", 137, 146], ["rapamycin", "CHEMICAL", 243, 252], ["RTB101", "CHEMICAL", 254, 260], ["everolimus", "CHEMICAL", 262, 272], ["SARS", "DISEASE", 369, 373], ["infection", "DISEASE", 380, 389], ["frailty", "DISEASE", 438, 445], ["infections", "DISEASE", 488, 498], ["quercetin", "CHEMICAL", 21, 30], ["dasatinib", "CHEMICAL", 32, 41], ["ruxolitinib", "CHEMICAL", 43, 54], ["rapamycin", "CHEMICAL", 243, 252], ["RTB101", "CHEMICAL", 254, 260], ["everolimus", "CHEMICAL", 262, 272], ["quercetin", "SIMPLE_CHEMICAL", 21, 30], ["dasatinib", "SIMPLE_CHEMICAL", 32, 41], ["ruxolitinib", "SIMPLE_CHEMICAL", 43, 54], ["SARS-CoV-2", "ORGANISM", 126, 136], ["rapamycin", "SIMPLE_CHEMICAL", 243, 252], ["RTB101", "SIMPLE_CHEMICAL", 254, 260], ["everolimus", "SIMPLE_CHEMICAL", 262, 272], ["humans", "ORGANISM", 298, 304], ["SARS-CoV-2", "ORGANISM", 369, 379], ["cytokine", "PROTEIN", 166, 174], ["humans", "SPECIES", 298, 304], ["SARS-CoV-2", "SPECIES", 126, 136], ["humans", "SPECIES", 298, 304], ["SARS-CoV", "SPECIES", 369, 377], ["Senolytic drugs", "TREATMENT", 0, 15], ["quercetin", "TREATMENT", 21, 30], ["dasatinib", "TREATMENT", 32, 41], ["ruxolitinib", "TREATMENT", 43, 54], ["SARS", "PROBLEM", 126, 130], ["CoV", "PROBLEM", 131, 134], ["2 infection", "PROBLEM", 135, 146], ["attenuating the cytokine storm", "TREATMENT", 150, 180], ["mTor inhibitors (eg", "TREATMENT", 222, 241], ["rapamycin", "TREATMENT", 243, 252], ["RTB101", "TREATMENT", 254, 260], ["everolimus", "TREATMENT", 262, 272], ["SARS", "PROBLEM", 369, 373], ["CoV-2 infection", "PROBLEM", 374, 389], ["the immune system", "PROBLEM", 400, 417], ["comorbidities", "PROBLEM", 447, 460], ["high susceptibility to infections", "PROBLEM", 465, 498], ["infections", "OBSERVATION", 488, 498]]], ["This immune decline can be a predisposing condition sustaining COVID-19 serious complications and explaining high mortality rates in older people with COVID-19.", [["people", "ORGANISM", 139, 145], ["people", "SPECIES", 139, 145], ["This immune decline", "PROBLEM", 0, 19], ["a predisposing condition", "PROBLEM", 27, 51], ["serious complications", "PROBLEM", 72, 93], ["high mortality rates", "PROBLEM", 109, 129], ["COVID", "TEST", 151, 156]]], ["We hypothesize that COVID-19 can be a future cause of accelerated aging and frailty in multiple animal models (69) .", [["COVID-19", "CHEMICAL", 20, 28], ["frailty", "DISEASE", 76, 83], ["COVID-19", "GENE_OR_GENE_PRODUCT", 20, 28], ["accelerated aging and frailty", "PROBLEM", 54, 83]]], ["A limited number of clinical trials with these drugs are currently being conducted to evaluate their effectiveness against COVID-19 (Table 2 ) (70) .", [["COVID-19", "CHEMICAL", 123, 131], ["these drugs", "TREATMENT", 41, 52], ["COVID", "TEST", 123, 128]]], ["Comorbidities such as hypertension, coronary heart disease or type 2 diabetes are additional risk factors for COVID-19 pathology and complications (71) .", [["coronary", "ANATOMY", 36, 44], ["heart", "ANATOMY", 45, 50], ["hypertension", "DISEASE", 22, 34], ["coronary heart disease", "DISEASE", 36, 58], ["type 2 diabetes", "DISEASE", 62, 77], ["COVID", "DISEASE", 110, 115], ["heart", "ORGAN", 45, 50], ["Comorbidities", "PROBLEM", 0, 13], ["hypertension", "PROBLEM", 22, 34], ["coronary heart disease", "PROBLEM", 36, 58], ["type 2 diabetes", "PROBLEM", 62, 77], ["additional risk factors", "PROBLEM", 82, 105], ["COVID", "TEST", 110, 115], ["complications", "PROBLEM", 133, 146], ["hypertension", "OBSERVATION", 22, 34], ["coronary heart", "ANATOMY", 36, 50], ["disease", "OBSERVATION", 51, 58], ["diabetes", "OBSERVATION", 69, 77]]], ["These comorbidities are also considered to be aging-associated diseases.", [["These comorbidities", "PROBLEM", 0, 19], ["associated diseases", "PROBLEM", 52, 71], ["comorbidities", "OBSERVATION", 6, 19], ["diseases", "OBSERVATION", 63, 71]]], ["Current geroscience research aims at determining biological age and could help in the future to determine which older adults are most at risk for complication when infected by SARS-CoV-2.", [["SARS", "DISEASE", 176, 180], ["adults", "ORGANISM", 118, 124], ["SARS-CoV-2", "ORGANISM", 176, 186], ["SARS-CoV", "SPECIES", 176, 184], ["complication", "PROBLEM", 146, 158], ["CoV", "TEST", 181, 184]]], ["This approach is not specific to COVID-19, and it could be a benefic prevention to protect older adults against future epidemics.Geroscience: a global approach to treat and prevent COVID-19 or future pandemicThe potential long-term effects of COVID-19 are still unclear.", [["COVID", "DISEASE", 181, 186], ["COVID-19", "CHEMICAL", 243, 251], ["COVID-19", "CHEMICAL", 243, 251], ["COVID-19", "GENE_OR_GENE_PRODUCT", 243, 251], ["COVID", "TEST", 33, 38], ["a benefic prevention", "TREATMENT", 59, 79], ["a global approach", "TREATMENT", 142, 159], ["COVID", "TEST", 181, 186], ["COVID", "TREATMENT", 243, 248], ["long-term effects", "OBSERVATION_MODIFIER", 222, 239]]], ["This infection could be a future cause of accelerated aging and frailty.", [["infection", "DISEASE", 5, 14], ["frailty", "DISEASE", 64, 71], ["This infection", "PROBLEM", 0, 14], ["accelerated aging and frailty", "PROBLEM", 42, 71], ["infection", "OBSERVATION", 5, 14]]], ["Using geroscience approaches will help to identify this risk.Conclusions and PerspectiveIn summary, SARS-CoV-2 is an emerging highly transmissible coronavirus that causes high mortality in the aging population (6, 7, 72, 73) .", [["coronavirus", "DISEASE", 147, 158], ["SARS-CoV-2", "ORGANISM", 100, 110], ["coronavirus", "ORGANISM", 147, 158], ["SARS-CoV-2", "SPECIES", 100, 110], ["transmissible coronavirus", "SPECIES", 133, 158], ["geroscience approaches", "TREATMENT", 6, 28], ["SARS", "TEST", 100, 104], ["CoV", "TEST", 105, 108], ["an emerging highly transmissible coronavirus", "PROBLEM", 114, 158], ["high mortality", "PROBLEM", 171, 185], ["transmissible coronavirus", "OBSERVATION", 133, 158], ["high", "OBSERVATION_MODIFIER", 171, 175], ["mortality", "OBSERVATION_MODIFIER", 176, 185]]], ["The aging population is heterogeneous but most have comorbidities.", [["comorbidities", "PROBLEM", 52, 65], ["population", "OBSERVATION", 10, 20], ["heterogeneous", "OBSERVATION_MODIFIER", 24, 37]]], ["These comorbidities (eg, hypertension, cardiovascular diseases, obesity, diabetes) are correlated with COVID-19 serious complications (4) .Conclusions and PerspectiveThe SARS-CoV-2 virus infects human cells by a recognition between the viral spike protein and the human ACE2 receptor (13) .", [["cardiovascular", "ANATOMY", 39, 53], ["cells", "ANATOMY", 201, 206], ["hypertension", "DISEASE", 25, 37], ["cardiovascular diseases", "DISEASE", 39, 62], ["obesity", "DISEASE", 64, 71], ["diabetes", "DISEASE", 73, 81], ["cardiovascular", "ANATOMICAL_SYSTEM", 39, 53], ["SARS-CoV-2 virus", "ORGANISM", 170, 186], ["human", "ORGANISM", 195, 200], ["cells", "CELL", 201, 206], ["human", "ORGANISM", 264, 269], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 270, 283], ["human cells", "CELL_TYPE", 195, 206], ["viral spike protein", "PROTEIN", 236, 255], ["human ACE2 receptor", "PROTEIN", 264, 283], ["CoV-2 virus", "SPECIES", 175, 186], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 264, 269], ["SARS-CoV-2 virus", "SPECIES", 170, 186], ["human", "SPECIES", 195, 200], ["human", "SPECIES", 264, 269], ["These comorbidities (eg", "PROBLEM", 0, 23], ["hypertension", "PROBLEM", 25, 37], ["cardiovascular diseases", "PROBLEM", 39, 62], ["obesity", "PROBLEM", 64, 71], ["diabetes", "PROBLEM", 73, 81], ["serious complications", "PROBLEM", 112, 133], ["Conclusions", "TEST", 139, 150], ["The SARS", "TEST", 166, 174], ["CoV", "TEST", 175, 178], ["the viral spike protein", "TEST", 232, 255], ["the human ACE2 receptor", "TREATMENT", 260, 283], ["comorbidities", "OBSERVATION", 6, 19], ["hypertension", "OBSERVATION", 25, 37], ["cardiovascular", "ANATOMY", 39, 53], ["diseases", "OBSERVATION", 54, 62], ["obesity", "OBSERVATION", 64, 71], ["viral spike", "OBSERVATION", 236, 247]]], ["The increase of the ACE2 receptor expression with age is still debated; but the peak viral load seems correlated with age (35) .Conclusions and PerspectiveDuring aging, immunosenescence and inflammaging are suggested to stand at the origin of frailty and diseases in older individuals (43) .", [["inflammaging", "DISEASE", 190, 202], ["frailty", "DISEASE", 243, 250], ["ACE2 receptor", "GENE_OR_GENE_PRODUCT", 20, 33], ["ACE2", "PROTEIN", 20, 24], ["the peak viral load", "TEST", 76, 95], ["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["The inflammaging results of a chronic inflammation, with low-grade production of inflammatory mediators; and the immunosenescence is characterized by a loss in adaptive immune functions that reinforces the need to find treatments that stimulate the innate immune response to protect the organism from infection (42) .", [["inflammation", "DISEASE", 38, 50], ["infection", "DISEASE", 301, 310], ["inflammatory mediators", "PROTEIN", 81, 103], ["a chronic inflammation", "PROBLEM", 28, 50], ["low-grade production of inflammatory mediators", "PROBLEM", 57, 103], ["a loss in adaptive immune functions", "PROBLEM", 150, 185], ["treatments", "TREATMENT", 219, 229], ["the organism", "PROBLEM", 283, 295], ["infection", "PROBLEM", 301, 310], ["chronic", "OBSERVATION_MODIFIER", 30, 37], ["inflammation", "OBSERVATION", 38, 50], ["low-grade", "OBSERVATION_MODIFIER", 57, 66], ["production", "OBSERVATION_MODIFIER", 67, 77], ["inflammatory mediators", "OBSERVATION", 81, 103], ["infection", "OBSERVATION", 301, 310]]], ["Immunosenescence and inflammaging occurring in some older adults, could be predisposing conditions that sustain the mechanisms by which the SARS-CoV-2 escape the immune surveillance and leads to serious COVID-19 ( Figure 1) .Conclusions and PerspectiveThe effect of aging on the immune system is not uniform among individuals.", [["immune system", "ANATOMY", 279, 292], ["Immunosenescence", "DISEASE", 0, 16], ["inflammaging", "DISEASE", 21, 33], ["SARS", "DISEASE", 140, 144], ["SARS-CoV-2", "ORGANISM", 140, 150], ["Immunosenescence", "PROBLEM", 0, 16], ["inflammaging", "PROBLEM", 21, 33], ["predisposing conditions", "PROBLEM", 75, 98], ["the SARS", "TEST", 136, 144], ["CoV", "TEST", 145, 148], ["the immune surveillance", "TEST", 158, 181], ["serious COVID", "TEST", 195, 208], ["aging on the immune system", "PROBLEM", 266, 292]]], ["Now that countries are striking down stay-at-home orders, an ultimate goal would be to identify at-risk older people through their aging profile and develop a personalized approach to limit COVID-19 complications.", [["people", "ORGANISM", 110, 116], ["people", "SPECIES", 110, 116], ["a personalized approach", "TREATMENT", 157, 180], ["complications", "PROBLEM", 199, 212]]], ["We propose to use geroscience approaches to identify at-risk people (74) , develop drugs targeting molecular pathway of aging, and prevent COVID-19 serious complications (66, 75) .", [["COVID", "DISEASE", 139, 144], ["people", "ORGANISM", 61, 67], ["people", "SPECIES", 61, 67], ["geroscience approaches", "TREATMENT", 18, 40], ["drugs", "TREATMENT", 83, 88], ["serious complications", "PROBLEM", 148, 169]]]], "76f6aea613271a480dfda7643b1c74bdcdc269f4": [["IntroductionThe health emergency is the first challenge each country is facing in the fight to SARS-CoV-2.", [["SARS", "DISEASE", 95, 99], ["SARS-CoV", "SPECIES", 95, 103]]], ["The next challenge, even more critical, is the safe reactivation of the production processes to prevent economic and social crises.", [["economic and social crises", "DISEASE", 104, 130], ["the production processes", "TREATMENT", 68, 92], ["economic and social crises", "PROBLEM", 104, 130]]], ["Although the specialists agree that the study of a vaccine will have success, its distribution to the whole population will require more than one year, thus forcing a long coexistence with the virus.", [["the study", "TEST", 36, 45], ["a vaccine", "TREATMENT", 49, 58], ["the virus", "PROBLEM", 189, 198]]], ["During this time, it will be crucial to understand how the infection is spreading across the population and take the best countermeasures to contain it without further lockdowns.", [["infection", "DISEASE", 59, 68], ["the infection", "PROBLEM", 55, 68], ["further lockdowns", "TREATMENT", 160, 177], ["infection", "OBSERVATION", 59, 68]]], ["An effective tool to partially analyse the current virus spread situations and identify the presence of infected individuals is the use of swabs, which have been used extensively.", [["An effective tool", "PROBLEM", 0, 17], ["infected individuals", "PROBLEM", 104, 124], ["swabs", "TREATMENT", 139, 144], ["infected", "OBSERVATION", 104, 112]]], ["Nonetheless, the limited availability and the time required to test a large number of subjects makes them only a partial answer to the reconstruction of the disease transmission among the population.", [["the reconstruction", "TREATMENT", 131, 149], ["the disease transmission", "PROBLEM", 153, 177], ["large", "OBSERVATION_MODIFIER", 70, 75], ["disease", "OBSERVATION", 157, 164]]], ["The scientific community agrees that contact-tracing applications could provide micro-scale data useful to contain the infection by driving the choice of the daily swab selection process.", [["infection", "DISEASE", 119, 128], ["micro-scale data", "TEST", 80, 96], ["the infection", "PROBLEM", 115, 128], ["the daily swab selection process", "TREATMENT", 154, 186], ["infection", "OBSERVATION", 119, 128]]], ["These applications can generate millions of punctual data that are combined with the clinical data available to ATS to reconstruct infection chains and networks, so as to identify potentially infected people.", [["infection", "DISEASE", 131, 140], ["people", "ORGANISM", 201, 207], ["people", "SPECIES", 201, 207], ["punctual data", "TEST", 44, 57], ["the clinical data", "TEST", 81, 98], ["infected", "OBSERVATION", 192, 200]]], ["1 At the moment, only direct contacts with the proven positive subjects are tested for SARS-CoV-2, while a more accurate analysis can suggest testing those subjects which have a high probability of being infected but only had indirect contact with the positive one.", [["SARS-CoV", "SPECIES", 87, 95], ["SARS", "PROBLEM", 87, 91], ["infected", "OBSERVATION", 204, 212]]], ["However, dealing with millions of data is unaffordable for humans and, therefore, Artificial Intelligence (AI) techniques are commonly considered the most promising technology for such tasks.", [["humans", "ORGANISM", 59, 65], ["humans", "SPECIES", 59, 65], ["humans", "SPECIES", 59, 65], ["Artificial Intelligence (AI) techniques", "TREATMENT", 82, 121]]], ["Indeed, AI is capable of producing predictive models from data and reasoning on them to suggest where and when to use swabs to test for infected people.", [["people", "ORGANISM", 145, 151], ["people", "SPECIES", 145, 151], ["swabs", "TEST", 118, 123]]], ["More importantly, their applicability is limited by the severe European privacy regulation that requires the information on the individuals to only reside on their personal devices in an anonymized fashion.", [["the severe European privacy regulation", "PROBLEM", 52, 90], ["severe", "OBSERVATION_MODIFIER", 56, 62]]], ["As a result, most of the current research regarding the spread of the SARS-CoV-2 is focused on the analysis of the behaviour of the disease by using epidemic models with or without the countermeasures used by the different nations.", [["SARS", "DISEASE", 70, 74], ["the analysis", "TEST", 95, 107], ["the disease", "PROBLEM", 128, 139], ["the countermeasures", "TREATMENT", 181, 200], ["disease", "OBSERVATION", 132, 139]]], ["Conversely, to the best of our knowledge, few works study decisional methods, leading the individuals' choice to be tested during the daily tests for SARS-CoV-2.IntroductionOriginal contributions.", [["SARS", "DISEASE", 150, 154], ["SARS-CoV", "SPECIES", 150, 158], ["the daily tests", "TEST", 130, 145], ["SARS", "PROBLEM", 150, 154]]], ["In this work, we present an AI-based algorithm, namely PPTO, capable, in a distributed fashion as to avoid the violation of the privacy regulation, of identifying two classes of people whose roles are prominent in the infection: asymptomatic and presymptomatic subjects.", [["infection", "DISEASE", 218, 227], ["people", "ORGANISM", 178, 184], ["people", "SPECIES", 178, 184], ["PPTO", "TEST", 55, 59], ["the infection", "PROBLEM", 214, 227], ["asymptomatic", "PROBLEM", 229, 241], ["presymptomatic subjects", "PROBLEM", 246, 269], ["prominent", "OBSERVATION_MODIFIER", 201, 210], ["infection", "OBSERVATION", 218, 227], ["asymptomatic", "OBSERVATION_MODIFIER", 229, 241]]], ["The former ones are an important fraction of the infected people, and their identification is difficult, while the latter can transmit it with high probability.", [["people", "ORGANISM", 58, 64], ["people", "SPECIES", 58, 64], ["infected", "OBSERVATION", 49, 57]]], ["Our algorithm exploits a recently developed micro-scale epidemic model Ferretti et al. (2020) to reconstruct the infection chains from tracing app data and ranks the individuals according to the likelihood of being infected, so that the limited amount of daily tests available to the healthcare authorities can be used effectively.", [["infection", "DISEASE", 113, 122], ["the infection chains", "PROBLEM", 109, 129], ["tracing app data", "TEST", 135, 151], ["daily tests", "TEST", 255, 266], ["infection", "OBSERVATION", 113, 122], ["infected", "OBSERVATION", 215, 223]]], ["Furthermore, we evaluate the algorithm in a synthetic setting.Related WorksA large effort has been put in the modeling of the disease with predictive models depending on the different areas of diffusion of the virus, e.g., Girardi et al. (2020) and Gaeta (2020) for Italy, Toubiana and Bouaud (2020) for France, and Chen et al. (2020) for China.", [["the algorithm", "TEST", 25, 38], ["WorksA large effort", "PROBLEM", 70, 89], ["the disease", "PROBLEM", 122, 133], ["predictive models", "PROBLEM", 139, 156], ["the virus", "PROBLEM", 206, 215], ["large", "OBSERVATION_MODIFIER", 77, 82], ["effort", "OBSERVATION", 83, 89], ["disease", "OBSERVATION", 126, 133]]], ["We mention other interesting works: Li et al. (2020) study the evolution over time of the virus behaviour, Hsiang et al. (2020) and Liu et al. (2020) analyse the effect of different contagion containment countermeasures, and Peak et al. (2020) analyse the monitor monitoring strategies.", [["the monitor monitoring strategies", "TREATMENT", 252, 285]]], ["Staszkiewicz et al. (2020) provide a broader study to identify the main factors influencing the virus spread over the different countries, showing that the spread and mortality are determined by the number of connections among the continent (e.g., the airline traffic) and by some local characteristics of the country (e.g., the availability of medical personnel and the average air pollution).", [["a broader study", "TEST", 35, 50], ["the virus spread", "PROBLEM", 92, 108], ["the average air pollution", "TREATMENT", 367, 392], ["virus", "OBSERVATION", 96, 101], ["spread", "OBSERVATION_MODIFIER", 156, 162]]], ["The aforementioned studies are mainly based on data regarding the number of infected individuals and on mathematical epidemic models describing the macro evolution a generic disease.", [["The aforementioned studies", "TEST", 0, 26], ["infected individuals", "PROBLEM", 76, 96], ["mathematical epidemic models", "PROBLEM", 104, 132], ["a generic disease", "PROBLEM", 164, 181], ["infected", "OBSERVATION", 76, 84], ["generic disease", "OBSERVATION", 166, 181]]], ["These epidemic models provide a macro-scale description of the spread, which allows to forecast the hospitals' load during the lockdown, but are partially ineffective to prevent a new lockdown.", [["a macro-scale description", "TEST", 30, 55], ["a new lockdown", "PROBLEM", 178, 192], ["new", "OBSERVATION_MODIFIER", 180, 183]]], ["Moreover, they do not take into account explicitly the data on the contacts between individuals, which are the main cause of the disease spread for the SARS-CoV-2 virus.Related WorksPrasse et al. study the evolution of the disease over the network, using a large-scale approximation of the contacts, in which every city is represented as a node of a graph.", [["SARS", "DISEASE", 152, 156], ["SARS-CoV-2 virus", "ORGANISM", 152, 168], ["CoV-2 virus", "SPECIES", 157, 168], ["SARS-CoV-2 virus", "SPECIES", 152, 168], ["the disease spread", "PROBLEM", 125, 143], ["the SARS", "PROBLEM", 148, 156], ["CoV", "TEST", 157, 160], ["the disease", "PROBLEM", 219, 230], ["a large-scale approximation", "TREATMENT", 255, 282], ["disease", "OBSERVATION", 129, 136], ["disease", "OBSERVATION", 223, 230], ["large", "OBSERVATION_MODIFIER", 257, 262], ["node", "OBSERVATION", 340, 344]]], ["This way we might take decision on a macro-scale, i.e., how many test distribute in the different areas, but no suggestions on the single individuals are provided.", [["no", "UNCERTAINTY", 109, 111]]], ["The goal of the work by Shaghaghian and Coates (2017) is to infer the path that an infection has traversed in order to reach an arbitrary node in the SIR (Susceptible Infected Recovered) epidemiological model.", [["node", "ANATOMY", 138, 142], ["infection", "DISEASE", 83, 92], ["node", "MULTI-TISSUE_STRUCTURE", 138, 142], ["an infection", "PROBLEM", 80, 92], ["an arbitrary node", "PROBLEM", 125, 142], ["infection", "OBSERVATION", 83, 92], ["node", "OBSERVATION", 138, 142]]], ["This approach does not provide a clear decision on the tests to perform.", [["the tests", "TEST", 51, 60]]], ["An alternative solution is the use of tracing apps, which can be used to identify the individuals with the most likelihood of being infected and their selection for the SARS-CoV-2 swab test (see Ahmed et al. (2020) for an extensive review).", [["An alternative solution", "TREATMENT", 0, 23], ["tracing apps", "TEST", 38, 50], ["the SARS", "TEST", 165, 173], ["CoV", "TEST", 174, 177], ["swab test", "TEST", 180, 189], ["an extensive review", "TEST", 219, 238], ["infected", "OBSERVATION", 132, 140]]], ["2 This allows the people using these apps to preserve the personal information about the contacts she/he had in the past days and, at the same time, allow the authorities to determine which are the people who have been the most exposed to infected individuals.", [["people", "ORGANISM", 18, 24], ["people", "ORGANISM", 198, 204], ["people", "SPECIES", 18, 24], ["people", "SPECIES", 198, 204]]], ["The method we are going to design is based on such apps and is in line with the PACT protocol and uses apps in line with the Apple-Google technological guidelines.Epidemic ModelIn this work, we use a new epidemic model that allows us to simulate the spread in a fine-grained fashion.", [["the PACT protocol", "TREATMENT", 76, 93], ["a new epidemic model", "TREATMENT", 198, 218]]], ["In this model, namely SAPSR, at each time t \u2208 {1, . . . , T }, the individuals of a population U are partitioned into 5 classes:Epidemic Model\u2022 S t : Susceptible individuals that did not contract the virus before t; \u2022 A t : Asymptomatic individuals that contracted the virus before t and will not manifest any symptom during the whole development of the disease; \u2022 P t : Presymptomatic individuals that contracted the virus before t without manifesting any symptom, but they will manifest some symptoms from some time \u03c4 \u2265 t; \u2022 Y t : Symptomatic individuals that contracted the virus before t and present some symptom; \u2022 R t : Recovered individuals that were either asymptomatics or symptomatics before t, but that at t are not infected anymore.", [["individuals", "ORGANISM", 162, 173], ["individuals", "ORGANISM", 237, 248], ["individuals", "ORGANISM", 386, 397], ["SAPSR", "PROTEIN", 22, 27], ["Susceptible individuals", "PROBLEM", 150, 173], ["Asymptomatic individuals", "PROBLEM", 224, 248], ["the virus", "PROBLEM", 265, 274], ["any symptom", "PROBLEM", 306, 317], ["the disease", "PROBLEM", 350, 361], ["Presymptomatic individuals", "PROBLEM", 371, 397], ["the virus", "PROBLEM", 414, 423], ["any symptom", "PROBLEM", 453, 464], ["some symptoms", "PROBLEM", 489, 502], ["Symptomatic individuals", "PROBLEM", 533, 556], ["the virus", "PROBLEM", 573, 582], ["some symptom", "PROBLEM", 604, 616], ["symptomatics", "PROBLEM", 682, 694], ["infected", "OBSERVATION", 727, 735]]], ["This category, at t, cannot infect other people and are immune to the disease.Epidemic ModelThe separation between asymptomatic and presymptomatic individuals in epidemic models is proposed by Ferretti et al. (2020) to capture properly the SARS-CoV-2 outbreak dynamics, as the virus transmission is mainly conveyed by these two classes of individuals.", [["SARS", "DISEASE", 240, 244], ["people", "ORGANISM", 41, 47], ["people", "SPECIES", 41, 47], ["the disease", "PROBLEM", 66, 77], ["The separation between asymptomatic and presymptomatic individuals", "PROBLEM", 92, 158], ["the SARS", "TEST", 236, 244], ["disease", "OBSERVATION", 70, 77], ["asymptomatic", "OBSERVATION_MODIFIER", 115, 127]]], ["Indeed, symptomatic people are less likely to spread the contagion since they usually are promptly isolated as symptoms occur, while asymptomatics and presymptomatics have frequent contacts with susceptibles individuals, which consequently are more likely infected by individuals from these classes.", [["people", "ORGANISM", 20, 26], ["people", "SPECIES", 20, 26], ["symptoms", "PROBLEM", 111, 119], ["symptomatic", "OBSERVATION_MODIFIER", 8, 19], ["less likely", "UNCERTAINTY", 31, 42], ["more likely", "UNCERTAINTY", 244, 255]]], ["However, once a contact occurs, symptomatics have the largest probability to infect a new individual, followed by presymptomatics and asymptomatics, who have the lowest probability of passing the disease.", [["passing the disease", "PROBLEM", 184, 203], ["disease", "OBSERVATION", 196, 203]]], ["Therefore, the probability of spreading the disease should be differentiated among the three classes.Epidemic ModelOur model describing contacts and contagions among individuals is as follows.", [["spreading the disease", "PROBLEM", 30, 51], ["disease", "OBSERVATION", 44, 51]]], ["The set of possible contacts occurring among different individuals is described by a graph G c (U, E c ), where the nodes U represents the entire population and E c is the set of undirected edges indicating if two nodes may have a contact.", [["nodes", "ANATOMY", 214, 219], ["G c", "GENE_OR_GENE_PRODUCT", 91, 94], ["E c", "GENE_OR_GENE_PRODUCT", 161, 164], ["E c", "DNA", 161, 164], ["nodes", "OBSERVATION", 116, 121], ["nodes", "OBSERVATION", 214, 219]]], ["We associate a weight w u,v (t) to each edge in E c denoting the probability that two nodes u and v have a contact at time t.", [["nodes", "OBSERVATION", 86, 91]]], ["The rationale behind the choice of setting a different value for each pair of nodes is that some individuals pairs has recurrent and frequent contacts (e.g., family members, colleagues, and friends), while others have only sporadic encounters (e.g., people using public transportation).", [["nodes", "MULTI-TISSUE_STRUCTURE", 78, 83], ["people", "ORGANISM", 250, 256], ["people", "SPECIES", 250, 256], ["each pair of nodes", "PROBLEM", 65, 83], ["nodes", "OBSERVATION", 78, 83]]], ["Notice that in the current study we focus on the transmission of the virus by direct contact between couples of people, i.e., occurred by exchanging respiratory droplets, since it has been shown that the virus can only survive few hours outside the human body Khadka et al. (2020) .", [["respiratory droplets", "ANATOMY", 149, 169], ["body", "ANATOMY", 255, 259], ["people", "ORGANISM", 112, 118], ["human", "ORGANISM", 249, 254], ["people", "SPECIES", 112, 118], ["human", "SPECIES", 249, 254], ["human", "SPECIES", 249, 254], ["the current study", "TEST", 15, 32], ["the virus", "PROBLEM", 65, 74], ["exchanging respiratory droplets", "TREATMENT", 138, 169], ["the virus", "PROBLEM", 200, 209], ["respiratory droplets", "OBSERVATION", 149, 169], ["virus", "OBSERVATION", 204, 209]]], ["However, this approach can be easily generalized to models and settings that include environemental contagions.Epidemic ModelA contact between two individuals u and v is denoted with c u,v (t), and it is defined as a tuple (l u,v , r u,v , t), where l u,v denotes the distance between u and v, r u,v denotes the duration of the contact, and t is the time the contact between u and v occurred.", [["environemental contagions", "TREATMENT", 85, 110]]], ["3 Let us denote with w u,v the probability that a specific contact between u and v occurs, and with C = {c u,v (t)} the set of all the contacts occurred between pair of nodes over a predefined time span, e.g., over two weeks.", [["nodes", "OBSERVATION", 169, 174]]], ["The contagion probability p(u, v, l u,v , r u,v ) between two individuals u and v depends on the state of the two nodes (one of them should be susceptible and one should have contracted the SARS-CoV-2), and on the duration r u,v and distance l u,v of the contact.", [["SARS", "DISEASE", 190, 194], ["The contagion probability", "TEST", 0, 25], ["nodes", "OBSERVATION", 114, 119]]], ["More specifically, once a susceptible node u \u2208 S t gets infected, it is removed from the population S t and it is included either in A t or P t according to the value of the probability of being symptomatic \u03b1 s (u).Epidemic ModelIf an individual becomes asymptomatic at a specific time t 0 , she/he will remain in the asymptomatic population A t for a time span of t \u2208 (t 0 , t 0 + \u03c4 u ), where \u03c4 u is the time required by an asymptomatic u to recover from the virus, i.e., to result not infected anymore, and may vary for each specific individual.", [["node", "ANATOMY", 38, 42], ["a susceptible node u", "PROBLEM", 24, 44], ["infected", "PROBLEM", 56, 64], ["asymptomatic", "PROBLEM", 254, 266], ["the virus", "PROBLEM", 457, 466], ["node", "OBSERVATION", 38, 42], ["infected", "OBSERVATION", 488, 496]]], ["Conversely, if an individual becomes presymptomatic at time t 0 , she/he will remain in the population P t for t \u2208 (t 0 , t 0 + \u03c4 u ), and at time t + u , she/he will be included in the symptomatic population Y t+ u , where u denotes the incubation time that might be different for each individual.Epidemic ModelNow we describe how the containment measures affect the contact and contagion probabilities among individuals.", [["presymptomatic", "PROBLEM", 37, 51]]], ["At each time t, a set of K t nodes can be tested.", [["K t nodes", "TREATMENT", 25, 34], ["nodes", "OBSERVATION", 29, 34]]], ["Each test v t \u2208 V t is defined by a tuple (u, o u,t ), where u is the node tested Input: population sets S0, A0, P0, Y0, R0, contacts graph G c , time horizon T , tests policy P Output:Epidemic Modeland o u,t \u2208 {POSITIVE, NEGATIVE, WAITING} is the test outcome.", [["node", "ANATOMY", 70, 74], ["V t", "DNA", 16, 19], ["Each test", "TEST", 0, 9], ["the node", "TEST", 66, 74], ["population sets S0", "TEST", 89, 107], ["A0", "TEST", 109, 111], ["P0", "TEST", 113, 115], ["Output", "TEST", 178, 184], ["node", "OBSERVATION", 70, 74]]], ["The probability of getting a false negative is \u03b2 f (u t ) and depends on the population to which u belongs.Epidemic ModelNotice that the model we presented is flexible enough to be applied to infections others than the SARS-CoV-2 one.", [["infections", "DISEASE", 192, 202], ["SARS", "DISEASE", 219, 223], ["SARS-CoV", "SPECIES", 219, 227], ["infections", "PROBLEM", 192, 202], ["the SARS", "TEST", 215, 223], ["infections", "OBSERVATION", 192, 202]]], ["Indeed, modifying the contagion probabilities p(u, v, l u,v , r u,v ) as well as the false negative rate \u03b2(u t ), one might model also a large class of outbreaks.Epidemic ModelIn Algorithm 1, we provide a high level description about how our the interaction between couples of individuals is modeled.", [["large", "OBSERVATION_MODIFIER", 137, 142], ["class", "OBSERVATION_MODIFIER", 143, 148], ["outbreaks", "OBSERVATION", 152, 161]]], ["At first, we initialize the set V of the individuals we already tested for SARS-CoV-2, the set C of the contacts occurred so far, and the set D containing the information stored by all the devices.", [["SARS", "DISEASE", 75, 79], ["SARS-CoV", "SPECIES", 75, 83], ["SARS", "TEST", 75, 79], ["CoV", "TEST", 80, 83]]], ["Initially, they are all empty.", [["empty", "OBSERVATION", 24, 29]]], ["At each time t, we determine if a new contact occurred between each pair of individuals, which are stored in C new , and the corresponding data D u and D v are stored in the devices of the two individuals u and v (detailed in Algorithm 2).", [["D v", "GENE_OR_GENE_PRODUCT", 152, 155]]], ["For each of the new contacts in C new we determine if a contagion between the involved nodes occurred (detailed in Algorithm 3), and update the populations S t , A t , P t , Y t , and R t depending if the contagion caused the creation of a new asymptomatic or presymptomatic infection and on the recovery of some of the individuals.", [["infection", "DISEASE", 275, 284], ["nodes", "MULTI-TISSUE_STRUCTURE", 87, 92], ["the involved nodes", "PROBLEM", 74, 92], ["a new asymptomatic or presymptomatic infection", "PROBLEM", 238, 284], ["nodes", "OBSERVATION", 87, 92], ["new", "OBSERVATION_MODIFIER", 240, 243], ["asymptomatic", "OBSERVATION_MODIFIER", 244, 256], ["presymptomatic", "OBSERVATION_MODIFIER", 260, 274], ["infection", "OBSERVATION", 275, 284]]], ["Finally, we establish which are the nodes to be tested according to a tests policy P. The tested individuals, in case of positive outcome, will be isolated and, therefore, will not have contacts with other individuals in the following period.Epidemic ModelContract tracing apps represent one the main tools that the governments adopted to tackle this outbreak.", [["individuals", "ORGANISM", 97, 108], ["Epidemic ModelContract tracing apps", "PROBLEM", 242, 277], ["nodes", "OBSERVATION", 36, 41]]], ["These constraints brought the development of different solutions that exploit Bluetooth technologies and security protocols to preserve users privacy.", [["different solutions", "TREATMENT", 45, 64], ["Bluetooth technologies", "TREATMENT", 78, 100], ["security protocols", "TREATMENT", 105, 123]]], ["4 The data update procedure occurring on each individual's device is detailed in Algorithm 2.", [["procedure", "TREATMENT", 18, 27], ["each individual's device", "TREATMENT", 41, 65]]], ["Subsequently, it updates the data stored in each individual's device D u and D v with an entry listing the time t the contact occurred, the tokens of the two individuals and the distance l u,v and duration r u,v of the contact.", [["D v", "GENE_OR_GENE_PRODUCT", 77, 80]]], ["To summarize, each entry d \u2208 D u in a user's u device database is a tuple d = (t, h u,t , h v,t , l u,v , r u,v ) characterizing the contact she/he has had in the past.Epidemic ModelThe evolution of the populations set describing the virus evolution is detailed in Algorithm 3.", [["t", "TEST", 94, 95], ["the populations", "PROBLEM", 199, 214], ["the virus evolution", "PROBLEM", 230, 249], ["populations", "OBSERVATION_MODIFIER", 203, 214], ["virus", "OBSERVATION", 234, 239]]], ["At first if checks if any new contact in C new generated a new infected individual, according to the contagion probability p(u, v, l u,v , r u,v ).", [["checks", "TEST", 12, 18], ["a new infected individual", "PROBLEM", 57, 82]]], ["According to the response of the individuals, i.e., she/he can be categorized as a presymptomatic or an asymptomatic patient, she/he is moved from the susceptible set S to either the set P or A, respectively.", [["patient", "ORGANISM", 117, 124], ["P", "DNA", 187, 188], ["patient", "SPECIES", 117, 124]]], ["After that, we check if any presymptomatic u \u2208 P showed some symptoms and, therefore, is moved to the symptomatic set Y .", [["P", "DNA", 47, 48], ["some symptoms", "PROBLEM", 56, 69]]], ["Finally, the contagion evolves by moving the status of all the asymptomatics and symptomatics who recovered to the set R.Problem FormulationGiven a population U and a time horizon T \u2208 N, ideally, we aim at finding, at each day t \u2208 {1, . . . , T }, a subset X t \u2282 U of K t nodes to isolate to minimize the total number of infected over the time horizon T .", [["K t nodes", "DNA", 268, 277], ["K t nodes", "TREATMENT", 268, 277], ["total", "OBSERVATION_MODIFIER", 305, 310], ["number", "OBSERVATION_MODIFIER", 311, 317], ["infected", "OBSERVATION", 321, 329]]], ["Unfortunately, in our scenario, this information is not available since the structure of the network changes Algorithm 2 updateDevicesData(D u , D v , c u,v,t ) Input: devices data Du, Dv, new contact cu,v,t Output: updated data (Du, Dv) hu,t \u2190 RandomToken() hv,t \u2190 RandomToken() Du \u2190 Du \u222a {(t, hu,t, hv,t, lu,v, ru,v)} Dv \u2190 Dv \u222a {(t, hv,t, hu,t, lu,v, ru,v)} Algorithm 3 contagionStep(C new , S, A, P, Y, R) Input: new contacts set Cnew, population sets S, A, P , Y , R Output: updated populations sets S,Problem Formulationover time, and due to the privacy policies of the contact tracing apps.", [["(t, hu,t, hv,t, lu,v, ru,v)}", "CHEMICAL", 291, 319], ["Dv \u2190 Dv \u222a {(t, hv,t, hu,t, lu,v, ru,v)}", "CHEMICAL", 320, 359], ["hu,t, lu,v, ru,v)}", "SIMPLE_CHEMICAL", 341, 359], ["hu", "TEST", 295, 297], [",t", "TEST", 297, 299], ["hv", "TEST", 301, 303], ["lu", "TEST", 307, 309], ["Dv", "TEST", 320, 322], ["t", "TEST", 332, 333], ["hv", "TEST", 335, 337], ["hu", "TEST", 341, 343], [",t", "TEST", 343, 345], ["lu", "TEST", 347, 349], ["v", "TEST", 350, 351], ["ru", "TEST", 353, 355], ["Algorithm", "TEST", 360, 369], ["lu", "ANATOMY", 307, 309], ["hu", "ANATOMY", 341, 343], ["lu", "ANATOMY", 347, 349]]], ["Indeed, we are able only to exploit the data coming from the different devices D u in a decentralized fashion, since collecting centralized contacts data is forbidden .", [["the data", "TEST", 36, 44]]], ["A natural reformulation of the problem when this information is lacking consists in assuming that all the individuals might have contacts with each other individuals, or, formally, that the contact graph is complete G c .Problem FormulationAs a consequence, we are allowed only to use as available data the device database D u , and the probability of getting infected for each contact between individuals p (u, v, d u,v , r u,v ) .", [["Problem Formulation", "TREATMENT", 221, 240]]], ["We reformulate the problem of minimizing the virus spread as the task of finding, at a time step t, the subset of nodes X t \u2208 U with the K t largest probability of being contagious.", [["the virus spread", "PROBLEM", 41, 57], ["nodes", "OBSERVATION", 114, 119], ["contagious", "OBSERVATION", 170, 180]]], ["Furthermore, assuming that an individual can be isolated if she/he has evident symptoms or after resulting positive from a test, and that the symptomatic individuals are known, the problem can be formally cast as the one of selecting the nodes that with largest probability of being contagious p c (u):Problem Formulationwhere | \u00b7 | denotes the cardinality operator.", [["individuals", "ORGANISM", 154, 165], ["symptoms", "PROBLEM", 79, 87], ["a test", "TEST", 121, 127], ["the symptomatic individuals", "PROBLEM", 138, 165], ["nodes", "OBSERVATION", 238, 243]]], ["In what follows, we describe the algorithm able to estimate the probabilities p c (u), inducing the policy P to perform the swab tests for SARS-CoV-2.Proposed MethodWe start by introducing the assumptions required by our method.", [["SARS-CoV", "SPECIES", 139, 147], ["the swab tests", "TEST", 120, 134], ["SARS", "TEST", 139, 143], ["CoV", "TEST", 144, 147]]], ["Our solution aim at exploiting a huge amount of data collected by the devices of the individuals to select the individuals which are most likely infected.", [["infected", "PROBLEM", 145, 153], ["most likely", "UNCERTAINTY", 133, 144], ["infected", "OBSERVATION", 145, 153]]], ["The effectiveness of this method is strictly related to the individuals collaboration.", [["this method", "TREATMENT", 21, 32]]], ["Indeed, as shown by some previous study, it is necessary that a large portion of the individuals uses the contact tracing applications.", [["some previous study", "TEST", 20, 39], ["large", "OBSERVATION_MODIFIER", 64, 69]]], ["Moreover, we require that all the individuals that present symptoms or results to be positive to a test communicate it to the local authorities, so that this information can be exploited to send notifications to high-risk individuals.Proposed MethodInput: number of available tests K, number of iterations N , current time step t, time window tw, set of newly positive discovered individuals Qt, contacts of the positive individuals ci Output: individuals to test Xt for n \u2208 {1, . . . , N } do Sample randomly node i \u2208 Qt sendRequest(n, ci, t)Proposed MethodThe key idea of our method, namely Privacy Preserving Test Optimization (PPTO), is to exploit all devices to find the solution of the problem in Equation 1.", [["present symptoms", "PROBLEM", 51, 67], ["K", "TEST", 282, 283], ["newly positive discovered individuals Qt", "PROBLEM", 354, 394], ["ci Output", "TEST", 433, 442], ["test Xt", "TEST", 459, 466], ["Sample", "TEST", 494, 500], ["node i", "TEST", 510, 516], ["Qt", "TEST", 519, 521], ["ci", "TEST", 537, 539], ["all devices", "TREATMENT", 652, 663], ["node", "OBSERVATION", 510, 514]]], ["Starting from the devices of symptomatic (positive) individuals, we aim at identifying asymptomatic and presymptomatic individuals by reconstructing infection trajectories, i.e., path of infection occurred by contacts between couple of people, exploiting the contact tracing apps data.", [["infection", "DISEASE", 149, 158], ["infection", "DISEASE", 187, 196], ["people", "ORGANISM", 236, 242], ["people", "SPECIES", 236, 242], ["symptomatic (positive) individuals", "PROBLEM", 29, 63], ["asymptomatic and presymptomatic individuals", "PROBLEM", 87, 130], ["reconstructing infection trajectories", "PROBLEM", 134, 171], ["infection", "PROBLEM", 187, 196], ["infection", "OBSERVATION", 187, 196]]], ["The algorithm assign at each user a score representing the infection risk level and indicating how many times a monte carlo-simulated infection trajectory included its device.", [["infection", "DISEASE", 59, 68], ["infection", "DISEASE", 134, 143], ["the infection risk level", "PROBLEM", 55, 79], ["a monte carlo-simulated infection trajectory", "TREATMENT", 110, 154], ["its device", "TREATMENT", 164, 174], ["infection", "OBSERVATION", 59, 68], ["infection", "OBSERVATION", 134, 143]]], ["Finally, given a limited amount of K available tests, the algorithm will suggests a set X t of the K individuals with the highest score.Proposed MethodIn Algorithm 4 we provide a the core algorithm of our method, while Algorithm 5 we provide the operations required by the devices to allow a decentralized manner.", [["K available tests", "TEST", 35, 52], ["the algorithm", "TEST", 54, 67], ["the operations", "TREATMENT", 242, 256], ["the devices", "TREATMENT", 269, 280]]], ["The PPTO algorithm takes as input the number of available tests K, the number of iterations N , the current time step t and a time window t w for which we have to look for contagious people during the past time steps.", [["people", "ORGANISM", 183, 189], ["PPTO", "DNA", 4, 8], ["people", "SPECIES", 183, 189], ["The PPTO algorithm", "TREATMENT", 0, 18], ["tests K", "TEST", 58, 65]]], ["The definition of the iteration N is required to limit the computational effort of the algorithm we run.", [["the iteration N", "TREATMENT", 18, 33]]], ["Moreover, the algorithm required to have the set of nodes Q t that recently, i.e., in the last t w time steps, resulted to be positive in a test and communicated it to the authorities together with her/his the set of tokens used in the recent past, i.e., for each node i \u2208 Q t , we need c i = {h i,j } t j=t\u2212tw .", [["nodes", "OBSERVATION", 52, 57]]], ["Then, for N iterations, the algorithm samples a positive infected node i from Q t and simulate trajectories starting from it.", [["node", "ANATOMY", 66, 70], ["N iterations", "TREATMENT", 10, 22], ["the algorithm samples", "TEST", 24, 45], ["a positive infected node i", "PROBLEM", 46, 72], ["infected", "OBSERVATION_MODIFIER", 57, 65], ["node", "OBSERVATION", 66, 70]]], ["A simulation is started by sending a request (sendRequest(n, c i , t)) to the device associated to the token c i .", [["the device", "TREATMENT", 74, 84]]], ["Each device i receives all the requests sent to the network, but only if the token transmitted in the request message is included in device dataset D i , then the score g is incremented, a flag f n associated to the current iteration n is set to True and the trajectory is propagated backward and forward to other network nodes, where the details of these procedures are described in Algorithm 6 and Algorithm 7, respectively.", [["network nodes", "MULTI-TISSUE_STRUCTURE", 314, 327], ["these procedures", "TREATMENT", 350, 366], ["nodes", "OBSERVATION", 322, 327]]], ["Finally, once a stop condition is satisfied, e.g., after a pre-specified time has passed, each device u communicates its score s to a central unit, so that it can communicate the set X t of K individuals with the largest score.Proposed MethodUsing Algorithm 6 the trajectory is propagated backward to one of the contacts c \u2208 C B , with c = (t , h u,t , h v,t , l u,v , r u,v ), that occurred for all time steps j \u2208 {t \u2212 t w , . . . , t} according to a probability mass function \u03b3(c).", [["c", "TEST", 336, 337], ["u", "TEST", 347, 348], ["v", "TEST", 355, 356], ["v", "TEST", 365, 366], ["mass", "OBSERVATION", 464, 468]]], ["This function represents an unnormalized probability that a node is infected and is defined using the duration, distance, and order in which each contacts occurred:Proposed Methodwhere c = (t , h u,t , h v,t , l u,v , r u,v ).", [["node", "ANATOMY", 60, 64], ["node", "MULTI-TISSUE_STRUCTURE", 60, 64], ["a node", "PROBLEM", 58, 64], ["infected", "PROBLEM", 68, 76], ["t", "TEST", 198, 199], ["t", "TEST", 206, 207], ["v", "TEST", 214, 215], ["node", "OBSERVATION", 60, 64], ["infected", "OBSERVATION_MODIFIER", 68, 76]]], ["Finally, according to the probability distribution induced by \u03b3(c) a single contact\u0109 is selected and a request is sent for the token\u0125 corresponding to the current device from\u0109.Proposed MethodIn Algorithm 7 the trajectory is forward propagated to the contacts c occurred at time j \u2208 {t, . . . , t + t w } according to the contagion probability p c (l u,v , r u,v ).", [["Proposed MethodIn Algorithm", "TREATMENT", 176, 203], ["the contagion probability", "TEST", 317, 342], ["l u", "TEST", 348, 351]]], ["More specifically, we send the token of the current device h present in the contact c if after the contagion occurred, i.e., we model this event as a Bernoulli variable with expected value p c (l u,v , r u,v )).Experimental ResultsHere, we present an empirical evaluation of our method in different settings generated by a simulated environment and we compare its performance with the ones obtained with the following baseline testing policies:Algorithm 5 PPTO -Device SideInput: number of iterations N , starting time step t, time window tw Output: score g Initialize score g \u2190 0 h u,t , h v,t , lu,v, ru,v) , d \u2208 Du | h v,t = h \u2227 fn = F alse then fn \u2190 T rue g \u2190 g + 1 backwardTrajectory(t , n, tw) forwardTrajectory(t , n, tw) x = randomCode() s = (x, g) sendScore(s) Algorithm 6 backwardTrajectory(t , n, t w ) Input: starting time t , iteration index n, time window tw C B \u2190 {d = (j, hu,j, hv,j, lu,v, ru,v)Algorithm 5 PPTO -Device SideExtract the token\u0125 corresponding to the current device from\u0109 sendRequest(n,\u0125) Algorithm 7 forwardTrajectory(t , n, t w ) Input: starting time tx, iteration index n, time window tw C F = {d = (j, hu,j, hv,j, lu,v, ru,v) , d \u2208 Di : t < j < t + tw} for c \u2208 C F do simulate a contagion with probability pc (lu,v, ru,v) if the contagion occurred then Extract the token h corresponding to the current device from c sendRequest(n, h)Algorithm 5 PPTO -Device Side\u2022 TS: test all the newly symptomatics individuals.", [["{d = (j, hu,j, hv,j, lu,v, ru,v)", "CHEMICAL", 1126, 1158], ["PPTO", "PROTEIN", 923, 927], ["an empirical evaluation", "TEST", 248, 271], ["Output", "TEST", 542, 548], ["score", "TEST", 550, 555], ["g", "TEST", 556, 557], ["score", "TEST", 569, 574], ["g", "TEST", 575, 576], ["\u2190", "TEST", 577, 578], ["u", "TEST", 583, 584], ["t", "TEST", 585, 586], ["v", "TEST", 591, 592], ["t", "TEST", 593, 594], ["lu", "TEST", 597, 599], ["v", "TEST", 600, 601], ["ru", "TEST", 603, 605], ["Du", "TEST", 615, 617], ["v", "TEST", 622, 623], ["fn", "TEST", 632, 634], ["alse", "TEST", 639, 643], ["fn", "TEST", 649, 651], ["T", "TEST", 654, 655], ["rue", "TEST", 656, 659], ["g", "TEST", 660, 661], ["g", "TEST", 664, 665], ["Trajectory", "TEST", 678, 688], ["t", "TEST", 689, 690], ["n", "TEST", 693, 694], ["tw", "TEST", 696, 698], ["Trajectory", "TEST", 707, 717], ["t", "TEST", 718, 719], ["tw", "TEST", 725, 727], ["randomCode", "TEST", 733, 743], ["s", "TEST", 746, 747], ["g", "TEST", 754, 755], ["sendScore", "TEST", 757, 766], ["Algorithm", "TEST", 770, 779], ["Trajectory", "TEST", 790, 800], ["t", "TEST", 801, 802], ["hu", "TEST", 888, 890], ["j", "TEST", 891, 892], ["hv", "TEST", 894, 896], ["j", "TEST", 897, 898], ["v", "TEST", 903, 904], ["ru", "TEST", 906, 908], ["Algorithm", "TEST", 911, 920], ["the current device", "TREATMENT", 976, 994], ["iteration index", "TEST", 1086, 1101], ["hu", "TEST", 1135, 1137], ["j", "TEST", 1138, 1139], ["hv", "TEST", 1141, 1143], ["j", "TEST", 1144, 1145], ["c \u2208 C F", "PROBLEM", 1190, 1197], ["the current device", "TREATMENT", 1323, 1341], ["hu", "ANATOMY", 888, 890], ["j", "ANATOMY", 897, 898], ["lu", "ANATOMY", 900, 902], ["hu", "ANATOMY", 1135, 1137], ["j", "ANATOMY", 1144, 1145], ["lu", "ANATOMY", 1147, 1149]]], ["If all the available test are not exploited, then the nodes to be tested are selected randomly.Algorithm 5 PPTO -Device Side\u2022 TSDC: test the infected nodes and their direct contacts .", [["nodes", "ANATOMY", 150, 155], ["nodes", "MULTI-TISSUE_STRUCTURE", 150, 155], ["all the available test", "TEST", 3, 25], ["Algorithm", "TEST", 95, 104], ["the infected nodes", "PROBLEM", 137, 155], ["nodes", "OBSERVATION", 54, 59], ["infected", "OBSERVATION_MODIFIER", 141, 149], ["nodes", "OBSERVATION", 150, 155]]], ["If all the available tests are not exploited, then the nodes to be tested are selected randomly.Algorithm 5 PPTO -Device SideWe consider a setting with |U | = 10000 individuals, |E C | = 500000 and w u,v is set s.t., for each \u00ecndividual u \u2208 U , the average number of daily contacts is 10.", [["all the available tests", "TEST", 3, 26], ["nodes", "OBSERVATION", 55, 60]]], ["We assume that the number of daily available tests is K = 100 and we set, at day t = 0, an initial number of infected nodes |Y 0 | = 5.", [["nodes", "ANATOMY", 118, 123], ["K", "TEST", 54, 55], ["infected", "OBSERVATION_MODIFIER", 109, 117], ["nodes", "OBSERVATION", 118, 123]]], ["At each day t, we test K individuals, and we assume that the tests results are available after one or two days with equal probability.", [["test K individuals", "TEST", 18, 36], ["the tests", "TEST", 57, 66]]], ["In Figure 1 , we show the evolution populations |A t |, |P t |, |Y t |, |R t | without any containment measure, i.e., in a setting with K = 0.", [["any containment measure", "TEST", 87, 110], ["K", "TEST", 136, 137]]], ["We notice that after 30 days, the asymptomatic, presymptomatic and symptomatic populations reach the 33%, 2.48 and the 2.3% of the whole population, while only the 0.35% of the individuals have recovered from the desease.", [["individuals", "ORGANISM", 177, 188], ["the asymptomatic, presymptomatic and symptomatic populations", "PROBLEM", 30, 90], ["symptomatic", "OBSERVATION_MODIFIER", 67, 78], ["populations", "OBSERVATION_MODIFIER", 79, 90]]], ["In Figure 2 , we show how the number of infected individuals grow depending on the testing policy we adopt.", [["infected individuals", "PROBLEM", 40, 60], ["infected", "OBSERVATION", 40, 48]]], ["Although, in these settings, there is not any policy that allows to stop the spread, we notice significant differencies in the containment of the spread depending on the policy we perform.", [["significant differencies", "PROBLEM", 95, 119], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["differencies", "OBSERVATION_MODIFIER", 107, 119]]], ["More precisely, the adoption of our approach would bring to a reduction of the number of infected of the 50% if compared with TS approach, while it would determine a reduction of the 20% of the infected individuals if compared with the TSDC approach.Discussion and Future WorksIn this paper we presented a novel algorithm for the identification of individuals that have high probability to spread the infection during the SARS-CoV-2 outbreak.", [["infection", "DISEASE", 401, 410], ["SARS", "DISEASE", 422, 426], ["individuals", "ORGANISM", 348, 359], ["SARS-CoV", "SPECIES", 422, 430], ["TS approach", "TREATMENT", 126, 137], ["the TSDC approach", "TREATMENT", 232, 249], ["a novel algorithm", "TEST", 304, 321], ["high probability", "PROBLEM", 370, 386], ["the infection", "PROBLEM", 397, 410], ["the SARS", "TEST", 418, 426], ["reduction", "OBSERVATION_MODIFIER", 62, 71], ["infected", "OBSERVATION", 89, 97], ["reduction", "OBSERVATION_MODIFIER", 166, 175], ["infected", "OBSERVATION", 194, 202], ["infection", "OBSERVATION", 401, 410]]], ["We showed how to use the so called contact tracing apps and the data stored therein, to provide with a suggestions on the individuals to test for the positivity of the virus.", [["the virus", "PROBLEM", 164, 173]]], ["This is crucial task for the containment of the contagion, due to the limited number of available tests the public healt organization are able to perform each day.", [["crucial task", "OBSERVATION", 8, 20]]], ["Our algorithm suggests the set of individuals that should be tested to limit the spread by an innovative AI-based algorithm which communicate only by means of token generated by the different devices, thus preserving the private information of the app users.Discussion and Future WorksAs immediate future work, we will evaluate our method in realistic scenarios comparing it with tests policies currently employed by governments.", [["Our algorithm", "TEST", 0, 13]]], ["For this reason, beyond exploiting information provided by new works in the scientific literature, we will design methods to estimate them by combining aggregated data about this epidemics.", [["this epidemics", "PROBLEM", 174, 188]]], ["Furthermore, a further improvement will be the development of a framework in which these parameters can be estimated online gathering information trough the tests.Discussion and Future WorksIn this work, we focused on designing an algorithm that satisfies the privacy requirements.", [["the tests", "TEST", 153, 162]]], ["Moreover, it would be interesting to compare our method with other state-of-the-art AI solutions that exploits centralized datasets to infer the probability of each individual of being contagious, and provide an analysis of the trade-off between privacy requirements satisfaction and effectiveness on the epidemics containment. u, v, l, r) probability of a contagion from u to v probability pc(u) probability of being contagious for u wu,v probability a contact between u and v lu,v distance of the contact between u and v ru,v duration of the contact between u and v C B set of contacts occurred between individuals \u03b1(u) probability of being asymptomatic for u Vt tests set v \u2208 Vt tuple (u, ou,t) representing a test ou,t \u2208 V test result \u03b2(u) false negative test probability \u03b2(u) false negative test probability N algorithm iterations Du device of individual u d \u2208 Du tuple in device dataset hu,t \u2208 d token sent by user u to user v hv,t \u2208 d token received by user u from user v 0.02 p(u \u2208 Pt, v \u2208 St, l = 0, r \u2208 {0, 1}) 0.05 p(u \u2208 Yt, v \u2208 St, l = 0, r \u2208 {0, 1}) 0.07 p(u \u2208 At, v \u2208 St, l = 1, r \u2208 {0, 1}) 0.03 p(u \u2208 Pt, v \u2208 St, l = 1, r \u2208 {0, 1}) 0.06 p(u \u2208 Yt, v \u2208 St, l = 1, r \u2208 {0, 1}) 0.08 \u03b1 0.1 \u03b2(u \u2208 At) 0.4 \u03b2(u \u2208 Pt) 0.2 \u03b2(u \u2208 Yt) 0.05 \u03c4min 5 \u03c4max 15 min 1 max 12", [["Pt", "CHEMICAL", 1220, 1222], ["the-art AI solutions", "TREATMENT", 76, 96], ["an analysis", "TEST", 209, 220], ["privacy requirements satisfaction", "TREATMENT", 246, 279], ["the epidemics containment", "TREATMENT", 301, 326], ["u Vt tests", "TEST", 660, 670], ["a test", "TEST", 711, 717], ["hu", "TEST", 893, 895], ["Pt", "TEST", 990, 992], ["St", "TEST", 998, 1000], ["u", "TEST", 1028, 1029], ["\u2208", "TEST", 1030, 1031], ["Yt", "TEST", 1032, 1034], ["v", "TEST", 1036, 1037], ["St", "TEST", 1040, 1042], ["u", "TEST", 1070, 1071], ["\u2208", "TEST", 1072, 1073], ["At", "TEST", 1074, 1076], ["v", "TEST", 1078, 1079], ["St", "TEST", 1082, 1084], ["u", "TEST", 1112, 1113], ["\u2208", "TEST", 1114, 1115], ["Pt", "TEST", 1116, 1118], ["v", "TEST", 1120, 1121], ["St", "TEST", 1124, 1126], ["u", "TEST", 1154, 1155], ["Yt", "TEST", 1158, 1160], ["v", "TEST", 1162, 1163], ["St", "TEST", 1166, 1168], ["l", "TEST", 1170, 1171], ["\u03b2", "TEST", 1200, 1201], ["u", "TEST", 1216, 1217], ["Pt", "TEST", 1220, 1222], ["Yt", "TEST", 1234, 1236], ["\u03c4min", "TEST", 1243, 1247], ["\u03c4max", "TEST", 1250, 1254]]]], "PMC7109995": [["INTRODUCTIONImproved feed efficiency (FE) has become a major goal in pig research and breeding programs for economic, environmental and food security reasons.", [["pig", "ORGANISM", 69, 72], ["pig", "SPECIES", 69, 72], ["breeding programs", "TREATMENT", 86, 103]]], ["Residual feed intake (RFI) has been adopted as a reliable method for measuring, selecting for and studying FE.", [["feed intake", "OBSERVATION", 9, 20]]], ["Pigs with low RFI (LRFI) consume less feed for a given amount of growth and backfat than pigs with greater RFI (HRFI; Gilbert et al., 2007; Cai et al., 2008).", [["Pigs", "ORGANISM", 0, 4], ["backfat", "TISSUE", 76, 83], ["pigs", "ORGANISM", 89, 93], ["Pigs", "SPECIES", 0, 4], ["pigs", "SPECIES", 89, 93], ["pigs", "SPECIES", 89, 93], ["low RFI (LRFI)", "TREATMENT", 10, 24], ["low RFI", "OBSERVATION_MODIFIER", 10, 17]]], ["Yorkshire pigs selected for LRFI for 5 generations differed by up to 124 g/day in ADFI with no significant reduction in BW gain compared with randomly selected HRFI pigs (Boddicker et al., 2011).", [["Yorkshire pigs", "ORGANISM", 0, 14], ["pigs", "ORGANISM", 165, 169], ["pigs", "SPECIES", 10, 14], ["pigs", "SPECIES", 165, 169], ["Yorkshire pigs", "TREATMENT", 0, 14], ["LRFI", "TREATMENT", 28, 32], ["significant reduction in BW gain", "PROBLEM", 95, 127], ["no", "UNCERTAINTY", 92, 94], ["significant", "OBSERVATION_MODIFIER", 95, 106], ["reduction", "OBSERVATION_MODIFIER", 107, 116]]], ["However, the physiology that underlies this improved FE has been poorly defined.INTRODUCTIONInflammation can have a major impact on growth performance and FE (Schinckel et al., 1995) and could contribute to decreased maintenance nutrient requirements in pigs selected for reduced RFI (Barea et al., 2010; Boddicker et al., 2011).", [["pigs", "ORGANISM", 254, 258], ["pigs", "SPECIES", 254, 258], ["pigs", "SPECIES", 254, 258], ["decreased maintenance nutrient requirements", "PROBLEM", 207, 250], ["poorly defined", "OBSERVATION_MODIFIER", 65, 79], ["nutrient requirements", "OBSERVATION", 229, 250]]], ["Lipopolysaccharide (LPS), a Gram negative bacterial outer membrane component referred also as endotoxin, is a chronic innate immune stimulator in pigs (Webel et al., 1997; Gabler et al., 2008; Weber and Kerr, 2008).", [["outer membrane", "ANATOMY", 52, 66], ["Lipopolysaccharide", "CHEMICAL", 0, 18], ["LPS", "CHEMICAL", 20, 23], ["endotoxin", "CHEMICAL", 94, 103], ["Lipopolysaccharide", "SIMPLE_CHEMICAL", 0, 18], ["LPS", "SIMPLE_CHEMICAL", 20, 23], ["endotoxin", "GENE_OR_GENE_PRODUCT", 94, 103], ["pigs", "ORGANISM", 146, 150], ["endotoxin", "PROTEIN", 94, 103], ["pigs", "SPECIES", 146, 150], ["pigs", "SPECIES", 146, 150], ["Lipopolysaccharide (LPS", "TEST", 0, 23], ["a Gram negative bacterial outer membrane component", "PROBLEM", 26, 76], ["a chronic innate immune stimulator", "TREATMENT", 108, 142], ["bacterial outer", "OBSERVATION_MODIFIER", 42, 57], ["membrane component", "OBSERVATION", 58, 76], ["chronic", "OBSERVATION_MODIFIER", 110, 117]]], ["Importantly, Gram negative bacteria are present in the gastrointestinal tract in large amounts and can serve as a major source of systemic endotoxin (Ravin et al., 1960; Cani and Delzenne, 2010).", [["gastrointestinal tract", "ANATOMY", 55, 77], ["Gram negative bacteria", "GENE_OR_GENE_PRODUCT", 13, 35], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 55, 77], ["endotoxin", "SIMPLE_CHEMICAL", 139, 148], ["Gram negative bacteria", "PROBLEM", 13, 35], ["systemic endotoxin", "TREATMENT", 130, 148], ["negative bacteria", "OBSERVATION_MODIFIER", 18, 35], ["gastrointestinal tract", "ANATOMY", 55, 77], ["large amounts", "OBSERVATION_MODIFIER", 81, 94]]], ["However, intestinal barrier integrity plays critical host defense functions against luminal immunogens such as endotoxin.", [["intestinal barrier", "ANATOMY", 9, 27], ["luminal", "ANATOMY", 84, 91], ["luminal", "CHEMICAL", 84, 91], ["endotoxin", "CHEMICAL", 111, 120], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 9, 27], ["luminal", "IMMATERIAL_ANATOMICAL_ENTITY", 84, 91], ["endotoxin", "GENE_OR_GENE_PRODUCT", 111, 120], ["endotoxin", "PROTEIN", 111, 120], ["intestinal barrier integrity", "TREATMENT", 9, 37], ["luminal immunogens", "TREATMENT", 84, 102], ["endotoxin", "PROBLEM", 111, 120], ["intestinal", "ANATOMY", 9, 19], ["barrier integrity", "OBSERVATION", 20, 37], ["host defense", "OBSERVATION", 53, 65]]], ["Once in circulation, endotoxin activates the immune system via toll like receptors (TLR), which result in cytokine and acute phase protein production and the repartitioning of nutrients for immune function, rather than toward anabolism (Kimball et al., 2003; Rakhshandeh and de Lange, 2012).", [["immune system", "ANATOMY", 45, 58], ["endotoxin", "CHEMICAL", 21, 30], ["endotoxin", "SIMPLE_CHEMICAL", 21, 30], ["toll like receptors", "GENE_OR_GENE_PRODUCT", 63, 82], ["TLR", "GENE_OR_GENE_PRODUCT", 84, 87], ["endotoxin", "PROTEIN", 21, 30], ["toll like receptors", "PROTEIN", 63, 82], ["TLR", "PROTEIN", 84, 87], ["cytokine", "PROTEIN", 106, 114], ["endotoxin", "TREATMENT", 21, 30], ["cytokine and acute phase protein production", "PROBLEM", 106, 149], ["the repartitioning of nutrients", "TREATMENT", 154, 185], ["immune function", "PROBLEM", 190, 205], ["acute", "OBSERVATION_MODIFIER", 119, 124]]], ["Additionally, detoxification processes can prevent the negative effects of endotoxin (Elsbach, 2000).", [["endotoxin", "CHEMICAL", 75, 84], ["endotoxin", "SIMPLE_CHEMICAL", 75, 84]]], ["Therefore, our objective was to examine the relationship between intestinal barrier integrity, endotoxin and inflammation with FE, using pig lines divergently selected for RFI as a model.Animals and Experimental Design ::: MATERIALS AND METHODSTwelve pigs per line (62 \u00b1 3 kg, BW) were selected and matched across lines for age and weight from the seventh generation of the Iowa State University RFI selection project (Cai et al., 2008).", [["intestinal barrier", "ANATOMY", 65, 83], ["endotoxin", "CHEMICAL", 95, 104], ["inflammation", "DISEASE", 109, 121], ["intestinal barrier", "TISSUE", 65, 83], ["endotoxin", "SIMPLE_CHEMICAL", 95, 104], ["pig", "ORGANISM", 137, 140], ["pigs", "ORGANISM", 251, 255], ["pigs", "SPECIES", 251, 255], ["pig", "SPECIES", 137, 140], ["intestinal barrier integrity", "TREATMENT", 65, 93], ["endotoxin", "PROBLEM", 95, 104], ["inflammation", "PROBLEM", 109, 121], ["FE", "TREATMENT", 127, 129], ["pig lines", "TREATMENT", 137, 146], ["METHODSTwelve pigs per line", "TREATMENT", 237, 264], ["intestinal", "ANATOMY", 65, 75], ["inflammation", "OBSERVATION", 109, 121]]], ["Pigs were individually penned and had free access to water and feed at all times.", [["Pigs", "ORGANISM", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4]]], ["All pigs were fed a common commercial corn-soybean meal-distillers dry grain with soluble diet formulated to meet or exceed the nutrient requirements for this size pig (NRC, 1998).", [["pigs", "ORGANISM", 4, 8], ["pig", "ORGANISM", 164, 167], ["pigs", "SPECIES", 4, 8], ["corn-soybean", "SPECIES", 38, 50], ["pigs", "SPECIES", 4, 8], ["pig", "SPECIES", 164, 167], ["a common commercial corn-soybean meal", "TREATMENT", 18, 55], ["soluble diet", "TREATMENT", 82, 94]]], ["Feed intake and BW were recorded on a weekly basis and used to calculate ADG and RFI for each pig, as previously described (Cai et al., 2008; Young et al., 2011).Animals and Experimental Design ::: MATERIALS AND METHODSAfter 5 wk, all pigs were fasted overnight and whole blood (10 mL) was collected via venipuncture and serum separated by centrifugation at 2000 \u00d7 g for 10 min at 4\u00b0C. Thereafter, pigs were euthanized via captive bolt followed by exsanguination.", [["whole blood", "ANATOMY", 266, 277], ["serum", "ANATOMY", 321, 326], ["pig", "ORGANISM", 94, 97], ["pigs", "ORGANISM", 235, 239], ["blood", "ORGANISM_SUBSTANCE", 272, 277], ["serum", "ORGANISM_SUBSTANCE", 321, 326], ["pigs", "ORGANISM", 398, 402], ["pigs", "SPECIES", 235, 239], ["pigs", "SPECIES", 398, 402], ["pig", "SPECIES", 94, 97], ["pigs", "SPECIES", 235, 239], ["pigs", "SPECIES", 398, 402], ["pigs", "TREATMENT", 398, 402], ["captive bolt", "TREATMENT", 423, 435], ["exsanguination", "PROBLEM", 448, 462], ["captive bolt", "OBSERVATION", 423, 435]]], ["Immediately after euthanasia, segments of ileum and mid colon were collected and flushed with ice cold Krebs-Henseleit buffer (consisting of, in mmol/L: 25 NaHCO3, 120 NaCl, 1 MgSO4, 6.3 KCl, 2 CaCl2, 0.32 NaH2PO4; pH 7.4) to remove any undigested food material.", [["ileum", "ANATOMY", 42, 47], ["mid colon", "ANATOMY", 52, 61], ["NaCl", "CHEMICAL", 168, 172], ["CaCl2", "CHEMICAL", 194, 199], ["NaHCO3", "CHEMICAL", 156, 162], ["NaCl", "CHEMICAL", 168, 172], ["MgSO4", "CHEMICAL", 176, 181], ["KCl", "CHEMICAL", 187, 190], ["CaCl2", "CHEMICAL", 194, 199], ["NaH2PO4", "CHEMICAL", 206, 213], ["ileum", "MULTI-TISSUE_STRUCTURE", 42, 47], ["colon", "ORGAN", 56, 61], ["euthanasia", "PROBLEM", 18, 28], ["segments of ileum and mid colon", "PROBLEM", 30, 61], ["ice cold Krebs", "TREATMENT", 94, 108], ["Henseleit buffer", "TREATMENT", 109, 125], ["NaHCO3", "TREATMENT", 156, 162], ["NaCl", "TREATMENT", 168, 172], ["MgSO4", "TREATMENT", 176, 181], ["KCl", "TREATMENT", 187, 190], ["CaCl2", "TEST", 194, 199], ["NaH2PO4", "TEST", 206, 213], ["pH", "TEST", 215, 217], ["any undigested food material", "PROBLEM", 233, 261], ["euthanasia", "OBSERVATION", 18, 28], ["segments", "ANATOMY_MODIFIER", 30, 38], ["ileum", "ANATOMY", 42, 47], ["mid", "ANATOMY_MODIFIER", 52, 55], ["colon", "ANATOMY", 56, 61]]], ["Fresh ileum and colon segments were used for ex vivo integrity measures and for mucosal scrapings.", [["Fresh ileum", "ANATOMY", 0, 11], ["colon segments", "ANATOMY", 16, 30], ["mucosal", "ANATOMY", 80, 87], ["Fresh ileum", "MULTI-TISSUE_STRUCTURE", 0, 11], ["colon segments", "MULTI-TISSUE_STRUCTURE", 16, 30], ["mucosal scrapings", "MULTI-TISSUE_STRUCTURE", 80, 97], ["colon segments", "TREATMENT", 16, 30], ["ex vivo integrity measures", "TREATMENT", 45, 71], ["mucosal scrapings", "PROBLEM", 80, 97], ["ileum", "ANATOMY", 6, 11], ["colon", "ANATOMY", 16, 21], ["segments", "ANATOMY_MODIFIER", 22, 30], ["mucosal", "ANATOMY", 80, 87], ["scrapings", "OBSERVATION", 88, 97]]], ["A 20 cm segment of ileum 150 cm from the ileal-cecal junction and a 10 cm segment of proximal colon 60 cm from the rectum were isolated.", [["ileum", "ANATOMY", 19, 24], ["ileal-cecal junction", "ANATOMY", 41, 61], ["colon", "ANATOMY", 94, 99], ["rectum", "ANATOMY", 115, 121], ["ileum", "MULTI-TISSUE_STRUCTURE", 19, 24], ["ileal-", "MULTI-TISSUE_STRUCTURE", 41, 47], ["cecal junction", "MULTI-TISSUE_STRUCTURE", 47, 61], ["colon", "ORGAN", 94, 99], ["rectum", "ORGAN", 115, 121], ["A 20 cm segment of ileum", "TREATMENT", 0, 24], ["20 cm", "OBSERVATION_MODIFIER", 2, 7], ["segment", "ANATOMY_MODIFIER", 8, 15], ["ileum", "ANATOMY", 19, 24], ["150 cm", "OBSERVATION_MODIFIER", 25, 31], ["ileal", "ANATOMY", 41, 46], ["cecal junction", "ANATOMY", 47, 61], ["10 cm", "OBSERVATION_MODIFIER", 68, 73], ["segment", "ANATOMY_MODIFIER", 74, 81], ["proximal", "ANATOMY_MODIFIER", 85, 93], ["colon", "ANATOMY", 94, 99], ["60 cm", "OBSERVATION", 100, 105], ["rectum", "ANATOMY", 115, 121]]], ["Ileum and colon segments were flushed with ice cold Krebs-Henseleit buffer.", [["Ileum", "ANATOMY", 0, 5], ["colon segments", "ANATOMY", 10, 24], ["Ileum", "MULTI-TISSUE_STRUCTURE", 0, 5], ["colon segments", "MULTI-TISSUE_STRUCTURE", 10, 24], ["ice cold Krebs", "TREATMENT", 43, 57], ["Henseleit buffer", "TREATMENT", 58, 74], ["colon", "ANATOMY", 10, 15], ["segments", "ANATOMY_MODIFIER", 16, 24]]], ["For mucosal scrapings, intestinal segments were then cut open longitudinally along the mesenteric border and the epithelial layer gently scrapped with a glass slide without disturbing the underlying lamina propria.", [["mucosal scrapings", "ANATOMY", 4, 21], ["intestinal segments", "ANATOMY", 23, 42], ["mesenteric border", "ANATOMY", 87, 104], ["epithelial layer", "ANATOMY", 113, 129], ["lamina propria", "ANATOMY", 199, 213], ["mucosal scrapings", "MULTI-TISSUE_STRUCTURE", 4, 21], ["intestinal segments", "MULTI-TISSUE_STRUCTURE", 23, 42], ["mesenteric border", "MULTI-TISSUE_STRUCTURE", 87, 104], ["epithelial layer", "TISSUE", 113, 129], ["lamina propria", "TISSUE", 199, 213], ["mucosal scrapings", "PROBLEM", 4, 21], ["intestinal segments", "TREATMENT", 23, 42], ["a glass slide", "TREATMENT", 151, 164], ["mucosal", "ANATOMY", 4, 11], ["scrapings", "OBSERVATION", 12, 21], ["intestinal segments", "ANATOMY", 23, 42], ["mesenteric", "ANATOMY", 87, 97], ["border", "ANATOMY_MODIFIER", 98, 104], ["epithelial", "ANATOMY_MODIFIER", 113, 123], ["layer", "OBSERVATION_MODIFIER", 124, 129], ["glass slide", "OBSERVATION", 153, 164], ["lamina propria", "ANATOMY", 199, 213]]], ["Ileum and colon samples that were not used for ex vivo work were then snap frozen in liquid nitrogen and stored at \u201380\u00b0C until analysis.Intestinal Integrity ::: MATERIALS AND METHODSElectrophysiological measurements were taken using modified Ussing chambers as previously described (Albin et al., 2007; Gabler et al., 2009; Moeser et al., 2012).", [["Ileum", "ANATOMY", 0, 5], ["colon samples", "ANATOMY", 10, 23], ["Intestinal", "ANATOMY", 136, 146], ["nitrogen", "CHEMICAL", 92, 100], ["Ileum", "CELL", 0, 5], ["colon samples", "CANCER", 10, 23], ["Intestinal", "ORGAN", 136, 146], ["Ileum and colon samples", "TEST", 0, 23], ["snap frozen in liquid nitrogen", "TREATMENT", 70, 100], ["analysis", "TEST", 127, 135], ["METHODSElectrophysiological measurements", "TEST", 175, 215], ["modified Ussing chambers", "TREATMENT", 233, 257], ["colon", "ANATOMY", 10, 15]]], ["Briefly, fresh segments of the ileum and colon were removed and placed on ice in Krebs-Henseleit buffer for transport to the laboratory, kept under constant aeration until clamped in the modified Ussing chambers.", [["ileum", "ANATOMY", 31, 36], ["colon", "ANATOMY", 41, 46], ["ileum", "MULTI-TISSUE_STRUCTURE", 31, 36], ["colon", "ORGAN", 41, 46], ["fresh", "OBSERVATION", 9, 14], ["segments", "ANATOMY_MODIFIER", 15, 23], ["ileum", "ANATOMY", 31, 36], ["colon", "ANATOMY", 41, 46]]], ["To assess tight junction integrity and the mucosal to serosal endotoxin transport, tissues stripped of outer serosal layers were immediately mounted in a modified Ussing Chamber, with each chamber connected to a pair of dual channel current and voltage electrodes submerged in 3% noble agar bridges and filled with 3M potassium chloride for electrical conductance (Physiologic Instruments Inc., San Diego, CA and World Precision Instruments Inc., New Haven, CT).", [["tight junction", "ANATOMY", 10, 24], ["mucosal", "ANATOMY", 43, 50], ["serosal", "ANATOMY", 54, 61], ["tissues", "ANATOMY", 83, 90], ["serosal layers", "ANATOMY", 109, 123], ["potassium chloride", "CHEMICAL", 318, 336], ["potassium chloride", "CHEMICAL", 318, 336], ["tight junction", "MULTI-TISSUE_STRUCTURE", 10, 24], ["mucosal", "MULTI-TISSUE_STRUCTURE", 43, 50], ["tissues", "TISSUE", 83, 90], ["serosal layers", "MULTI-TISSUE_STRUCTURE", 109, 123], ["potassium chloride", "SIMPLE_CHEMICAL", 318, 336], ["tight junction integrity", "TREATMENT", 10, 34], ["serosal endotoxin transport", "TEST", 54, 81], ["outer serosal layers", "PROBLEM", 103, 123], ["a modified Ussing Chamber", "TREATMENT", 152, 177], ["each chamber", "TREATMENT", 184, 196], ["dual channel current and voltage electrodes", "TREATMENT", 220, 263], ["3% noble agar bridges", "TREATMENT", 277, 298], ["3M potassium chloride", "TREATMENT", 315, 336], ["electrical conductance", "TREATMENT", 341, 363], ["CT", "TEST", 458, 460], ["tight junction", "OBSERVATION_MODIFIER", 10, 24], ["mucosal", "ANATOMY", 43, 50], ["outer", "ANATOMY_MODIFIER", 103, 108], ["serosal layers", "ANATOMY", 109, 123]]], ["Each segment (0.71 cm2) was bathed on its mucosal and serosal sides with Krebs buffer and constantly gassed with 95% O2\u20135% CO2 mixture.", [["mucosal", "ANATOMY", 42, 49], ["serosal sides", "ANATOMY", 54, 67], ["CO2", "CHEMICAL", 123, 126], ["CO2", "CHEMICAL", 123, 126], ["mucosal", "TISSUE", 42, 49], ["serosal sides", "MULTI-TISSUE_STRUCTURE", 54, 67], ["O2\u20135", "SIMPLE_CHEMICAL", 117, 121], ["CO2", "SIMPLE_CHEMICAL", 123, 126], ["Krebs buffer", "TREATMENT", 73, 85], ["95% O2\u20135% CO2 mixture", "TREATMENT", 113, 134], ["segment", "ANATOMY_MODIFIER", 5, 12], ["0.71 cm2", "OBSERVATION_MODIFIER", 14, 22], ["mucosal", "ANATOMY", 42, 49], ["serosal sides", "ANATOMY", 54, 67]]], ["The temperature of all tissues and apparatus was constantly maintained at 37\u00b0C using circulating warm water.", [["tissues", "ANATOMY", 23, 30], ["tissues", "TISSUE", 23, 30], ["C", "SIMPLE_CHEMICAL", 77, 78], ["circulating warm water", "TREATMENT", 85, 107], ["all tissues", "ANATOMY", 19, 30]]], ["A short circuit current was established and stabilized for 10 min and transepithelial resistance (TER) was measured using the included software (Acquire and Analyze, Physiological instruments).Intestinal Integrity ::: MATERIALS AND METHODSAfter recording the basal electrophysiological measurements, the mucosal to serosal macromolecule transport of fluorescein isothiocyanate labeled dextran (4.4 KDa; FITC-Dextran) was assessed to measure the integrity of both ileum and colon, as previously described (Wang et al., 2001).", [["transepithelial", "ANATOMY", 70, 85], ["Intestinal", "ANATOMY", 193, 203], ["mucosal", "ANATOMY", 304, 311], ["serosal", "ANATOMY", 315, 322], ["ileum", "ANATOMY", 463, 468], ["colon", "ANATOMY", 473, 478], ["fluorescein isothiocyanate", "CHEMICAL", 350, 376], ["dextran", "CHEMICAL", 385, 392], ["FITC-Dextran", "CHEMICAL", 403, 415], ["fluorescein isothiocyanate", "CHEMICAL", 350, 376], ["FITC", "CHEMICAL", 403, 407], ["transepithelial", "MULTI-TISSUE_STRUCTURE", 70, 85], ["Intestinal", "ORGAN", 193, 203], ["mucosal", "MULTI-TISSUE_STRUCTURE", 304, 311], ["serosal", "MULTI-TISSUE_STRUCTURE", 315, 322], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 350, 376], ["dextran", "SIMPLE_CHEMICAL", 385, 392], ["FITC-Dextran", "SIMPLE_CHEMICAL", 403, 415], ["ileum", "MULTI-TISSUE_STRUCTURE", 463, 468], ["colon", "ORGAN", 473, 478], ["A short circuit", "TREATMENT", 0, 15], ["transepithelial resistance (TER)", "TREATMENT", 70, 102], ["the basal electrophysiological measurements", "TEST", 255, 298], ["fluorescein isothiocyanate labeled dextran", "TREATMENT", 350, 392], ["FITC-Dextran", "TREATMENT", 403, 415], ["basal", "ANATOMY_MODIFIER", 259, 264], ["mucosal", "ANATOMY", 304, 311], ["integrity", "ANATOMY_MODIFIER", 445, 454], ["both", "ANATOMY_MODIFIER", 458, 462], ["ileum", "ANATOMY", 463, 468], ["colon", "ANATOMY", 473, 478]]], ["Briefly, the mucosal chambers were treated with 2.2 mg/mL FITC-Dextran, and chamber samples from both sides were collected every 10 to 15 min.", [["mucosal chambers", "ANATOMY", 13, 29], ["samples", "ANATOMY", 84, 91], ["FITC-Dextran", "CHEMICAL", 58, 70], ["FITC", "CHEMICAL", 58, 62], ["mucosal chambers", "MULTI-TISSUE_STRUCTURE", 13, 29], ["FITC-Dextran", "SIMPLE_CHEMICAL", 58, 70], ["Dextran", "TREATMENT", 63, 70], ["chamber samples from both sides", "TREATMENT", 76, 107], ["mucosal chambers", "ANATOMY", 13, 29]]], ["The relative fluorescence was then determined using a fluorescent plate reader (Bio-Tek, Winooski, VT), with excitation and emission wavelengths of 485 and 520 nm, respectively.", [["a fluorescent plate", "TREATMENT", 52, 71], ["emission wavelengths", "TEST", 124, 144]]], ["An apparent permeability coefficient (Papp) was then calculated using the area of the membrane and rate of FITC-Dextran transport, where dQ/dt = transport rate (\u00b5g/min); C0 = initial concentration in the donor chamber (\u00b5g/mL); A = area of the membrane (cm2): Papp = dQ/(dt\u00d7A\u00d7C0).Intestinal Integrity ::: MATERIALS AND METHODSThe mucosal to serosal transport of LPS was also assessed as previously described by Tomita et al. (2004).", [["membrane", "ANATOMY", 86, 94], ["membrane", "ANATOMY", 243, 251], ["Intestinal", "ANATOMY", 279, 289], ["mucosal", "ANATOMY", 329, 336], ["serosal", "ANATOMY", 340, 347], ["Dextran", "CHEMICAL", 112, 119], ["LPS", "CHEMICAL", 361, 364], ["FITC", "CHEMICAL", 107, 111], ["membrane", "CELLULAR_COMPONENT", 86, 94], ["FITC", "SIMPLE_CHEMICAL", 107, 111], ["Dextran", "SIMPLE_CHEMICAL", 112, 119], ["membrane", "CELLULAR_COMPONENT", 243, 251], ["Intestinal", "ORGAN", 279, 289], ["mucosal", "MULTI-TISSUE_STRUCTURE", 329, 336], ["serosal", "MULTI-TISSUE_STRUCTURE", 340, 347], ["LPS", "SIMPLE_CHEMICAL", 361, 364], ["FITC-Dextran transport", "TREATMENT", 107, 129], ["transport rate", "TEST", 145, 159], ["C0", "TEST", 170, 172], ["initial concentration in the donor chamber", "TREATMENT", 175, 217], ["Papp", "TEST", 259, 263], ["permeability coefficient", "OBSERVATION_MODIFIER", 12, 36], ["chamber", "ANATOMY_MODIFIER", 210, 217], ["mucosal", "ANATOMY", 329, 336]]], ["Briefly, the mucosal chambers were challenged with 20 \u00b5g/mL fluorescein isothiocyanate labeled LPS (FITC-LPS) and chamber samples from both sides were collected every 10 to 15 min.", [["mucosal chambers", "ANATOMY", 13, 29], ["samples", "ANATOMY", 122, 129], ["sides", "ANATOMY", 140, 145], ["fluorescein isothiocyanate", "CHEMICAL", 60, 86], ["LPS", "CHEMICAL", 95, 98], ["FITC-LPS", "CHEMICAL", 100, 108], ["fluorescein isothiocyanate", "CHEMICAL", 60, 86], ["FITC", "CHEMICAL", 100, 104], ["mucosal chambers", "MULTI-TISSUE_STRUCTURE", 13, 29], ["fluorescein isothiocyanate", "SIMPLE_CHEMICAL", 60, 86], ["LPS", "SIMPLE_CHEMICAL", 95, 98], ["FITC-LPS", "SIMPLE_CHEMICAL", 100, 108], ["the mucosal chambers", "TREATMENT", 9, 29], ["20 \u00b5g/mL fluorescein isothiocyanate labeled LPS", "TREATMENT", 51, 98], ["FITC-LPS", "TREATMENT", 100, 108], ["chamber samples", "TEST", 114, 129], ["mucosal chambers", "ANATOMY", 13, 29]]], ["The fluorescence and apparent permeability coefficient was calculated as described for FITC-Dextran.Circulating Endotoxin ::: MATERIALS AND METHODSSerum endotoxin concentrations were measured by an end point fluorescent assay using the recombinant factor C (rFC) system (Lonza, Basel, Switzerland).", [["FITC-Dextran", "CHEMICAL", 87, 99], ["Endotoxin", "CHEMICAL", 112, 121], ["FITC", "CHEMICAL", 87, 91], ["FITC-Dextran", "SIMPLE_CHEMICAL", 87, 99], ["Endotoxin", "GENE_OR_GENE_PRODUCT", 112, 121], ["factor C", "GENE_OR_GENE_PRODUCT", 248, 256], ["Endotoxin", "PROTEIN", 112, 121], ["recombinant factor C", "PROTEIN", 236, 256], ["rFC", "PROTEIN", 258, 261], ["The fluorescence", "TEST", 0, 16], ["apparent permeability coefficient", "PROBLEM", 21, 54], ["FITC-Dextran", "TREATMENT", 87, 99], ["METHODSSerum endotoxin concentrations", "TEST", 140, 177], ["fluorescent assay", "TEST", 208, 225], ["Endotoxin", "OBSERVATION", 112, 121]]], ["Briefly, the serum samples were diluted 1000X in pyrogen free water and 100 \u03bcL of the samples and standards were added to a 96 well round bottom plate and incubated at 37\u00b0C for 10 min.", [["serum samples", "ANATOMY", 13, 26], ["samples", "ANATOMY", 86, 93], ["serum samples", "ORGANISM_SUBSTANCE", 13, 26], ["the serum samples", "TEST", 9, 26], ["pyrogen free water", "TREATMENT", 49, 67], ["a 96 well round bottom plate", "TREATMENT", 122, 150]]], ["After incubation, 100 \u03bcL of rFC enzyme, rFC assay buffer and rFC substrate were added at a ratio of 1:4:5 to the plate and an initial reading were taken followed by 1 h incubation at 37\u00b0C. Thereafter, the relative fluorescence unit (RFU) for each well was determined (excitation 380 nm and emission 440 nm).", [["rFC", "SIMPLE_CHEMICAL", 40, 43], ["rFC enzyme", "PROTEIN", 28, 38], ["rFC enzyme", "TREATMENT", 28, 38], ["rFC assay buffer", "TREATMENT", 40, 56], ["rFC substrate", "TREATMENT", 61, 74]]], ["The concentration of the endotoxin was interpolated from the standard curve constructed from the standards and corrected for sample dilution.Alkaline Phosphatase activity ::: MATERIALS AND METHODSAlkaline phosphatase (ALP) activity was measured using the Quantichrom ALP assay kit (DALP-250, Gentaur, Bioassay systems, Hayward, CA).", [["endotoxin", "SIMPLE_CHEMICAL", 25, 34], ["Alkaline Phosphatase", "GENE_OR_GENE_PRODUCT", 141, 161], ["METHODSAlkaline phosphatase", "GENE_OR_GENE_PRODUCT", 189, 216], ["ALP", "GENE_OR_GENE_PRODUCT", 218, 221], ["endotoxin", "PROTEIN", 25, 34], ["Alkaline Phosphatase", "PROTEIN", 141, 161], ["METHODSAlkaline phosphatase", "PROTEIN", 189, 216], ["ALP", "PROTEIN", 218, 221], ["ALP", "PROTEIN", 267, 270], ["the endotoxin", "TREATMENT", 21, 34], ["sample dilution", "TEST", 125, 140], ["Alkaline Phosphatase activity", "TEST", 141, 170], ["METHODSAlkaline phosphatase", "TEST", 189, 216], ["ALP) activity", "TEST", 218, 231], ["the Quantichrom ALP assay", "TEST", 251, 276], ["DALP", "TEST", 282, 286], ["concentration", "OBSERVATION_MODIFIER", 4, 17]]], ["Protein was extracted using potassium phosphate buffer (PPB), pH 6.0 from liver and ileum and the protein concentration was determined using BCA assay (Pierce, Rockford, IL) and 50 \u03bcL of sample was added to a 150 \u03bcL working solution containing magnesium acetate, p-nitrophenyl phosphate and assay buffer in a 96 well plate.", [["liver", "ANATOMY", 74, 79], ["ileum", "ANATOMY", 84, 89], ["sample", "ANATOMY", 187, 193], ["potassium phosphate", "CHEMICAL", 28, 47], ["magnesium acetate", "CHEMICAL", 244, 261], ["p-nitrophenyl phosphate", "CHEMICAL", 263, 286], ["potassium phosphate", "CHEMICAL", 28, 47], ["magnesium acetate", "CHEMICAL", 244, 261], ["p-nitrophenyl phosphate", "CHEMICAL", 263, 286], ["potassium phosphate buffer", "SIMPLE_CHEMICAL", 28, 54], ["liver", "ORGAN", 74, 79], ["ileum", "ORGAN", 84, 89], ["magnesium acetate", "SIMPLE_CHEMICAL", 244, 261], ["p-nitrophenyl phosphate", "SIMPLE_CHEMICAL", 263, 286], ["Protein", "TEST", 0, 7], ["potassium phosphate buffer", "TREATMENT", 28, 54], ["PPB", "TEST", 56, 59], ["pH", "TEST", 62, 64], ["the protein concentration", "TEST", 94, 119], ["BCA assay", "TEST", 141, 150], ["a 150 \u03bcL working solution", "TREATMENT", 207, 232], ["magnesium acetate", "TREATMENT", 244, 261], ["p-nitrophenyl phosphate", "TREATMENT", 263, 286], ["assay buffer", "TREATMENT", 291, 303], ["liver", "ANATOMY", 74, 79], ["ileum", "ANATOMY", 84, 89]]], ["The optical density at 405 nm was measured at time 0 and after 4 min using a Synergy 4 microplate reader (Bio-Tek) and ALP activity was calculated according to the manufacturer's instructions.Myeloperoxidase Activity ::: MATERIALS AND METHODSMyeloperoxidase (MPO) activity was measured in the whole ileal tissue as an indicator of inflammation and neutrophil infiltration using an o-dianasidine assay (Suzuki et al., 1983; de La Serre et al., 2010).", [["ileal tissue", "ANATOMY", 299, 311], ["neutrophil", "ANATOMY", 348, 358], ["inflammation", "DISEASE", 331, 343], ["o-dianasidine", "CHEMICAL", 381, 394], ["ALP", "GENE_OR_GENE_PRODUCT", 119, 122], ["Myeloperoxidase", "GENE_OR_GENE_PRODUCT", 192, 207], ["METHODSMyeloperoxidase", "GENE_OR_GENE_PRODUCT", 235, 257], ["MPO", "SIMPLE_CHEMICAL", 259, 262], ["ileal tissue", "TISSUE", 299, 311], ["neutrophil", "CELL", 348, 358], ["ALP", "PROTEIN", 119, 122], ["Myeloperoxidase", "PROTEIN", 192, 207], ["MPO", "PROTEIN", 259, 262], ["a Synergy 4 microplate reader (Bio-Tek)", "TREATMENT", 75, 114], ["ALP activity", "TEST", 119, 131], ["METHODSMyeloperoxidase (MPO) activity", "TREATMENT", 235, 272], ["inflammation", "PROBLEM", 331, 343], ["neutrophil infiltration", "PROBLEM", 348, 371], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["density", "OBSERVATION", 12, 19], ["405 nm", "OBSERVATION_MODIFIER", 23, 29], ["ileal tissue", "ANATOMY", 299, 311], ["indicator of", "UNCERTAINTY", 318, 330], ["inflammation", "OBSERVATION", 331, 343], ["neutrophil infiltration", "OBSERVATION", 348, 371]]], ["Tissue samples were homogenized in PPB pH 6.0, containing 0.5% hexadecyltrimethylammonium bromide (HTAB) and then freeze-thawed on ice and vortexed 3 times.", [["Tissue samples", "ANATOMY", 0, 14], ["hexadecyltrimethylammonium bromide", "CHEMICAL", 63, 97], ["HTAB", "CHEMICAL", 99, 103], ["hexadecyltrimethylammonium bromide", "CHEMICAL", 63, 97], ["HTAB", "CHEMICAL", 99, 103], ["Tissue samples", "CANCER", 0, 14], ["hexadecyltrimethylammonium bromide", "SIMPLE_CHEMICAL", 63, 97], ["HTAB", "SIMPLE_CHEMICAL", 99, 103], ["Tissue samples", "TEST", 0, 14], ["PPB pH", "TEST", 35, 41], ["0.5% hexadecyltrimethylammonium bromide", "TREATMENT", 58, 97], ["ice", "TREATMENT", 131, 134]]], ["Samples were then centrifuged at 10,000 \u00d7 g for 15 min at 4\u00b0C. The resulting supernatant was transferred to a new tube and the remaining pellet was resuspended in 500 \u03bcL of PPB + 0.5% HTAB.", [["Samples", "ANATOMY", 0, 7], ["supernatant", "ANATOMY", 77, 88], ["tube", "ANATOMY", 114, 118], ["pellet", "ANATOMY", 137, 143], ["PPB", "CHEMICAL", 173, 176], ["HTAB", "CHEMICAL", 184, 188], ["HTAB", "CHEMICAL", 184, 188], ["tube", "TISSUE", 114, 118], ["HTAB", "SIMPLE_CHEMICAL", 184, 188], ["Samples", "TEST", 0, 7], ["a new tube", "TREATMENT", 108, 118], ["the remaining pellet", "TREATMENT", 123, 143], ["PPB", "TREATMENT", 173, 176], ["supernatant", "OBSERVATION_MODIFIER", 77, 88], ["tube", "OBSERVATION", 114, 118]]], ["The resuspended pellet was freeze-thawed and homogenized twice and 500 \u03bcL of this solution was transferred to a new tube.", [["pellet", "ANATOMY", 16, 22], ["tube", "TISSUE", 116, 120], ["this solution", "TREATMENT", 77, 90], ["a new tube", "TREATMENT", 110, 120], ["new", "OBSERVATION_MODIFIER", 112, 115], ["tube", "OBSERVATION", 116, 120]]], ["Samples were then centrifuged again at 10,000 \u00d7 g for 15 min at 4\u00b0C and the supernatant was collected.", [["Samples", "ANATOMY", 0, 7], ["supernatant", "ANATOMY", 76, 87], ["C", "GENE_OR_GENE_PRODUCT", 66, 67]]], ["The final supernatant was mixed with o-dianasidine dihydrochloride and 0.005% hydrogen peroxide.", [["supernatant", "ANATOMY", 10, 21], ["o-dianasidine dihydrochloride", "CHEMICAL", 37, 66], ["hydrogen peroxide", "CHEMICAL", 78, 95], ["o-dianasidine dihydrochloride", "CHEMICAL", 37, 66], ["hydrogen peroxide", "CHEMICAL", 78, 95], ["o-dianasidine dihydrochloride", "SIMPLE_CHEMICAL", 37, 66], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 78, 95], ["o-dianasidine dihydrochloride", "TREATMENT", 37, 66], ["0.005% hydrogen peroxide", "TREATMENT", 71, 95]]], ["One unit of MPO activity was expressed as the amount of MPO needed to degrade 1 \u00b5mol of hydrogen peroxide/min/mL.", [["hydrogen peroxide", "CHEMICAL", 88, 105], ["hydrogen peroxide", "CHEMICAL", 88, 105], ["MPO", "SIMPLE_CHEMICAL", 12, 15], ["MPO", "SIMPLE_CHEMICAL", 56, 59], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 88, 105], ["MPO", "PROTEIN", 12, 15], ["MPO", "PROTEIN", 56, 59], ["MPO activity", "TREATMENT", 12, 24], ["hydrogen peroxide", "TREATMENT", 88, 105]]], ["Absorbance was read at 460 nm for 10 min reaction time and absorbance was calculated on mL sample/mg tissue basis.Lysozyme activity ::: MATERIALS AND METHODSWhole ileum and liver samples were analyzed for lysozyme activity using the EnzChek fluorescent assay which compares sample lysozyme activity to lysozyme activity on Micrococcus Lysodeikticus cell walls (Invitrogen-Molecular Probes, Carlsbad, California).", [["tissue", "ANATOMY", 101, 107], ["METHODSWhole ileum", "ANATOMY", 150, 168], ["liver samples", "ANATOMY", 173, 186], ["cell walls", "ANATOMY", 349, 359], ["tissue", "TISSUE", 101, 107], ["Lysozyme", "GENE_OR_GENE_PRODUCT", 114, 122], ["METHODSWhole ileum", "CANCER", 150, 168], ["liver samples", "CANCER", 173, 186], ["lysozyme", "GENE_OR_GENE_PRODUCT", 205, 213], ["lysozyme", "GENE_OR_GENE_PRODUCT", 302, 310], ["Micrococcus Lysodeikticus cell", "CELL", 323, 353], ["lysozyme", "PROTEIN", 205, 213], ["lysozyme", "PROTEIN", 281, 289], ["lysozyme", "PROTEIN", 302, 310], ["Micrococcus Lysodeikticus", "SPECIES", 323, 348], ["Micrococcus Lysodeikticus", "SPECIES", 323, 348], ["absorbance", "TEST", 59, 69], ["liver samples", "TEST", 173, 186], ["lysozyme activity", "TREATMENT", 205, 222], ["the EnzChek fluorescent assay", "TEST", 229, 258], ["lysozyme activity", "TEST", 302, 319], ["Micrococcus Lysodeikticus cell walls", "TEST", 323, 359], ["Invitrogen", "TEST", 361, 371], ["ileum", "ANATOMY", 163, 168], ["liver", "ANATOMY", 173, 178], ["Lysodeikticus cell walls", "OBSERVATION", 335, 359]]], ["Samples were diluted and fluorescence was measured using excitation emission wavelengths of 485 and 530 nm and the lysozyme activity were interpolated from the standard curve constructed from the standards and corrected for sample dilution.Ileal Interleukin-8 and Systemic Acute Phase Protein Assays ::: MATERIALS AND METHODSIleal protein (100 \u03bcg) was extracted using PPB, pH 6.0 and analyzed for IL-8 concentration using a porcine-specific ELISA (DuoSet Porcine IL8, catalog number DY535, R&D Systems, Minneapolis, MN) per the manufacturer's instructions.", [["Samples", "ANATOMY", 0, 7], ["lysozyme", "GENE_OR_GENE_PRODUCT", 115, 123], ["Interleukin-8", "GENE_OR_GENE_PRODUCT", 246, 259], ["IL-8", "GENE_OR_GENE_PRODUCT", 397, 401], ["porcine", "ORGANISM", 424, 431], ["lysozyme", "PROTEIN", 115, 123], ["Ileal Interleukin-8", "PROTEIN", 240, 259], ["METHODSIleal protein", "PROTEIN", 318, 338], ["IL", "PROTEIN", 397, 399], ["IL8", "PROTEIN", 463, 466], ["Porcine", "SPECIES", 455, 462], ["Samples", "TEST", 0, 7], ["fluorescence", "TEST", 25, 37], ["excitation emission wavelengths", "TEST", 57, 88], ["the lysozyme activity", "TEST", 111, 132], ["sample dilution", "TEST", 224, 239], ["Ileal Interleukin", "TEST", 240, 257], ["Systemic Acute Phase Protein Assays", "TEST", 264, 299], ["METHODSIleal protein", "TREATMENT", 318, 338], ["PPB", "TEST", 368, 371], ["pH", "TEST", 373, 375], ["IL", "TEST", 397, 399], ["a porcine-specific ELISA (DuoSet Porcine IL8", "TREATMENT", 422, 466], ["530 nm", "OBSERVATION_MODIFIER", 100, 106], ["Acute", "OBSERVATION_MODIFIER", 273, 278]]], ["Serum haptoglobin, C-reactive protein (CRP; ALPCO Diagnostics, Salem, NH) and LPS binding protein (LBP; Hycult Biotech, Plymouth, PA) were analyzed using commercially available ELISA kits.", [["Serum", "ANATOMY", 0, 5], ["LPS", "CHEMICAL", 78, 81], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 6, 17], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 19, 37], ["CRP", "GENE_OR_GENE_PRODUCT", 39, 42], ["LPS binding protein", "GENE_OR_GENE_PRODUCT", 78, 97], ["PA", "GENE_OR_GENE_PRODUCT", 130, 132], ["haptoglobin", "PROTEIN", 6, 17], ["C-reactive protein", "PROTEIN", 19, 37], ["CRP", "PROTEIN", 39, 42], ["LPS binding protein", "PROTEIN", 78, 97], ["LBP", "PROTEIN", 99, 102], ["Serum haptoglobin", "TEST", 0, 17], ["C-reactive protein", "TEST", 19, 37], ["CRP", "TEST", 39, 42], ["ALPCO", "TEST", 44, 49], ["Diagnostics", "TEST", 50, 61], ["LPS binding protein", "TEST", 78, 97], ["LBP", "TEST", 99, 102], ["Hycult Biotech", "TREATMENT", 104, 118]]], ["Briefly, serum samples were added to wells adsorbed with anti-porcine haptoglobin, CRP and LBP antibodies.", [["serum samples", "ANATOMY", 9, 22], ["serum samples", "ORGANISM_SUBSTANCE", 9, 22], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 70, 81], ["CRP", "GENE_OR_GENE_PRODUCT", 83, 86], ["LBP antibodies", "GENE_OR_GENE_PRODUCT", 91, 105], ["anti-porcine haptoglobin", "PROTEIN", 57, 81], ["CRP", "PROTEIN", 83, 86], ["LBP antibodies", "PROTEIN", 91, 105], ["serum samples", "TEST", 9, 22], ["anti-porcine haptoglobin", "TEST", 57, 81], ["CRP", "TEST", 83, 86], ["LBP antibodies", "TEST", 91, 105]]], ["After washing, horseradish peroxidase (HRP) conjugated anti haptoglobin, CRP and LBP antibodies were added to the plate.", [["horseradish peroxidase", "SIMPLE_CHEMICAL", 15, 37], ["HRP", "SIMPLE_CHEMICAL", 39, 42], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 60, 71], ["CRP", "GENE_OR_GENE_PRODUCT", 73, 76], ["LBP antibodies", "GENE_OR_GENE_PRODUCT", 81, 95], ["horseradish peroxidase", "PROTEIN", 15, 37], ["HRP", "PROTEIN", 39, 42], ["anti haptoglobin", "PROTEIN", 55, 71], ["CRP", "PROTEIN", 73, 76], ["LBP antibodies", "PROTEIN", 81, 95], ["horseradish", "SPECIES", 15, 26], ["horseradish peroxidase (HRP) conjugated anti haptoglobin", "TEST", 15, 71], ["CRP", "TEST", 73, 76], ["LBP antibodies", "TREATMENT", 81, 95], ["plate", "ANATOMY", 114, 119]]], ["After another washing, the HRP was assayed by the addition of the chromogenic substrate 3,3',5,5'-tetramethylbenzidine (TMB) and the absorbance was measured at 450 nm.", [["3,3',5,5'-tetramethylbenzidine", "CHEMICAL", 88, 118], ["TMB", "CHEMICAL", 120, 123], ["3,3',5,5'-tetramethylbenzidine", "CHEMICAL", 88, 118], ["TMB", "CHEMICAL", 120, 123], ["HRP", "SIMPLE_CHEMICAL", 27, 30], ["3,3',5,5'-tetramethylbenzidine", "SIMPLE_CHEMICAL", 88, 118], ["TMB", "SIMPLE_CHEMICAL", 120, 123], ["HRP", "PROTEIN", 27, 30], ["another washing", "TREATMENT", 6, 21], ["the HRP", "TEST", 23, 30], ["the chromogenic substrate", "TREATMENT", 62, 87], ["tetramethylbenzidine", "TREATMENT", 98, 118], ["the absorbance", "TEST", 129, 143]]], ["The quantity of haptoglobin, CRP and LBP in the test samples was interpolated from the standard curve constructed from the standards and corrected for sample dilution.Quantitative Real-time PCR ::: MATERIALS AND METHODSTotal RNA was isolated from tissue samples using Trizol (Invitrogen Inc.) reagent according to the manufacturer's protocol and the RNA pellets were resuspended in nuclease free water.", [["samples", "ANATOMY", 53, 60], ["tissue samples", "ANATOMY", 247, 261], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 16, 27], ["CRP", "GENE_OR_GENE_PRODUCT", 29, 32], ["LBP", "GENE_OR_GENE_PRODUCT", 37, 40], ["tissue samples", "TISSUE", 247, 261], ["haptoglobin", "PROTEIN", 16, 27], ["CRP", "PROTEIN", 29, 32], ["LBP", "PROTEIN", 37, 40], ["METHODSTotal RNA", "RNA", 212, 228], ["nuclease", "PROTEIN", 382, 390], ["haptoglobin", "TEST", 16, 27], ["CRP", "TEST", 29, 32], ["LBP", "PROBLEM", 37, 40], ["the test samples", "TEST", 44, 60], ["the standard curve", "TEST", 83, 101], ["sample dilution", "TEST", 151, 166], ["Quantitative Real-time PCR", "TEST", 167, 193], ["METHODSTotal RNA", "TREATMENT", 212, 228], ["Trizol (Invitrogen Inc.) reagent", "TREATMENT", 268, 300], ["the manufacturer's protocol", "TREATMENT", 314, 341], ["the RNA pellets", "TREATMENT", 346, 361], ["quantity", "OBSERVATION_MODIFIER", 4, 12], ["haptoglobin", "OBSERVATION_MODIFIER", 16, 27], ["LBP", "OBSERVATION_MODIFIER", 37, 40]]], ["To eliminate potential genomic DNA contamination, the RNA samples were treated with a DNase I kit (DNA-free, Ambion Inc., Austin, TX) per the manufacturer's instructions.", [["samples", "ANATOMY", 58, 65], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["DNA", "CELLULAR_COMPONENT", 99, 102], ["DNase I", "PROTEIN", 86, 93], ["potential genomic DNA contamination", "PROBLEM", 13, 48], ["the RNA samples", "TEST", 50, 65], ["a DNase I kit", "TREATMENT", 84, 97], ["TX", "TREATMENT", 130, 132], ["genomic DNA contamination", "OBSERVATION", 23, 48]]], ["Total RNA was quantified by measuring the absorbance at 260nm using a spectrophotometer (ND-100, NanoDrop Technologies, Rockland, DE) and the purity was assessed by determining the ratio of the absorbance at 260 and 280 nm.", [["Total RNA", "TEST", 0, 9], ["the absorbance", "TEST", 38, 52], ["a spectrophotometer (ND", "TREATMENT", 68, 91]]], ["All samples had 260/280 nm ratios above 1.8.", [["samples", "ANATOMY", 4, 11], ["All samples", "TEST", 0, 11], ["nm ratios", "TEST", 24, 33]]], ["The integrity of the RNA preparations was verified by visualization of the 18S and 28S ribosomal bands stained with ethidium bromide after electrophoresis on 1.2% agarose gels (E-gel; Invitrogen Inc.).", [["ethidium bromide", "CHEMICAL", 116, 132], ["ethidium bromide", "CHEMICAL", 116, 132], ["28S", "CELLULAR_COMPONENT", 83, 86], ["ribosomal", "CELLULAR_COMPONENT", 87, 96], ["ethidium bromide", "SIMPLE_CHEMICAL", 116, 132], ["18S", "DNA", 75, 78], ["visualization", "TEST", 54, 67], ["the 18S", "TEST", 71, 78], ["28S ribosomal bands", "TEST", 83, 102], ["ethidium bromide", "TREATMENT", 116, 132], ["electrophoresis", "TEST", 139, 154], ["1.2% agarose gels", "TREATMENT", 158, 175], ["E-gel", "TREATMENT", 177, 182], ["integrity", "OBSERVATION_MODIFIER", 4, 13]]], ["A good preparation was indicated by the presence of 28S and 18S bands that were not smeared and by the 28S band stained with a greater intensity than the 18S band.", [["28S", "CELLULAR_COMPONENT", 52, 55], ["28S", "DNA", 52, 55], ["18S bands", "TEST", 60, 69], ["the 28S band", "TEST", 99, 111], ["the 18S band", "TEST", 150, 162], ["greater intensity", "OBSERVATION_MODIFIER", 127, 144], ["18S band", "OBSERVATION", 154, 162]]], ["Total RNA (1 \u03bcg) was reverse transcribed using a commercially available cDNA synthesis kit (iScript, BioRad Laboratories, Hercules, CA).", [["Total RNA", "TEST", 0, 9]]], ["The iScript kit used a blend of oligo (dT) and random hexamer primers for cDNA synthesis and the reverse transcriptase is RNase H+ to ensure removal of the RNA template.", [["RNase H+", "GENE_OR_GENE_PRODUCT", 122, 130], ["reverse transcriptase", "PROTEIN", 97, 118], ["RNase H", "PROTEIN", 122, 129], ["RNA template", "RNA", 156, 168], ["oligo (dT)", "TREATMENT", 32, 42], ["random hexamer primers", "TREATMENT", 47, 69], ["cDNA synthesis", "TREATMENT", 74, 88], ["the reverse transcriptase", "TREATMENT", 93, 118], ["removal of the RNA template", "TREATMENT", 141, 168]]], ["The primers used for real-time reverse-transcription real time (RT)-PCR are presented in Table 1.Quantitative Real-time PCR ::: MATERIALS AND METHODSAmplification was performed in a total volume of 25 \u03bcL containing 1X iQ SYBR Green Supermix (BioRad Laboratories), forward and reverse primers (0.1 \u03bcg/\u03bcL) and 1 \u03bcL of the 20 \u03bcL cDNA reaction.", [["The primers", "TREATMENT", 0, 11], ["PCR", "TEST", 68, 71], ["a total volume", "TEST", 180, 194], ["the 20 \u03bcL cDNA reaction", "TREATMENT", 316, 339]]], ["Optical detection was performed at 72\u00b0C. At the end of the PCR, melt curve analysis was conducted to validate the specificity of the primers.", [["Optical detection", "TEST", 0, 17], ["the PCR", "TEST", 55, 62], ["melt curve analysis", "TEST", 64, 83]]], ["A non-template control was run with every assay and all determinations were performed in duplicate.", [["A non-template control", "TREATMENT", 0, 22], ["every assay", "TEST", 36, 47], ["all determinations", "TEST", 52, 70]]], ["Presence of a single PCR product of the correct size for each primer set was verified by visualizing the PCR products via electrophoresis on 1% agarose gels stained with ethidium bromide.", [["ethidium bromide", "CHEMICAL", 170, 186], ["ethidium bromide", "CHEMICAL", 170, 186], ["agarose", "SIMPLE_CHEMICAL", 144, 151], ["ethidium bromide", "SIMPLE_CHEMICAL", 170, 186], ["PCR products", "DNA", 105, 117], ["a single PCR product", "TREATMENT", 12, 32], ["the PCR products", "TREATMENT", 101, 117], ["electrophoresis", "TEST", 122, 137], ["1% agarose gels", "TREATMENT", 141, 156], ["ethidium bromide", "TREATMENT", 170, 186], ["size", "OBSERVATION_MODIFIER", 48, 52]]], ["The mRNA abundance values for each sample were normalized to \u03b22 microglobulin according to the \u0394CT method (Livak and Schmittgen, 2001).", [["sample", "ANATOMY", 35, 41], ["\u03b22 microglobulin", "GENE_OR_GENE_PRODUCT", 61, 77], ["\u03b22 microglobulin", "PROTEIN", 61, 77], ["The mRNA abundance values", "TEST", 0, 25], ["each sample", "TEST", 30, 41], ["microglobulin", "TEST", 64, 77], ["the \u0394CT method", "TEST", 91, 105]]], ["The expression of \u03b22 microglobulin did not differ (P > 0.5) between the RFI lines.Statistical Analyses ::: MATERIALS AND METHODSAll results were expressed as least squares (LS) means \u00b1 SEM.", [["\u03b22 microglobulin", "GENE_OR_GENE_PRODUCT", 18, 34], ["\u03b22 microglobulin", "PROTEIN", 18, 34], ["RFI lines", "CELL_LINE", 72, 81], ["\u03b22 microglobulin", "TEST", 18, 34], ["P", "TEST", 51, 52], ["RFI lines", "OBSERVATION", 72, 81]]], ["The main effect of line (HRFI vs. LRFI) was determined by the Proc Mixed procedure (SAS Inst.", [["line (HRFI vs. LRFI)", "TREATMENT", 19, 39], ["the Proc Mixed procedure", "TREATMENT", 58, 82], ["main", "OBSERVATION_MODIFIER", 4, 8], ["effect", "OBSERVATION_MODIFIER", 9, 15], ["line", "OBSERVATION", 19, 23]]], ["However, for Ussing chamber data, tissue (colon versus ileum) was also included as a fixed effect.", [["tissue", "ANATOMY", 34, 40], ["colon", "ANATOMY", 42, 47], ["ileum", "ANATOMY", 55, 60], ["tissue", "TISSUE", 34, 40], ["colon", "MULTI-TISSUE_STRUCTURE", 42, 47], ["ileum", "MULTI-TISSUE_STRUCTURE", 55, 60], ["Ussing chamber data", "TEST", 13, 32], ["a fixed effect", "PROBLEM", 83, 97], ["colon", "ANATOMY", 42, 47], ["ileum", "ANATOMY", 55, 60]]], ["Statistical significance of differences was determined by Tukey's range test for pair wise comparisons.", [["Tukey's range test", "TEST", 58, 76], ["pair wise comparisons", "TEST", 81, 102]]], ["Differences were deemed significant at P \u2264 0.05 and tendencies at P \u2264 0.10.", [["P", "TEST", 39, 40], ["tendencies", "TEST", 52, 62], ["significant", "OBSERVATION_MODIFIER", 24, 35]]], ["Phenotypic correlations between serum endotoxin and acute phase proteins, ileum endotoxin permeability, ALP and lysozyme with RFI, ADG, ADFI and G:F were computed based on residuals derived from the above models using the CORR procedure of SAS.RESULTSTwelve gilts per line weighing approximately (62 \u00b1 3, kg BW) were used for the study.", [["serum", "ANATOMY", 32, 37], ["ileum", "ANATOMY", 74, 79], ["endotoxin", "CHEMICAL", 38, 47], ["SAS", "DISEASE", 240, 243], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["endotoxin", "SIMPLE_CHEMICAL", 38, 47], ["ileum", "MULTI-TISSUE_STRUCTURE", 74, 79], ["ALP", "GENE_OR_GENE_PRODUCT", 104, 107], ["lysozyme", "GENE_OR_GENE_PRODUCT", 112, 120], ["G:F", "GENE_OR_GENE_PRODUCT", 145, 148], ["serum endotoxin", "PROTEIN", 32, 47], ["acute phase proteins", "PROTEIN", 52, 72], ["ileum endotoxin", "PROTEIN", 74, 89], ["ALP", "PROTEIN", 104, 107], ["lysozyme", "PROTEIN", 112, 120], ["Phenotypic correlations", "TEST", 0, 23], ["serum endotoxin", "TEST", 32, 47], ["acute phase proteins", "TEST", 52, 72], ["ileum endotoxin permeability", "TEST", 74, 102], ["ALP", "TEST", 104, 107], ["lysozyme", "TEST", 112, 120], ["RFI", "TEST", 126, 129], ["residuals", "TEST", 172, 181], ["the CORR procedure", "TREATMENT", 218, 236], ["SAS", "PROBLEM", 240, 243], ["RESULTSTwelve gilts per line weighing", "TREATMENT", 244, 281], ["the study", "TEST", 326, 335], ["acute phase", "OBSERVATION_MODIFIER", 52, 63], ["ileum", "ANATOMY", 74, 79]]], ["At the end of the experimental period, growth performance was measured.", [["growth performance", "TEST", 39, 57]]], ["As expected, the LRFI pigs consumed less feed than their HRFI counterparts (ADFI: 1.90 vs. 2.23 kg/day, P < 0.001).", [["pigs", "ORGANISM", 22, 26], ["pigs", "SPECIES", 22, 26], ["pigs", "SPECIES", 22, 26], ["the LRFI pigs", "TREATMENT", 13, 26], ["ADFI", "TEST", 76, 80], ["P", "TEST", 104, 105]]], ["However, the ADG did not differ between the lines (0.67 vs. 0.65, kg/day, P = 0.72).", [["P", "TEST", 74, 75]]], ["Because the LRFI pigs consumed less feed for the same ADG, their G:F ratio was greater than that of the HRFI pigs (0.35 vs. 0.29, P = 0.019).", [["LRFI pigs", "ORGANISM", 12, 21], ["G:F", "GENE_OR_GENE_PRODUCT", 65, 68], ["HRFI pigs", "ORGANISM", 104, 113], ["pigs", "SPECIES", 17, 21], ["pigs", "SPECIES", 109, 113], ["pigs", "SPECIES", 17, 21], ["the LRFI pigs", "TREATMENT", 8, 21], ["their G:F ratio", "TEST", 59, 74], ["P", "TEST", 130, 131]]], ["These results confirm that the effect of selection for RFI was maintained in the gilts used for this study.RESULTSIntestinal integrity was assessed by measuring the TER and macromolecule permeability in freshly isolated ileum and colon samples.", [["ileum", "ANATOMY", 220, 225], ["colon samples", "ANATOMY", 230, 243], ["ileum", "MULTI-TISSUE_STRUCTURE", 220, 225], ["colon samples", "CANCER", 230, 243], ["selection for RFI", "TREATMENT", 41, 58], ["this study", "TEST", 96, 106], ["the TER and macromolecule permeability", "TEST", 161, 199], ["ileum", "ANATOMY", 220, 225], ["colon", "ANATOMY", 230, 235]]], ["Transepithelial resistance, an electrophysiological measure of intestinal integrity, was not different in either the ileum or colon of pigs divergently selected for RFI (Table 2).", [["intestinal", "ANATOMY", 63, 73], ["ileum", "ANATOMY", 117, 122], ["colon", "ANATOMY", 126, 131], ["Transepithelial", "MULTI-TISSUE_STRUCTURE", 0, 15], ["intestinal", "ORGAN", 63, 73], ["ileum", "MULTI-TISSUE_STRUCTURE", 117, 122], ["colon", "ORGAN", 126, 131], ["pigs", "ORGANISM", 135, 139], ["pigs", "SPECIES", 135, 139], ["pigs", "SPECIES", 135, 139], ["Transepithelial resistance", "PROBLEM", 0, 26], ["resistance", "OBSERVATION_MODIFIER", 16, 26], ["intestinal", "ANATOMY", 63, 73], ["integrity", "OBSERVATION", 74, 83], ["ileum", "ANATOMY", 117, 122], ["colon", "ANATOMY", 126, 131]]], ["However, irrespective of line, colon TER was significantly less than in the ileum (P < 0.05).", [["colon", "ANATOMY", 31, 36], ["ileum", "ANATOMY", 76, 81], ["colon TER", "CELL", 31, 40], ["ileum", "ORGAN", 76, 81], ["line", "OBSERVATION", 25, 29], ["colon", "ANATOMY", 31, 36], ["significantly", "OBSERVATION_MODIFIER", 45, 58], ["less", "OBSERVATION_MODIFIER", 59, 63], ["ileum", "ANATOMY", 76, 81]]], ["Further, these data were supported by additional ex vivo analysis of intestinal integrity using FITC-Dextran, a macromolecule permeability marker.", [["intestinal", "ANATOMY", 69, 79], ["FITC-Dextran", "CHEMICAL", 96, 108], ["FITC", "CHEMICAL", 96, 100], ["intestinal", "ORGAN", 69, 79], ["FITC-Dextran", "SIMPLE_CHEMICAL", 96, 108], ["intestinal integrity", "TREATMENT", 69, 89], ["FITC-Dextran", "TREATMENT", 96, 108], ["a macromolecule permeability marker", "TREATMENT", 110, 145], ["intestinal", "ANATOMY", 69, 79]]], ["No differences between lines were observed in Papp for either the ileum or colon (P > 0.05, Table 2).RESULTSEx vivo intestinal endotoxin transport characteristics were also assessed using FITC-LPS in modified Ussing chambers in the 2 RFI lines.", [["ileum", "ANATOMY", 66, 71], ["colon", "ANATOMY", 75, 80], ["intestinal", "ANATOMY", 116, 126], ["FITC", "CHEMICAL", 188, 192], ["lines", "CELL", 23, 28], ["ileum", "MULTI-TISSUE_STRUCTURE", 66, 71], ["colon", "ORGAN", 75, 80], ["intestinal", "ORGAN", 116, 126], ["FITC", "SIMPLE_CHEMICAL", 188, 192], ["RFI lines", "CELL_LINE", 234, 243], ["differences between lines", "PROBLEM", 3, 28], ["FITC-LPS", "TREATMENT", 188, 196], ["modified Ussing chambers in the 2 RFI lines", "TREATMENT", 200, 243], ["ileum", "ANATOMY", 66, 71], ["colon", "ANATOMY", 75, 80], ["intestinal", "ANATOMY", 116, 126], ["RFI lines", "OBSERVATION", 234, 243]]], ["Similar to the TER and FITC-Dextran values, we found no differences between the lines in either ileum and colon FITC-LPS transport (P > 0.05, Table 2).", [["ileum", "ANATOMY", 96, 101], ["colon", "ANATOMY", 106, 111], ["LPS", "CHEMICAL", 117, 120], ["FITC", "CHEMICAL", 23, 27], ["FITC", "CHEMICAL", 112, 116], ["TER", "CELL", 15, 18], ["FITC-Dextran", "SIMPLE_CHEMICAL", 23, 35], ["ileum", "MULTI-TISSUE_STRUCTURE", 96, 101], ["colon", "ORGAN", 106, 111], ["FITC", "SIMPLE_CHEMICAL", 112, 116], ["LPS", "SIMPLE_CHEMICAL", 117, 120], ["the TER and FITC-Dextran values", "TEST", 11, 42], ["colon FITC", "TEST", 106, 116], ["LPS transport", "TEST", 117, 130], ["P", "TEST", 132, 133], ["lines", "OBSERVATION", 80, 85], ["ileum", "ANATOMY", 96, 101], ["colon", "ANATOMY", 106, 111]]], ["The tight junction proteins claudin 3 and 4, and occludin are 3 important proteins involved in intestinal barrier function and integrity.", [["tight junction", "ANATOMY", 4, 18], ["intestinal barrier", "ANATOMY", 95, 113], ["claudin 3", "GENE_OR_GENE_PRODUCT", 28, 37], ["4", "GENE_OR_GENE_PRODUCT", 42, 43], ["occludin", "GENE_OR_GENE_PRODUCT", 49, 57], ["intestinal barrier", "MULTI-TISSUE_STRUCTURE", 95, 113], ["tight junction proteins", "PROTEIN", 4, 27], ["claudin 3 and 4", "PROTEIN", 28, 43], ["occludin", "PROTEIN", 49, 57], ["The tight junction proteins claudin", "TREATMENT", 0, 35], ["intestinal barrier function", "TREATMENT", 95, 122], ["tight", "OBSERVATION_MODIFIER", 4, 9], ["junction", "OBSERVATION", 10, 18], ["intestinal", "ANATOMY", 95, 105], ["barrier function", "OBSERVATION", 106, 122]]], ["Gene expression analysis of these tight junction proteins also indicated no difference between the lines (P > 0.05, Table 3).RESULTSSerum endotoxin concentrations were found to be lower in the LRFI than in the HRFI gilts (P < 0.05, Fig. 1).", [["tight junction", "ANATOMY", 34, 48], ["HRFI gilts", "ANATOMY", 210, 220], ["endotoxin", "CHEMICAL", 138, 147], ["tight junction proteins", "PROTEIN", 34, 57], ["HRFI", "SPECIES", 210, 214], ["Gene expression analysis", "TEST", 0, 24], ["these tight junction proteins", "TEST", 28, 57], ["the lines", "TREATMENT", 95, 104], ["P", "TEST", 106, 107], ["RESULTSSerum endotoxin concentrations", "TEST", 125, 162], ["no", "UNCERTAINTY", 73, 75], ["difference", "OBSERVATION_MODIFIER", 76, 86], ["HRFI gilts", "ANATOMY", 210, 220]]], ["Furthermore, the serum acute phase protein, haptoglobin, was also less in LRFI pigs than in HRFI gilts (P < 0.05, Table 4).", [["serum", "ANATOMY", 17, 22], ["HRFI gilts", "ANATOMY", 92, 102], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 44, 55], ["pigs", "ORGANISM", 79, 83], ["serum acute phase protein", "PROTEIN", 17, 42], ["haptoglobin", "PROTEIN", 44, 55], ["pigs", "SPECIES", 79, 83], ["pigs", "SPECIES", 79, 83], ["HRFI", "SPECIES", 92, 96], ["the serum acute phase protein", "TEST", 13, 42], ["haptoglobin", "TEST", 44, 55]]], ["Lipopolysaccharide binding protein concentrations were 25% less in the HRFI gilts, compared with their LRFI counterparts (P = 0.38, Table 4).", [["Lipopolysaccharide", "CHEMICAL", 0, 18], ["Lipopolysaccharide binding protein", "GENE_OR_GENE_PRODUCT", 0, 34], ["Lipopolysaccharide binding protein", "PROTEIN", 0, 34], ["Lipopolysaccharide binding protein concentrations", "TEST", 0, 49], ["P", "TEST", 122, 123]]], ["The presence of a greater endotoxin load and the consequent increase in haptoglobin secretion has the potential to cause a generalized inflammation.", [["endotoxin", "CHEMICAL", 26, 35], ["inflammation", "DISEASE", 135, 147], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 72, 83], ["haptoglobin", "PROTEIN", 72, 83], ["a greater endotoxin load", "PROBLEM", 16, 40], ["haptoglobin secretion", "PROBLEM", 72, 93], ["a generalized inflammation", "PROBLEM", 121, 147], ["greater", "OBSERVATION_MODIFIER", 18, 25], ["endotoxin load", "OBSERVATION", 26, 40], ["consequent", "OBSERVATION_MODIFIER", 49, 59], ["increase", "OBSERVATION_MODIFIER", 60, 68], ["haptoglobin secretion", "OBSERVATION", 72, 93], ["potential to cause", "UNCERTAINTY", 102, 120], ["generalized", "OBSERVATION_MODIFIER", 123, 134], ["inflammation", "OBSERVATION", 135, 147]]], ["There was also a tendency (P = 0.08) for serum CRP to be increased in the HRFI pigs (Table 4).", [["serum", "ANATOMY", 41, 46], ["serum", "ORGANISM_SUBSTANCE", 41, 46], ["CRP", "GENE_OR_GENE_PRODUCT", 47, 50], ["pigs", "ORGANISM", 79, 83], ["CRP", "PROTEIN", 47, 50], ["pigs", "SPECIES", 79, 83], ["HRFI pigs", "SPECIES", 74, 83], ["a tendency", "PROBLEM", 15, 25], ["serum CRP", "TEST", 41, 50], ["tendency", "OBSERVATION_MODIFIER", 17, 25], ["increased", "OBSERVATION_MODIFIER", 57, 66]]], ["The ileum was also assessed for the presence of general inflammatory markers.", [["ileum", "ANATOMY", 4, 9], ["ileum", "MULTI-TISSUE_STRUCTURE", 4, 9], ["general inflammatory markers", "PROTEIN", 48, 76], ["general inflammatory markers", "PROBLEM", 48, 76], ["ileum", "ANATOMY", 4, 9], ["inflammatory", "OBSERVATION", 56, 68]]], ["Ileum myeloperoxidase activity was lower in the LRFI pigs than in the HRFI pigs (P = 0.047, Table 4).", [["Ileum", "ANATOMY", 0, 5], ["Ileum", "GENE_OR_GENE_PRODUCT", 0, 5], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 6, 21], ["pigs", "ORGANISM", 53, 57], ["HRFI pigs", "ORGANISM", 70, 79], ["myeloperoxidase", "PROTEIN", 6, 21], ["pigs", "SPECIES", 53, 57], ["pigs", "SPECIES", 75, 79], ["LRFI pigs", "SPECIES", 48, 57], ["HRFI pigs", "SPECIES", 70, 79], ["Ileum myeloperoxidase activity", "PROBLEM", 0, 30], ["myeloperoxidase activity", "OBSERVATION", 6, 30], ["lower", "OBSERVATION_MODIFIER", 35, 40]]], ["The proinflammatory cytokine, IL-8 protein expression, also tended to be less in the ileum of LRFI versus HRFI pigs (P = 0.062, Table 4).RESULTSAlkaline phosphatase activity (Fig. 2) was measured and found to be significantly increased in the LRFI pigs in both liver (P < 0.018) and ileum (P < 0.01).", [["ileum", "ANATOMY", 85, 90], ["LRFI", "ANATOMY", 94, 98], ["liver", "ANATOMY", 261, 266], ["ileum", "ANATOMY", 283, 288], ["IL-8", "GENE_OR_GENE_PRODUCT", 30, 34], ["ileum", "ORGAN", 85, 90], ["RESULTSAlkaline phosphatase", "GENE_OR_GENE_PRODUCT", 137, 164], ["pigs", "ORGANISM", 248, 252], ["liver", "ORGAN", 261, 266], ["ileum", "ORGAN", 283, 288], ["proinflammatory cytokine", "PROTEIN", 4, 28], ["IL-8 protein", "PROTEIN", 30, 42], ["RESULTSAlkaline phosphatase", "PROTEIN", 137, 164], ["pigs", "SPECIES", 111, 115], ["pigs", "SPECIES", 248, 252], ["pigs", "SPECIES", 248, 252], ["The proinflammatory cytokine", "TREATMENT", 0, 28], ["IL-8 protein expression", "TREATMENT", 30, 53], ["HRFI pigs", "TREATMENT", 106, 115], ["RESULTSAlkaline phosphatase activity", "TEST", 137, 173], ["ileum", "TEST", 283, 288], ["proinflammatory cytokine", "OBSERVATION", 4, 28], ["less", "OBSERVATION_MODIFIER", 73, 77], ["ileum", "ANATOMY", 85, 90], ["significantly", "OBSERVATION_MODIFIER", 212, 225], ["increased", "OBSERVATION", 226, 235], ["both", "ANATOMY_MODIFIER", 256, 260], ["liver", "ANATOMY", 261, 266], ["ileum", "ANATOMY", 283, 288]]], ["Lysozyme activity in the liver was not different between the lines but ileum lysozyme activity in LRFI pigs was almost twice as high as in HRFI pigs (P < 0.01, Fig. 3).", [["liver", "ANATOMY", 25, 30], ["lines", "ANATOMY", 61, 66], ["ileum", "ANATOMY", 71, 76], ["Lysozyme", "GENE_OR_GENE_PRODUCT", 0, 8], ["liver", "ORGAN", 25, 30], ["ileum", "MULTI-TISSUE_STRUCTURE", 71, 76], ["lysozyme", "GENE_OR_GENE_PRODUCT", 77, 85], ["LRFI pigs", "ORGANISM", 98, 107], ["Lysozyme", "PROTEIN", 0, 8], ["lysozyme", "PROTEIN", 77, 85], ["pigs", "SPECIES", 103, 107], ["pigs", "SPECIES", 144, 148], ["pigs", "SPECIES", 103, 107], ["Lysozyme activity in the liver", "PROBLEM", 0, 30], ["ileum lysozyme activity", "PROBLEM", 71, 94], ["LRFI pigs", "TREATMENT", 98, 107], ["liver", "ANATOMY", 25, 30], ["not different", "OBSERVATION_MODIFIER", 35, 48], ["lines", "OBSERVATION", 61, 66], ["ileum", "ANATOMY", 71, 76], ["lysozyme activity", "OBSERVATION", 77, 94]]], ["Although we saw differences in activity of these enzymes, surprisingly, no difference was found in the mRNA expression in either ileum or liver (Table 5).", [["ileum", "ANATOMY", 129, 134], ["liver", "ANATOMY", 138, 143], ["ileum", "MULTI-TISSUE_STRUCTURE", 129, 134], ["liver", "ORGAN", 138, 143], ["enzymes", "PROTEIN", 49, 56], ["these enzymes", "TEST", 43, 56], ["ileum", "ANATOMY", 129, 134], ["liver", "ANATOMY", 138, 143]]], ["The mRNA expression of LPS detoxification gene acyloxyacyl hydrolase (AOAH) present in liver and ileum tissues was quantified to assess differences between the 2 lines.", [["liver", "ANATOMY", 87, 92], ["ileum tissues", "ANATOMY", 97, 110], ["LPS", "CHEMICAL", 23, 26], ["acyloxyacyl", "CHEMICAL", 47, 58], ["LPS", "SIMPLE_CHEMICAL", 23, 26], ["acyloxyacyl hydrolase", "GENE_OR_GENE_PRODUCT", 47, 68], ["AOAH", "GENE_OR_GENE_PRODUCT", 70, 74], ["liver", "ORGAN", 87, 92], ["ileum tissues", "TISSUE", 97, 110], ["LPS detoxification gene acyloxyacyl hydrolase", "PROTEIN", 23, 68], ["AOAH", "PROTEIN", 70, 74], ["LPS detoxification gene acyloxyacyl hydrolase (AOAH)", "TREATMENT", 23, 75], ["liver", "ANATOMY", 87, 92], ["ileum tissues", "ANATOMY", 97, 110]]], ["The expression profiles of these genes was not different, indicating that at the mRNA level, LPS detoxification enzyme AOAH expression was not altered due to blood endotoxin, selection for RFI, or FE (Table 5).RESULTSResidual correlations of performance traits with endotoxin transport and serum concentrations, ALP and RFI were generally moderate (Table 6).", [["blood", "ANATOMY", 158, 163], ["serum", "ANATOMY", 290, 295], ["LPS", "CHEMICAL", 93, 96], ["endotoxin", "CHEMICAL", 164, 173], ["endotoxin", "CHEMICAL", 266, 275], ["LPS", "SIMPLE_CHEMICAL", 93, 96], ["AOAH", "GENE_OR_GENE_PRODUCT", 119, 123], ["blood", "ORGANISM_SUBSTANCE", 158, 163], ["endotoxin", "SIMPLE_CHEMICAL", 266, 275], ["serum", "ORGANISM_SUBSTANCE", 290, 295], ["ALP", "GENE_OR_GENE_PRODUCT", 312, 315], ["AOAH", "PROTEIN", 119, 123], ["blood endotoxin", "PROTEIN", 158, 173], ["endotoxin", "PROTEIN", 266, 275], ["ALP", "PROTEIN", 312, 315], ["the mRNA level", "TEST", 77, 91], ["LPS detoxification enzyme", "TEST", 93, 118], ["blood endotoxin", "TEST", 158, 173], ["RFI", "TEST", 189, 192], ["performance traits", "TEST", 242, 260], ["endotoxin transport", "TEST", 266, 285], ["serum concentrations", "TEST", 290, 310], ["ALP", "TEST", 312, 315], ["RFI", "TEST", 320, 323], ["moderate", "OBSERVATION_MODIFIER", 339, 347]]], ["Feed efficiency (G:F) was moderately negatively correlated with RFI index, serum haptoglobin and C-reactive protein (P < 0.05).", [["serum", "ANATOMY", 75, 80], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 81, 92], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 97, 115], ["serum haptoglobin", "PROTEIN", 75, 92], ["C-reactive protein", "PROTEIN", 97, 115], ["RFI index", "TEST", 64, 73], ["serum haptoglobin", "TEST", 75, 92], ["C", "TEST", 97, 98], ["reactive protein", "TEST", 99, 115], ["P", "TEST", 117, 118]]], ["Furthermore, there tended to be a moderate negative correlation between FE and serum endotoxin (P = 0.052), but not ileum endotoxin permeability (P = 0.13).", [["serum", "ANATOMY", 79, 84], ["ileum", "ANATOMY", 116, 121], ["endotoxin", "CHEMICAL", 85, 94], ["endotoxin", "CHEMICAL", 122, 131], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["endotoxin", "SIMPLE_CHEMICAL", 85, 94], ["ileum", "MULTI-TISSUE_STRUCTURE", 116, 121], ["serum endotoxin", "PROTEIN", 79, 94], ["FE", "TEST", 72, 74], ["serum endotoxin", "TEST", 79, 94], ["P", "TEST", 96, 97], ["ileum endotoxin permeability", "TEST", 116, 144], ["P", "TEST", 146, 147], ["moderate", "OBSERVATION_MODIFIER", 34, 42], ["negative", "OBSERVATION", 43, 51], ["ileum", "ANATOMY", 116, 121]]], ["However, no significant correlations existed with pig RFI index.", [["pig", "ORGANISM", 50, 53], ["pig", "SPECIES", 50, 53], ["pig RFI index", "TEST", 50, 63], ["no", "UNCERTAINTY", 9, 11]]], ["Interestingly, this is the first data to our knowledge in swine that shows a significant positive correlation between intestinal endotoxin transport and circulating endotoxin (P = 0.019).", [["intestinal", "ANATOMY", 118, 128], ["endotoxin", "CHEMICAL", 129, 138], ["endotoxin", "CHEMICAL", 165, 174], ["swine", "ORGANISM", 58, 63], ["intestinal", "ORGAN", 118, 128], ["endotoxin", "SIMPLE_CHEMICAL", 129, 138], ["endotoxin", "SIMPLE_CHEMICAL", 165, 174], ["circulating endotoxin", "PROTEIN", 153, 174], ["swine", "SPECIES", 58, 63], ["swine", "SPECIES", 58, 63], ["intestinal endotoxin transport", "TREATMENT", 118, 148], ["significant", "OBSERVATION_MODIFIER", 77, 88], ["positive", "OBSERVATION", 89, 97], ["intestinal", "ANATOMY", 118, 128]]], ["Furthermore, ileum ALP activity was moderately negatively correlated with endotoxin concentration (P = 0.027).", [["ileum", "ANATOMY", 13, 18], ["endotoxin", "CHEMICAL", 74, 83], ["ileum", "MULTI-TISSUE_STRUCTURE", 13, 18], ["ALP", "GENE_OR_GENE_PRODUCT", 19, 22], ["endotoxin", "SIMPLE_CHEMICAL", 74, 83], ["ALP", "PROTEIN", 19, 22], ["endotoxin", "PROTEIN", 74, 83], ["ileum ALP activity", "TEST", 13, 31], ["endotoxin concentration", "TEST", 74, 97], ["ileum", "ANATOMY", 13, 18]]], ["Lysozyme activity and LBP were poorly correlated with all variables.DISCUSSIONThe current study was conducted to identify if differences in intestinal integrity, circulating endotoxin and its associated inflammatory markers may partially be responsible for difference in FE between pigs that were divergently selected for RFI.", [["intestinal", "ANATOMY", 140, 150], ["LBP", "DISEASE", 22, 25], ["endotoxin", "CHEMICAL", 174, 183], ["Lysozyme", "GENE_OR_GENE_PRODUCT", 0, 8], ["intestinal", "ORGAN", 140, 150], ["endotoxin", "GENE_OR_GENE_PRODUCT", 174, 183], ["pigs", "ORGANISM", 282, 286], ["Lysozyme", "PROTEIN", 0, 8], ["circulating endotoxin", "PROTEIN", 162, 183], ["inflammatory markers", "PROTEIN", 203, 223], ["pigs", "SPECIES", 282, 286], ["pigs", "SPECIES", 282, 286], ["Lysozyme activity", "TEST", 0, 17], ["LBP", "PROBLEM", 22, 25], ["The current study", "TEST", 78, 95], ["circulating endotoxin", "TREATMENT", 162, 183], ["its associated inflammatory markers", "PROBLEM", 188, 223], ["FE between pigs", "TREATMENT", 271, 286], ["intestinal", "ANATOMY", 140, 150], ["inflammatory", "OBSERVATION", 203, 215]]], ["The physiological mechanisms underlying RFI or FE in swine are poorly defined.", [["swine", "SPECIES", 53, 58], ["swine", "SPECIES", 53, 58], ["FE in swine", "PROBLEM", 47, 58]]], ["However, differences in nutrients and energy digestibility, metabolic efficiency of nutrient use, basal metabolic rate and energy expenditure are presumed to be contributing to differences in RFI, either alone or in combination (Herd and Arthur, 2009; Barea et al., 2010; Boddicker et al., 2011).", [["basal metabolic rate and energy expenditure", "PROBLEM", 98, 141], ["metabolic efficiency", "OBSERVATION", 60, 80], ["energy expenditure", "OBSERVATION", 123, 141]]], ["Endotoxin and its associated inflammation can reduce digestibility and alter intestinal nutrient transport and post-absorptive metabolism (Albin et al., 2007; Rakhshandeh and de Lange, 2012).", [["intestinal", "ANATOMY", 77, 87], ["Endotoxin", "CHEMICAL", 0, 9], ["inflammation", "DISEASE", 29, 41], ["Endotoxin", "GENE_OR_GENE_PRODUCT", 0, 9], ["intestinal", "ORGAN", 77, 87], ["Endotoxin", "TREATMENT", 0, 9], ["its associated inflammation", "PROBLEM", 14, 41], ["inflammation", "OBSERVATION", 29, 41], ["intestinal", "ANATOMY", 77, 87]]], ["The net effect of increased circulating endotoxin or endotoxemia is reduced growth, increased energy expenditure and antagonizing lean tissue accretion (Orellana et al., 2007).", [["lean tissue", "ANATOMY", 130, 141], ["endotoxin", "CHEMICAL", 40, 49], ["endotoxemia", "DISEASE", 53, 64], ["endotoxin", "SIMPLE_CHEMICAL", 40, 49], ["lean tissue", "TISSUE", 130, 141], ["increased circulating endotoxin", "PROBLEM", 18, 49], ["endotoxemia", "PROBLEM", 53, 64], ["reduced growth", "PROBLEM", 68, 82], ["increased energy expenditure", "PROBLEM", 84, 112], ["antagonizing lean tissue accretion", "PROBLEM", 117, 151], ["net", "OBSERVATION_MODIFIER", 4, 7], ["effect", "OBSERVATION_MODIFIER", 8, 14], ["increased", "OBSERVATION_MODIFIER", 18, 27], ["circulating endotoxin", "OBSERVATION", 28, 49], ["endotoxemia", "OBSERVATION", 53, 64], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["growth", "OBSERVATION_MODIFIER", 76, 82], ["increased", "OBSERVATION_MODIFIER", 84, 93], ["energy expenditure", "OBSERVATION", 94, 112]]], ["Thus, partitioning of energy and other nutrients away from growth and toward immune system requirements may contribute to differences in FE.DISCUSSIONIn the present study, although acute compared with that typically used in LPS challenge models, endogenous blood endotoxin concentration was increased threefold in HRFI gilts.", [["immune system", "ANATOMY", 77, 90], ["blood", "ANATOMY", 257, 262], ["endotoxin", "CHEMICAL", 263, 272], ["LPS", "SIMPLE_CHEMICAL", 224, 227], ["blood", "ORGANISM_SUBSTANCE", 257, 262], ["immune system requirements", "TREATMENT", 77, 103], ["the present study", "TEST", 153, 170], ["LPS challenge models", "TREATMENT", 224, 244], ["endogenous blood endotoxin concentration", "PROBLEM", 246, 286], ["acute", "OBSERVATION_MODIFIER", 181, 186]]], ["Although, characterization of intestinal microbial populations was not within the scope of this study, we cannot rule out RFI line specific differences in Enterobacteriaceae populations that may partially explain the increase in circulating endotoxin.", [["intestinal", "ANATOMY", 30, 40], ["endotoxin", "CHEMICAL", 241, 250], ["intestinal", "ORGAN", 30, 40], ["Enterobacteriaceae populations", "CELL", 155, 185], ["endotoxin", "GENE_OR_GENE_PRODUCT", 241, 250], ["circulating endotoxin", "PROTEIN", 229, 250], ["intestinal microbial populations", "PROBLEM", 30, 62], ["this study", "TEST", 91, 101], ["RFI line specific differences", "PROBLEM", 122, 151], ["Enterobacteriaceae populations", "PROBLEM", 155, 185], ["the increase in circulating endotoxin", "PROBLEM", 213, 250], ["intestinal", "ANATOMY", 30, 40], ["Enterobacteriaceae populations", "OBSERVATION", 155, 185], ["may partially explain", "UNCERTAINTY", 191, 212], ["increase", "OBSERVATION_MODIFIER", 217, 225], ["circulating endotoxin", "OBSERVATION", 229, 250]]], ["Interestingly, the presence of greater circulating endotoxin also has the potential to affect intestinal health and function (Gardiner et al., 1995; Albin et al., 2007).", [["intestinal", "ANATOMY", 94, 104], ["endotoxin", "CHEMICAL", 51, 60], ["endotoxin", "GENE_OR_GENE_PRODUCT", 51, 60], ["intestinal", "ORGAN", 94, 104], ["greater circulating endotoxin", "PROBLEM", 31, 60], ["greater", "OBSERVATION_MODIFIER", 31, 38], ["circulating endotoxin", "OBSERVATION", 39, 60]]], ["As such, we reported greater ileal MPO activity and IL-8 protein expression in the HRFI pigs with augmented serum endotoxin.", [["ileal", "ANATOMY", 29, 34], ["serum", "ANATOMY", 108, 113], ["endotoxin", "CHEMICAL", 114, 123], ["ileal", "MULTI-TISSUE_STRUCTURE", 29, 34], ["MPO", "SIMPLE_CHEMICAL", 35, 38], ["IL-8", "GENE_OR_GENE_PRODUCT", 52, 56], ["pigs", "ORGANISM", 88, 92], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["endotoxin", "SIMPLE_CHEMICAL", 114, 123], ["MPO", "PROTEIN", 35, 38], ["IL-8", "PROTEIN", 52, 56], ["serum endotoxin", "PROTEIN", 108, 123], ["pigs", "SPECIES", 88, 92], ["pigs", "SPECIES", 88, 92], ["IL-8 protein expression", "TREATMENT", 52, 75], ["the HRFI pigs", "TREATMENT", 79, 92], ["augmented serum endotoxin", "TREATMENT", 98, 123], ["ileal MPO", "ANATOMY", 29, 38]]], ["Both of these markers are commonly used for assessing intestinal inflammation and neutrophil infiltration (Suzuki et al., 1983).", [["intestinal", "ANATOMY", 54, 64], ["neutrophil", "ANATOMY", 82, 92], ["inflammation", "DISEASE", 65, 77], ["intestinal", "ORGAN", 54, 64], ["neutrophil", "CELL", 82, 92], ["intestinal inflammation", "PROBLEM", 54, 77], ["neutrophil infiltration", "PROBLEM", 82, 105], ["intestinal", "ANATOMY", 54, 64], ["inflammation", "OBSERVATION", 65, 77], ["neutrophil infiltration", "OBSERVATION", 82, 105]]], ["Remarkably, little has been reported with regard to pig FE and \u201cleaky\u201d or porous gut and intestinal integrity.", [["gut", "ANATOMY", 81, 84], ["intestinal", "ANATOMY", 89, 99], ["pig", "ORGANISM", 52, 55], ["gut", "ORGANISM_SUBDIVISION", 81, 84], ["intestinal", "ORGAN", 89, 99], ["pig", "SPECIES", 52, 55], ["pig", "SPECIES", 52, 55], ["pig FE", "TREATMENT", 52, 58], ["intestinal", "ANATOMY", 89, 99], ["integrity", "OBSERVATION", 100, 109]]], ["No differences between the lines were observed in intestinal TER.", [["intestinal", "ANATOMY", 50, 60], ["lines", "CELL", 27, 32], ["intestinal", "ORGAN", 50, 60], ["the lines", "TREATMENT", 23, 32], ["differences", "OBSERVATION_MODIFIER", 3, 14], ["lines", "OBSERVATION", 27, 32], ["intestinal", "ANATOMY", 50, 60]]], ["This was corroborated further by no differences in the paracellular transport of 4.4 kDa FITC-Dextran or FITC-LPS.", [["paracellular", "ANATOMY", 55, 67], ["FITC-Dextran", "CHEMICAL", 89, 101], ["FITC-LPS", "CHEMICAL", 105, 113], ["FITC", "CHEMICAL", 89, 93], ["FITC", "CHEMICAL", 105, 109], ["paracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 55, 67], ["FITC-Dextran", "SIMPLE_CHEMICAL", 89, 101], ["FITC-LPS", "SIMPLE_CHEMICAL", 105, 113], ["the paracellular transport", "TEST", 51, 77], ["Dextran", "TREATMENT", 94, 101], ["FITC-LPS", "TREATMENT", 105, 113]]], ["Although decreased expression of tight junction proteins claudin 3 and 4 during inflammation have been implicated in increased intestinal permeability (Pinton et al., 2010), the mRNA expressions of occludin, claudins 3 and 4 were not different between the our pig lines.", [["tight junction", "ANATOMY", 33, 47], ["intestinal", "ANATOMY", 127, 137], ["inflammation", "DISEASE", 80, 92], ["tight junction proteins claudin 3", "GENE_OR_GENE_PRODUCT", 33, 66], ["4", "GENE_OR_GENE_PRODUCT", 71, 72], ["intestinal", "ORGAN", 127, 137], ["occludin", "GENE_OR_GENE_PRODUCT", 198, 206], ["claudins 3", "GENE_OR_GENE_PRODUCT", 208, 218], ["4", "GENE_OR_GENE_PRODUCT", 223, 224], ["pig", "ORGANISM", 260, 263], ["tight junction proteins", "PROTEIN", 33, 56], ["claudin 3 and 4", "PROTEIN", 57, 72], ["occludin", "PROTEIN", 198, 206], ["claudins 3 and 4", "PROTEIN", 208, 224], ["pig", "SPECIES", 260, 263], ["pig", "SPECIES", 260, 263], ["decreased expression of tight junction proteins claudin", "PROBLEM", 9, 64], ["inflammation", "PROBLEM", 80, 92], ["increased intestinal permeability", "PROBLEM", 117, 150], ["occludin, claudins", "TREATMENT", 198, 216], ["decreased", "OBSERVATION_MODIFIER", 9, 18], ["tight junction", "OBSERVATION_MODIFIER", 33, 47], ["increased", "OBSERVATION_MODIFIER", 117, 126], ["intestinal", "ANATOMY", 127, 137], ["permeability", "OBSERVATION_MODIFIER", 138, 150], ["pig lines", "OBSERVATION", 260, 269]]], ["These data agree with the intestinal integrity LPS challenge data reported by Albin et al. (2007).", [["intestinal", "ANATOMY", 26, 36], ["LPS", "CHEMICAL", 47, 50], ["intestinal", "ORGAN", 26, 36], ["intestinal", "ANATOMY", 26, 36]]], ["Altogether, these data indicate that in healthy pigs, intestinal integrity is tightly controlled and may not contribute significantly to differences in FE.DISCUSSIONThe presence of greater blood endotoxin has the potential to contribute to the development of an inflammatory state and reduce growth potential.", [["intestinal", "ANATOMY", 54, 64], ["blood", "ANATOMY", 189, 194], ["endotoxin", "CHEMICAL", 195, 204], ["pigs", "ORGANISM", 48, 52], ["intestinal", "ORGAN", 54, 64], ["blood", "ORGANISM_SUBSTANCE", 189, 194], ["pigs", "SPECIES", 48, 52], ["pigs", "SPECIES", 48, 52], ["intestinal integrity", "PROBLEM", 54, 74], ["greater blood endotoxin", "PROBLEM", 181, 204], ["an inflammatory state", "PROBLEM", 259, 280], ["intestinal", "ANATOMY", 54, 64], ["integrity", "OBSERVATION", 65, 74], ["greater", "OBSERVATION_MODIFIER", 181, 188], ["blood endotoxin", "OBSERVATION", 189, 204], ["inflammatory", "OBSERVATION", 262, 274], ["growth", "OBSERVATION_MODIFIER", 292, 298]]], ["In our study, serum endotoxin and the acute phase protein, haptoglobin, were found to be significantly lower in the LRFI pigs.", [["serum", "ANATOMY", 14, 19], ["endotoxin", "CHEMICAL", 20, 29], ["serum", "ORGANISM_SUBSTANCE", 14, 19], ["endotoxin", "SIMPLE_CHEMICAL", 20, 29], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 59, 70], ["pigs", "ORGANISM", 121, 125], ["serum endotoxin", "PROTEIN", 14, 29], ["acute phase protein", "PROTEIN", 38, 57], ["haptoglobin", "PROTEIN", 59, 70], ["pigs", "SPECIES", 121, 125], ["LRFI pigs", "SPECIES", 116, 125], ["our study", "TEST", 3, 12], ["serum endotoxin", "TEST", 14, 29], ["the acute phase protein", "TEST", 34, 57], ["haptoglobin", "TEST", 59, 70], ["acute", "OBSERVATION_MODIFIER", 38, 43]]], ["Our values for haptoglobin, CRP and LBP are in agreement with the values reported in non-challenged pigs (Barbe et al., 2011; Diack et al., 2011).", [["haptoglobin", "GENE_OR_GENE_PRODUCT", 15, 26], ["CRP", "GENE_OR_GENE_PRODUCT", 28, 31], ["LBP", "GENE_OR_GENE_PRODUCT", 36, 39], ["pigs", "ORGANISM", 100, 104], ["haptoglobin", "PROTEIN", 15, 26], ["CRP", "PROTEIN", 28, 31], ["pigs", "SPECIES", 100, 104], ["pigs", "SPECIES", 100, 104], ["Our values", "TEST", 0, 10], ["haptoglobin", "TEST", 15, 26], ["CRP", "TEST", 28, 31], ["LBP", "PROBLEM", 36, 39]]], ["However, serum concentrations of acute-phase proteins are known to increase after stress and inflammation (Pineiro et al., 2007; Pineiro et al., 2009) and the magnitude of the response is generally related to the severity of the stress or disease (Hall et al., 1992; Murata et al., 2004; Williams et al., 2009).", [["serum", "ANATOMY", 9, 14], ["inflammation", "DISEASE", 93, 105], ["serum", "ORGANISM_SUBSTANCE", 9, 14], ["acute-phase proteins", "PROTEIN", 33, 53], ["serum concentrations", "TEST", 9, 29], ["acute-phase proteins", "PROBLEM", 33, 53], ["stress and inflammation", "PROBLEM", 82, 105], ["the stress", "PROBLEM", 225, 235], ["disease", "PROBLEM", 239, 246], ["acute", "OBSERVATION_MODIFIER", 33, 38], ["inflammation", "OBSERVATION", 93, 105]]], ["Even though our pigs were considered healthy, we observed an acute increase in serum haptoglobin and CRP in our HRFI gilts, compared with their LRFI, more FE counterparts.", [["serum", "ANATOMY", 79, 84], ["pigs", "ORGANISM", 16, 20], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 85, 96], ["CRP", "GENE_OR_GENE_PRODUCT", 101, 104], ["serum haptoglobin", "PROTEIN", 79, 96], ["CRP", "PROTEIN", 101, 104], ["pigs", "SPECIES", 16, 20], ["pigs", "SPECIES", 16, 20], ["an acute increase", "PROBLEM", 58, 75], ["serum haptoglobin", "TEST", 79, 96], ["CRP", "TEST", 101, 104], ["their LRFI", "TEST", 138, 148], ["acute", "OBSERVATION_MODIFIER", 61, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["serum haptoglobin", "OBSERVATION_MODIFIER", 79, 96]]], ["Although difficult to interpret, we speculate that an increase in acute phase proteins is a response to acute tissue damage, inflammation or stress.", [["tissue", "ANATOMY", 110, 116], ["inflammation", "DISEASE", 125, 137], ["tissue", "TISSUE", 110, 116], ["acute phase proteins", "PROTEIN", 66, 86], ["an increase in acute phase proteins", "PROBLEM", 51, 86], ["acute tissue damage", "PROBLEM", 104, 123], ["inflammation", "PROBLEM", 125, 137], ["stress", "PROBLEM", 141, 147], ["increase", "OBSERVATION_MODIFIER", 54, 62], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["phase", "OBSERVATION_MODIFIER", 72, 77], ["acute tissue", "OBSERVATION_MODIFIER", 104, 116], ["damage", "OBSERVATION", 117, 123], ["inflammation", "OBSERVATION", 125, 137]]], ["Studies have reported no straight forward correlations with LPS and acute phase proteins in pig serum (Van Gucht et al., 2006).", [["serum", "ANATOMY", 96, 101], ["LPS", "CHEMICAL", 60, 63], ["LPS", "SIMPLE_CHEMICAL", 60, 63], ["pig", "ORGANISM", 92, 95], ["serum", "ORGANISM_SUBSTANCE", 96, 101], ["acute phase proteins", "PROTEIN", 68, 88], ["pig", "SPECIES", 92, 95], ["pig", "SPECIES", 92, 95], ["LPS", "PROBLEM", 60, 63], ["acute phase proteins", "PROBLEM", 68, 88], ["pig serum", "TEST", 92, 101], ["acute", "OBSERVATION_MODIFIER", 68, 73]]], ["However, we observed a significant and moderate correlation between serum LPS and haptoglobin, but not CRP.DISCUSSIONInterestingly, the high immune response of HRFI pigs doesn't appear to be a result of increased intestinal permeability, but could be a result of differences in detoxification processes.", [["serum", "ANATOMY", 68, 73], ["intestinal", "ANATOMY", 213, 223], ["LPS", "CHEMICAL", 74, 77], ["serum", "ORGANISM_SUBSTANCE", 68, 73], ["LPS", "SIMPLE_CHEMICAL", 74, 77], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 82, 93], ["HRFI pigs", "ORGANISM", 160, 169], ["intestinal", "ORGAN", 213, 223], ["haptoglobin", "PROTEIN", 82, 93], ["pigs", "SPECIES", 165, 169], ["serum LPS", "TEST", 68, 77], ["haptoglobin", "TEST", 82, 93], ["HRFI pigs", "TREATMENT", 160, 169], ["increased intestinal permeability", "PROBLEM", 203, 236], ["significant", "OBSERVATION_MODIFIER", 23, 34], ["moderate", "OBSERVATION_MODIFIER", 39, 47], ["increased", "OBSERVATION_MODIFIER", 203, 212], ["intestinal permeability", "OBSERVATION", 213, 236]]], ["Animals and humans harbor reduced concentrations of circulating endotoxin even in normal and healthy conditions (Erridge et al., 2007).", [["endotoxin", "CHEMICAL", 64, 73], ["Animals", "ORGANISM", 0, 7], ["humans", "ORGANISM", 12, 18], ["endotoxin", "GENE_OR_GENE_PRODUCT", 64, 73], ["humans", "SPECIES", 12, 18], ["humans", "SPECIES", 12, 18], ["circulating endotoxin", "TREATMENT", 52, 73]]], ["The potential biological process that might account for the decreased endotoxin concentrations in the LRFI pigs may include the greater efficiency in endotoxin clearance, neutralization or detoxification.", [["endotoxin", "CHEMICAL", 70, 79], ["endotoxin", "CHEMICAL", 150, 159], ["endotoxin", "SIMPLE_CHEMICAL", 70, 79], ["LRFI pigs", "ORGANISM", 102, 111], ["endotoxin", "SIMPLE_CHEMICAL", 150, 159], ["pigs", "SPECIES", 107, 111], ["the decreased endotoxin concentrations", "PROBLEM", 56, 94], ["the LRFI pigs", "TREATMENT", 98, 111], ["endotoxin clearance", "TREATMENT", 150, 169], ["neutralization", "TREATMENT", 171, 185], ["detoxification", "TREATMENT", 189, 203], ["might account for", "UNCERTAINTY", 38, 55], ["greater efficiency", "OBSERVATION_MODIFIER", 128, 146], ["endotoxin clearance", "OBSERVATION", 150, 169]]], ["These processes occur in various tissues, including immune cells, liver, kidney and intestine.", [["tissues", "ANATOMY", 33, 40], ["immune cells", "ANATOMY", 52, 64], ["liver", "ANATOMY", 66, 71], ["kidney", "ANATOMY", 73, 79], ["intestine", "ANATOMY", 84, 93], ["tissues", "TISSUE", 33, 40], ["immune cells", "CELL", 52, 64], ["liver", "ORGAN", 66, 71], ["kidney", "ORGAN", 73, 79], ["intestine", "ORGAN", 84, 93], ["immune cells", "CELL_TYPE", 52, 64], ["immune cells, liver, kidney and intestine", "PROBLEM", 52, 93], ["various tissues", "OBSERVATION", 25, 40], ["immune cells", "OBSERVATION", 52, 64], ["liver", "ANATOMY", 66, 71], ["kidney", "ANATOMY", 73, 79], ["intestine", "ANATOMY", 84, 93]]], ["Furthermore, various binding proteins and enzymes such as ALP, lysozyme, and AOAH are involved (Munford et al., 2009).", [["ALP", "GENE_OR_GENE_PRODUCT", 58, 61], ["lysozyme", "GENE_OR_GENE_PRODUCT", 63, 71], ["AOAH", "GENE_OR_GENE_PRODUCT", 77, 81], ["binding proteins", "PROTEIN", 21, 37], ["enzymes", "PROTEIN", 42, 49], ["ALP", "PROTEIN", 58, 61], ["lysozyme", "PROTEIN", 63, 71], ["AOAH", "PROTEIN", 77, 81], ["various binding proteins", "TEST", 13, 37], ["enzymes", "TEST", 42, 49], ["ALP", "TEST", 58, 61]]], ["Alkaline phosphatase is a hydrolase enzyme present in liver, intestine and kidney tubules and it dephosphorylates bacterial LPS and reduces its toxicity (Poelstra et al., 1997; Bates et al., 2007).", [["liver", "ANATOMY", 54, 59], ["intestine", "ANATOMY", 61, 70], ["kidney tubules", "ANATOMY", 75, 89], ["LPS", "CHEMICAL", 124, 127], ["toxicity", "DISEASE", 144, 152], ["Alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 0, 20], ["liver", "ORGAN", 54, 59], ["intestine", "ORGAN", 61, 70], ["kidney tubules", "TISSUE", 75, 89], ["LPS", "SIMPLE_CHEMICAL", 124, 127], ["Alkaline phosphatase", "PROTEIN", 0, 20], ["hydrolase enzyme", "PROTEIN", 26, 42], ["Alkaline phosphatase", "TEST", 0, 20], ["a hydrolase enzyme", "TEST", 24, 42], ["it dephosphorylates bacterial LPS", "PROBLEM", 94, 127], ["its toxicity", "PROBLEM", 140, 152], ["liver", "ANATOMY", 54, 59], ["intestine", "ANATOMY", 61, 70], ["kidney", "ANATOMY", 75, 81], ["tubules", "ANATOMY_MODIFIER", 82, 89], ["bacterial LPS", "OBSERVATION", 114, 127]]], ["Greater ALP activity in both liver and ileum of LRFI pigs indicates that they deactivated or neutralized endotoxin more efficiently.", [["liver", "ANATOMY", 29, 34], ["ileum", "ANATOMY", 39, 44], ["ALP", "GENE_OR_GENE_PRODUCT", 8, 11], ["liver", "ORGAN", 29, 34], ["ileum", "ORGAN", 39, 44], ["LRFI pigs", "ORGANISM", 48, 57], ["endotoxin", "SIMPLE_CHEMICAL", 105, 114], ["ALP", "PROTEIN", 8, 11], ["endotoxin", "PROTEIN", 105, 114], ["pigs", "SPECIES", 53, 57], ["Greater ALP activity", "PROBLEM", 0, 20], ["neutralized endotoxin", "TREATMENT", 93, 114], ["ALP activity", "OBSERVATION", 8, 20], ["both", "ANATOMY_MODIFIER", 24, 28], ["liver", "ANATOMY", 29, 34], ["ileum", "ANATOMY", 39, 44]]], ["It is speculated that pigs are vulnerable to enteric infections and susceptible diarrhea, and growth-check due to compromised mucosal alkaline phosphatase (Lackeyram et al., 2010).", [["mucosal", "ANATOMY", 126, 133], ["enteric infections", "DISEASE", 45, 63], ["diarrhea", "DISEASE", 80, 88], ["pigs", "ORGANISM", 22, 26], ["mucosal", "ORGAN", 126, 133], ["mucosal alkaline phosphatase", "PROTEIN", 126, 154], ["pigs", "SPECIES", 22, 26], ["pigs", "SPECIES", 22, 26], ["enteric infections", "PROBLEM", 45, 63], ["susceptible diarrhea", "PROBLEM", 68, 88], ["growth", "TEST", 94, 100], ["compromised mucosal alkaline phosphatase", "PROBLEM", 114, 154], ["enteric", "OBSERVATION_MODIFIER", 45, 52], ["infections", "OBSERVATION", 53, 63], ["susceptible", "OBSERVATION_MODIFIER", 68, 79], ["diarrhea", "OBSERVATION", 80, 88]]], ["Further, intestinal ALP reduces trans-mucosal passage of bacteria and also protects against LPS-induced inflammation (Lall\u00e8s, 2010).", [["intestinal", "ANATOMY", 9, 19], ["mucosal", "ANATOMY", 38, 45], ["LPS", "CHEMICAL", 92, 95], ["inflammation", "DISEASE", 104, 116], ["intestinal", "ORGAN", 9, 19], ["ALP", "GENE_OR_GENE_PRODUCT", 20, 23], ["mucosal", "PATHOLOGICAL_FORMATION", 38, 45], ["LPS", "SIMPLE_CHEMICAL", 92, 95], ["intestinal ALP", "PROTEIN", 9, 23], ["intestinal ALP", "TEST", 9, 23], ["bacteria", "PROBLEM", 57, 65], ["LPS", "PROBLEM", 92, 95], ["inflammation", "PROBLEM", 104, 116], ["intestinal", "ANATOMY", 9, 19], ["mucosal", "ANATOMY", 38, 45], ["bacteria", "OBSERVATION", 57, 65], ["against LPS", "OBSERVATION_MODIFIER", 84, 95], ["inflammation", "OBSERVATION", 104, 116]]], ["This may be affirmed by the moderately negative correlation between ALP and serum endotoxin concentration in our study.", [["serum", "ANATOMY", 76, 81], ["endotoxin", "CHEMICAL", 82, 91], ["ALP", "GENE_OR_GENE_PRODUCT", 68, 71], ["serum", "ORGANISM_SUBSTANCE", 76, 81], ["endotoxin", "SIMPLE_CHEMICAL", 82, 91], ["ALP", "PROTEIN", 68, 71], ["serum endotoxin", "PROTEIN", 76, 91], ["ALP", "TEST", 68, 71], ["serum endotoxin concentration", "TEST", 76, 105], ["our study", "TEST", 109, 118]]], ["Further evidence suggests that ALP can also mitigate BW loss after an immune challenge (Bol-Schoenmakers et al., 2010).DISCUSSIONTo further explore the difference in endotoxin metabolism, we measured AOAH mRNA expression.", [["BW loss", "DISEASE", 53, 60], ["endotoxin", "CHEMICAL", 166, 175], ["ALP", "GENE_OR_GENE_PRODUCT", 31, 34], ["endotoxin", "SIMPLE_CHEMICAL", 166, 175], ["AOAH", "GENE_OR_GENE_PRODUCT", 200, 204], ["ALP", "PROTEIN", 31, 34], ["AOAH mRNA", "RNA", 200, 209], ["BW loss", "PROBLEM", 53, 60], ["an immune challenge", "TREATMENT", 67, 86], ["the difference in endotoxin metabolism", "PROBLEM", 148, 186]]], ["Acyloxyacyl hydrolase is an important lipase enzyme that selectively removes the secondary fatty acyl chains attached to the primary chains in the lipid A moiety and detoxifies endotoxin (McDermott and Fenwick, 1992).", [["Acyloxyacyl", "CHEMICAL", 0, 11], ["Acyloxyacyl", "CHEMICAL", 0, 11], ["fatty acyl", "CHEMICAL", 91, 101], ["Acyloxyacyl hydrolase", "GENE_OR_GENE_PRODUCT", 0, 21], ["lipase", "GENE_OR_GENE_PRODUCT", 38, 44], ["lipid A moiety", "SIMPLE_CHEMICAL", 147, 161], ["endotoxin", "SIMPLE_CHEMICAL", 177, 186], ["Acyloxyacyl hydrolase", "PROTEIN", 0, 21], ["lipase enzyme", "PROTEIN", 38, 51], ["Acyloxyacyl hydrolase", "TREATMENT", 0, 21], ["an important lipase enzyme", "TEST", 25, 51], ["the secondary fatty acyl chains", "TREATMENT", 77, 108], ["acyl chains", "OBSERVATION", 97, 108]]], ["This leads to an LPS molecule which could bind the signaling proteins MD2/TLR4, but does not have the potential to initiate the signal or can only be a partial agonist (Lu et al., 2005).", [["LPS", "CHEMICAL", 17, 20], ["LPS", "SIMPLE_CHEMICAL", 17, 20], ["MD2", "GENE_OR_GENE_PRODUCT", 70, 73], ["TLR4", "GENE_OR_GENE_PRODUCT", 74, 78], ["signaling proteins", "PROTEIN", 51, 69], ["MD2", "PROTEIN", 70, 73], ["TLR4", "PROTEIN", 74, 78], ["an LPS molecule", "PROBLEM", 14, 29], ["LPS molecule", "OBSERVATION", 17, 29]]], ["The fact that we did not see evidence of differential AOAH mRNA expression in the intestine or liver was surprising.", [["intestine", "ANATOMY", 82, 91], ["liver", "ANATOMY", 95, 100], ["AOAH", "GENE_OR_GENE_PRODUCT", 54, 58], ["intestine", "ORGAN", 82, 91], ["liver", "ORGAN", 95, 100], ["AOAH mRNA", "RNA", 54, 63], ["differential AOAH mRNA expression in the intestine or liver", "PROBLEM", 41, 100], ["intestine", "ANATOMY", 82, 91], ["liver", "ANATOMY", 95, 100]]], ["However, AOAH mRNA and activity appear to be correlated in a tissue or cell specific manner (Feulner et al., 2004).", [["tissue", "ANATOMY", 61, 67], ["cell", "ANATOMY", 71, 75], ["AOAH", "GENE_OR_GENE_PRODUCT", 9, 13], ["tissue", "TISSUE", 61, 67], ["cell", "CELL", 71, 75], ["AOAH mRNA", "RNA", 9, 18], ["AOAH mRNA", "PROBLEM", 9, 18]]], ["Therefore, liver and intestinal mRNA expression may not be correlated in swine or immune and Kupffer cell specific expression needs to be determined, where activity and expression of AOAH are greater.DISCUSSIONLysozyme is another important antimicrobial peptide secreted by various cells of the body, including cells in the intestine and liver.", [["liver", "ANATOMY", 11, 16], ["intestinal", "ANATOMY", 21, 31], ["Kupffer cell", "ANATOMY", 93, 105], ["cells", "ANATOMY", 282, 287], ["body", "ANATOMY", 295, 299], ["cells", "ANATOMY", 311, 316], ["intestine", "ANATOMY", 324, 333], ["liver", "ANATOMY", 338, 343], ["liver", "ORGAN", 11, 16], ["intestinal", "ORGAN", 21, 31], ["swine", "ORGANISM", 73, 78], ["immune", "CELL", 82, 88], ["Kupffer cell", "CELL", 93, 105], ["AOAH", "GENE_OR_GENE_PRODUCT", 183, 187], ["cells", "CELL", 282, 287], ["body", "ORGANISM_SUBDIVISION", 295, 299], ["cells", "CELL", 311, 316], ["intestine", "ORGAN", 324, 333], ["liver", "ORGAN", 338, 343], ["AOAH", "PROTEIN", 183, 187], ["swine", "SPECIES", 73, 78], ["swine", "SPECIES", 73, 78], ["DISCUSSIONLysozyme", "TREATMENT", 200, 218], ["important antimicrobial peptide", "TREATMENT", 230, 261], ["liver", "ANATOMY", 11, 16], ["intestinal", "ANATOMY", 21, 31], ["may not be", "UNCERTAINTY", 48, 58], ["greater", "OBSERVATION_MODIFIER", 192, 199], ["various cells", "OBSERVATION", 274, 287], ["body", "ANATOMY", 295, 299], ["intestine", "ANATOMY", 324, 333], ["liver", "ANATOMY", 338, 343]]], ["Lysozyme regulates microbial populations by lysing the bacterial cell wall component peptidoglycan and also binds to and detoxifies LPS (Takada et al., 1994).", [["cell wall", "ANATOMY", 65, 74], ["LPS", "CHEMICAL", 132, 135], ["Lysozyme", "GENE_OR_GENE_PRODUCT", 0, 8], ["cell wall", "CELLULAR_COMPONENT", 65, 74], ["LPS", "SIMPLE_CHEMICAL", 132, 135], ["Lysozyme", "PROTEIN", 0, 8], ["Lysozyme regulates microbial populations", "TREATMENT", 0, 40], ["the bacterial cell wall component peptidoglycan", "TREATMENT", 51, 98], ["bacterial cell", "OBSERVATION", 55, 69], ["wall", "ANATOMY_MODIFIER", 70, 74], ["component", "OBSERVATION_MODIFIER", 75, 84], ["peptidoglycan", "OBSERVATION_MODIFIER", 85, 98]]], ["In our study, although lysozyme activity in the liver was not different between the 2 lines and ileum lysozyme activity was greater in LRFI pigs.", [["liver", "ANATOMY", 48, 53], ["ileum", "ANATOMY", 96, 101], ["lysozyme", "GENE_OR_GENE_PRODUCT", 23, 31], ["liver", "ORGAN", 48, 53], ["ileum", "ORGAN", 96, 101], ["lysozyme", "GENE_OR_GENE_PRODUCT", 102, 110], ["LRFI pigs", "ORGANISM", 135, 144], ["lysozyme", "PROTEIN", 23, 31], ["lysozyme", "PROTEIN", 102, 110], ["pigs", "SPECIES", 140, 144], ["pigs", "SPECIES", 140, 144], ["our study", "TEST", 3, 12], ["lysozyme activity in the liver", "PROBLEM", 23, 53], ["the 2 lines", "TREATMENT", 80, 91], ["ileum lysozyme activity", "TREATMENT", 96, 119], ["lysozyme activity", "OBSERVATION", 23, 40], ["liver", "ANATOMY", 48, 53], ["different", "OBSERVATION_MODIFIER", 62, 71], ["ileum", "ANATOMY", 96, 101], ["lysozyme activity", "OBSERVATION", 102, 119], ["greater", "OBSERVATION_MODIFIER", 124, 131]]], ["This may explain the decreased serum endotoxin and haptoglobin concentrations in the LRFI pigs and greater FE.", [["serum", "ANATOMY", 31, 36], ["endotoxin", "CHEMICAL", 37, 46], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["endotoxin", "SIMPLE_CHEMICAL", 37, 46], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 51, 62], ["LRFI pigs", "ORGANISM", 85, 94], ["serum endotoxin", "PROTEIN", 31, 46], ["haptoglobin", "PROTEIN", 51, 62], ["pigs", "SPECIES", 90, 94], ["the decreased serum endotoxin", "PROBLEM", 17, 46], ["haptoglobin concentrations", "TEST", 51, 77], ["the LRFI pigs", "TREATMENT", 81, 94], ["decreased", "OBSERVATION_MODIFIER", 21, 30], ["serum endotoxin", "OBSERVATION_MODIFIER", 31, 46]]], ["Supporting this hypothesis, recent studies found that feeding lysozyme to pigs improved their health and FE (May et al., 2012; Nyachoti et al., 2012).", [["lysozyme", "GENE_OR_GENE_PRODUCT", 62, 70], ["pigs", "ORGANISM", 74, 78], ["pigs", "SPECIES", 74, 78], ["pigs", "SPECIES", 74, 78], ["recent studies", "TEST", 28, 42], ["feeding lysozyme", "TREATMENT", 54, 70]]], ["However, tissue lysozyme activity was not determined in these studies.", [["tissue", "ANATOMY", 9, 15], ["tissue", "TISSUE", 9, 15], ["lysozyme", "PROTEIN", 16, 24], ["tissue lysozyme activity", "TEST", 9, 33], ["these studies", "TEST", 56, 69], ["lysozyme activity", "OBSERVATION", 16, 33]]], ["Surprisingly, although ALP and lysozyme activity was different between the 2 lines in ileum and liver, mRNA expression of both enzymes were not different, indicating a post-translational mechanism which may act differently in the 2 lines of pigs.DISCUSSIONWe speculate that the LRFI pigs are exposed to comparatively lower concentrations of endotoxin and stress intermittently, although the 2 lines shared the same environmental conditions (i.e., housing and diets).", [["ileum", "ANATOMY", 86, 91], ["liver", "ANATOMY", 96, 101], ["endotoxin", "CHEMICAL", 341, 350], ["ALP", "GENE_OR_GENE_PRODUCT", 23, 26], ["lysozyme", "GENE_OR_GENE_PRODUCT", 31, 39], ["ileum", "MULTI-TISSUE_STRUCTURE", 86, 91], ["liver", "ORGAN", 96, 101], ["pigs", "ORGANISM", 241, 245], ["LRFI pigs", "ORGANISM", 278, 287], ["endotoxin", "SIMPLE_CHEMICAL", 341, 350], ["ALP", "PROTEIN", 23, 26], ["lysozyme", "PROTEIN", 31, 39], ["enzymes", "PROTEIN", 127, 134], ["pigs", "SPECIES", 241, 245], ["pigs", "SPECIES", 283, 287], ["pigs", "SPECIES", 241, 245], ["pigs", "SPECIES", 283, 287], ["ALP and lysozyme activity", "PROBLEM", 23, 48], ["both enzymes", "TEST", 122, 134], ["a post-translational mechanism", "PROBLEM", 166, 196], ["the LRFI pigs", "TREATMENT", 274, 287], ["endotoxin", "TREATMENT", 341, 350], ["the 2 lines", "TREATMENT", 387, 398], ["lysozyme activity", "OBSERVATION", 31, 48], ["ileum", "ANATOMY", 86, 91], ["liver", "ANATOMY", 96, 101], ["post-translational mechanism", "OBSERVATION", 168, 196]]], ["We hypothesize that the HRFI pigs with reduced endotoxin detoxification would have increased stress and acute tissue damage compared with the LRFI gilts.", [["tissue", "ANATOMY", 110, 116], ["endotoxin", "CHEMICAL", 47, 56], ["HRFI pigs", "ORGANISM", 24, 33], ["endotoxin", "SIMPLE_CHEMICAL", 47, 56], ["tissue", "TISSUE", 110, 116], ["pigs", "SPECIES", 29, 33], ["pigs", "SPECIES", 29, 33], ["the HRFI pigs", "TREATMENT", 20, 33], ["reduced endotoxin detoxification", "TREATMENT", 39, 71], ["increased stress", "PROBLEM", 83, 99], ["acute tissue damage", "PROBLEM", 104, 123], ["the LRFI gilts", "TREATMENT", 138, 152], ["acute tissue", "OBSERVATION_MODIFIER", 104, 116], ["damage", "OBSERVATION", 117, 123]]], ["Together, this would explain the increase in acute phase proteins.", [["acute phase proteins", "PROTEIN", 45, 65], ["acute phase proteins", "PROBLEM", 45, 65], ["increase", "OBSERVATION_MODIFIER", 33, 41], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["phase proteins", "OBSERVATION", 51, 65]]], ["Pigs repeatedly exposed to endotoxin have augmented haptoglobin concentrations compared with a single endotoxin exposure (Dritz et al., 1996; Wright et al., 2000).", [["endotoxin", "CHEMICAL", 27, 36], ["endotoxin", "CHEMICAL", 102, 111], ["Pigs", "ORGANISM", 0, 4], ["endotoxin", "SIMPLE_CHEMICAL", 27, 36], ["haptoglobin", "GENE_OR_GENE_PRODUCT", 52, 63], ["haptoglobin", "PROTEIN", 52, 63], ["Pigs", "SPECIES", 0, 4], ["Pigs", "SPECIES", 0, 4], ["Pigs", "TREATMENT", 0, 4], ["endotoxin", "TREATMENT", 27, 36], ["augmented haptoglobin concentrations", "PROBLEM", 42, 78], ["a single endotoxin exposure", "TREATMENT", 93, 120], ["haptoglobin concentrations", "OBSERVATION", 52, 78]]], ["In addition, increased reactive oxygen species production and reduced mitochondrial coupling may also explain our data.", [["mitochondrial", "ANATOMY", 70, 83], ["oxygen", "CHEMICAL", 32, 38], ["oxygen", "CHEMICAL", 32, 38], ["reactive oxygen species", "SIMPLE_CHEMICAL", 23, 46], ["mitochondrial", "CELLULAR_COMPONENT", 70, 83], ["increased reactive oxygen species production", "PROBLEM", 13, 57], ["reduced mitochondrial coupling", "PROBLEM", 62, 92], ["increased", "OBSERVATION_MODIFIER", 13, 22], ["reactive", "OBSERVATION_MODIFIER", 23, 31], ["oxygen species", "OBSERVATION", 32, 46]]], ["Reactive oxygen species production increases protein carbonyl formation in low FE broiler (Bottje et al., 2006) and steer (Sandelin, 2005) tissues.", [["tissues", "ANATOMY", 139, 146], ["oxygen", "CHEMICAL", 9, 15], ["carbonyl", "CHEMICAL", 53, 61], ["oxygen", "CHEMICAL", 9, 15], ["carbonyl", "CHEMICAL", 53, 61], ["Reactive oxygen species", "SIMPLE_CHEMICAL", 0, 23], ["carbonyl", "SIMPLE_CHEMICAL", 53, 61], ["tissues", "TISSUE", 139, 146], ["Reactive oxygen species production", "PROBLEM", 0, 34], ["protein carbonyl formation in low FE broiler", "TREATMENT", 45, 89], ["oxygen species", "OBSERVATION", 9, 23], ["production", "OBSERVATION_MODIFIER", 24, 34], ["increases", "OBSERVATION_MODIFIER", 35, 44], ["protein carbonyl formation", "OBSERVATION", 45, 71]]], ["Importantly, these proteins may be more susceptible to degradation and turnover which would contribute to the acute phase protein response we report herein and the reduced FE phenotype.DISCUSSIONIn conclusion, our results indicate that LRFI pigs seem to have a more robust intestinal and liver endotoxin detoxification and greater active anti-microbial enzymes including ALP, ileum lysozyme and the inflammatory mediator enzyme myeloperoxidase, and that HRFI pigs seem to be undergoing a greater level of basal inflammation.", [["intestinal", "ANATOMY", 273, 283], ["liver", "ANATOMY", 288, 293], ["ileum", "ANATOMY", 376, 381], ["endotoxin", "CHEMICAL", 294, 303], ["inflammation", "DISEASE", 511, 523], ["LRFI pigs", "ORGANISM", 236, 245], ["intestinal", "ORGAN", 273, 283], ["liver", "ORGAN", 288, 293], ["endotoxin", "SIMPLE_CHEMICAL", 294, 303], ["ALP", "GENE_OR_GENE_PRODUCT", 371, 374], ["ileum lysozyme", "GENE_OR_GENE_PRODUCT", 376, 390], ["myeloperoxidase", "GENE_OR_GENE_PRODUCT", 428, 443], ["HRFI pigs", "ORGANISM", 454, 463], ["anti-microbial enzymes", "PROTEIN", 338, 360], ["ALP", "PROTEIN", 371, 374], ["ileum lysozyme", "PROTEIN", 376, 390], ["inflammatory mediator enzyme", "PROTEIN", 399, 427], ["myeloperoxidase", "PROTEIN", 428, 443], ["pigs", "SPECIES", 241, 245], ["pigs", "SPECIES", 459, 463], ["the acute phase protein response", "PROBLEM", 106, 138], ["liver endotoxin detoxification", "TREATMENT", 288, 318], ["greater active anti-microbial enzymes", "TEST", 323, 360], ["ALP, ileum lysozyme", "TEST", 371, 390], ["the inflammatory mediator enzyme myeloperoxidase", "TEST", 395, 443], ["basal inflammation", "PROBLEM", 505, 523], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["intestinal", "ANATOMY", 273, 283], ["liver", "ANATOMY", 288, 293], ["ileum", "ANATOMY", 376, 381], ["inflammatory", "OBSERVATION_MODIFIER", 399, 411], ["basal", "ANATOMY_MODIFIER", 505, 510], ["inflammation", "OBSERVATION", 511, 523]]], ["Although decreased serum endotoxin and the associated decreased inflammatory markers and the enhanced activities of antimicrobial enzymes in the LRFI pigs may not explain the line difference in FE wholly, it has the potential to be a significant contributing factor.", [["serum", "ANATOMY", 19, 24], ["endotoxin", "CHEMICAL", 25, 34], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["endotoxin", "GENE_OR_GENE_PRODUCT", 25, 34], ["LRFI pigs", "ORGANISM", 145, 154], ["serum endotoxin", "PROTEIN", 19, 34], ["inflammatory markers", "PROTEIN", 64, 84], ["antimicrobial enzymes", "PROTEIN", 116, 137], ["pigs", "SPECIES", 150, 154], ["decreased serum endotoxin", "PROBLEM", 9, 34], ["the associated decreased inflammatory markers", "PROBLEM", 39, 84], ["antimicrobial enzymes", "TEST", 116, 137], ["the line difference in FE", "PROBLEM", 171, 196], ["a significant contributing factor", "PROBLEM", 232, 265], ["decreased", "OBSERVATION_MODIFIER", 9, 18], ["serum endotoxin", "OBSERVATION_MODIFIER", 19, 34], ["decreased", "OBSERVATION_MODIFIER", 54, 63], ["inflammatory markers", "OBSERVATION", 64, 84]]], ["Further studies are needed to identify other mechanisms that contribute to the reduced endotoxin concentrations in the LRFI pigs and how this is associated with their greater FE.", [["endotoxin", "CHEMICAL", 87, 96], ["endotoxin", "SIMPLE_CHEMICAL", 87, 96], ["pigs", "ORGANISM", 124, 128], ["endotoxin", "PROTEIN", 87, 96], ["pigs", "SPECIES", 124, 128], ["Further studies", "TEST", 0, 15], ["the reduced endotoxin concentrations", "PROBLEM", 75, 111], ["reduced", "OBSERVATION_MODIFIER", 79, 86], ["endotoxin", "OBSERVATION", 87, 96]]]], "00a0ab182dc01b6c2e737dfae585f050dcf9a7a5": [["Brief history of the localised epidemic.The world was made aware of a newly discovered coronavirus via an email from Dr. Ali Mohamed Zaki, an Egyptian virologist working at the Dr. Soliman Fakeeh Hospital in Jeddah in The Kingdom of Saudi Arabia (KSA).", [["coronavirus", "ORGANISM", 87, 98], ["the localised epidemic", "PROBLEM", 17, 39], ["localised", "OBSERVATION_MODIFIER", 21, 30], ["epidemic", "OBSERVATION", 31, 39]]], ["That first case was a 60 year old man from Bisha in the KSA and, thanks to the email, the rapid discovery of a second case of the virus, this time in an ill patient from Qatar, was transferred to the United Kingdom for care ( Fig. 1) (Bermingham et al., 2012) .", [["man", "ORGANISM", 34, 37], ["patient", "ORGANISM", 157, 164], ["man", "SPECIES", 34, 37], ["patient", "SPECIES", 157, 164], ["the virus", "PROBLEM", 126, 135], ["virus", "OBSERVATION", 130, 135]]], ["As of 20th January 2015, there have been 969 detections of viral RNA or virus-specific antibodies reported publicly, 955 confirmed by the World Health Organization (WHO), with over a third of the positive people dying (n = 351, 37%; data from public sources including the WHO and Ministries of Health).", [["people", "ORGANISM", 205, 211], ["viral RNA", "RNA", 59, 68], ["virus-specific antibodies", "PROTEIN", 72, 97], ["people", "SPECIES", 205, 211], ["viral RNA", "PROBLEM", 59, 68], ["virus", "PROBLEM", 72, 77], ["viral RNA", "OBSERVATION", 59, 68]]], ["First known as novel coronavirus (nCoV), the following two to three years were a slow discovery process revealing a virus that appears well established among dromedary camels (DC; Camelus dromedarius) across the Arabian Peninsula and parts of Africa.", [["DC", "ANATOMY", 176, 178], ["Camelus dromedarius", "ORGANISM", 180, 199], ["DC", "CELL_TYPE", 176, 178], ["Camelus dromedarius", "SPECIES", 180, 199], ["Camelus dromedarius", "SPECIES", 180, 199], ["novel coronavirus", "PROBLEM", 15, 32], ["a slow discovery process", "PROBLEM", 79, 103], ["a virus", "PROBLEM", 114, 121], ["coronavirus", "OBSERVATION", 21, 32], ["virus", "OBSERVATION", 116, 121], ["Arabian Peninsula", "ANATOMY", 212, 229]]], ["From infected DCs, the virus is thought to infrequently infect exposed humans.", [["DCs", "ANATOMY", 14, 17], ["DCs", "CELL", 14, 17], ["humans", "ORGANISM", 71, 77], ["DCs", "CELL_TYPE", 14, 17], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 71, 77], ["infected DCs", "PROBLEM", 5, 17], ["the virus", "PROBLEM", 19, 28], ["infected DCs", "OBSERVATION", 5, 17], ["thought to", "UNCERTAINTY", 32, 42]]], ["Concern was raised early on that patenting of the first viral isolate would lead to restricted access to the virus and to viral diagnostics (Sciencemag, 2014) .", [["the first viral isolate", "PROBLEM", 46, 69], ["the virus", "PROBLEM", 105, 114], ["viral diagnostics", "TEST", 122, 139]]], ["However, sensitive, validated reverse transcriptase real-time polymerase chain reaction (RT-rtPCR)-based diagnostics were available (Abdel-Moneim, 2014) almost immediately.", [["reverse transcriptase", "PROTEIN", 30, 51], ["time polymerase chain reaction", "PROBLEM", 57, 87], ["RT-rtPCR", "TEST", 89, 97]]], ["Virus was also made freely available subject to routine biosafety considerations, supporting many of the research findings described herein.", [["Virus", "ORGANISM", 0, 5], ["Virus", "PROBLEM", 0, 5]]], ["In search of an animal host, bats were implicated in August 2013 but in that same month a DC link was reported (Reusken et al., 2013c) and that link has matured into a verifiable association.", [["DC", "ANATOMY", 90, 92], ["bats", "ORGANISM", 29, 33], ["DC", "CELL_TYPE", 90, 92]]], ["In humans, overt disease was finally given the name Middle East respiratory syndrome and the acronym MERS.", [["Middle East respiratory syndrome", "DISEASE", 52, 84], ["humans", "ORGANISM", 3, 9], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["overt disease", "PROBLEM", 11, 24], ["respiratory syndrome", "PROBLEM", 64, 84], ["overt", "OBSERVATION_MODIFIER", 11, 16], ["disease", "OBSERVATION", 17, 24], ["respiratory syndrome", "OBSERVATION", 64, 84]]], ["From these animal-to-human spillover events, the MERS coronavirus (MERS-CoV; see Section 3 for variation in naming) spread sporadically among people, causing more severe disease among older males with underlying diseases.", [["human", "ORGANISM", 21, 26], ["MERS coronavirus", "ORGANISM", 49, 65], ["MERS-CoV", "ORGANISM", 67, 75], ["people", "ORGANISM", 142, 148], ["human", "SPECIES", 21, 26], ["people", "SPECIES", 142, 148], ["human", "SPECIES", 21, 26], ["MERS coronavirus", "SPECIES", 49, 65], ["MERS-CoV", "SPECIES", 67, 75], ["human spillover events", "PROBLEM", 21, 43], ["the MERS coronavirus", "PROBLEM", 45, 65], ["more severe disease", "PROBLEM", 158, 177], ["underlying diseases", "PROBLEM", 201, 220], ["severe", "OBSERVATION_MODIFIER", 163, 169], ["disease", "OBSERVATION", 170, 177], ["diseases", "OBSERVATION", 212, 220]]], ["The proportion of infected people who are confirmed to have died from MERS-CoV infection is much higher than for severe acute respiratory syndrome (SARS)-CoV, influenza virus or many other pathogens.", [["MERS-CoV infection", "DISEASE", 70, 88], ["acute respiratory syndrome (SARS)-CoV, influenza virus", "DISEASE", 120, 174], ["people", "ORGANISM", 27, 33], ["MERS-CoV", "ORGANISM", 70, 78], ["SARS)-CoV", "ORGANISM", 148, 157], ["influenza virus", "ORGANISM", 159, 174], ["people", "SPECIES", 27, 33], ["influenza virus", "SPECIES", 159, 174], ["MERS-CoV", "SPECIES", 70, 78], ["severe acute respiratory syndrome (SARS)-CoV", "SPECIES", 113, 157], ["influenza virus", "SPECIES", 159, 174], ["MERS", "PROBLEM", 70, 74], ["CoV infection", "PROBLEM", 75, 88], ["severe acute respiratory syndrome", "PROBLEM", 113, 146], ["SARS)", "PROBLEM", 148, 153], ["CoV", "PROBLEM", 154, 157], ["influenza virus", "PROBLEM", 159, 174], ["many other pathogens", "PROBLEM", 178, 198], ["infected", "OBSERVATION", 18, 26], ["CoV", "OBSERVATION_MODIFIER", 75, 78], ["infection", "OBSERVATION", 79, 88], ["acute", "OBSERVATION_MODIFIER", 120, 125], ["respiratory syndrome", "OBSERVATION", 126, 146]]], ["The spread of MERS-CoV among humans has often been associated with outbreaks in hospitals, which in 2012-2014 usually commenced in March (Mackay, 2014; Maltezou and Tsiodras, 2014) .", [["MERS-CoV", "ORGANISM", 14, 22], ["humans", "ORGANISM", 29, 35], ["humans", "SPECIES", 29, 35], ["MERS-CoV", "SPECIES", 14, 22], ["humans", "SPECIES", 29, 35], ["spread", "OBSERVATION_MODIFIER", 4, 10]]], ["This spread may be linked to some seasonal environmental changes, change in host animal behaviour, or perhaps simple coincidence between season and successive hospital outbreaks.", [["some seasonal environmental changes", "PROBLEM", 29, 64]]], ["Approximately a fifth of all cases to date have involved healthcare workers (HCWs), spiking alongside periods of increased total case numbers.", [["increased total case numbers", "PROBLEM", 113, 141]]], ["Social media, blogs and the mainstream media have kept close tabs on the spread of MERS-CoV to 23 countries in Europe, Asia and the United States of America (USA; Fig. 2 ), mostly with an origin in the KSA from where 88% of viral detections have occurred.", [["MERS-CoV", "ORGANISM", 83, 91], ["MERS-CoV", "SPECIES", 83, 91], ["viral detections", "TEST", 224, 240]]], ["Twitter in particular has provided a global forum through specific hashtags like #MERS and the Arabic hashtag #AF4FD? or #Coruna.", [["#Coruna", "PROBLEM", 121, 128]]], ["This degree of engagement was not possible in 2002/2003 when the SARS global outbreak began its rise to 8100 human cases including 770 deaths (proportion of fatal cases, or PFC, of 9.5%).", [["SARS", "DISEASE", 65, 69], ["deaths", "DISEASE", 135, 141], ["human", "ORGANISM", 109, 114], ["human", "SPECIES", 109, 114], ["human", "SPECIES", 109, 114], ["the SARS global outbreak", "PROBLEM", 61, 85], ["PFC", "TEST", 173, 176], ["engagement", "OBSERVATION", 15, 25], ["not possible", "UNCERTAINTY", 30, 42]]], ["The ubiquity of social media appears to have changed what the public expects from a State when it communicates about new or existing infectious disease outbreaks and epidemics, and how quickly they expect that to occur.Middle East respiratory syndrome (MERS)Patients with MERS often present themselves to a hospital with systemic and lower respiratory tract (LRT) signs and symptoms of disease which usually include fever, chills or rigors, dry or productive cough, shortness of breath (dyspnea) and one or more comorbidities including diabetes (prevalent in the KSA), chronic kidney disease including renal failure, chronic heart disease and heart failure, recent surgery, hypertension, chronic lung disease, asthma, obesity, smoking, malignant disease or steroid use (Arabi et al., 2014; Assiri et al., 2013a; Hijawi et al., 2013; Zaki et al., 2012) .", [["lower respiratory tract", "ANATOMY", 334, 357], ["kidney", "ANATOMY", 577, 583], ["renal", "ANATOMY", 602, 607], ["heart", "ANATOMY", 625, 630], ["heart", "ANATOMY", 643, 648], ["lung", "ANATOMY", 696, 700], ["Middle East respiratory syndrome", "DISEASE", 219, 251], ["systemic and lower respiratory tract (LRT) signs", "DISEASE", 321, 369], ["fever", "DISEASE", 416, 421], ["chills", "DISEASE", 423, 429], ["rigors", "DISEASE", 433, 439], ["cough", "DISEASE", 459, 464], ["shortness of breath", "DISEASE", 466, 485], ["dyspnea", "DISEASE", 487, 494], ["diabetes", "DISEASE", 536, 544], ["chronic kidney disease", "DISEASE", 569, 591], ["renal failure", "DISEASE", 602, 615], ["chronic heart disease", "DISEASE", 617, 638], ["heart failure", "DISEASE", 643, 656], ["hypertension", "DISEASE", 674, 686], ["chronic lung disease", "DISEASE", 688, 708], ["asthma", "DISEASE", 710, 716], ["obesity", "DISEASE", 718, 725], ["smoking", "CHEMICAL", 727, 734], ["malignant disease", "DISEASE", 736, 753], ["steroid", "CHEMICAL", 757, 764], ["steroid", "CHEMICAL", 757, 764], ["Patients", "ORGANISM", 258, 266], ["lower", "ORGANISM_SUBDIVISION", 334, 339], ["respiratory tract", "ORGANISM_SUBDIVISION", 340, 357], ["kidney", "ORGAN", 577, 583], ["renal", "ORGAN", 602, 607], ["heart", "ORGAN", 625, 630], ["heart", "ORGAN", 643, 648], ["lung", "ORGAN", 696, 700], ["Patients", "SPECIES", 258, 266], ["existing infectious disease outbreaks", "PROBLEM", 124, 161], ["Middle East respiratory syndrome", "PROBLEM", 219, 251], ["systemic and lower respiratory tract (LRT) signs", "PROBLEM", 321, 369], ["symptoms", "PROBLEM", 374, 382], ["disease", "PROBLEM", 386, 393], ["fever", "PROBLEM", 416, 421], ["chills", "PROBLEM", 423, 429], ["rigors", "PROBLEM", 433, 439], ["dry or productive cough", "PROBLEM", 441, 464], ["shortness of breath", "PROBLEM", 466, 485], ["dyspnea", "PROBLEM", 487, 494], ["diabetes", "PROBLEM", 536, 544], ["chronic kidney disease", "PROBLEM", 569, 591], ["renal failure", "PROBLEM", 602, 615], ["chronic heart disease", "PROBLEM", 617, 638], ["heart failure", "PROBLEM", 643, 656], ["recent surgery", "TREATMENT", 658, 672], ["hypertension", "PROBLEM", 674, 686], ["chronic lung disease", "PROBLEM", 688, 708], ["asthma", "PROBLEM", 710, 716], ["obesity", "PROBLEM", 718, 725], ["malignant disease", "PROBLEM", 736, 753], ["infectious", "OBSERVATION_MODIFIER", 133, 143], ["respiratory syndrome", "OBSERVATION", 231, 251], ["lower", "ANATOMY_MODIFIER", 334, 339], ["respiratory tract", "ANATOMY", 340, 357], ["disease", "OBSERVATION", 386, 393], ["productive", "OBSERVATION_MODIFIER", 448, 458], ["cough", "OBSERVATION", 459, 464], ["diabetes", "OBSERVATION", 536, 544], ["chronic", "OBSERVATION_MODIFIER", 569, 576], ["kidney", "ANATOMY", 577, 583], ["disease", "OBSERVATION", 584, 591], ["renal", "ANATOMY", 602, 607], ["failure", "OBSERVATION", 608, 615], ["chronic", "OBSERVATION_MODIFIER", 617, 624], ["heart", "ANATOMY", 625, 630], ["disease", "OBSERVATION", 631, 638], ["heart", "ANATOMY", 643, 648], ["failure", "OBSERVATION", 649, 656], ["surgery", "OBSERVATION", 665, 672], ["hypertension", "OBSERVATION", 674, 686], ["chronic", "OBSERVATION_MODIFIER", 688, 695], ["lung", "ANATOMY", 696, 700], ["disease", "OBSERVATION", 701, 708], ["asthma", "OBSERVATION", 710, 716], ["obesity", "OBSERVATION", 718, 725], ["malignant", "OBSERVATION_MODIFIER", 736, 745]]], ["MERS-CoV may be identified in patients with severe hypoxaemic respiratory failure and extrapulmonary organ dysfunction which can precede death in over a third of infections (Arabi et al., 2014; Assiri et al., 2013a; Hijawi et al., 2013; Zaki et al., 2012) .", [["respiratory", "ANATOMY", 62, 73], ["extrapulmonary organ", "ANATOMY", 86, 106], ["hypoxaemic respiratory failure", "DISEASE", 51, 81], ["extrapulmonary organ dysfunction", "DISEASE", 86, 118], ["death", "DISEASE", 137, 142], ["infections", "DISEASE", 162, 172], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["patients", "ORGANISM", 30, 38], ["organ", "ORGAN", 101, 106], ["patients", "SPECIES", 30, 38], ["MERS-CoV", "SPECIES", 0, 8], ["severe hypoxaemic respiratory failure", "PROBLEM", 44, 81], ["extrapulmonary organ dysfunction", "PROBLEM", 86, 118], ["severe", "OBSERVATION_MODIFIER", 44, 50], ["hypoxaemic", "OBSERVATION_MODIFIER", 51, 61], ["respiratory failure", "OBSERVATION", 62, 81], ["extrapulmonary organ", "ANATOMY", 86, 106], ["dysfunction", "OBSERVATION", 107, 118]]], ["Extrapulmonary disease manifestations include circulatory, renal, hepatic and hematologic dysfunction.", [["circulatory", "ANATOMY", 46, 57], ["renal", "ANATOMY", 59, 64], ["hepatic", "ANATOMY", 66, 73], ["hematologic", "ANATOMY", 78, 89], ["circulatory, renal, hepatic and hematologic dysfunction", "DISEASE", 46, 101], ["renal", "ORGAN", 59, 64], ["hepatic", "MULTI-TISSUE_STRUCTURE", 66, 73], ["Extrapulmonary disease manifestations", "PROBLEM", 0, 37], ["circulatory, renal, hepatic and hematologic dysfunction", "PROBLEM", 46, 101], ["disease", "OBSERVATION", 15, 22], ["circulatory", "OBSERVATION", 46, 57], ["renal", "ANATOMY", 59, 64], ["hepatic", "ANATOMY", 66, 73], ["hematologic dysfunction", "OBSERVATION", 78, 101]]], ["Gastrointestinal symptoms have been seen in 20-33% of cases (Assiri et al., 2013a; Mailles et al., 2013; Memish et al., 2013b; Zumla and Memish, 2014) , manifesting as diarrhea, vomiting and abdominal pain.", [["Gastrointestinal", "ANATOMY", 0, 16], ["abdominal", "ANATOMY", 191, 200], ["diarrhea", "DISEASE", 168, 176], ["vomiting", "DISEASE", 178, 186], ["abdominal pain", "DISEASE", 191, 205], ["Gastrointestinal", "ORGAN", 0, 16], ["abdominal", "ORGANISM_SUBDIVISION", 191, 200], ["Gastrointestinal symptoms", "PROBLEM", 0, 25], ["Zumla", "TEST", 127, 132], ["diarrhea", "PROBLEM", 168, 176], ["vomiting", "PROBLEM", 178, 186], ["abdominal pain", "PROBLEM", 191, 205], ["abdominal", "ANATOMY", 191, 200], ["pain", "OBSERVATION", 201, 205]]], ["Gastrointestinal symptoms were not seen at all in one family cluster (Omrani et al., 2013) nor among symptomatic children in another .", [["Gastrointestinal", "ANATOMY", 0, 16], ["Gastrointestinal", "ORGAN", 0, 16], ["children", "ORGANISM", 113, 121], ["children", "SPECIES", 113, 121], ["Gastrointestinal symptoms", "PROBLEM", 0, 25]]], ["On occasion, fever and gastrointestinal upset may form a prodrome, after which symptoms decline to be are later followed by more severe systemic and respiratory signs and symptoms (Kraaij-Dirkzwager et al., 2014; Mailles et al., 2013) .", [["gastrointestinal", "ANATOMY", 23, 39], ["respiratory", "ANATOMY", 149, 160], ["fever", "DISEASE", 13, 18], ["gastrointestinal", "ORGAN", 23, 39], ["fever", "PROBLEM", 13, 18], ["gastrointestinal upset", "PROBLEM", 23, 45], ["a prodrome", "PROBLEM", 55, 65], ["symptoms", "PROBLEM", 79, 87], ["more severe systemic and respiratory signs", "PROBLEM", 124, 166], ["symptoms", "PROBLEM", 171, 179], ["gastrointestinal", "ANATOMY", 23, 39], ["respiratory", "ANATOMY", 149, 160]]], ["Rarely, MERS-CoV has been detected in a person with fever but no respiratory or gastrointestinal symptoms .", [["respiratory", "ANATOMY", 65, 76], ["gastrointestinal", "ANATOMY", 80, 96], ["fever", "DISEASE", 52, 57], ["respiratory or gastrointestinal symptoms", "DISEASE", 65, 105], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 8, 16], ["gastrointestinal", "ORGAN", 80, 96], ["person", "SPECIES", 40, 46], ["MERS-CoV", "SPECIES", 8, 16], ["fever", "PROBLEM", 52, 57], ["respiratory or gastrointestinal symptoms", "PROBLEM", 65, 105], ["no", "UNCERTAINTY", 62, 64], ["respiratory", "ANATOMY", 65, 76], ["gastrointestinal", "ANATOMY", 80, 96]]], ["The extent to which infection by other gastrointestinal pathogens affect this variability is unknown.Middle East respiratory syndrome (MERS)Chest radiography of MERS patients, as distinct from MERS-CoV positive people with a subclinical infection, reveal infiltrates consistent with acute viral pneumonia (Assiri et al., 2013a; Devi et al., 2014; Tsiodras et al., 2014; Zaki et al., 2012) .", [["gastrointestinal", "ANATOMY", 39, 55], ["infection", "DISEASE", 20, 29], ["Middle East respiratory syndrome", "DISEASE", 101, 133], ["infection", "DISEASE", 237, 246], ["viral pneumonia", "DISEASE", 289, 304], ["gastrointestinal", "ORGAN", 39, 55], ["patients", "ORGANISM", 166, 174], ["MERS-CoV", "ORGANISM", 193, 201], ["people", "ORGANISM", 211, 217], ["patients", "SPECIES", 166, 174], ["people", "SPECIES", 211, 217], ["MERS-CoV", "SPECIES", 193, 201], ["infection", "PROBLEM", 20, 29], ["other gastrointestinal pathogens", "PROBLEM", 33, 65], ["Middle East respiratory syndrome", "PROBLEM", 101, 133], ["Chest radiography", "TEST", 140, 157], ["a subclinical infection", "PROBLEM", 223, 246], ["infiltrates", "PROBLEM", 255, 266], ["acute viral pneumonia", "PROBLEM", 283, 304], ["infection", "OBSERVATION", 20, 29], ["gastrointestinal", "ANATOMY", 39, 55], ["pathogens", "OBSERVATION", 56, 65], ["respiratory syndrome", "OBSERVATION", 113, 133], ["Chest", "ANATOMY", 140, 145], ["subclinical", "OBSERVATION_MODIFIER", 225, 236], ["infection", "OBSERVATION", 237, 246], ["infiltrates", "OBSERVATION", 255, 266], ["consistent with", "UNCERTAINTY", 267, 282], ["acute", "OBSERVATION_MODIFIER", 283, 288], ["viral", "OBSERVATION_MODIFIER", 289, 294], ["pneumonia", "OBSERVATION", 295, 304]]], ["Only on rare occasions have studies described upper respiratory tract (URT) signs and symptoms.", [["upper respiratory tract", "ANATOMY", 46, 69], ["upper respiratory tract (URT) signs", "DISEASE", 46, 81], ["upper respiratory", "ORGANISM_SUBDIVISION", 46, 63], ["tract", "ORGANISM_SUBDIVISION", 64, 69], ["studies", "TEST", 28, 35], ["upper respiratory tract (URT) signs and symptoms", "PROBLEM", 46, 94], ["upper", "ANATOMY_MODIFIER", 46, 51], ["respiratory tract", "ANATOMY", 52, 69]]], ["In one example, approximately 15-25% of cases presented with rhinorrhoea and/or sore throat Memish et al., 2013b; Payne et al., 2014; Zumla and Memish, 2014) .", [["rhinorrhoea", "DISEASE", 61, 72], ["rhinorrhoea", "PROBLEM", 61, 72], ["sore throat", "PROBLEM", 80, 91]]], ["To date, MERS has been an opportunistic disease.", [["an opportunistic disease", "PROBLEM", 23, 47], ["opportunistic", "OBSERVATION_MODIFIER", 26, 39], ["disease", "OBSERVATION", 40, 47]]], ["Severe MERS has been defined by admission to an intensive care unit; use of extracorporeal membrane oxygenation (ECMO), mechanical ventilation or vasopressors; cases being reported as critical or severe; a fatal outcome (Arabi et al., 2014) .", [["extracorporeal membrane", "ANATOMY", 76, 99], ["MERS", "DISEASE", 7, 11], ["Severe MERS", "PROBLEM", 0, 11], ["extracorporeal membrane oxygenation", "TREATMENT", 76, 111], ["ECMO", "TREATMENT", 113, 117], ["mechanical ventilation", "TREATMENT", 120, 142], ["vasopressors", "TREATMENT", 146, 158], ["MERS", "OBSERVATION", 7, 11], ["severe", "OBSERVATION_MODIFIER", 196, 202]]], ["The relative speed of disease progression may relate to MERS-CoV reaching earlier peak viral loads and infecting different cells than the SARS-CoV (Drosten, 2013) .", [["cells", "ANATOMY", 123, 128], ["SARS", "DISEASE", 138, 142], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 56, 64], ["cells", "CELL", 123, 128], ["SARS-CoV", "ORGANISM", 138, 146], ["MERS-CoV", "SPECIES", 56, 64], ["SARS-CoV", "SPECIES", 138, 146], ["disease progression", "PROBLEM", 22, 41], ["MERS", "PROBLEM", 56, 60], ["CoV", "PROBLEM", 61, 64], ["earlier peak viral loads", "PROBLEM", 74, 98], ["infecting different cells", "PROBLEM", 103, 128], ["disease", "OBSERVATION", 22, 29]]], ["With increased laboratory testing, particularly of contacts of confirmed MERS cases, a number of MERS-CoV positive individuals without comorbidities have been detected who experience a mild illness or no symptoms at all (Al-Tawfiq and .", [["MERS", "DISEASE", 73, 77], ["illness", "DISEASE", 190, 197], ["MERS-CoV", "ORGANISM", 97, 105], ["individuals", "ORGANISM", 115, 126], ["MERS-CoV", "SPECIES", 97, 105], ["increased laboratory testing", "TEST", 5, 33], ["comorbidities", "PROBLEM", 135, 148], ["a mild illness", "PROBLEM", 183, 197], ["symptoms", "PROBLEM", 204, 212], ["increased", "OBSERVATION_MODIFIER", 5, 14], ["mild", "OBSERVATION_MODIFIER", 185, 189], ["illness", "OBSERVATION", 190, 197]]], ["This demonstrates that MERS, like most respiratory viruses, is associated with a wide spectrum of symptoms and degrees of severity.Middle East respiratory syndrome (MERS)The mean incubation period in a study of 47 cases was 5.2 days, with 95% of cases having shown symptoms within 12.4 days (Assiri et al., 2013a) .", [["respiratory viruses", "DISEASE", 39, 58], ["Middle East respiratory syndrome", "DISEASE", 131, 163], ["MERS", "PROBLEM", 23, 27], ["most respiratory viruses", "PROBLEM", 34, 58], ["a wide spectrum of symptoms", "PROBLEM", 79, 106], ["severity", "PROBLEM", 122, 130], ["Middle East respiratory syndrome", "PROBLEM", 131, 163], ["a study", "TEST", 200, 207], ["symptoms", "PROBLEM", 265, 273], ["MERS", "OBSERVATION", 23, 27], ["most", "OBSERVATION_MODIFIER", 34, 38], ["respiratory viruses", "OBSERVATION", 39, 58], ["wide", "OBSERVATION_MODIFIER", 81, 85], ["severity", "OBSERVATION_MODIFIER", 122, 130], ["respiratory syndrome", "OBSERVATION", 143, 163]]], ["In a smaller study the incubation period ranged between one and nine days, with 13-14 days between when illness began in one person and subsequently spread to another .", [["illness", "DISEASE", 104, 111], ["person", "SPECIES", 125, 131], ["illness", "PROBLEM", 104, 111], ["smaller", "OBSERVATION_MODIFIER", 5, 12]]], ["The length and nature of the prodrome is undefined to date.", [["the prodrome", "PROBLEM", 25, 37], ["length", "OBSERVATION_MODIFIER", 4, 10], ["prodrome", "OBSERVATION", 29, 37]]], ["The first WHO case definition (World Health Organization, 2014a) defined probable cases of MERS based on the presence of febrile illness, cough, requirement for hospitalization with suspicion of LRT involvement and included roles for contact with a probable or confirmed case or for travel or residence within the Arabian peninsula.", [["MERS", "DISEASE", 91, 95], ["febrile illness", "DISEASE", 121, 136], ["cough", "DISEASE", 138, 143], ["MERS", "PROBLEM", 91, 95], ["febrile illness", "PROBLEM", 121, 136], ["cough", "PROBLEM", 138, 143], ["LRT involvement", "PROBLEM", 195, 210], ["Arabian peninsula", "ANATOMY", 314, 331]]], ["If strictly adhered to, only the severe syndrome would meet the case definition and be subject to laboratory testing, which was the paradigm early on (Assiri et al., 2013a) .", [["the severe syndrome", "PROBLEM", 29, 48], ["laboratory testing", "TEST", 98, 116], ["severe", "OBSERVATION_MODIFIER", 33, 39], ["syndrome", "OBSERVATION", 40, 48]]], ["Apart from reports from the WHO and KSA Ministry of Health, asymptomatic or subclinical cases of MERS-CoV infection have also been documented in the scientific literature Memish et al., 2014b) .", [["MERS-CoV infection", "DISEASE", 97, 115], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["MERS-CoV", "SPECIES", 97, 105], ["asymptomatic", "PROBLEM", 60, 72], ["MERS", "PROBLEM", 97, 101], ["CoV infection", "PROBLEM", 102, 115]]], ["In one such case, a HCW shed virus for 42 days in the absence of disease (Al-Gethamy et al., 2014) .Middle East respiratory syndrome (MERS)MERS can progress to an acute respiratory distress syndrome (ARDS) requiring external ventilation and then to multiorgan failure (Devi et al., 2014; Reuss et al., 2014; Zaki et al., 2012) similar to severe influenza and SARS cases .", [["respiratory", "ANATOMY", 169, 180], ["multiorgan", "ANATOMY", 249, 259], ["Middle East respiratory syndrome", "DISEASE", 100, 132], ["acute respiratory distress syndrome", "DISEASE", 163, 198], ["ARDS", "DISEASE", 200, 204], ["multiorgan failure", "DISEASE", 249, 267], ["influenza", "DISEASE", 345, 354], ["SARS", "DISEASE", 359, 363], ["HCW shed virus", "SPECIES", 20, 34], ["disease", "PROBLEM", 65, 72], ["Middle East respiratory syndrome", "PROBLEM", 100, 132], ["an acute respiratory distress syndrome", "PROBLEM", 160, 198], ["ARDS", "PROBLEM", 200, 204], ["external ventilation", "TREATMENT", 216, 236], ["multiorgan failure", "PROBLEM", 249, 267], ["severe influenza and SARS cases", "PROBLEM", 338, 369], ["disease", "OBSERVATION", 65, 72], ["respiratory syndrome", "OBSERVATION", 112, 132], ["acute", "OBSERVATION_MODIFIER", 163, 168], ["respiratory distress", "OBSERVATION", 169, 189], ["ARDS", "OBSERVATION", 200, 204], ["multiorgan", "ANATOMY", 249, 259], ["failure", "OBSERVATION", 260, 267], ["severe", "OBSERVATION_MODIFIER", 338, 344], ["influenza", "OBSERVATION", 345, 354]]], ["Acute renal failure can occur in MERS patients, doing so sooner than it did among SARS patients (Eckerle et al., 2013) .", [["renal", "ANATOMY", 6, 11], ["Acute renal failure", "DISEASE", 0, 19], ["SARS", "DISEASE", 82, 86], ["renal", "ORGAN", 6, 11], ["patients", "ORGANISM", 38, 46], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 87, 95], ["Acute renal failure", "PROBLEM", 0, 19], ["renal", "ANATOMY", 6, 11], ["failure", "OBSERVATION", 12, 19]]], ["Progressive impairment of renal function and acute kidney injury can start 9-12 days after symptom onset among MERS patients, compared to a median of 20 days for SARS patients (Chu et al., 2005; Eckerle et al., 2013; Zaki et al., 2012) .", [["renal", "ANATOMY", 26, 31], ["kidney", "ANATOMY", 51, 57], ["impairment of renal function", "DISEASE", 12, 40], ["acute kidney injury", "DISEASE", 45, 64], ["MERS", "DISEASE", 111, 115], ["SARS", "DISEASE", 162, 166], ["renal", "ORGAN", 26, 31], ["kidney", "ORGAN", 51, 57], ["patients", "ORGANISM", 116, 124], ["patients", "ORGANISM", 167, 175], ["patients", "SPECIES", 116, 124], ["patients", "SPECIES", 167, 175], ["Progressive impairment of renal function", "PROBLEM", 0, 40], ["acute kidney injury", "PROBLEM", 45, 64], ["impairment", "OBSERVATION", 12, 22], ["renal", "ANATOMY", 26, 31], ["function", "OBSERVATION", 32, 40], ["acute", "OBSERVATION_MODIFIER", 45, 50], ["kidney", "ANATOMY", 51, 57], ["injury", "OBSERVATION", 58, 64]]], ["This may be due to direct infection of renal tissue by MERS-CoV (Arabi et al., 2014; Zaki et al., 2012) .", [["renal tissue", "ANATOMY", 39, 51], ["infection", "DISEASE", 26, 35], ["renal tissue", "TISSUE", 39, 51], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["MERS-CoV", "SPECIES", 55, 63], ["direct infection of renal tissue", "PROBLEM", 19, 51], ["may be due to", "UNCERTAINTY", 5, 18], ["infection", "OBSERVATION", 26, 35], ["renal tissue", "ANATOMY", 39, 51]]], ["Haematologic changes in MERS cases include thrombocytopenia (Assiri et al., 2013a; Drosten et al., 2013; Omrani et al., 2013) and lymphocytosis (Assiri et al., 2013a) or lymphopenia (Assiri et al., 2013a; Omrani et al., 2013) on admission (Assiri et al., 2013a) .", [["thrombocytopenia", "DISEASE", 43, 59], ["lymphocytosis", "DISEASE", 130, 143], ["lymphopenia", "DISEASE", 170, 181], ["Haematologic changes in MERS cases", "PROBLEM", 0, 34], ["thrombocytopenia", "PROBLEM", 43, 59], ["lymphocytosis", "PROBLEM", 130, 143], ["lymphopenia", "PROBLEM", 170, 181], ["thrombocytopenia", "OBSERVATION", 43, 59], ["lymphocytosis", "OBSERVATION", 130, 143], ["lymphopenia", "OBSERVATION", 170, 181]]], ["Monocyte numbers are often normal (Assiri et al., 2013a) while neutrophils may be raised or normal (Assiri et al., 2013a) .Middle East respiratory syndrome (MERS)As a group, children have rarely been reported to be positive for the virus.", [["Monocyte", "ANATOMY", 0, 8], ["neutrophils", "ANATOMY", 63, 74], ["Middle East respiratory syndrome", "DISEASE", 123, 155], ["Monocyte", "CELL", 0, 8], ["neutrophils", "CELL", 63, 74], ["children", "ORGANISM", 174, 182], ["neutrophils", "CELL_TYPE", 63, 74], ["children", "SPECIES", 174, 182], ["Monocyte numbers", "TEST", 0, 16], ["Middle East respiratory syndrome", "PROBLEM", 123, 155], ["the virus", "PROBLEM", 228, 237], ["respiratory syndrome", "OBSERVATION", 135, 155]]], ["In Amman, Jordan, 1005 samples from hospitalised children under the age of 2-years with fever and/or respiratory signs and symptoms were tested but none were positive for MERS-CoV RNA, despite being collected at a similar time to the first known outbreak of MERS-CoV in the neighbouring town of Al-Zarqa (Khuri-Bulos et al., 2013) .", [["samples", "ANATOMY", 23, 30], ["respiratory", "ANATOMY", 101, 112], ["fever", "DISEASE", 88, 93], ["children", "ORGANISM", 49, 57], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 171, 179], ["MERS-CoV", "ORGANISM", 258, 266], ["MERS-CoV RNA", "RNA", 171, 183], ["children", "SPECIES", 49, 57], ["MERS-CoV", "SPECIES", 171, 179], ["MERS-CoV", "SPECIES", 258, 266], ["fever", "PROBLEM", 88, 93], ["respiratory signs", "PROBLEM", 101, 118], ["symptoms", "PROBLEM", 123, 131], ["MERS", "PROBLEM", 171, 175], ["CoV RNA", "PROBLEM", 176, 183], ["respiratory", "ANATOMY", 101, 112]]], ["A second trimester stillbirth occurred in a pregnant woman during an acute respiratory illness and while not RT-rtPCR positive, the mother subsequently developed antibodies to MERS-CoV, suggestive of recent infection .", [["respiratory", "ANATOMY", 75, 86], ["trimester stillbirth", "DISEASE", 9, 29], ["acute respiratory illness", "DISEASE", 69, 94], ["infection", "DISEASE", 207, 216], ["woman", "ORGANISM", 53, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 176, 184], ["antibodies", "PROTEIN", 162, 172], ["woman", "SPECIES", 53, 58], ["MERS-CoV", "SPECIES", 176, 184], ["A second trimester stillbirth", "PROBLEM", 0, 29], ["an acute respiratory illness", "PROBLEM", 66, 94], ["RT-rtPCR", "TEST", 109, 117], ["antibodies to MERS", "PROBLEM", 162, 180], ["CoV", "PROBLEM", 181, 184], ["recent infection", "PROBLEM", 200, 216], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["respiratory illness", "OBSERVATION", 75, 94], ["suggestive of", "UNCERTAINTY", 186, 199], ["infection", "OBSERVATION", 207, 216]]], ["Her exposure history to a MERS-CoV RT-rtPCR positive relative and an antibody-reactive husband, her incubation period and her symptom history met the WHO criteria for being a probable MERS-CoV case .The Middle East respiratory syndrome coronavirus (MERS-CoV)The virus associated with MERS was initially identified as the \"novel coronavirus\" or nCOV; a problematic choice given that other novel coronaviruses could be discovered and were being discovered with regularity prior to and since the identification of MERS-CoV.", [["respiratory syndrome coronavirus", "DISEASE", 215, 247], ["MERS-CoV", "ORGANISM", 26, 34], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 203, 247], ["MERS-CoV", "ORGANISM", 249, 257], ["coronavirus", "ORGANISM", 328, 339], ["coronaviruses", "ORGANISM", 394, 407], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 511, 519], ["MERS-CoV", "SPECIES", 184, 192], ["Middle East respiratory syndrome coronavirus", "SPECIES", 203, 247], ["MERS-CoV", "SPECIES", 249, 257], ["MERS-CoV", "SPECIES", 511, 519], ["a MERS", "TEST", 24, 30], ["CoV RT-rtPCR", "TEST", 31, 43], ["an antibody", "TEST", 66, 77], ["her symptom", "PROBLEM", 122, 133], ["The Middle East respiratory syndrome coronavirus", "PROBLEM", 199, 247], ["The virus", "PROBLEM", 258, 267], ["MERS", "PROBLEM", 284, 288], ["other novel coronaviruses", "PROBLEM", 382, 407], ["CoV", "PROBLEM", 516, 519], ["reactive", "OBSERVATION_MODIFIER", 78, 86], ["Middle", "ANATOMY_MODIFIER", 203, 209], ["respiratory syndrome coronavirus", "OBSERVATION", 215, 247], ["coronaviruses", "OBSERVATION", 394, 407]]], ["When the first genome of a human variant was sequenced it was named human betacoronavirus 2c EMC (subsequently referred to here as EMC/2012), with the implication that it was a human not animal coronavirus.", [["human", "ORGANISM", 27, 32], ["human", "ORGANISM", 68, 73], ["betacoronavirus 2c EMC", "CELL", 74, 96], ["human", "ORGANISM", 177, 182], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 177, 182], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 177, 182], ["animal coronavirus", "PROBLEM", 187, 205]]], ["Ten months after its discovery, the coronavirus study group assembled an international consensus and the virus was renamed and given the acronym of MERS-CoV (de Groot et al., 2013) .The viral genomeMERS-CoV is a putative member of a new species (van Boheemen et al., 2012) within the order Nidovirales, family Coronaviridae, subfamily Coronavirinae, genus Betacoronavirus, subgroup 2c (Raj et al., 2014b) .", [["coronavirus", "ORGANISM", 36, 47], ["MERS-CoV", "ORGANISM", 148, 156], ["genomeMERS-CoV", "ORGANISM", 192, 206], ["Nidovirales", "GENE_OR_GENE_PRODUCT", 290, 301], ["Coronaviridae", "GENE_OR_GENE_PRODUCT", 310, 323], ["viral genomeMERS-CoV", "DNA", 186, 206], ["MERS-CoV", "SPECIES", 148, 156], ["genomeMERS-CoV", "SPECIES", 192, 206], ["the coronavirus study", "TEST", 32, 53], ["the virus", "PROBLEM", 101, 110], ["The viral genomeMERS", "TEST", 182, 202], ["viral genomeMERS", "OBSERVATION", 186, 202]]], ["The first full sequence defined a singlestranded, positive sense, 30,119 nucleotide (nt) long genome ( Fig. 3) (van Boheemen et al., 2012; Zaki et al., 2012) .", [["nucleotide", "CHEMICAL", 73, 83], ["30,119 nucleotide (nt) long genome", "DNA", 66, 100], ["The first full sequence", "TEST", 0, 23], ["nucleotide (nt) long genome", "PROBLEM", 73, 100]]], ["Based on analysis of 42 complete sequences, the genome is predicted to be evolving at 1.12 \u00d7 10 \u22123 substitutions per site (Cotten et al., 2014) .", [["genome", "CELLULAR_COMPONENT", 48, 54], ["analysis", "TEST", 9, 17], ["42 complete sequences", "TEST", 21, 42]]], ["This permitted a predictive calculation of the time to most recent viral ancestor (tMRCA) for most of the variants, which suggested MERS-CoV first appeared around March 2012 (ranging from December 2011 to July 2012) (Cotten et al., 2014) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 132, 140], ["MERS-CoV", "SPECIES", 132, 140]]], ["Comparison of the first open reading frame's (ORF 1ab) amino acid sequence to that from its closest betacoronavirus relatives, Tylonycteris bat HKU4 and Pipistrellus bat HKU5, found there was less than 80% identity which supported the conclusion that MERS-CoV was a novel and distinct virus.", [["amino acid", "CHEMICAL", 55, 65], ["amino acid", "CHEMICAL", 55, 65], ["amino acid", "AMINO_ACID", 55, 65], ["betacoronavirus", "GENE_OR_GENE_PRODUCT", 100, 115], ["Tylonycteris bat HKU4", "ORGANISM", 127, 148], ["Pipistrellus bat HKU5", "ORGANISM", 153, 174], ["MERS-CoV", "ORGANISM", 251, 259], ["open reading frame", "DNA", 24, 42], ["Tylonycteris bat", "SPECIES", 127, 143], ["Pipistrellus bat", "SPECIES", 153, 169], ["Tylonycteris bat", "SPECIES", 127, 143], ["Pipistrellus bat", "SPECIES", 153, 169], ["MERS-CoV", "SPECIES", 251, 259], ["ORF 1ab) amino acid sequence", "TEST", 46, 74], ["Tylonycteris bat HKU4", "TEST", 127, 148], ["Pipistrellus bat HKU5", "TEST", 153, 174], ["CoV", "PROBLEM", 256, 259], ["a novel and distinct virus", "PROBLEM", 264, 290]]], ["This genomic region is a key taxonomic identifier of CoV species.", [["CoV", "ORGANISM", 53, 56], ["genomic region", "DNA", 5, 19], ["CoV species", "PROBLEM", 53, 64], ["taxonomic identifier", "OBSERVATION", 29, 49], ["CoV species", "OBSERVATION", 53, 64]]], ["MERS-CoV is predicted to encode at least ten open reading frames bracketed by /2012 variant isolated from sputum of a 60-year old man from Bisha, KSA) .", [["sputum", "ANATOMY", 106, 112], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["man", "ORGANISM", 130, 133], ["MERS-CoV", "DNA", 0, 8], ["open reading frames", "DNA", 45, 64], ["man", "SPECIES", 130, 133], ["MERS-CoV", "SPECIES", 0, 8], ["sputum", "TEST", 106, 112]]], ["Open reading frames are indicated as yellow rectangles bracketed by terminal untranslated regions (UTR; grey rectangles).", [["Open reading frames", "DNA", 0, 19], ["yellow rectangles", "DNA", 37, 54], ["terminal untranslated regions", "DNA", 68, 97], ["UTR", "DNA", 99, 102], ["yellow rectangles", "PROBLEM", 37, 54], ["yellow rectangles", "OBSERVATION", 37, 54], ["terminal", "OBSERVATION_MODIFIER", 68, 76], ["untranslated", "OBSERVATION_MODIFIER", 77, 89]]], ["The 5 UTR includes the predicted leader (L) transcription-regulatory sequence.", [["5 UTR", "DNA", 4, 9], ["leader (L) transcription-regulatory sequence", "DNA", 33, 77], ["the predicted leader (L) transcription", "TREATMENT", 19, 57]]], ["FS-frame-shift.", [["FS", "TEST", 0, 2]]], ["Predicted papain-like proteinase cleavage sites are indicated with orange arrows resulting in \u223c16 cleavage non-structural protein products (based on (van Boheemen et al., 2012) ).", [["papain-like proteinase", "GENE_OR_GENE_PRODUCT", 10, 32], ["papain", "PROTEIN", 10, 16], ["\u223c16 cleavage non-structural protein products", "PROTEIN", 94, 138], ["Predicted papain", "TREATMENT", 0, 16], ["proteinase cleavage sites", "TREATMENT", 22, 47], ["cleavage non-structural protein products", "TREATMENT", 98, 138]]], ["The genome is drawn to scale using Geneious v6.1.6 and annotated using Adobe Illustrator.", [["Geneious v6.1.6", "DNA", 35, 50]]], ["MERS-CoV EMC/2012 sequence GenBank accession number JX869059 5 and 3 untranslated regions (Raj et al., 2014b) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV EMC/2012 sequence GenBank accession number JX869059 5 and 3 untranslated regions", "DNA", 0, 89]]], ["Structural proteins include the spike (S), envelope (E), membrane (M) and nucleocapsid (N) (van Boheemen et al., 2012) .", [["membrane", "ANATOMY", 57, 65], ["membrane", "CELLULAR_COMPONENT", 57, 65], ["spike (S), envelope (E)", "PROTEIN", 32, 55], ["Structural proteins", "TEST", 0, 19]]], ["Nonstructural proteins (nsps) from the products of ORF1a and ORF1b have been predicted, following identification of conserved domains and after comparative analysis with other coronaviral proteins.", [["Nonstructural proteins", "GENE_OR_GENE_PRODUCT", 0, 22], ["nsps", "GENE_OR_GENE_PRODUCT", 24, 28], ["ORF1a", "GENE_OR_GENE_PRODUCT", 51, 56], ["ORF1b", "GENE_OR_GENE_PRODUCT", 61, 66], ["Nonstructural proteins", "PROTEIN", 0, 22], ["nsps", "PROTEIN", 24, 28], ["ORF1a", "PROTEIN", 51, 56], ["ORF1b", "PROTEIN", 61, 66], ["conserved domains", "PROTEIN", 116, 133], ["coronaviral proteins", "PROTEIN", 176, 196], ["Nonstructural proteins (nsps", "PROBLEM", 0, 28], ["comparative analysis", "TEST", 144, 164], ["other coronaviral proteins", "PROBLEM", 170, 196]]], ["The nsps include a papainlike protease (PLpro; nsp4 (Kilianski et al., 2013; Lin et al., 2014) transmembrane domains (nsp4, nsp6), a 3C-like protease (3CLpro; nsp5 (Kilianski et al., 2013) ), an RNA-dependent RNA polymerase (RdRp; nsp12), a helicase (nsp13) and an exonuclease (nsp14) (van Boheemen et al., 2012) .The viral genomeComplete genome deduction using deep sequencing methods has been the predominant tool for genome analysis during the emergence of MERS-CoV (Cotten et al., 2013a (Cotten et al., ,b, 2014 the first time it's use has been so pervasive for the study of a viral outbreak with global reach.", [["nsps", "GENE_OR_GENE_PRODUCT", 4, 8], ["papainlike protease", "GENE_OR_GENE_PRODUCT", 19, 38], ["nsp4", "GENE_OR_GENE_PRODUCT", 118, 122], ["nsp6", "GENE_OR_GENE_PRODUCT", 124, 128], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 195, 223], ["nsp12", "GENE_OR_GENE_PRODUCT", 231, 236], ["nsp13", "GENE_OR_GENE_PRODUCT", 251, 256], ["MERS-CoV", "ORGANISM", 460, 468], ["nsps", "PROTEIN", 4, 8], ["papainlike protease", "PROTEIN", 19, 38], ["transmembrane domains", "PROTEIN", 95, 116], ["nsp4", "PROTEIN", 118, 122], ["nsp6", "PROTEIN", 124, 128], ["3C", "PROTEIN", 133, 135], ["protease", "PROTEIN", 141, 149], ["3CLpro", "PROTEIN", 151, 157], ["nsp5", "PROTEIN", 159, 163], ["2013", "PROTEIN", 183, 187], ["RNA-dependent RNA polymerase", "PROTEIN", 195, 223], ["RdRp", "PROTEIN", 225, 229], ["nsp12", "PROTEIN", 231, 236], ["helicase", "PROTEIN", 241, 249], ["nsp13", "PROTEIN", 251, 256], ["exonuclease", "PROTEIN", 265, 276], ["nsp14", "PROTEIN", 278, 283], ["viral genomeComplete genome", "DNA", 318, 345], ["MERS-CoV", "SPECIES", 460, 468], ["a papainlike protease (PLpro", "TREATMENT", 17, 45], ["transmembrane domains", "TEST", 95, 116], ["nsp4", "TEST", 118, 122], ["a 3C", "TEST", 131, 135], ["protease (3CLpro", "TREATMENT", 141, 157], ["an RNA", "TEST", 192, 198], ["a helicase (nsp13", "TREATMENT", 239, 256], ["an exonuclease (nsp14", "TREATMENT", 262, 283], ["The viral genomeComplete genome deduction", "TREATMENT", 314, 355], ["deep sequencing methods", "TEST", 362, 385], ["genome analysis", "TEST", 420, 435], ["the study", "TEST", 566, 575], ["viral", "OBSERVATION", 318, 323], ["genomeComplete genome", "OBSERVATION", 324, 345]]], ["While the error rate can be higher than for traditional Sanger sequencing, the near-complete genomic length covered by just a single run (e.g. 90% of the MERS-CoV EMC/2012 genome) and the depth of coverage at each nucleotide is such that deep sequencing corrects for erroneous nucleotide van Boheemen et al., 2012) .", [["nucleotide", "CHEMICAL", 277, 287], ["nucleotide", "CHEMICAL", 214, 224], ["MERS-CoV EMC/2012 genome", "DNA", 154, 178], ["the error rate", "TEST", 6, 20], ["traditional Sanger sequencing", "TEST", 44, 73], ["the MERS", "TEST", 150, 158], ["the depth of coverage at each nucleotide", "TREATMENT", 184, 224], ["length", "OBSERVATION_MODIFIER", 101, 107]]], ["Subgenomic sequencing, a mainstay of viral genotyping and molecular epidemiology to this point, has been used rarely for MERS-CoV identification or confirmation, despite assays having been suggested early on Corman et al. (2012b) .", [["MERS-CoV", "SPECIES", 121, 129], ["Subgenomic sequencing", "TEST", 0, 21], ["viral genotyping", "TEST", 37, 53], ["CoV identification", "TEST", 126, 144]]], ["It's utility has since been demonstrated using molecular assays to amplify and sequence a 615 nucleotide long fragment of the spike S2 domain gene fragment (Smits et al., 2015) .", [["nucleotide", "CHEMICAL", 94, 104], ["615 nucleotide long fragment", "DNA", 90, 118], ["spike S2 domain gene fragment", "DNA", 126, 155], ["molecular assays", "TEST", 47, 63], ["a 615 nucleotide long fragment", "TREATMENT", 88, 118], ["the spike S2 domain gene fragment", "PROBLEM", 122, 155], ["fragment", "OBSERVATION_MODIFIER", 147, 155]]], ["This assay agreed with the results generated by the sequencing of full genomes and defined additional sequence groupings within an existing MERS-CoV clade.", [["MERS-CoV", "ORGANISM", 140, 148], ["MERS-CoV clade", "DNA", 140, 154], ["This assay", "TEST", 0, 10]]], ["With the addition of more genomes over time from both humans and from DCs, two clades have become apparent; A and B. Clade A contains only human-derived MERS-CoV genomes ( Fig. 4) .Genomic variability and molecular epidemiologyTo date, the MERS-CoV genomes collected from samples spanning just two years are genetically very similar to each other.", [["DCs", "ANATOMY", 70, 73], ["samples", "ANATOMY", 272, 279], ["humans", "ORGANISM", 54, 60], ["DCs", "CELL", 70, 73], ["B. Clade A", "ORGANISM", 114, 124], ["human", "ORGANISM", 139, 144], ["MERS-CoV", "ORGANISM", 153, 161], ["MERS-CoV", "ORGANISM", 240, 248], ["DCs", "CELL_TYPE", 70, 73], ["human-derived MERS-CoV genomes", "DNA", 139, 169], ["MERS-CoV genomes", "DNA", 240, 256], ["humans", "SPECIES", 54, 60], ["human", "SPECIES", 139, 144], ["humans", "SPECIES", 54, 60], ["human", "SPECIES", 139, 144], ["MERS-CoV", "SPECIES", 153, 161], ["MERS-CoV", "SPECIES", 240, 248], ["Genomic variability", "PROBLEM", 181, 200], ["CoV genomes", "PROBLEM", 245, 256]]], ["An alignment of 56 complete or near-complete MERS-CoV genomes sampled from 2012 to 2014 differed by 0-0.38%.", [["56 complete or near-complete MERS-CoV genomes", "DNA", 16, 61], ["An alignment", "TEST", 0, 12], ["CoV genomes", "TEST", 50, 61], ["alignment", "OBSERVATION_MODIFIER", 3, 12]]], ["For comparison, an alignment of 31 complete HCoV-NL63 genomes from samples collected between 1983 and 2009 shows they diverge by 0.5% at the nucleotide level (data not shown; theoretically equates to 145nt for a 27,553nt genome).", [["samples", "ANATOMY", 67, 74], ["nucleotide", "CHEMICAL", 141, 151], ["HCoV", "GENE_OR_GENE_PRODUCT", 44, 48], ["samples", "CANCER", 67, 74], ["HCoV-NL63 genomes", "DNA", 44, 61], ["27,553nt genome", "DNA", 212, 227], ["an alignment of 31 complete HCoV", "TEST", 16, 48], ["a 27,553nt genome", "TREATMENT", 210, 227]]], ["There is as yet no study which attaches clinical relevance to the clades or smaller groupings of MERS-CoV nor any of the genomic variation noted to date .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["MERS-CoV", "SPECIES", 97, 105], ["study", "TEST", 19, 24], ["CoV", "PROBLEM", 102, 105], ["the genomic variation", "PROBLEM", 117, 138], ["genomic variation", "OBSERVATION", 121, 138]]], ["It is interesting that Clade A contains only the African green monkey kidney (Vero; innate immune deficient cells) cell-culture passaged EMC/2012 variant and two variants of the Jordan-N3 variant from 2012, but no camel-derived MERS-CoV genomes .", [["kidney", "ANATOMY", 70, 76], ["cells", "ANATOMY", 108, 113], ["cell", "ANATOMY", 115, 119], ["green monkey kidney", "ORGANISM", 57, 76], ["Vero", "CELL", 78, 82], ["innate immune deficient cells", "CELL", 84, 113], ["cell", "CELL", 115, 119], ["MERS-CoV", "ORGANISM", 228, 236], ["African green monkey kidney (Vero; innate immune deficient cells", "CELL_LINE", 49, 113], ["Jordan-N3 variant", "CELL_LINE", 178, 195], ["camel-derived MERS-CoV genomes", "DNA", 214, 244], ["green monkey", "SPECIES", 57, 69], ["African green monkey", "SPECIES", 49, 69], ["MERS-CoV", "SPECIES", 228, 236], ["Vero", "TEST", 78, 82], ["cell", "TEST", 115, 119], ["culture", "TEST", 120, 127], ["kidney", "ANATOMY", 70, 76], ["N3 variant", "OBSERVATION", 185, 195], ["CoV genomes", "OBSERVATION", 233, 244]]], ["When the MERS-CoV genome of the variant from Bisha was re-sequenced directly from the original URT sample, the comparison of trimmed genomes (EMC/2012 vs. Bisha 1) revealed 115 nucleotide differences (0.38% difference) resolving Bisha 1 into Clade B .", [["URT sample", "ANATOMY", 95, 105], ["nucleotide", "CHEMICAL", 177, 187], ["nucleotide", "CHEMICAL", 177, 187], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["Bisha", "GENE_OR_GENE_PRODUCT", 45, 50], ["Clade B", "GENE_OR_GENE_PRODUCT", 242, 249], ["MERS-CoV genome", "DNA", 9, 24], ["Bisha", "DNA", 45, 50], ["trimmed genomes", "DNA", 125, 140], ["Bisha 1", "DNA", 229, 236], ["MERS-CoV", "SPECIES", 9, 17], ["Bisha", "TEST", 155, 160], ["nucleotide differences", "PROBLEM", 177, 199]]], ["This is unusual because when a Jordan-N3 virus was intentionally serially passed through Vero or MRC5 cell culture (Jordan-N3/2012 MG167), only 2nt changes occurred within the entire coding region of the resultant sequence, despite eight passages (Frey et al., 2014) .", [["MRC5 cell culture", "ANATOMY", 97, 114], ["Jordan-N3 virus", "ORGANISM", 31, 46], ["Vero", "CELL", 89, 93], ["MRC5 cell culture", "CELL", 97, 114], ["Jordan-N3/2012 MG167", "CELL", 116, 136], ["MRC5 cell culture", "CELL_LINE", 97, 114], ["Jordan-N3 virus", "SPECIES", 31, 46], ["a Jordan-N3 virus", "PROBLEM", 29, 46], ["Vero or MRC5 cell culture", "TEST", 89, 114]]], ["For comparison, after three passages through Vero cell culture, no genetic changes were found in a DC MERS-CoV variant of Qatar 2 2014 .Genomic variability and molecular epidemiologyA very divergent MERS-CoV variant originated from an Egyptian DC likely imported from Sudan was identified as NRCE-HKU205|Nile|2013.", [["cell", "ANATOMY", 50, 54], ["DC", "ANATOMY", 99, 101], ["DC", "ANATOMY", 244, 246], ["Vero cell", "CELL", 45, 54], ["MERS-CoV", "ORGANISM", 199, 207], ["Vero cell culture", "CELL_LINE", 45, 62], ["DC", "CELL_TYPE", 99, 101], ["MERS-CoV variant", "DNA", 199, 215], ["Egyptian DC", "CELL_TYPE", 235, 246], ["MERS-CoV", "SPECIES", 199, 207], ["Vero cell culture", "TEST", 45, 62], ["genetic changes", "PROBLEM", 67, 82], ["Genomic variability", "PROBLEM", 136, 155], ["CoV variant", "PROBLEM", 204, 215]]], ["It constructs a lineage outside the current clades, perhaps comprising the first occupant of Clade C Cotten et al., 2013b; Smits et al., 2015) .", [["lineage", "OBSERVATION_MODIFIER", 16, 23]]], ["This lineage may represent additional diversity of MERS-CoV variants remaining to be discovered in DC from outside the Arabian peninsula.", [["DC", "ANATOMY", 99, 101], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 51, 59], ["MERS-CoV variants", "DNA", 51, 68], ["DC", "CELL_TYPE", 99, 101], ["MERS-CoV", "SPECIES", 51, 59], ["MERS-CoV variants", "PROBLEM", 51, 68], ["may represent", "UNCERTAINTY", 13, 26], ["additional", "OBSERVATION_MODIFIER", 27, 37], ["diversity", "OBSERVATION", 38, 47], ["CoV variants", "OBSERVATION", 56, 68], ["Arabian", "ANATOMY_MODIFIER", 119, 126], ["peninsula", "ANATOMY_MODIFIER", 127, 136]]], ["A virus sequenced from a Neoromicia capensis bat was more closely related to MERS-CoV than previous bat sequences had been, providing a link between human, camel and bat viruses as members of the same CoV species .", [["Neoromicia capensis", "ORGANISM", 25, 44], ["bat", "ORGANISM", 45, 48], ["MERS-CoV", "ORGANISM", 77, 85], ["bat", "ORGANISM", 100, 103], ["human", "ORGANISM", 149, 154], ["camel", "ORGANISM", 156, 161], ["bat viruses", "ORGANISM", 166, 177], ["CoV", "ORGANISM", 201, 204], ["MERS-CoV", "DNA", 77, 85], ["Neoromicia capensis bat", "SPECIES", 25, 48], ["human", "SPECIES", 149, 154], ["camel", "SPECIES", 156, 161], ["A virus", "SPECIES", 0, 7], ["Neoromicia capensis bat", "SPECIES", 25, 48], ["MERS-CoV", "SPECIES", 77, 85], ["human", "SPECIES", 149, 154], ["camel", "SPECIES", 156, 161], ["A virus", "PROBLEM", 0, 7], ["a Neoromicia capensis bat", "TEST", 23, 48], ["previous bat sequences", "TEST", 91, 113], ["virus", "OBSERVATION", 2, 7]]], ["Despite usually comprising \u22641% of the total genome, in silico comparison shows that viral genetic changes among variants permit geographic tracking of the spread of variants and identification that Riyadh, in particular, harbours a wide range of MERS-CoV variants ( Fig. 4) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 246, 254], ["Riyadh", "DNA", 198, 204], ["MERS-CoV variants", "DNA", 246, 263], ["MERS-CoV", "SPECIES", 246, 254], ["silico comparison", "TEST", 55, 72], ["viral genetic changes among variants", "PROBLEM", 84, 120], ["viral genetic", "OBSERVATION", 84, 97], ["spread", "OBSERVATION_MODIFIER", 155, 161], ["wide", "OBSERVATION_MODIFIER", 232, 236]]], ["This process of molecular epidemiology can also imply some physical direction to the movement of MERS-CoV around the region and over time (Cotten et al., 2014) .Genomic variability and molecular epidemiologyWhen compared to Bisha 1 2012, most single nucleotide differences among variants were located in the last third of the genome, encompassing the S protein (Fig. 5 ) and accessory proteins .", [["nucleotide", "CHEMICAL", 250, 260], ["nucleotide", "CHEMICAL", 250, 260], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["S protein", "PROTEIN", 351, 360], ["Fig. 5", "PROTEIN", 362, 368], ["accessory proteins", "PROTEIN", 375, 393], ["MERS-CoV", "SPECIES", 97, 105], ["Genomic variability", "PROBLEM", 161, 180], ["most single nucleotide differences among variants", "PROBLEM", 238, 287], ["the S protein", "TEST", 347, 360], ["accessory proteins", "PROBLEM", 375, 393], ["region", "ANATOMY_MODIFIER", 117, 123], ["genome", "OBSERVATION", 326, 332]]], ["At least nine MERS-CoV genomes harbour amino acid substitutions in the ribosome binding domain (RBD) of the spike protein and codons 158 (N-terminal region), 460 (RBD), 1020 (in heptad repeat 1), 1202 and 1208 bear investigation as markers of adaptive change (Cotten et al., 2014; Raj et al., 2014a) .", [["amino acid", "CHEMICAL", 39, 49], ["amino acid", "CHEMICAL", 39, 49], ["N", "CHEMICAL", 138, 139], ["MERS-CoV", "ORGANISM", 14, 22], ["amino acid", "AMINO_ACID", 39, 49], ["MERS-CoV genomes", "DNA", 14, 30], ["ribosome binding domain", "PROTEIN", 71, 94], ["RBD", "PROTEIN", 96, 99], ["spike protein", "PROTEIN", 108, 121], ["codons 158 (N-terminal region", "DNA", 126, 155], ["RBD", "PROTEIN", 163, 166], ["heptad repeat 1", "PROTEIN", 178, 193], ["MERS-CoV", "SPECIES", 14, 22], ["CoV genomes harbour amino acid substitutions", "PROBLEM", 19, 63], ["the spike protein", "TEST", 104, 121], ["codons", "TEST", 126, 132], ["heptad repeat", "TEST", 178, 191], ["bear investigation", "TEST", 210, 228], ["acid substitutions", "OBSERVATION", 45, 63]]], ["Studies are needed to determine whether there any functional outcomes on virus replication and transmission due to these and future changes (Cotten et al., 2014 ).", [["Studies", "TEST", 0, 7], ["virus replication", "TREATMENT", 73, 90]]], ["An early in vitro analysis did not find differences in shedding, replication or immune escape among viruses isolated up to May 2014 .", [["An early in vitro analysis", "TEST", 0, 26], ["immune escape among viruses", "PROBLEM", 80, 107]]], ["The location and crystal structure of the RBD was described in several reports from mid-2013 Du et al., 2013b; Lu et al., 2013; Mou et al., 2013; Wang et al., 2013) .Molecular detection of MERS-CoV infectionEarly diagnostic methods appeared within days of the ProMED email announcing the first MERS case.", [["RBD", "DISEASE", 42, 45], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 189, 197], ["RBD", "PROTEIN", 42, 45], ["MERS-CoV", "SPECIES", 189, 197], ["The location and crystal structure of the RBD", "PROBLEM", 0, 45], ["MERS", "PROBLEM", 189, 193], ["crystal", "OBSERVATION_MODIFIER", 17, 24], ["RBD", "OBSERVATION", 42, 45]]], ["These included Vero and LLC-MK2 cell culture and several in-house RT-rtPCR assays (Fig. 6 ) (Corman et al., 2012a,b; Zaki et al., 2012) .", [["Vero", "ANATOMY", 15, 19], ["cell", "ANATOMY", 32, 36], ["Vero", "CELL", 15, 19], ["LLC-MK2 cell", "CELL", 24, 36], ["MK2 cell culture", "CELL_LINE", 28, 44], ["Vero", "TEST", 15, 19], ["LLC", "TEST", 24, 27], ["MK2 cell culture", "TEST", 28, 44], ["LLC", "ANATOMY", 24, 27], ["MK2 cell", "OBSERVATION", 28, 36]]], ["Antibody testing of human sera remains rare.Molecular detection of MERS-CoV infectionRT-rtPCR assays validated by Corman et al. were quickly recommended by the WHO having been shown to be sensitive The genetic relationship between all near-complete and complete MERS-CoV genome nucleotide sequences (downloaded from GenBank using the listed accession numbers; England2 was obtained from http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/MERSCoV/respPartialgeneticsequenceofnovelcoronavirus/%5D).", [["sera", "ANATOMY", 26, 30], ["nucleotide", "CHEMICAL", 278, 288], ["human", "ORGANISM", 20, 25], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["MERS-CoV", "ORGANISM", 67, 75], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 262, 270], ["MERS-CoV genome nucleotide sequences", "DNA", 262, 298], ["England2", "DNA", 360, 368], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["MERS-CoV", "SPECIES", 67, 75], ["MERS-CoV", "SPECIES", 262, 270], ["Antibody testing", "TEST", 0, 16], ["human sera", "TEST", 20, 30], ["Molecular detection", "TEST", 44, 63], ["MERS-CoV infectionRT-rtPCR assays", "PROBLEM", 67, 100]]], ["This neighbour joining tree was created in MEGA v6 using an alignment of human and DC-derived MERS-CoV sequences (Geneious v6).", [["DC", "ANATOMY", 83, 85], ["human", "ORGANISM", 73, 78], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 94, 102], ["MEGA v6", "DNA", 43, 50], ["DC", "CELL_TYPE", 83, 85], ["MERS-CoV sequences", "DNA", 94, 112], ["Geneious v6", "DNA", 114, 125], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["MERS-CoV", "SPECIES", 94, 102], ["CoV sequences", "TEST", 99, 112]]], ["The tree was rooted using NRCE-HKU205 CAMEL KJ477102.", [["tree", "OBSERVATION_MODIFIER", 4, 8]]], ["Camel icons denote genomes from DC.", [["DC", "ANATOMY", 32, 34], ["DC", "CELL", 32, 34], ["DC", "CELL_TYPE", 32, 34], ["genomes", "OBSERVATION", 19, 26]]], ["MERS-CoV sequences described as originating from the same patient either before (Bisha 1) or after (EMC/2012) passage in cell culture are starred (red).", [["cell culture", "ANATOMY", 121, 133], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["patient", "ORGANISM", 58, 65], ["cell culture", "CELL", 121, 133], ["MERS-CoV sequences", "DNA", 0, 18], ["patient", "SPECIES", 58, 65], ["MERS-CoV", "SPECIES", 0, 8], ["CoV sequences", "TEST", 5, 18], ["passage in cell culture", "TEST", 110, 133]]], ["Identical genomes from a human and one of his ill camels from Jeddah (Azhar et al., 2014a) , the KSA are also starred (yellow).", [["human", "ORGANISM", 25, 30], ["human", "SPECIES", 25, 30], ["human", "SPECIES", 25, 30], ["genomes", "OBSERVATION", 10, 17]]], ["The target sequences of the recommended screening assays remained conserved among genomes until at least mid-2014 when last checked by IMM (Fig. 6) .Molecular detection of MERS-CoV infectionRT-rtPCR on the upstream E region (upE; Fig. 6 6 .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 172, 180], ["MERS-CoV infectionRT-rtPCR", "DNA", 172, 198], ["upstream E region", "DNA", 206, 223], ["upE", "DNA", 225, 228], ["MERS-CoV", "SPECIES", 172, 180], ["the recommended screening assays", "TEST", 24, 56], ["Molecular detection", "TEST", 149, 168], ["MERS", "PROBLEM", 172, 176], ["CoV infectionRT-rtPCR", "PROBLEM", 177, 198]]], ["A schematic depicting the location of primers (blue arrows indicate direction) and oligoprobes (green rectangles) for the earliest RT-rtPCR screening assays and conventional, semi-nested (three primers) RT-PCR confirmatory sequencing assays (Corman et al., 2012a,b performed the Hajj in 2013, with no cases being identified (Memish et al., 2014d) .", [["oligoprobes", "DNA", 83, 94], ["oligoprobes (green rectangles", "TREATMENT", 83, 112], ["the earliest RT-rtPCR screening assays", "TEST", 118, 156], ["semi-nested (three primers", "TREATMENT", 175, 201], ["RT-PCR confirmatory sequencing assays", "TEST", 203, 240]]], ["This may reflect the absence of MERS-CoV, no LRT testing (Memish et al., 2014d) or that 61% of pilgrims were arriving from countries without any known MERS-CoV circulation.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["pilgrims", "ORGANISM", 95, 103], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 151, 159], ["MERS-CoV", "SPECIES", 32, 40], ["MERS-CoV", "SPECIES", 151, 159], ["LRT testing", "TEST", 45, 56]]], ["Similarly, no MERS-CoV was identified during the 2012 in Hajj among the nasal swabs from 154 pilgrims tested by RT-rtPCR (Corman et al., 2012a) before leaving for and departing from, the KSA nor from 114 swabbed pilgrims with influenza-like illness in the KSA during the Hajj in 2013 (Barasheed et al., 2014; Gautret et al., 2013) .", [["nasal swabs", "ANATOMY", 72, 83], ["influenza-like illness", "DISEASE", 226, 248], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 72, 83], ["MERS-CoV", "SPECIES", 14, 22], ["MERS", "PROBLEM", 14, 18], ["CoV", "PROBLEM", 19, 22], ["the nasal swabs", "TEST", 68, 83], ["influenza", "PROBLEM", 226, 235], ["no", "UNCERTAINTY", 11, 13], ["MERS", "OBSERVATION", 14, 18], ["nasal swabs", "ANATOMY", 72, 83]]], ["Across a period of rapid case accumulation and intense screening in Jeddah during March to July 2014 (called the Jeddah-2014 outbreak hereafter), \u223c5000 samples were tested in a month yielding \u223c140 MERS-CoV detections (\u223c3% prevalence) (MERS, 2014g).", [["samples", "ANATOMY", 152, 159], ["rapid case accumulation", "PROBLEM", 19, 42], ["CoV detections", "TEST", 202, 216]]], ["Among 5065 individuals sampled and tested across the KSA between 1st October 2012 and 30th September 2013, 108 (2.1%) detections were made using the upE and ORF 1a assays.", [["upE and ORF 1a", "DNA", 149, 163], ["the upE and ORF 1a assays", "TEST", 145, 170]]], ["During times of high MERS-CoV activity, its 2-3% prevalence is not very different from a more hospital-based prevalence for other HCoVs (Mackay et al., 2012) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 21, 29], ["MERS-CoV", "SPECIES", 21, 29], ["high MERS", "PROBLEM", 16, 25], ["high MERS", "OBSERVATION", 16, 25]]], ["Given the proportion of deaths among those infected with MERS-CoV, it is not a virus that should reasonably be described as a \"storm in a teacup\", however to date it has been given many \"opportunities\" for worldwide spread and it has not yet taken any of them.Specimen types and length of viral sheddingData have shown one or more RT-rtPCR negative URT samples from clinically suspect MERS cases may be contradicted by further URT sampling or the preferred use of LRT samples (Bermingham et al., 2012; Omrani et al., 2013) .", [["URT samples", "ANATOMY", 349, 360], ["deaths", "DISEASE", 24, 30], ["MERS", "DISEASE", 385, 389], ["MERS-CoV", "ORGANISM", 57, 65], ["URT samples", "CANCER", 349, 360], ["MERS-CoV", "SPECIES", 57, 65], ["a virus", "PROBLEM", 77, 84], ["Specimen types", "TEST", 260, 274], ["viral sheddingData", "TEST", 289, 307], ["RT-rtPCR", "TEST", 331, 339], ["URT samples", "TEST", 349, 360], ["further URT sampling", "TEST", 419, 439]]], ["Higher viral loads occur in the LRT compared to the URT, especially with increasing time from onset of symptoms (CDC, 2014; Drosten et al., 2013; Memish et al., 2013b) .", [["Higher viral loads", "PROBLEM", 0, 18], ["symptoms", "PROBLEM", 103, 111], ["viral loads", "OBSERVATION", 7, 18], ["URT", "ANATOMY", 52, 55]]], ["Since the majority of disease symptoms appear to have been manifesting as systemic and LRT disease, this may not be surprising (Assiri et al., 2013a) .", [["systemic and LRT disease", "DISEASE", 74, 98], ["disease symptoms", "PROBLEM", 22, 38], ["systemic and LRT disease", "PROBLEM", 74, 98], ["disease", "OBSERVATION", 22, 29], ["systemic", "OBSERVATION_MODIFIER", 74, 82], ["LRT disease", "OBSERVATION", 87, 98], ["may not be", "UNCERTAINTY", 105, 115]]], ["However at writing, no human data exist to define whether the virus replicates solely in the LRT, the URT, has a preference for one over the other, or replicates in other human tissues in vivo.", [["tissues", "ANATOMY", 177, 184], ["human", "ORGANISM", 23, 28], ["human", "ORGANISM", 171, 176], ["tissues", "TISSUE", 177, 184], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 171, 176], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 171, 176], ["the virus", "PROBLEM", 58, 67], ["virus", "OBSERVATION", 62, 67], ["URT", "ANATOMY", 102, 105]]], ["Sampling of the URT has been frequently noted from the largest human MERS-CoV investigative studies (Gautret et al., 2013 ; Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team, 2013; Memish et al., 2014b,d) and, if noted, for other smaller investigative MERS-CoV testing (Kraaij-Dirkzwager et al., 2014; Memish et al., 2013b) .", [["URT", "CANCER", 16, 19], ["human", "ORGANISM", 63, 68], ["URT", "DNA", 16, 19], ["human", "SPECIES", 63, 68], ["human MERS-CoV", "SPECIES", 63, 77], ["CoV investigative studies", "TEST", 74, 99], ["CoV testing", "TEST", 278, 289], ["URT", "ANATOMY", 16, 19]]], ["In a macaque monkey model, MERS-CoV RNA was shed from both the URT and LRT (deWit et al., 2013) .", [["macaque", "ORGANISM", 5, 12], ["monkey", "ORGANISM", 13, 19], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["MERS-CoV RNA", "RNA", 27, 39], ["macaque monkey", "SPECIES", 5, 19], ["macaque monkey", "SPECIES", 5, 19], ["MERS-CoV", "SPECIES", 27, 35], ["URT", "ANATOMY", 63, 66]]], ["In a human case, throat swabs were positive for six days, and again after a gap (Kraaij-Dirkzwager et al., 2014) .", [["throat swabs", "ANATOMY", 17, 29], ["human", "ORGANISM", 5, 10], ["throat swabs", "ORGANISM_SUBSTANCE", 17, 29], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["throat swabs", "TEST", 17, 29], ["a gap", "TEST", 74, 79], ["throat", "ANATOMY", 17, 23]]], ["In another case, a 40-year old female HCW shed MERS-CoV RNA from the URT (Ziad A. Memish, personal communication) for at least 42-days between April and June 2014 (Al-Gethamy et al., 2014) .", [["female", "ORGANISM", 31, 37], ["HCW", "ORGANISM", 38, 41], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 47, 55], ["MERS-CoV RNA", "RNA", 47, 59], ["MERS-CoV", "SPECIES", 47, 55], ["URT", "ANATOMY", 69, 72]]], ["She did not show signs of disease during her time shedding virus.", [["disease", "PROBLEM", 26, 33], ["her time shedding virus", "PROBLEM", 41, 64], ["disease", "OBSERVATION", 26, 33]]], ["In a study of MERS cases in an intensive care setting, three of 12 patients shed virus for 12-22 days (Arabi et al., 2014) .", [["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["a study", "TEST", 3, 10]]], ["Elsewhere, viral RNA was detected in human oronasal swabs for 16 days and in pharyngeal or endotracheal aspirates for 24 days .", [["oronasal swabs", "ANATOMY", 43, 57], ["pharyngeal", "ANATOMY", 77, 87], ["endotracheal aspirates", "ANATOMY", 91, 113], ["human", "ORGANISM", 37, 42], ["oronasal swabs", "ORGANISM_SUBSTANCE", 43, 57], ["pharyngeal", "ORGAN", 77, 87], ["endotracheal aspirates", "MULTI-TISSUE_STRUCTURE", 91, 113], ["viral RNA", "RNA", 11, 20], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42], ["viral RNA", "PROBLEM", 11, 20], ["human oronasal swabs", "TEST", 37, 57], ["pharyngeal or endotracheal aspirates", "PROBLEM", 77, 113], ["viral RNA", "OBSERVATION", 11, 20], ["pharyngeal", "ANATOMY", 77, 87], ["endotracheal", "ANATOMY", 91, 103]]], ["Over three quarters of MERS cases shed viral RNA in their lower respiratory tract specimens (tracheal aspirates and sputum) for at least 30 days while only 30% of contacts were still shedding RNA in their upper respiratory specimens (Memish et al., 2014e) .Specimen types and length of viral sheddingThe LRT is a WHO-recommended sampling site for MERS-CoV RT-rtPCR testing, especially when collection of samples will be delayed by a week or more after symptom onset (World Health Organization, 2013b) .", [["lower respiratory tract specimens", "ANATOMY", 58, 91], ["tracheal aspirates", "ANATOMY", 93, 111], ["sputum", "ANATOMY", 116, 122], ["upper respiratory specimens", "ANATOMY", 205, 232], ["Specimen", "ANATOMY", 257, 265], ["samples", "ANATOMY", 404, 411], ["lower", "ORGANISM_SUBDIVISION", 58, 63], ["respiratory tract", "ORGANISM_SUBDIVISION", 64, 81], ["specimens", "ORGANISM_SUBSTANCE", 82, 91], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 93, 111], ["sputum", "ORGANISM_SUBSTANCE", 116, 122], ["viral RNA", "RNA", 39, 48], ["shedding RNA", "RNA", 183, 195], ["LRT", "DNA", 304, 307], ["WHO-recommended sampling site", "DNA", 313, 342], ["viral RNA", "PROBLEM", 39, 48], ["tracheal aspirates", "TEST", 93, 111], ["sputum", "TEST", 116, 122], ["Specimen types", "TEST", 257, 271], ["viral shedding", "PROBLEM", 286, 300], ["sampling site", "TEST", 329, 342], ["MERS", "TEST", 347, 351], ["CoV RT-rtPCR testing", "TEST", 352, 372], ["viral RNA", "OBSERVATION", 39, 48], ["lower", "ANATOMY_MODIFIER", 58, 63], ["respiratory tract", "ANATOMY", 64, 81], ["tracheal", "ANATOMY", 93, 101], ["aspirates", "OBSERVATION", 102, 111], ["upper", "ANATOMY_MODIFIER", 205, 210], ["respiratory", "ANATOMY", 211, 222], ["length", "OBSERVATION_MODIFIER", 276, 282]]], ["Samples to test include bronchoalveolar lavage (BAL), tracheal/tracheobronchial aspirate, pleural fluid and sputum (CDC, 2014; World Health Organization, 2013b) .", [["Samples", "ANATOMY", 0, 7], ["bronchoalveolar lavage", "ANATOMY", 24, 46], ["BAL", "ANATOMY", 48, 51], ["tracheal", "ANATOMY", 54, 62], ["tracheobronchial aspirate", "ANATOMY", 63, 88], ["pleural fluid", "ANATOMY", 90, 103], ["sputum", "ANATOMY", 108, 114], ["bronchoalveolar lavage", "MULTI-TISSUE_STRUCTURE", 24, 46], ["BAL", "MULTI-TISSUE_STRUCTURE", 48, 51], ["tracheal", "MULTI-TISSUE_STRUCTURE", 54, 62], ["tracheobronchial aspirate", "MULTI-TISSUE_STRUCTURE", 63, 88], ["pleural fluid", "ORGANISM_SUBSTANCE", 90, 103], ["sputum", "ORGANISM_SUBSTANCE", 108, 114], ["Samples to test", "TEST", 0, 15], ["bronchoalveolar lavage", "TEST", 24, 46], ["BAL)", "TEST", 48, 52], ["tracheal/tracheobronchial aspirate", "TEST", 54, 88], ["pleural fluid", "PROBLEM", 90, 103], ["sputum", "TEST", 108, 114], ["bronchoalveolar lavage", "OBSERVATION", 24, 46], ["tracheal", "ANATOMY", 54, 62], ["tracheobronchial", "ANATOMY", 63, 79], ["aspirate", "OBSERVATION", 80, 88], ["pleural", "ANATOMY", 90, 97], ["fluid", "OBSERVATION", 98, 103]]], ["Fresh samples yield better diagnostic results than refrigerated material and if delays of \u226572 h are likely, samples (except for blood) should be frozen at \u221270 \u2022 C (CDC, 2014).", [["Fresh samples", "ANATOMY", 0, 13], ["samples", "ANATOMY", 108, 115], ["blood", "ANATOMY", 128, 133], ["blood", "ORGANISM_SUBSTANCE", 128, 133], ["Fresh samples", "TEST", 0, 13], ["blood", "TEST", 128, 133]]], ["Lung biopsy or autopsy tissues can also be tested if available (World Health Organization, 2013b) .", [["Lung biopsy", "ANATOMY", 0, 11], ["autopsy tissues", "ANATOMY", 15, 30], ["Lung biopsy", "MULTI-TISSUE_STRUCTURE", 0, 11], ["autopsy tissues", "TISSUE", 15, 30], ["Lung biopsy", "TEST", 0, 11], ["autopsy tissues", "PROBLEM", 15, 30], ["biopsy", "OBSERVATION", 5, 11]]], ["From the URT, which is a less invasive and convenient sampling site, a combined nose and throat swab or a nasopharyngeal aspirate is recommended (CDC, 2014) .", [["nose", "ANATOMY", 80, 84], ["throat swab", "ANATOMY", 89, 100], ["nasopharyngeal aspirate", "ANATOMY", 106, 129], ["nose", "ORGANISM_SUBDIVISION", 80, 84], ["nasopharyngeal aspirate", "MULTI-TISSUE_STRUCTURE", 106, 129], ["a less invasive and convenient sampling site", "PROBLEM", 23, 67], ["a combined nose and throat swab", "TEST", 69, 100], ["a nasopharyngeal aspirate", "TEST", 104, 129], ["URT", "ANATOMY", 9, 12], ["less", "OBSERVATION_MODIFIER", 25, 29], ["invasive", "OBSERVATION_MODIFIER", 30, 38], ["throat", "ANATOMY", 89, 95], ["nasopharyngeal", "ANATOMY", 106, 120], ["aspirate", "OBSERVATION", 121, 129]]], ["Paired sera, collected two to three weeks apart are preferable for serological testing while a single sample is preferred if collected two weeks after onset of disease (World Health Organization, 2013b).Specimen types and length of viral sheddingUrine has been found to contain MERS-CoV RNA 12 and 13 days after symptom onset and stool samples were RT-rtPCR positive up to 16 days after onset Kraaij-Dirkzwager et al., 2014) ; both sample types should be considered (CDC, 2014; World Health Organization, 2013b) .", [["sera", "ANATOMY", 7, 11], ["stool samples", "ANATOMY", 330, 343], ["sera", "ORGANISM_SUBSTANCE", 7, 11], ["Urine", "ORGANISM_SUBSTANCE", 246, 251], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 278, 286], ["MERS-CoV RNA", "RNA", 278, 290], ["MERS-CoV", "SPECIES", 278, 286], ["Paired sera", "TEST", 0, 11], ["serological testing", "TEST", 67, 86], ["a single sample", "TEST", 93, 108], ["disease", "PROBLEM", 160, 167], ["Specimen types", "TEST", 203, 217], ["viral sheddingUrine", "TEST", 232, 251], ["CoV RNA", "TEST", 283, 290], ["symptom onset", "TEST", 312, 325], ["stool samples", "TEST", 330, 343], ["RT-rtPCR", "TEST", 349, 357], ["Kraaij", "TEST", 393, 399]]], ["In two cases that arrived in the Netherlands, urine was RT-rtPCR negative but faeces was weakly positive while sera were RT-rtPCR positive for five days or more (Kraaij-Dirkzwager et al., 2014) .", [["urine", "ANATOMY", 46, 51], ["faeces", "ANATOMY", 78, 84], ["sera", "ANATOMY", 111, 115], ["urine", "ORGANISM_SUBSTANCE", 46, 51], ["faeces", "ORGANISM_SUBSTANCE", 78, 84], ["sera", "ORGANISM_SUBSTANCE", 111, 115], ["urine", "TEST", 46, 51], ["RT-rtPCR", "TEST", 56, 64], ["weakly positive", "PROBLEM", 89, 104], ["sera", "TEST", 111, 115], ["RT", "TEST", 121, 123], ["rtPCR", "TEST", 124, 129]]], ["MERS-CoV viral RNA detection in serum has proven a useful retrospective source of PCR template when respiratory samples were not available (Hijawi et al., 2013) .", [["serum", "ANATOMY", 32, 37], ["respiratory samples", "ANATOMY", 100, 119], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["serum", "ORGANISM_SUBSTANCE", 32, 37], ["MERS-CoV viral RNA", "RNA", 0, 18], ["CoV viral RNA detection", "TEST", 5, 28], ["PCR template", "PROBLEM", 82, 94], ["respiratory samples", "TEST", 100, 119]]], ["RNAaemia may also correlate with disease severity; signs of virus cleared from serum in one recovered human case while lingering until the death of another (Faure et al., 2014) .Specimen types and length of viral sheddingIn a study of different sample types (64 nasopharyngeal [NPA], 30 tracheal aspirates, 13 sputa and 3 BAL), tracheal aspirates and BAL returned the best viral load values followed by NPA and sputum, which generally equated with whole genome sequencing success (Memish et al., 2014c) .", [["serum", "ANATOMY", 79, 84], ["Specimen", "ANATOMY", 178, 186], ["sample", "ANATOMY", 245, 251], ["nasopharyngeal", "ANATOMY", 262, 276], ["NPA", "ANATOMY", 278, 281], ["tracheal aspirates", "ANATOMY", 287, 305], ["sputa", "ANATOMY", 310, 315], ["BAL", "ANATOMY", 322, 325], ["tracheal aspirates", "ANATOMY", 328, 346], ["BAL", "ANATOMY", 351, 354], ["sputum", "ANATOMY", 411, 417], ["death", "DISEASE", 139, 144], ["serum", "ORGANISM_SUBSTANCE", 79, 84], ["human", "ORGANISM", 102, 107], ["nasopharyngeal", "CANCER", 262, 276], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 287, 305], ["tracheal aspirates", "MULTI-TISSUE_STRUCTURE", 328, 346], ["BAL", "ORGANISM_SUBSTANCE", 351, 354], ["sputum", "ORGANISM_SUBSTANCE", 411, 417], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["disease severity", "PROBLEM", 33, 49], ["virus", "PROBLEM", 60, 65], ["Specimen types", "TEST", 178, 192], ["viral shedding", "PROBLEM", 207, 221], ["a study", "TEST", 224, 231], ["nasopharyngeal [NPA", "TEST", 262, 281], ["tracheal aspirates", "TEST", 287, 305], ["sputa", "TEST", 310, 315], ["tracheal aspirates", "TEST", 328, 346], ["BAL", "TEST", 351, 354], ["the best viral load values", "TEST", 364, 390], ["NPA and sputum", "TEST", 403, 417], ["may also correlate with", "UNCERTAINTY", 9, 32], ["disease", "OBSERVATION", 33, 40], ["virus", "OBSERVATION", 60, 65], ["length", "OBSERVATION_MODIFIER", 197, 203], ["nasopharyngeal", "ANATOMY", 262, 276], ["tracheal", "ANATOMY", 287, 295], ["tracheal", "ANATOMY", 328, 336], ["aspirates", "OBSERVATION", 337, 346]]], ["This represents the only study of the effect of sample type on molecular analysis and it confirmed both the importance of LRT sampling for whole genome sequencing, while noting that 57% of samples from 112 distinct patients in the KSA in fact originated from the URT (Memish et al., 2014c) .MERS-CoV and other viruses and bacteriaMany studies make no mention of additional testing for endemic human respiratory viruses or bacteria (Assiri et al., 2013a,b; Devi et al., 2014) .", [["samples", "ANATOMY", 189, 196], ["respiratory viruses", "DISEASE", 399, 418], ["samples", "CANCER", 189, 196], ["patients", "ORGANISM", 215, 223], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 291, 299], ["human", "ORGANISM", 393, 398], ["patients", "SPECIES", 215, 223], ["human", "SPECIES", 393, 398], ["MERS-CoV", "SPECIES", 291, 299], ["human", "SPECIES", 393, 398], ["molecular analysis", "TEST", 63, 81], ["LRT sampling", "TEST", 122, 134], ["whole genome sequencing", "TEST", 139, 162], ["samples", "TEST", 189, 196], ["CoV", "PROBLEM", 296, 299], ["other viruses", "PROBLEM", 304, 317], ["bacteriaMany studies", "TEST", 322, 342], ["additional testing", "TEST", 362, 380], ["endemic human respiratory viruses", "PROBLEM", 385, 418], ["bacteria", "PROBLEM", 422, 430], ["URT", "ANATOMY", 263, 266]]], ["When viruses are sought, they include some of the following: human herpesvirus (HHV), rhinovirus (HRV), enterovirus (EV), respiratory syncytial virus (RSV), parainfluenzavirus types 1, 2 and 3 (PIVs), influenzaviruses (IFVs), endemic HCoVs, adenoviruses (AdVs) and metapneumovirus (MPV) and co-detections with MERS-CoV do occur (Bermingham et al., 2012; Drosten et al., 2013 ; Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team, 2013; Memish et al., 2013b) .", [["human herpesvirus (HHV), rhinovirus (HRV), enterovirus (EV), respiratory syncytial virus", "DISEASE", 61, 149], ["human herpesvirus (HHV)", "ORGANISM", 61, 84], ["rhinovirus", "ORGANISM", 86, 96], ["enterovirus (EV),", "ORGANISM", 104, 121], ["respiratory syncytial virus", "ORGANISM", 122, 149], ["RSV", "ORGANISM", 151, 154], ["parainfluenzavirus types 1, 2", "GENE_OR_GENE_PRODUCT", 157, 186], ["3", "GENE_OR_GENE_PRODUCT", 191, 192], ["PIVs", "GENE_OR_GENE_PRODUCT", 194, 198], ["influenzaviruses", "GENE_OR_GENE_PRODUCT", 201, 217], ["HCoVs", "GENE_OR_GENE_PRODUCT", 234, 239], ["adenoviruses", "ORGANISM", 241, 253], ["AdVs", "GENE_OR_GENE_PRODUCT", 255, 259], ["metapneumovirus", "ORGANISM", 265, 280], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 310, 318], ["human", "SPECIES", 61, 66], ["respiratory syncytial virus", "SPECIES", 122, 149], ["human herpesvirus", "SPECIES", 61, 78], ["HHV", "SPECIES", 80, 83], ["HRV", "SPECIES", 98, 101], ["EV", "SPECIES", 117, 119], ["respiratory syncytial virus", "SPECIES", 122, 149], ["RSV", "SPECIES", 151, 154], ["AdVs", "SPECIES", 255, 259], ["MPV", "SPECIES", 282, 285], ["MERS-CoV", "SPECIES", 310, 318], ["human herpesvirus (HHV", "PROBLEM", 61, 83], ["rhinovirus", "PROBLEM", 86, 96], ["enterovirus", "PROBLEM", 104, 115], ["respiratory syncytial virus", "PROBLEM", 122, 149], ["parainfluenzavirus types", "PROBLEM", 157, 181], ["PIVs", "TREATMENT", 194, 198], ["influenzaviruses (IFVs)", "PROBLEM", 201, 224], ["endemic HCoVs", "PROBLEM", 226, 239], ["adenoviruses", "PROBLEM", 241, 253], ["metapneumovirus", "PROBLEM", 265, 280], ["respiratory syncytial", "ANATOMY", 122, 143]]], ["When included, other viruses are often absent in the samples positive for MERS-CoV Bermingham et al., 2012; Kraaij-Dirkzwager et al., 2014; Omrani et al., 2013) but have been found in samples negative for MERS-CoV during such rare MERS investigations (Reuss et al., 2014) .", [["samples", "ANATOMY", 53, 60], ["samples", "ANATOMY", 184, 191], ["samples", "CANCER", 184, 191], ["MERS-CoV", "ORGANISM", 205, 213], ["MERS-CoV", "SPECIES", 205, 213], ["other viruses", "PROBLEM", 15, 28], ["MERS", "PROBLEM", 74, 78], ["Kraaij", "TEST", 108, 114], ["MERS", "PROBLEM", 205, 209]]], ["Tests on the first human case in the KSA used a LRT sample to isolate MERS-CoV in culture, conduct immunofluorescence for some viruses (negative for IFV, PIVs, RSV and AdVs) and RT-PCR for other viruses (negative for AdV, EVs, MPV and HHVs) .", [["human", "ORGANISM", 19, 24], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 70, 78], ["IFV", "GENE_OR_GENE_PRODUCT", 149, 152], ["PIVs", "GENE_OR_GENE_PRODUCT", 154, 158], ["RSV", "ORGANISM", 160, 163], ["AdVs", "GENE_OR_GENE_PRODUCT", 168, 172], ["AdV", "ORGANISM", 217, 220], ["EVs", "GENE_OR_GENE_PRODUCT", 222, 225], ["MPV", "GENE_OR_GENE_PRODUCT", 227, 230], ["HHVs", "GENE_OR_GENE_PRODUCT", 235, 239], ["KSA", "DNA", 37, 40], ["IFV", "PROTEIN", 149, 152], ["PIVs", "PROTEIN", 154, 158], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24], ["MERS-CoV", "SPECIES", 70, 78], ["IFV", "SPECIES", 149, 152], ["RSV", "SPECIES", 160, 163], ["AdV", "SPECIES", 217, 220], ["Tests", "TEST", 0, 5], ["a LRT sample", "TEST", 46, 58], ["CoV in culture", "TEST", 75, 89], ["conduct immunofluorescence", "TEST", 91, 117], ["some viruses", "PROBLEM", 122, 134], ["IFV", "PROBLEM", 149, 152], ["PIVs", "TREATMENT", 154, 158], ["RSV", "PROBLEM", 160, 163], ["AdVs", "TEST", 168, 172], ["RT-PCR", "TEST", 178, 184], ["other viruses", "PROBLEM", 189, 202], ["AdV", "PROBLEM", 217, 220], ["EVs", "TEST", 222, 225], ["MPV", "TEST", 227, 230], ["HHVs", "TEST", 235, 239]]], ["RT-PCR also detected MERS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 21, 29], ["MERS-CoV", "PROTEIN", 21, 29], ["MERS-CoV", "SPECIES", 21, 29], ["RT-PCR", "TEST", 0, 6], ["CoV", "OBSERVATION_MODIFIER", 26, 29]]], ["A case exported to Greece in April-2014 was tested (and found negative) for IFVs, Legionella and Pneumococcus .", [["Pneumococcus", "CHEMICAL", 97, 109], ["IFVs", "PROBLEM", 76, 80], ["Legionella", "PROBLEM", 82, 92], ["Pneumococcus", "PROBLEM", 97, 109], ["Pneumococcus", "OBSERVATION", 97, 109]]], ["Other bacterial testing has been conducted but the impact of bacterial copresence is also unclear Devi et al., 2014; Memish et al., 2013b; Tsiodras et al., 2014) .", [["Other bacterial testing", "TEST", 0, 23], ["bacterial copresence", "PROBLEM", 61, 81]]], ["Two MERS cases that travelled from the KSA to the Netherlands were negative for RSV, AdV, bocavirus (BoV), PIVs, HCoVs, HRV, IFVs, RSV and MPV (Kraaij-Dirkzwager et al., 2014) .", [["RSV", "ORGANISM", 80, 83], ["AdV", "ORGANISM", 85, 88], ["bocavirus", "GENE_OR_GENE_PRODUCT", 90, 99], ["BoV", "GENE_OR_GENE_PRODUCT", 101, 104], ["PIVs", "GENE_OR_GENE_PRODUCT", 107, 111], ["HCoVs", "GENE_OR_GENE_PRODUCT", 113, 118], ["RSV", "ORGANISM", 131, 134], ["RSV", "SPECIES", 80, 83], ["AdV", "SPECIES", 85, 88], ["BoV", "SPECIES", 101, 104], ["HCoVs", "SPECIES", 113, 118], ["HRV", "SPECIES", 120, 123], ["RSV", "SPECIES", 131, 134], ["Two MERS cases", "PROBLEM", 0, 14], ["RSV", "PROBLEM", 80, 83], ["bocavirus", "PROBLEM", 90, 99], ["PIVs", "TREATMENT", 107, 111], ["HRV", "PROBLEM", 120, 123], ["IFVs", "TREATMENT", 125, 129], ["RSV", "PROBLEM", 131, 134], ["MPV", "TEST", 139, 142], ["RSV", "ANATOMY", 131, 134]]], ["Testing for other respiratory pathogens is strongly recommended (World Health Organization, 2013b) but limited data address the occurrence of co-infections or alternative viral diagnoses among both cases and contacts suspected of MERS-CoV infection.", [["respiratory pathogens", "DISEASE", 18, 39], ["co-infections", "DISEASE", 142, 155], ["MERS-CoV infection", "DISEASE", 230, 248], ["MERS-CoV", "ORGANISM", 230, 238], ["MERS-CoV", "SPECIES", 230, 238], ["other respiratory pathogens", "PROBLEM", 12, 39], ["co-infections", "PROBLEM", 142, 155], ["MERS", "PROBLEM", 230, 234], ["CoV infection", "PROBLEM", 235, 248], ["CoV", "ANATOMY", 235, 238], ["infection", "OBSERVATION", 239, 248]]], ["Little is known of other causes of MERS-like pneumonia in the KSA or of the general burden of disease due to the known classical respiratory viruses including endemic other human coronaviruses.Serological surveys to identify prior MERS-CoV infectionDespite widespread use in elucidating the role of DCs as a source for MERS-CoV, no strategic and widespread sero-surveys have been conducted in humans using samples collected post-2012.", [["DCs", "ANATOMY", 299, 302], ["samples", "ANATOMY", 406, 413], ["pneumonia", "DISEASE", 45, 54], ["respiratory viruses", "DISEASE", 129, 148], ["MERS-CoV infection", "DISEASE", 231, 249], ["human", "ORGANISM", 173, 178], ["MERS-CoV", "ORGANISM", 231, 239], ["DCs", "CELL", 299, 302], ["MERS-CoV", "ORGANISM", 319, 327], ["humans", "ORGANISM", 393, 399], ["DCs", "CELL_TYPE", 299, 302], ["human", "SPECIES", 173, 178], ["humans", "SPECIES", 393, 399], ["human coronaviruses", "SPECIES", 173, 192], ["MERS-CoV", "SPECIES", 231, 239], ["MERS-CoV", "SPECIES", 319, 327], ["humans", "SPECIES", 393, 399], ["MERS", "PROBLEM", 35, 39], ["pneumonia", "PROBLEM", 45, 54], ["the general burden of disease", "PROBLEM", 72, 101], ["the known classical respiratory viruses", "PROBLEM", 109, 148], ["endemic other human coronaviruses", "PROBLEM", 159, 192], ["Serological surveys", "TEST", 193, 212], ["prior MERS", "PROBLEM", 225, 235], ["CoV infection", "PROBLEM", 236, 249], ["MERS", "PROBLEM", 319, 323], ["CoV", "PROBLEM", 324, 327], ["known of", "UNCERTAINTY", 10, 18], ["MERS", "OBSERVATION", 35, 39], ["pneumonia", "OBSERVATION", 45, 54], ["disease", "OBSERVATION", 94, 101], ["respiratory viruses", "OBSERVATION", 129, 148], ["human coronaviruses", "OBSERVATION", 173, 192], ["infection", "OBSERVATION", 240, 249]]], ["The development of robust serological assays hinges on the accessibility of a reliable panel of well-characterised animal or human sera including those positive for antibodies specific to MERS-CoV and to likely agents of cross-reaction .", [["sera", "ANATOMY", 131, 135], ["human", "ORGANISM", 125, 130], ["sera", "ORGANISM_SUBSTANCE", 131, 135], ["MERS-CoV", "ORGANISM", 188, 196], ["antibodies", "PROTEIN", 165, 175], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 125, 130], ["MERS-CoV", "SPECIES", 188, 196], ["robust serological assays", "TEST", 19, 44], ["a reliable panel", "TEST", 76, 92], ["human sera", "TEST", 125, 135], ["antibodies", "PROBLEM", 165, 175], ["cross-reaction", "PROBLEM", 221, 235], ["robust", "OBSERVATION_MODIFIER", 19, 25]]], ["Obtaining these control materials has been problematic and has slowed the development and commercialization of assays for human testing .", [["human", "ORGANISM", 122, 127], ["human", "SPECIES", 122, 127], ["human", "SPECIES", 122, 127], ["human testing", "TEST", 122, 135]]], ["One company has produced an ELISA kit to detect IgG in camels using a recombinant S1 receptor-binding subunit of MERS-CoV S protein as the antigen and produces a diagnostic reagent for immunofluorescence EUROIMMUN Medizinische Labordiagnostika AGf, 2014) .", [["IgG", "GENE_OR_GENE_PRODUCT", 48, 51], ["camels", "ORGANISM", 55, 61], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 113, 123], ["IgG", "PROTEIN", 48, 51], ["recombinant S1 receptor-binding subunit", "PROTEIN", 70, 109], ["MERS-CoV S protein", "PROTEIN", 113, 131], ["camels", "SPECIES", 55, 61], ["an ELISA kit", "TEST", 25, 37], ["IgG in camels", "PROBLEM", 48, 61], ["a recombinant S1 receptor", "TREATMENT", 68, 93], ["the antigen", "TEST", 135, 146]]], ["Serosurveys are essential to determine a baseline of animal and community exposures to MERS-CoV among countries in the Arabian Peninsula.", [["MERS-CoV", "ORGANISM", 87, 95], ["MERS-CoV", "SPECIES", 87, 95], ["Arabian", "ANATOMY_MODIFIER", 119, 126], ["Peninsula", "ANATOMY_MODIFIER", 127, 136]]], ["Early sero-surveys of humans used conventional immunofluorescent assays (IFA) in which antibodies, if present in patient sera, attach to MERS-CoV infected cell cultures to identify the presence of IgG, IgM or neutralising antibodies (Corman et al., 2012b; Drosten et al., 2013; Zaki et al., 2012) .", [["sera", "ANATOMY", 121, 125], ["cell cultures", "ANATOMY", 155, 168], ["humans", "ORGANISM", 22, 28], ["patient", "ORGANISM", 113, 120], ["sera", "ORGANISM_SUBSTANCE", 121, 125], ["MERS-CoV", "ORGANISM", 137, 145], ["cell cultures", "CELL", 155, 168], ["IgG", "GENE_OR_GENE_PRODUCT", 197, 200], ["IgM", "GENE_OR_GENE_PRODUCT", 202, 205], ["antibodies", "PROTEIN", 87, 97], ["MERS-CoV infected cell cultures", "CELL_LINE", 137, 168], ["IgG", "PROTEIN", 197, 200], ["IgM", "PROTEIN", 202, 205], ["neutralising antibodies", "PROTEIN", 209, 232], ["humans", "SPECIES", 22, 28], ["patient", "SPECIES", 113, 120], ["humans", "SPECIES", 22, 28], ["MERS-CoV", "SPECIES", 137, 145], ["conventional immunofluorescent assays", "TEST", 34, 71], ["CoV infected cell cultures", "TEST", 142, 168], ["IgG", "TEST", 197, 200], ["IgM", "TEST", 202, 205], ["neutralising antibodies", "TEST", 209, 232]]], ["No sign of MERS-CoV antibody was found among 2400 sera from patients visiting the Dr. Soliman Fakeeh Hospital in Jeddah, KSA from 2010 through 2012 , and no sign of prior MERS-CoV infection was found among 130 healthy blood donors screened at King Abdulaziz University Hospital in Jeddah (collected between January and December 2012).", [["sera", "ANATOMY", 50, 54], ["blood", "ANATOMY", 218, 223], ["MERS-CoV infection", "DISEASE", 171, 189], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 11, 19], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["patients", "ORGANISM", 60, 68], ["MERS-CoV", "ORGANISM", 171, 179], ["blood", "ORGANISM_SUBSTANCE", 218, 223], ["donors", "ORGANISM", 224, 230], ["MERS-CoV antibody", "PROTEIN", 11, 28], ["patients", "SPECIES", 60, 68], ["MERS-CoV", "SPECIES", 11, 19], ["MERS-CoV", "SPECIES", 171, 179], ["MERS", "PROBLEM", 11, 15], ["CoV antibody", "TEST", 16, 28], ["prior MERS", "PROBLEM", 165, 175], ["CoV infection", "PROBLEM", 176, 189], ["sign of", "UNCERTAINTY", 3, 10], ["MERS", "OBSERVATION", 11, 15], ["no sign of", "UNCERTAINTY", 154, 164], ["infection", "OBSERVATION", 180, 189]]], ["Eight of 226 slaughterhouse workers were positive by IFA, but those results could not be confirmed by neutralization (NT) test.", [["workers", "ORGANISM", 28, 35], ["neutralization (NT) test", "TEST", 102, 126]]], ["The study indicated that HCoV-HKU1 was a likely source of cross-reactive antigen by IFA (Aburizaiza et al., 2014 ).", [["HCoV-HKU1", "GENE_OR_GENE_PRODUCT", 25, 34], ["HCoV", "PROTEIN", 25, 29], ["HKU1", "PROTEIN", 30, 34], ["cross-reactive antigen", "PROTEIN", 58, 80], ["HCoV", "SPECIES", 25, 29], ["The study", "TEST", 0, 9], ["HCoV", "TEST", 25, 29], ["cross-reactive antigen", "PROBLEM", 58, 80]]], ["An absence of MERS-CoV antibodies among slaughterhouse workers may reflect the killing of older DCs which are less often MERS-CoV positive (see Table 1 ), the rarity of infected animals, a limited transmission risk associated with slaughtering DCs (Aburizaiza et al., 2014) , a weak immune response by humans who do not get severe MERS, or an overall low risk of MERS-CoV transmission by contact.", [["DCs", "ANATOMY", 96, 99], ["DCs", "ANATOMY", 244, 247], ["MERS", "DISEASE", 331, 335], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["DCs", "CELL", 96, 99], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 121, 129], ["DCs", "CELL", 244, 247], ["humans", "ORGANISM", 302, 308], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 363, 371], ["MERS-CoV antibodies", "PROTEIN", 14, 33], ["DCs", "CELL_TYPE", 96, 99], ["DCs", "CELL_TYPE", 244, 247], ["humans", "SPECIES", 302, 308], ["MERS-CoV", "SPECIES", 14, 22], ["MERS-CoV", "SPECIES", 121, 129], ["humans", "SPECIES", 302, 308], ["MERS-CoV", "SPECIES", 363, 371], ["MERS", "PROBLEM", 14, 18], ["CoV antibodies", "TEST", 19, 33], ["older DCs", "PROBLEM", 90, 99], ["infected animals", "PROBLEM", 169, 185], ["severe MERS", "PROBLEM", 324, 335], ["infected", "OBSERVATION", 169, 177]]], ["IFA also suffered from some cross-reactivity with convalescent SARS patient sera which could not be resolved by an NT test (Chan et al., 2013b) .", [["sera", "ANATOMY", 76, 80], ["SARS", "DISEASE", 63, 67], ["IFA", "SIMPLE_CHEMICAL", 0, 3], ["patient", "ORGANISM", 68, 75], ["sera", "ORGANISM_SUBSTANCE", 76, 80], ["patient", "SPECIES", 68, 75], ["some cross-reactivity", "PROBLEM", 23, 44], ["convalescent SARS patient sera", "PROBLEM", 50, 80], ["an NT test", "TEST", 112, 122]]], ["The need for well-validated assays was further emphasised when publicly released MERS-CoV antibody test results indicated that a handshake and two face-to-face meetings were sufficient for MERS-CoV transmission between two people in the USA (CDC Newsroom, 2014; Sampathkumar, 2014) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 81, 89], ["MERS-CoV", "ORGANISM", 189, 197], ["people", "ORGANISM", 223, 229], ["MERS", "PROTEIN", 81, 85], ["people", "SPECIES", 223, 229], ["MERS-CoV", "SPECIES", 189, 197], ["validated assays", "TEST", 18, 34], ["CoV antibody test", "TEST", 86, 103], ["MERS", "PROBLEM", 189, 193]]], ["These results were subsequently retracted because they did not withstand further confirmatory analysis with the less rapid, but highly specific, NT assay (CDC Newsroom, 2014) .Serological surveys to identify prior MERS-CoV infectionA more biologically safe IFA was developed that did not require infectious virus but was instead based on transfected cells expressing recombinant portions of the MERS-CoV N and S genes (Corman et al., 2012b; Reuss et al., 2014) .", [["cells", "ANATOMY", 350, 355], ["MERS-CoV", "ORGANISM", 214, 222], ["cells", "CELL", 350, 355], ["MERS-CoV N", "GENE_OR_GENE_PRODUCT", 395, 405], ["transfected cells", "CELL_LINE", 338, 355], ["MERS-CoV N and S genes", "DNA", 395, 417], ["MERS-CoV", "SPECIES", 214, 222], ["MERS-CoV", "SPECIES", 395, 403], ["further confirmatory analysis", "TEST", 73, 102], ["NT assay", "TEST", 145, 153], ["Serological surveys", "TEST", 176, 195], ["prior MERS", "PROBLEM", 208, 218], ["CoV infectionA", "PROBLEM", 219, 233], ["infectious virus", "PROBLEM", 296, 312]]], ["Recombinant lentiviruses expressing MERS-CoV S protein and luciferase are also safer and simpler diagnostic alternatives to working with infectious MERS-CoV Zhao et al., 2013) .", [["lentiviruses", "ORGANISM", 12, 24], ["luciferase", "GENE_OR_GENE_PRODUCT", 59, 69], ["MERS-CoV", "PROTEIN", 36, 44], ["S protein", "PROTEIN", 45, 54], ["luciferase", "PROTEIN", 59, 69], ["S protein and luciferase", "PROBLEM", 45, 69], ["lentiviruses", "OBSERVATION", 12, 24], ["MERS-CoV", "OBSERVATION", 36, 44]]], ["A pseudo particle neutralization (ppNT) assay has seen widespread use in animal studies and is at least as sensitive as the microneutralization (MNT) test (Hemida et al., 2013 (Hemida et al., , 2014a (Hemida et al., , 2015 Perera et al., 2013; Reusken et al., 2013b) .", [["A pseudo particle neutralization (ppNT) assay", "TEST", 0, 45], ["animal studies", "TEST", 73, 87], ["pseudo", "OBSERVATION", 2, 8], ["particle neutralization", "OBSERVATION", 9, 32]]], ["In a study of sera collected at the King Fahd Hospital, Eastern region of the KSA (158 from children with LRT infections between May 2010 and May 2011 and 110 from 19 to 52 year old male blood donors) no evidence of MERS-CoV neutralising antibody could be found using the ppNT assay (Gierer et al., 2013) .", [["sera", "ANATOMY", 14, 18], ["blood", "ANATOMY", 187, 192], ["LRT infections", "DISEASE", 106, 120], ["sera", "ORGANISM_SUBSTANCE", 14, 18], ["children", "ORGANISM", 92, 100], ["blood", "ORGANISM", 187, 192], ["donors", "ORGANISM", 193, 199], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 216, 224], ["MERS-CoV neutralising antibody", "PROTEIN", 216, 246], ["children", "SPECIES", 92, 100], ["MERS-CoV", "SPECIES", 216, 224], ["a study", "TEST", 3, 10], ["LRT infections", "PROBLEM", 106, 120], ["blood donors", "TEST", 187, 199], ["MERS", "PROBLEM", 216, 220], ["CoV neutralising antibody", "TEST", 221, 246], ["the ppNT assay", "TEST", 268, 282], ["no evidence of", "UNCERTAINTY", 201, 215]]], ["Similarly, in a study of four herdsmen in contact with an infected DC herd in Al-Ahsa, eight people who had intermittent contact with the herd, 30 veterinary surgeons and support staff who were not exposed to the herd, three unprotected abattoir workers in Al-Ahsa and 146 controls who were not exposed to camels in any professional role, none had serological evidence of past MERS-CoV infection using the ppNT assay (Hemida et al., 2015) .Serological surveys to identify prior MERS-CoV infectionMERS-CoV does not appear to be easily transmitted from DCs to humans, or perhaps it does not trigger a detectable immune response if only mild disease or asymptomatic infection results.Serological surveys to identify prior MERS-CoV infectionA study of such cases is an important missing link for interpretation of these negative human serology data.", [["DC", "ANATOMY", 67, 69], ["DCs", "ANATOMY", 551, 554], ["MERS-CoV infection", "DISEASE", 377, 395], ["infection", "DISEASE", 663, 672], ["people", "ORGANISM", 93, 99], ["MERS-CoV", "ORGANISM", 377, 385], ["MERS-CoV infectionMERS-CoV", "ORGANISM", 478, 504], ["DCs", "CELL", 551, 554], ["humans", "ORGANISM", 558, 564], ["MERS-CoV", "ORGANISM", 719, 727], ["human", "ORGANISM", 825, 830], ["DCs", "CELL_TYPE", 551, 554], ["people", "SPECIES", 93, 99], ["humans", "SPECIES", 558, 564], ["human", "SPECIES", 825, 830], ["MERS-CoV", "SPECIES", 377, 385], ["MERS-CoV infectionMERS-CoV", "SPECIES", 478, 504], ["humans", "SPECIES", 558, 564], ["MERS-CoV", "SPECIES", 719, 727], ["human", "SPECIES", 825, 830], ["a study", "TEST", 14, 21], ["CoV infection", "PROBLEM", 382, 395], ["Serological surveys", "TEST", 440, 459], ["prior MERS", "PROBLEM", 472, 482], ["CoV infectionMERS", "PROBLEM", 483, 500], ["CoV", "PROBLEM", 501, 504], ["mild disease", "PROBLEM", 634, 646], ["asymptomatic infection results", "PROBLEM", 650, 680], ["Serological surveys", "TEST", 681, 700], ["prior MERS", "TEST", 713, 723], ["CoV infectionA study", "TEST", 724, 744], ["infection", "OBSERVATION", 386, 395], ["mild", "OBSERVATION_MODIFIER", 634, 638], ["disease", "OBSERVATION", 639, 646], ["asymptomatic", "OBSERVATION_MODIFIER", 650, 662], ["infection", "OBSERVATION", 663, 672]]], ["A Jordanian outbreak of acute LRT disease in a hospital in Al-Zarqa in 2012, which predated the first KSA case of MERS, was retrospectively found to have been associated with MERS-CoV infection, initially via RT-rtPCR, but subsequently, and on a larger scale, using positivity by ELISA and IFA or MNT test Hijawi et al., 2013; Payne et al., 2014) .", [["acute LRT disease", "DISEASE", 24, 41], ["MERS-CoV infection", "DISEASE", 175, 193], ["MERS", "CANCER", 114, 118], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 175, 183], ["MERS-CoV", "SPECIES", 175, 183], ["acute LRT disease", "PROBLEM", 24, 41], ["MERS", "PROBLEM", 114, 118], ["MERS", "PROBLEM", 175, 179], ["CoV infection", "PROBLEM", 180, 193], ["RT-rtPCR", "TEST", 209, 217], ["a larger scale", "TREATMENT", 244, 258], ["ELISA", "TEST", 280, 285], ["MNT test", "TEST", 297, 305], ["Jordanian", "OBSERVATION_MODIFIER", 2, 11], ["outbreak", "OBSERVATION_MODIFIER", 12, 20], ["acute", "OBSERVATION_MODIFIER", 24, 29], ["LRT disease", "OBSERVATION", 30, 41], ["CoV", "OBSERVATION_MODIFIER", 180, 183], ["infection", "OBSERVATION", 184, 193]]], ["The ELISA used a recombinant N protein from the group 2 betacoronavirus (Pipistrellus) bat-CoV HKU5 to identify antibodies against the equivalent cross-reactive MERS-CoV protein and was validated using 545 sera including some from people known to have had previous HCoV-OC43, HCoV-229E, SARS-CoV, HCoV-NL63, HRV, HMPV or influenza A(H1N1) infections .", [["sera", "ANATOMY", 206, 210], ["influenza A(H1N1) infections", "DISEASE", 321, 349], ["Pipistrellus) bat-CoV", "ORGANISM", 73, 94], ["HKU5", "ORGANISM", 95, 99], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["sera", "ORGANISM_SUBSTANCE", 206, 210], ["people", "ORGANISM", 231, 237], ["HCoV-OC43", "ORGANISM", 265, 274], ["HCoV-229E", "ORGANISM", 276, 285], ["SARS-CoV", "ORGANISM", 287, 295], ["HCoV-NL63", "ORGANISM", 297, 306], ["HRV", "ORGANISM", 308, 311], ["HMPV", "ORGANISM", 313, 317], ["influenza A(H1N1)", "ORGANISM", 321, 338], ["recombinant N protein", "PROTEIN", 17, 38], ["CoV HKU5", "PROTEIN", 91, 99], ["antibodies", "PROTEIN", 112, 122], ["MERS-CoV protein", "PROTEIN", 161, 177], ["people", "SPECIES", 231, 237], ["influenza A(H1N1", "SPECIES", 321, 337], ["Pipistrellus) bat-CoV", "SPECIES", 73, 94], ["MERS-CoV", "SPECIES", 161, 169], ["HCoV", "SPECIES", 265, 269], ["HCoV-229E", "SPECIES", 276, 285], ["SARS-CoV", "SPECIES", 287, 295], ["HCoV", "SPECIES", 297, 301], ["HRV", "SPECIES", 308, 311], ["HMPV", "SPECIES", 313, 317], ["influenza A(H1N1)", "SPECIES", 321, 338], ["The ELISA", "TEST", 0, 9], ["a recombinant N protein", "TREATMENT", 15, 38], ["antibodies", "TEST", 112, 122], ["CoV protein", "TEST", 166, 177], ["previous HCoV", "TEST", 256, 269], ["OC43", "TEST", 270, 274], ["HCoV", "TEST", 276, 280], ["SARS", "TEST", 287, 291], ["CoV", "TEST", 292, 295], ["HCoV", "TEST", 297, 301], ["NL63", "PROBLEM", 302, 306], ["HRV", "PROBLEM", 308, 311], ["HMPV", "PROBLEM", 313, 317], ["influenza A(H1N1) infections", "PROBLEM", 321, 349], ["HMPV", "OBSERVATION", 313, 317], ["influenza", "OBSERVATION", 321, 330]]], ["A protein microarray expressing the S1 protein subunit has also been validated and widely used for DC testing (see Table 1 ) (Reusken et al., 2013a) but not for human screening to date.", [["DC", "ANATOMY", 99, 101], ["S1", "GENE_OR_GENE_PRODUCT", 36, 38], ["human", "ORGANISM", 161, 166], ["S1 protein subunit", "PROTEIN", 36, 54], ["DC", "CELL_TYPE", 99, 101], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166], ["A protein microarray", "TEST", 0, 20], ["DC testing", "TEST", 99, 109], ["human screening", "TEST", 161, 176]]], ["Using the most immunogenic portion or subunit of a specific viral antigen is considered the best approach for producing reliable serological assays .", [["viral antigen", "PROTEIN", 60, 73], ["a specific viral antigen", "TEST", 49, 73]]], ["Detection of MERS-CoV infection using ELISA or S1 subunit protein microarray (Reusken et al., 2013a) has usually been followed by confirmatory IFA and/or a plaque-reduction neutralization (PRNT) test (Aburizaiza et al., 2014; Drosten et al., 2013; Reusken et al., 2013c) or MNT test Perera et al., 2013; Reusken et al., 2013c) .", [["plaque", "ANATOMY", 156, 162], ["infection", "DISEASE", 22, 31], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 13, 21], ["S1 subunit", "GENE_OR_GENE_PRODUCT", 47, 57], ["S1 subunit protein", "PROTEIN", 47, 65], ["MERS-CoV", "SPECIES", 13, 21], ["MERS", "PROBLEM", 13, 17], ["CoV infection", "PROBLEM", 18, 31], ["ELISA", "TEST", 38, 43], ["a plaque-reduction neutralization", "TREATMENT", 154, 187], ["CoV infection", "OBSERVATION", 18, 31], ["plaque", "OBSERVATION", 156, 162]]], ["The confirmatory methods ensure the antibodies detected using more subjective screening methods that may also employ a spectrum of potentially cross-reactive antigens, are able to specifically neutralise the intended virus and are not more broadly reactive to other coronaviruses found in DCs (bovine CoV, BCoV) or humans (HC0V-OC43, HCoV-229E, HCoV-NL63, HCoV-HKU1, SARS-CoV).MERS-CoV cell, tissue tropism and receptorEarly work identified that a range of cells underwent cytopathic changes when infected with MERS-CoV in culture.", [["DCs", "ANATOMY", 289, 292], ["BCoV", "ANATOMY", 306, 310], ["cell", "ANATOMY", 386, 390], ["tissue", "ANATOMY", 392, 398], ["cells", "ANATOMY", 457, 462], ["coronaviruses", "ORGANISM", 266, 279], ["DCs", "CELL", 289, 292], ["bovine CoV", "ORGANISM", 294, 304], ["BCoV", "GENE_OR_GENE_PRODUCT", 306, 310], ["humans", "ORGANISM", 315, 321], ["HC0V-OC43", "ORGANISM", 323, 332], ["HCoV-229E", "CELL", 334, 343], ["HCoV-NL63", "CELL", 345, 354], ["HCoV-HKU1", "ORGANISM", 356, 365], ["SARS-CoV", "ORGANISM", 367, 375], ["MERS-CoV cell", "CELL", 377, 390], ["tissue", "TISSUE", 392, 398], ["cells", "CELL", 457, 462], ["MERS-CoV", "ORGANISM", 511, 519], ["antibodies", "PROTEIN", 36, 46], ["cross-reactive antigens", "PROTEIN", 143, 166], ["DCs", "CELL_TYPE", 289, 292], ["bovine", "SPECIES", 294, 300], ["humans", "SPECIES", 315, 321], ["bovine CoV", "SPECIES", 294, 304], ["BCoV", "SPECIES", 306, 310], ["humans", "SPECIES", 315, 321], ["HC0V", "SPECIES", 323, 327], ["SARS-CoV", "SPECIES", 367, 375], ["MERS-CoV", "SPECIES", 511, 519], ["The confirmatory methods", "TEST", 0, 24], ["the antibodies", "TEST", 32, 46], ["subjective screening methods", "TEST", 67, 95], ["potentially cross-reactive antigens", "PROBLEM", 131, 166], ["other coronaviruses", "PROBLEM", 260, 279], ["bovine CoV", "TEST", 294, 304], ["BCoV", "TEST", 306, 310], ["humans", "TEST", 315, 321], ["HC0V", "TEST", 323, 327], ["OC43", "TEST", 328, 332], ["HCoV", "TEST", 334, 338], ["HCoV", "TEST", 345, 349], ["NL63", "TEST", 350, 354], ["HCoV", "TEST", 356, 360], ["HKU1", "TEST", 361, 365], ["SARS", "TEST", 367, 371], ["cytopathic changes", "PROBLEM", 473, 491], ["MERS", "PROBLEM", 511, 515], ["CoV in culture", "TEST", 516, 530], ["CoV cell", "OBSERVATION", 382, 390], ["cytopathic", "OBSERVATION_MODIFIER", 473, 483]]], ["These included cells from (Eckerle et al., 2013; Zaki et al., 2012; Zielecki et al., 2013) :MERS-CoV cell, tissue tropism and receptor\u2022 human tracheobronchial epithelium, \u2022 human primary renal epithelium, \u2022 African green monkey kidney (Vero and Vero E6; IFN-deficient),MERS-CoV cell, tissue tropism and receptor\u2022 rhesus monkey kidney (LLC-MK2),MERS-CoV cell, tissue tropism and receptor\u2022 human bronchial epithelium (Calu-3).MERS-CoV cell, tissue tropism and receptorMERS-CoV grows more efficiently than SARS-CoV in primary bronchial cells and in primary kidney cells (Eckerle et al., 2013) .MERS-CoV cell, tissue tropism and receptorOther cells or cell lines that support MERS-CoV transcription include Muller et al., 2012) :MERS-CoV cell, tissue tropism and receptor\u2022 porcine kidney cancer (PS), \u2022 human kidney cancer (769-P), \u2022 human alveolar adenocarcinoma (A549), \u2022 bat kidney (Rousettus aegyptiacus, RoNi/7; Pipistrellus pipistrellus, PipNi/1 and PipNi/3; Carollia perspicillata, CarNi/1), \u2022 bat lung (Rhinolophus landeri, RhiLu; Myotis daubentonii,MERS-CoV cell, tissue tropism and receptorDC umbilical cord (TT-R.B) and bat kidney (PipNi) hosted MERS-CoV replication detected by RT-PCR and those from goat also produced the greatest amount of viable virus, followed by monkey, human, alpaca and bat cells .", [["cells", "ANATOMY", 15, 20], ["cell", "ANATOMY", 101, 105], ["tissue", "ANATOMY", 107, 113], ["tracheobronchial epithelium", "ANATOMY", 142, 169], ["primary renal epithelium", "ANATOMY", 179, 203], ["kidney", "ANATOMY", 228, 234], ["Vero", "ANATOMY", 236, 240], ["MERS-CoV cell", "ANATOMY", 269, 282], ["tissue", "ANATOMY", 284, 290], ["kidney", "ANATOMY", 327, 333], ["LLC-MK2", "ANATOMY", 335, 342], ["MERS-CoV cell", "ANATOMY", 344, 357], ["tissue", "ANATOMY", 359, 365], ["bronchial epithelium", "ANATOMY", 394, 414], ["cell", "ANATOMY", 433, 437], ["tissue", "ANATOMY", 439, 445], ["primary bronchial cells", "ANATOMY", 515, 538], ["primary kidney cells", "ANATOMY", 546, 566], ["cell", "ANATOMY", 600, 604], ["tissue", "ANATOMY", 606, 612], ["receptorOther cells", "ANATOMY", 625, 644], ["cell lines", "ANATOMY", 648, 658], ["cell", "ANATOMY", 734, 738], ["tissue", "ANATOMY", 740, 746], ["kidney cancer", "ANATOMY", 777, 790], ["kidney cancer", "ANATOMY", 805, 818], ["alveolar adenocarcinoma", "ANATOMY", 836, 859], ["A549", "ANATOMY", 861, 865], ["kidney", "ANATOMY", 874, 880], ["lung", "ANATOMY", 1001, 1005], ["MERS-CoV cell", "ANATOMY", 1054, 1067], ["tissue", "ANATOMY", 1069, 1075], ["receptorDC umbilical cord", "ANATOMY", 1088, 1113], ["kidney", "ANATOMY", 1131, 1137], ["bat cells", "ANATOMY", 1302, 1311], ["kidney cancer", "DISEASE", 777, 790], ["kidney cancer", "DISEASE", 805, 818], ["alveolar adenocarcinoma", "DISEASE", 836, 859], ["cells", "CELL", 15, 20], ["MERS-CoV cell", "CELL", 92, 105], ["tissue", "TISSUE", 107, 113], ["human", "ORGANISM", 136, 141], ["tracheobronchial epithelium", "TISSUE", 142, 169], ["human", "ORGANISM", 173, 178], ["renal epithelium", "TISSUE", 187, 203], ["green monkey", "ORGANISM", 215, 227], ["kidney", "ORGAN", 228, 234], ["Vero", "CELL", 236, 240], ["Vero E6", "ORGANISM", 245, 252], ["IFN", "GENE_OR_GENE_PRODUCT", 254, 257], ["MERS-CoV cell", "CELL", 269, 282], ["tissue", "TISSUE", 284, 290], ["rhesus", "ORGANISM", 313, 319], ["monkey", "ORGANISM", 320, 326], ["kidney", "ORGAN", 327, 333], ["LLC-MK2", "CELL", 335, 342], ["MERS-CoV cell", "CELL", 344, 357], ["tissue", "TISSUE", 359, 365], ["human", "ORGANISM", 388, 393], ["bronchial epithelium", "TISSUE", 394, 414], ["Calu-3", "CELL", 416, 422], ["MERS-CoV cell", "CELL", 424, 437], ["tissue", "TISSUE", 439, 445], ["receptorMERS-CoV", "GENE_OR_GENE_PRODUCT", 458, 474], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 503, 511], ["bronchial cells", "CELL", 523, 538], ["kidney cells", "CELL", 554, 566], ["MERS-CoV cell", "CELL", 591, 604], ["tissue", "TISSUE", 606, 612], ["receptorOther cells", "CELL", 625, 644], ["cell lines", "CELL", 648, 658], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 672, 680], ["MERS-CoV cell", "CELL", 725, 738], ["tissue", "TISSUE", 740, 746], ["kidney cancer", "CANCER", 777, 790], ["PS", "CANCER", 792, 794], ["human", "ORGANISM", 799, 804], ["kidney cancer", "CANCER", 805, 818], ["human", "ORGANISM", 830, 835], ["alveolar adenocarcinoma", "CANCER", 836, 859], ["A549", "CELL", 861, 865], ["bat", "ORGANISM", 870, 873], ["kidney", "ORGAN", 874, 880], ["Rousettus aegyptiacus", "ORGANISM", 882, 903], ["RoNi/7", "ORGANISM", 905, 911], ["Pipistrellus pipistrellus", "ORGANISM", 913, 938], ["PipNi/1", "ORGANISM", 940, 947], ["PipNi/3", "ORGANISM", 952, 959], ["Carollia perspicillata", "ORGANISM", 961, 983], ["CarNi/1", "ORGANISM", 985, 992], ["bat", "ORGANISM", 997, 1000], ["lung", "ORGAN", 1001, 1005], ["Rhinolophus landeri", "ORGANISM", 1007, 1026], ["RhiLu; Myotis daubentonii", "ORGANISM", 1028, 1053], ["MERS-CoV cell", "CELL", 1054, 1067], ["tissue", "TISSUE", 1069, 1075], ["receptorDC umbilical cord", "TISSUE", 1088, 1113], ["TT-R.B", "CELL", 1115, 1121], ["bat", "ORGANISM", 1127, 1130], ["kidney", "ORGAN", 1131, 1137], ["MERS-CoV", "ORGANISM", 1153, 1161], ["goat", "ORGANISM", 1208, 1212], ["monkey", "ORGANISM", 1276, 1282], ["human", "ORGANISM", 1284, 1289], ["alpaca", "ORGANISM", 1291, 1297], ["bat cells", "CELL", 1302, 1311], ["IFN", "PROTEIN", 254, 257], ["MERS-CoV cell", "CELL_LINE", 269, 282], ["primary bronchial cells", "CELL_TYPE", 515, 538], ["primary kidney cells", "CELL_TYPE", 546, 566], ["MERS-CoV cell", "CELL_LINE", 591, 604], ["receptorOther cells", "CELL_LINE", 625, 644], ["cell lines", "CELL_LINE", 648, 658], ["human, alpaca and bat cells", "CELL_TYPE", 1284, 1311], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 173, 178], ["green monkey", "SPECIES", 215, 227], ["rhesus monkey", "SPECIES", 313, 326], ["human", "SPECIES", 388, 393], ["porcine", "SPECIES", 769, 776], ["human", "SPECIES", 799, 804], ["human", "SPECIES", 830, 835], ["Rousettus aegyptiacus", "SPECIES", 882, 903], ["Pipistrellus pipistrellus", "SPECIES", 913, 938], ["Carollia perspicillata", "SPECIES", 961, 983], ["Rhinolophus landeri", "SPECIES", 1007, 1026], ["Myotis daubentonii", "SPECIES", 1035, 1053], ["goat", "SPECIES", 1208, 1212], ["monkey", "SPECIES", 1276, 1282], ["human", "SPECIES", 1284, 1289], ["human", "SPECIES", 136, 141], ["human", "SPECIES", 173, 178], ["African green monkey", "SPECIES", 207, 227], ["MERS-CoV", "SPECIES", 269, 277], ["rhesus monkey", "SPECIES", 313, 326], ["MERS-CoV", "SPECIES", 344, 352], ["human", "SPECIES", 388, 393], ["MERS-CoV", "SPECIES", 424, 432], ["receptorMERS-CoV", "SPECIES", 458, 474], ["SARS-CoV", "SPECIES", 503, 511], ["MERS-CoV", "SPECIES", 725, 733], ["human", "SPECIES", 799, 804], ["human", "SPECIES", 830, 835], ["Rousettus aegyptiacus", "SPECIES", 882, 903], ["Pipistrellus pipistrellus", "SPECIES", 913, 938], ["Carollia perspicillata", "SPECIES", 961, 983], ["Rhinolophus landeri", "SPECIES", 1007, 1026], ["Myotis daubentonii", "SPECIES", 1035, 1053], ["MERS-CoV", "SPECIES", 1054, 1062], ["MERS-CoV", "SPECIES", 1153, 1161], ["goat", "SPECIES", 1208, 1212], ["monkey", "SPECIES", 1276, 1282], ["human", "SPECIES", 1284, 1289], ["MERS", "PROBLEM", 92, 96], ["tissue tropism", "TEST", 107, 121], ["receptor\u2022 human tracheobronchial epithelium", "PROBLEM", 126, 169], ["Vero", "TEST", 236, 240], ["Vero E6", "TEST", 245, 252], ["IFN", "TEST", 254, 257], ["deficient)", "PROBLEM", 258, 268], ["MERS", "PROBLEM", 269, 273], ["CoV cell", "PROBLEM", 274, 282], ["tissue tropism", "TEST", 284, 298], ["receptor\u2022 rhesus", "TEST", 303, 319], ["LLC", "TEST", 335, 338], ["MERS", "PROBLEM", 344, 348], ["CoV cell", "PROBLEM", 349, 357], ["tissue tropism", "TEST", 359, 373], ["receptor\u2022 human bronchial epithelium", "PROBLEM", 378, 414], ["tissue tropism", "TEST", 439, 453], ["receptorMERS", "TEST", 458, 470], ["CoV", "PROBLEM", 471, 474], ["SARS", "PROBLEM", 503, 507], ["CoV in primary bronchial cells", "PROBLEM", 508, 538], ["CoV cell", "PROBLEM", 596, 604], ["tissue tropism", "PROBLEM", 606, 620], ["receptorOther cells", "TREATMENT", 625, 644], ["cell lines", "TREATMENT", 648, 658], ["MERS", "PROBLEM", 725, 729], ["CoV cell", "PROBLEM", 730, 738], ["tissue tropism", "PROBLEM", 740, 754], ["receptor\u2022 porcine kidney cancer", "PROBLEM", 759, 790], ["\u2022 human kidney cancer", "PROBLEM", 797, 818], ["\u2022 human alveolar adenocarcinoma", "PROBLEM", 828, 859], ["\u2022 bat kidney", "PROBLEM", 868, 880], ["Rousettus", "TEST", 882, 891], ["aegyptiacus", "TEST", 892, 903], ["RoNi", "TEST", 905, 909], ["Pipistrellus pipistrellus", "PROBLEM", 913, 938], ["PipNi", "TEST", 940, 945], ["PipNi", "TEST", 952, 957], ["Carollia", "TEST", 961, 969], ["\u2022 bat lung (Rhinolophus landeri", "PROBLEM", 995, 1026], ["RhiLu", "PROBLEM", 1028, 1033], ["Myotis daubentonii", "PROBLEM", 1035, 1053], ["MERS", "PROBLEM", 1054, 1058], ["CoV cell", "PROBLEM", 1059, 1067], ["tissue tropism", "TEST", 1069, 1083], ["receptorDC umbilical cord", "TEST", 1088, 1113], ["TT", "TEST", 1115, 1117], ["CoV replication", "PROBLEM", 1158, 1173], ["RT-PCR", "TEST", 1186, 1192], ["viable virus", "PROBLEM", 1250, 1262], ["CoV cell", "OBSERVATION", 97, 105], ["tissue tropism", "OBSERVATION", 107, 121], ["tracheobronchial epithelium", "ANATOMY", 142, 169], ["renal epithelium", "ANATOMY", 187, 203], ["kidney", "ANATOMY", 228, 234], ["CoV cell", "OBSERVATION", 274, 282], ["tissue tropism", "OBSERVATION", 284, 298], ["kidney", "ANATOMY", 327, 333], ["LLC", "ANATOMY", 335, 338], ["CoV cell", "OBSERVATION", 349, 357], ["tissue tropism", "OBSERVATION", 359, 373], ["bronchial epithelium", "ANATOMY", 394, 414], ["CoV cell", "OBSERVATION", 429, 437], ["tissue tropism", "OBSERVATION", 439, 453], ["bronchial cells", "ANATOMY", 523, 538], ["kidney cells", "ANATOMY", 554, 566], ["CoV cell", "OBSERVATION", 596, 604], ["cell lines", "OBSERVATION", 648, 658], ["CoV cell", "OBSERVATION", 730, 738], ["tissue tropism", "OBSERVATION", 740, 754], ["kidney", "ANATOMY", 777, 783], ["cancer", "OBSERVATION", 784, 790], ["kidney", "ANATOMY", 805, 811], ["cancer", "OBSERVATION", 812, 818], ["alveolar", "ANATOMY", 836, 844], ["adenocarcinoma", "OBSERVATION", 845, 859], ["kidney", "ANATOMY", 874, 880], ["lung", "ANATOMY", 1001, 1005], ["Myotis", "ANATOMY", 1035, 1041], ["CoV cell", "OBSERVATION", 1059, 1067], ["tissue tropism", "OBSERVATION", 1069, 1083], ["umbilical cord", "ANATOMY", 1099, 1113], ["kidney", "ANATOMY", 1131, 1137], ["greatest", "OBSERVATION_MODIFIER", 1231, 1239], ["viable virus", "OBSERVATION", 1250, 1262]]], ["MERS-CoV N protein was produced by a range of infected mammalian cells including (Chan et al., 2013a,c) :MERS-CoV cell, tissue tropism and receptor\u2022 human ex vivo bronchial and lung tissue, \u2022 Calu-3, \u2022 embryonic foetal lung fibroblasts (HFL), \u2022 gastrointestinal (Caco-2), \u2022 liver (Huh-7), \u2022 kidney (HEK), \u2022 histiocytoma (His-1), \u2022 porcine kidney (PK-15),MERS-CoV cell, tissue tropism and receptor\u2022 civet lung (CL-1), \u2022 monkey kidney (LLC-MK2, Vero, Vero E6).MERS-CoV cell, tissue tropism and receptorSome cell lines did not support MERS-CoV growth, including (Chan et al., 2013a; Muller et al., 2012) :MERS-CoV cell, tissue tropism and receptor\u2022 baby hamster kidney (BHK), \u2022 African green monkey kidney (MA104),MERS-CoV cell, tissue tropism and receptorKidney cells are a common source of passaged cell lines used in virology and they feature prominently in the list of MERS-CoVpermissive cell lines.", [["cells", "ANATOMY", 65, 70], ["cell", "ANATOMY", 114, 118], ["tissue", "ANATOMY", 120, 126], ["bronchial", "ANATOMY", 163, 172], ["lung tissue", "ANATOMY", 177, 188], ["Calu-3", "ANATOMY", 192, 198], ["embryonic foetal lung fibroblasts", "ANATOMY", 202, 235], ["HFL", "ANATOMY", 237, 240], ["gastrointestinal", "ANATOMY", 245, 261], ["Caco-2", "ANATOMY", 263, 269], ["liver", "ANATOMY", 274, 279], ["Huh-7", "ANATOMY", 281, 286], ["kidney", "ANATOMY", 291, 297], ["HEK", "ANATOMY", 299, 302], ["\u2022 histiocytoma", "ANATOMY", 305, 319], ["kidney", "ANATOMY", 339, 345], ["MERS-CoV cell", "ANATOMY", 354, 367], ["tissue", "ANATOMY", 369, 375], ["lung", "ANATOMY", 404, 408], ["kidney", "ANATOMY", 426, 432], ["Vero", "ANATOMY", 443, 447], ["cell", "ANATOMY", 467, 471], ["tissue", "ANATOMY", 473, 479], ["receptorSome cell lines", "ANATOMY", 492, 515], ["cell", "ANATOMY", 611, 615], ["tissue", "ANATOMY", 617, 623], ["kidney", "ANATOMY", 659, 665], ["BHK", "ANATOMY", 667, 670], ["kidney", "ANATOMY", 696, 702], ["MA104", "ANATOMY", 704, 709], ["MERS-CoV cell", "ANATOMY", 711, 724], ["tissue", "ANATOMY", 726, 732], ["receptorKidney cells", "ANATOMY", 745, 765], ["cell lines", "ANATOMY", 798, 808], ["MERS-CoVpermissive cell lines", "ANATOMY", 870, 899], ["histiocytoma", "DISEASE", 307, 319], ["MERS-CoV N", "GENE_OR_GENE_PRODUCT", 0, 10], ["mammalian cells", "CELL", 55, 70], ["MERS-CoV cell", "CELL", 105, 118], ["tissue", "TISSUE", 120, 126], ["human", "ORGANISM", 149, 154], ["bronchial", "MULTI-TISSUE_STRUCTURE", 163, 172], ["lung tissue", "TISSUE", 177, 188], ["Calu-3", "CELL", 192, 198], ["\u2022 embryonic foetal lung fibroblasts", "CELL", 200, 235], ["HFL", "CELL", 237, 240], ["gastrointestinal", "ORGAN", 245, 261], ["Caco-2", "CANCER", 263, 269], ["liver", "ORGAN", 274, 279], ["Huh-7", "CANCER", 281, 286], ["kidney", "ORGAN", 291, 297], ["HEK", "CELL", 299, 302], ["\u2022 histiocytoma", "CANCER", 305, 319], ["His-1", "CELL", 321, 326], ["porcine", "ORGANISM", 331, 338], ["kidney", "ORGAN", 339, 345], ["PK-15", "CELL", 347, 352], ["MERS-CoV cell", "CELL", 354, 367], ["tissue", "TISSUE", 369, 375], ["lung", "ORGAN", 404, 408], ["CL-1", "CELL", 410, 414], ["monkey", "ORGANISM", 419, 425], ["kidney", "ORGAN", 426, 432], ["LLC-MK2", "CELL", 434, 441], ["Vero", "CELL", 443, 447], ["Vero E6", "ORGANISM", 449, 456], ["MERS-CoV cell", "CELL", 458, 471], ["tissue", "TISSUE", 473, 479], ["receptorSome cell lines", "CELL", 492, 515], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 532, 540], ["MERS-CoV cell", "CELL", 602, 615], ["tissue", "TISSUE", 617, 623], ["receptor\u2022 baby hamster", "ORGANISM", 636, 658], ["kidney", "ORGAN", 659, 665], ["BHK", "CELL", 667, 670], ["green monkey", "ORGANISM", 683, 695], ["kidney", "ORGAN", 696, 702], ["MA104", "CELL", 704, 709], ["MERS-CoV cell", "CELL", 711, 724], ["tissue tropism", "CELL", 726, 740], ["receptorKidney cells", "CELL", 745, 765], ["cell lines", "CELL", 798, 808], ["MERS-CoVpermissive cell lines", "CELL", 870, 899], ["MERS-CoV N protein", "PROTEIN", 0, 18], ["infected mammalian cells", "CELL_TYPE", 46, 70], ["embryonic foetal lung fibroblasts", "CELL_TYPE", 202, 235], ["HFL", "CELL_TYPE", 237, 240], ["MERS-CoV cell", "CELL_LINE", 458, 471], ["receptorSome cell lines", "CELL_LINE", 492, 515], ["MERS-CoV cell", "CELL_LINE", 711, 724], ["receptorKidney cells", "CELL_LINE", 745, 765], ["passaged cell lines", "CELL_LINE", 789, 808], ["MERS-CoVpermissive cell lines", "CELL_LINE", 870, 899], ["human", "SPECIES", 149, 154], ["porcine", "SPECIES", 331, 338], ["monkey", "SPECIES", 419, 425], ["hamster", "SPECIES", 651, 658], ["green monkey", "SPECIES", 683, 695], ["human", "SPECIES", 149, 154], ["MERS-CoV", "SPECIES", 354, 362], ["Vero E6", "SPECIES", 449, 456], ["MERS-CoV", "SPECIES", 532, 540], ["hamster", "SPECIES", 651, 658], ["BHK", "SPECIES", 667, 670], ["African green monkey", "SPECIES", 675, 695], ["MA104", "SPECIES", 704, 709], ["MERS-CoV", "SPECIES", 711, 719], ["infected mammalian cells", "PROBLEM", 46, 70], ["MERS", "PROBLEM", 105, 109], ["CoV cell", "PROBLEM", 110, 118], ["tissue tropism", "TEST", 120, 134], ["receptor\u2022 human ex vivo", "TREATMENT", 139, 162], ["lung tissue", "TEST", 177, 188], ["Calu", "TEST", 192, 196], ["embryonic foetal lung fibroblasts", "PROBLEM", 202, 235], ["HFL", "TEST", 237, 240], ["Caco", "TEST", 263, 267], ["Huh", "TEST", 281, 284], ["\u2022 histiocytoma", "PROBLEM", 305, 319], ["\u2022 porcine kidney", "PROBLEM", 329, 345], ["PK", "TEST", 347, 349], ["MERS", "PROBLEM", 354, 358], ["CoV cell", "PROBLEM", 359, 367], ["tissue tropism", "TEST", 369, 383], ["receptor\u2022 civet lung (CL", "TEST", 388, 412], ["LLC", "TEST", 434, 437], ["MK2", "TEST", 438, 441], ["Vero", "TEST", 443, 447], ["tissue tropism", "PROBLEM", 473, 487], ["receptorSome cell lines", "TREATMENT", 492, 515], ["CoV cell", "PROBLEM", 607, 615], ["tissue tropism", "PROBLEM", 617, 631], ["MERS-CoV cell", "PROBLEM", 711, 724], ["tissue tropism", "PROBLEM", 726, 740], ["receptorKidney cells", "PROBLEM", 745, 765], ["passaged cell lines", "TREATMENT", 789, 808], ["CoVpermissive cell lines", "TREATMENT", 875, 899], ["infected mammalian cells", "OBSERVATION", 46, 70], ["CoV cell", "OBSERVATION", 110, 118], ["tissue tropism", "OBSERVATION", 120, 134], ["bronchial", "ANATOMY", 163, 172], ["lung tissue", "ANATOMY", 177, 188], ["foetal", "ANATOMY_MODIFIER", 212, 218], ["lung", "ANATOMY", 219, 223], ["fibroblasts", "OBSERVATION", 224, 235], ["gastrointestinal", "ANATOMY", 245, 261], ["liver", "ANATOMY", 274, 279], ["kidney", "ANATOMY", 291, 297], ["HEK", "ANATOMY", 299, 302], ["histiocytoma", "OBSERVATION", 307, 319], ["kidney", "ANATOMY", 339, 345], ["CoV cell", "OBSERVATION", 359, 367], ["tissue tropism", "OBSERVATION", 369, 383], ["lung", "ANATOMY", 404, 408], ["kidney", "ANATOMY", 426, 432], ["LLC", "ANATOMY", 434, 437], ["CoV cell", "OBSERVATION", 463, 471], ["cell lines", "OBSERVATION", 505, 515], ["CoV cell", "OBSERVATION", 607, 615], ["tissue tropism", "OBSERVATION", 617, 631], ["kidney", "ANATOMY", 659, 665], ["kidney", "ANATOMY", 696, 702], ["CoV cell", "OBSERVATION", 716, 724], ["tissue tropism", "OBSERVATION", 726, 740], ["passaged cell lines", "OBSERVATION", 789, 808], ["cell lines", "OBSERVATION", 889, 899]]], ["It is noteworthy that diabetes is also one of the underlying diseases among two thirds of MERS-CoV positive people and that renal damage features among patients with severe disease (Assiri et al., 2013a) .", [["renal", "ANATOMY", 124, 129], ["diabetes", "DISEASE", 22, 30], ["renal damage", "DISEASE", 124, 136], ["MERS-CoV", "ORGANISM", 90, 98], ["people", "ORGANISM", 108, 114], ["renal", "ORGAN", 124, 129], ["patients", "ORGANISM", 152, 160], ["people", "SPECIES", 108, 114], ["patients", "SPECIES", 152, 160], ["MERS-CoV", "SPECIES", 90, 98], ["diabetes", "PROBLEM", 22, 30], ["the underlying diseases", "PROBLEM", 46, 69], ["CoV positive people", "PROBLEM", 95, 114], ["renal damage features", "PROBLEM", 124, 145], ["severe disease", "PROBLEM", 166, 180], ["diabetes", "OBSERVATION", 22, 30], ["diseases", "OBSERVATION", 61, 69], ["renal", "ANATOMY", 124, 129], ["damage", "OBSERVATION", 130, 136], ["severe", "OBSERVATION_MODIFIER", 166, 172], ["disease", "OBSERVATION", 173, 180]]], ["When a pseudovirus expressing the MERS-CoV S protein was used to examine the binding of S to the cellular receptor for SARS-CoV (angiotensin-converting enzyme 2; ACE2), MHV (carcinoembryonic antigen-related cell adhesion molecule; CEACAM1) or HCoV-229E (CD13) which were expressed in nonpermissive 293T cells, it did not enter those cells, indicating these were not the receptor molecules for MERS-CoV .", [["cellular", "ANATOMY", 97, 105], ["293T cells", "ANATOMY", 298, 308], ["cells", "ANATOMY", 333, 338], ["angiotensin", "CHEMICAL", 129, 140], ["pseudovirus", "ORGANISM", 7, 18], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 34, 44], ["cellular", "CELL", 97, 105], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 119, 127], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 129, 160], ["ACE2", "GENE_OR_GENE_PRODUCT", 162, 166], ["MHV", "ORGANISM", 169, 172], ["carcinoembryonic antigen-related cell adhesion molecule", "GENE_OR_GENE_PRODUCT", 174, 229], ["CEACAM1", "GENE_OR_GENE_PRODUCT", 231, 238], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 243, 252], ["CD13", "GENE_OR_GENE_PRODUCT", 254, 258], ["293T cells", "CELL", 298, 308], ["cells", "CELL", 333, 338], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 393, 401], ["MERS-CoV S protein", "PROTEIN", 34, 52], ["cellular receptor", "PROTEIN", 97, 114], ["SARS-CoV (angiotensin-converting enzyme 2", "PROTEIN", 119, 160], ["ACE2", "PROTEIN", 162, 166], ["MHV", "PROTEIN", 169, 172], ["carcinoembryonic antigen-related cell adhesion molecule", "PROTEIN", 174, 229], ["CEACAM1", "PROTEIN", 231, 238], ["HCoV", "PROTEIN", 243, 247], ["229E", "PROTEIN", 248, 252], ["CD13", "PROTEIN", 254, 258], ["nonpermissive 293T cells", "CELL_LINE", 284, 308], ["receptor molecules", "PROTEIN", 370, 388], ["MERS-CoV", "PROTEIN", 393, 401], ["SARS-CoV", "SPECIES", 119, 127], ["MHV", "SPECIES", 169, 172], ["MERS-CoV", "SPECIES", 393, 401], ["the MERS-CoV S protein", "TEST", 30, 52], ["SARS", "PROBLEM", 119, 123], ["CoV", "TEST", 124, 127], ["angiotensin", "TEST", 129, 140], ["enzyme", "TEST", 152, 158], ["ACE2", "TEST", 162, 166], ["MHV (carcinoembryonic antigen", "TEST", 169, 198], ["cell adhesion molecule", "TEST", 207, 229], ["CEACAM1", "TEST", 231, 238], ["HCoV", "TEST", 243, 247], ["CoV", "PROBLEM", 398, 401], ["293T cells", "OBSERVATION", 298, 308]]], ["When ACE2 was expressed in otherwise non-permissive BHK cells, only SARS-CoV could infect them (Muller et al., 2012) .", [["BHK cells", "ANATOMY", 52, 61], ["ACE2", "GENE_OR_GENE_PRODUCT", 5, 9], ["BHK cells", "CELL", 52, 61], ["SARS-CoV", "ORGANISM", 68, 76], ["ACE2", "PROTEIN", 5, 9], ["BHK cells", "CELL_LINE", 52, 61], ["SARS-CoV", "SPECIES", 68, 76], ["non-permissive BHK cells", "PROBLEM", 37, 61], ["SARS", "PROBLEM", 68, 72], ["BHK cells", "OBSERVATION", 52, 61]]], ["Additionally, blockade of ACE2 by antibodies only prevented SARS-CoV infection of cells otherwise permissive to that virus while MERS-CoV could still infect them (Muller et al., 2012 ).MERS-CoV cell, tissue tropism and receptorAn extract from cells permissive for MERS-CoV infection (Huh-7 and Vero) yielded a \u223c110 kDa protein bound by a recombinant MERS-CoV S protein domain S1.", [["cells", "ANATOMY", 82, 87], ["cell", "ANATOMY", 194, 198], ["tissue", "ANATOMY", 200, 206], ["cells", "ANATOMY", 243, 248], ["infection", "DISEASE", 69, 78], ["receptorAn extract", "CHEMICAL", 219, 237], ["infection", "DISEASE", 273, 282], ["ACE2", "GENE_OR_GENE_PRODUCT", 26, 30], ["SARS-CoV", "ORGANISM", 60, 68], ["cells", "CELL", 82, 87], ["MERS-CoV", "ORGANISM", 129, 137], ["MERS-CoV cell", "CELL", 185, 198], ["tissue", "TISSUE", 200, 206], ["receptorAn", "GENE_OR_GENE_PRODUCT", 219, 229], ["cells", "CELL", 243, 248], ["MERS-CoV", "ORGANISM", 264, 272], ["Huh-7", "CELL", 284, 289], ["Vero", "CELL", 294, 298], ["MERS-CoV S protein domain S1", "GENE_OR_GENE_PRODUCT", 350, 378], ["ACE2", "PROTEIN", 26, 30], ["antibodies", "PROTEIN", 34, 44], ["\u223c110 kDa protein", "PROTEIN", 310, 326], ["recombinant MERS-CoV S protein domain S1", "PROTEIN", 338, 378], ["SARS-CoV", "SPECIES", 60, 68], ["MERS-CoV", "SPECIES", 129, 137], ["MERS-CoV", "SPECIES", 185, 193], ["MERS-CoV", "SPECIES", 264, 272], ["blockade of ACE2", "TREATMENT", 14, 30], ["SARS", "PROBLEM", 60, 64], ["CoV infection of cells", "PROBLEM", 65, 87], ["that virus", "PROBLEM", 112, 122], ["CoV", "PROBLEM", 134, 137], ["CoV cell", "PROBLEM", 190, 198], ["tissue tropism", "TEST", 200, 214], ["receptorAn extract", "TREATMENT", 219, 237], ["MERS", "PROBLEM", 264, 268], ["CoV infection", "PROBLEM", 269, 282], ["Huh", "TEST", 284, 287], ["Vero", "TEST", 294, 298], ["a \u223c110 kDa protein bound", "PROBLEM", 308, 332], ["a recombinant MERS", "TEST", 336, 354], ["CoV S protein domain S1", "PROBLEM", 355, 378], ["CoV cell", "OBSERVATION", 190, 198], ["tissue tropism", "OBSERVATION", 200, 214], ["infection", "OBSERVATION", 273, 282]]], ["It was identified by mass spectrometry as the exopeptidase dipeptidyl peptidase 4 (DPP4; also called CD26), a type-II transmembrane glycoprotein .", [["exopeptidase dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 46, 81], ["DPP4", "GENE_OR_GENE_PRODUCT", 83, 87], ["CD26", "GENE_OR_GENE_PRODUCT", 101, 105], ["type-II transmembrane glycoprotein", "GENE_OR_GENE_PRODUCT", 110, 144], ["exopeptidase dipeptidyl peptidase 4", "PROTEIN", 46, 81], ["DPP4", "PROTEIN", 83, 87], ["CD26", "PROTEIN", 101, 105], ["type-II transmembrane glycoprotein", "PROTEIN", 110, 144], ["mass spectrometry", "TEST", 21, 38], ["the exopeptidase dipeptidyl peptidase", "TEST", 42, 79], ["DPP4", "TEST", 83, 87], ["CD26", "TEST", 101, 105], ["a type-II transmembrane glycoprotein", "TREATMENT", 108, 144], ["mass", "OBSERVATION", 21, 25]]], ["The receptor's identity was confirmed by the use of soluble DPP4 to competitively inhibit MERS-CoV infection of Vero cells as well as by transient expression of DPP4 in COS-7 cells which rendered them permissive to MERS-CoV (Memish et al., 2014f; Raj et al., 2013) .", [["Vero cells", "ANATOMY", 112, 122], ["COS-7 cells", "ANATOMY", 169, 180], ["DPP4", "GENE_OR_GENE_PRODUCT", 60, 64], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 90, 98], ["Vero cells", "CELL", 112, 122], ["DPP4", "GENE_OR_GENE_PRODUCT", 161, 165], ["COS-7 cells", "CELL", 169, 180], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 215, 223], ["DPP4", "PROTEIN", 60, 64], ["Vero cells", "CELL_LINE", 112, 122], ["DPP4", "PROTEIN", 161, 165], ["COS-7 cells", "CELL_LINE", 169, 180], ["MERS-CoV", "SPECIES", 90, 98], ["MERS-CoV", "SPECIES", 215, 223], ["soluble DPP4", "TREATMENT", 52, 64], ["CoV infection of Vero cells", "PROBLEM", 95, 122], ["DPP4 in COS", "TEST", 161, 172], ["Vero cells", "OBSERVATION", 112, 122]]], ["Anti-DPP4 antibodies also blocked human and DC MERS-CoV variants from infecting otherwise permissive human bronchial epithelial cells or Huh-7 cells respectively while inhibitors of the DPP4 function did not, indicating that structure, rather than function, was important for MERS-CoV attachment .MERS-CoV cell, tissue tropism and receptorDPP4 RNA-positive cells were detected by RT-PCR derived from goat lung, alpaca kidney, camel umbilical cord, bat kidney, human lung and monkey kidney .", [["DC", "ANATOMY", 44, 46], ["bronchial epithelial cells", "ANATOMY", 107, 133], ["Huh-7 cells", "ANATOMY", 137, 148], ["cell", "ANATOMY", 306, 310], ["tissue", "ANATOMY", 312, 318], ["cells", "ANATOMY", 357, 362], ["lung", "ANATOMY", 405, 409], ["kidney", "ANATOMY", 418, 424], ["camel umbilical cord", "ANATOMY", 426, 446], ["kidney", "ANATOMY", 452, 458], ["lung", "ANATOMY", 466, 470], ["kidney", "ANATOMY", 482, 488], ["Anti-DPP4", "GENE_OR_GENE_PRODUCT", 0, 9], ["human", "ORGANISM", 34, 39], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 47, 55], ["human", "ORGANISM", 101, 106], ["bronchial epithelial cells", "CELL", 107, 133], ["Huh-7 cells", "CELL", 137, 148], ["DPP4", "GENE_OR_GENE_PRODUCT", 186, 190], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 276, 284], ["MERS-CoV cell", "CELL", 297, 310], ["tissue", "TISSUE", 312, 318], ["receptorDPP4", "GENE_OR_GENE_PRODUCT", 331, 343], ["goat", "ORGANISM", 400, 404], ["lung", "ORGAN", 405, 409], ["alpaca", "ORGANISM", 411, 417], ["kidney", "ORGAN", 418, 424], ["camel", "ORGANISM", 426, 431], ["umbilical cord", "TISSUE", 432, 446], ["bat", "ORGANISM", 448, 451], ["kidney", "ORGAN", 452, 458], ["human", "ORGANISM", 460, 465], ["lung", "ORGAN", 466, 470], ["monkey", "ORGANISM", 475, 481], ["kidney", "ORGAN", 482, 488], ["Anti-DPP4 antibodies", "PROTEIN", 0, 20], ["human and DC MERS-CoV variants", "CELL_LINE", 34, 64], ["human bronchial epithelial cells", "CELL_TYPE", 101, 133], ["Huh-7 cells", "CELL_LINE", 137, 148], ["DPP4", "PROTEIN", 186, 190], ["receptorDPP4 RNA", "RNA", 331, 347], ["human", "SPECIES", 34, 39], ["human", "SPECIES", 101, 106], ["goat", "SPECIES", 400, 404], ["camel", "SPECIES", 426, 431], ["human", "SPECIES", 460, 465], ["monkey", "SPECIES", 475, 481], ["human", "SPECIES", 34, 39], ["MERS-CoV", "SPECIES", 47, 55], ["human", "SPECIES", 101, 106], ["MERS-CoV", "SPECIES", 276, 284], ["goat", "SPECIES", 400, 404], ["camel", "SPECIES", 426, 431], ["human", "SPECIES", 460, 465], ["Anti-DPP4 antibodies", "TEST", 0, 20], ["CoV variants", "PROBLEM", 52, 64], ["permissive human bronchial epithelial cells", "PROBLEM", 90, 133], ["Huh", "TEST", 137, 140], ["the DPP4 function", "TEST", 182, 199], ["tissue tropism", "TEST", 312, 326], ["receptorDPP4 RNA", "TEST", 331, 347], ["positive cells", "PROBLEM", 348, 362], ["RT", "TEST", 380, 382], ["PCR", "TEST", 383, 386], ["alpaca kidney, camel umbilical cord, bat kidney, human lung and monkey kidney", "PROBLEM", 411, 488], ["bronchial", "ANATOMY", 107, 116], ["epithelial cells", "OBSERVATION", 117, 133], ["CoV cell", "OBSERVATION", 302, 310], ["positive cells", "OBSERVATION", 348, 362], ["lung", "ANATOMY", 405, 409], ["alpaca", "ANATOMY_MODIFIER", 411, 417], ["kidney", "ANATOMY", 418, 424], ["camel", "ANATOMY_MODIFIER", 426, 431], ["umbilical cord", "ANATOMY", 432, 446], ["bat", "ANATOMY_MODIFIER", 448, 451], ["kidney", "ANATOMY", 452, 458], ["human", "ANATOMY_MODIFIER", 460, 465], ["lung", "ANATOMY", 466, 470], ["monkey", "ANATOMY_MODIFIER", 475, 481], ["kidney", "ANATOMY", 482, 488]]], ["DPP4 protein was also found on epithelial cells of different species from organs including the kidney and renal ducts, small intestine, lung, umbilical cord, liver, prostate, activated leukocytes and in elevated levels in a soluble form in the blood of those with allergic asthma (Lun et al., 2007; Raj et al., 2013) .", [["epithelial cells", "ANATOMY", 31, 47], ["organs", "ANATOMY", 74, 80], ["kidney", "ANATOMY", 95, 101], ["renal ducts", "ANATOMY", 106, 117], ["small intestine", "ANATOMY", 119, 134], ["lung", "ANATOMY", 136, 140], ["umbilical cord", "ANATOMY", 142, 156], ["liver", "ANATOMY", 158, 163], ["prostate", "ANATOMY", 165, 173], ["leukocytes", "ANATOMY", 185, 195], ["blood", "ANATOMY", 244, 249], ["allergic asthma", "DISEASE", 264, 279], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["epithelial cells", "CELL", 31, 47], ["organs", "ORGAN", 74, 80], ["kidney", "ORGAN", 95, 101], ["renal ducts", "MULTI-TISSUE_STRUCTURE", 106, 117], ["small intestine", "ORGAN", 119, 134], ["lung", "ORGAN", 136, 140], ["umbilical cord", "TISSUE", 142, 156], ["liver", "ORGAN", 158, 163], ["prostate", "ORGAN", 165, 173], ["leukocytes", "CELL", 185, 195], ["blood", "ORGANISM_SUBSTANCE", 244, 249], ["DPP4 protein", "PROTEIN", 0, 12], ["epithelial cells", "CELL_TYPE", 31, 47], ["activated leukocytes", "CELL_TYPE", 175, 195], ["DPP4 protein", "TEST", 0, 12], ["epithelial cells", "PROBLEM", 31, 47], ["different species", "PROBLEM", 51, 68], ["small intestine, lung, umbilical cord, liver, prostate", "PROBLEM", 119, 173], ["activated leukocytes", "PROBLEM", 175, 195], ["elevated levels", "PROBLEM", 203, 218], ["allergic asthma", "PROBLEM", 264, 279], ["epithelial cells", "OBSERVATION", 31, 47], ["different species", "OBSERVATION", 51, 68], ["kidney", "ANATOMY", 95, 101], ["renal ducts", "ANATOMY", 106, 117], ["small intestine", "ANATOMY", 119, 134], ["lung", "ANATOMY", 136, 140], ["umbilical cord", "ANATOMY", 142, 156], ["liver", "ANATOMY", 158, 163], ["prostate", "ANATOMY", 165, 173], ["activated leukocytes", "OBSERVATION", 175, 195], ["elevated", "OBSERVATION_MODIFIER", 203, 211], ["levels", "OBSERVATION_MODIFIER", 212, 218], ["allergic asthma", "OBSERVATION", 264, 279]]], ["Limited DPP4 expression was found in the lung of MERS-CoV non-permissive animals including mice and Syrian hamsters, but it was present.", [["lung", "ANATOMY", 41, 45], ["DPP4", "GENE_OR_GENE_PRODUCT", 8, 12], ["lung", "ORGAN", 41, 45], ["MERS-CoV", "ORGANISM", 49, 57], ["animals", "ORGANISM", 73, 80], ["mice", "ORGANISM", 91, 95], ["Syrian hamsters", "ORGANISM", 100, 115], ["DPP4", "PROTEIN", 8, 12], ["mice", "SPECIES", 91, 95], ["Syrian hamsters", "SPECIES", 100, 115], ["MERS-CoV", "SPECIES", 49, 57], ["mice", "SPECIES", 91, 95], ["Syrian hamsters", "SPECIES", 100, 115], ["lung", "ANATOMY", 41, 45]]], ["DPP4 expression was also seen in ferret, DC, sheep, goat and cow bronchial/bronchiolar tissues and renal tubular tissues (Coleman et al., 2014b; van Doremalen et al., 2014) .", [["ferret", "ANATOMY", 33, 39], ["DC", "ANATOMY", 41, 43], ["bronchial", "ANATOMY", 65, 74], ["bronchiolar tissues", "ANATOMY", 75, 94], ["renal tubular tissues", "ANATOMY", 99, 120], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["ferret", "ORGANISM", 33, 39], ["DC", "CELL", 41, 43], ["sheep", "ORGANISM", 45, 50], ["goat", "ORGANISM", 52, 56], ["cow", "ORGANISM", 61, 64], ["bronchial", "TISSUE", 65, 74], ["bronchiolar tissues", "TISSUE", 75, 94], ["renal tubular tissues", "TISSUE", 99, 120], ["DPP4", "PROTEIN", 0, 4], ["DC", "CELL_TYPE", 41, 43], ["ferret", "SPECIES", 33, 39], ["sheep", "SPECIES", 45, 50], ["goat", "SPECIES", 52, 56], ["cow", "SPECIES", 61, 64], ["ferret", "SPECIES", 33, 39], ["sheep", "SPECIES", 45, 50], ["goat", "SPECIES", 52, 56], ["cow", "SPECIES", 61, 64], ["DPP4 expression", "TEST", 0, 15], ["cow bronchial/bronchiolar tissues and renal tubular tissues", "PROBLEM", 61, 120], ["bronchial", "ANATOMY", 65, 74], ["bronchiolar tissues", "ANATOMY", 75, 94], ["renal", "ANATOMY", 99, 104], ["tubular", "ANATOMY_MODIFIER", 105, 112]]], ["When the structure of DPP4 from animals was modelled, a host-barrier restriction was predicted to exist among different mammals; DPP4 was present but some animals do not support MERS-CoV infection (van Doremalen et al., 2014) .", [["MERS-CoV infection", "DISEASE", 178, 196], ["DPP4", "GENE_OR_GENE_PRODUCT", 22, 26], ["DPP4", "GENE_OR_GENE_PRODUCT", 129, 133], ["MERS-CoV", "ORGANISM", 178, 186], ["DPP4", "PROTEIN", 22, 26], ["DPP4", "PROTEIN", 129, 133], ["MERS-CoV", "SPECIES", 178, 186], ["DPP4", "TEST", 22, 26], ["a host-barrier restriction", "TREATMENT", 54, 80], ["DPP4", "TREATMENT", 129, 133], ["CoV infection", "PROBLEM", 183, 196]]], ["When a human DPP4 was \"hamsterized\" by exchanging five key MERS-CoV Sprotein-interacting residues and introduced into non-permissive BHK cells, they were not rendered permissive, whereas introduction of the human DPP4 into BHK cells successfully permitted their infection (van Doremalen et al., 2014) .", [["BHK cells", "ANATOMY", 133, 142], ["BHK cells", "ANATOMY", 223, 232], ["infection", "DISEASE", 262, 271], ["human", "ORGANISM", 7, 12], ["DPP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["BHK cells", "CELL", 133, 142], ["human", "ORGANISM", 207, 212], ["DPP4", "GENE_OR_GENE_PRODUCT", 213, 217], ["BHK cells", "CELL", 223, 232], ["human DPP4", "PROTEIN", 7, 17], ["MERS-CoV Sprotein-interacting residues", "PROTEIN", 59, 97], ["non-permissive BHK cells", "CELL_LINE", 118, 142], ["human DPP4", "PROTEIN", 207, 217], ["BHK cells", "CELL_LINE", 223, 232], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 207, 212], ["human", "SPECIES", 7, 12], ["human", "SPECIES", 207, 212], ["a human DPP4", "TREATMENT", 5, 17], ["CoV Sprotein-interacting residues", "TREATMENT", 64, 97], ["non-permissive BHK cells", "PROBLEM", 118, 142], ["the human DPP4 into BHK cells", "TREATMENT", 203, 232], ["their infection", "PROBLEM", 256, 271], ["infection", "OBSERVATION", 262, 271]]], ["Because of the high affinity of MERS-CoV for human DPP4, similar to that for animal DPP4 molecules, it is possible that the MERS-CoV which was detected in humans in 2012 was already modestly adapted to humans and that both DCs and horses, and to a lesser extent goats, should all be considered as sources for intrusion of the virus into human populations because of their degree of binding affinity (Barlan et al., 2014; Raj et al., 2014a) .", [["DCs", "ANATOMY", 223, 226], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 32, 40], ["human", "ORGANISM", 45, 50], ["DPP4", "GENE_OR_GENE_PRODUCT", 51, 55], ["DPP4", "GENE_OR_GENE_PRODUCT", 84, 88], ["MERS-CoV", "ORGANISM", 124, 132], ["humans", "ORGANISM", 155, 161], ["humans", "ORGANISM", 202, 208], ["DCs", "CELL", 223, 226], ["horses", "ORGANISM", 231, 237], ["goats", "ORGANISM", 262, 267], ["human", "ORGANISM", 337, 342], ["MERS-CoV", "PROTEIN", 32, 40], ["human DPP4", "PROTEIN", 45, 55], ["animal DPP4 molecules", "PROTEIN", 77, 98], ["DCs", "CELL_TYPE", 223, 226], ["human", "SPECIES", 45, 50], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 202, 208], ["human", "SPECIES", 337, 342], ["MERS-CoV", "SPECIES", 32, 40], ["human", "SPECIES", 45, 50], ["MERS-CoV", "SPECIES", 124, 132], ["humans", "SPECIES", 155, 161], ["humans", "SPECIES", 202, 208], ["goats", "SPECIES", 262, 267], ["human", "SPECIES", 337, 342], ["human DPP4", "TREATMENT", 45, 55], ["animal DPP4 molecules", "PROBLEM", 77, 98], ["the MERS-CoV", "PROBLEM", 120, 132], ["the virus into human populations", "PROBLEM", 322, 354]]], ["To date, no sign of natural MERS-CoV infection has been found in goat, sheep, cow or alpaca, despite small seroprevalence studies.", [["MERS-CoV infection", "DISEASE", 28, 46], ["MERS-CoV", "ORGANISM", 28, 36], ["goat", "ORGANISM", 65, 69], ["sheep", "ORGANISM", 71, 76], ["cow", "ORGANISM", 78, 81], ["alpaca", "ORGANISM", 85, 91], ["goat", "SPECIES", 65, 69], ["sheep", "SPECIES", 71, 76], ["cow", "SPECIES", 78, 81], ["MERS-CoV", "SPECIES", 28, 36], ["goat", "SPECIES", 65, 69], ["sheep", "SPECIES", 71, 76], ["cow", "SPECIES", 78, 81], ["natural MERS", "PROBLEM", 20, 32], ["CoV infection", "PROBLEM", 33, 46], ["alpaca", "PROBLEM", 85, 91], ["small seroprevalence studies", "TEST", 101, 129], ["no sign of", "UNCERTAINTY", 9, 19], ["natural MERS", "OBSERVATION", 20, 32], ["infection", "OBSERVATION", 37, 46], ["alpaca", "OBSERVATION_MODIFIER", 85, 91], ["small", "OBSERVATION_MODIFIER", 101, 106]]], ["However, the DPP4 data suggest the possibility and these animals should be further examined as potential animal hosts (see Table 1 for detail on DCs).MERS-CoV cell, tissue tropism and receptorAsthmatics have been identified among MERS patients.", [["DCs", "ANATOMY", 145, 148], ["cell", "ANATOMY", 159, 163], ["tissue", "ANATOMY", 165, 171], ["DPP4", "GENE_OR_GENE_PRODUCT", 13, 17], ["DCs", "CELL", 145, 148], ["MERS-CoV cell", "CELL", 150, 163], ["tissue", "TISSUE", 165, 171], ["patients", "ORGANISM", 235, 243], ["DPP4", "PROTEIN", 13, 17], ["DCs", "CELL_TYPE", 145, 148], ["patients", "SPECIES", 235, 243], ["the DPP4 data", "TEST", 9, 22], ["tissue tropism", "PROBLEM", 165, 179], ["receptorAsthmatics", "TREATMENT", 184, 202], ["suggest the possibility", "UNCERTAINTY", 23, 46], ["CoV cell", "OBSERVATION", 155, 163], ["tissue tropism", "OBSERVATION", 165, 179]]], ["DPP4 secretion may decrease in proportion to the level of cellular inflammation and the molecule has a role in T-cell activation and hence immune regulation (Boonacker and Van Noorden, 2003) , which may be important for asthmatic airway and MERS-CoV infection.", [["cellular", "ANATOMY", 58, 66], ["T-cell", "ANATOMY", 111, 117], ["airway", "ANATOMY", 230, 236], ["inflammation", "DISEASE", 67, 79], ["asthmatic airway and MERS-CoV infection", "DISEASE", 220, 259], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["cellular", "CELL", 58, 66], ["T-cell", "CELL", 111, 117], ["airway", "MULTI-TISSUE_STRUCTURE", 230, 236], ["MERS-CoV", "ORGANISM", 241, 249], ["DPP4", "PROTEIN", 0, 4], ["MERS-CoV", "SPECIES", 241, 249], ["DPP4 secretion", "TEST", 0, 14], ["cellular inflammation", "PROBLEM", 58, 79], ["the molecule", "PROBLEM", 84, 96], ["T-cell activation", "TREATMENT", 111, 128], ["asthmatic airway", "PROBLEM", 220, 236], ["MERS", "PROBLEM", 241, 245], ["CoV infection", "PROBLEM", 246, 259], ["decrease", "OBSERVATION_MODIFIER", 19, 27], ["cellular inflammation", "OBSERVATION", 58, 79], ["airway", "ANATOMY", 230, 236], ["CoV infection", "OBSERVATION", 246, 259]]], ["While few studies have looked at DPP4 in the URT and none did so in relation to MERS-CoV, relevant enzymatic activity has been identified there and shown to decrease in the nasal mucosa of patients with rhinitis (inflammation), returning to normal after treatment and/or improvement (Grouzmann et al., 2002) .MERS-CoV cell, tissue tropism and receptorTo date, the RBD of MERS-CoV have not undergone noteworthy genetic change, which could indicate that the RBD is not a crucial factor for species adaptation (Barlan et al., 2014) , or that time spent in humans has been too short to see such change develop.", [["nasal mucosa", "ANATOMY", 173, 185], ["cell", "ANATOMY", 318, 322], ["tissue", "ANATOMY", 324, 330], ["rhinitis", "DISEASE", 203, 211], ["inflammation", "DISEASE", 213, 225], ["RBD", "DISEASE", 456, 459], ["DPP4", "GENE_OR_GENE_PRODUCT", 33, 37], ["URT", "CANCER", 45, 48], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 80, 88], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 173, 185], ["patients", "ORGANISM", 189, 197], ["MERS-CoV cell", "CELL", 309, 322], ["tissue", "TISSUE", 324, 330], ["MERS-CoV", "ORGANISM", 371, 379], ["humans", "ORGANISM", 553, 559], ["DPP4", "PROTEIN", 33, 37], ["RBD", "PROTEIN", 364, 367], ["RBD", "PROTEIN", 456, 459], ["patients", "SPECIES", 189, 197], ["humans", "SPECIES", 553, 559], ["MERS-CoV", "SPECIES", 80, 88], ["MERS-CoV", "SPECIES", 371, 379], ["humans", "SPECIES", 553, 559], ["few studies", "TEST", 6, 17], ["DPP4", "TEST", 33, 37], ["CoV", "PROBLEM", 85, 88], ["relevant enzymatic activity", "PROBLEM", 90, 117], ["rhinitis", "PROBLEM", 203, 211], ["inflammation", "PROBLEM", 213, 225], ["treatment", "TREATMENT", 254, 263], ["tissue tropism", "PROBLEM", 324, 338], ["the RBD", "PROBLEM", 452, 459], ["URT", "ANATOMY", 45, 48], ["enzymatic activity", "OBSERVATION", 99, 117], ["decrease", "OBSERVATION_MODIFIER", 157, 165], ["nasal mucosa", "ANATOMY", 173, 185], ["rhinitis", "OBSERVATION", 203, 211], ["inflammation", "OBSERVATION", 213, 225], ["CoV cell", "OBSERVATION", 314, 322], ["tissue tropism", "OBSERVATION", 324, 338]]], ["There is wide genetic diversity among the DPP4 sequences from different animal species, but those with the strongest affinity for MERS-CoV recombinant S protein are more closely related and have the most conservation among 14 amino acids within the human DPP4 sequence predicted to come into contact with the S protein (Barlan et al., 2014) .Animal models and the pathogenesis of MERSAutopsy material is not available from fatal MERS cases however such material reflects mostly late stage disease in patients who received numerous therapies and have spent time under mechanical ventilation (Chan et al., 2013c) .", [["amino acids", "CHEMICAL", 226, 237], ["MERS", "DISEASE", 429, 433], ["amino acids", "CHEMICAL", 226, 237], ["DPP4", "GENE_OR_GENE_PRODUCT", 42, 46], ["MERS-CoV recombinant S protein", "GENE_OR_GENE_PRODUCT", 130, 160], ["amino acids", "AMINO_ACID", 226, 237], ["human", "ORGANISM", 249, 254], ["DPP4", "GENE_OR_GENE_PRODUCT", 255, 259], ["patients", "ORGANISM", 500, 508], ["DPP4 sequences", "DNA", 42, 56], ["MERS-CoV recombinant S protein", "PROTEIN", 130, 160], ["human DPP4 sequence", "PROTEIN", 249, 268], ["S protein", "PROTEIN", 309, 318], ["human", "SPECIES", 249, 254], ["patients", "SPECIES", 500, 508], ["MERS-CoV", "SPECIES", 130, 138], ["human", "SPECIES", 249, 254], ["wide genetic diversity", "PROBLEM", 9, 31], ["the DPP4 sequences", "TEST", 38, 56], ["different animal species", "PROBLEM", 62, 86], ["MERS", "PROBLEM", 130, 134], ["CoV recombinant S protein", "PROBLEM", 135, 160], ["amino acids", "TEST", 226, 237], ["the human DPP4 sequence", "TEST", 245, 268], ["Animal models", "PROBLEM", 342, 355], ["the pathogenesis of MERSAutopsy material", "PROBLEM", 360, 400], ["such material", "PROBLEM", 448, 461], ["mostly late stage disease", "PROBLEM", 471, 496], ["numerous therapies", "TREATMENT", 522, 540], ["mechanical ventilation", "TREATMENT", 567, 589], ["wide", "OBSERVATION_MODIFIER", 9, 13], ["genetic diversity", "OBSERVATION", 14, 31], ["late stage", "OBSERVATION_MODIFIER", 478, 488], ["disease", "OBSERVATION", 489, 496]]], ["Therefore a disease model system is essential to study pathogenesis without the confounding influence of a raft of supportive medical procedures and of pre-existing chronic disease.Small animalsNeither mice nor Syrian hamsters have supported natural MERS-CoV replication (Coleman et al., 2014b; Drosten, 2013) .", [["chronic disease", "DISEASE", 165, 180], ["mice", "ORGANISM", 202, 206], ["Syrian hamsters", "ORGANISM", 211, 226], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 250, 258], ["mice", "SPECIES", 202, 206], ["Syrian hamsters", "SPECIES", 211, 226], ["mice", "SPECIES", 202, 206], ["Syrian hamsters", "SPECIES", 211, 226], ["MERS-CoV", "SPECIES", 250, 258], ["a disease model system", "PROBLEM", 10, 32], ["supportive medical procedures", "TREATMENT", 115, 144], ["pre-existing chronic disease", "PROBLEM", 152, 180], ["Small animals", "PROBLEM", 181, 194], ["disease", "OBSERVATION", 12, 19], ["chronic", "OBSERVATION_MODIFIER", 165, 172], ["disease", "OBSERVATION", 173, 180], ["animals", "OBSERVATION", 187, 194]]], ["To get around the divergence between murine and human DPP4, a mouse model was constructed by introducing a human DPP4 gene ).", [["murine", "ORGANISM", 37, 43], ["human", "ORGANISM", 48, 53], ["DPP4", "GENE_OR_GENE_PRODUCT", 54, 58], ["mouse", "ORGANISM", 62, 67], ["human", "ORGANISM", 107, 112], ["DPP4", "GENE_OR_GENE_PRODUCT", 113, 117], ["murine and human DPP4", "PROTEIN", 37, 58], ["human DPP4 gene", "DNA", 107, 122], ["murine", "SPECIES", 37, 43], ["human", "SPECIES", 48, 53], ["mouse", "SPECIES", 62, 67], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 48, 53], ["mouse", "SPECIES", 62, 67], ["human", "SPECIES", 107, 112], ["murine and human DPP4", "TREATMENT", 37, 58], ["a mouse model", "TREATMENT", 60, 73], ["a human DPP4 gene", "TREATMENT", 105, 122]]], ["An adenoviral vector carrying the gene transduced cells in the mouse airway resulting in animals that were receptive to MERS-CoV infection for 17-22 days.", [["cells", "ANATOMY", 50, 55], ["airway", "ANATOMY", 69, 75], ["infection", "DISEASE", 129, 138], ["adenoviral", "ORGANISM", 3, 13], ["cells", "CELL", 50, 55], ["mouse", "ORGANISM", 63, 68], ["airway", "ORGAN", 69, 75], ["MERS-CoV", "ORGANISM", 120, 128], ["mouse", "SPECIES", 63, 68], ["mouse", "SPECIES", 63, 68], ["MERS-CoV", "SPECIES", 120, 128], ["An adenoviral vector", "TREATMENT", 0, 20], ["the gene transduced cells", "TREATMENT", 30, 55], ["CoV infection", "PROBLEM", 125, 138], ["adenoviral vector", "OBSERVATION", 3, 20], ["transduced cells", "OBSERVATION", 39, 55], ["mouse airway", "ANATOMY", 63, 75]]], ["Infection induced pneumonia in the animals and viral clearance followed 6-8 days after infection .", [["pneumonia", "DISEASE", 18, 27], ["infection", "DISEASE", 87, 96], ["Infection induced pneumonia in the animals", "PROBLEM", 0, 42], ["viral clearance", "TEST", 47, 62], ["infection", "PROBLEM", 87, 96], ["pneumonia", "OBSERVATION", 18, 27], ["infection", "OBSERVATION", 87, 96]]], ["The model found limited cross-protection afforded by prior exposure to SARS-CoV.", [["SARS", "DISEASE", 71, 75], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["SARS-CoV", "SPECIES", 71, 79]]], ["Using this model, a Venezuelan equine encephalitis-based replicon expressing MERS-CoV spike protein was shown to be an efficacious vaccine candidate, producing a protective immune response .", [["encephalitis", "DISEASE", 38, 50], ["Venezuelan", "ORGANISM", 20, 30], ["equine encephalitis", "ORGANISM", 31, 50], ["MERS-CoV", "ORGANISM", 77, 85], ["MERS-CoV spike protein", "PROTEIN", 77, 99], ["Venezuelan equine encephalitis", "SPECIES", 20, 50], ["Venezuelan equine encephalitis", "SPECIES", 20, 50], ["MERS-CoV", "SPECIES", 77, 85], ["this model", "TREATMENT", 6, 16], ["a Venezuelan equine encephalitis", "TREATMENT", 18, 50], ["CoV spike protein", "PROBLEM", 82, 99]]], ["Subsequently a transgenic mouse model was created in which the human DPP4 was globally expressed resulting in a fully permissive model of severe MERS (Agrawal et al., 2015) .", [["MERS", "DISEASE", 145, 149], ["mouse", "ORGANISM", 26, 31], ["human", "ORGANISM", 63, 68], ["DPP4", "GENE_OR_GENE_PRODUCT", 69, 73], ["human DPP4", "PROTEIN", 63, 73], ["mouse", "SPECIES", 26, 31], ["human", "SPECIES", 63, 68], ["mouse", "SPECIES", 26, 31], ["human", "SPECIES", 63, 68], ["a transgenic mouse model", "TREATMENT", 13, 37], ["the human DPP4", "TREATMENT", 59, 73], ["severe MERS", "PROBLEM", 138, 149], ["severe", "OBSERVATION_MODIFIER", 138, 144]]], ["A report of a mouse model for infection by a MERS-CoV close relative, batCoV HKU5, noted that vaccine designs for any emerging CoV should include elements from that particular virus since different members of the same genus are insufficiently similar to elicit immunological crossprotection .", [["infection", "DISEASE", 30, 39], ["mouse", "ORGANISM", 14, 19], ["MERS-CoV", "ORGANISM", 45, 53], ["batCoV HKU5", "ORGANISM", 70, 81], ["CoV", "ORGANISM", 127, 130], ["mouse", "SPECIES", 14, 19], ["mouse", "SPECIES", 14, 19], ["MERS-CoV", "SPECIES", 45, 53], ["batCoV", "SPECIES", 70, 76], ["CoV", "SPECIES", 127, 130], ["infection", "PROBLEM", 30, 39], ["vaccine designs", "TREATMENT", 94, 109], ["any emerging CoV", "PROBLEM", 114, 130], ["particular virus", "PROBLEM", 165, 181], ["infection", "OBSERVATION", 30, 39]]], ["Use of transduced knockout mice revealed that TLR-dependent and IFN-signalling pathways were important for control of MERS-CoV replication .", [["mice", "ORGANISM", 27, 31], ["TLR", "GENE_OR_GENE_PRODUCT", 46, 49], ["IFN", "GENE_OR_GENE_PRODUCT", 64, 67], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 118, 126], ["TLR", "PROTEIN", 46, 49], ["IFN", "PROTEIN", 64, 67], ["mice", "SPECIES", 27, 31], ["mice", "SPECIES", 27, 31], ["MERS-CoV", "SPECIES", 118, 126], ["transduced knockout mice", "TREATMENT", 7, 31], ["IFN", "TREATMENT", 64, 67], ["signalling pathways", "PROBLEM", 68, 87], ["CoV replication", "TREATMENT", 123, 138]]], ["Pre-infection delivery of poly I:C, IFN\u2424 or IFN\u2425 speeded the clearance of MERS-CoV from infected mice and did so more effectively than if poly I:C was given post-infection .", [["poly I:C", "CHEMICAL", 26, 34], ["IFN", "CHEMICAL", 36, 39], ["IFN", "CHEMICAL", 44, 47], ["poly I:C", "CHEMICAL", 138, 146], ["poly I:C", "CHEMICAL", 138, 146], ["poly I:C", "SIMPLE_CHEMICAL", 26, 34], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 36, 40], ["IFN", "GENE_OR_GENE_PRODUCT", 44, 47], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 74, 82], ["mice", "ORGANISM", 97, 101], ["poly I:C", "SIMPLE_CHEMICAL", 138, 146], ["poly I:C", "PROTEIN", 26, 34], ["IFN", "PROTEIN", 36, 39], ["IFN", "PROTEIN", 44, 47], ["mice", "SPECIES", 97, 101], ["MERS-CoV", "SPECIES", 74, 82], ["mice", "SPECIES", 97, 101], ["IFN", "PROBLEM", 44, 47], ["post-infection", "PROBLEM", 157, 171]]], ["IFN\u24232b given with ribavirin improved clinical status and virological control in macaques, in association with reduced systemic and local levels of proinflammatory markers and viral load .", [["IFN\u24232b", "CHEMICAL", 0, 6], ["ribavirin", "CHEMICAL", 18, 27], ["ribavirin", "CHEMICAL", 18, 27], ["IFN\u24232b", "GENE_OR_GENE_PRODUCT", 0, 6], ["ribavirin", "SIMPLE_CHEMICAL", 18, 27], ["macaques", "ORGANISM", 80, 88], ["IFN", "PROTEIN", 0, 3], ["proinflammatory markers", "PROTEIN", 147, 170], ["IFN", "TREATMENT", 0, 3], ["ribavirin", "TREATMENT", 18, 27], ["virological control", "TREATMENT", 57, 76], ["reduced systemic", "PROBLEM", 110, 126], ["proinflammatory markers", "TEST", 147, 170], ["viral load", "TEST", 175, 185], ["viral load", "OBSERVATION", 175, 185]]], ["T-cells were shown to be necessary for virus clearance in mice and immunodominant epitopes attracting CD8 T-cell responses are present in the MERS-CoV S protein ).", [["T-cells", "ANATOMY", 0, 7], ["CD8 T-cell", "ANATOMY", 102, 112], ["T-cells", "CELL", 0, 7], ["mice", "ORGANISM", 58, 62], ["CD8", "GENE_OR_GENE_PRODUCT", 102, 105], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 142, 152], ["T-cells", "CELL_TYPE", 0, 7], ["immunodominant epitopes", "PROTEIN", 67, 90], ["CD8", "PROTEIN", 102, 105], ["MERS-CoV S protein", "PROTEIN", 142, 160], ["mice", "SPECIES", 58, 62], ["mice", "SPECIES", 58, 62], ["MERS-CoV", "SPECIES", 142, 150], ["virus clearance", "PROBLEM", 39, 54], ["immunodominant epitopes", "TEST", 67, 90]]], ["The mouse model has shown that immune-deficient mice succumbed to more severe disease, as do humans with comorbidities that may affect their immune function.Larger animalsTo date the only non-transduced animal model for MERS-CoV infection is the rhesus macaque monkey; an expensive animal to house and work with.", [["MERS-CoV infection", "DISEASE", 220, 238], ["mouse", "ORGANISM", 4, 9], ["mice", "ORGANISM", 48, 52], ["humans", "ORGANISM", 93, 99], ["MERS-CoV", "ORGANISM", 220, 228], ["rhesus", "ORGANISM", 246, 252], ["macaque", "ORGANISM", 253, 260], ["monkey", "ORGANISM", 261, 267], ["mouse", "SPECIES", 4, 9], ["mice", "SPECIES", 48, 52], ["humans", "SPECIES", 93, 99], ["rhesus macaque monkey", "SPECIES", 246, 267], ["mouse", "SPECIES", 4, 9], ["mice", "SPECIES", 48, 52], ["humans", "SPECIES", 93, 99], ["MERS-CoV", "SPECIES", 220, 228], ["rhesus macaque monkey", "SPECIES", 246, 267], ["immune-deficient mice", "PROBLEM", 31, 52], ["more severe disease", "PROBLEM", 66, 85], ["comorbidities", "PROBLEM", 105, 118], ["Larger animals", "PROBLEM", 157, 171], ["MERS", "PROBLEM", 220, 224], ["CoV infection", "PROBLEM", 225, 238], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["disease", "OBSERVATION", 78, 85], ["infection", "OBSERVATION", 229, 238]]], ["A multi-site infection protocol delivered 7 \u00d7 10 6 50% tissue culture infectious doses (TCID 50 ) of MERS-CoV to 6-12 year old macaques via a combination of intranasal, oral, ocular and intratracheal routes attempting to recreate the disease seen in humans (Yao et al., 2014) .", [["tissue", "ANATOMY", 55, 61], ["oral", "ANATOMY", 169, 173], ["ocular", "ANATOMY", 175, 181], ["infection", "DISEASE", 13, 22], ["tissue", "TISSUE", 55, 61], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 101, 109], ["macaques", "ORGANISM", 127, 135], ["oral", "ORGANISM_SUBDIVISION", 169, 173], ["humans", "ORGANISM", 250, 256], ["macaques", "SPECIES", 127, 135], ["humans", "SPECIES", 250, 256], ["MERS-CoV", "SPECIES", 101, 109], ["humans", "SPECIES", 250, 256], ["A multi-site infection protocol", "TREATMENT", 0, 31], ["MERS", "PROBLEM", 101, 105], ["intranasal", "TREATMENT", 157, 167], ["oral, ocular and intratracheal routes", "TREATMENT", 169, 206], ["the disease", "PROBLEM", 230, 241], ["infection", "OBSERVATION", 13, 22], ["ocular", "ANATOMY", 175, 181], ["disease", "OBSERVATION", 234, 241]]], ["This resulted in a transient mild-to-moderate clinical disease, including a leucocytosis, with acute localised-to-widespread radiographic changes consistent with pneumonia .", [["leucocytosis", "DISEASE", 76, 88], ["pneumonia", "DISEASE", 162, 171], ["a transient mild-to-moderate clinical disease", "PROBLEM", 17, 62], ["a leucocytosis", "PROBLEM", 74, 88], ["acute localised-to-widespread radiographic changes", "PROBLEM", 95, 145], ["pneumonia", "PROBLEM", 162, 171], ["transient", "OBSERVATION_MODIFIER", 19, 28], ["mild", "OBSERVATION_MODIFIER", 29, 33], ["-to-moderate", "OBSERVATION_MODIFIER", 33, 45], ["disease", "OBSERVATION", 55, 62], ["leucocytosis", "OBSERVATION", 76, 88], ["acute", "OBSERVATION_MODIFIER", 95, 100], ["localised", "OBSERVATION_MODIFIER", 101, 110], ["widespread", "OBSERVATION_MODIFIER", 114, 124], ["radiographic", "OBSERVATION", 125, 137], ["consistent with", "UNCERTAINTY", 146, 161], ["pneumonia", "OBSERVATION", 162, 171]]], ["Three days after infection, viral RNA was detected in the conjunctiva, nasal mucosa and also at day six in the tonsils, trachea, bronchus, mediastinal lymph nodes and lung, but mostly at reduced levels to those from day three (deWit et al., 2013) .", [["conjunctiva", "ANATOMY", 58, 69], ["nasal mucosa", "ANATOMY", 71, 83], ["tonsils", "ANATOMY", 111, 118], ["trachea", "ANATOMY", 120, 127], ["bronchus", "ANATOMY", 129, 137], ["mediastinal lymph nodes", "ANATOMY", 139, 162], ["lung", "ANATOMY", 167, 171], ["infection", "DISEASE", 17, 26], ["conjunctiva", "ORGAN", 58, 69], ["nasal mucosa", "MULTI-TISSUE_STRUCTURE", 71, 83], ["tonsils", "ORGAN", 111, 118], ["trachea", "MULTI-TISSUE_STRUCTURE", 120, 127], ["bronchus", "MULTI-TISSUE_STRUCTURE", 129, 137], ["mediastinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 139, 162], ["lung", "ORGAN", 167, 171], ["viral RNA", "RNA", 28, 37], ["infection", "PROBLEM", 17, 26], ["viral RNA", "PROBLEM", 28, 37], ["trachea, bronchus, mediastinal lymph nodes and lung", "PROBLEM", 120, 171], ["infection", "OBSERVATION", 17, 26], ["viral RNA", "OBSERVATION", 28, 37], ["conjunctiva", "ANATOMY", 58, 69], ["nasal mucosa", "ANATOMY", 71, 83], ["tonsils", "ANATOMY", 111, 118], ["trachea", "ANATOMY", 120, 127], ["bronchus", "ANATOMY", 129, 137], ["mediastinal", "ANATOMY", 139, 150], ["lymph nodes", "OBSERVATION", 151, 162], ["lung", "ANATOMY", 167, 171]]], ["By day six, virus was mostly undetectable in the URT, generally decreasing in quantity by day three and at its highest load one day after inoculation (deWit et al., 2013) .", [["virus", "PROBLEM", 12, 17], ["mostly", "OBSERVATION_MODIFIER", 22, 28], ["undetectable", "OBSERVATION", 29, 41], ["URT", "ANATOMY", 49, 52], ["generally", "OBSERVATION_MODIFIER", 54, 63], ["decreasing", "OBSERVATION_MODIFIER", 64, 74]]], ["This is much shorter than has been found when serial samples from a human case were analysed (Kraaij-Dirkzwager et al., 2014) .", [["samples", "ANATOMY", 53, 60], ["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["serial samples", "TEST", 46, 60]]], ["Shedding from the respiratory tract continued until day six in two of three macaques (deWit et al., 2013) .", [["respiratory tract", "ANATOMY", 18, 35], ["respiratory tract", "ORGANISM_SUBDIVISION", 18, 35], ["macaques", "ORGANISM", 76, 84], ["Shedding from the respiratory tract", "PROBLEM", 0, 35], ["respiratory tract", "ANATOMY", 18, 35]]], ["Levels of viral RNA remained high in BAL samples on day one and three (deWit et al., 2013) .", [["BAL samples", "ANATOMY", 37, 48], ["viral RNA", "RNA", 10, 19], ["Levels", "TEST", 0, 6], ["viral RNA", "TEST", 10, 19], ["viral RNA", "OBSERVATION", 10, 19], ["high", "OBSERVATION_MODIFIER", 29, 33]]], ["Virus or viral RNA was not found in the kidney, nor were pathological kidney changes or kidney failure noted among macaques (deWit et al., 2013; Yao et al., 2014) .", [["kidney", "ANATOMY", 40, 46], ["kidney", "ANATOMY", 70, 76], ["kidney", "ANATOMY", 88, 94], ["kidney failure", "DISEASE", 88, 102], ["Virus", "ORGANISM", 0, 5], ["kidney", "ORGAN", 40, 46], ["kidney", "ORGAN", 70, 76], ["kidney", "ORGAN", 88, 94], ["macaques", "ORGANISM", 115, 123], ["viral RNA", "RNA", 9, 18], ["Virus", "PROBLEM", 0, 5], ["viral RNA", "PROBLEM", 9, 18], ["pathological kidney changes", "PROBLEM", 57, 84], ["kidney failure", "PROBLEM", 88, 102], ["viral RNA", "OBSERVATION", 9, 18], ["kidney", "ANATOMY", 40, 46], ["kidney", "ANATOMY", 70, 76], ["kidney", "ANATOMY", 88, 94], ["failure", "OBSERVATION", 95, 102]]], ["Microarray analysis of MERS-CoV infected macaque samples identified a rapid innate immune activation with increased expression of genes involved in proinflammatory processes and cell recruitment including interleukin 6 (IL-6), chemokine C-X-C ligand 1 (CXCL1) and matrix metalloproteinase 9 (MMP9) (deWit et al., 2013) .", [["samples", "ANATOMY", 49, 56], ["cell", "ANATOMY", 178, 182], ["MERS-CoV", "ORGANISM", 23, 31], ["macaque", "ORGANISM", 41, 48], ["cell", "CELL", 178, 182], ["interleukin 6", "GENE_OR_GENE_PRODUCT", 205, 218], ["IL-6", "GENE_OR_GENE_PRODUCT", 220, 224], ["chemokine C-X-C ligand 1", "GENE_OR_GENE_PRODUCT", 227, 251], ["CXCL1", "GENE_OR_GENE_PRODUCT", 253, 258], ["matrix metalloproteinase 9", "GENE_OR_GENE_PRODUCT", 264, 290], ["MMP9", "GENE_OR_GENE_PRODUCT", 292, 296], ["interleukin 6 (IL-6", "PROTEIN", 205, 224], ["chemokine C-X-C ligand 1", "PROTEIN", 227, 251], ["CXCL1", "PROTEIN", 253, 258], ["matrix metalloproteinase 9", "PROTEIN", 264, 290], ["MMP9", "PROTEIN", 292, 296], ["CoV infected macaque", "SPECIES", 28, 48], ["MERS-CoV", "SPECIES", 23, 31], ["Microarray analysis", "TEST", 0, 19], ["MERS", "PROBLEM", 23, 27], ["CoV infected macaque samples", "PROBLEM", 28, 56], ["a rapid innate immune activation", "PROBLEM", 68, 100], ["increased expression of genes", "PROBLEM", 106, 135], ["proinflammatory processes", "PROBLEM", 148, 173], ["cell recruitment", "TREATMENT", 178, 194], ["interleukin", "TEST", 205, 216], ["IL", "TEST", 220, 222], ["chemokine C", "TEST", 227, 238], ["CXCL1", "TEST", 253, 258], ["matrix metalloproteinase", "TEST", 264, 288], ["proinflammatory processes", "OBSERVATION", 148, 173], ["cell recruitment", "OBSERVATION", 178, 194]]], ["By day six post inoculation, gene expression in macaque peripheral blood mononuclear cells and lung had returned to baseline (deWit et al., 2013) .", [["peripheral blood mononuclear cells", "ANATOMY", 56, 90], ["lung", "ANATOMY", 95, 99], ["macaque", "ORGANISM", 48, 55], ["peripheral blood mononuclear cells", "CELL", 56, 90], ["lung", "ORGAN", 95, 99], ["macaque peripheral blood mononuclear cells", "CELL_TYPE", 48, 90], ["inoculation", "TREATMENT", 16, 27], ["gene expression", "TEST", 29, 44], ["macaque peripheral blood mononuclear cells", "TEST", 48, 90], ["macaque", "ANATOMY_MODIFIER", 48, 55], ["peripheral", "ANATOMY_MODIFIER", 56, 66], ["blood", "ANATOMY", 67, 72], ["mononuclear cells", "OBSERVATION", 73, 90], ["lung", "ANATOMY", 95, 99]]], ["While the viral dosage and spread of delivery may be unrealistic, we have since learned that much milder disease is not uncommon among MERS-CoV-positive humans, especially those who are younger and do not have underlying comorbidities.", [["MERS-CoV", "ORGANISM", 135, 143], ["humans", "ORGANISM", 153, 159], ["humans", "SPECIES", 153, 159], ["MERS-CoV", "SPECIES", 135, 143], ["humans", "SPECIES", 153, 159], ["the viral dosage", "TREATMENT", 6, 22], ["delivery", "TREATMENT", 37, 45], ["much milder disease", "PROBLEM", 93, 112], ["underlying comorbidities", "PROBLEM", 210, 234], ["viral dosage", "OBSERVATION", 10, 22]]], ["The macaque model fulfilled the need to see a purified viral preparation produce disease akin to that seen among some human cases .", [["macaque", "ORGANISM", 4, 11], ["human", "ORGANISM", 118, 123], ["human", "SPECIES", 118, 123], ["human", "SPECIES", 118, 123], ["a purified viral preparation", "TREATMENT", 44, 72], ["disease akin", "PROBLEM", 81, 93]]], ["The direct LRT component of virus delivery in this model likely reflects some proportion of the human route of virus acquisition and some of the notable human disease involving the LRT.", [["human", "ORGANISM", 96, 101], ["human", "ORGANISM", 153, 158], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 153, 158], ["The direct LRT component", "TREATMENT", 0, 24], ["virus delivery", "TREATMENT", 28, 42], ["virus acquisition", "TEST", 111, 128], ["the notable human disease", "PROBLEM", 141, 166], ["virus", "OBSERVATION", 28, 33], ["notable", "OBSERVATION_MODIFIER", 145, 152], ["human disease", "OBSERVATION", 153, 166]]], ["However, it may also bias against study of any potential URT response to first contact between virus and host and therefore overlook routes of ingress and the length and nature of the prodrome.", [["URT", "CANCER", 57, 60], ["virus and host", "TREATMENT", 95, 109], ["the prodrome", "PROBLEM", 180, 192]]], ["While MERS-CoV is believed to the cause of MERS in humans, such causality can only be extrapolated from these studies in the macaque model .The immunobiology of MERS-CoV in tissue and cell cultureMERS-CoV and SARS-CoV were compared using human airway epithelial (HAE) cultures.", [["tissue", "ANATOMY", 173, 179], ["cell", "ANATOMY", 184, 188], ["airway epithelial", "ANATOMY", 244, 261], ["HAE", "ANATOMY", 263, 266], ["cultures", "ANATOMY", 268, 276], ["MERS", "DISEASE", 43, 47], ["HAE", "DISEASE", 263, 266], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["humans", "ORGANISM", 51, 57], ["macaque", "ORGANISM", 125, 132], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["tissue", "TISSUE", 173, 179], ["cell", "CELL", 184, 188], ["cultureMERS-CoV", "ORGANISM", 189, 204], ["SARS-CoV", "ORGANISM", 209, 217], ["human", "ORGANISM", 238, 243], ["airway epithelial (HAE) cultures", "CELL", 244, 276], ["human airway epithelial (HAE) cultures", "CELL_LINE", 238, 276], ["humans", "SPECIES", 51, 57], ["human", "SPECIES", 238, 243], ["MERS-CoV", "SPECIES", 6, 14], ["humans", "SPECIES", 51, 57], ["MERS-CoV", "SPECIES", 161, 169], ["SARS-CoV", "SPECIES", 209, 217], ["human", "SPECIES", 238, 243], ["these studies", "TEST", 104, 117], ["CoV in tissue", "PROBLEM", 166, 179], ["cell cultureMERS", "TEST", 184, 200], ["CoV", "PROBLEM", 201, 204], ["SARS", "PROBLEM", 209, 213], ["CoV", "PROBLEM", 214, 217], ["human airway epithelial (HAE) cultures", "TEST", 238, 276], ["MERS", "OBSERVATION", 43, 47], ["airway epithelial", "ANATOMY", 244, 261]]], ["These comprised bronchial epithelial cells that had been differentiated at the air liquid interface to contain basal, secretory, columnar and ciliated cells that generated mucous (Kindler et al., 2013) .", [["bronchial epithelial cells", "ANATOMY", 16, 42], ["secretory", "ANATOMY", 118, 127], ["columnar", "ANATOMY", 129, 137], ["ciliated cells", "ANATOMY", 142, 156], ["mucous", "ANATOMY", 172, 178], ["bronchial epithelial cells", "CELL", 16, 42], ["columnar", "CELL", 129, 137], ["ciliated cells", "CELL", 142, 156], ["mucous", "TISSUE", 172, 178], ["bronchial epithelial cells", "CELL_TYPE", 16, 42], ["basal, secretory, columnar and ciliated cells", "CELL_TYPE", 111, 156], ["These comprised bronchial epithelial cells", "PROBLEM", 0, 42], ["basal, secretory, columnar and ciliated cells", "PROBLEM", 111, 156], ["bronchial", "ANATOMY", 16, 25], ["epithelial cells", "OBSERVATION", 26, 42], ["air liquid interface", "OBSERVATION", 79, 99], ["basal", "ANATOMY_MODIFIER", 111, 116], ["columnar", "ANATOMY_MODIFIER", 129, 137], ["ciliated cells", "OBSERVATION", 142, 156], ["mucous", "ANATOMY", 172, 178]]], ["This system aimed to recreate the main epithelial lining which is possibly the site of first contact between host and MERS-CoV (Kindler et al., 2013) .", [["epithelial lining", "ANATOMY", 39, 56], ["epithelial lining", "TISSUE", 39, 56], ["MERS-CoV", "ORGANISM", 118, 126], ["MERS-CoV", "SPECIES", 118, 126], ["main", "OBSERVATION_MODIFIER", 34, 38], ["epithelial lining", "OBSERVATION", 39, 56]]], ["Pre-treatment of cultures with interferon \u2423 (IFN\u2423) and IFN\u24253 proved effective at reducing the replication of MERS-CoV, SARS-CoV and HCoV-229E (Kindler et al., 2013) .", [["interferon \u2423", "GENE_OR_GENE_PRODUCT", 31, 43], ["IFN", "GENE_OR_GENE_PRODUCT", 45, 48], ["IFN\u24253", "GENE_OR_GENE_PRODUCT", 55, 60], ["MERS-CoV", "ORGANISM", 109, 117], ["SARS-CoV", "ORGANISM", 119, 127], ["HCoV-229E", "ORGANISM", 132, 141], ["interferon \u2423", "PROTEIN", 31, 43], ["IFN", "PROTEIN", 45, 48], ["IFN", "PROTEIN", 55, 58], ["MERS-CoV", "SPECIES", 109, 117], ["SARS-CoV", "SPECIES", 119, 127], ["HCoV-229E", "SPECIES", 132, 141], ["cultures", "TEST", 17, 25], ["interferon", "TEST", 31, 41], ["IFN", "TEST", 55, 58], ["SARS", "PROBLEM", 119, 123], ["HCoV", "TEST", 132, 136]]], ["When IFN\u2423 or IFN\u2424 was added to ex vivo bronchial or lung tissues one hour after MERS-CoV infection, virus titre and RNA levels decreased more noticeably for MERS-CoV than for SARS-CoV and MERS-CoV also elicited a comparatively poor proinflammatory and cytokine response, but to the same extent as when pre-treated (Chan et al., 2013c) .", [["bronchial", "ANATOMY", 39, 48], ["lung tissues", "ANATOMY", 52, 64], ["IFN", "CHEMICAL", 5, 8], ["IFN", "CHEMICAL", 13, 16], ["SARS", "DISEASE", 175, 179], ["IFN\u2423", "GENE_OR_GENE_PRODUCT", 5, 9], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 13, 17], ["bronchial", "TISSUE", 39, 48], ["lung tissues", "TISSUE", 52, 64], ["MERS-CoV", "ORGANISM", 80, 88], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 157, 165], ["SARS-CoV", "ORGANISM", 175, 183], ["MERS-CoV", "ORGANISM", 188, 196], ["IFN", "PROTEIN", 5, 8], ["IFN", "PROTEIN", 13, 16], ["cytokine", "PROTEIN", 252, 260], ["MERS-CoV", "SPECIES", 80, 88], ["MERS-CoV", "SPECIES", 157, 165], ["SARS-CoV", "SPECIES", 175, 183], ["MERS-CoV", "SPECIES", 188, 196], ["IFN\u2424", "TREATMENT", 13, 17], ["MERS", "PROBLEM", 80, 84], ["CoV infection", "PROBLEM", 85, 98], ["virus titre", "TEST", 100, 111], ["RNA levels", "TEST", 116, 126], ["MERS", "PROBLEM", 157, 161], ["SARS", "PROBLEM", 175, 179], ["CoV", "PROBLEM", 180, 183], ["CoV", "PROBLEM", 193, 196], ["a comparatively poor proinflammatory and cytokine response", "PROBLEM", 211, 269], ["bronchial", "ANATOMY", 39, 48], ["lung", "ANATOMY", 52, 56], ["infection", "OBSERVATION", 89, 98]]], ["MERS-CoV failed to induce IFN\u2424 or tumour necrosis factor alpha (TNF\u2423) or to upregulate IL-1\u2424, MCP-1 or regulated on activation, normal T-cell expressed and secreted (RANTES) mRNA (Chan et al., 2013c) .", [["T-cell", "ANATOMY", 135, 141], ["necrosis", "DISEASE", 41, 49], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 26, 30], ["tumour necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 34, 62], ["TNF\u2423", "GENE_OR_GENE_PRODUCT", 64, 68], ["IL-1\u2424", "GENE_OR_GENE_PRODUCT", 87, 92], ["MCP-1", "GENE_OR_GENE_PRODUCT", 94, 99], ["T-cell", "CELL", 135, 141], ["RANTES", "GENE_OR_GENE_PRODUCT", 166, 172], ["IFN", "PROTEIN", 26, 29], ["tumour necrosis factor alpha", "PROTEIN", 34, 62], ["TNF", "PROTEIN", 64, 67], ["IL-1", "PROTEIN", 87, 91], ["MCP-1", "PROTEIN", 94, 99], ["RANTES) mRNA", "RNA", 166, 178], ["MERS-CoV", "SPECIES", 0, 8], ["IFN\u2424", "PROBLEM", 26, 30], ["tumour necrosis", "PROBLEM", 34, 49], ["alpha (TNF\u2423", "TEST", 57, 68], ["IL", "TEST", 87, 89], ["MCP", "TEST", 94, 97], ["tumour", "OBSERVATION_MODIFIER", 34, 40], ["necrosis", "OBSERVATION", 41, 49]]], ["However, MERS-CoV was perhaps a better replicator in these tissues than SARS-CoV and it's targeting of Type I and Type II alveolar cells within the lungs indicated its potential to hinder lung regeneration after infection, since Type II cells are important for repair (Chan et al., 2013c) .", [["tissues", "ANATOMY", 59, 66], ["Type II alveolar cells", "ANATOMY", 114, 136], ["lungs", "ANATOMY", 148, 153], ["lung", "ANATOMY", 188, 192], ["Type II cells", "ANATOMY", 229, 242], ["infection", "DISEASE", 212, 221], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 9, 17], ["tissues", "TISSUE", 59, 66], ["SARS-CoV", "ORGANISM", 72, 80], ["Type I", "GENE_OR_GENE_PRODUCT", 103, 109], ["Type II alveolar cells", "CELL", 114, 136], ["lungs", "ORGAN", 148, 153], ["lung", "ORGAN", 188, 192], ["Type II cells", "CELL", 229, 242], ["MERS", "PROTEIN", 9, 13], ["Type I and Type II alveolar cells", "CELL_TYPE", 103, 136], ["Type II cells", "CELL_TYPE", 229, 242], ["MERS-CoV", "SPECIES", 9, 17], ["SARS-CoV", "SPECIES", 72, 80], ["MERS-CoV", "PROBLEM", 9, 17], ["SARS-CoV", "PROBLEM", 72, 80], ["Type I and Type II alveolar cells within the lungs", "PROBLEM", 103, 153], ["hinder lung regeneration", "PROBLEM", 181, 205], ["infection", "PROBLEM", 212, 221], ["Type II cells", "PROBLEM", 229, 242], ["repair", "TREATMENT", 261, 267], ["alveolar cells", "OBSERVATION", 122, 136], ["lungs", "ANATOMY", 148, 153], ["lung", "ANATOMY", 188, 192], ["regeneration", "OBSERVATION", 193, 205], ["infection", "OBSERVATION", 212, 221]]], ["By comparison, HCoV-229E, a generally more mild pathogen, did not replicate in lung tissue while influenza A(H5N1) virus, known to be associated with viral pneumonia, did (Chan et al., 2013c) .The immunobiology of MERS-CoV in tissue and cell cultureFurther immunobiological analysis using cell lines supported that MERS-CoV grows better, but is more sensitive to IFN\u2424, than SARS-CoV.", [["lung tissue", "ANATOMY", 79, 90], ["tissue", "ANATOMY", 226, 232], ["cell", "ANATOMY", 237, 241], ["cell lines", "ANATOMY", 289, 299], ["HCoV-229E", "CHEMICAL", 15, 24], ["influenza A(H5N1) virus", "DISEASE", 97, 120], ["viral pneumonia", "DISEASE", 150, 165], ["SARS", "DISEASE", 374, 378], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 15, 24], ["lung tissue", "TISSUE", 79, 90], ["influenza A(H5N1) virus", "ORGANISM", 97, 120], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 214, 222], ["tissue", "TISSUE", 226, 232], ["cell", "CELL", 237, 241], ["cell lines", "CELL", 289, 299], ["MERS-CoV", "ORGANISM", 315, 323], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 363, 367], ["SARS-CoV", "ORGANISM", 374, 382], ["MERS", "PROTEIN", 214, 218], ["cell lines", "CELL_LINE", 289, 299], ["IFN\u2424", "PROTEIN", 363, 367], ["influenza A(H5N1", "SPECIES", 97, 113], ["HCoV-229E", "SPECIES", 15, 24], ["influenza A(H5N1) virus", "SPECIES", 97, 120], ["MERS-CoV", "SPECIES", 214, 222], ["MERS-CoV", "SPECIES", 315, 323], ["SARS-CoV", "SPECIES", 374, 382], ["HCoV", "TEST", 15, 19], ["a generally more mild pathogen", "PROBLEM", 26, 56], ["influenza A(H5N1) virus", "PROBLEM", 97, 120], ["viral pneumonia", "PROBLEM", 150, 165], ["CoV in tissue", "PROBLEM", 219, 232], ["cell cultureFurther immunobiological analysis", "TEST", 237, 282], ["cell lines", "TREATMENT", 289, 299], ["mild", "OBSERVATION_MODIFIER", 43, 47], ["pathogen", "OBSERVATION", 48, 56], ["lung", "ANATOMY", 79, 83], ["viral", "OBSERVATION_MODIFIER", 150, 155], ["pneumonia", "OBSERVATION", 156, 165], ["cell lines", "OBSERVATION", 289, 299]]], ["MERS-CoV is also a very weak inducer of IFN, most likely through an immune dampening effect that both it and SARS-CoV mediate via retention of interferon regulatory factor 3 (IRF-3) in the cytoplasm of infected cells (Zielecki et al., 2013) .", [["cytoplasm", "ANATOMY", 189, 198], ["cells", "ANATOMY", 211, 216], ["MERS-CoV", "ORGANISM", 0, 8], ["IFN", "GENE_OR_GENE_PRODUCT", 40, 43], ["SARS-CoV", "ORGANISM", 109, 117], ["interferon regulatory factor 3", "GENE_OR_GENE_PRODUCT", 143, 173], ["IRF-3", "GENE_OR_GENE_PRODUCT", 175, 180], ["cytoplasm", "ORGANISM_SUBSTANCE", 189, 198], ["cells", "CELL", 211, 216], ["MERS-CoV", "PROTEIN", 0, 8], ["IFN", "PROTEIN", 40, 43], ["interferon regulatory factor 3", "PROTEIN", 143, 173], ["IRF-3", "PROTEIN", 175, 180], ["infected cells", "CELL_TYPE", 202, 216], ["MERS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 109, 117], ["a very weak inducer of IFN", "PROBLEM", 17, 43], ["an immune dampening effect", "PROBLEM", 65, 91], ["SARS", "PROBLEM", 109, 113], ["interferon regulatory factor", "TREATMENT", 143, 171], ["IRF", "TEST", 175, 178], ["infected cells", "PROBLEM", 202, 216], ["very weak", "OBSERVATION_MODIFIER", 19, 28], ["most likely", "UNCERTAINTY", 45, 56], ["infected cells", "OBSERVATION", 202, 216]]], ["MERS-CoV was again shown to be more sensitive to IFN\u2424, although this was based on pre-treatment of cells, a situation that does not mimic clinical reality for human cases of MERS (Zielecki et al., 2013) .", [["cells", "ANATOMY", 99, 104], ["MERS", "DISEASE", 174, 178], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 49, 53], ["cells", "CELL", 99, 104], ["human", "ORGANISM", 159, 164], ["IFN\u2424", "PROTEIN", 49, 53], ["human", "SPECIES", 159, 164], ["MERS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 159, 164]]], ["Kindler et al. noted that the comparatively limited transcriptional response after infection of HAE cultures by any CoV, with no induction of IFN\u2424 and only mild induction of proinflammatory cytokines, may mean that MERS-CoV is already adapted to growing in these cells (Kindler et al., 2013) .", [["HAE cultures", "ANATOMY", 96, 108], ["cells", "ANATOMY", 263, 268], ["infection", "DISEASE", 83, 92], ["HAE", "DISEASE", 96, 99], ["HAE cultures", "CELL", 96, 108], ["CoV", "ORGANISM", 116, 119], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 142, 146], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 215, 223], ["cells", "CELL", 263, 268], ["HAE cultures", "CELL_LINE", 96, 108], ["IFN", "PROTEIN", 142, 145], ["proinflammatory cytokines", "PROTEIN", 174, 199], ["MERS", "PROTEIN", 215, 219], ["MERS-CoV", "SPECIES", 215, 223], ["HAE cultures", "TEST", 96, 108], ["any CoV", "TEST", 112, 119], ["IFN", "TREATMENT", 142, 145], ["proinflammatory cytokines", "PROBLEM", 174, 199], ["MERS-CoV", "PROBLEM", 215, 223], ["mild", "OBSERVATION_MODIFIER", 156, 160], ["proinflammatory cytokines", "OBSERVATION", 174, 199]]], ["Professional cytokine-producing cells such as plasmacytoid and conventional dendritic cells and macrophages were lacking in the HAE system but were present in the ex vivo tissues above.", [["cells", "ANATOMY", 32, 37], ["plasmacytoid", "ANATOMY", 46, 58], ["dendritic cells", "ANATOMY", 76, 91], ["macrophages", "ANATOMY", 96, 107], ["tissues", "ANATOMY", 171, 178], ["HAE", "DISEASE", 128, 131], ["cells", "CELL", 32, 37], ["plasmacytoid", "CELL", 46, 58], ["dendritic cells", "CELL", 76, 91], ["macrophages", "CELL", 96, 107], ["tissues", "TISSUE", 171, 178], ["cytokine", "PROTEIN", 13, 21], ["plasmacytoid and conventional dendritic cells", "CELL_TYPE", 46, 91], ["macrophages", "CELL_TYPE", 96, 107], ["Professional cytokine-producing cells", "TREATMENT", 0, 37], ["plasmacytoid and conventional dendritic cells", "TREATMENT", 46, 91], ["macrophages", "PROBLEM", 96, 107], ["lacking in the HAE system", "PROBLEM", 113, 138], ["dendritic cells", "OBSERVATION", 76, 91]]], ["These cells are needed to see the full extent of the immune response to CoVs (Kindler et al., 2013) .", [["cells", "ANATOMY", 6, 11], ["cells", "CELL", 6, 11], ["CoVs", "SIMPLE_CHEMICAL", 72, 76]]], ["Use of an embryonal lung fibroblast cell line (HFL), to allow growth of HCoV-229E, identified more IFN\u2424 and IP-10 induction than that by MERS-CoV.", [["embryonal lung fibroblast cell line", "ANATOMY", 10, 45], ["HFL", "ANATOMY", 47, 50], ["HCoV-229E", "ANATOMY", 72, 81], ["embryonal lung fibroblast cell line", "CELL", 10, 45], ["HFL", "CELL", 47, 50], ["HCoV-229E", "CELL", 72, 81], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 99, 103], ["IP-10", "GENE_OR_GENE_PRODUCT", 108, 113], ["MERS-CoV", "ORGANISM", 137, 145], ["embryonal lung fibroblast cell line", "CELL_LINE", 10, 45], ["HFL", "CELL_LINE", 47, 50], ["IFN", "PROTEIN", 99, 102], ["HCoV-229E", "SPECIES", 72, 81], ["MERS-CoV", "SPECIES", 137, 145], ["an embryonal lung fibroblast cell line", "TREATMENT", 7, 45], ["HCoV", "TEST", 72, 76], ["IP", "TREATMENT", 108, 110], ["embryonal", "OBSERVATION_MODIFIER", 10, 19], ["lung", "ANATOMY", 20, 24], ["fibroblast cell line", "OBSERVATION", 25, 45]]], ["In polarised Calu-3 cells, MERS-CoV and SARS-CoV differed in their elicitation of cytokine gene transcription (Lau et al., 2013) .", [["Calu-3 cells", "ANATOMY", 13, 25], ["Calu-3 cells", "CELL", 13, 25], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["SARS-CoV", "ORGANISM", 40, 48], ["polarised Calu-3 cells", "CELL_LINE", 3, 25], ["cytokine gene", "DNA", 82, 95], ["MERS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 40, 48], ["MERS", "PROBLEM", 27, 31], ["SARS", "PROBLEM", 40, 44], ["cytokine gene transcription", "TREATMENT", 82, 109]]], ["In a three-way virus comparison of MERS-CoV, SARS-CoV and HCoV-229E, 15 cellular mRNAs were analysed in response to type I IFN and type III IFN and CoV infection (Kindler et al., 2013) .", [["cellular", "ANATOMY", 72, 80], ["CoV infection", "DISEASE", 148, 161], ["MERS-CoV", "ORGANISM", 35, 43], ["SARS-CoV", "ORGANISM", 45, 53], ["HCoV-229E", "CELL", 58, 67], ["cellular", "CELL", 72, 80], ["type I IFN", "GENE_OR_GENE_PRODUCT", 116, 126], ["type III IFN", "GENE_OR_GENE_PRODUCT", 131, 143], ["CoV", "ORGANISM", 148, 151], ["MERS-CoV, SARS-CoV and HCoV-229E", "DNA", 35, 67], ["cellular mRNAs", "RNA", 72, 86], ["type I IFN", "PROTEIN", 116, 126], ["MERS-CoV", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 45, 53], ["HCoV-229E", "SPECIES", 58, 67], ["MERS", "TEST", 35, 39], ["CoV", "TEST", 40, 43], ["SARS", "TEST", 45, 49], ["CoV", "TEST", 50, 53], ["HCoV", "TEST", 58, 62], ["cellular mRNAs", "TEST", 72, 86], ["type I IFN", "PROBLEM", 116, 126], ["type III IFN", "PROBLEM", 131, 143], ["CoV infection", "PROBLEM", 148, 161], ["CoV", "OBSERVATION_MODIFIER", 148, 151], ["infection", "OBSERVATION", 152, 161]]], ["Proinflammatory gene (IL-1\u2424, IL-6 and IL-8) mRNA (and IL-8 protein) levels were increased in MERS-CoV infections compared to SARS-CoV, while innate antiviral genes (TNF\u2423, IFN\u2424 [and protein] and IP-10) were comparatively decreased from 30 h post-infection (Lau et al., 2013) .", [["infections", "DISEASE", 102, 112], ["SARS", "DISEASE", 125, 129], ["infection", "DISEASE", 245, 254], ["IL-1\u2424", "GENE_OR_GENE_PRODUCT", 22, 27], ["IL-6", "GENE_OR_GENE_PRODUCT", 29, 33], ["IL-8", "GENE_OR_GENE_PRODUCT", 38, 42], ["IL-8", "GENE_OR_GENE_PRODUCT", 54, 58], ["MERS-CoV", "ORGANISM", 93, 101], ["SARS-CoV", "ORGANISM", 125, 133], ["TNF\u2423", "GENE_OR_GENE_PRODUCT", 165, 169], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 171, 175], ["IP-10", "GENE_OR_GENE_PRODUCT", 194, 199], ["innate antiviral genes", "DNA", 141, 163], ["TNF", "PROTEIN", 165, 168], ["IFN", "PROTEIN", 171, 174], ["MERS-CoV", "SPECIES", 93, 101], ["SARS-CoV", "SPECIES", 125, 133], ["Proinflammatory gene", "TEST", 0, 20], ["IL", "TEST", 22, 24], ["IL", "TEST", 29, 31], ["IL", "TEST", 38, 40], ["mRNA", "TEST", 44, 48], ["IL", "TEST", 54, 56], ["levels", "TEST", 68, 74], ["MERS", "PROBLEM", 93, 97], ["CoV infections", "PROBLEM", 98, 112], ["SARS", "PROBLEM", 125, 129], ["CoV", "TEST", 130, 133], ["innate antiviral genes", "TEST", 141, 163], ["TNF", "TEST", 165, 168], ["IFN\u2424", "TEST", 171, 175], ["protein", "TEST", 181, 188], ["IP", "TEST", 194, 196], ["infection", "PROBLEM", 245, 254], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["CoV infections", "OBSERVATION", 98, 112], ["infection", "OBSERVATION", 245, 254]]], ["Apart from a reduced innate antiviral response, timing of the response also differed, with MERS-CoV appearing to delay cytokine induction.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["cytokine", "PROTEIN", 119, 127], ["MERS-CoV", "SPECIES", 91, 99], ["a reduced innate antiviral response", "PROBLEM", 11, 46], ["delay cytokine induction", "TREATMENT", 113, 137], ["reduced", "OBSERVATION_MODIFIER", 13, 20], ["innate antiviral response", "OBSERVATION", 21, 46]]], ["MERS-CoV produced less IL-8 or IFN\u2424 at 48 h compared to SARS-CoV.", [["SARS", "DISEASE", 56, 60], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["IL-8", "GENE_OR_GENE_PRODUCT", 23, 27], ["IFN", "GENE_OR_GENE_PRODUCT", 31, 34], ["SARS-CoV", "ORGANISM", 56, 64], ["IL-8", "PROTEIN", 23, 27], ["IFN", "PROTEIN", 31, 34], ["MERS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 56, 64]]], ["SARS-CoV also grew less efficiently and destructively than MERS-CoV in Calu-3 cells, as it did in primary bronchial and primary kidney cells and it took longer to reach peak viral production (Eckerle et al., 2013; Kindler et al., 2013) .The immunobiology of MERS-CoV in tissue and cell cultureThe growth of MERS-CoV and SARS-CoV was also compared in cell cultures including primary undifferentiated human tracheobronchial epithelial cells (HTBE), Calu-3, Vero, human embryonic kidney (293) and in A549 cells.", [["Calu-3 cells", "ANATOMY", 71, 83], ["primary bronchial", "ANATOMY", 98, 115], ["kidney cells", "ANATOMY", 128, 140], ["tissue", "ANATOMY", 270, 276], ["cell culture", "ANATOMY", 281, 293], ["cell cultures", "ANATOMY", 350, 363], ["tracheobronchial epithelial cells", "ANATOMY", 405, 438], ["HTBE", "ANATOMY", 440, 444], ["Calu-3", "ANATOMY", 447, 453], ["Vero", "ANATOMY", 455, 459], ["embryonic kidney", "ANATOMY", 467, 483], ["293", "ANATOMY", 485, 488], ["A549 cells", "ANATOMY", 497, 507], ["SARS", "DISEASE", 0, 4], ["SARS-CoV", "ORGANISM", 0, 8], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 59, 67], ["Calu-3 cells", "CELL", 71, 83], ["kidney cells", "CELL", 128, 140], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 258, 266], ["tissue", "TISSUE", 270, 276], ["cell", "CELL", 281, 285], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 307, 315], ["SARS-CoV", "ORGANISM", 320, 328], ["cell cultures", "CELL", 350, 363], ["human", "ORGANISM", 399, 404], ["tracheobronchial epithelial cells", "CELL", 405, 438], ["HTBE", "CELL", 440, 444], ["Calu-3", "CELL", 447, 453], ["Vero", "CELL", 455, 459], ["human", "ORGANISM", 461, 466], ["embryonic kidney", "CELL", 467, 483], ["293", "CELL", 485, 488], ["A549 cells", "CELL", 497, 507], ["Calu-3 cells", "CELL_LINE", 71, 83], ["primary bronchial and primary kidney cells", "CELL_TYPE", 98, 140], ["cell cultures", "CELL_LINE", 350, 363], ["primary undifferentiated human tracheobronchial epithelial cells", "CELL_TYPE", 374, 438], ["HTBE", "CELL_LINE", 440, 444], ["Calu-3", "CELL_LINE", 447, 453], ["Vero", "CELL_LINE", 455, 459], ["human embryonic kidney (293", "CELL_LINE", 461, 488], ["A549 cells", "CELL_LINE", 497, 507], ["human", "SPECIES", 399, 404], ["human", "SPECIES", 461, 466], ["SARS-CoV", "SPECIES", 0, 8], ["MERS-CoV", "SPECIES", 59, 67], ["MERS-CoV", "SPECIES", 258, 266], ["MERS-CoV", "SPECIES", 307, 315], ["SARS-CoV", "SPECIES", 320, 328], ["human", "SPECIES", 399, 404], ["human", "SPECIES", 461, 466], ["SARS-CoV", "TEST", 0, 8], ["CoV in Calu", "TEST", 64, 75], ["primary bronchial and primary kidney cells", "PROBLEM", 98, 140], ["CoV in tissue", "PROBLEM", 263, 276], ["cell culture", "TEST", 281, 293], ["MERS", "PROBLEM", 307, 311], ["CoV", "PROBLEM", 312, 315], ["SARS", "PROBLEM", 320, 324], ["CoV", "PROBLEM", 325, 328], ["cell cultures", "TEST", 350, 363], ["primary undifferentiated human tracheobronchial epithelial cells", "PROBLEM", 374, 438], ["HTBE", "TEST", 440, 444], ["Calu", "TEST", 447, 451], ["Vero, human embryonic kidney", "TEST", 455, 483], ["bronchial", "ANATOMY", 106, 115], ["primary kidney cells", "OBSERVATION", 120, 140], ["growth", "OBSERVATION_MODIFIER", 297, 303], ["tracheobronchial epithelial cells", "OBSERVATION", 405, 438], ["embryonic", "ANATOMY_MODIFIER", 467, 476], ["kidney", "ANATOMY", 477, 483], ["A549 cells", "OBSERVATION", 497, 507]]], ["Both SARS-CoV and MERS-CoV grew with similar kinetics in Calu-3 cells (Zielecki et al., 2013) , but Josset et al. noted MERS-CoV induced more significant cytopathic changes accompanying earlier and distinctive changes to the global transcriptome (Josset et al., 2013) .", [["Calu-3 cells", "ANATOMY", 57, 69], ["SARS-CoV", "ORGANISM", 5, 13], ["MERS-CoV", "ORGANISM", 18, 26], ["Calu-3 cells", "CELL", 57, 69], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 120, 128], ["Calu-3 cells", "CELL_LINE", 57, 69], ["MERS-CoV", "PROTEIN", 120, 128], ["SARS-CoV", "SPECIES", 5, 13], ["MERS-CoV", "SPECIES", 18, 26], ["MERS-CoV", "SPECIES", 120, 128], ["Both SARS", "TEST", 0, 9], ["significant cytopathic changes", "PROBLEM", 142, 172], ["SARS", "OBSERVATION", 5, 9], ["CoV induced", "OBSERVATION_MODIFIER", 125, 136], ["more", "OBSERVATION_MODIFIER", 137, 141], ["significant", "OBSERVATION_MODIFIER", 142, 153], ["cytopathic", "OBSERVATION", 154, 164], ["distinctive", "OBSERVATION_MODIFIER", 198, 209], ["global", "OBSERVATION_MODIFIER", 225, 231], ["transcriptome", "OBSERVATION_MODIFIER", 232, 245]]], ["Fourteen-fold more differentially expressed genes were noted from MERS-CoV; uniquely down-regulated genes related to antigen presentation and lymphocyte signalling and up-regulated related to cAMPmediated signalling and ubiquitination (Josset et al., 2013) .", [["lymphocyte", "ANATOMY", 142, 152], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 66, 74], ["antigen", "GENE_OR_GENE_PRODUCT", 117, 124], ["lymphocyte", "CELL", 142, 152], ["cAMPmediated", "GENE_OR_GENE_PRODUCT", 192, 204], ["MERS-CoV", "DNA", 66, 74], ["MERS-CoV", "SPECIES", 66, 74], ["CoV", "PROBLEM", 71, 74], ["antigen presentation", "PROBLEM", 117, 137], ["lymphocyte signalling", "PROBLEM", 142, 163]]], ["The increased relative growth of SARS-CoV in Calu-3 cells compared to using HAE cultures above might reflect the latter's variable expression of the SARS-CoV receptor (Josset et al., 2013 (Josset et al., 2013; Kindler et al., 2013) .", [["Calu-3 cells", "ANATOMY", 45, 57], ["HAE cultures", "ANATOMY", 76, 88], ["SARS", "DISEASE", 33, 37], ["HAE", "DISEASE", 76, 79], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["Calu-3 cells", "CELL", 45, 57], ["HAE cultures", "CELL", 76, 88], ["SARS-CoV receptor", "GENE_OR_GENE_PRODUCT", 149, 166], ["Calu-3 cells", "CELL_LINE", 45, 57], ["HAE cultures", "CELL_LINE", 76, 88], ["SARS-CoV receptor", "PROTEIN", 149, 166], ["SARS-CoV", "SPECIES", 33, 41], ["SARS-CoV", "SPECIES", 149, 157], ["The increased relative growth of SARS", "PROBLEM", 0, 37], ["CoV in Calu-3 cells", "TREATMENT", 38, 57], ["HAE cultures", "TEST", 76, 88], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["relative", "OBSERVATION_MODIFIER", 14, 22], ["growth", "OBSERVATION_MODIFIER", 23, 29]]], ["Both SARS-CoV and MERS-CoV upregulated viral recognition and innate immune pathway activation genes (IL17-related and interferon regulatory factor [IRF]) and down-regulated metabolic genes (Josset et al., 2013) .", [["SARS-CoV", "ORGANISM", 5, 13], ["MERS-CoV", "ORGANISM", 18, 26], ["IL17", "GENE_OR_GENE_PRODUCT", 101, 105], ["interferon regulatory factor", "GENE_OR_GENE_PRODUCT", 118, 146], ["IRF", "GENE_OR_GENE_PRODUCT", 148, 151], ["innate immune pathway activation genes", "DNA", 61, 99], ["IL17", "DNA", 101, 105], ["interferon regulatory factor", "PROTEIN", 118, 146], ["IRF", "PROTEIN", 148, 151], ["down-regulated metabolic genes", "DNA", 158, 188], ["SARS-CoV", "SPECIES", 5, 13], ["MERS-CoV", "SPECIES", 18, 26], ["Both SARS", "PROBLEM", 0, 9], ["CoV upregulated viral recognition", "TREATMENT", 23, 56], ["innate immune pathway activation genes", "TREATMENT", 61, 99], ["interferon regulatory factor", "TREATMENT", 118, 146], ["metabolic genes", "OBSERVATION", 173, 188]]], ["Because of the rapidity of MERS-CoV host cell expression changes, post-infection treatment with a kinase inhibitor was not as effective as pre-treatment (Josset et al., 2013) , reinforcing the challenges faced in treatment of MERS cases who present once disease processes are well engaged.The immunobiology of MERS-CoV in tissue and cell cultureMERS-CoV has been shown to infect and replicate within primary human monocyte-derived macrophages and produce considerable virus, in contrast to SARS-CoV which could enter, but not propagate within dendritic cells (Zhou et al., 2014) .", [["cell", "ANATOMY", 41, 45], ["tissue", "ANATOMY", 322, 328], ["cell", "ANATOMY", 333, 337], ["monocyte", "ANATOMY", 414, 422], ["macrophages", "ANATOMY", 431, 442], ["dendritic cells", "ANATOMY", 543, 558], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["cell", "CELL", 41, 45], ["MERS-CoV", "ORGANISM", 310, 318], ["tissue", "TISSUE", 322, 328], ["cell", "CELL", 333, 337], ["cultureMERS-CoV", "ORGANISM", 338, 353], ["human", "ORGANISM", 408, 413], ["monocyte-derived macrophages", "CELL", 414, 442], ["SARS-CoV", "ORGANISM", 490, 498], ["dendritic cells", "CELL", 543, 558], ["primary human monocyte-derived macrophages", "CELL_TYPE", 400, 442], ["dendritic cells", "CELL_TYPE", 543, 558], ["human", "SPECIES", 408, 413], ["MERS-CoV", "SPECIES", 27, 35], ["MERS-CoV", "SPECIES", 310, 318], ["cultureMERS-CoV", "SPECIES", 338, 353], ["human", "SPECIES", 408, 413], ["SARS-CoV", "SPECIES", 490, 498], ["MERS", "PROBLEM", 27, 31], ["CoV host cell expression changes", "PROBLEM", 32, 64], ["post-infection treatment", "TREATMENT", 66, 90], ["a kinase inhibitor", "TREATMENT", 96, 114], ["CoV in tissue", "PROBLEM", 315, 328], ["cell cultureMERS", "TEST", 333, 349], ["CoV", "PROBLEM", 350, 353], ["primary human monocyte", "TEST", 400, 422], ["considerable virus", "PROBLEM", 455, 473], ["SARS", "PROBLEM", 490, 494], ["CoV", "PROBLEM", 495, 498], ["rapidity", "OBSERVATION_MODIFIER", 15, 23], ["CoV host cell expression", "OBSERVATION", 32, 56], ["considerable", "OBSERVATION_MODIFIER", 455, 467], ["virus", "OBSERVATION", 468, 473], ["dendritic cells", "OBSERVATION", 543, 558]]], ["Interestingly, MERS-CoV antigens were not found to co-localise with macrophages in infected ex vivo lung tissue (Chan et al., 2013c) .", [["macrophages", "ANATOMY", 68, 79], ["lung tissue", "ANATOMY", 100, 111], ["MERS-CoV antigens", "GENE_OR_GENE_PRODUCT", 15, 32], ["macrophages", "CELL", 68, 79], ["lung tissue", "TISSUE", 100, 111], ["MERS-CoV antigens", "PROTEIN", 15, 32], ["macrophages", "CELL_TYPE", 68, 79], ["MERS-CoV", "SPECIES", 15, 23], ["CoV antigens", "TEST", 20, 32], ["macrophages", "PROBLEM", 68, 79], ["macrophages", "OBSERVATION", 68, 79], ["infected ex vivo", "OBSERVATION", 83, 99], ["lung", "ANATOMY", 100, 104]]], ["In contrast to the work in the HAE system, dendritic cell infection resulted in up-regulation of IFN\u2423 (though not IFN\u2424) and of the proinflammatory cytokines TNF\u2423 and IL-6 (Zhou et al., 2014) .", [["dendritic cell", "ANATOMY", 43, 57], ["HAE", "DISEASE", 31, 34], ["infection", "DISEASE", 58, 67], ["dendritic cell", "CELL", 43, 57], ["IFN\u2423", "GENE_OR_GENE_PRODUCT", 97, 101], ["IFN\u2424", "GENE_OR_GENE_PRODUCT", 114, 118], ["TNF\u2423", "GENE_OR_GENE_PRODUCT", 157, 161], ["IL-6", "GENE_OR_GENE_PRODUCT", 166, 170], ["IFN\u2423", "PROTEIN", 97, 101], ["IFN", "PROTEIN", 114, 117], ["proinflammatory cytokines", "PROTEIN", 131, 156], ["TNF", "PROTEIN", 157, 160], ["IL-6", "PROTEIN", 166, 170], ["dendritic cell infection", "PROBLEM", 43, 67], ["IFN\u2423", "PROBLEM", 97, 101], ["the proinflammatory cytokines TNF", "TEST", 127, 160], ["IL", "TEST", 166, 168], ["dendritic cell infection", "OBSERVATION", 43, 67], ["proinflammatory", "OBSERVATION_MODIFIER", 131, 146]]], ["Also, infection triggered significantly higher levels of IP-1o and RANTES than the equivalent dose of SARS-CoV (Zhou et al., 2014) .", [["infection", "DISEASE", 6, 15], ["SARS", "DISEASE", 102, 106], ["IP-1o", "GENE_OR_GENE_PRODUCT", 57, 62], ["RANTES", "GENE_OR_GENE_PRODUCT", 67, 73], ["SARS-CoV", "ORGANISM", 102, 110], ["IP-1o", "PROTEIN", 57, 62], ["RANTES", "PROTEIN", 67, 73], ["SARS-CoV", "SPECIES", 102, 110], ["infection", "PROBLEM", 6, 15], ["RANTES", "TREATMENT", 67, 73], ["SARS", "PROBLEM", 102, 106], ["infection", "OBSERVATION", 6, 15], ["significantly", "OBSERVATION_MODIFIER", 26, 39], ["higher", "OBSERVATION_MODIFIER", 40, 46]]], ["In clinical practice, two MERS patients in France were found to differ in their IFN\u2423 responses (Faure et al., 2014) .", [["patients", "ORGANISM", 31, 39], ["IFN", "PROTEIN", 80, 83], ["patients", "SPECIES", 31, 39]]], ["Patient 1, who died, did not mount a robust type I IFN response while Patient 2, who survived, did mount a response; particularly notable in Patient 1 was the absence of IFN\u2423 and comparatively little RIG-I, MDA5, IRF3, IRF7, IL-12 and IFN\u2425 (Faure et al., 2014) .", [["IFN", "GENE_OR_GENE_PRODUCT", 170, 173], ["RIG-I", "GENE_OR_GENE_PRODUCT", 200, 205], ["MDA5", "GENE_OR_GENE_PRODUCT", 207, 211], ["IRF3", "GENE_OR_GENE_PRODUCT", 213, 217], ["IRF7", "GENE_OR_GENE_PRODUCT", 219, 223], ["IL-12", "GENE_OR_GENE_PRODUCT", 225, 230], ["IFN", "GENE_OR_GENE_PRODUCT", 235, 238], ["IFN", "PROTEIN", 51, 54], ["IFN", "PROTEIN", 170, 173], ["RIG", "PROTEIN", 200, 203], ["MDA5", "PROTEIN", 207, 211], ["IRF3", "PROTEIN", 213, 217], ["IRF7", "PROTEIN", 219, 223], ["IL-12", "PROTEIN", 225, 230], ["IFN", "PROTEIN", 235, 238], ["Patient", "SPECIES", 0, 7], ["Patient", "SPECIES", 70, 77], ["Patient", "SPECIES", 141, 148], ["IFN\u2423", "PROBLEM", 170, 174], ["IRF7", "TEST", 219, 223], ["IL", "TEST", 225, 227]]], ["IFN\u2423 promotes the antiviral adaptive Th-1 immune response to clear virus.", [["IFN", "CHEMICAL", 0, 3], ["IFN", "GENE_OR_GENE_PRODUCT", 0, 3], ["Th-1", "GENE_OR_GENE_PRODUCT", 37, 41], ["IFN", "PROTEIN", 0, 3], ["the antiviral adaptive Th", "TREATMENT", 14, 39], ["clear virus", "PROBLEM", 61, 72]]], ["Patient 1 also had a comparatively increased level of IL-1o (with its immunosuppressive role (Sabat, 2010) ), a spike in CXCL10 (a proinflammatory role) late in the course of disease and both patients had raised IL-17A (also proinflammatory).The immunobiology of MERS-CoV in tissue and cell cultureThese immune studies raise questions about whether age and immune status or genetic disorders which affect IFN signalling and production could be a risk factor for severe MERS or whether the actions of MERS-CoV itself are sufficient to interfere with signalling.Animal origins and route of acquisition of the MERS-CoVAn animal as source and intermediate host(s) were considered very early on in the MERS outbreak with three of the first five cases having contact with DCs (Albarrak et al., 2012; ProMED, 2012; Reuss et al., 2014) .", [["tissue", "ANATOMY", 275, 281], ["cell culture", "ANATOMY", 286, 298], ["DCs", "ANATOMY", 766, 769], ["MERS", "DISEASE", 469, 473], ["IL-1o", "GENE_OR_GENE_PRODUCT", 54, 59], ["CXCL10", "GENE_OR_GENE_PRODUCT", 121, 127], ["patients", "ORGANISM", 192, 200], ["IL-17A", "GENE_OR_GENE_PRODUCT", 212, 218], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 263, 271], ["tissue", "TISSUE", 275, 281], ["cell", "CELL", 286, 290], ["IFN", "GENE_OR_GENE_PRODUCT", 405, 408], ["MERS-CoV", "ORGANISM", 500, 508], ["DCs", "CELL", 766, 769], ["IL-1o", "PROTEIN", 54, 59], ["CXCL10", "PROTEIN", 121, 127], ["IL-17A", "PROTEIN", 212, 218], ["IFN", "PROTEIN", 405, 408], ["DCs", "CELL_TYPE", 766, 769], ["Patient", "SPECIES", 0, 7], ["patients", "SPECIES", 192, 200], ["MERS-CoV", "SPECIES", 263, 271], ["MERS-CoV", "SPECIES", 500, 508], ["a spike in CXCL10", "PROBLEM", 110, 127], ["disease", "PROBLEM", 175, 182], ["CoV in tissue", "PROBLEM", 268, 281], ["cell culture", "TEST", 286, 298], ["These immune studies", "TEST", 298, 318], ["immune status", "PROBLEM", 357, 370], ["genetic disorders", "PROBLEM", 374, 391], ["IFN signalling", "PROBLEM", 405, 419], ["a risk factor", "PROBLEM", 444, 457], ["severe MERS", "PROBLEM", 462, 473]]], ["While unclear at that time, approximately 12 MERS-CoV detections from a community outbreak in Hafr Al-Batin between June and August 2013 were possibly triggered by the index case having had DC contact (Memish et al., 2014g) .", [["DC", "ANATOMY", 190, 192], ["DC", "CELL_TYPE", 190, 192]]], ["Today, animal MERS-CoV infections must be reported to the world organization for animal health (OIE) as an emerging disease (2014f) .", [["MERS-CoV infections", "DISEASE", 14, 33], ["MERS-CoV", "ORGANISM", 14, 22], ["MERS-CoV", "SPECIES", 14, 22], ["CoV infections", "PROBLEM", 19, 33]]], ["Animal contact with humans was defined in a summary of the first MERS cases as being direct and within 10 days prior to symptom onset (The WHO MERS-CoV Research Group, 2013) .", [["humans", "ORGANISM", 20, 26], ["humans", "SPECIES", 20, 26], ["humans", "SPECIES", 20, 26]]], ["This definition made no specific allowance for acquisition through a droplet-based route, which is still assumed to be the most common route for acquisition of a virus that predominantly causes respiratory disease (Assiri et al., 2013a,b; Zumla and Memish, 2014) .", [["respiratory", "ANATOMY", 194, 205], ["respiratory disease", "DISEASE", 194, 213], ["a droplet", "TEST", 67, 76], ["a virus", "PROBLEM", 160, 167], ["respiratory disease", "PROBLEM", 194, 213], ["virus", "OBSERVATION", 162, 167], ["respiratory disease", "OBSERVATION", 194, 213]]], ["Providing some support for a droplet transmission route, one report identified viral RNA in an air sample collected in a barn housing an infected DC (Azhar et al., 2014b ).", [["air sample", "ANATOMY", 95, 105], ["DC", "ANATOMY", 146, 148], ["viral RNA", "RNA", 79, 88], ["infected DC", "CELL_TYPE", 137, 148], ["some support", "TREATMENT", 10, 22], ["a droplet transmission route", "TREATMENT", 27, 55], ["viral RNA", "PROBLEM", 79, 88], ["an air sample", "PROBLEM", 92, 105], ["viral RNA", "OBSERVATION", 79, 88], ["infected", "OBSERVATION", 137, 145]]], ["The precise route by which humans acquire MERS-CoV remains unproven.", [["humans", "ORGANISM", 27, 33], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 42, 50], ["humans", "SPECIES", 27, 33], ["humans", "SPECIES", 27, 33], ["MERS-CoV", "SPECIES", 42, 50]]], ["From early on and continuing throughout the MERS epidemic in the KSA, older human males have featured prominently, especially among index cases, implying behavioural factors may play a role (Penttinen et al., 2013) , and these factors may provide important clues as to why so few human cases report DC contact and are reported to have had contact with an infected human, leaving this group without any obvious route of acquisition (Fig. 7) .", [["DC", "ANATOMY", 299, 301], ["human", "ORGANISM", 76, 81], ["human", "ORGANISM", 280, 285], ["human", "ORGANISM", 364, 369], ["DC", "CELL_TYPE", 299, 301], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 280, 285], ["human", "SPECIES", 364, 369], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 280, 285], ["human", "SPECIES", 364, 369]]], ["Whether the above definition of animal contact is sufficient to capture exposure to this respiratory virus remains unclear.", [["respiratory virus", "DISEASE", 89, 106], ["this respiratory virus", "PROBLEM", 84, 106], ["respiratory virus", "OBSERVATION", 89, 106]]], ["No alternative path for acquiring infection is reported in many of these instances.", [["infection", "DISEASE", 34, 43], ["acquiring infection", "PROBLEM", 24, 43], ["infection", "OBSERVATION", 34, 43]]], ["Fewer than half of human cases have reported camel contact (Gossner et al., 2014) but what constitutes a definition of \"contact\" during these interviews is unclear.", [["human", "ORGANISM", 19, 24], ["human", "SPECIES", 19, 24], ["human", "SPECIES", 19, 24]]], ["In a May 2014 WHO update and risk assessment, specific wording focused on consumption of camel products while equivalent wording was not used to ascribe risk to a potential droplet route for acquisition of MERS-CoV from DC.", [["DC", "ANATOMY", 220, 222], ["camel", "ORGANISM", 89, 94], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 206, 214], ["DC", "CELL", 220, 222], ["DC", "CELL_TYPE", 220, 222], ["camel", "SPECIES", 89, 94], ["MERS-CoV", "SPECIES", 206, 214], ["risk assessment", "TEST", 29, 44], ["camel products", "TREATMENT", 89, 103]]], ["For example:Animal origins and route of acquisition of the MERS-CoV\"Until more is understood about MERS, people at high risk of severe disease (those with diabetes, renal failure, chronic lung disease, and immunocompromised persons), should take precautions when visiting farms and markets where camels are present.", [["renal", "ANATOMY", 165, 170], ["lung", "ANATOMY", 188, 192], ["diabetes", "DISEASE", 155, 163], ["renal failure", "DISEASE", 165, 178], ["chronic lung disease", "DISEASE", 180, 200], ["people", "ORGANISM", 105, 111], ["renal", "ORGAN", 165, 170], ["lung", "ORGAN", 188, 192], ["persons", "ORGANISM", 224, 231], ["camels", "ORGANISM_SUBDIVISION", 296, 302], ["people", "SPECIES", 105, 111], ["persons", "SPECIES", 224, 231], ["MERS-CoV", "SPECIES", 59, 67], ["severe disease", "PROBLEM", 128, 142], ["diabetes", "PROBLEM", 155, 163], ["renal failure", "PROBLEM", 165, 178], ["chronic lung disease", "PROBLEM", 180, 200], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["disease", "OBSERVATION", 135, 142], ["renal", "ANATOMY", 165, 170], ["failure", "OBSERVATION", 171, 178], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["lung", "ANATOMY", 188, 192], ["disease", "OBSERVATION", 193, 200]]], ["These precautions include: avoiding contact with camels; not drinking raw camel milk or camel urine; and not eating meat that has not been thoroughly cooked\" (World Health Organization, 2014c).Animal origins and route of acquisition of the MERS-CoVDespite the early evidence of DC contact, the diversity of coronaviruses known to exist among bats made them a more widely discussed initial focus (Fig. 7) (Shi, 2013; Smith and Wang, 2013; Woo et al., 2009) .", [["urine", "ANATOMY", 94, 99], ["meat", "ANATOMY", 116, 120], ["DC", "ANATOMY", 278, 280], ["milk", "ORGANISM_SUBSTANCE", 80, 84], ["camel", "ORGANISM_SUBDIVISION", 88, 93], ["urine", "ORGANISM_SUBSTANCE", 94, 99], ["meat", "ORGANISM_SUBDIVISION", 116, 120], ["coronaviruses", "ORGANISM", 307, 320], ["DC", "CELL_TYPE", 278, 280], ["milk", "SPECIES", 80, 84], ["camel", "SPECIES", 88, 93], ["camel", "SPECIES", 74, 79], ["coronaviruses", "PROBLEM", 307, 320]]], ["Nonetheless, to date the only MERS-CoV-specific data pointing to bats originate with a 190nt amplified fragment of the RNA-dependent RNA polymerase gene of the MERS-CoV genome identified in the fecal pellet from an insectivorous Emballonuridae bat, Taphozous perforatus, commonly called the Egyptian tomb bat, from Bisha, KSA .", [["fecal pellet", "ANATOMY", 194, 206], ["MERS-CoV", "ORGANISM", 30, 38], ["bats", "ORGANISM", 65, 69], ["MERS-CoV", "ORGANISM", 160, 168], ["fecal pellet", "ORGANISM_SUBSTANCE", 194, 206], ["Emballonuridae bat", "ORGANISM", 229, 247], ["Taphozous perforatus", "ORGANISM", 249, 269], ["tomb bat", "ORGANISM", 300, 308], ["190nt amplified fragment", "DNA", 87, 111], ["RNA-dependent RNA polymerase gene", "DNA", 119, 152], ["MERS-CoV genome", "DNA", 160, 175], ["Emballonuridae bat", "SPECIES", 229, 247], ["Taphozous perforatus", "SPECIES", 249, 269], ["MERS-CoV", "SPECIES", 160, 168], ["Emballonuridae bat", "SPECIES", 229, 247], ["Taphozous perforatus", "SPECIES", 249, 269], ["Egyptian tomb bat", "SPECIES", 291, 308], ["specific data", "TEST", 39, 52], ["a 190nt amplified fragment", "TREATMENT", 85, 111], ["the RNA", "TEST", 115, 122], ["the MERS", "PROBLEM", 156, 164], ["CoV genome", "PROBLEM", 165, 175], ["CoV genome", "OBSERVATION", 165, 175], ["fecal", "ANATOMY", 194, 199]]], ["While very short, the sequence of the fragment defined it as a diagnostic discovery and at writing no better sequence match exists on the GenBank sequence database.", [["fragment", "CELLULAR_COMPONENT", 38, 46], ["the fragment", "PROBLEM", 34, 46], ["the GenBank sequence database", "TEST", 134, 163], ["short", "OBSERVATION_MODIFIER", 11, 16], ["fragment", "OBSERVATION", 38, 46]]], ["Unfortunately further sequence from this sample could not be obtained because the cold chain was broken when samples shipped to the USA for study thawed and decayed.", [["samples", "ANATOMY", 109, 116], ["further sequence", "TEST", 14, 30], ["this sample", "TEST", 36, 47], ["the cold chain", "PROBLEM", 78, 92], ["study", "TEST", 140, 145]]], ["The role of bats as the natural host of MERS-CoV or the host of a MERS-CoVlike virus remains to be proven.Animal origins and route of acquisition of the MERS-CoVDromedary camels, which make up 95% of all camels, have a central presence in the Arabian Peninsula and human-DC contact ranges from little to close (Gossner et al., 2014; MERS, 2014d) .", [["DC", "ANATOMY", 271, 273], ["bats", "ORGANISM", 12, 16], ["MERS-CoV", "ORGANISM", 40, 48], ["MERS-CoVlike virus", "ORGANISM", 66, 84], ["human", "ORGANISM", 265, 270], ["human", "SPECIES", 265, 270], ["MERS-CoV", "SPECIES", 40, 48], ["MERS-CoVlike virus", "SPECIES", 66, 84], ["human", "SPECIES", 265, 270], ["CoV", "PROBLEM", 45, 48], ["a MERS", "PROBLEM", 64, 70], ["CoVlike virus", "PROBLEM", 71, 84]]], ["Camel densities are greatest in and around the horn of Africa, specifically Ethiopia, Somalia, Kenya, Sudan and South Sudan (Gossner et al., 2014) .", [["Camel densities", "PROBLEM", 0, 15], ["densities", "OBSERVATION", 6, 15], ["greatest", "OBSERVATION_MODIFIER", 20, 28], ["horn", "ANATOMY_MODIFIER", 47, 51], ["Africa", "ANATOMY_MODIFIER", 55, 61]]], ["Near the KSA, Yemen has the highest density of camels, and within the country the Ha'il region is most densely populated with DCs (Gossner et al., 2014) despite there being no human MERS cases from this region.", [["DCs", "ANATOMY", 126, 129], ["DCs", "CELL", 126, 129], ["human", "ORGANISM", 176, 181], ["MERS", "CANCER", 182, 186], ["DCs", "CELL_TYPE", 126, 129], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 176, 181], ["highest", "OBSERVATION_MODIFIER", 28, 35], ["density", "OBSERVATION", 36, 43], ["Ha'il", "ANATOMY", 82, 87], ["region", "ANATOMY_MODIFIER", 88, 94], ["most", "OBSERVATION_MODIFIER", 98, 102], ["densely", "OBSERVATION_MODIFIER", 103, 110]]], ["There are several large wellattended festivals, races, sales and parades which feature DCs and DCs are also kept and bred close to populated areas in the KSA (2014d).", [["DCs", "ANATOMY", 87, 90], ["DCs", "ANATOMY", 95, 98], ["DCs", "CELL", 87, 90], ["DCs", "CELL", 95, 98], ["DCs", "CELL_TYPE", 87, 90], ["DCs", "CELL_TYPE", 95, 98], ["several large wellattended festivals", "PROBLEM", 10, 46], ["DCs", "TREATMENT", 95, 98], ["several", "OBSERVATION_MODIFIER", 10, 17], ["large", "OBSERVATION_MODIFIER", 18, 23], ["wellattended", "OBSERVATION_MODIFIER", 24, 36], ["festivals", "OBSERVATION", 37, 46]]], ["DC milk and meat are widely collected and consumed and the DC is an animal of ritual significance after the Hajj pilgrimage.", [["DC milk", "ANATOMY", 0, 7], ["meat", "ANATOMY", 12, 16], ["DC", "ANATOMY", 59, 61], ["milk", "ORGANISM_SUBSTANCE", 3, 7], ["meat", "ORGANISM_SUBDIVISION", 12, 16], ["DC", "CELL_TYPE", 0, 2], ["DC", "CELL_TYPE", 59, 61], ["milk", "SPECIES", 3, 7], ["meat", "SPECIES", 12, 16], ["the Hajj pilgrimage", "TREATMENT", 104, 123]]], ["However, MERS-CoV infection frequency appears much lower than does the more widespread and frequent habit of eating, drinking and preparing camel products.", [["infection", "DISEASE", 18, 27], ["MERS-CoV", "ORGANISM", 9, 17], ["camel", "ORGANISM", 140, 145], ["MERS-CoV", "SPECIES", 9, 17], ["camel", "SPECIES", 140, 145], ["CoV infection frequency", "PROBLEM", 14, 37], ["CoV", "OBSERVATION_MODIFIER", 14, 17], ["infection", "OBSERVATION", 18, 27], ["much lower", "OBSERVATION_MODIFIER", 46, 56], ["widespread", "OBSERVATION_MODIFIER", 76, 86]]], ["Daily ingestion of fresh unpasteurised DC milk is common among the desert Bedouin and many others in the KSA.", [["DC milk", "ANATOMY", 39, 46], ["milk", "ORGANISM_SUBSTANCE", 42, 46], ["fresh unpasteurised DC milk", "TREATMENT", 19, 46]]], ["Apart from its nutritional value, other perceived health benefits and availability, camel milk has been reported as an adjunct to standard type 1 diabetes management (Agrawal et al., 2009; Mohamad et al., 2009) .", [["diabetes", "DISEASE", 146, 154], ["camel", "ORGANISM", 84, 89], ["milk", "ORGANISM_SUBSTANCE", 90, 94], ["camel", "SPECIES", 84, 89], ["standard type 1 diabetes management", "TREATMENT", 130, 165], ["nutritional value", "OBSERVATION_MODIFIER", 15, 32]]], ["DC urine is also consumed or used for supposed health benefits including a belief that it will keep hair parasite-free and has reported application as an aspirin-like anti-platelet-aggregation substance (Alhaidar et al., 2011) and as a specific anti-cancer and immune modulation substance (Al-Yousef et al., 2012) .Animal origins and route of acquisition of the MERS-CoVIn August 2013, Reusken et al. reported the first sero-survey of livestock living in the region during 2012-2013 (Table 1) (Reusken et al., 2013c) .", [["DC urine", "ANATOMY", 0, 8], ["hair", "ANATOMY", 100, 104], ["aspirin", "CHEMICAL", 154, 161], ["aspirin", "CHEMICAL", 154, 161], ["urine", "ORGANISM_SUBSTANCE", 3, 8], ["aspirin", "SIMPLE_CHEMICAL", 154, 161], ["anti-cancer", "CANCER", 245, 256], ["DC", "CELL_TYPE", 0, 2], ["an aspirin", "TREATMENT", 151, 161], ["urine", "OBSERVATION", 3, 8]]], ["DCs were sampled from a mostly Canary Island-born (originally imported from the Horn of Africa in the 15th century) herd and from Omani DCs (mostly imported in high numbers and with high turnover, from Africa) retired from racing and tested using a protein microarray that expressed a portion of the receptorbinding S1 subunit of the S proteins from SARS-CoV, MERS-CoV and HCoV-OC43 (Reusken et al., 2013a,c) .", [["DCs", "ANATOMY", 0, 3], ["DCs", "ANATOMY", 136, 139], ["DCs", "CELL", 0, 3], ["SARS-CoV", "ORGANISM", 350, 358], ["MERS-CoV", "ORGANISM", 360, 368], ["HCoV-OC43", "ORGANISM", 373, 382], ["DCs", "CELL_TYPE", 0, 3], ["Omani DCs", "CELL_TYPE", 130, 139], ["receptorbinding S1 subunit", "PROTEIN", 300, 326], ["S proteins", "PROTEIN", 334, 344], ["SARS-CoV", "SPECIES", 350, 358], ["MERS-CoV", "SPECIES", 360, 368], ["a protein microarray", "TEST", 247, 267], ["SARS", "PROBLEM", 350, 354], ["CoV", "TEST", 355, 358]]], ["A range of other animals was also tested.", [["animals", "ORGANISM", 17, 24], ["range", "OBSERVATION_MODIFIER", 2, 7]]], ["All non-DC sera tested negative for MERS-CoV antibodies.", [["sera", "ANATOMY", 11, 15], ["sera", "ORGANISM_SUBSTANCE", 11, 15], ["MERS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 36, 55], ["MERS-CoV antibodies", "PROTEIN", 36, 55], ["MERS-CoV", "SPECIES", 36, 44], ["All non-DC sera", "TEST", 0, 15], ["MERS", "PROBLEM", 36, 40], ["CoV antibodies", "TEST", 41, 55]]], ["A neutralising antibody assay found that 10% of strongly seropositive Canary Island DC sera could neutralise the virus while all of the Omani DC sera had high levels of specific MERS-CoV neutralising antibody (Reusken et al., 2013c) .", [["DC sera", "ANATOMY", 84, 91], ["DC sera", "ANATOMY", 142, 149], ["sera", "ORGANISM_SUBSTANCE", 87, 91], ["sera", "ORGANISM_SUBSTANCE", 145, 149], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 178, 186], ["MERS-CoV neutralising antibody", "PROTEIN", 178, 208], ["MERS-CoV", "SPECIES", 178, 186], ["A neutralising antibody assay", "TEST", 0, 29], ["the virus", "PROBLEM", 109, 118], ["the Omani DC sera", "TEST", 132, 149], ["high levels of specific MERS", "PROBLEM", 154, 182], ["CoV neutralising antibody", "TEST", 183, 208]]], ["This indicated that DCs had in the past been infected by MERS-CoV, or a very similar virus, but its spread to camels beyond these borders remained unclear.Animal origins and route of acquisition of the MERS-CoVSince this study, a host of peer-reviewed reports have looked at DCs, and other animals, and the possibility that they may play host to MERS-CoV infection (Table 1 ).", [["DCs", "ANATOMY", 20, 23], ["DCs", "ANATOMY", 275, 278], ["MERS-CoV infection", "DISEASE", 346, 364], ["DCs", "CELL", 20, 23], ["MERS-CoV", "ORGANISM", 57, 65], ["camels", "ORGANISM", 110, 116], ["DCs", "CELL", 275, 278], ["MERS-CoV", "ORGANISM", 346, 354], ["DCs", "CELL_TYPE", 20, 23], ["DCs", "CELL_TYPE", 275, 278], ["MERS-CoV", "SPECIES", 57, 65], ["MERS-CoV", "SPECIES", 346, 354], ["DCs", "PROBLEM", 20, 23], ["CoV", "PROBLEM", 62, 65], ["a very similar virus", "PROBLEM", 70, 90], ["this study", "TEST", 216, 226], ["CoV infection", "PROBLEM", 351, 364], ["virus", "OBSERVATION", 85, 90]]], ["Seropositive DCs have been found throughout the Arabian Peninsula and in Africa Reusken et al., 2013c Reusken et al., , 2014b .", [["DCs", "ANATOMY", 13, 16], ["DCs", "CELL", 13, 16], ["DCs", "CELL_TYPE", 13, 16], ["Seropositive DCs", "PROBLEM", 0, 16]]], ["Other animals tested include sheep, cows, pigs, horses, birds, water buffalo, goats, Bactrian camels, llamas and guanaco (south American camelids).", [["sheep", "ORGANISM", 29, 34], ["cows", "ORGANISM", 36, 40], ["pigs", "ORGANISM", 42, 46], ["horses", "ORGANISM_SUBDIVISION", 48, 54], ["goats", "ORGANISM", 78, 83], ["Bactrian camels", "ORGANISM", 85, 100], ["llamas", "ORGANISM", 102, 108], ["sheep", "SPECIES", 29, 34], ["cows", "SPECIES", 36, 40], ["pigs", "SPECIES", 42, 46], ["horses", "SPECIES", 48, 54], ["goats", "SPECIES", 78, 83], ["llamas", "SPECIES", 102, 108], ["sheep", "SPECIES", 29, 34], ["pigs", "SPECIES", 42, 46], ["buffalo", "SPECIES", 69, 76], ["goats", "SPECIES", 78, 83], ["Bactrian camels", "SPECIES", 85, 100], ["llamas", "ANATOMY", 102, 108]]], ["Many of these animals have only been tested in small numbers and rats, mice, cats, and baboons (wide-ranging in Saudi Arabia and known to come into contact with humans and travel to caves possibly frequented by bats) have yet to be tested at all (Alagaili et al., 2014; Alexandersen et al., 2014; Meyer et al., 2014b; Perera et al., 2013; Reusken et al., 2013b,c) .", [["rats", "ORGANISM", 65, 69], ["mice", "ORGANISM", 71, 75], ["cats", "ORGANISM", 77, 81], ["baboons", "ORGANISM", 87, 94], ["humans", "ORGANISM", 161, 167], ["rats", "SPECIES", 65, 69], ["mice", "SPECIES", 71, 75], ["cats", "SPECIES", 77, 81], ["humans", "SPECIES", 161, 167], ["mice", "SPECIES", 71, 75], ["humans", "SPECIES", 161, 167], ["small", "OBSERVATION_MODIFIER", 47, 52], ["numbers", "OBSERVATION_MODIFIER", 53, 60]]], ["In a large study of 1053 sera from equids (horses, donkeys and mules) from the UAE and Spain, none harboured signs of neutralising antibody against MERS-CoV (Meyer et al., 2015) .Animal origins and route of acquisition of the MERS-CoVInitially, serological tools were employed and cautious analysis reported positive DCs as being seropositive to MERS-CoV, or a closely related virus (Alexandersen et al., 2014; Perera et al., 2013; Reusken et al., 2013c) .", [["sera", "ANATOMY", 25, 29], ["DCs", "ANATOMY", 317, 320], ["sera", "ORGANISM_SUBSTANCE", 25, 29], ["horses", "ORGANISM_SUBDIVISION", 43, 49], ["MERS-CoV", "ORGANISM", 148, 156], ["DCs", "CELL", 317, 320], ["MERS-CoV", "ORGANISM", 346, 354], ["neutralising antibody", "PROTEIN", 118, 139], ["positive DCs", "CELL_TYPE", 308, 320], ["horses", "SPECIES", 43, 49], ["MERS-CoV", "SPECIES", 148, 156], ["MERS-CoV", "SPECIES", 346, 354], ["a large study", "TEST", 3, 16], ["neutralising antibody", "TEST", 118, 139], ["the MERS", "TEST", 222, 230], ["serological tools", "TEST", 245, 262], ["cautious analysis", "TEST", 281, 298], ["positive DCs", "PROBLEM", 308, 320], ["large", "OBSERVATION_MODIFIER", 5, 10]]], ["Subsequently, diagnostic detection of MERS-CoV RNA and recovery of infectious virus has occurred from DC samples (Alagaili et al., 2014; Azhar et al., 2014a; Chu et al., 2014; Haagmans et al., 2014; Hemida et al., 2014a; Nowotny and Kolodziejek, 2014; Raj et al., 2014a) and from some of these, the full or majority length genomes of MERS-CoV have been sequenced Haagmans et al., 2014; Hemida et al., 2014a) .", [["DC samples", "ANATOMY", 102, 112], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 38, 46], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 334, 342], ["MERS-CoV RNA", "RNA", 38, 50], ["DC", "CELL_TYPE", 102, 104], ["MERS-CoV", "SPECIES", 38, 46], ["MERS-CoV", "SPECIES", 334, 342], ["diagnostic detection", "TEST", 14, 34], ["MERS", "PROBLEM", 38, 42], ["CoV RNA", "PROBLEM", 43, 50], ["infectious virus", "PROBLEM", 67, 83], ["infectious virus", "OBSERVATION", 67, 83]]], ["These findings confirmed that DC versions of MERS-CoV were at least as similar to and just as genetically phylogentically interleaved, as were variants detected from different humans over time and across distance (Fig. 4) .", [["DC", "ANATOMY", 30, 32], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 45, 53], ["humans", "ORGANISM", 176, 182], ["DC", "CELL_TYPE", 30, 32], ["MERS-CoV", "DNA", 45, 53], ["humans", "SPECIES", 176, 182], ["MERS-CoV", "SPECIES", 45, 53], ["humans", "SPECIES", 176, 182], ["CoV", "PROBLEM", 50, 53]]], ["Only one other animal, a Taphozous perforatus bat, has contained any traces of MERS-CoV RNA to date .Animal origins and route of acquisition of the MERS-CoVAntibody screening assays sometimes detect cross-reactive antibodies in sera.", [["sera", "ANATOMY", 228, 232], ["Taphozous perforatus bat", "ORGANISM", 25, 49], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 79, 87], ["sera", "ORGANISM_SUBSTANCE", 228, 232], ["MERS-CoV RNA", "RNA", 79, 91], ["cross-reactive antibodies", "PROTEIN", 199, 224], ["Taphozous perforatus", "SPECIES", 25, 45], ["Taphozous perforatus bat", "SPECIES", 25, 49], ["MERS-CoV", "SPECIES", 79, 87], ["a Taphozous perforatus bat", "PROBLEM", 23, 49], ["CoV RNA", "PROBLEM", 84, 91], ["the MERS", "TEST", 144, 152], ["CoVAntibody screening assays", "TEST", 153, 181], ["cross-reactive antibodies in sera", "PROBLEM", 199, 232]]], ["These are identified as such by screening sera against likely viral culprits, for example BCoV or HCoV-OC43 (as an antigenic facsimile for BCoV).", [["sera", "ANATOMY", 42, 46], ["HCoV-OC43", "CHEMICAL", 98, 107], ["sera", "ORGANISM_SUBSTANCE", 42, 46], ["BCoV", "GENE_OR_GENE_PRODUCT", 90, 94], ["HCoV-OC43", "ORGANISM", 98, 107], ["BCoV", "CANCER", 139, 143], ["BCoV", "SPECIES", 90, 94], ["HCoV-OC43", "SPECIES", 98, 107], ["BCoV", "SPECIES", 139, 143], ["screening sera", "TEST", 32, 46], ["viral culprits", "PROBLEM", 62, 76], ["BCoV", "TEST", 90, 94], ["HCoV", "TEST", 98, 102], ["OC43", "PROBLEM", 103, 107], ["BCoV", "TEST", 139, 143]]], ["It is possible that other MERS-CoV-like viruses also reside within camels, but this would in no way detract from the current definitive characterization of identical MERS-CoV sequences found in camels.Animal origins and route of acquisition of the MERS-CoVCamel screening studies have shown that juvenile DCs are more often virus or viral RNA positive while older DCs are more likely to be seropositive and RNA or virus negative or if RNA positive in the process of sero-converting, indicative of recent infection (Hemida et al., 2013 (Hemida et al., , 2014a .", [["DCs", "ANATOMY", 305, 308], ["DCs", "ANATOMY", 364, 367], ["infection", "DISEASE", 504, 513], ["MERS-CoV-like viruses", "ORGANISM", 26, 47], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 166, 174], ["camels", "ORGANISM", 194, 200], ["DCs", "CELL", 305, 308], ["DCs", "CELL", 364, 367], ["MERS-CoV sequences", "DNA", 166, 184], ["juvenile DCs", "CELL_TYPE", 296, 308], ["DCs", "CELL_TYPE", 364, 367], ["MERS-CoV", "SPECIES", 26, 34], ["MERS-CoV", "SPECIES", 166, 174], ["other MERS", "PROBLEM", 20, 30], ["CoV-like viruses", "PROBLEM", 31, 47], ["CoV sequences", "TEST", 171, 184], ["the MERS", "TEST", 244, 252], ["CoVCamel screening studies", "TEST", 253, 279], ["juvenile DCs", "PROBLEM", 296, 308], ["viral RNA positive", "PROBLEM", 333, 351], ["seropositive and RNA or virus", "PROBLEM", 390, 419], ["RNA positive", "PROBLEM", 435, 447], ["recent infection", "PROBLEM", 497, 513], ["viruses", "OBSERVATION", 40, 47], ["indicative of", "UNCERTAINTY", 483, 496], ["infection", "OBSERVATION", 504, 513]]], ["In adults, MERS-CoV RNA has been detected among animals with pre-existing antibody suggesting re-infection is also possible (Hemida et al., 2014a) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 11, 19], ["MERS-CoV RNA", "RNA", 11, 23], ["MERS-CoV", "SPECIES", 11, 19], ["CoV RNA", "PROBLEM", 16, 23], ["pre-existing antibody", "PROBLEM", 61, 82], ["re-infection", "PROBLEM", 94, 106], ["re-infection", "OBSERVATION", 94, 106]]], ["Viral loads among positive camels can be very high (Alagaili et al., 2014; Hemida et al., 2013 Hemida et al., , 2014a Nowotny and Kolodziejek, 2014) and camels have been found positive both when ill with URT respiratory signs (Adney et al., 2014; Azhar et al., 2014a; Hemida et al., 2014a; Memish et al., 2014f) or not obviously unwell.", [["respiratory signs", "DISEASE", 208, 225], ["Viral", "ORGANISM", 0, 5], ["camels", "ORGANISM", 153, 159], ["Viral loads", "TEST", 0, 11], ["positive camels", "PROBLEM", 18, 33], ["URT respiratory signs", "PROBLEM", 204, 225], ["obviously unwell", "PROBLEM", 319, 335], ["unwell", "OBSERVATION", 329, 335]]], ["These findings indicate camels can host natural MERS-CoV infections.", [["MERS-CoV infections", "DISEASE", 48, 67], ["camels", "ORGANISM", 24, 30], ["MERS-CoV", "ORGANISM", 48, 56], ["MERS-CoV", "SPECIES", 48, 56], ["CoV infections", "PROBLEM", 53, 67], ["CoV", "OBSERVATION_MODIFIER", 53, 56], ["infections", "OBSERVATION", 57, 67]]], ["Furthermore, stored camel sera have revealed signs of MERS-CoV in camels which date back over two decades (Alagaili et al., 2014; Alexandersen et al., 2014) .", [["sera", "ANATOMY", 26, 30], ["camel", "ORGANISM", 20, 25], ["sera", "ORGANISM_SUBSTANCE", 26, 30], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 54, 62], ["camels", "ORGANISM", 66, 72], ["camel", "SPECIES", 20, 25], ["camel", "SPECIES", 20, 25], ["MERS-CoV", "SPECIES", 54, 62], ["stored camel sera", "TEST", 13, 30], ["signs of MERS", "PROBLEM", 45, 58], ["CoV in camels", "PROBLEM", 59, 72]]], ["Older sera have not been tested and so precisely how long camels have been afflicted by MERS-CoV, whether the virus is enzootic among them, only introduced to them 20-years ago from bats, or they are the subject of regular but short-lived viral incursions perhaps occasionally from humans themselves, cannot yet be answered.", [["sera", "ANATOMY", 6, 10], ["sera", "ORGANISM_SUBSTANCE", 6, 10], ["camels", "ORGANISM", 58, 64], ["MERS-CoV", "ORGANISM", 88, 96], ["humans", "ORGANISM", 282, 288], ["humans", "SPECIES", 282, 288], ["MERS-CoV", "SPECIES", 88, 96], ["humans", "SPECIES", 282, 288], ["the virus", "PROBLEM", 106, 115]]], ["The next step was to prove a direction for infection; were DCs transmitting virus to humans or were humans infecting camels?", [["DCs", "ANATOMY", 59, 62], ["infection", "DISEASE", 43, 52], ["DCs", "CELL", 59, 62], ["humans", "ORGANISM", 85, 91], ["humans", "ORGANISM", 100, 106], ["camels", "ORGANISM", 117, 123], ["DCs", "CELL_TYPE", 59, 62], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 100, 106], ["humans", "SPECIES", 85, 91], ["humans", "SPECIES", 100, 106], ["infection", "PROBLEM", 43, 52], ["infection", "OBSERVATION", 43, 52]]], ["At a Qatari site, a farm owner and his employee became ill in mid-October 2013 and tested positive for MERS-CoV RNA in a sputum and throat swab sample, respectively.", [["sputum", "ANATOMY", 121, 127], ["throat swab sample", "ANATOMY", 132, 150], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 103, 111], ["MERS-CoV RNA", "RNA", 103, 115], ["MERS-CoV", "SPECIES", 103, 111], ["ill", "PROBLEM", 55, 58], ["MERS", "PROBLEM", 103, 107], ["CoV RNA", "PROBLEM", 108, 115], ["a sputum", "TEST", 119, 127], ["throat swab sample", "TEST", 132, 150], ["throat", "ANATOMY", 132, 138]]], ["RT-rtPCRs found MERS-CoV RNA in 11 of 14 positive camel nasal swabs at the farm; six (43%) met the international criteria of being positive by two or more assays .", [["nasal swabs", "ANATOMY", 56, 67], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["camel", "ORGANISM", 50, 55], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 56, 67], ["MERS-CoV RNA", "RNA", 16, 28], ["MERS-CoV", "SPECIES", 16, 24], ["camel", "SPECIES", 50, 55], ["RT", "TEST", 0, 2], ["CoV RNA", "TEST", 21, 28], ["MERS", "OBSERVATION", 16, 20], ["CoV RNA", "OBSERVATION", 21, 28]]], ["These results indicated a recent outbreak had occurred in this herd; the first indication of MERS-CoV RNA found within DCs with a temporal association to human infections.", [["DCs", "ANATOMY", 119, 122], ["infections", "DISEASE", 160, 170], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["DCs", "CELL", 119, 122], ["human", "ORGANISM", 154, 159], ["MERS-CoV RNA", "RNA", 93, 105], ["DCs", "CELL_TYPE", 119, 122], ["human", "SPECIES", 154, 159], ["MERS-CoV", "SPECIES", 93, 101], ["human", "SPECIES", 154, 159], ["a recent outbreak", "PROBLEM", 24, 41], ["MERS", "PROBLEM", 93, 97], ["CoV RNA", "PROBLEM", 98, 105], ["human infections", "PROBLEM", 154, 170], ["infections", "OBSERVATION", 160, 170]]], ["Three positive DC samples were confirmed by sequencing a 358nt portion of the S gene; these sequences were identical to each other, with close homology to other human and camel MERS-CoV sequences .", [["DC samples", "ANATOMY", 15, 25], ["human", "ORGANISM", 161, 166], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 177, 185], ["358nt portion", "DNA", 57, 70], ["S gene", "DNA", 78, 84], ["human and camel MERS-CoV sequences", "DNA", 161, 195], ["human", "SPECIES", 161, 166], ["camel", "SPECIES", 171, 176], ["human", "SPECIES", 161, 166], ["camel MERS-CoV", "SPECIES", 171, 185], ["these sequences", "TEST", 86, 101]]], ["The DCs and human contacts yielded ORF1a and ORF4b sequences differing by only a single nucleotide each, clustering closely with the Hafr-Al-Batin 1 2013 variant .", [["DCs", "ANATOMY", 4, 7], ["nucleotide", "CHEMICAL", 88, 98], ["nucleotide", "CHEMICAL", 88, 98], ["DCs", "CELL", 4, 7], ["human", "ORGANISM", 12, 17], ["ORF1a", "GENE_OR_GENE_PRODUCT", 35, 40], ["ORF4b", "GENE_OR_GENE_PRODUCT", 45, 50], ["DCs", "CELL_TYPE", 4, 7], ["ORF1a and ORF4b sequences", "DNA", 35, 60], ["Hafr-Al-Batin 1 2013 variant", "DNA", 133, 161], ["human", "SPECIES", 12, 17], ["human", "SPECIES", 12, 17], ["ORF4b sequences", "TEST", 45, 60], ["a single nucleotide each", "TREATMENT", 79, 103]]], ["Subsequently, another case study found evidence of a concurrent human and camel infection and the direction of that infection was inferred to be from the ill DCs and to their human owners (Azhar et al., 2014a; Drosten et al., 2014a; Memish et al., 2014f) .", [["DCs", "ANATOMY", 158, 161], ["human and camel infection", "DISEASE", 64, 89], ["infection", "DISEASE", 116, 125], ["human", "ORGANISM", 64, 69], ["camel", "ORGANISM", 74, 79], ["DCs", "CELL", 158, 161], ["human", "ORGANISM", 175, 180], ["DCs", "CELL_TYPE", 158, 161], ["human", "SPECIES", 64, 69], ["camel", "SPECIES", 74, 79], ["human", "SPECIES", 175, 180], ["human", "SPECIES", 64, 69], ["camel", "SPECIES", 74, 79], ["human", "SPECIES", 175, 180], ["another case study", "TEST", 14, 32], ["a concurrent human and camel infection", "PROBLEM", 51, 89], ["that infection", "PROBLEM", 111, 125], ["infection", "OBSERVATION", 80, 89], ["infection", "OBSERVATION", 116, 125]]], ["Partial genome sequences indicated that a human and a MERS-CoV RT-rtPCR positive camel had been infected by a variant of the same virus, harbouring the same distinct pattern of nucleotide polymorphisms (Memish et al., 2014f) .", [["nucleotide", "CHEMICAL", 177, 187], ["human", "ORGANISM", 42, 47], ["MERS-CoV RT", "ORGANISM", 54, 65], ["camel", "ORGANISM", 81, 86], ["MERS-CoV RT-rtPCR positive camel", "DNA", 54, 86], ["human", "SPECIES", 42, 47], ["camel", "SPECIES", 81, 86], ["human", "SPECIES", 42, 47], ["MERS-CoV", "SPECIES", 54, 62], ["camel", "SPECIES", 81, 86], ["Partial genome sequences", "TEST", 0, 24], ["a MERS", "TEST", 52, 58], ["CoV RT-rtPCR", "TEST", 59, 71], ["the same virus", "PROBLEM", 121, 135], ["nucleotide polymorphisms", "OBSERVATION", 177, 201]]], ["All nine camels in the owner's herd, serially sampled, reacted in a recombinant S1 antigen ELISA, with the two animals that had been RT-rtPCR positive showing a small, verifiable rise in antibody titre (Memish et al., 2014f) .", [["camels", "ORGANISM", 9, 15], ["recombinant S1 antigen", "PROTEIN", 68, 90], ["RT-rtPCR", "TEST", 133, 141], ["a small, verifiable rise in antibody titre", "PROBLEM", 159, 201], ["small", "OBSERVATION_MODIFIER", 161, 166], ["rise", "OBSERVATION_MODIFIER", 179, 183], ["antibody titre", "OBSERVATION", 187, 201]]], ["A rise in titre theoretically begins 10-21 days after camel infection (Memish et al., 2014f) .", [["camel infection", "DISEASE", 54, 69], ["camel", "ORGANISM", 54, 59], ["camel", "SPECIES", 54, 59], ["A rise in titre theoretically", "PROBLEM", 0, 29], ["camel infection", "PROBLEM", 54, 69], ["rise", "OBSERVATION_MODIFIER", 2, 6], ["titre", "OBSERVATION", 10, 15]]], ["While samples were few, the authors of this and a subsequently published study of the same farmer and camel herd in which samples were collected a few days earlier, suggested that the rise in titre in camel sera which occurred alongside a declining RNA load, while the patient was actively ill and hospitalised, indicated that the camels were infected first followed by the owner (Azhar et al., 2014a; Memish et al., 2014f) .", [["samples", "ANATOMY", 6, 13], ["samples", "ANATOMY", 122, 129], ["sera", "ANATOMY", 207, 211], ["samples", "CANCER", 6, 13], ["camel", "ORGANISM", 102, 107], ["herd", "ORGANISM_SUBDIVISION", 108, 112], ["samples", "CANCER", 122, 129], ["camel", "ORGANISM", 201, 206], ["sera", "ORGANISM_SUBSTANCE", 207, 211], ["patient", "ORGANISM", 269, 276], ["camels", "ORGANISM", 331, 337], ["camel", "SPECIES", 102, 107], ["patient", "SPECIES", 269, 276], ["camel", "SPECIES", 102, 107], ["camel", "SPECIES", 201, 206], ["a subsequently published study", "TEST", 48, 78], ["the rise in titre in camel sera", "PROBLEM", 180, 211], ["a declining RNA load", "PROBLEM", 237, 257]]], ["Bovine coronavirus (BCoV) antibodies were also present and rising in one of the two RT-rtPCR positive animals but no animal's antibodies could neutralise BCoV infection (Memish et al., 2014f) .Animal origins and route of acquisition of the MERS-CoVThese studies show that DCs, but perhaps not one of the other animal species tested, are a reservoir for the MERS-CoV by which they seem to be often infected.", [["DCs", "ANATOMY", 272, 275], ["infection", "DISEASE", 159, 168], ["Bovine coronavirus", "ORGANISM", 0, 18], ["BCoV", "ORGANISM", 20, 24], ["rtPCR", "GENE_OR_GENE_PRODUCT", 87, 92], ["DCs", "CELL", 272, 275], ["MERS-CoV", "ORGANISM", 357, 365], ["Bovine coronavirus (BCoV) antibodies", "PROTEIN", 0, 36], ["DCs", "CELL_TYPE", 272, 275], ["Bovine", "SPECIES", 0, 6], ["coronavirus", "SPECIES", 7, 18], ["Bovine coronavirus", "SPECIES", 0, 18], ["BCoV", "SPECIES", 20, 24], ["BCoV", "SPECIES", 154, 158], ["MERS-CoV", "SPECIES", 357, 365], ["Bovine coronavirus (BCoV) antibodies", "TEST", 0, 36], ["animal's antibodies", "TEST", 117, 136], ["BCoV infection", "PROBLEM", 154, 168], ["the MERS", "TEST", 236, 244], ["CoVThese studies", "TEST", 245, 261], ["DCs", "PROBLEM", 272, 275], ["a reservoir", "TREATMENT", 337, 348], ["coronavirus", "OBSERVATION", 7, 18], ["no", "UNCERTAINTY", 114, 116], ["infected", "OBSERVATION", 397, 405]]], ["Camels have been exposed to MERS-CoV, in some way, for at least two decades.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["MERS-CoV", "SPECIES", 28, 36]]], ["It remains unknown whether isolating the reservoir would stop sporadic transmission of MERS-CoV to humans (Nishiura et al., 2014) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["humans", "ORGANISM", 99, 105], ["humans", "SPECIES", 99, 105], ["MERS-CoV", "SPECIES", 87, 95], ["humans", "SPECIES", 99, 105], ["the reservoir", "TREATMENT", 37, 50]]], ["When three adult DCs were infected intranasally, intracheally and conjunctivally with 10 7 TCID 50 of MERS-CoV in a study in the United States, an amount similar to that shed by an infected camel, mild URT disease and mostly URT-localised virus replication resulted (Adney et al., 2014) .", [["DCs", "ANATOMY", 17, 20], ["intranasally", "ANATOMY", 35, 47], ["URT disease", "DISEASE", 202, 213], ["DCs", "CELL", 17, 20], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["camel", "ORGANISM", 190, 195], ["DCs", "CELL_TYPE", 17, 20], ["camel", "SPECIES", 190, 195], ["MERS-CoV", "SPECIES", 102, 110], ["camel", "SPECIES", 190, 195], ["a study", "TEST", 114, 121], ["an infected camel", "PROBLEM", 178, 195], ["mild URT disease", "PROBLEM", 197, 213], ["localised virus replication", "PROBLEM", 229, 256], ["infected", "OBSERVATION", 181, 189], ["mild", "OBSERVATION_MODIFIER", 197, 201], ["URT", "ANATOMY", 202, 205], ["disease", "OBSERVATION", 206, 213], ["URT", "ANATOMY", 225, 228]]], ["Infectious virus was also detected in the trachea and one of four lung lobes tested as well as in retropharyngeal, mediastinal, mesenteric, and tracheobronchial lymph nodes.", [["trachea", "ANATOMY", 42, 49], ["lung lobes", "ANATOMY", 66, 76], ["retropharyngeal", "ANATOMY", 98, 113], ["mediastinal", "ANATOMY", 115, 126], ["mesenteric", "ANATOMY", 128, 138], ["tracheobronchial lymph nodes", "ANATOMY", 144, 172], ["trachea", "ORGAN", 42, 49], ["lung lobes", "MULTI-TISSUE_STRUCTURE", 66, 76], ["retropharyngeal", "ORGAN", 98, 113], ["mesenteric", "MULTI-TISSUE_STRUCTURE", 128, 138], ["tracheobronchial lymph nodes", "MULTI-TISSUE_STRUCTURE", 144, 172], ["Infectious virus", "SPECIES", 0, 16], ["Infectious virus", "PROBLEM", 0, 16], ["retropharyngeal, mediastinal, mesenteric, and tracheobronchial lymph nodes", "PROBLEM", 98, 172], ["trachea", "ANATOMY", 42, 49], ["one", "OBSERVATION_MODIFIER", 54, 57], ["four", "ANATOMY_MODIFIER", 61, 65], ["lung", "ANATOMY", 66, 70], ["lobes", "ANATOMY_MODIFIER", 71, 76], ["retropharyngeal", "ANATOMY", 98, 113], ["mediastinal", "ANATOMY", 115, 126], ["mesenteric", "ANATOMY", 128, 138], ["tracheobronchial", "ANATOMY", 144, 160], ["lymph nodes", "OBSERVATION", 161, 172]]], ["URT shedding of infectious virus continued for seven days after inoculation while viral RNA could be detected for 35 days in nasal swabs.", [["nasal swabs", "ANATOMY", 125, 136], ["URT", "CHEMICAL", 0, 3], ["URT", "GENE_OR_GENE_PRODUCT", 0, 3], ["nasal swabs", "MULTI-TISSUE_STRUCTURE", 125, 136], ["viral RNA", "RNA", 82, 91], ["URT shedding of infectious virus", "PROBLEM", 0, 32], ["inoculation", "PROBLEM", 64, 75], ["viral RNA", "PROBLEM", 82, 91], ["nasal swabs", "TREATMENT", 125, 136], ["infectious virus", "OBSERVATION", 16, 32]]], ["Small quantities of viral RNA, but not culturable virus, were detected in exhaled breath but no virus or viral RNA was detected in serum or whole blood and no viral RNA could be detected in faeces or urine for 42 days post inoculation (Adney et al., 2014) .", [["serum", "ANATOMY", 131, 136], ["whole blood", "ANATOMY", 140, 151], ["faeces", "ANATOMY", 190, 196], ["urine", "ANATOMY", 200, 205], ["exhaled breath", "ORGANISM_SUBSTANCE", 74, 88], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["whole blood", "ORGANISM_SUBSTANCE", 140, 151], ["faeces", "ORGANISM_SUBSTANCE", 190, 196], ["urine", "ORGANISM_SUBSTANCE", 200, 205], ["viral RNA", "RNA", 20, 29], ["viral RNA", "RNA", 105, 114], ["viral RNA", "RNA", 159, 168], ["Small quantities of viral RNA", "PROBLEM", 0, 29], ["culturable virus", "PROBLEM", 39, 55], ["exhaled breath", "TEST", 74, 88], ["virus", "PROBLEM", 96, 101], ["viral RNA", "PROBLEM", 105, 114], ["serum", "TEST", 131, 136], ["whole blood", "TEST", 140, 151], ["viral RNA", "PROBLEM", 159, 168], ["inoculation", "PROBLEM", 223, 234], ["viral RNA", "OBSERVATION", 20, 29], ["no", "UNCERTAINTY", 93, 95], ["virus", "OBSERVATION", 96, 101], ["viral RNA", "OBSERVATION", 105, 114], ["no", "UNCERTAINTY", 156, 158], ["viral RNA", "OBSERVATION", 159, 168]]], ["A strong neutralising antibody response was produced by the camels from 14 days post inoculation.Animal origins and route of acquisition of the MERS-CoVWe also do not know whether camels are essential to maintaining chains of human infection which subsequently amplify into more apparent clusters and outbreaks by spreading from humanto-human.", [["infection", "DISEASE", 232, 241], ["camels", "ORGANISM", 180, 186], ["human", "ORGANISM", 226, 231], ["human", "ORGANISM", 337, 342], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 337, 342], ["A strong neutralising antibody response", "TEST", 0, 39], ["human infection", "PROBLEM", 226, 241], ["strong", "OBSERVATION_MODIFIER", 2, 8], ["neutralising", "OBSERVATION", 9, 21], ["infection", "OBSERVATION", 232, 241]]], ["Parturition in DCs occurs in the winter months (early in the Gregorian calendar year) which may be a driver of the subsequent spike in human cases seen during 2013 and 2014 (Memish et al., 2014f) .", [["DCs", "ANATOMY", 15, 18], ["DCs", "CELL", 15, 18], ["human", "ORGANISM", 135, 140], ["DCs", "CELL_TYPE", 15, 18], ["human", "SPECIES", 135, 140], ["human", "SPECIES", 135, 140], ["the subsequent spike in human cases", "PROBLEM", 111, 146]]], ["Juvenile camels appear to host active infection more often than adult camels and this may help explain why the slaughter of camels, which must be five years of age or older, does not contribute to significantly to exposure among slaughterhouse workers (Nowotny and Kolodziejek, 2014) .", [["infection", "DISEASE", 38, 47], ["camels", "ORGANISM", 9, 15], ["camels", "ORGANISM", 124, 130], ["Juvenile camels", "PROBLEM", 0, 15], ["host active infection", "PROBLEM", 26, 47], ["host", "OBSERVATION_MODIFIER", 26, 30], ["active", "OBSERVATION_MODIFIER", 31, 37], ["infection", "OBSERVATION", 38, 47]]], ["Small numbers of tested DCs from Australia were not seropositive, but expanded virological investigations of Australian (a source of export) and African camels as well as bats may lead to findings of a more ancestral viral variant or more seropositive animals and geographic areas.", [["DCs", "ANATOMY", 24, 27], ["DCs", "CELL", 24, 27], ["DCs", "CELL_TYPE", 24, 27], ["seropositive", "PROBLEM", 52, 64], ["African camels", "TREATMENT", 145, 159], ["a more ancestral viral variant", "PROBLEM", 200, 230], ["numbers", "OBSERVATION_MODIFIER", 6, 13], ["viral variant", "OBSERVATION", 217, 230], ["geographic", "OBSERVATION_MODIFIER", 264, 274]]], ["Identifying the animal source for zoonotic spread is important to inform options for reducing human exposures Hemida et al., 2013) .Animal origins and route of acquisition of the MERS-CoVThe MERS-CoV genome does not appear to have changed significantly during its movement through humans in 2012-2014, nor during human and camel spillovers; human variants show very little divergence from camel MERS-CoV variants.", [["human", "ORGANISM", 94, 99], ["humans", "ORGANISM", 281, 287], ["human", "ORGANISM", 313, 318], ["camel", "ORGANISM", 323, 328], ["human", "ORGANISM", 341, 346], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 395, 403], ["MERS-CoVThe MERS-CoV genome", "DNA", 179, 206], ["camel MERS-CoV variants", "DNA", 389, 412], ["human", "SPECIES", 94, 99], ["humans", "SPECIES", 281, 287], ["human", "SPECIES", 313, 318], ["human", "SPECIES", 341, 346], ["human", "SPECIES", 94, 99], ["MERS-CoVThe MERS-CoV", "SPECIES", 179, 199], ["humans", "SPECIES", 281, 287], ["human", "SPECIES", 313, 318], ["camel", "SPECIES", 323, 328], ["human", "SPECIES", 341, 346], ["camel MERS-CoV", "SPECIES", 389, 403], ["zoonotic spread", "PROBLEM", 34, 49], ["the MERS", "TEST", 175, 183], ["CoV genome", "PROBLEM", 196, 206], ["human variants", "TEST", 341, 355]]], ["This implies that the major source for human acquisition is the camel, rather than another animal, but more testing of other animal species is needed to support that conclusion.", [["human", "ORGANISM", 39, 44], ["camel", "ORGANISM_SUBDIVISION", 64, 69], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44], ["other animal species", "PROBLEM", 119, 139]]], ["Over a month, a DC virus sequenced on different occasions, did not change at all genetically, indicating a high level of genomic stability and supporting the possibility that DCs might be the natural, rather than intermediate, host for MERS-CoV we know today (Hemida et al., 2014a) .Animal origins and route of acquisition of the MERS-CoVThe precise role for camels and the route(s) of human acquisition of MERS-CoV from camels in sporadic infections remains to be determined.", [["DC", "ANATOMY", 16, 18], ["DCs", "ANATOMY", 175, 178], ["infections", "DISEASE", 440, 450], ["DCs", "CELL", 175, 178], ["MERS-CoV", "ORGANISM", 236, 244], ["camels", "ORGANISM", 359, 365], ["human", "ORGANISM", 386, 391], ["MERS-CoV", "ORGANISM", 407, 415], ["camels", "ORGANISM", 421, 427], ["DCs", "CELL_TYPE", 175, 178], ["human", "SPECIES", 386, 391], ["MERS-CoV", "SPECIES", 236, 244], ["human", "SPECIES", 386, 391], ["MERS-CoV", "SPECIES", 407, 415], ["a DC virus", "TREATMENT", 14, 24], ["a high level of genomic stability", "PROBLEM", 105, 138], ["sporadic infections", "PROBLEM", 431, 450], ["genomic stability", "OBSERVATION", 121, 138], ["sporadic", "OBSERVATION_MODIFIER", 431, 439], ["infections", "OBSERVATION", 440, 450]]], ["Nonetheless in the absence of any other likely animal source and in the interest of public health, risk reduction activities now recommend reducing contact with camels, especially when ill, and limiting contact with camel secretions and excretions including the handling of camel milk and meat and the butchering of camels.", [["milk", "ANATOMY", 280, 284], ["meat", "ANATOMY", 289, 293], ["camel", "ORGANISM", 216, 221], ["secretions", "ORGANISM_SUBDIVISION", 222, 232], ["camel", "ORGANISM", 274, 279], ["milk", "ORGANISM_SUBSTANCE", 280, 284], ["meat", "ORGANISM_SUBDIVISION", 289, 293], ["camels", "ORGANISM_SUBDIVISION", 316, 322], ["milk", "SPECIES", 280, 284], ["camel", "SPECIES", 216, 221], ["camel", "SPECIES", 274, 279], ["risk reduction activities", "TREATMENT", 99, 124], ["excretions", "TREATMENT", 237, 247], ["the handling of camel milk", "TREATMENT", 258, 284]]], ["The potential for aerosol-generation by all these procedures, yet to be defined, described or studied, has not been acknowledged in plain language as a risk to date (see Section 9.1 for aerosols and risk).", [["aerosol-generation", "TREATMENT", 18, 36]]], ["Thus, camels develop signs of URT disease, shed infectious virus in high quantities in URT secretions and the possibility exists that they may aerosolise that virus.Transmission of MERS-CoV among humansTransmission of MERS-CoV has been defined as sporadic, intrafamilial and healthcare associated (Memish et al., 2014e) .", [["URT secretions", "ANATOMY", 87, 101], ["URT disease", "DISEASE", 30, 41], ["camels", "ORGANISM", 6, 12], ["URT", "GENE_OR_GENE_PRODUCT", 30, 33], ["MERS-CoV", "ORGANISM", 181, 189], ["humans", "ORGANISM", 196, 202], ["MERS-CoV", "ORGANISM", 218, 226], ["humans", "SPECIES", 196, 202], ["MERS-CoV", "SPECIES", 181, 189], ["humans", "SPECIES", 196, 202], ["MERS-CoV", "SPECIES", 218, 226], ["URT disease", "PROBLEM", 30, 41], ["shed infectious virus", "PROBLEM", 43, 64], ["URT secretions", "PROBLEM", 87, 101], ["aerosolise that virus", "PROBLEM", 143, 164], ["MERS", "PROBLEM", 181, 185], ["URT", "ANATOMY", 30, 33], ["disease", "OBSERVATION", 34, 41], ["infectious", "OBSERVATION_MODIFIER", 48, 58], ["high quantities", "OBSERVATION_MODIFIER", 68, 83], ["URT", "ANATOMY", 87, 90], ["secretions", "OBSERVATION", 91, 101]]], ["The virus was characterised because of its role in causing severe and therefore more obvious illness in humans; we were the early sentinels highlighting its incursion.", [["humans", "ORGANISM", 104, 110], ["humans", "SPECIES", 104, 110], ["humans", "SPECIES", 104, 110], ["The virus", "PROBLEM", 0, 9], ["obvious illness in humans", "PROBLEM", 85, 110], ["virus", "OBSERVATION", 4, 9], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["more", "OBSERVATION_MODIFIER", 80, 84], ["obvious", "OBSERVATION_MODIFIER", 85, 92], ["illness", "OBSERVATION", 93, 100]]], ["Spread of MERS-CoV within families Omrani et al., 2013) and between people has been well documented ; Health Protection Agency (HPA) UK Novel Coronavirus Investigation Team, 2013; MERS, 2014b; Puzelli et al., 2013) however the first known MERS outbreak was one of acute LRT disease in a healthcare setting (Hijawi et al., 2013) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 10, 18], ["people", "ORGANISM", 68, 74], ["people", "SPECIES", 68, 74], ["MERS-CoV", "SPECIES", 10, 18], ["acute LRT disease", "PROBLEM", 264, 281], ["acute", "OBSERVATION_MODIFIER", 264, 269], ["LRT disease", "OBSERVATION", 270, 281]]], ["This occurred in Al-Zarqa, Jordan and was retrospectively linked to the MERS-CoV after some detailed laboratory and epidemiological analyses (Hijawi et al., 2013) .", [["MERS-CoV", "ORGANISM", 72, 80], ["MERS-CoV", "SPECIES", 72, 80], ["epidemiological analyses", "TEST", 116, 140]]], ["A BAL and a serum sample from two cases were found to be MERS-CoV RT-rtPCR positive and a number of probable cases were subsequently added to this outbreak (Hijawi et al., 2013) .", [["BAL", "ANATOMY", 2, 5], ["serum sample", "ANATOMY", 12, 24], ["BAL", "ORGANISM_SUBSTANCE", 2, 5], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["MERS-CoV", "SPECIES", 57, 65], ["A BAL", "TEST", 0, 5], ["a serum sample", "TEST", 10, 24], ["MERS", "TEST", 57, 61], ["CoV RT-rtPCR", "TEST", 62, 74], ["BAL", "OBSERVATION", 2, 5]]], ["Further investigations deployed an ELISA employing the genetically and antigenically similar btHKU5.2 recombinant nucleocapsid antigen (Chan et al., 2013c) , a MERS-CoV Hu/Jordan-N3/2012 infected Vero cell IFA, and an MNT test .", [["Vero cell", "ANATOMY", 196, 205], ["nucleocapsid antigen", "GENE_OR_GENE_PRODUCT", 114, 134], ["Vero cell", "CELL", 196, 205], ["btHKU5.2 recombinant nucleocapsid antigen", "PROTEIN", 93, 134], ["Further investigations", "TEST", 0, 22], ["an ELISA", "TEST", 32, 40], ["a MERS", "TEST", 158, 164], ["Vero cell IFA", "TEST", 196, 209], ["an MNT test", "TEST", 215, 226], ["Vero cell", "OBSERVATION", 196, 205]]], ["These found additional cases from among the sera of 124 subjects .", [["sera", "ANATOMY", 44, 48], ["sera", "ORGANISM_SUBSTANCE", 44, 48], ["the sera", "TEST", 40, 48]]], ["While serology alone does not meet the current WHO definition of a case, optimised and thoroughly validated sero-assays employed alongside good clinical histories do still identify previous occurrences of infection.", [["infection", "DISEASE", 205, 214], ["sero-assays", "TEST", 108, 119], ["infection", "PROBLEM", 205, 214], ["infection", "OBSERVATION", 205, 214]]], ["Just as with PCR testing on occasion, serology usually finds a viral footprint in the absence of any clear signs and symptoms of disease (Knibbs et al., 2014) .", [["PCR testing", "TEST", 13, 24], ["serology", "TEST", 38, 46], ["a viral footprint", "PROBLEM", 61, 78], ["symptoms of disease", "PROBLEM", 117, 136], ["viral footprint", "OBSERVATION", 63, 78]]], ["And as is also the case with molecular testing, care is needed when moving a newly developed diagnostic serology algorithm from a research setting to one that informs public health decisions (CDC Newsroom, 2014) .Transmission of MERS-CoV among humansFor some time, testing of samples focussed on those collected from patients with severe illness and not on milder acute respiratory tract infections, nor on conducting prospective case-control studies.", [["samples", "ANATOMY", 276, 283], ["respiratory tract", "ANATOMY", 370, 387], ["illness", "DISEASE", 338, 345], ["respiratory tract infections", "DISEASE", 370, 398], ["MERS-CoV", "ORGANISM", 229, 237], ["humans", "ORGANISM", 244, 250], ["patients", "ORGANISM", 317, 325], ["tract", "ORGANISM_SUBDIVISION", 382, 387], ["humans", "SPECIES", 244, 250], ["patients", "SPECIES", 317, 325], ["MERS-CoV", "SPECIES", 229, 237], ["humans", "SPECIES", 244, 250], ["molecular testing", "TEST", 29, 46], ["diagnostic serology algorithm", "TEST", 93, 122], ["testing of samples", "TEST", 265, 283], ["severe illness", "PROBLEM", 331, 345], ["milder acute respiratory tract infections", "PROBLEM", 357, 398], ["severe", "OBSERVATION_MODIFIER", 331, 337], ["illness", "OBSERVATION", 338, 345], ["respiratory tract", "ANATOMY", 370, 387], ["infections", "OBSERVATION", 388, 398]]], ["Contacts of confirmed MERS cases were observed for illness, but, in the absence of signs and symptoms, samples were generally not tested by a laboratory, biasing early data towards more ill and hospitalised patients; often described as just \"the tip of the iceberg\".", [["illness", "DISEASE", 51, 58], ["MERS", "CANCER", 22, 26], ["patients", "ORGANISM", 207, 215], ["patients", "SPECIES", 207, 215], ["illness", "PROBLEM", 51, 58], ["signs and symptoms", "PROBLEM", 83, 101]]], ["As testing paradigms changed with increased testing of contacts, more asymptomatic and mild infections were recognised.Transmission of MERS-CoV among humansA rise in the proportion of asymptomatic cases (which enlarges the denominator for calculations of the proportion of fatal cases (Dudley and Mackay, 2013) ) and a drop in the proportion of fatal cases (the numerator) was identified in September 2013 (Penttinen et al., 2013) .", [["infections", "DISEASE", 92, 102], ["MERS-CoV", "ORGANISM", 135, 143], ["humans", "ORGANISM", 150, 156], ["humans", "SPECIES", 150, 156], ["MERS-CoV", "SPECIES", 135, 143], ["humans", "SPECIES", 150, 156], ["testing paradigms", "TEST", 3, 20], ["mild infections", "PROBLEM", 87, 102], ["asymptomatic cases", "PROBLEM", 184, 202], ["mild", "OBSERVATION_MODIFIER", 87, 91], ["infections", "OBSERVATION", 92, 102], ["drop", "OBSERVATION_MODIFIER", 319, 323], ["fatal", "OBSERVATION_MODIFIER", 345, 350]]], ["Historically, such rises are consistent with changing definitions and laboratory and clinical responses to, and understanding of, a newly discovered virus that was first noted among the severely ill.", [["a newly discovered virus", "PROBLEM", 130, 154], ["consistent with", "UNCERTAINTY", 29, 44], ["virus", "OBSERVATION", 149, 154], ["severely", "OBSERVATION_MODIFIER", 186, 194], ["ill", "OBSERVATION", 195, 198]]], ["As adjustments to testing occurred, more cases of milder disease and those with subclinical infections were noted among MERS-CoV positive people.", [["infections", "DISEASE", 92, 102], ["MERS-CoV", "ORGANISM", 120, 128], ["people", "ORGANISM", 138, 144], ["people", "SPECIES", 138, 144], ["MERS-CoV", "SPECIES", 120, 128], ["testing", "TEST", 18, 25], ["milder disease", "PROBLEM", 50, 64], ["subclinical infections", "PROBLEM", 80, 102]]], ["Over time there has been an apparent cyclical pattern to the average weekly age of people positive for MERS-CoV (Fig. 9A ) however the age distribution changed most notably after the Jeddah-2014 outbreak during which a shift towards younger people became evident (Fig. 9B-G) .Transmission of MERS-CoV among humansAs a group, HCWs comprised 19% of MERS-CoV detections and it is apparent from closely following publicly released case data that the weekly proportion of infected HCWs increases dramatically alongside each spike in overall detections (Fig. 10 ).", [["people", "ORGANISM", 83, 89], ["MERS-CoV", "ORGANISM", 103, 111], ["people", "ORGANISM", 241, 247], ["9B-G", "GENE_OR_GENE_PRODUCT", 269, 273], ["MERS-CoV", "ORGANISM", 292, 300], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 347, 355], ["people", "SPECIES", 83, 89], ["people", "SPECIES", 241, 247], ["MERS-CoV", "SPECIES", 103, 111], ["MERS-CoV", "SPECIES", 292, 300], ["MERS-CoV", "SPECIES", 347, 355], ["an apparent cyclical pattern", "PROBLEM", 25, 53], ["MERS", "PROBLEM", 103, 107], ["CoV detections", "TEST", 352, 366], ["infected HCWs", "PROBLEM", 467, 480], ["cyclical", "OBSERVATION_MODIFIER", 37, 45], ["infected", "OBSERVATION_MODIFIER", 467, 475], ["HCWs", "OBSERVATION", 476, 480]]], ["These spikes drive observed decreases in average age during each event because afflicted HCWs as well as families are usually younger than inpatients with MERS.", [["These spikes drive", "PROBLEM", 0, 18], ["decreases", "OBSERVATION_MODIFIER", 28, 37]]], ["Healthcare facilities have therefore been a regular target for suggested improvements aimed at bolstering weaknesses in infection prevention and control (IPC) procedures (Penttinen et al., 2013; World Health Organization, 2014f) .", [["infection", "DISEASE", 120, 129], ["infection prevention", "TREATMENT", 120, 140], ["infection", "OBSERVATION", 120, 129]]], ["In May 2013, the WHO published guidelines for IPC during care of probable or confirmed cases of MERS-CoV infection in a healthcare setting (World Health Organization, 2013a).Transmission of MERS-CoV among humansThe Jeddah-2014 outbreak was the largest and most rapid accumulation of MERS-CoV detections to date (Fig. 11) with April having the greatest number of MERS-CoV detections of any month on record (Fig. 11B) .", [["MERS-CoV infection", "DISEASE", 96, 114], ["MERS-CoV", "ORGANISM", 96, 104], ["MERS-CoV", "ORGANISM", 190, 198], ["humans", "ORGANISM", 205, 211], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 283, 291], ["humans", "SPECIES", 205, 211], ["MERS-CoV", "SPECIES", 96, 104], ["MERS-CoV", "SPECIES", 190, 198], ["humans", "SPECIES", 205, 211], ["MERS-CoV", "SPECIES", 283, 291], ["MERS-CoV", "SPECIES", 362, 370], ["IPC during care", "TREATMENT", 46, 61], ["MERS", "PROBLEM", 96, 100], ["CoV infection", "PROBLEM", 101, 114], ["infection", "OBSERVATION", 105, 114], ["largest", "OBSERVATION_MODIFIER", 244, 251]]], ["The outbreak was mostly (>60% of cases) associated with human-to-human spread within hospital environments, and was thought to have resulted from a lack of, or breakdown in, IPC (Brown, 2014; Zumla and Hui, 2014) .", [["human", "ORGANISM", 56, 61], ["human", "ORGANISM", 65, 70], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 65, 70], ["breakdown", "PROBLEM", 160, 169], ["IPC", "PROBLEM", 174, 177]]], ["Following the rapid increase in case numbers, a rise in fatalities ensued (Fig. 11A) .Transmission of MERS-CoV among humansGenome sequences indicate viral change, and if the virus is well characterised, such changes may flag alterations to transmissibility, replication, lethality and response to drugs.", [["fatalities", "DISEASE", 56, 66], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 102, 110], ["humans", "ORGANISM", 117, 123], ["humans", "SPECIES", 117, 123], ["MERS-CoV", "SPECIES", 102, 110], ["humans", "SPECIES", 117, 123], ["Genome sequences", "TEST", 123, 139], ["viral change", "PROBLEM", 149, 161], ["the virus", "PROBLEM", 170, 179], ["flag alterations", "PROBLEM", 220, 236], ["lethality", "PROBLEM", 271, 280], ["drugs", "TREATMENT", 297, 302], ["rapid", "OBSERVATION_MODIFIER", 14, 19], ["increase", "OBSERVATION_MODIFIER", 20, 28], ["rise", "OBSERVATION_MODIFIER", 48, 52], ["viral change", "OBSERVATION", 149, 161]]], ["While genetic sequences examined in 2012 and 2013 showed that multiple variants circulated among people and camels in the KSA , by comparison to the massive genome sequencing approach taken towards tracking Ebola virus transmission and evolution in west Africa during 2014 (Chan et al., 2013b) , only a handful of MERS-CoV genome sequences were reported during 2014, when the majority of all MERS-CoV detections to date occurred.", [["Ebola virus transmission", "DISEASE", 207, 231], ["people", "ORGANISM", 97, 103], ["Ebola virus", "ORGANISM", 207, 218], ["MERS-CoV", "ORGANISM", 314, 322], ["MERS-CoV", "ORGANISM", 392, 400], ["MERS-CoV genome sequences", "DNA", 314, 339], ["people", "SPECIES", 97, 103], ["Ebola virus", "SPECIES", 207, 218], ["Ebola virus", "SPECIES", 207, 218], ["MERS-CoV", "SPECIES", 314, 322], ["MERS-CoV", "SPECIES", 392, 400], ["genetic sequences", "TEST", 6, 23], ["multiple variants", "PROBLEM", 62, 79], ["the massive genome sequencing approach", "TREATMENT", 145, 183], ["tracking Ebola virus transmission", "PROBLEM", 198, 231], ["CoV genome sequences", "TEST", 319, 339]]], ["How the index case(s) for either outbreak acquired MERS-CoV remains unknown.Transmission of MERS-CoV among humansGenomic sequence can also be used to define the boundaries of a cluster or outbreak based on the similarity of the variants present among the infected humans and animals and at different healthcare facilities (Fig. 4) (Cotten et al., 2014) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 51, 59], ["MERS-CoV", "ORGANISM", 92, 100], ["humans", "ORGANISM", 107, 113], ["humans", "ORGANISM", 264, 270], ["MERS-CoV", "DNA", 92, 100], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 264, 270], ["MERS-CoV", "SPECIES", 51, 59], ["MERS-CoV", "SPECIES", 92, 100], ["humans", "SPECIES", 107, 113], ["humans", "SPECIES", 264, 270], ["outbreak acquired MERS", "PROBLEM", 33, 55], ["a cluster or outbreak", "PROBLEM", 175, 196], ["infected", "OBSERVATION", 255, 263]]], ["This approach was most clearly seen when defining the geographically constrained hospital MERS outbreak in Al-Ahsa, which occurred between 1st April and 23rd May 2013, as well as clusters in Buraidah and a community outbreak in Hafr Al-Batin, KSA.", [["MERS", "DISEASE", 90, 94]]], ["Cotton et al. employed molecular epidemiology and found that there had been no sign of transmission chains extending beyond two to three months, so extensive opportunities for the virus adaptation to humans through sustained serial transmission have been infrequent (Cotten et al., 2014) .", [["humans", "ORGANISM", 200, 206], ["humans", "SPECIES", 200, 206], ["humans", "SPECIES", 200, 206], ["transmission chains", "PROBLEM", 87, 106], ["the virus adaptation", "TREATMENT", 176, 196], ["no sign of", "UNCERTAINTY", 76, 86]]], ["Sequencing of MERS-CoV genomes from the 2013 Al-Ahsa hospital outbreak indicated that multiple viral variants contributed to the cases but that most were similar enough to each other to be consistent with human-to-human transmission (Assiri et al., 2013a,b; Cotten et al., 2013b) .", [["human-to-human transmission", "DISEASE", 205, 232], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["human", "ORGANISM", 205, 210], ["human", "ORGANISM", 214, 219], ["MERS-CoV genomes", "DNA", 14, 30], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 214, 219], ["MERS-CoV", "SPECIES", 14, 22], ["human", "SPECIES", 205, 210], ["human", "SPECIES", 214, 219], ["CoV genomes", "TEST", 19, 30], ["multiple viral variants", "PROBLEM", 86, 109], ["multiple", "OBSERVATION_MODIFIER", 86, 94], ["viral variants", "OBSERVATION", 95, 109]]], ["Contact tracing has been described in detail for MERS cases exported beyond the Middle East.", [["Contact tracing", "TEST", 0, 15], ["Middle", "ANATOMY_MODIFIER", 80, 86]]], ["Tracing usually identifies dozens of potential cases per confirmed case and while it is a time consuming and expensive process it is essential for understanding transmission and for containing a virus about which little is known.", [["a virus", "PROBLEM", 193, 200]]], ["Eighty-three symptomatic or asymptomatic contacts of a case imported to Germany from the United Arab Emirates (UAE) harboured no sign of virus or antibody (Reuss et al., 2014) and similar examples of very limited to no onward transmission have been the hallmark of contact tracing results to date.", [["virus", "PROBLEM", 137, 142], ["antibody", "PROBLEM", 146, 154], ["symptomatic", "OBSERVATION_MODIFIER", 13, 24], ["no sign of", "UNCERTAINTY", 126, 136], ["virus", "OBSERVATION", 137, 142]]], ["In a study of 123 contacts of a case imported to France, only seven matched the definition for a possible case and were tested; one who had shared a 20 m 2 room while in a bed 1.5 m apart from the index case was positive and this was determined to be a nosocomial acquisition (Mailles et al., 2013) .", [["a study", "TEST", 3, 10]]], ["It is possible that further mild yet positive cases may have been identified had all contacts been tested regardless of symptoms.", [["further mild yet positive cases", "PROBLEM", 20, 51], ["symptoms", "PROBLEM", 120, 128], ["mild", "OBSERVATION_MODIFIER", 28, 32]]], ["No contacts of the first two MERS cases imported into the USA in 2014 tested positive (Bialek et al., 2014) and none among 78 contacts of two cases imported to the Netherlands develop MERS-CoV antibodies (Kraaij-Dirkzwager et al., 2014) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 184, 192], ["MERS-CoV antibodies", "PROTEIN", 184, 203], ["MERS-CoV", "SPECIES", 184, 192], ["MERS", "TEST", 184, 188], ["CoV antibodies", "TEST", 189, 203]]], ["Apart from clearly defined case studies of nosocomial infection, nosocomial spread is also suspected among a number of MERS cases noted through analysis of public data (author's observations).", [["nosocomial infection", "DISEASE", 43, 63], ["nosocomial infection", "PROBLEM", 43, 63], ["nosocomial spread", "PROBLEM", 65, 82], ["public data", "TEST", 156, 167], ["nosocomial", "OBSERVATION_MODIFIER", 43, 53], ["infection", "OBSERVATION", 54, 63], ["nosocomial spread", "OBSERVATION", 65, 82]]], ["These are cases admitted to hospital for support of a non-respiratory medical condition, who then develop respiratory symptoms and test positive for MERS-CoV within the incubation period of MERS-CoV infection.", [["respiratory", "ANATOMY", 106, 117], ["respiratory symptoms", "DISEASE", 106, 126], ["infection", "DISEASE", 199, 208], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 149, 157], ["MERS-CoV", "ORGANISM", 190, 198], ["MERS-CoV", "SPECIES", 149, 157], ["MERS-CoV", "SPECIES", 190, 198], ["a non-respiratory medical condition", "PROBLEM", 52, 87], ["respiratory symptoms", "PROBLEM", 106, 126], ["test", "TEST", 131, 135], ["MERS", "PROBLEM", 149, 153], ["CoV", "PROBLEM", 154, 157], ["MERS", "PROBLEM", 190, 194], ["CoV infection", "PROBLEM", 195, 208], ["CoV infection", "OBSERVATION", 195, 208]]], ["One example identified the likely role of a mild or asymptomatic case, present in a hospital during their admission for other reasons, as the likeliest index case for a family cluster (Omrani et al., 2013) .", [["a mild or asymptomatic case", "PROBLEM", 42, 69], ["mild", "OBSERVATION_MODIFIER", 44, 48]]], ["Such studies validate the laboratory testing of mild cases when accompanied by a process that restricts exposure of others, especially older family members and friends with underlying disease, to a MERS-CoV infected person.Virus survival in the environmentInfectious MERS-CoV added to camel, goat or cow milk and stored at 4 \u2022 C could be recovered at least 72 h later and, at 22 \u2022 C, for up to 48 h afterwards (van Doremalen et al., 2013) .", [["milk", "ANATOMY", 304, 308], ["MERS-CoV infected", "DISEASE", 198, 215], ["MERS-CoV", "ORGANISM", 198, 206], ["person", "ORGANISM", 216, 222], ["Virus", "ORGANISM", 223, 228], ["MERS-CoV", "ORGANISM", 267, 275], ["camel", "ORGANISM", 285, 290], ["goat", "ORGANISM", 292, 296], ["cow", "ORGANISM", 300, 303], ["milk", "ORGANISM_SUBSTANCE", 304, 308], ["person", "SPECIES", 216, 222], ["camel", "SPECIES", 285, 290], ["goat", "SPECIES", 292, 296], ["cow", "SPECIES", 300, 303], ["MERS-CoV", "SPECIES", 198, 206], ["Infectious MERS-CoV", "SPECIES", 256, 275], ["camel", "SPECIES", 285, 290], ["goat", "SPECIES", 292, 296], ["cow", "SPECIES", 300, 303], ["Such studies", "TEST", 0, 12], ["the laboratory testing", "TEST", 22, 44], ["mild cases", "PROBLEM", 48, 58], ["underlying disease", "PROBLEM", 173, 191], ["Virus survival", "TREATMENT", 223, 237], ["disease", "OBSERVATION", 184, 191], ["environment", "OBSERVATION_MODIFIER", 245, 256], ["Infectious", "OBSERVATION", 256, 266]]], ["This is in keeping with HCoV-229E being capable of retaining viability in water for 2 days up to a predicted 588 days depending on the type of water and temperature (Gundy et al., 2009) .", [["HCoV-229E", "CHEMICAL", 24, 33], ["HCoV-229E", "CHEMICAL", 24, 33], ["HCoV-229E", "CELL", 24, 33], ["HCoV", "PROBLEM", 24, 28]]], ["MERS-CoV titre decreased somewhat when recovered from milk at 22 \u2022 C but pasteurization ablated MERS-CoV infectivity (van Doremalen et al., 2013) .", [["milk", "ANATOMY", 54, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["milk", "ORGANISM_SUBSTANCE", 54, 58], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 96, 104], ["MERS-CoV", "SPECIES", 96, 104], ["CoV titre", "TEST", 5, 14], ["CoV infectivity", "PROBLEM", 101, 116]]], ["In a subsequent study, MERS-CoV RNA was identified in the milk, nasal secretion and faeces of camels from Qatar .Virus survival in the environmentPlastic or steel surfaces were inoculated with 10 6 TCID 50 of MERS-CoV at 20 \u2022 C, 47% relative humidity (RH) and virus recovery was attempted in cell culture (van Doremalen et al., 2013) .", [["milk", "ANATOMY", 58, 62], ["nasal", "ANATOMY", 64, 69], ["faeces", "ANATOMY", 84, 90], ["Plastic", "ANATOMY", 146, 153], ["cell", "ANATOMY", 292, 296], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["milk", "ORGANISM_SUBSTANCE", 58, 62], ["nasal", "ORGANISM_SUBDIVISION", 64, 69], ["faeces", "ORGANISM_SUBDIVISION", 84, 90], ["Virus", "ORGANISM", 113, 118], ["MERS-CoV", "SIMPLE_CHEMICAL", 209, 217], ["cell", "CELL", 292, 296], ["MERS-CoV RNA", "RNA", 23, 35], ["milk", "SPECIES", 58, 62], ["MERS-CoV", "SPECIES", 23, 31], ["MERS-CoV", "SPECIES", 209, 217], ["a subsequent study", "TEST", 3, 21], ["CoV RNA", "PROBLEM", 28, 35], ["Virus survival", "TREATMENT", 113, 127], ["Plastic or steel surfaces", "TREATMENT", 146, 171], ["MERS", "TEST", 209, 213], ["CoV", "TEST", 214, 217], ["virus recovery", "TREATMENT", 260, 274], ["cell culture", "TEST", 292, 304], ["milk", "ANATOMY", 58, 62], ["nasal", "ANATOMY", 64, 69]]], ["At 30 \u2022 C and 80% RH, MERS-CoV remained viable for 8 h and for 24 h at 30 \u2022 C, 30% RH (van Doremalen et al., 2013) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["MERS-CoV", "SPECIES", 22, 30]]], ["By comparison, influenza A virus A/Mexico/4108/2009 (H1N1) could not be recovered in Madin-Darby canine kidney (MDCK) cells beyond 4 h under any conditions (van Doremalen et al., 2013) .", [["canine kidney (MDCK) cells", "ANATOMY", 97, 123], ["influenza A virus A", "ORGANISM", 15, 34], ["Mexico/4108/2009", "ORGANISM", 35, 51], ["H1N1", "ORGANISM", 53, 57], ["Madin-Darby canine kidney (MDCK) cells", "CELL", 85, 123], ["Madin-Darby canine kidney (MDCK) cells", "CELL_LINE", 85, 123], ["influenza A virus", "SPECIES", 15, 32], ["influenza A virus A/Mexico/4108/2009 (H1N1", "SPECIES", 15, 57], ["canine", "SPECIES", 97, 103], ["kidney", "ANATOMY", 104, 110]]], ["Aerosol experiments found MERS-CoV viability decreased by 89% at 70% RH but only decreased 7% at 40% RH when an aerosol was generated at 20 \u2022 C while influenza A virus A/Mexico/4108/2009 (H1N1) decreased by 62% and 95% respectively (van Doremalen et al., 2013) .", [["influenza A virus A", "ORGANISM", 150, 169], ["Mexico/4108/2009", "ORGANISM", 170, 186], ["H1N1", "ORGANISM", 188, 192], ["influenza A virus", "SPECIES", 150, 167], ["influenza A virus A/Mexico/4108/2009 (H1N1", "SPECIES", 150, 192], ["Aerosol experiments", "TREATMENT", 0, 19], ["CoV viability", "TEST", 31, 44], ["an aerosol", "TREATMENT", 109, 119]]], ["MERS-CoV survival is inferior to that previously demonstrated by SARS-CoV (Chan et al., 2011) however for context, pathogenic bacteria can remain viable for 45 min in a coughed aerosol and can spread 4 m, thus MERS-CoV's ability to remain viable over long time periods gives it the capacity to thoroughly contaminate a room occupied by an infected and symptomatic patient (Knibbs et al., 2014) .", [["SARS-CoV", "ORGANISM", 65, 73], ["MERS-CoV", "ORGANISM", 210, 218], ["patient", "ORGANISM", 364, 371], ["patient", "SPECIES", 364, 371], ["SARS-CoV", "SPECIES", 65, 73], ["MERS-CoV", "SPECIES", 210, 218], ["pathogenic bacteria", "PROBLEM", 115, 134], ["a coughed aerosol", "TREATMENT", 167, 184], ["the capacity", "PROBLEM", 278, 290], ["infected", "OBSERVATION", 339, 347]]], ["Such findings expand our understanding of the risks associated with bioaerosols for transmission of respiratory viruses in many settings, including hospital waiting rooms, emergency departments, treatment rooms, open intensive care facilities and private patient rooms.", [["respiratory viruses", "DISEASE", 100, 119], ["patient", "ORGANISM", 255, 262], ["patient", "SPECIES", 255, 262], ["bioaerosols", "TREATMENT", 68, 79], ["respiratory viruses", "PROBLEM", 100, 119], ["respiratory viruses", "OBSERVATION", 100, 119]]], ["The nature and quality of air exchange, circulation and filtration is an important variable in risk measurement and reduction.", [["air exchange", "TREATMENT", 26, 38], ["filtration", "TREATMENT", 56, 66], ["air exchange", "OBSERVATION", 26, 38]]], ["Droplet spread between humans is considered the mechanism of human-to-human transmission and the need for droplet precautions has been emphasised after the Al-Ahsa hospital outbreak Assiri et al., 2013a,b; Zumla and Memish, 2014) .", [["humans", "ORGANISM", 23, 29], ["human", "ORGANISM", 61, 66], ["human", "ORGANISM", 70, 75], ["humans", "SPECIES", 23, 29], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 70, 75], ["humans", "SPECIES", 23, 29], ["human", "SPECIES", 61, 66], ["human", "SPECIES", 70, 75], ["Droplet spread", "PROBLEM", 0, 14], ["droplet precautions", "TREATMENT", 106, 125]]], ["By extrapolation, aerosol-generating events involving camels (urination, defecation, and the processes of preparation and consumption of camel products) should be factored into risk measurement and reduction efforts and the need to define whether a more stringent level of personal protective equipment should be worn by HCWs and animal handlers remains a priority.MERS-CoV and pandemic potentialWhen the MERS-CoV detection tally sat below 120, analyses of the basic reproduction number (R 0 ) -the average number of infections caused by one infected individual in a fully susceptible population -returned values below 1, indicating that a pandemic was not likely (Bauch and Oraby, 2013; Breban et al., 2013; Cauchemez et al., 2014; Poletto et al., 2013) .", [["infections", "DISEASE", 517, 527], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 365, 373], ["MERS-CoV", "SPECIES", 365, 373], ["MERS-CoV", "SPECIES", 405, 413], ["aerosol", "TREATMENT", 18, 25], ["defecation", "PROBLEM", 73, 83], ["camel products", "TREATMENT", 137, 151], ["reduction efforts", "TREATMENT", 198, 215], ["personal protective equipment", "TREATMENT", 273, 302], ["the MERS", "TEST", 401, 409], ["CoV detection tally sat", "TEST", 410, 433], ["infections", "PROBLEM", 517, 527], ["infections", "OBSERVATION", 517, 527], ["not likely", "UNCERTAINTY", 653, 663]]], ["With more data and correction for observation bias, this conclusion was maintained (Chowell et al., 2014) .", [["observation bias", "TEST", 34, 50]]], ["These analyses reflected charting of small public data sources and indicated that while cases could climb suddenly, such as during the Al-Ahsa outbreak , the climb was not logarithmic.", [["These analyses", "TEST", 0, 14], ["small", "OBSERVATION_MODIFIER", 37, 42]]], ["Methods used in these studies vary but some make allowance for more extensive case numbers than may have been publicly reported (Cauchemez et al., 2014; Poletto et al., 2013) .", [["Methods", "TREATMENT", 0, 7], ["these studies", "TEST", 16, 29]]], ["The impact of incomplete case contact tracing, limited community testing and clinically defined cases in the absence of laboratory confirmation might affect some R 0 calculations and make it difficult to identify patterns among case occurrence.", [["limited community testing", "TEST", 47, 72], ["laboratory confirmation", "TEST", 120, 143]]], ["The implication is that more positives among these population groups could have occurred and thus a greater transmission efficiency and higher R 0 value may be possible.", [["a greater transmission efficiency", "PROBLEM", 98, 131], ["may be possible", "UNCERTAINTY", 153, 168]]], ["When narrowing an analysis to index cases (the case with the earliest onset date of a cluster) and inferring secondary case numbers, one study predicted that the R 0 could be slightly above 1.0 (0.8-1.3 with an upper bound of 1.2-1.5 depending on method used) (Cauchemez et al., 2014) .", [["an analysis", "TEST", 15, 26], ["one study", "TEST", 133, 142], ["an upper bound", "TEST", 208, 222]]], ["This study hypothesised that a high proportion of infections were not being detected (Cauchemez et al., 2014) .", [["infections", "DISEASE", 50, 60], ["This study", "TEST", 0, 10], ["infections", "PROBLEM", 50, 60], ["infections", "OBSERVATION", 50, 60]]], ["Similar analyses are awaited following the Jeddah-2014 outbreak.MERS-CoV and pandemic potentialMost cases of MERS have resulted from human-to-human transmission, however that transmission was inefficient Memish et al., 2013b; Omrani et al., 2013) and defined as sporadic rather than sustained (Fig. 12) .", [["MERS", "DISEASE", 109, 113], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 64, 72], ["MERS", "CANCER", 109, 113], ["human", "ORGANISM", 133, 138], ["human", "ORGANISM", 142, 147], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 142, 147], ["MERS-CoV", "SPECIES", 64, 72], ["human", "SPECIES", 133, 138], ["human", "SPECIES", 142, 147]]], ["Based on observational studies, human spread requires close contact to occur.", [["human", "ORGANISM", 32, 37], ["human", "SPECIES", 32, 37], ["human", "SPECIES", 32, 37], ["observational studies", "TEST", 9, 30]]], ["Relevant data are scant but it appears that the majority of human cases of MERS-CoV do not transmit to more than one other human and to date, the localised epidemic of MERS-CoV has not been selfsustaining (Poletto et al., 2013) .", [["human", "ORGANISM", 60, 65], ["MERS-CoV", "ORGANISM", 75, 83], ["human", "ORGANISM", 123, 128], ["MERS-CoV", "ORGANISM", 168, 176], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 123, 128], ["human", "SPECIES", 60, 65], ["MERS-CoV", "SPECIES", 75, 83], ["human", "SPECIES", 123, 128], ["MERS-CoV", "SPECIES", 168, 176]]], ["Index or sporadic cases have been of age and sex during the Jeddah-2014 outbreak, arbitrarily defined as spanning from the week beginning 17th March 2014 and ending in the week beginning7th July 2014; data are based on laboratory confirmed cases collated into the author's curated line list as at 19th January 2015.", [["sporadic cases", "PROBLEM", 9, 23]]], ["Note the changed x-axis scale between B/C and D/E/F/G. Sources of these public data include the World Health Organization, Ministries of Health and FluTrackers (Ministry of Health, Saudi Arabia.", [["B/C", "CELL", 38, 41]]], ["(Mackay, 1997) and blog (Mackay, 2013) .MERS-CoV and pandemic potentialolder and it has yet to be established whether infections thought to have been acquired from an animal source produce a more severe outcome than those spread between humans (The WHO MERS-CoV Research Group, 2013) .", [["infections", "DISEASE", 118, 128], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 40, 48], ["humans", "ORGANISM", 237, 243], ["humans", "SPECIES", 237, 243], ["MERS-CoV", "SPECIES", 40, 48], ["humans", "SPECIES", 237, 243], ["infections", "PROBLEM", 118, 128], ["severe", "OBSERVATION_MODIFIER", 196, 202]]], ["Strategic sero-assays have yet to investigate the extent to which milder or asymptomatic cases contribute to the MERS-CoV transmission chain.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 113, 121], ["MERS-CoV transmission chain", "PROTEIN", 113, 140], ["MERS-CoV", "SPECIES", 113, 121], ["Strategic sero-assays", "TEST", 0, 21], ["asymptomatic cases", "PROBLEM", 76, 94]]], ["In a household study, 14 of 280 (5%) contacts of 26 MERS-CoV positive index patients were RNA or antibody positive .Therapeutic options for the MERS-CoVThere is no specific drug or vaccine currently available to treat infection by the MERS-CoV.", [["infection", "DISEASE", 218, 227], ["MERS-CoV", "ORGANISM", 52, 60], ["patients", "ORGANISM", 76, 84], ["MERS-CoV", "ORGANISM", 235, 243], ["patients", "SPECIES", 76, 84], ["MERS-CoV", "SPECIES", 52, 60], ["MERS-CoV", "SPECIES", 235, 243], ["a household study", "TEST", 3, 20], ["CoV positive index", "TEST", 57, 75], ["RNA", "TEST", 90, 93], ["antibody positive", "PROBLEM", 97, 114], ["Therapeutic options", "TREATMENT", 116, 135], ["vaccine", "TREATMENT", 181, 188], ["infection", "PROBLEM", 218, 227]]], ["For context, there is still no vaccine available against SARS, mostly attributable to the brevity of the SARS-CoV global emergence.", [["SARS", "DISEASE", 57, 61], ["SARS", "DISEASE", 105, 109], ["SARS-CoV", "ORGANISM", 105, 113], ["SARS-CoV", "SPECIES", 105, 113], ["vaccine", "TREATMENT", 31, 38], ["SARS", "PROBLEM", 57, 61], ["the SARS", "PROBLEM", 101, 109]]], ["It is impossible to predict whether a MERS-CoV vaccine for human use will fall victim to a lack of commercial interest or remain relevant in the time it will take to be developed, however a vaccine for use in camels is a more practical option given the identity shared between human and camel viral variants and the apparent rarity of MERS-CoV spillover to humans.", [["MERS-CoV", "ORGANISM", 38, 46], ["human", "ORGANISM", 59, 64], ["camels", "ORGANISM", 209, 215], ["human", "ORGANISM", 277, 282], ["camel viral", "ORGANISM", 287, 298], ["MERS-CoV", "ORGANISM", 335, 343], ["humans", "ORGANISM", 357, 363], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 277, 282], ["humans", "SPECIES", 357, 363], ["MERS-CoV", "SPECIES", 38, 46], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 277, 282], ["MERS-CoV", "SPECIES", 335, 343], ["humans", "SPECIES", 357, 363], ["a MERS-CoV vaccine", "TREATMENT", 36, 54], ["a vaccine", "TREATMENT", 188, 197], ["human and camel viral variants", "TREATMENT", 277, 307]]], ["If applied to young camels ahead of their first virus acquisition, such a vaccine may be capable of eradicating MERS-CoV from herds.", [["MERS-CoV", "ORGANISM", 112, 120], ["MERS-CoV", "SPECIES", 112, 120], ["their first virus acquisition", "TEST", 36, 65], ["a vaccine", "TREATMENT", 72, 81]]], ["But if the source of camel infections is bats, newly imported camels or other herds, any vaccine would need to be used in an ongoing manner and be able to reach feral camel herds as well.", [["camel infections", "DISEASE", 21, 37], ["camel", "ORGANISM", 21, 26], ["camels", "ORGANISM", 62, 68], ["camel", "ORGANISM", 167, 172], ["camel", "SPECIES", 21, 26], ["camel", "SPECIES", 167, 172], ["camel infections", "PROBLEM", 21, 37], ["any vaccine", "TREATMENT", 85, 96]]], ["Care of hospitalised patients remains supportive, with vigilance for complications (The WHO MERS-CoV Research Group, 2013) .", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["complications", "PROBLEM", 69, 82]]], ["No empirical use of antimicrobial agents has improved severe disease nor have high dose steroids succeeded in reversing the progression of respiratory disease (The WHO MERS-CoV Research Group, 2013) .", [["respiratory", "ANATOMY", 139, 150], ["steroids", "CHEMICAL", 88, 96], ["respiratory disease", "DISEASE", 139, 158], ["steroids", "CHEMICAL", 88, 96], ["antimicrobial agents", "TREATMENT", 20, 40], ["severe disease", "PROBLEM", 54, 68], ["high dose steroids", "TREATMENT", 78, 96], ["respiratory disease", "PROBLEM", 139, 158], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["disease", "OBSERVATION", 61, 68], ["progression", "OBSERVATION_MODIFIER", 124, 135], ["respiratory disease", "OBSERVATION", 139, 158]]], ["The development and registration of drugs for human use is not suitably rapid to use effectively against an emerging infectious agent (de Wilde et al., 2014; Dyall et al., 2014) .", [["human", "ORGANISM", 46, 51], ["human", "SPECIES", 46, 51], ["human", "SPECIES", 46, 51], ["drugs", "TREATMENT", 36, 41]]], ["However, research advances in this area have been made.Therapeutic options for the MERS-CoVTesting of formulations previously approved by the Food and Drug Agency (FDA; USA) at the Small-molecule Inhibitor Leads Versus Emerging and neglected RNA viruses (SILVER) project described four existing compounds (chloroquine, chlorpromazine, loperamide and lopinavir) that inhibit MERS-CoV, SARS-CoV and HCoV-229E replication in cell culture (de Wilde et al., 2014; SILVER consortium, 2015) .", [["cell culture", "ANATOMY", 422, 434], ["chloroquine", "CHEMICAL", 306, 317], ["chlorpromazine", "CHEMICAL", 319, 333], ["loperamide", "CHEMICAL", 335, 345], ["lopinavir", "CHEMICAL", 350, 359], ["chloroquine", "CHEMICAL", 306, 317], ["chlorpromazine", "CHEMICAL", 319, 333], ["loperamide", "CHEMICAL", 335, 345], ["lopinavir", "CHEMICAL", 350, 359], ["chloroquine", "SIMPLE_CHEMICAL", 306, 317], ["chlorpromazine", "SIMPLE_CHEMICAL", 319, 333], ["loperamide", "SIMPLE_CHEMICAL", 335, 345], ["lopinavir", "SIMPLE_CHEMICAL", 350, 359], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 374, 382], ["SARS-CoV", "ORGANISM", 384, 392], ["HCoV-229E", "GENE_OR_GENE_PRODUCT", 397, 406], ["cell culture", "CELL", 422, 434], ["MERS-CoV", "SPECIES", 374, 382], ["SARS-CoV", "SPECIES", 384, 392], ["HCoV-229E", "SPECIES", 397, 406], ["Therapeutic options", "TREATMENT", 55, 74], ["CoVTesting of formulations", "TREATMENT", 88, 114], ["the Small-molecule Inhibitor Leads", "TREATMENT", 177, 211], ["Emerging and neglected RNA viruses", "PROBLEM", 219, 253], ["chloroquine", "TREATMENT", 306, 317], ["chlorpromazine", "TREATMENT", 319, 333], ["loperamide", "TREATMENT", 335, 345], ["lopinavir", "TREATMENT", 350, 359], ["SARS", "PROBLEM", 384, 388], ["HCoV", "TREATMENT", 397, 401], ["cell culture", "TEST", 422, 434]]], ["In another study, 33 drugs with the ability to impart >50% inhibition upon MERS-CoV growth in culture have been described as candidates for future clinical MERS intervention studies (Dyall et al., 2014) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 75, 83], ["MERS-CoV", "SPECIES", 75, 83], ["another study", "TEST", 3, 16], ["33 drugs", "TREATMENT", 18, 26], ["MERS", "PROBLEM", 75, 79], ["CoV growth in culture", "PROBLEM", 80, 101]]], ["These were also identified following investigation of pre-existing, FDA-approved clinical drugs and encompass 13 different classes of therapeutic (Dyall et al., 2014) .", [["clinical drugs", "TREATMENT", 81, 95]]], ["A novel molecule, K22, showed promise both directly and as an example that it was possible to target and specifically disrupt very conserved viral replication processes such as double membrane vesicle-associated RNA replication, without causing cellular toxicity (Lundin et al., 2014) .Therapeutic options for the MERS-CoVAnother approach has been to target the interface between the MERS-CoV RBD and the receptor by employing competitive substrates or inhibitors of the enzymatic function of DPP4 (Kawalec et al., 2014) .", [["membrane vesicle", "ANATOMY", 184, 200], ["cellular", "ANATOMY", 245, 253], ["toxicity", "DISEASE", 254, 262], ["K22", "GENE_OR_GENE_PRODUCT", 18, 21], ["membrane vesicle", "CELLULAR_COMPONENT", 184, 200], ["cellular", "CELL", 245, 253], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 384, 392], ["DPP4", "GENE_OR_GENE_PRODUCT", 493, 497], ["K22", "PROTEIN", 18, 21], ["MERS-CoV RBD", "PROTEIN", 384, 396], ["DPP4", "PROTEIN", 493, 497], ["MERS-CoV", "SPECIES", 384, 392], ["A novel molecule, K22", "TEST", 0, 21], ["viral replication processes", "PROBLEM", 141, 168], ["double membrane vesicle", "PROBLEM", 177, 200], ["RNA replication", "PROBLEM", 212, 227], ["cellular toxicity", "PROBLEM", 245, 262], ["Therapeutic options", "TREATMENT", 286, 305], ["the MERS-CoVAnother approach", "TREATMENT", 310, 338], ["competitive substrates", "TREATMENT", 427, 449], ["inhibitors", "TREATMENT", 453, 463], ["DPP4", "TEST", 493, 497], ["viral replication", "OBSERVATION", 141, 158], ["RNA replication", "OBSERVATION", 212, 227], ["without causing", "UNCERTAINTY", 229, 244], ["cellular toxicity", "OBSERVATION", 245, 262]]], ["DPP4 inhibitors, in their role as anti-diabetes drugs, already exist, are tolerated and are not associated with adverse events (Kawalec et al., 2014) although it is unclear whether they may already be in use among MERS patients with underlying kidney disease.", [["kidney", "ANATOMY", 244, 250], ["kidney disease", "DISEASE", 244, 258], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["patients", "ORGANISM", 219, 227], ["kidney", "ORGAN", 244, 250], ["patients", "SPECIES", 219, 227], ["DPP4 inhibitors", "TREATMENT", 0, 15], ["anti-diabetes drugs", "TREATMENT", 34, 53], ["adverse events", "PROBLEM", 112, 126], ["underlying kidney disease", "PROBLEM", 233, 258], ["kidney", "ANATOMY", 244, 250], ["disease", "OBSERVATION", 251, 258]]], ["Additionally, targeting the viral MERS-CoV 3C protease, important for replicase polyprotein maturation, may be a viable strategy in the future because it has so far remained conserved (Cotten et al., 2014) .Therapeutic options for the MERS-CoVThe company Novavax has produced an experimental recombinant nanoparticle vaccine candidate based on the MERS-CoV S protein and it has generated important anti-MERS-CoV antibodies in a mouse model (Coleman et al., 2014a) .", [["Novavax", "CHEMICAL", 255, 262], ["MERS-CoV 3C", "GENE_OR_GENE_PRODUCT", 34, 45], ["MERS-CoV S", "GENE_OR_GENE_PRODUCT", 348, 358], ["anti-MERS-CoV antibodies", "GENE_OR_GENE_PRODUCT", 398, 422], ["mouse", "ORGANISM", 428, 433], ["viral MERS-CoV 3C protease", "PROTEIN", 28, 54], ["MERS-CoV S protein", "PROTEIN", 348, 366], ["anti-MERS-CoV antibodies", "PROTEIN", 398, 422], ["mouse", "SPECIES", 428, 433], ["MERS-CoV", "SPECIES", 348, 356], ["mouse", "SPECIES", 428, 433], ["the viral MERS", "PROBLEM", 24, 38], ["CoV 3C protease", "TREATMENT", 39, 54], ["replicase polyprotein maturation", "TREATMENT", 70, 102], ["Therapeutic options", "TREATMENT", 207, 226], ["Novavax", "TREATMENT", 255, 262], ["an experimental recombinant nanoparticle vaccine", "TREATMENT", 276, 324], ["CoV S protein", "TEST", 353, 366], ["viral MERS", "OBSERVATION", 28, 38]]], ["Monoclonal antibodies (e.g. MERS-4, MERS-27 and 3B11) directed towards the S protein are capable of neutralising infection by the MERS-CoV and hold future promise for use as a therapeutic and prophylactic Tang et al., 2014) .", [["infection", "DISEASE", 113, 122], ["MERS-4", "GENE_OR_GENE_PRODUCT", 28, 34], ["MERS-27", "GENE_OR_GENE_PRODUCT", 36, 43], ["3B11", "GENE_OR_GENE_PRODUCT", 48, 52], ["MERS-CoV", "ORGANISM", 130, 138], ["Monoclonal antibodies", "PROTEIN", 0, 21], ["MERS", "PROTEIN", 28, 32], ["MERS", "PROTEIN", 36, 40], ["3B11", "PROTEIN", 48, 52], ["S protein", "PROTEIN", 75, 84], ["MERS-CoV", "SPECIES", 130, 138], ["Monoclonal antibodies", "TEST", 0, 21], ["MERS", "TEST", 28, 32], ["MERS", "TEST", 36, 40], ["neutralising infection", "PROBLEM", 100, 122]]], ["A replication-competent, propagation-deficient E gene-deleted mutant of MERS-CoV variant EMC/2012 (rMERS-CoV-E) may also prove to be a useful vaccine candidate while a truncated RBD of MERS-CoV has been shown to elicit antibodies in mice (Almaz\u00e1n et al., 2013; Du et al., 2013a) .", [["E", "GENE_OR_GENE_PRODUCT", 47, 48], ["MERS-CoV", "ORGANISM", 72, 80], ["rMERS-CoV-E", "GENE_OR_GENE_PRODUCT", 99, 110], ["MERS-CoV", "ORGANISM", 185, 193], ["mice", "ORGANISM", 233, 237], ["E gene", "DNA", 47, 53], ["RBD", "PROTEIN", 178, 181], ["MERS", "PROTEIN", 185, 189], ["antibodies", "PROTEIN", 219, 229], ["mice", "SPECIES", 233, 237], ["MERS-CoV", "SPECIES", 72, 80], ["MERS-CoV", "SPECIES", 185, 193], ["mice", "SPECIES", 233, 237], ["A replication", "TREATMENT", 0, 13], ["a truncated RBD of MERS", "PROBLEM", 166, 189]]], ["A conserved peptide in the RdRp of all HCoVs was also identified, and that may provide the basis for an epitope-directed universal vaccine (Sharmin and Islam, 2014) .Therapeutic options for the MERS-CoVIFN treatment has shown promise in culture-based experiments (MERS, 2014a) but in macaques, early application was required for effectiveness.", [["MERS-CoVIFN", "CHEMICAL", 194, 205], ["HCoVs", "GENE_OR_GENE_PRODUCT", 39, 44], ["macaques", "ORGANISM", 284, 292], ["RdRp", "PROTEIN", 27, 31], ["HCoVs", "PROTEIN", 39, 44], ["A conserved peptide", "PROBLEM", 0, 19], ["an epitope-directed universal vaccine", "TREATMENT", 101, 138], ["Therapeutic options", "TREATMENT", 166, 185], ["CoVIFN treatment", "TREATMENT", 199, 215], ["culture", "TEST", 237, 244], ["all", "OBSERVATION_MODIFIER", 35, 38], ["HCoVs", "OBSERVATION", 39, 44]]], ["Macaques were infected with 7 \u00d7 10 6 TCID 50 of MERS-CoV and, 8 h after infection, they were treated with substantial amounts of subcutaneous IFN-\u24232b along with intravenous ribavirin, followed by ribavirin doses intramuscularly every 8 h and with IFN-\u24232b every 16 h until 72 h after infection .", [["Macaques", "ANATOMY", 0, 8], ["subcutaneous", "ANATOMY", 129, 141], ["intravenous", "ANATOMY", 161, 172], ["infection", "DISEASE", 72, 81], ["IFN-\u24232b", "CHEMICAL", 142, 149], ["ribavirin", "CHEMICAL", 173, 182], ["ribavirin", "CHEMICAL", 196, 205], ["IFN-\u24232b", "CHEMICAL", 247, 254], ["infection", "DISEASE", 283, 292], ["ribavirin", "CHEMICAL", 173, 182], ["ribavirin", "CHEMICAL", 196, 205], ["MERS-CoV", "ORGANISM", 48, 56], ["IFN-\u24232b", "GENE_OR_GENE_PRODUCT", 142, 149], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 161, 172], ["ribavirin", "SIMPLE_CHEMICAL", 173, 182], ["ribavirin", "SIMPLE_CHEMICAL", 196, 205], ["IFN-\u24232b", "GENE_OR_GENE_PRODUCT", 247, 254], ["IFN", "PROTEIN", 142, 145], ["IFN", "PROTEIN", 247, 250], ["MERS-CoV", "SPECIES", 48, 56], ["MERS", "TEST", 48, 52], ["CoV", "TEST", 53, 56], ["infection", "PROBLEM", 72, 81], ["subcutaneous IFN", "TREATMENT", 129, 145], ["intravenous ribavirin", "TREATMENT", 161, 182], ["ribavirin doses intramuscularly", "TREATMENT", 196, 227], ["IFN", "TREATMENT", 247, 250], ["infection", "PROBLEM", 283, 292], ["infection", "OBSERVATION", 72, 81], ["infection", "OBSERVATION", 283, 292]]], ["Treatment prevented any signs of increased respiration, leucocytosis (neutrophilia) or reduction in oxygen saturation seen in the untreated animals plus treated macaques had very little to no radiographic evidence of pneumonia .", [["leucocytosis", "DISEASE", 56, 68], ["neutrophilia", "DISEASE", 70, 82], ["oxygen", "CHEMICAL", 100, 106], ["pneumonia", "DISEASE", 217, 226], ["oxygen", "CHEMICAL", 100, 106], ["oxygen", "SIMPLE_CHEMICAL", 100, 106], ["macaques", "ORGANISM", 161, 169], ["Treatment", "TREATMENT", 0, 9], ["increased respiration", "PROBLEM", 33, 54], ["leucocytosis", "PROBLEM", 56, 68], ["neutrophilia", "PROBLEM", 70, 82], ["oxygen saturation", "TEST", 100, 117], ["pneumonia", "PROBLEM", 217, 226], ["increased", "OBSERVATION_MODIFIER", 33, 42], ["respiration", "OBSERVATION_MODIFIER", 43, 54], ["leucocytosis", "OBSERVATION", 56, 68], ["reduction", "OBSERVATION_MODIFIER", 87, 96], ["oxygen saturation", "OBSERVATION", 100, 117], ["evidence of", "UNCERTAINTY", 205, 216], ["pneumonia", "OBSERVATION", 217, 226]]], ["The viral load in daily BALs did not differ between treated and untreated macaques but loads were reduced in the treated animal's postmortem tissues and fewer tissues were MERS-CoV RT-PCR positive.", [["postmortem tissues", "ANATOMY", 130, 148], ["tissues", "ANATOMY", 159, 166], ["macaques", "ORGANISM", 74, 82], ["postmortem tissues", "TISSUE", 130, 148], ["tissues", "TISSUE", 159, 166], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 172, 180], ["The viral load in daily BALs", "TEST", 0, 28], ["untreated macaques", "PROBLEM", 64, 82], ["fewer tissues", "PROBLEM", 153, 166], ["MERS", "TEST", 172, 176], ["CoV RT-PCR", "TEST", 177, 187], ["viral load", "OBSERVATION", 4, 14]]], ["Since MERS seems to be a prolonged disease that is well engaged (Mackay, 1997) and blog (Mackay, 2013) . upon presentation for medical help, it is unclear how this drug cocktail could be delivered early enough to moderate severe disease.", [["a prolonged disease", "PROBLEM", 23, 42], ["this drug cocktail", "TREATMENT", 159, 177], ["moderate severe disease", "PROBLEM", 213, 236], ["seems to be", "UNCERTAINTY", 11, 22], ["prolonged", "OBSERVATION_MODIFIER", 25, 34], ["disease", "OBSERVATION", 35, 42], ["moderate", "OBSERVATION_MODIFIER", 213, 221], ["severe", "OBSERVATION_MODIFIER", 222, 228], ["disease", "OBSERVATION", 229, 236]]], ["When trialled on five critically ill patients with comorbidities and a median time between hospitalization and treatment of 19 days (range 10-22 days), no response to treatment was evident .", [["critically ill", "DISEASE", 22, 36], ["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["comorbidities", "PROBLEM", 51, 64], ["treatment", "TREATMENT", 111, 120], ["treatment", "TREATMENT", 167, 176]]], ["Through Global Alert and Response (GAR) Disease Outbreak News (DON) releases, the WHO kept the world updated with detailed, deidentified case information provided soon after they had been forwarded on to them from each country's Ministry of Health or equivalent, as per the transparency required by the International Health Regulations (IHR), 2005.", [["DON", "CHEMICAL", 63, 66]]], ["Cases announced via the KSA Ministry of Health website have often had data inconsistencies including errors, format variations, have often lacked key information including dates, have presented deaths with insufficient information to permit linkage with the announced case and over one hundred cases remain devoid of all key data, excluding them from most epidemiological analyses.", [["deaths", "DISEASE", 194, 200]]], ["This was a particular problem during periods when rapid case accumulation became a concern for the global community.", [["a particular problem", "PROBLEM", 9, 29], ["rapid case accumulation", "PROBLEM", 50, 73]]], ["When available, WHO DONs fill in vital missing detail, with additional important demographic data like age, sex or essential dates permitting improved understanding of when illness onset occurred, when cases were hospitalised, whether they were asymptomatic and if the newly announced case was a contact of another case, an animal or an animal product.", [["illness", "DISEASE", 173, 180]]], ["However DONs are only effective when the underlying data is forwarded to the WHO.", [["DONs", "SIMPLE_CHEMICAL", 8, 12]]], ["Such comprehensive data permits other calculations, for instance the likely laboratory turnaround time, the possibility for nosocomial spread occurring and the location of cases as a determining factor in whether a cluster has become an outbreak or a local epidemic.", [["other calculations", "TEST", 32, 50], ["nosocomial spread", "PROBLEM", 124, 141], ["a local epidemic", "PROBLEM", 249, 265]]], ["Such experts report to many levels of Health management and government who seek to understand threats to their own population so as to make the most informed judgements.", [["Health management", "TREATMENT", 38, 55]]], ["The decisions which follow may include the need to raise alert levels, prepare laboratory capacity, create educational materials, free specific response funds, ramp up messaging, manage and alter border controls or issue travel alerts.", [["alert levels", "TEST", 57, 69], ["laboratory capacity", "TEST", 79, 98], ["ramp up messaging", "TREATMENT", 160, 177]]], ["The activities of the WHO have been essential for global preparedness against MERS.", [["MERS", "PROBLEM", 78, 82]]], ["The WHO rapidly and comprehensively adopted, updated and publicly promoted diagnostic tools and testing algorithms, case definitions and guidelines for investigations, research study protocols, IPC guidance, travel advice, risk assessments and summary updates via a purpose-built coronavirus-focussed website.", [["coronavirus", "ORGANISM", 280, 291], ["testing algorithms", "TEST", 96, 114], ["investigations", "TEST", 152, 166], ["research study protocols", "TEST", 168, 192], ["built coronavirus", "PROBLEM", 274, 291]]], ["The role of WHO as a nexus for collaboration laid the groundwork for the accumulation and advancement of knowledge about MERS and the MERS-CoV through the formation of, and reporting by, the IHR (2005) Emergency Committee concerning MERS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 134, 142], ["MERS-CoV", "ORGANISM", 233, 241], ["MERS-CoV", "SPECIES", 134, 142], ["MERS-CoV", "SPECIES", 233, 241], ["the accumulation", "PROBLEM", 69, 85]]], ["Upon request, the WHO has also sent risk assessment teams to the region to gauge the MERS situation.", [["risk assessment", "TEST", 36, 51]]], ["Gregory H\u00e4rtl, Coordinator of the Department of Communications for the WHO, noted that \"the more answers public health experts can provide now, the greater the public's trust in these institutions will be if and when the virus should become easily transmissible between humans and cause more widespread morbidity and mortality\" (Hartl, 2013) .", [["humans", "ORGANISM", 270, 276], ["humans", "SPECIES", 270, 276], ["humans", "SPECIES", 270, 276], ["the virus", "PROBLEM", 217, 226]]], ["This is a comment that applies equally well to the emergence of any infectious disease.", [["infectious disease", "DISEASE", 68, 86], ["any infectious disease", "PROBLEM", 64, 86], ["infectious", "OBSERVATION", 68, 78]]], ["By comparison, officials within the KSA were widely and regularly criticised for moving slowly, shunning collaborations and failing to show proactive action in commencing local research into MERS and MERS-CoV (2014c; Editorial, 2014; Holmes, 2014; Kupferschmidt, 2014; Reuters, 2014; World Health Organization, 2014f) .Communicating risk to the publicDespite data in the scientific literature strongly indicating that camels harboured MERS-CoV or a very closely related virus, communication about camels posing a risk to humans as the zoonotic sources for infections did not became a mainstream public health message until late April of 2014; two years after the discovery of the virus.", [["infections", "DISEASE", 556, 566], ["camels", "ORGANISM", 418, 424], ["MERS-CoV", "ORGANISM", 435, 443], ["camels", "ORGANISM", 497, 503], ["humans", "ORGANISM", 521, 527], ["humans", "SPECIES", 521, 527], ["MERS-CoV", "SPECIES", 435, 443], ["humans", "SPECIES", 521, 527], ["a very closely related virus", "PROBLEM", 447, 475], ["infections", "PROBLEM", 556, 566], ["the virus", "PROBLEM", 676, 685]]], ["This shift correlated with a change in the KSA Minister of Health, requests for help in containing the Jeddah-2014 outbreak and a new WHO risk assessment, which included mention of camels (World Health Organization, 2014e) .", [["risk assessment", "TEST", 138, 153]]], ["Despite that, internet-driven information has played a vital role in rapidly tracking and unearthing cases, clusters and outbreaks of disease in recent years.", [["disease", "PROBLEM", 134, 141]]], ["At this stage, many who follow infectious disease clusters, outbreaks and pandemics through social media are well informed by exposure to a distillation of the most recent events, reports, commentary and news stories from all over the world.", [["infectious", "OBSERVATION_MODIFIER", 31, 41]]], ["Professionals who use this communication medium are clearly appreciated by their funding stakeholders, the public.", [["this communication medium", "TREATMENT", 22, 47]]], ["Sometimes these forms of mass communication are useful to those seeking information about a disease outbreak in their own country.", [["mass communication", "PROBLEM", 25, 43], ["a disease outbreak", "PROBLEM", 90, 108], ["mass", "OBSERVATION", 25, 29]]], ["The President John F. Kennedy quote, \"One person can make a difference, and everyone should try\" seems an apt one to describe these dedicated people who, often without any paid incentives, devote their personal time, effort and money to better understand and communicate about infectious disease.", [["infectious disease", "DISEASE", 277, 295], ["people", "ORGANISM", 142, 148], ["person", "SPECIES", 42, 48], ["people", "SPECIES", 142, 148], ["infectious disease", "PROBLEM", 277, 295]]], ["Frequently updated data repositories such as the small FluTrackers group constantly compile, actively curate and condense worldwide news sources into threads of information that often assemble into patterns that can predict emerging infectious disease events well before they reach the mainstream media, and their line list of MERS-CoV detections (Ministry of Health, Saudi Arabia.", [["MERS-CoV", "ORGANISM", 327, 335], ["MERS-CoV", "SPECIES", 327, 335], ["emerging infectious disease events", "PROBLEM", 224, 258]]], ["2014) has been a cornerstone of case numbering, detail and clarity; Crawford Kilian's H5N1 blog (Kilian, 2014) outstrips its name by providing links to other reliable sources as well as excerpts and highly eloquent and thought-provoking commentary on a range of microbial infectious disease stories, of which MERS-CoV is just one; Michael Coston's Avian Flu Diary (Coston, 2014 ) also focusses and comments on emerging infectious diseases augmented by astute and experienced public health commentary, resources and a large inventory of past posts that are used to good effect when creating new and informative ones; the Programme for Monitoring Emerging Diseases (ProMED) is an internet-based reporting system maintained by a panel of authoritative professionals and rapporteurs who prepare daily digests of the latest infectious disease happenings which they freely circulate using widely read emails (Program for Monitoring Emerging Diseases, 2014); for a more workforce-oriented view of MERS and infectious disease, Shane Granger's Random Analytics provides an excellent perspective of the less frequently discussed impact of infectious diseases on humans (Granger, 2012) ; my own blog, Virology Down Under seeks to distill some of the more complex virology-related happenings and present data on emerging viral disease in a more graphical, accessible and open access way (Mackay, 1997 (Mackay, , 2013 ; Maia Majumder who applies an engineering systems expertise to the epidemiology of the disease (Majumder, 2014) .", [["infectious diseases", "DISEASE", 419, 438], ["infectious disease", "DISEASE", 999, 1017], ["infectious diseases", "DISEASE", 1129, 1148], ["viral disease", "DISEASE", 1309, 1322], ["MERS-CoV", "ORGANISM", 309, 317], ["humans", "ORGANISM", 1152, 1158], ["humans", "SPECIES", 1152, 1158], ["MERS-CoV", "SPECIES", 309, 317], ["humans", "SPECIES", 1152, 1158], ["microbial infectious disease stories", "PROBLEM", 262, 298], ["the latest infectious disease happenings", "PROBLEM", 808, 848], ["infectious disease", "PROBLEM", 999, 1017], ["emerging viral disease", "PROBLEM", 1300, 1322], ["infectious", "OBSERVATION", 419, 429], ["infectious", "OBSERVATION", 1129, 1139], ["viral disease", "OBSERVATION", 1309, 1322], ["disease", "OBSERVATION", 1493, 1500]]], ["These are just a few resources and each is part of an interconnected web of other sources, contacts and personal experience that exist on the internet; they have all chased and tracked the emergence of MERS-CoV as doggedly as a professional science writer.", [["MERS-CoV", "ORGANISM", 202, 210], ["MERS-CoV", "SPECIES", 202, 210], ["few", "OBSERVATION_MODIFIER", 17, 20], ["interconnected", "OBSERVATION_MODIFIER", 54, 68], ["web", "OBSERVATION", 69, 72]]], ["While it is often overlooked and perhaps underestimated by some professional scientists and clinicians, flublogia compiles or uses publicly available, deidentified data and adds publicly relevant interpretation which is greatly appreciated, much more widely read and far, far more often cited than anything seen in the professional scientific literature.", [["deidentified data", "TEST", 151, 168]]], ["It is also a factual source of such information Salathe et al., 2013) .SummaryThe MERS-CoV appears to be an entrenched camel virus infecting the URT which may have its origins among bats.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 82, 90], ["camel virus", "ORGANISM", 119, 130], ["URT", "CANCER", 145, 148], ["MERS-CoV", "SPECIES", 82, 90], ["camel virus", "SPECIES", 119, 130], ["URT", "ANATOMY", 145, 148]]], ["Human infection may result from rare zoonotic spillover to humans.", [["infection", "DISEASE", 6, 15], ["Human", "ORGANISM", 0, 5], ["humans", "ORGANISM", 59, 65], ["Human", "SPECIES", 0, 5], ["humans", "SPECIES", 59, 65], ["Human", "SPECIES", 0, 5], ["humans", "SPECIES", 59, 65], ["Human infection", "PROBLEM", 0, 15], ["infection", "OBSERVATION", 6, 15], ["zoonotic spillover", "OBSERVATION", 37, 55]]], ["Many potential animal, human and environmental sources await further testing but thanks to quick action, the sensitive and rapid molecular diagnostic tools required to achieve this goal have been in place and available since the virus was made known to the public.", [["human", "ORGANISM", 23, 28], ["human", "SPECIES", 23, 28], ["human", "SPECIES", 23, 28], ["further testing", "TEST", 61, 76], ["the sensitive and rapid molecular diagnostic tools", "PROBLEM", 105, 155], ["the virus", "PROBLEM", 225, 234]]], ["Serological tools for research application, after a much slower start, are now emerging as robust, validated and ready for wider use, with care.", [["Serological tools", "TEST", 0, 17], ["research application", "TREATMENT", 22, 42]]], ["Commercial unavailability remains an issue for more widespread use and so collaboration with the relevant research groups must be the immediate option for future studies.", [["future studies", "TEST", 155, 169]]], ["The MERS-CoV can spread from human-to-human but seems to do so only sporadically and sustained chains of transmission have not been evident to date.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["human", "ORGANISM", 29, 34], ["human", "ORGANISM", 38, 43], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 38, 43], ["MERS-CoV", "SPECIES", 4, 12], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 38, 43]]], ["There is also no evidence that MERS-CoV is a virus of pandemic concern, despite many opportunities for it to become so.", [["MERS-CoV", "ORGANISM", 31, 39], ["MERS-CoV", "SPECIES", 31, 39], ["CoV", "PROBLEM", 36, 39], ["no evidence", "UNCERTAINTY", 14, 25], ["MERS", "OBSERVATION", 31, 35]]], ["But vigilance is key for a virus with a genetic makeup that has only been observed for three years.", [["a virus", "PROBLEM", 25, 32]]], ["Of those known to be infected, over a third have died.", [["infected", "OBSERVATION", 21, 29]]], ["Central to future vigilance is continued screening, sequencing, analysis and timely data sharing.", [["continued screening", "TEST", 31, 50], ["analysis", "TEST", 64, 72]]], ["While whole genome sequencing has been used extensively to study MERS-CoV, it remains a tool for experts and collaborations have again been key for less equipped or experienced researchers to decode the MERS-CoV as it moves through people, over time and across distance in the KSA and beyond its borders.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 203, 211], ["people", "ORGANISM", 232, 238], ["people", "SPECIES", 232, 238], ["MERS-CoV", "SPECIES", 65, 73], ["MERS-CoV", "SPECIES", 203, 211]]], ["Nonetheless, figures modelling efficiency of transmission will need confirmation once better serological and RT-rtPCR-based studies of humans, covering more of the community, have been conducted.", [["humans", "ORGANISM", 135, 141], ["humans", "SPECIES", 135, 141], ["humans", "SPECIES", 135, 141], ["confirmation", "TEST", 68, 80], ["better serological", "TEST", 86, 104], ["RT-rtPCR", "TEST", 109, 117]]], ["It has become very clear that the MERS-CoV may spread poorly from human-to-human, but that spread is at its most effective around a hospital environment.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["human", "ORGANISM", 66, 71], ["human", "ORGANISM", 75, 80], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 75, 80], ["MERS-CoV", "SPECIES", 34, 42], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 75, 80], ["very", "OBSERVATION_MODIFIER", 14, 18], ["clear", "OBSERVATION", 19, 24]]], ["The virus has its greatest impact on those with underlying diseases and such cases, sometimes suffering multiple comorbidities, are likely to visit hospital for treatment, creating a perfect storm of exposure, transmission and mortality.", [["The virus", "PROBLEM", 0, 9], ["underlying diseases", "PROBLEM", 48, 67], ["multiple comorbidities", "PROBLEM", 104, 126], ["treatment", "TREATMENT", 161, 170], ["virus", "OBSERVATION", 4, 9], ["greatest", "OBSERVATION_MODIFIER", 18, 26], ["diseases", "OBSERVATION", 59, 67]]], ["Educational programmes will be important tools to combat the spread of MERS-CoV.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 71, 79], ["MERS-CoV", "SPECIES", 71, 79], ["Educational programmes", "TREATMENT", 0, 22]]], ["While MERS and SARS have some similarities they also diverge significantly.", [["SARS", "DISEASE", 15, 19], ["SARS", "PROBLEM", 15, 19]]], ["Characteristics including the higher PFC among MERS cases (above 50% in 2013 and currently at 30-40%; well above the 9.5% of SARS), the association between fatal disease and older males with underlying comorbidities, the very broad tropism of MERS-CoV, its rapid in vitro growth, rapid induction of cytopathogenic change, robust yet distinct transcriptional responses, use of a different receptor, its induction of a more proinflammatory but reduced and delayed innate antiviral response and its sensitivity to external IFN\u2423 or IFN\u2424 all signal differences from SARS-CoV to some degree.SummaryMERS has had little direct impact on populations outside the Arabian Peninsula with relatively few cases acquired outside the KSA to date.", [["SARS", "DISEASE", 125, 129], ["SARS", "DISEASE", 561, 565], ["PFC", "CANCER", 37, 40], ["MERS-CoV", "ORGANISM", 243, 251], ["IFN", "GENE_OR_GENE_PRODUCT", 520, 523], ["IFN", "GENE_OR_GENE_PRODUCT", 528, 531], ["SARS-CoV", "ORGANISM", 561, 569], ["IFN", "PROTEIN", 520, 523], ["IFN", "PROTEIN", 528, 531], ["MERS-CoV", "SPECIES", 243, 251], ["SARS-CoV", "SPECIES", 561, 569], ["SARS", "PROBLEM", 125, 129], ["fatal disease", "PROBLEM", 156, 169], ["underlying comorbidities", "PROBLEM", 191, 215], ["CoV", "PROBLEM", 248, 251], ["its rapid in vitro growth", "PROBLEM", 253, 278], ["cytopathogenic change", "PROBLEM", 299, 320], ["a different receptor", "TREATMENT", 376, 396], ["delayed innate antiviral response", "PROBLEM", 454, 487], ["external IFN\u2423", "TEST", 511, 524], ["IFN", "PROBLEM", 528, 531], ["all signal differences", "PROBLEM", 533, 555], ["SARS", "PROBLEM", 561, 565], ["higher", "OBSERVATION_MODIFIER", 30, 36], ["PFC", "OBSERVATION_MODIFIER", 37, 40], ["fatal", "OBSERVATION_MODIFIER", 156, 161], ["disease", "OBSERVATION", 162, 169], ["cytopathogenic", "OBSERVATION", 299, 313], ["antiviral response", "OBSERVATION", 469, 487], ["some degree", "OBSERVATION_MODIFIER", 573, 584]]], ["From those studies conducted thus far that screen people beyond the most severely ill, there appears to be a 2-3% prevalence of MERS-CoV in the KSA with a 5% chance of secondary transmission within the household.", [["people", "ORGANISM", 50, 56], ["MERS-CoV", "ORGANISM", 128, 136], ["people", "SPECIES", 50, 56], ["MERS-CoV", "SPECIES", 128, 136], ["those studies", "TEST", 5, 18], ["MERS", "PROBLEM", 128, 132], ["CoV", "PROBLEM", 133, 136]]], ["Despite two mass gatherings that have afforded the virus many millions of opportunities to spread, there have, remarkably, been no reported outbreaks of MERS or MERS-CoV during or immediately after these events.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 161, 169], ["MERS-CoV", "SPECIES", 161, 169], ["two mass gatherings", "PROBLEM", 8, 27], ["the virus", "PROBLEM", 47, 56], ["mass", "OBSERVATION", 12, 16]]], ["Nonetheless, hospitals across the KSA continue to describe MERS cases and so the other 22 countries who have experienced MERS and the rest of the world remain on alert for imported cases, especially during and after mass gathering events including Umrah, Ramadan and Hajj pilgrimages.SummaryMuch remains unknown about MERS-CoV and MERS.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 318, 326], ["MERS-CoV", "SPECIES", 318, 326], ["mass gathering events", "PROBLEM", 216, 237]]], ["Further cooperative data-sharing and research is needed to address questions which include:Summary\u2022 What is the natural host for the MERS-CoV?Summary\u2022 Are camels the source of sporadic human infections and if so, why is MERS-CoV seroprevalence among humans working closely with camels, so low? \u2022 What is the route of transmission to humans and between humans and what is the best personal protective equipment to be adopted by frontline HCWs? \u2022 Which hospital IPC measures are insufficient or insufficiently employed to halt the transmission of MERS-CoV and what is the extent of transmission and clinical impact of, and nosocomial infection by, other co-occurring respiratory viruses in these settings in the KSA? \u2022 Why are males more often afflicted than females?", [["infections", "DISEASE", 191, 201], ["infection", "DISEASE", 632, 641], ["respiratory viruses", "DISEASE", 665, 684], ["MERS-CoV", "ORGANISM", 133, 141], ["human", "ORGANISM", 185, 190], ["MERS-CoV", "ORGANISM", 220, 228], ["humans", "ORGANISM", 250, 256], ["humans", "ORGANISM", 333, 339], ["humans", "ORGANISM", 352, 358], ["MERS-CoV", "ORGANISM", 545, 553], ["human", "SPECIES", 185, 190], ["humans", "SPECIES", 250, 256], ["humans", "SPECIES", 333, 339], ["humans", "SPECIES", 352, 358], ["MERS-CoV", "SPECIES", 133, 141], ["human", "SPECIES", 185, 190], ["MERS-CoV", "SPECIES", 220, 228], ["humans", "SPECIES", 250, 256], ["humans", "SPECIES", 333, 339], ["humans", "SPECIES", 352, 358], ["MERS-CoV", "SPECIES", 545, 553], ["sporadic human infections", "PROBLEM", 176, 201], ["hospital IPC measures", "TREATMENT", 451, 472], ["nosocomial infection", "PROBLEM", 621, 641], ["other co-occurring respiratory viruses", "PROBLEM", 646, 684], ["infections", "OBSERVATION", 191, 201], ["nosocomial", "OBSERVATION_MODIFIER", 621, 631], ["infection", "OBSERVATION", 632, 641], ["respiratory viruses", "OBSERVATION", 665, 684]]], ["What is the prevalence of underlying disease between the sexes? \u2022 Does MERS-CoV infection generally result in a subclinical outcome except in those with comorbidities? \u2022 Do current serological tools have the sensitivity to detect the immune response to a mild, subclinical or asymptomatic MERS-CoV infection?", [["infection", "DISEASE", 80, 89], ["MERS-CoV infection", "DISEASE", 289, 307], ["MERS-CoV", "ORGANISM", 71, 79], ["MERS-CoV", "ORGANISM", 289, 297], ["MERS-CoV", "SPECIES", 71, 79], ["MERS-CoV", "SPECIES", 289, 297], ["underlying disease", "PROBLEM", 26, 44], ["MERS-CoV infection", "PROBLEM", 71, 89], ["a subclinical outcome", "PROBLEM", 110, 131], ["the sensitivity", "TEST", 204, 219], ["a mild, subclinical or asymptomatic MERS", "PROBLEM", 253, 293], ["CoV infection", "PROBLEM", 294, 307], ["disease", "OBSERVATION", 37, 44], ["CoV", "OBSERVATION_MODIFIER", 76, 79], ["infection", "OBSERVATION", 80, 89], ["mild", "OBSERVATION_MODIFIER", 255, 259], ["CoV infection", "OBSERVATION", 294, 307]]], ["If not, might MERS-CoV be a rare, seasonal and endemic infection of humans like other HCoVs? \u2022 For how long does the average period of MERS-CoV shedding continue from infected humans and does this differ with age, sex and vocation? \u2022 March and April seem to be when human outbreaks of MERS begin-what are the events occurring in and around this time of year that may increase human exposure to MERS-CoV? \u2022 Why does MERS-CoV continue to affect such a wide area of the KSA but in such very low numbers-is there an as-yet-unidentified role for mass gatherings in virus acquisition and subsequent geographic dissemination? \u2022 What proportion of acute respiratory tract disease cases continue to go untested because they do not manifest as severe disease and could these clarify gaps in the transmission chains of some cases? \u2022 Have cases of MERS been going undiagnosed among people in African countries that are known to host seropositive or viruspositive camels? \u2022 Are there divergent MERS-CoV variants and viral clades to be found in camels, humans and bats beyond the Arabian peninsula?SummaryThe localised MERS-CoV epidemic reminds us of the importance of communication at all levels and perhaps the need to rethink how stakeholders are informed of the progress of chasing down and studying new disease threats.", [["respiratory tract", "ANATOMY", 646, 663], ["infection", "DISEASE", 55, 64], ["MERS", "DISEASE", 285, 289], ["acute respiratory tract disease", "DISEASE", 640, 671], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["humans", "ORGANISM", 68, 74], ["HCoVs", "CANCER", 86, 91], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 135, 143], ["humans", "ORGANISM", 176, 182], ["human", "ORGANISM", 266, 271], ["human", "ORGANISM", 376, 381], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 415, 423], ["KSA", "CANCER", 467, 470], ["people", "ORGANISM", 870, 876], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 981, 989], ["humans", "ORGANISM", 1039, 1045], ["humans", "SPECIES", 68, 74], ["humans", "SPECIES", 176, 182], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 376, 381], ["people", "SPECIES", 870, 876], ["humans", "SPECIES", 1039, 1045], ["MERS-CoV", "SPECIES", 14, 22], ["humans", "SPECIES", 68, 74], ["MERS-CoV", "SPECIES", 135, 143], ["humans", "SPECIES", 176, 182], ["human", "SPECIES", 266, 271], ["human", "SPECIES", 376, 381], ["MERS-CoV", "SPECIES", 415, 423], ["humans", "SPECIES", 1039, 1045], ["MERS-CoV", "SPECIES", 1105, 1113], ["seasonal and endemic infection of humans", "PROBLEM", 34, 74], ["MERS", "PROBLEM", 135, 139], ["CoV shedding", "PROBLEM", 140, 152], ["mass", "PROBLEM", 541, 545], ["virus acquisition", "TEST", 560, 577], ["acute respiratory tract disease cases", "PROBLEM", 640, 677], ["severe disease", "PROBLEM", 734, 748], ["divergent MERS", "PROBLEM", 971, 985], ["CoV variants", "PROBLEM", 986, 998], ["viral clades", "PROBLEM", 1003, 1015], ["new disease threats", "PROBLEM", 1290, 1309], ["endemic", "OBSERVATION_MODIFIER", 47, 54], ["infection", "OBSERVATION", 55, 64], ["acute", "OBSERVATION_MODIFIER", 640, 645], ["respiratory tract", "ANATOMY", 646, 663], ["CoV variants", "OBSERVATION", 986, 998], ["localised", "OBSERVATION_MODIFIER", 1095, 1104], ["MERS", "OBSERVATION", 1105, 1109]]], ["In May 2014, two cases of MERS-CoV were imported into the USA.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 26, 34], ["MERS-CoV", "SPECIES", 26, 34], ["MERS-CoV", "TREATMENT", 26, 34]]], ["A third person was proposed to be the first local transmission event but was subsequently declared a false-positive.", [["person", "SPECIES", 8, 14]]], ["Social and mainstream media and press conferences comprehensively informed the public of the extensive findings generated by expert health care supported by laboratory analysis.", [["laboratory analysis", "TEST", 157, 176]]], ["And yet lessons were still learned about balancing real-time transparency and the need for suitable laboratory confirmation of results.", [["suitable laboratory confirmation", "TEST", 91, 123]]], ["This case highlighted the effectiveness of social media in communicating digestible information to expectant stakeholders compared to the use of a generally slower and more elite peer-reviewed scientific publication pipeline which is often better suited to detailed research description over the long haul, but with some exceptions, a process unsuited for informing a concerned global and always-online public of potential threats to its immediate health or providing context to those threats.SummaryHowever, while MERS-CoV is not a rapidly spreading global contagion, it may evolve further to become that or another may emerge in the future and vigilance and rapid communication will be key to a timely response and early containment.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 515, 523], ["MERS-CoV", "SPECIES", 515, 523], ["social media", "TREATMENT", 43, 55]]], ["One constant in all this however is the human; it is we who fan the flames of a disease cluster until it becomes an outbreak, epidemic or pandemic.", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45], ["a disease cluster", "PROBLEM", 78, 95], ["pandemic", "PROBLEM", 138, 146], ["constant", "OBSERVATION_MODIFIER", 4, 12]]], ["Viruses do not emerge and gain a foothold without our aid, or our lapses in vigilance.", [["Viruses", "PROBLEM", 0, 7]]], ["MERS highlighted that some paradigms can be stumbling blocks to seeking and communicating knowledge and containing and understanding the spread and nature of a virus.", [["stumbling blocks", "PROBLEM", 44, 60], ["a virus", "PROBLEM", 158, 165]]], ["It also served as yet another reminder to us that global human and animal health, politics, agriculture and economies are all intimately interwoven and it takes just a single tiny virus to tip a very fine balance.", [["human", "ORGANISM", 57, 62], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["tiny", "OBSERVATION_MODIFIER", 175, 179], ["virus", "OBSERVATION", 180, 185]]]], "09ec8daa8e32168d92d05b86de1784c639685fb4": [["SUMMARY 26Many viruses globally shut off host gene expression to inhibit activation of cell-intrinsic antiviral 27 responses.", [["cell", "ANATOMY", 87, 91], ["cell", "CELL", 87, 91], ["Many viruses", "PROBLEM", 10, 22], ["viruses", "OBSERVATION", 15, 22]]], ["However, host shutoff is not indiscriminate, since viral proteins and host proteins 28 required for viral replication are still synthesized during shutoff.", [["viral proteins", "PROTEIN", 51, 65], ["host proteins 28", "PROTEIN", 70, 86], ["host shutoff", "TREATMENT", 9, 21], ["viral proteins", "TEST", 51, 65], ["host proteins", "TEST", 70, 83], ["viral replication", "TREATMENT", 100, 117], ["host shutoff", "OBSERVATION", 9, 21]]], ["The molecular determinants of 29 target selectivity in host shutoff remain incompletely understood.", [["host shutoff", "OBSERVATION", 55, 67]]], ["Here, we report that the 30 influenza A virus shutoff factor PA-X usurps RNA splicing to selectively target host RNAs for 31 destruction.", [["30", "ORGANISM", 25, 27], ["influenza A virus", "ORGANISM", 28, 45], ["PA-X", "GENE_OR_GENE_PRODUCT", 61, 65], ["shutoff factor", "PROTEIN", 46, 60], ["X", "PROTEIN", 64, 65], ["host RNAs", "RNA", 108, 117], ["influenza A virus", "SPECIES", 28, 45], ["influenza A virus", "SPECIES", 28, 45], ["the 30 influenza A virus shutoff factor PA", "TREATMENT", 21, 63], ["31 destruction", "PROBLEM", 122, 136], ["host RNAs", "OBSERVATION", 108, 117], ["destruction", "OBSERVATION", 125, 136]]], ["PA-X preferentially degrades spliced mRNAs, both transcriptome-wide and in 32 reporter assays.", [["PA-X", "GENE_OR_GENE_PRODUCT", 0, 4], ["X", "DNA", 3, 4], ["spliced mRNAs", "RNA", 29, 42], ["spliced mRNAs", "OBSERVATION", 29, 42]]], ["Moreover, proximity-labeling proteomics revealed that PA-X interacts with 33 cellular proteins involved in RNA splicing.", [["cellular", "ANATOMY", 77, 85], ["PA-X", "GENE_OR_GENE_PRODUCT", 54, 58], ["cellular", "CELL", 77, 85], ["33 cellular proteins", "PROTEIN", 74, 94], ["labeling proteomics", "TEST", 20, 39], ["PA", "TEST", 54, 56], ["33 cellular proteins", "PROBLEM", 74, 94], ["RNA splicing", "OBSERVATION", 107, 119]]], ["The interaction with splicing contributes to target 34 discrimination and is unique among viral host shutoff nucleases.", [["viral host shutoff nucleases", "PROTEIN", 90, 118], ["target 34 discrimination", "PROBLEM", 45, 69], ["viral host shutoff nucleases", "TREATMENT", 90, 118]]], ["This novel mechanism sheds 35 light on the specificity of viral control of host gene expression and may provide opportunities for 36 development of new host-targeted antivirals.", [["targeted antivirals", "TREATMENT", 157, 176]]], ["No reuse allowed without permission.SUMMARY 26The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint INTRODUCTION 9 infected cells and in the ectopic overexpression model.", [["cells", "ANATOMY", 216, 221], ["https://doi.org/10.1101/442996", "CHEMICAL", 139, 169], ["cells", "CELL", 216, 221], ["The copyright holder", "TREATMENT", 46, 66], ["bioRxiv preprint INTRODUCTION 9 infected cells", "TREATMENT", 175, 221], ["the ectopic overexpression model", "PROBLEM", 229, 261], ["infected cells", "OBSERVATION", 207, 221], ["ectopic overexpression model", "OBSERVATION", 233, 261]]], ["We found that the RT-qPCR results 154 agreed with the RNAseq data in terms of the selective effects on the tested transcripts ( Figure 155 2C).", [["the RT-qPCR", "TEST", 14, 25], ["the RNAseq data", "TEST", 50, 65]]], ["Moreover, the mRNA levels were similarly affected by overexpression of PA-X from the 156 A/Udorn/72 H3N2 (Udorn) strain, suggesting that target selection by PA-X is conserved between 157 different virus strains ( Figure 2D ).", [["PA-X", "GENE_OR_GENE_PRODUCT", 71, 75], ["156 A/Udorn/72 H3N2 (Udorn) strain", "ORGANISM", 85, 119], ["PA-X", "GENE_OR_GENE_PRODUCT", 157, 161], ["PA-X", "DNA", 71, 75], ["X", "DNA", 160, 161], ["A/Udorn/72 H3N2", "SPECIES", 89, 104], ["the mRNA levels", "TEST", 10, 25], ["PA", "TEST", 71, 73], ["H3N2", "PROBLEM", 100, 104], ["strain", "PROBLEM", 113, 119], ["PA", "TEST", 157, 159], ["157 different virus strains", "PROBLEM", 183, 210]]], ["Collectively, these data demonstrate that PA-X broadly 158 targets RNA for degradation, while a subset of RNAs remains unaffected.", [["PA-X", "GENE_OR_GENE_PRODUCT", 42, 46], ["RNAs", "RNA", 106, 110], ["these data", "TEST", 14, 24], ["PA", "TEST", 42, 44]]], ["159 160 Specific functional classes of host RNAs are differentially sensitive to PA-X 161SUMMARY 26Although most RNAs were down-regulated by PA-X, the levels of ~25% of RNAs remained 162 largely unchanged ( Figures 1C, 2A) .", [["PA-X 161SUMMARY 26Although", "GENE_OR_GENE_PRODUCT", 81, 107], ["PA-X", "GENE_OR_GENE_PRODUCT", 141, 145], ["host RNAs", "RNA", 39, 48], ["X 161SUMMARY", "DNA", 84, 96], ["RNAs", "RNA", 169, 173], ["PA-X 161SUMMARY", "TEST", 81, 96], ["most RNAs", "PROBLEM", 108, 117], ["PA", "TEST", 141, 143], ["the levels", "TEST", 147, 157], ["RNAs", "TEST", 169, 173], ["host RNAs", "OBSERVATION", 39, 48], ["unchanged", "OBSERVATION_MODIFIER", 195, 204]]], ["To identify these differentially-regulated RNAs, we used k-163 means clustering to group RNAs with similar patterns of regulation (Gasch and Eisen, 2002) .", [["regulated RNAs", "RNA", 33, 47], ["group RNAs", "RNA", 83, 93], ["k", "TEST", 57, 58], ["RNAs", "OBSERVATION_MODIFIER", 43, 47]]], ["164SUMMARY 26Clustering was carried out based on the relative RNA levels in PA-X-overexpressing vs. control 165 cells or IAV-infected vs. mock-infected cells in the eight datasets we collected ( Figures 1C, S1B , 166 2A).", [["cells", "ANATOMY", 112, 117], ["cells", "ANATOMY", 152, 157], ["PA-X", "GENE_OR_GENE_PRODUCT", 76, 80], ["cells", "CELL", 112, 117], ["IAV", "ORGANISM", 121, 124], ["cells", "CELL", 152, 157], ["PA-X-overexpressing vs. control 165 cells", "CELL_LINE", 76, 117], ["infected cells", "CELL_TYPE", 143, 157], ["PA", "TEST", 76, 78], ["IAV", "PROBLEM", 121, 124], ["infected cells", "PROBLEM", 143, 157], ["infected", "OBSERVATION", 125, 133], ["infected cells", "OBSERVATION", 143, 157]]], ["Two sets of RNAs, comprising 55% of the RNAs that were detected in all conditions, were 167 identified as true PA-X targets ( Figure 3A ).", [["PA-X", "GENE_OR_GENE_PRODUCT", 111, 115], ["RNAs", "RNA", 12, 16], ["RNAs", "RNA", 40, 44], ["X targets", "DNA", 114, 123], ["RNAs", "TEST", 12, 16], ["the RNAs", "TEST", 36, 44], ["true PA", "TEST", 106, 113], ["RNAs", "OBSERVATION_MODIFIER", 12, 16]]], ["They were down-regulated in a PA-X-dependent 168 manner both during infection and by PA-X ectopic expression.", [["infection", "DISEASE", 68, 77], ["PA-X", "GENE_OR_GENE_PRODUCT", 30, 34], ["PA-X", "GENE_OR_GENE_PRODUCT", 85, 89], ["infection", "PROBLEM", 68, 77], ["infection", "OBSERVATION", 68, 77]]], ["The first group was completely 169 PA-X-specific, because their levels were largely unchanged in IAV PA(\u0394X) infected cells 170 ( Figure 3A , left panel).", [["cells", "ANATOMY", 117, 122], ["PA-X", "GENE_OR_GENE_PRODUCT", 35, 39], ["PA", "GENE_OR_GENE_PRODUCT", 101, 103], ["cells", "CELL", 117, 122], ["IAV", "SPECIES", 97, 100], ["their levels", "TEST", 58, 70], ["IAV PA", "TEST", 97, 103], ["infected cells", "TEST", 108, 122], ["Figure 3A", "TEST", 129, 138], ["left panel", "TEST", 141, 151], ["unchanged", "OBSERVATION_MODIFIER", 84, 93], ["left", "ANATOMY_MODIFIER", 141, 145]]], ["The RNAs in the second group were PA-X-sensitive, but were partially 171 down-regulated by other mechanisms during IAV PA(\u0394X) infection ( Figure 3A , right panel).", [["infection", "DISEASE", 126, 135], ["PA-X", "GENE_OR_GENE_PRODUCT", 34, 38], ["PA", "GENE_OR_GENE_PRODUCT", 119, 121], ["IAV", "SPECIES", 115, 118], ["The RNAs", "TEST", 0, 8], ["PA", "TEST", 34, 36], ["IAV PA(\u0394X) infection", "PROBLEM", 115, 135], ["right panel", "TEST", 150, 161], ["RNAs", "OBSERVATION_MODIFIER", 4, 8], ["infection", "OBSERVATION", 126, 135], ["right", "ANATOMY_MODIFIER", 150, 155]]], ["By 172 contrast, 28% of the RNAs were host shutoff resistant and were not down-regulated by infection 173 or PA-X expression ( Figure 3B ).", [["infection", "DISEASE", 92, 101], ["PA-X", "GENE_OR_GENE_PRODUCT", 109, 113], ["the RNAs", "TREATMENT", 24, 32], ["infection", "PROBLEM", 92, 101], ["PA", "TEST", 109, 111], ["infection", "OBSERVATION", 92, 101]]], ["In addition, the k-means algorithm identified a group of RNAs 174 that were down-regulated during infection by a PA-X-independent mechanism, and yet were PA-175 X-sensitive in PA-X-expressing cells ( Figure 3C ).", [["cells", "ANATOMY", 192, 197], ["infection", "DISEASE", 98, 107], ["PA-X", "GENE_OR_GENE_PRODUCT", 113, 117], ["PA-175 X", "GENE_OR_GENE_PRODUCT", 154, 162], ["PA-X", "GENE_OR_GENE_PRODUCT", 176, 180], ["cells", "CELL", 192, 197], ["RNAs 174", "RNA", 57, 65], ["PA-X-expressing cells", "CELL_LINE", 176, 197], ["the k-means algorithm", "TEST", 13, 34], ["a group of RNAs", "TEST", 46, 61], ["infection", "PROBLEM", 98, 107], ["a PA", "TEST", 111, 115], ["PA", "TEST", 154, 156], ["PA", "TEST", 176, 178]]], ["No reuse allowed without permission.SUMMARY 26The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint substantially decreased by other regulatory mechanisms during infection, such that their targeting 177 by PA-X is masked.", [["infection", "DISEASE", 254, 263], ["https://doi.org/10.1101/442996", "CHEMICAL", 139, 169], ["PA-X", "GENE_OR_GENE_PRODUCT", 298, 302], ["The copyright holder", "TREATMENT", 46, 66], ["bioRxiv", "TREATMENT", 175, 182], ["infection", "PROBLEM", 254, 263], ["decreased", "OBSERVATION_MODIFIER", 206, 215], ["infection", "OBSERVATION", 254, 263]]], ["Interestingly, based on gene ontology (GO) term analysis, the host shutoff-178 resistant RNAs were significantly enriched for genes involved in transcription and translation, 179 including ribosomal RNA processing, ribosomal proteins, and membrane protein synthesis 180 ( Figure 3D ).", [["ribosomal", "ANATOMY", 189, 198], ["ribosomal", "ANATOMY", 215, 224], ["membrane", "ANATOMY", 239, 247], ["ribosomal", "CELLULAR_COMPONENT", 189, 198], ["ribosomal", "CELLULAR_COMPONENT", 215, 224], ["membrane", "CELLULAR_COMPONENT", 239, 247], ["host shutoff-178 resistant RNAs", "RNA", 62, 93], ["ribosomal RNA", "RNA", 189, 202], ["ribosomal proteins", "PROTEIN", 215, 233], ["membrane protein synthesis 180", "PROTEIN", 239, 269], ["term analysis", "TEST", 43, 56], ["the host shutoff", "TEST", 58, 74], ["resistant RNAs", "PROBLEM", 79, 93], ["ribosomal RNA processing", "PROBLEM", 189, 213], ["ribosomal proteins", "TEST", 215, 233], ["membrane protein synthesis", "TEST", 239, 265]]], ["This result is consistent with the IAV requirement for host biosynthetic machinery IAV infection, as demonstrated by their higher expression compared to all detected RNAs, their 189 levels were even higher in the absence of PA-X ( Figure 3E ).", [["infection", "DISEASE", 87, 96], ["IAV", "ORGANISM", 83, 86], ["PA-X", "GENE_OR_GENE_PRODUCT", 224, 228], ["the IAV requirement", "PROBLEM", 31, 50], ["host biosynthetic machinery IAV infection", "PROBLEM", 55, 96], ["consistent with", "UNCERTAINTY", 15, 30], ["IAV", "OBSERVATION", 35, 38], ["IAV", "OBSERVATION_MODIFIER", 83, 86], ["infection", "OBSERVATION", 87, 96], ["higher", "OBSERVATION_MODIFIER", 199, 205]]], ["While only 12% of ISGs were up-190 regulated during wt IAV infection, and only 4% were induced more than two-fold, 35% of the 191 ISGs were up-regulated in IAV PA(\u0394X)-infected cells, with 15% above two-fold.", [["cells", "ANATOMY", 176, 181], ["IAV infection", "DISEASE", 55, 68], ["ISGs", "GENE_OR_GENE_PRODUCT", 18, 22], ["wt IAV", "ORGANISM", 52, 58], ["ISGs", "GENE_OR_GENE_PRODUCT", 130, 134], ["IAV", "ORGANISM", 156, 159], ["PA", "GENE_OR_GENE_PRODUCT", 160, 162], ["\u0394X", "GENE_OR_GENE_PRODUCT", 163, 165], ["cells", "CELL", 176, 181], ["ISGs", "DNA", 18, 22], ["ISGs", "DNA", 130, 134], ["infected cells", "CELL_TYPE", 167, 181], ["IAV", "SPECIES", 55, 58], ["IAV", "SPECIES", 156, 159], ["ISGs", "TEST", 18, 22], ["wt IAV infection", "PROBLEM", 52, 68], ["ISGs", "TEST", 130, 134], ["IAV PA", "TEST", 156, 162], ["infected cells", "PROBLEM", 167, 181], ["IAV", "OBSERVATION_MODIFIER", 55, 58], ["infection", "OBSERVATION", 59, 68], ["infected cells", "OBSERVATION", 167, 181]]], ["While the 192 activity of PA-X is clearly not limited to ISGs, these data indicate that PA-X contributes to 193 dampening the cell-intrinsic response to infection.", [["cell", "ANATOMY", 126, 130], ["infection", "DISEASE", 153, 162], ["PA-X", "GENE_OR_GENE_PRODUCT", 26, 30], ["PA-X", "GENE_OR_GENE_PRODUCT", 88, 92], ["cell", "CELL", 126, 130], ["X", "DNA", 29, 30], ["ISGs", "DNA", 57, 61], ["PA", "TEST", 26, 28], ["these data", "TEST", 63, 73], ["PA", "TEST", 88, 90], ["infection", "PROBLEM", 153, 162], ["intrinsic response", "OBSERVATION", 131, 149], ["infection", "OBSERVATION", 153, 162]]], ["194PA-X strongly and preferentially down-regulates spliced Pol II transcripts 196We have previously shown that PA-X preferentially degrades RNA transcribed by Pol II 197 (Khaperskyy et al., 2016) .", [["194PA-X", "GENE_OR_GENE_PRODUCT", 0, 7], ["Pol II", "GENE_OR_GENE_PRODUCT", 59, 65], ["196We", "GENE_OR_GENE_PRODUCT", 78, 83], ["PA-X", "GENE_OR_GENE_PRODUCT", 111, 115], ["Pol II", "GENE_OR_GENE_PRODUCT", 159, 165], ["194PA", "PROTEIN", 0, 5], ["Pol II transcripts 196We", "PROTEIN", 59, 83], ["X", "DNA", 114, 115], ["Pol II 197", "PROTEIN", 159, 169]]], ["A key difference between transcripts of Pol II and other cellular Pols 198 is that Pol II RNAs can be spliced.", [["cellular", "ANATOMY", 57, 65], ["Pol II", "GENE_OR_GENE_PRODUCT", 40, 46], ["cellular Pols 198", "GENE_OR_GENE_PRODUCT", 57, 74], ["Pol II", "GENE_OR_GENE_PRODUCT", 83, 89], ["Pol II", "PROTEIN", 40, 46], ["cellular Pols 198", "PROTEIN", 57, 74], ["Pol II RNAs", "RNA", 83, 94], ["Pol II", "TREATMENT", 40, 46], ["Pol II RNAs", "TREATMENT", 83, 94]]], ["The process of splicing is mechanistically linked to 199 IAV PA(\u0394X) virus ( Figure S4A ), suggesting that PA-X down-regulates IFN-\u03bb2 mRNA in 246 infected cells.", [["cells", "ANATOMY", 154, 159], ["IAV PA(\u0394X) virus", "ORGANISM", 57, 73], ["Figure S4A", "GENE_OR_GENE_PRODUCT", 76, 86], ["PA-X", "GENE_OR_GENE_PRODUCT", 106, 110], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 126, 132], ["cells", "CELL", 154, 159], ["IFN-\u03bb2 mRNA", "RNA", 126, 137], ["246 infected cells", "CELL_LINE", 141, 159], ["IAV PA", "TEST", 57, 63], ["PA", "TEST", 106, 108], ["IFN", "TEST", 126, 129], ["infected cells", "PROBLEM", 145, 159], ["splicing", "OBSERVATION", 15, 23], ["infected cells", "OBSERVATION", 145, 159]]], ["We co-transfected the IFN-l2 expression vectors with PR8 PA-X and a luciferase 247 construct containing an intron (Younis et al., 2010), which served as a positive control for PA-X 248 activity.", [["IFN-l2", "GENE_OR_GENE_PRODUCT", 22, 28], ["PR8", "ORGANISM", 53, 56], ["PA-X", "GENE_OR_GENE_PRODUCT", 57, 61], ["luciferase 247", "GENE_OR_GENE_PRODUCT", 68, 82], ["PA-X 248", "GENE_OR_GENE_PRODUCT", 176, 184], ["IFN-l2 expression vectors", "DNA", 22, 47], ["PR8 PA-X", "DNA", 53, 61], ["luciferase 247 construct", "DNA", 68, 92], ["the IFN-l2 expression vectors", "TREATMENT", 18, 47], ["PR8 PA", "TREATMENT", 53, 59], ["a luciferase", "TREATMENT", 66, 78]]], ["We confirmed that IFN-\u03bb2 mRNA was expressed and exported into the cytoplasm at 249 similar levels irrespective of the construct used ( Figures S4B, S4C) .", [["cytoplasm", "ANATOMY", 66, 75], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 18, 24], ["cytoplasm", "ORGANISM_SUBSTANCE", 66, 75], ["S4C", "GENE_OR_GENE_PRODUCT", 148, 151], ["IFN-\u03bb2 mRNA", "RNA", 18, 29], ["IFN", "TEST", 18, 21]]], ["We also checked that the 250 five introns were properly spliced by PCR analysis across the splice sites ( Figures 5E, S4D) .", [["250 five introns", "DNA", 25, 41], ["splice sites", "DNA", 91, 103], ["S4D", "DNA", 118, 121], ["PCR analysis", "TEST", 67, 79], ["splice sites", "OBSERVATION", 91, 103]]], ["251PA-X strongly and preferentially down-regulates spliced Pol II transcripts 196When we analyzed the effect of PA-X on the two mRNAs, we found that PA-X down-regulated 252 the IFN-\u03bb2 mRNA expressed from the full genomic region ( Figure 5B ).", [["251PA-X", "GENE_OR_GENE_PRODUCT", 0, 7], ["Pol II", "GENE_OR_GENE_PRODUCT", 59, 65], ["PA-X", "GENE_OR_GENE_PRODUCT", 112, 116], ["PA-X", "GENE_OR_GENE_PRODUCT", 149, 153], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 177, 183], ["251PA", "PROTEIN", 0, 5], ["Pol II", "PROTEIN", 59, 65], ["mRNAs", "RNA", 128, 133], ["X", "DNA", 152, 153], ["IFN-\u03bb2 mRNA", "RNA", 177, 188], ["full genomic region", "DNA", 208, 227], ["PA", "TEST", 149, 151], ["the IFN", "TEST", 173, 180]]], ["However, the levels of 253 the same IFN-\u03bb2 mRNA expressed from an intronless cDNA construct were only minimally 254 reduced ( Figure 5B ).", [["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 36, 42], ["IFN-\u03bb2 mRNA", "RNA", 36, 47], ["intronless cDNA construct", "DNA", 66, 91], ["the levels", "TEST", 9, 19], ["IFN", "TEST", 36, 39], ["an intronless cDNA construct", "TEST", 63, 91]]], ["In both conditions, the control luciferase reporter was down-regulated by 255 PA-X.", [["luciferase", "GENE_OR_GENE_PRODUCT", 32, 42], ["control luciferase reporter", "DNA", 24, 51], ["the control luciferase reporter", "TEST", 20, 51]]], ["PA-X proteins from the 2009 pandemic H1N1 strains (such as A/California/7/09(H1N1) 256 (CA/7) and A/Tennessee/1-560/2009) and the Udorn H3N2 strain also preferentially degraded 257 intron-containing target RNAs ( Figure 5C ).", [["PA-X", "GENE_OR_GENE_PRODUCT", 0, 4], ["2009 pandemic H1N1 strains", "ORGANISM", 23, 49], ["A/California/7/09(H1N1) 256 (CA/7", "ORGANISM", 59, 92], ["Udorn H3N2 strain", "ORGANISM", 130, 147], ["PA-X proteins", "PROTEIN", 0, 13], ["257 intron", "DNA", 177, 187], ["target RNAs", "RNA", 199, 210], ["Udorn H3N2", "SPECIES", 130, 140], ["A/California/7/09(H1N1)", "SPECIES", 59, 82], ["A/Tennessee/1-560/2009", "SPECIES", 98, 120], ["Udorn H3N2 strain", "SPECIES", 130, 147], ["PA-X proteins", "TEST", 0, 13], ["pandemic H1N1 strains", "PROBLEM", 28, 49], ["A/California", "TEST", 59, 71], ["CA", "TEST", 88, 90], ["the Udorn H3N2 strain", "PROBLEM", 126, 147]]], ["These results confirm the prediction based on our 258PA-X strongly and preferentially down-regulates spliced Pol II transcripts 196RNAseq data that splicing is important for PA-X substrate recognition.", [["258PA-X", "GENE_OR_GENE_PRODUCT", 50, 57], ["Pol II", "GENE_OR_GENE_PRODUCT", 109, 115], ["PA-X", "GENE_OR_GENE_PRODUCT", 174, 178], ["258PA", "DNA", 50, 55], ["X", "DNA", 56, 57], ["Pol II", "PROTEIN", 109, 115], ["RNAseq data", "TEST", 131, 142]]], ["In addition, we tested the 259 down-regulation of IFN-\u03bb2 mRNAs expressed from chimeric constructs that contained only one 260 of the five introns from the original genomic sequence, to determine whether one splicing event 261 was sufficient to restore PA-X targeting.", [["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 50, 56], ["PA-X", "GENE_OR_GENE_PRODUCT", 252, 256], ["IFN-\u03bb2 mRNAs", "RNA", 50, 62], ["chimeric constructs", "DNA", 78, 97], ["introns", "DNA", 138, 145], ["IFN", "TEST", 50, 53], ["PA", "TEST", 252, 254]]], ["Indeed, addition of single introns increased 262 susceptibility to PA-X ( Figure 5D ).", [["PA-X", "GENE_OR_GENE_PRODUCT", 67, 71], ["single introns", "DNA", 20, 34], ["single introns", "PROBLEM", 20, 34], ["PA", "TEST", 67, 69]]], ["Interestingly, not all introns were effective, in part because 263 of variable splicing efficiency.", [["introns", "DNA", 23, 30], ["variable splicing efficiency", "PROBLEM", 70, 98], ["splicing efficiency", "OBSERVATION", 79, 98]]], ["For example, intron 4 was not spliced efficiently in the absence of 264 other introns and also did not restore PA-X susceptibility ( Figure 5E ).", [["intron 4", "CELLULAR_COMPONENT", 13, 21], ["PA-X", "GENE_OR_GENE_PRODUCT", 111, 115], ["intron 4", "DNA", 13, 21], ["introns", "DNA", 78, 85]]], ["This result further 265 strengthens the link between splicing and PA-X susceptibility.", [["PA-X", "GENE_OR_GENE_PRODUCT", 66, 70], ["PA-X susceptibility", "TEST", 66, 85]]], ["No reuse allowed without permission.PA-X strongly and preferentially down-regulates spliced Pol II transcripts 196The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint Despite these results linking mRNA splicing and PA-X degradation, one unresolved issue is that 268 we and others have previously used intronless reporters to study PA-X, and these reporters 269 appeared to be efficiently degraded.", [["https://doi.org/10.1101/442996", "CHEMICAL", 207, 237], ["PA-X", "GENE_OR_GENE_PRODUCT", 36, 40], ["Pol II", "GENE_OR_GENE_PRODUCT", 92, 98], ["PA-X", "GENE_OR_GENE_PRODUCT", 308, 312], ["PA-X", "GENE_OR_GENE_PRODUCT", 424, 428], ["X", "DNA", 39, 40], ["Pol II", "PROTEIN", 92, 98], ["intronless reporters", "DNA", 394, 414], ["PA-X", "DNA", 424, 428], ["reporters 269", "DNA", 440, 453], ["PA", "TEST", 36, 38], ["bioRxiv", "TREATMENT", 243, 250], ["mRNA splicing", "PROBLEM", 290, 303], ["PA-X degradation", "PROBLEM", 308, 324], ["study PA", "TEST", 418, 426]]], ["To resolve this issue, we compared the fate of matching Interestingly, PA-X had a more robust effect on the spliced mRNA, although it could also down-273 regulate intronless luciferase mRNA ( Figure 5F ).", [["PA-X", "GENE_OR_GENE_PRODUCT", 71, 75], ["luciferase", "GENE_OR_GENE_PRODUCT", 174, 184], ["spliced mRNA", "RNA", 108, 120], ["luciferase mRNA", "RNA", 174, 189], ["the spliced mRNA", "PROBLEM", 104, 120], ["spliced mRNA", "OBSERVATION", 108, 120]]], ["These results suggest that addition of a single 274 splicing event further promotes degradation by PA-X.", [["PA-X.", "GENE_OR_GENE_PRODUCT", 99, 104]]], ["Reporters are selected for their robust 275 expression, although they are somewhat different from endogenous cellular mRNAs.", [["cellular", "ANATOMY", 109, 117], ["cellular", "CELL", 109, 117], ["endogenous cellular mRNAs", "RNA", 98, 123], ["endogenous cellular mRNAs", "OBSERVATION", 98, 123]]], ["Therefore, 276 it is possible that even intronless reporters associate with cellular factors that are important for 277 PA-X targeting.", [["cellular", "ANATOMY", 76, 84], ["cellular", "CELL", 76, 84], ["PA-X", "GENE_OR_GENE_PRODUCT", 120, 124], ["intronless reporters", "DNA", 40, 60], ["cellular factors", "PROTEIN", 76, 92]]], ["Nevertheless, our findings recommend the use of intron-containing reporters for 278 future cell-based studies of PA-X.", [["cell", "ANATOMY", 91, 95], ["cell", "CELL", 91, 95], ["PA-X.", "GENE_OR_GENE_PRODUCT", 113, 118], ["intron-containing reporters", "DNA", 48, 75], ["PA", "TEST", 113, 115]]], ["To identify cellular X-ORF-interacting proteins we used a proteomic technique called BioID, 287 which relies on non-specific proximity biotinylation of lysine residues by a modified E. coli 288 biotin ligase, BirA* (Roux et al., 2012).", [["cellular", "ANATOMY", 12, 20], ["lysine", "CHEMICAL", 152, 158], ["lysine", "CHEMICAL", 152, 158], ["biotin", "CHEMICAL", 194, 200], ["cellular", "CELL", 12, 20], ["lysine", "AMINO_ACID", 152, 158], ["E. coli", "ORGANISM", 182, 189], ["biotin", "GENE_OR_GENE_PRODUCT", 194, 200], ["cellular X-ORF", "DNA", 12, 26], ["interacting proteins", "PROTEIN", 27, 47], ["E. coli 288 biotin ligase", "PROTEIN", 182, 207], ["E. coli", "SPECIES", 182, 189], ["E. coli", "SPECIES", 182, 189], ["lysine residues", "TREATMENT", 152, 167], ["a modified E. coli", "TREATMENT", 171, 189], ["biotin ligase", "TEST", 194, 207], ["lysine residues", "OBSERVATION", 152, 167]]], ["Because there are two major classes of PA-X isoforms 289 that differ in X-ORF length (Shi et al., 2012), we fused BirA* to X-ORFs representative of each 290 All rights reserved.", [["PA-X", "GENE_OR_GENE_PRODUCT", 39, 43], ["BirA", "GENE_OR_GENE_PRODUCT", 114, 118], ["X isoforms 289", "PROTEIN", 42, 56], ["X-ORF length", "DNA", 72, 84], ["BirA", "DNA", 114, 118], ["X-ORFs", "DNA", 123, 129], ["PA-X isoforms", "TEST", 39, 52]]], ["No reuse allowed without permission.PA-X strongly and preferentially down-regulates spliced Pol II transcripts 196The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint class: the 61-aa PR8 X-ORF (X61) and the 41-aa CA/7 X-ORF (X41) ( Figure 6A ).", [["https://doi.org/10.1101/442996", "CHEMICAL", 207, 237], ["PA-X", "GENE_OR_GENE_PRODUCT", 36, 40], ["Pol II", "GENE_OR_GENE_PRODUCT", 92, 98], ["X", "DNA", 39, 40], ["Pol II", "PROTEIN", 92, 98], ["61-aa PR8 X-ORF", "DNA", 271, 286], ["X61", "DNA", 288, 291], ["41-aa CA/7 X-ORF", "DNA", 301, 317], ["X41", "DNA", 319, 322], ["PA", "TEST", 36, 38], ["aa CA", "TEST", 304, 309]]], ["As negative 291 controls, we used BirA* alone and BirA* fused to a mutated version of the PR8 X-ORF in which 292 four positively charged residues were substituted by alanine (X61(4A)).", [["alanine", "CHEMICAL", 166, 173], ["alanine", "CHEMICAL", 166, 173], ["alanine", "AMINO_ACID", 166, 173], ["BirA", "PROTEIN", 34, 38], ["PR8 X-ORF", "DNA", 90, 99]]], ["These mutations prevent 293 nuclear localization of a GFP-X-ORF fusion and disrupt mRNA degradation by full length PA-X 294 (Khaperskyy et al., 2016).", [["293 nuclear", "ANATOMY", 24, 35], ["GFP", "GENE_OR_GENE_PRODUCT", 54, 57], ["GFP-X-ORF fusion", "DNA", 54, 70], ["These mutations", "PROBLEM", 0, 15], ["a GFP-X-ORF fusion", "TREATMENT", 52, 70], ["disrupt mRNA degradation", "PROBLEM", 75, 99]]], ["As expected from our previous studies with GFP fusion and epitope-295 tagged proteins (Khaperskyy et al., 2016), fusion to the wt X-ORFs, but not X61(4A), led to 296 accumulation of BirA* in the nucleus ( Figure S5A ).", [["nucleus", "ANATOMY", 195, 202], ["GFP", "GENE_OR_GENE_PRODUCT", 43, 46], ["X", "GENE_OR_GENE_PRODUCT", 130, 131], ["X61(4A", "GENE_OR_GENE_PRODUCT", 146, 152], ["BirA", "GENE_OR_GENE_PRODUCT", 182, 186], ["nucleus", "CELLULAR_COMPONENT", 195, 202], ["GFP fusion and epitope-295 tagged proteins", "PROTEIN", 43, 85], ["wt X-ORFs", "DNA", 127, 136], ["X61", "DNA", 146, 149], ["BirA", "PROTEIN", 182, 186], ["our previous studies", "TEST", 17, 37], ["GFP fusion", "TREATMENT", 43, 53], ["epitope", "TEST", 58, 65], ["tagged proteins", "TEST", 70, 85], ["fusion", "TREATMENT", 113, 119], ["the wt X-ORFs", "TEST", 123, 136], ["nucleus", "ANATOMY", 195, 202]]], ["Moreover, BirA* alone and BirA-X-ORF fusion proteins.", [["BirA", "GENE_OR_GENE_PRODUCT", 10, 14], ["BirA-X", "GENE_OR_GENE_PRODUCT", 26, 32], ["BirA", "PROTEIN", 10, 14], ["BirA", "PROTEIN", 26, 30], ["X", "PROTEIN", 31, 32], ["ORF fusion proteins", "PROTEIN", 33, 52], ["BirA", "TEST", 26, 30], ["ORF fusion proteins", "TREATMENT", 33, 52]]], ["We prepared affinity-301 purified biotinylated proteins for quantitative mass spectrometry, using reductive dimethylation 302 to introduce stable epitope tags.", [["affinity-301 purified biotinylated proteins", "PROTEIN", 12, 55], ["purified biotinylated proteins", "TREATMENT", 25, 55], ["quantitative mass spectrometry", "PROBLEM", 60, 90], ["reductive dimethylation", "TREATMENT", 98, 121]]], ["These high-309 confidence hits were enriched more than two-fold over controls in at least two experiments or 310 more than 1.5-fold in all three experiments.", [["high", "OBSERVATION_MODIFIER", 6, 10]]], ["Figure 6C depicts the relative peptide abundance of 311 proteins in X61 samples compared to the X61(4A) control or BirA* alone control, with black 312 and red open circles identifying the high confidence hits.", [["X61 samples", "ANATOMY", 68, 79], ["X61 samples", "CANCER", 68, 79], ["311 proteins", "PROTEIN", 52, 64], ["BirA* alone control", "TREATMENT", 115, 134], ["red open circles", "TREATMENT", 155, 171], ["the high confidence hits", "PROBLEM", 184, 208], ["high", "OBSERVATION_MODIFIER", 188, 192]]], ["The red circles indicate two proteins 313 All rights reserved.", [["two proteins", "TEST", 25, 37], ["red circles", "OBSERVATION", 4, 15]]], ["No reuse allowed without permission.299The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint (nucleolin, nucleophosmin) that were enriched >2-fold compared to controls across all three 314 runs.", [["https://doi.org/10.1101/442996", "CHEMICAL", 132, 162], ["nucleolin", "GENE_OR_GENE_PRODUCT", 186, 195], ["nucleophosmin", "GENE_OR_GENE_PRODUCT", 197, 210], ["doi: bioRxiv preprint", "PROTEIN", 163, 184], ["nucleolin", "PROTEIN", 186, 195], ["nucleophosmin", "PROTEIN", 197, 210], ["bioRxiv preprint (nucleolin, nucleophosmin", "TREATMENT", 168, 210]]], ["Because nucleolin and nucleophosmin are abundant proteins that move in and out of 315 nucleoli, these interactions may explain the apparent nucleolar accumulation of biotinylated 316 proteins ( Figures S5A, S5C) .", [["nucleoli", "ANATOMY", 86, 94], ["nucleolar", "ANATOMY", 140, 149], ["nucleolin", "GENE_OR_GENE_PRODUCT", 8, 17], ["nucleophosmin", "GENE_OR_GENE_PRODUCT", 22, 35], ["nucleoli", "CELLULAR_COMPONENT", 86, 94], ["nucleolar", "CELLULAR_COMPONENT", 140, 149], ["S5A", "GENE_OR_GENE_PRODUCT", 202, 205], ["nucleolin", "PROTEIN", 8, 17], ["nucleophosmin", "PROTEIN", 22, 35], ["biotinylated 316 proteins", "PROTEIN", 166, 191], ["S5A", "PROTEIN", 202, 205], ["S5C", "PROTEIN", 207, 210], ["nucleolin", "PROBLEM", 8, 17], ["nucleophosmin", "PROBLEM", 22, 35], ["abundant proteins", "PROBLEM", 40, 57], ["the apparent nucleolar accumulation of biotinylated 316 proteins", "PROBLEM", 127, 191], ["nucleolar accumulation", "OBSERVATION", 140, 162]]], ["STRING protein-protein interaction network analysis of the hits 317 revealed several physical and functional interaction nodes, including protein trafficking, 318 transcription/translation and mRNA processing ( Figure 6D ).", [["STRING protein", "TEST", 0, 14], ["the hits", "TEST", 55, 63], ["several physical and functional interaction nodes", "PROBLEM", 77, 126], ["mRNA processing", "PROBLEM", 193, 208], ["interaction nodes", "OBSERVATION", 109, 126]]], ["Similarly, GO term analysis 319 revealed a strong association with mRNA processing, RNA splicing and mRNA metabolic 320 process functions among the high-confidence hits ( Figure 6E ).", [["GO term analysis", "TEST", 11, 27], ["mRNA processing", "PROBLEM", 67, 82], ["RNA splicing", "PROBLEM", 84, 96], ["mRNA metabolic 320 process functions", "PROBLEM", 101, 137]]], ["In particular, several proteins 321 associated with mRNA splicing (RBM39, PUF60, PRPF4) and/or polyadenylation (NUDT21/ 322 CPSF5, CPSF6) were identified as X-ORF-interacting proteins.", [["RBM39", "GENE_OR_GENE_PRODUCT", 67, 72], ["PUF60", "GENE_OR_GENE_PRODUCT", 74, 79], ["PRPF4", "GENE_OR_GENE_PRODUCT", 81, 86], ["NUDT21/ 322 CPSF5", "GENE_OR_GENE_PRODUCT", 112, 129], ["CPSF6", "GENE_OR_GENE_PRODUCT", 131, 136], ["X-ORF-interacting proteins", "GENE_OR_GENE_PRODUCT", 157, 183], ["321", "PROTEIN", 32, 35], ["RBM39", "PROTEIN", 67, 72], ["PUF60", "PROTEIN", 74, 79], ["PRPF4", "PROTEIN", 81, 86], ["NUDT21", "DNA", 112, 118], ["CPSF5", "DNA", 124, 129], ["CPSF6", "DNA", 131, 136], ["X-ORF", "DNA", 157, 162], ["interacting proteins", "PROTEIN", 163, 183], ["several proteins", "TEST", 15, 31], ["mRNA splicing", "PROBLEM", 52, 65], ["RBM39", "TEST", 67, 72], ["PUF60", "TEST", 74, 79], ["PRPF4", "TEST", 81, 86], ["polyadenylation", "TEST", 95, 110], ["CPSF5", "TEST", 124, 129], ["CPSF6", "TEST", 131, 136], ["X-ORF", "PROBLEM", 157, 162], ["mRNA splicing", "OBSERVATION", 52, 65]]], ["These data show that the PA-X 323 C-terminal X-ORF is physically recruited to protein complexes involved in nuclear mRNA 324 processing, which likely explains its preferential degradation of RNAs that have undergone 325 co/post-transcriptional processing.", [["nuclear", "ANATOMY", 108, 115], ["PA-X", "GENE_OR_GENE_PRODUCT", 25, 29], ["nuclear", "CELLULAR_COMPONENT", 108, 115], ["PA-X 323 C-terminal X-ORF", "DNA", 25, 50], ["protein complexes", "PROTEIN", 78, 95], ["nuclear mRNA 324", "RNA", 108, 124], ["RNAs", "RNA", 191, 195], ["These data", "TEST", 0, 10], ["the PA", "TEST", 21, 27], ["its preferential degradation of RNAs", "PROBLEM", 159, 195], ["co/post-transcriptional processing", "TREATMENT", 220, 254], ["likely explains", "UNCERTAINTY", 143, 158]]], ["326DISCUSSION 328A thorough understanding of the molecular mechanism of action of PA-X is required to 329 determine how it selectively degrades host RNAs and contributes to the control of the innate 330 immune response.", [["PA-X", "GENE_OR_GENE_PRODUCT", 82, 86], ["host RNAs", "RNA", 144, 153]]], ["In this study, we discovered a key aspect of the PA-X mechanism of action: 331 its selectivity for transcripts that have undergone splicing.", [["PA-X", "GENE_OR_GENE_PRODUCT", 49, 53], ["this study", "TEST", 3, 13], ["splicing", "OBSERVATION", 131, 139]]], ["Our transcriptomic results show that, 332 as expected, PA-X down-regulates many host RNAs, both on its own and in the context of 333 infection.", [["infection", "DISEASE", 133, 142], ["PA-X", "GENE_OR_GENE_PRODUCT", 55, 59], ["host RNAs", "RNA", 80, 89], ["PA", "TEST", 55, 57], ["many host RNAs", "PROBLEM", 75, 89], ["333 infection", "PROBLEM", 129, 142], ["host RNAs", "OBSERVATION", 80, 89], ["infection", "OBSERVATION", 133, 142]]], ["However, some RNAs are less susceptible or completely resistant to PA-X activity.", [["PA-X", "GENE_OR_GENE_PRODUCT", 67, 71], ["some RNAs", "PROBLEM", 9, 18], ["RNAs", "OBSERVATION", 14, 18]]], ["334DISCUSSION 328This difference is due in part to the fact that they are either intronless or have fewer introns.", [["introns", "DNA", 106, 113], ["fewer introns", "OBSERVATION", 100, 113]]], ["335DISCUSSION 328Moreover, based on proteomic analysis, the X-ORF of PA-X physically interacts with many 336 All rights reserved.", [["PA-X", "GENE_OR_GENE_PRODUCT", 69, 73], ["X-ORF", "DNA", 60, 65], ["X", "DNA", 72, 73], ["proteomic analysis", "TEST", 36, 54]]], ["No reuse allowed without permission.DISCUSSION 328The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint proteins involved in cellular RNA metabolism.", [["cellular", "ANATOMY", 217, 225], ["https://doi.org/10.1101/442996", "CHEMICAL", 143, 173], ["bioRxiv preprint proteins", "GENE_OR_GENE_PRODUCT", 179, 204], ["cellular", "CELL", 217, 225], ["doi: bioRxiv preprint proteins", "PROTEIN", 174, 204], ["The copyright holder", "TREATMENT", 50, 70], ["bioRxiv preprint proteins", "TREATMENT", 179, 204], ["cellular RNA metabolism", "OBSERVATION", 217, 240]]], ["These data point to a model whereby PA-X 337 associates with RNA metabolism proteins, and this association brings PA-X to target RNAs, 338 perhaps during transcription or early processing.", [["PA-X 337", "CHEMICAL", 36, 44], ["PA-X 337", "GENE_OR_GENE_PRODUCT", 36, 44], ["PA-X", "GENE_OR_GENE_PRODUCT", 114, 118], ["X 337", "PROTEIN", 39, 44], ["RNA metabolism proteins", "PROTEIN", 61, 84], ["RNA metabolism proteins", "PROBLEM", 61, 84], ["metabolism proteins", "OBSERVATION", 65, 84]]], ["Those RNAs that are not canonically processed, 339 including viral RNAs, are thus not targeted.", [["viral RNAs", "RNA", 61, 71], ["viral RNAs", "PROBLEM", 61, 71], ["viral RNAs", "OBSERVATION", 61, 71]]], ["340341Our results confirm that the PA-X-dependent down-regulation of host protein production 342 The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint341The key unexpected finding from our study is the link between PA-X and splicing.", [["340341", "CHEMICAL", 0, 6], ["PA-X", "GENE_OR_GENE_PRODUCT", 35, 39], ["PA-X", "GENE_OR_GENE_PRODUCT", 307, 311], ["340341", "SPECIES", 0, 6], ["the PA", "TEST", 31, 37], ["host protein production", "TEST", 69, 92], ["The copyright holder", "TREATMENT", 97, 117], ["bioRxiv", "TREATMENT", 226, 233], ["our study", "TEST", 277, 286]]], ["Viral host 360341shutoff RNases mostly act at some stage of mRNP loading into the translation apparatus.", [["mRNP", "ANATOMY", 60, 64], ["mRNP", "CELLULAR_COMPONENT", 60, 64], ["Viral host 360341shutoff RNases", "PROTEIN", 0, 31], ["shutoff RNases", "TREATMENT", 17, 31], ["mRNP loading", "OBSERVATION", 60, 72]]], ["For 361 example, alpha-herpesvirus vhs directly interacts with translation initiation factors, and it is 362 generally believed that these interactions mediate RNA targeting (Doepker et with RNAs through interactions with Pol II, and thus only Pol II transcripts are normally spliced 372 (Gu et al., 2013) .", [["alpha-herpesvirus vhs", "GENE_OR_GENE_PRODUCT", 17, 38], ["Pol II", "GENE_OR_GENE_PRODUCT", 222, 228], ["Pol II", "GENE_OR_GENE_PRODUCT", 244, 250], ["alpha-herpesvirus vhs", "PROTEIN", 17, 38], ["translation initiation factors", "PROTEIN", 63, 93], ["RNAs", "RNA", 191, 195], ["Pol II", "PROTEIN", 222, 228], ["Pol II transcripts", "PROTEIN", 244, 262], ["alpha-herpesvirus vhs", "PROBLEM", 17, 38]]], ["We hypothesize that protein-protein interactions with splicing factors may 373 bring PA-X to its transcript, an idea which is corroborated by the results of our proteomic 374 analysis ( Figure 6 ).", [["PA-X", "GENE_OR_GENE_PRODUCT", 85, 89], ["splicing factors", "PROTEIN", 54, 70], ["protein-protein interactions", "PROBLEM", 20, 48], ["splicing factors", "PROBLEM", 54, 70], ["our proteomic", "TEST", 157, 170]]], ["Indeed the C-terminal domain of PA-X interacts with several splicing 375 regulators (PUF60, RBM39, PRPF4) and polyadenylation proteins (CPSF5/NUDT21, CPSF6).", [["C", "CHEMICAL", 11, 12], ["PA-X", "GENE_OR_GENE_PRODUCT", 32, 36], ["PUF60", "GENE_OR_GENE_PRODUCT", 85, 90], ["RBM39", "GENE_OR_GENE_PRODUCT", 92, 97], ["PRPF4", "GENE_OR_GENE_PRODUCT", 99, 104], ["CPSF5", "GENE_OR_GENE_PRODUCT", 136, 141], ["NUDT21", "GENE_OR_GENE_PRODUCT", 142, 148], ["CPSF6", "GENE_OR_GENE_PRODUCT", 150, 155], ["C-terminal domain", "PROTEIN", 11, 28], ["PA", "PROTEIN", 32, 34], ["X", "PROTEIN", 35, 36], ["splicing 375 regulators", "PROTEIN", 60, 83], ["PUF60", "PROTEIN", 85, 90], ["RBM39", "PROTEIN", 92, 97], ["PRPF4", "PROTEIN", 99, 104], ["polyadenylation proteins", "PROTEIN", 110, 134], ["CPSF5", "PROTEIN", 136, 141], ["NUDT21", "PROTEIN", 142, 148], ["CPSF6", "PROTEIN", 150, 155], ["PUF60", "TEST", 85, 90], ["RBM39", "TEST", 92, 97], ["PRPF4", "TEST", 99, 104], ["polyadenylation proteins", "TEST", 110, 134], ["CPSF5", "TEST", 136, 141], ["CPSF6", "TEST", 150, 155]]], ["376341We speculate that more exons provide more chances for PA-X to be brought to the RNA by 377 some of these factors.", [["PA-X", "GENE_OR_GENE_PRODUCT", 60, 64], ["exons", "DNA", 29, 34]]], ["In turn, this may translate into more effective turnover of RNAs with more 378 splice sites.", [["RNAs", "RNA", 60, 64], ["378 splice sites", "DNA", 75, 91]]], ["379 380 A targeting strategy based on splicing offers a major benefit to the virus, because viral mRNAs 381 are synthesized by the RdRp and most of them are not spliced.", [["RdRp", "GENE_OR_GENE_PRODUCT", 131, 135], ["viral mRNAs 381", "RNA", 92, 107], ["RdRp", "PROTEIN", 131, 135], ["A targeting strategy", "TREATMENT", 8, 28], ["the virus", "PROBLEM", 73, 82], ["viral mRNAs", "TEST", 92, 103], ["the RdRp", "TREATMENT", 127, 135]]], ["The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint phenotype between IAV wt and PA(fs) (Jagger et al., 2012) .", [["PA", "GENE_OR_GENE_PRODUCT", 175, 177], ["The copyright holder", "TREATMENT", 0, 20], ["bioRxiv", "TREATMENT", 129, 136]]], ["However, they inserted the stop 406 codon after 16 aa, which was likely not sufficient to abolish PA-X activity ( Figure 1B ) (Jagger et 407 al., 2012) .", [["PA-X", "GENE_OR_GENE_PRODUCT", 98, 102], ["stop 406 codon", "DNA", 27, 41]]], ["The finding that truncating the X-ORF is sufficient to block PA-X activity in the virus 408 is also important, because single point mutations in the X-ORF sequence are less disruptive 409 changes than frameshifting mutations.", [["PA-X", "GENE_OR_GENE_PRODUCT", 61, 65], ["X-ORF", "DNA", 32, 37], ["X", "DNA", 64, 65], ["X-ORF sequence", "DNA", 149, 163], ["truncating the X-ORF", "PROBLEM", 17, 37], ["single point mutations", "PROBLEM", 119, 141], ["the X-ORF sequence", "TEST", 145, 163], ["frameshifting mutations", "PROBLEM", 201, 224]]], ["Thus, viruses carrying X-ORF mutations could be better 410 tools for in vivo studies of PA-X function and IAV pathogenesis. rescue activity, suggesting that the X-ORF is needed for additional functions (Hayashi et al., 416 2016 ).", [["PA-X", "GENE_OR_GENE_PRODUCT", 88, 92], ["IAV", "ORGANISM", 106, 109], ["X-ORF mutations", "DNA", 23, 38], ["X-ORF", "DNA", 161, 166], ["ORF mutations", "PROBLEM", 25, 38], ["vivo studies", "TEST", 72, 84], ["PA", "TEST", 88, 90], ["IAV pathogenesis", "PROBLEM", 106, 122], ["the X-ORF", "TREATMENT", 157, 166], ["IAV", "OBSERVATION", 106, 109]]], ["Our BioID results corroborate this idea, since we did not only find proteins involved in 417 nuclear import, but identified many proteins with various roles in RNA metabolism.", [["nuclear", "ANATOMY", 93, 100], ["nuclear", "CELLULAR_COMPONENT", 93, 100], ["RNA metabolism", "OBSERVATION", 160, 174]]], ["Also, by 418 examining the X-ORF in isolation, we likely excluded indirect interactions via RNA binding of 419 the RNase domain, as well as interactions that are important for PA rather than PA-X function.", [["RNase", "GENE_OR_GENE_PRODUCT", 115, 120], ["PA", "GENE_OR_GENE_PRODUCT", 176, 178], ["PA-X", "GENE_OR_GENE_PRODUCT", 191, 195], ["X-ORF", "DNA", 27, 32], ["RNase domain", "PROTEIN", 115, 127], ["RNA binding", "TEST", 92, 103], ["likely excluded", "UNCERTAINTY", 50, 65]]], ["420341Two proteins that we identified, nucleolin and nucleophosmin, were also reported in a proteomic 421 study of H5N1 PA-X interactors (Li et al., 2016), suggesting they interact with at least three 422 different PA-X variants.", [["nucleolin", "GENE_OR_GENE_PRODUCT", 39, 48], ["nucleophosmin", "GENE_OR_GENE_PRODUCT", 53, 66], ["H5N1", "ORGANISM", 115, 119], ["PA-X", "GENE_OR_GENE_PRODUCT", 120, 124], ["PA-X", "GENE_OR_GENE_PRODUCT", 215, 219], ["nucleolin", "PROTEIN", 39, 48], ["nucleophosmin", "PROTEIN", 53, 66], ["PA-X variants", "DNA", 215, 228]]], ["While nucleolin and nucleophosmin are highly abundant proteins, they 423 are unlikely to be artifacts because they were enriched in all the X-ORF samples relative to the 424 controls.", [["nucleolin", "GENE_OR_GENE_PRODUCT", 6, 15], ["nucleophosmin", "GENE_OR_GENE_PRODUCT", 20, 33], ["nucleolin", "PROTEIN", 6, 15], ["nucleophosmin", "PROTEIN", 20, 33], ["X-ORF samples", "DNA", 140, 153], ["nucleophosmin", "PROBLEM", 20, 33], ["artifacts", "PROBLEM", 92, 101], ["ORF samples", "TEST", 142, 153], ["unlikely to be", "UNCERTAINTY", 77, 91], ["artifacts", "OBSERVATION", 92, 101]]], ["The fact that biotinylated proteins accumulated in the nucleoli also supports the idea 425 that nucleolin and nucleophosmin, which traffic to nucleoli, come in contact with the BirA ORF was amplified by PCR and inserted into 497 All rights reserved.", [["nucleoli", "ANATOMY", 55, 63], ["nucleoli", "ANATOMY", 142, 150], ["nucleoli", "CELLULAR_COMPONENT", 55, 63], ["nucleolin", "GENE_OR_GENE_PRODUCT", 96, 105], ["nucleophosmin", "GENE_OR_GENE_PRODUCT", 110, 123], ["nucleoli", "CELLULAR_COMPONENT", 142, 150], ["BirA", "GENE_OR_GENE_PRODUCT", 177, 181], ["biotinylated proteins", "PROTEIN", 14, 35], ["nucleolin", "PROTEIN", 96, 105], ["nucleophosmin", "PROTEIN", 110, 123], ["BirA ORF", "DNA", 177, 185], ["biotinylated proteins", "PROBLEM", 14, 35], ["nucleolin", "TREATMENT", 96, 105], ["nucleophosmin", "TREATMENT", 110, 123], ["the BirA ORF", "TREATMENT", 173, 185], ["biotinylated proteins", "OBSERVATION", 14, 35]]], ["No reuse allowed without permission.341The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. globin reporter, HEK293T cells were plated in 24-well or 6-well plates (for fractionation 516 experiments) and transfected with 800 ng/ml total DNA (including 50 ng/ml PA-X construct) 517 using polyethylenimine (PEI).", [["HEK293T cells", "ANATOMY", 147, 160], ["polyethylenimine", "CHEMICAL", 324, 340], ["PEI", "CHEMICAL", 342, 345], ["polyethylenimine", "CHEMICAL", 324, 340], ["PEI", "CHEMICAL", 342, 345], ["globin", "GENE_OR_GENE_PRODUCT", 130, 136], ["HEK293T cells", "CELL", 147, 160], ["DNA", "CELLULAR_COMPONENT", 274, 277], ["polyethylenimine", "SIMPLE_CHEMICAL", 324, 340], ["PEI", "SIMPLE_CHEMICAL", 342, 345], ["globin reporter", "DNA", 130, 145], ["HEK293T cells", "CELL_LINE", 147, 160], ["globin reporter", "TEST", 130, 145], ["HEK293T cells", "TEST", 147, 160], ["fractionation", "TEST", 206, 219], ["total DNA", "TEST", 268, 277], ["50 ng/ml PA-X construct", "TREATMENT", 289, 312], ["polyethylenimine (PEI", "TREATMENT", 324, 345]]], ["Cells were collected 24 h later for fractionation and/or RNA 518 extraction and purification.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5], ["fractionation", "TEST", 36, 49], ["RNA 518 extraction", "TREATMENT", 57, 75], ["purification", "TREATMENT", 80, 92]]], ["150 mM NaCl, 1% Igepal, 0.5% sodium deoxycholate, 0.1% SDS) with protease inhibitor 541 cocktail (P8340, Sigma) and lysed at 4\u00b0C for 1 hour with gentle agitation, followed by passing 542 All rights reserved.", [["NaCl", "CHEMICAL", 7, 11], ["Igepal", "CHEMICAL", 16, 22], ["sodium deoxycholate", "CHEMICAL", 29, 48], ["agitation", "DISEASE", 152, 161], ["NaCl", "CHEMICAL", 7, 11], ["sodium deoxycholate", "CHEMICAL", 29, 48], ["Igepal", "SIMPLE_CHEMICAL", 16, 22], ["sodium deoxycholate", "SIMPLE_CHEMICAL", 29, 48], ["NaCl", "TREATMENT", 7, 11], ["1% Igepal", "TREATMENT", 13, 22], ["0.5% sodium deoxycholate", "TREATMENT", 24, 48], ["protease inhibitor", "TREATMENT", 65, 83], ["gentle agitation", "PROBLEM", 145, 161]]], ["No reuse allowed without permission.341The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint through a 21-gauge needle.", [["https://doi.org/10.1101/442996", "CHEMICAL", 132, 162], ["bioRxiv", "TREATMENT", 168, 175], ["a 21-gauge needle", "TREATMENT", 193, 210]]], ["Lysates were cleared by centrifugation at 4\u00b0C for 20 min at 20,000 x 543 g.", [["Lysates", "ANATOMY", 0, 7], ["Lysates", "ORGANISM_SUBSTANCE", 0, 7], ["Lysates", "TEST", 0, 7]]], ["544 545341Neutravidin pull-down 546 60 \u00b5l of 50% slurry of High Capacity Neutravidin Agarose Beads (Thermo) was used for each 547 500 \u00b5l of clarified whole cell lysate.", [["cell lysate", "ANATOMY", 156, 167], ["Neutravidin", "CHEMICAL", 10, 21], ["cell lysate", "CELL", 156, 167], ["Neutravidin pull", "TEST", 10, 26], ["High Capacity Neutravidin Agarose Beads (Thermo)", "TREATMENT", 59, 107], ["whole cell lysate", "TREATMENT", 150, 167]]], ["Beads were equilibrated in RIPA buffer by washing three 548 times for 10 mins at 4\u00b0C. In one of the BirA,**: p < 0.05, 0.01, B,C: ANOVA followed by Tukey's pairwise test; D: ANOVA followed by Dunnett's test, p values relative to cDNA construct-transfected cells; F: Student's t test.", [["cells", "ANATOMY", 256, 261], ["Beads", "CELL", 0, 5], ["cells", "CELL", 256, 261], ["cDNA construct", "DNA", 229, 243], ["transfected cells", "CELL_LINE", 244, 261], ["Tukey's pairwise test", "TEST", 148, 169], ["Dunnett's test", "TEST", 192, 206], ["p values", "TEST", 208, 216], ["cDNA construct", "TEST", 229, 243], ["Student's t test", "TEST", 266, 282]]], ["Addition of introns and splicing events promotes degradation by PA-X.All rights reserved.", [["introns", "DNA", 12, 19], ["introns and splicing events", "PROBLEM", 12, 39], ["introns", "OBSERVATION", 12, 19]]], ["Addition of introns and splicing events promotes degradation by PA-X.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint Figure 6 .", [["https://doi.org/10.1101/442996", "CHEMICAL", 162, 192], ["PA-X.", "GENE_OR_GENE_PRODUCT", 64, 69], ["introns", "DNA", 12, 19], ["introns and splicing events", "PROBLEM", 12, 39]]], ["The X-ORF interactome is enriched for proteins involved in mRNA processing.", [["X-ORF interactome", "DNA", 4, 21]]], ["(A) Schematic diagram of BirA* fusion baits used in BioID analysis of X-ORF interacting proteins.", [["X-ORF", "GENE_OR_GENE_PRODUCT", 70, 75], ["BirA", "PROTEIN", 25, 29], ["X-ORF interacting proteins", "PROTEIN", 70, 96], ["BirA* fusion baits", "TREATMENT", 25, 43]]], ["Numbers indicate independent runs employing each construct set, with BirA-X61(4A)-myc as negative controls.", [["BirA-X61(4A)-myc", "GENE_OR_GENE_PRODUCT", 69, 85], ["BirA", "PROTEIN", 69, 73], ["myc", "PROTEIN", 82, 85], ["BirA", "TEST", 69, 73]]], ["(B) Overlap between proteins identified by mass spectrometry by at least two unique peptides in the three BioID runs.", [["Overlap between proteins", "PROBLEM", 4, 28], ["mass spectrometry", "PROBLEM", 43, 60], ["mass", "OBSERVATION", 43, 47]]], ["(C) Average relative abundance of 286 proteins identified in at least two BioID experiments plotted as log2 ratio of medium vs. light (x axis, X-ORF / -) and medium vs. heavy (y axis, X-ORF / X61(4A).", [["ORF", "DNA", 145, 148], ["ORF", "DNA", 186, 189], ["light (x axis", "TEST", 128, 141], ["y axis", "OBSERVATION_MODIFIER", 176, 182]]], ["Green dots represent proteins with >1.5-fold enrichment over both negative controls, blue dots represent proteins with >1.5-fold enrichment over BirA-myc in at least 2 experiments or >1.5-fold enriched over BirA-X61(4A)-myc in all three experiments).", [["Green dots", "GENE_OR_GENE_PRODUCT", 0, 10], ["BirA-myc", "GENE_OR_GENE_PRODUCT", 145, 153], ["BirA-X61(4A)-myc", "GENE_OR_GENE_PRODUCT", 207, 223], ["BirA", "PROTEIN", 145, 149], ["myc", "PROTEIN", 150, 153], ["BirA", "PROTEIN", 207, 211], ["myc", "PROTEIN", 220, 223], ["Green dots", "TEST", 0, 10], ["proteins", "TEST", 21, 29], ["blue dots", "TEST", 85, 94], ["proteins", "TEST", 105, 113], ["BirA", "TEST", 207, 211]]], ["Red open circles highlight the two proteins, nucleolin (NCL) and nucleophosmin (NPM1), that were consistently enriched >2.0-fold over both negative controls in all three experiments.", [["nucleolin", "GENE_OR_GENE_PRODUCT", 45, 54], ["NCL", "GENE_OR_GENE_PRODUCT", 56, 59], ["nucleophosmin", "GENE_OR_GENE_PRODUCT", 65, 78], ["NPM1", "GENE_OR_GENE_PRODUCT", 80, 84], ["nucleolin", "PROTEIN", 45, 54], ["NCL", "PROTEIN", 56, 59], ["nucleophosmin", "PROTEIN", 65, 78], ["NPM1", "PROTEIN", 80, 84], ["Red open circles", "TEST", 0, 16], ["nucleolin (NCL", "TREATMENT", 45, 59], ["nucleophosmin (NPM1", "TEST", 65, 84], ["open circles", "OBSERVATION", 4, 16], ["negative", "OBSERVATION", 139, 147]]], ["(D) STRING protein-protein interaction network for X-ORF BioID high-confidence hits.", [["X-ORF BioID", "DNA", 51, 62], ["STRING protein", "TEST", 4, 18]]], ["Apparent nodes were differentially colored (annotations may overlap for individual proteins, only one grouping for each protein was shown for simplicity).", [["nodes", "ANATOMY", 9, 14], ["nodes", "MULTI-TISSUE_STRUCTURE", 9, 14], ["Apparent nodes", "PROBLEM", 0, 14], ["individual proteins", "PROBLEM", 72, 91], ["each protein", "TEST", 115, 127], ["nodes", "OBSERVATION", 9, 14]]], ["(E) Gene ontology (GO) enrichment analysis of X-ORF BioID hits identified by mass spectrometry (black and red circles in C).", [["X-ORF BioID hits", "DNA", 46, 62], ["enrichment analysis", "TEST", 23, 42], ["X-ORF BioID hits", "TEST", 46, 62], ["mass spectrometry", "PROBLEM", 77, 94]]], ["Fold enrichment and number of proteins are plotted for GO terms with p < 0.05.", [["Fold enrichment", "PROBLEM", 0, 15], ["enrichment", "OBSERVATION", 5, 15]]], ["Addition of introns and splicing events promotes degradation by PA-X.All rights reserved.", [["introns", "DNA", 12, 19], ["introns and splicing events", "PROBLEM", 12, 39], ["introns", "OBSERVATION", 12, 19]]], ["Addition of introns and splicing events promotes degradation by PA-X.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. , and the levels of all RNAs were measured by RNA-seq.", [["PA-X.", "GENE_OR_GENE_PRODUCT", 64, 69], ["introns", "DNA", 12, 19], ["RNAs", "RNA", 184, 188], ["introns and splicing events", "PROBLEM", 12, 39], ["the levels", "TEST", 166, 176], ["all RNAs", "TEST", 180, 188], ["all RNAs", "ANATOMY", 180, 188]]], ["The ratio between the levels in IAV-infected vs. mock-infected cells was computed for each RNA and the distribution of the ratios is plotted as a frequency histogram (wt and PA(\u0394X) plots are the same as Figure 1C ).", [["cells", "ANATOMY", 63, 68], ["IAV", "ORGANISM", 32, 35], ["cells", "CELL", 63, 68], ["The ratio", "TEST", 0, 9], ["the levels", "TEST", 18, 28], ["IAV", "PROBLEM", 32, 35], ["infected cells", "PROBLEM", 54, 68], ["the ratios", "TEST", 119, 129], ["a frequency histogram", "TEST", 144, 165], ["wt", "TEST", 167, 169], ["PA(\u0394X) plots", "TEST", 174, 186], ["IAV", "OBSERVATION_MODIFIER", 32, 35], ["infected", "OBSERVATION_MODIFIER", 36, 44], ["infected cells", "OBSERVATION", 54, 68]]], ["Addition of introns and splicing events promotes degradation by PA-X.All rights reserved.", [["introns", "DNA", 12, 19], ["introns and splicing events", "PROBLEM", 12, 39], ["introns", "OBSERVATION", 12, 19]]], ["Addition of introns and splicing events promotes degradation by PA-X.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.Figure S2All rights reserved.", [["PA-X.", "GENE_OR_GENE_PRODUCT", 64, 69], ["introns", "DNA", 12, 19], ["introns and splicing events", "PROBLEM", 12, 39], ["Figure S2All rights", "TREATMENT", 159, 178]]], ["No reuse allowed without permission.Figure S2The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the author/funder.Figure S4All rights reserved.", [["https://doi.org/10.1101/442996", "CHEMICAL", 138, 168], ["bioRxiv", "TREATMENT", 174, 181], ["The copyright holder", "TREATMENT", 191, 211]]], ["No reuse allowed without permission.Figure S4The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint Figure S4 (related to Figure 5 ).", [["https://doi.org/10.1101/442996", "CHEMICAL", 138, 168]]], ["IFN-\u03bb2 mRNA is expressed and exported at similar levels from both a genomic and a cDNA reporter constructs.", [["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 0, 6], ["IFN-\u03bb2 mRNA", "RNA", 0, 11], ["cDNA reporter constructs", "DNA", 82, 106], ["a cDNA reporter constructs", "TREATMENT", 80, 106]]], ["(A) The attomoles of IFN-\u03bb2 mRNA in cells infected with wt IAV or IAV PA(\u0394X) are plotted.", [["cells", "ANATOMY", 36, 41], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 21, 27], ["cells", "CELL", 36, 41], ["wt IAV", "ORGANISM", 56, 62], ["IAV PA", "ORGANISM", 66, 72], ["IFN-\u03bb2 mRNA", "RNA", 21, 32], ["IFN", "TEST", 21, 24], ["wt IAV", "TREATMENT", 56, 62]]], ["The IFN-\u03bb2 mRNA was undetectable in mock-infected cells (n.d. = not detected).", [["cells", "ANATOMY", 50, 55], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 4, 10], ["cells", "CELL", 50, 55], ["IFN-\u03bb2 mRNA", "RNA", 4, 15], ["mock-infected cells", "CELL_LINE", 36, 55], ["The IFN-\u03bb2 mRNA", "TEST", 0, 15], ["infected cells", "PROBLEM", 41, 55], ["infected cells", "OBSERVATION", 41, 55]]], ["N \u2265 2 (B) HEK293T cells were transfected with reporters expressing IFN-\u03bb2 mRNA from cDNA or the genomic locus.", [["N \u2265 2 (B) HEK293T cells", "ANATOMY", 0, 23], ["HEK293T cells", "CELL", 10, 23], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 67, 73], ["N \u2265 2 (B) HEK293T cells", "CELL_LINE", 0, 23], ["IFN-\u03bb2 mRNA", "RNA", 67, 78], ["cDNA", "DNA", 84, 88], ["genomic locus", "DNA", 96, 109], ["N \u2265 2 (B) HEK293T cells", "TEST", 0, 23], ["IFN", "TEST", 67, 70], ["genomic locus", "OBSERVATION", 96, 109]]], ["RNA samples were collected 24 h after transfection and analyzed by RT-qPCR.", [["samples", "ANATOMY", 4, 11], ["RNA samples", "TEST", 0, 11], ["transfection", "TEST", 38, 50]]], ["The levels of IFN-\u03bb 2 in the absence of PA-X are plotted relative to 18S cellular rRNA.", [["cellular", "ANATOMY", 73, 81], ["IFN-\u03bb 2", "GENE_OR_GENE_PRODUCT", 14, 21], ["PA-X", "GENE_OR_GENE_PRODUCT", 40, 44], ["cellular", "CELL", 73, 81], ["IFN-\u03bb 2", "PROTEIN", 14, 21], ["18S cellular rRNA", "RNA", 69, 86], ["The levels", "TEST", 0, 10], ["IFN", "TEST", 14, 17], ["PA", "TEST", 40, 42], ["18S cellular rRNA", "PROBLEM", 69, 86], ["18S cellular rRNA", "OBSERVATION", 69, 86]]], ["All values represent mean \u00b1 standard deviation.", [["All values", "TEST", 0, 10], ["mean \u00b1 standard deviation", "PROBLEM", 21, 46], ["mean \u00b1", "OBSERVATION", 21, 27], ["standard deviation", "OBSERVATION", 28, 46]]], ["(C) HEK293T cells were transfected with reporters expressing a luciferase mRNA, a GFP mRNA ending in a hammerhead ribozyme (GFP-HR) and IFN-\u03bb2 mRNAs from cDNA or the genomic locus.", [["HEK293T cells", "ANATOMY", 4, 17], ["HEK293T cells", "CELL", 4, 17], ["luciferase", "GENE_OR_GENE_PRODUCT", 63, 73], ["GFP", "GENE_OR_GENE_PRODUCT", 82, 85], ["GFP-HR", "GENE_OR_GENE_PRODUCT", 124, 130], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 136, 142], ["HEK293T cells", "CELL_LINE", 4, 17], ["luciferase mRNA", "RNA", 63, 78], ["GFP mRNA", "RNA", 82, 90], ["IFN-\u03bb2 mRNAs", "RNA", 136, 148], ["cDNA", "DNA", 154, 158], ["genomic locus", "DNA", 166, 179], ["a luciferase mRNA", "PROBLEM", 61, 78], ["a GFP mRNA", "TEST", 80, 90], ["a hammerhead ribozyme", "TEST", 101, 122], ["GFP", "TEST", 124, 127], ["HR", "TEST", 128, 130], ["IFN", "TEST", 136, 139], ["2 mRNAs from cDNA", "PROBLEM", 141, 158], ["genomic locus", "OBSERVATION", 166, 179]]], ["Cells were fractionated into nuclear and cytoplasmic fraction, and the ratio between cytoplasmic and nuclear RNA levels was calculated after normalization to 18S rRNA.", [["Cells", "ANATOMY", 0, 5], ["nuclear", "ANATOMY", 29, 36], ["cytoplasmic", "ANATOMY", 41, 52], ["cytoplasmic", "ANATOMY", 85, 96], ["nuclear", "ANATOMY", 101, 108], ["Cells", "CELL", 0, 5], ["nuclear", "CELLULAR_COMPONENT", 29, 36], ["cytoplasmic", "ORGANISM_SUBSTANCE", 41, 52], ["cytoplasmic", "ORGANISM_SUBSTANCE", 85, 96], ["nuclear", "CELLULAR_COMPONENT", 101, 108], ["18S", "GENE_OR_GENE_PRODUCT", 158, 161], ["rRNA", "CELLULAR_COMPONENT", 162, 166], ["18S rRNA", "RNA", 158, 166], ["Cells", "TEST", 0, 5], ["nuclear and cytoplasmic fraction", "TEST", 29, 61], ["the ratio", "TEST", 67, 76], ["nuclear RNA levels", "TEST", 101, 119], ["cytoplasmic fraction", "OBSERVATION", 41, 61], ["18S rRNA", "OBSERVATION", 158, 166]]], ["The cytoplasmic/nuclear ratio for the well-exported endogenous GAPDH mRNA and transfected luciferase mRNA, the nuclear-retained endogenous MALAT1 non-coding RNA, the poorly exported transfected GFP-HR mRNA and the test IFN-\u03bb2 mRNAs are plotted.", [["cytoplasmic", "ANATOMY", 4, 15], ["nuclear", "ANATOMY", 16, 23], ["nuclear", "ANATOMY", 111, 118], ["cytoplasmic", "ORGANISM_SUBSTANCE", 4, 15], ["nuclear", "CELLULAR_COMPONENT", 16, 23], ["GAPDH", "GENE_OR_GENE_PRODUCT", 63, 68], ["luciferase", "GENE_OR_GENE_PRODUCT", 90, 100], ["nuclear", "CELLULAR_COMPONENT", 111, 118], ["MALAT1", "GENE_OR_GENE_PRODUCT", 139, 145], ["GFP-HR", "GENE_OR_GENE_PRODUCT", 194, 200], ["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 219, 225], ["endogenous GAPDH mRNA", "RNA", 52, 73], ["luciferase mRNA", "RNA", 90, 105], ["MALAT1 non-coding RNA", "RNA", 139, 160], ["GFP-HR mRNA", "RNA", 194, 205], ["IFN-\u03bb2 mRNAs", "RNA", 219, 231], ["The cytoplasmic/nuclear ratio", "TEST", 0, 29], ["transfected luciferase mRNA", "PROBLEM", 78, 105], ["retained endogenous MALAT1 non-coding RNA", "PROBLEM", 119, 160], ["HR mRNA", "TEST", 198, 205], ["the test IFN", "TEST", 210, 222], ["endogenous GAPDH mRNA", "OBSERVATION", 52, 73], ["transfected luciferase mRNA", "OBSERVATION", 78, 105], ["endogenous MALAT1", "OBSERVATION", 128, 145], ["non-coding RNA", "OBSERVATION", 146, 160]]], ["All values represent mean \u00b1 standard deviation.", [["All values", "TEST", 0, 10], ["mean \u00b1 standard deviation", "PROBLEM", 21, 46], ["mean \u00b1", "OBSERVATION", 21, 27], ["standard deviation", "OBSERVATION", 28, 46]]], ["(D) The cDNAs from vector-transfected cells from Figure 5C were PCR amplified across the different introns to confirm splicing.", [["cells", "ANATOMY", 38, 43], ["cells", "CELL", 38, 43], ["Figure 5C", "CELL", 49, 58], ["cDNAs", "DNA", 8, 13], ["introns", "DNA", 99, 106], ["The cDNAs from vector", "TREATMENT", 4, 25], ["transfected cells", "PROBLEM", 26, 43], ["Figure 5C", "TREATMENT", 49, 58], ["PCR", "TEST", 64, 67], ["the different introns", "TREATMENT", 85, 106]]], ["The amplified PCR products are shown (gel image is representative of four experiments).", [["amplified PCR products", "DNA", 4, 26], ["The amplified PCR products", "TREATMENT", 0, 26], ["gel image", "TEST", 38, 47]]], ["A 1:1 mix of the constructs for IFN-\u03bb2 cDNA and genomic serves as a control to check that both products could be simultaneously amplified.", [["IFN-\u03bb2", "GENE_OR_GENE_PRODUCT", 32, 38], ["IFN-\u03bb2 cDNA", "DNA", 32, 43], ["the constructs", "TREATMENT", 13, 27], ["IFN-\u03bb2 cDNA", "TREATMENT", 32, 43]]], ["Figure S5 (related to Figure 6 ).", [["Figure S5", "PROBLEM", 0, 9]]], ["BirA-myc (-myc), BirA-X61(4A)-myc (-X61(4A)-myc), or BirA-X61-myc expressing cells.", [["cells", "ANATOMY", 77, 82], ["BirA-myc", "GENE_OR_GENE_PRODUCT", 0, 8], ["myc", "GENE_OR_GENE_PRODUCT", 11, 14], ["BirA-X61(4A)-myc", "GENE_OR_GENE_PRODUCT", 17, 33], ["-X61(4A)-myc", "GENE_OR_GENE_PRODUCT", 35, 47], ["BirA-X61-myc", "GENE_OR_GENE_PRODUCT", 53, 65], ["BirA", "PROTEIN", 0, 4], ["myc", "PROTEIN", 5, 8], ["myc", "PROTEIN", 11, 14], ["BirA", "PROTEIN", 17, 21], ["X61", "PROTEIN", 22, 25], ["myc", "PROTEIN", 30, 33], ["myc", "PROTEIN", 44, 47], ["BirA", "PROTEIN", 53, 57], ["X61", "PROTEIN", 58, 61], ["myc expressing cells", "CELL_LINE", 62, 82], ["BirA", "TEST", 0, 4], ["myc", "TEST", 5, 8], ["BirA", "TEST", 17, 21], ["myc", "TEST", 30, 33], ["BirA", "TEST", 53, 57], ["myc", "ANATOMY", 5, 8], ["expressing cells", "OBSERVATION", 66, 82]]], ["(B) Flow through (FT), wash 1 (W1), wash 4 (W4), and elution fractions of neutravidin agarose pulldown of proteins biotinylated using BirA-X61(4A)-myc (4A), or BirA-X61-myc biotinylated protein mix compared to proteins biotinylated by the other two baits.", [["neutravidin", "SIMPLE_CHEMICAL", 74, 85], ["X61-myc", "GENE_OR_GENE_PRODUCT", 165, 172], ["BirA", "PROTEIN", 134, 138], ["X61(4A)-myc (4A)", "PROTEIN", 139, 155], ["BirA", "PROTEIN", 160, 164], ["X61", "PROTEIN", 165, 168], ["myc biotinylated protein mix", "PROTEIN", 169, 197], ["Flow through (FT)", "TEST", 4, 21], ["elution fractions", "TEST", 53, 70], ["proteins biotinylated", "TEST", 106, 127], ["BirA", "TEST", 134, 138], ["BirA", "TEST", 160, 164], ["myc biotinylated protein mix", "TREATMENT", 169, 197]]], ["(C) Immunofluorescent staining of biotinylated proteins in cells transfected with BirA fused to full-length catalytically inactive PA-X mutant, BirA-myc expressing cells.", [["cells", "ANATOMY", 59, 64], ["cells", "ANATOMY", 164, 169], ["cells", "CELL", 59, 64], ["BirA", "GENE_OR_GENE_PRODUCT", 82, 86], ["PA-X", "GENE_OR_GENE_PRODUCT", 131, 135], ["BirA-myc", "GENE_OR_GENE_PRODUCT", 144, 152], ["cells", "CELL", 164, 169], ["biotinylated proteins", "PROTEIN", 34, 55], ["BirA", "PROTEIN", 82, 86], ["catalytically inactive PA-X mutant, BirA-myc expressing cells", "CELL_LINE", 108, 169], ["Immunofluorescent staining", "TEST", 4, 30], ["biotinylated proteins in cells", "PROBLEM", 34, 64], ["PA", "TEST", 131, 133], ["BirA", "TEST", 144, 148], ["expressing cells", "OBSERVATION", 153, 169]]], ["(D) Schematic diagram of BirA* fusion constructs used in panels B and C.Figure S4All rights reserved.", [["BirA* fusion constructs", "DNA", 25, 48], ["BirA* fusion constructs", "TREATMENT", 25, 48]]], ["No reuse allowed without permission.Figure S4The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint The copyright holder for this preprint (which was not peer-reviewed) is the author/funder. . https://doi.org/10.1101/442996 doi: bioRxiv preprint", [["https://doi.org/10.1101/442996", "CHEMICAL", 138, 168], ["https://doi.org/10.1101/442996", "CHEMICAL", 284, 314], ["bioRxiv", "TREATMENT", 174, 181], ["The copyright holder", "TREATMENT", 191, 211], ["bioRxiv", "TREATMENT", 320, 327]]]], "f949f62d52a1dd5407c0ae6445980103e809db73": [["INTRODUCTIONGenetic and environmental factors both play an important role in the pathogenesis of Parkinson disease (PD) (1Y6).", [["Parkinson disease", "DISEASE", 97, 114], ["PD", "DISEASE", 116, 118], ["Parkinson disease", "PROBLEM", 97, 114], ["Parkinson disease", "OBSERVATION", 97, 114]]], ["A gene that has recently been found to be involved in PD causation is leucine-rich repeat kinase 2 (LRRK2, PARK8) located in the chromosomal region 12q11.2-q13.1 (7Y9).INTRODUCTIONThe translated protein, Lrrk2, is made up of 51 exons with a total of 2527 amino acids.", [["chromosomal", "ANATOMY", 129, 140], ["PD", "DISEASE", 54, 56], ["leucine", "CHEMICAL", 70, 77], ["amino acids", "CHEMICAL", 255, 266], ["leucine", "CHEMICAL", 70, 77], ["amino acids", "CHEMICAL", 255, 266], ["leucine-rich repeat kinase 2", "GENE_OR_GENE_PRODUCT", 70, 98], ["LRRK2", "GENE_OR_GENE_PRODUCT", 100, 105], ["PARK8", "GENE_OR_GENE_PRODUCT", 107, 112], ["chromosomal", "CELLULAR_COMPONENT", 129, 140], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 204, 209], ["amino acids", "AMINO_ACID", 255, 266], ["leucine-rich repeat kinase 2", "PROTEIN", 70, 98], ["LRRK2", "PROTEIN", 100, 105], ["PARK8", "PROTEIN", 107, 112], ["chromosomal region 12q11.2-q13.1 (7Y9)", "DNA", 129, 167], ["Lrrk2", "PROTEIN", 204, 209], ["leucine", "TEST", 70, 77], ["repeat kinase", "TEST", 83, 96], ["LRRK2", "TEST", 100, 105], ["Lrrk2", "TEST", 204, 209], ["amino acids", "TREATMENT", 255, 266]]], ["Although it is a large and complex protein, it has nevertheless been highly conserved through evolution, indicating important physiological functions.", [["a large and complex protein", "PROBLEM", 15, 42], ["large", "OBSERVATION_MODIFIER", 17, 22], ["complex", "OBSERVATION_MODIFIER", 27, 34], ["protein", "OBSERVATION", 35, 42], ["physiological functions", "OBSERVATION", 126, 149]]], ["Lrrk2 belongs to the Roco protein family of the Ras/GTPase superfamily (8Y10).", [["Lrrk2", "GENE_OR_GENE_PRODUCT", 0, 5], ["Roco", "GENE_OR_GENE_PRODUCT", 21, 25], ["Ras", "GENE_OR_GENE_PRODUCT", 48, 51], ["GTPase", "GENE_OR_GENE_PRODUCT", 52, 58], ["Lrrk2", "PROTEIN", 0, 5], ["Roco protein family", "PROTEIN", 21, 40], ["Ras", "PROTEIN", 48, 51], ["GTPase superfamily", "PROTEIN", 52, 70], ["8Y10", "PROTEIN", 72, 76]]], ["The sequential structure includes a leucine-rich repeat zone (Lrr), a Ras of complex proteins (Roc), a C-terminal of Roc (Cor) domain, and a microtubuleassociated protein kinase kinase kinase (MAPKKK) domain, with termination in beta propeller forming repeats (WD 40).", [["leucine", "CHEMICAL", 36, 43], ["leucine", "CHEMICAL", 36, 43], ["C", "CHEMICAL", 103, 104], ["Ras", "GENE_OR_GENE_PRODUCT", 70, 73], ["Roc", "GENE_OR_GENE_PRODUCT", 95, 98], ["Roc", "GENE_OR_GENE_PRODUCT", 117, 120], ["microtubuleassociated protein kinase kinase kinase", "GENE_OR_GENE_PRODUCT", 141, 191], ["MAPKKK", "GENE_OR_GENE_PRODUCT", 193, 199], ["leucine-rich repeat zone", "PROTEIN", 36, 60], ["Lrr", "PROTEIN", 62, 65], ["Ras", "PROTEIN", 70, 73], ["complex proteins", "PROTEIN", 77, 93], ["Roc", "PROTEIN", 95, 98], ["C-terminal of Roc (Cor) domain", "PROTEIN", 103, 133], ["microtubuleassociated protein kinase kinase kinase (MAPKKK) domain", "PROTEIN", 141, 207], ["beta propeller forming repeats", "PROTEIN", 229, 259], ["a leucine", "TEST", 34, 43], ["Roc", "TEST", 95, 98], ["a C", "TEST", 101, 104], ["a microtubuleassociated protein kinase kinase kinase (MAPKKK) domain", "PROBLEM", 139, 207]]], ["Lrrk2 is thought to function, at least in part, as an active protein kinase (11) with mutations resulting in a gain of function (12) .INTRODUCTIONTo date, at least 19 putatively pathogenic amino acid substitutions have been identified in Lrrk2.", [["amino acid", "CHEMICAL", 189, 199], ["amino acid", "CHEMICAL", 189, 199], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 0, 5], ["amino acid", "AMINO_ACID", 189, 199], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 238, 243], ["Lrrk2", "PROTEIN", 0, 5], ["protein kinase", "PROTEIN", 61, 75], ["Lrrk2", "PROTEIN", 238, 243], ["Lrrk2", "PROBLEM", 0, 5], ["an active protein kinase", "TEST", 51, 75], ["mutations", "PROBLEM", 86, 95], ["pathogenic amino acid substitutions", "PROBLEM", 178, 213], ["thought to", "UNCERTAINTY", 9, 19], ["acid substitutions", "OBSERVATION", 195, 213]]], ["As examples, the mutations R1067Q, S1096C, I1122V, and S1228T occur in the LRR domain; whereas I1371V, R1441C, R1441G, and R1441H occur in the Roc domain; R1514Q, Y1699C, and M1869T occur in the Cor domain; R1941H, I2012T, G2019S, and I2020T occur in the MAPKKK domain; and T2356I and G2358R occur in the WD 40 domain.", [["R1441H", "AMINO_ACID", 123, 129], ["MAPKKK", "GENE_OR_GENE_PRODUCT", 255, 261], ["LRR domain", "PROTEIN", 75, 85], ["Roc domain", "PROTEIN", 143, 153], ["Cor domain", "PROTEIN", 195, 205], ["MAPKKK domain", "PROTEIN", 255, 268], ["T2356I", "PROTEIN", 274, 280], ["G2358R", "PROTEIN", 285, 291], ["WD 40 domain", "PROTEIN", 305, 317], ["the mutations", "TEST", 13, 26], ["G2019S", "TEST", 223, 229]]], ["In addition, R793M and Q930R occur N-terminal to the functional domains.", [["N", "CHEMICAL", 35, 36], ["R793M", "GENE_OR_GENE_PRODUCT", 13, 18], ["Q930R", "PROTEIN", 23, 28], ["N-terminal", "PROTEIN", 35, 45]]], ["The most prominent of these substitutions is G2019S, which is common in French and North African families as well as Ashkenazi Jews (13) .", [["Ashkenazi Jews", "DISEASE", 117, 131], ["G2019S", "AMINO_ACID", 45, 51], ["most prominent", "OBSERVATION_MODIFIER", 4, 18], ["substitutions", "OBSERVATION", 28, 41], ["G2019S", "OBSERVATION", 45, 51]]], ["It also occurs in approximately 1% of unselected PD cases, 3% to 6% of familial cases (13, 14) , and some normals.", [["PD", "DISEASE", 49, 51], ["familial cases", "TEST", 71, 85]]], ["Penetrance varies.", [["Penetrance", "DISEASE", 0, 10], ["Penetrance varies", "PROBLEM", 0, 17]]], ["In one study, penetrance was found to range from 17% at age 50 to 85% at age 70 (15) .", [["one study", "TEST", 3, 12], ["penetrance", "PROBLEM", 14, 24]]], ["Most postmortem studies on patients with LRRK2 mutations have revealed the typical PD findings of nigral cell loss and extensive Lewy body distribution, but some have demonstrated Alzheimer-like neurofibrillary pathology, some multiple system atrophy-type pathology, and some progressive supranuclear palsy-like pathology.INTRODUCTIONNorthern blot analyses of LRRK2 mRNA expression have detected a 9-kb mRNA transcript in all human tissues tested, including most regions of brain with highest levels being reported in the putamen and substantia nigra (SN) (9) .", [["nigral cell", "ANATOMY", 98, 109], ["body", "ANATOMY", 134, 138], ["supranuclear", "ANATOMY", 288, 300], ["tissues", "ANATOMY", 432, 439], ["brain", "ANATOMY", 474, 479], ["putamen", "ANATOMY", 522, 529], ["substantia nigra", "ANATOMY", 534, 550], ["PD", "DISEASE", 83, 85], ["nigral cell loss", "DISEASE", 98, 114], ["Alzheimer-like neurofibrillary pathology", "DISEASE", 180, 220], ["atrophy", "DISEASE", 243, 250], ["supranuclear palsy", "DISEASE", 288, 306], ["patients", "ORGANISM", 27, 35], ["LRRK2", "GENE_OR_GENE_PRODUCT", 41, 46], ["nigral cell", "CELL", 98, 109], ["body", "IMMATERIAL_ANATOMICAL_ENTITY", 134, 138], ["LRRK2", "GENE_OR_GENE_PRODUCT", 360, 365], ["human", "ORGANISM", 426, 431], ["tissues", "TISSUE", 432, 439], ["brain", "ORGAN", 474, 479], ["putamen", "MULTI-TISSUE_STRUCTURE", 522, 529], ["substantia nigra", "CANCER", 534, 550], ["LRRK2", "PROTEIN", 41, 46], ["LRRK2 mRNA", "RNA", 360, 370], ["9-kb mRNA transcript", "RNA", 398, 418], ["patients", "SPECIES", 27, 35], ["human", "SPECIES", 426, 431], ["human", "SPECIES", 426, 431], ["Most postmortem studies", "TEST", 0, 23], ["LRRK2 mutations", "TEST", 41, 56], ["nigral cell loss", "PROBLEM", 98, 114], ["extensive Lewy body distribution", "PROBLEM", 119, 151], ["Alzheimer-like neurofibrillary pathology", "PROBLEM", 180, 220], ["some multiple system atrophy", "PROBLEM", 222, 250], ["type pathology", "PROBLEM", 251, 265], ["some progressive supranuclear palsy", "PROBLEM", 271, 306], ["blot analyses", "TEST", 343, 356], ["nigral cell loss", "OBSERVATION", 98, 114], ["extensive", "OBSERVATION_MODIFIER", 119, 128], ["Lewy body distribution", "OBSERVATION", 129, 151], ["Alzheimer", "OBSERVATION", 180, 189], ["neurofibrillary pathology", "OBSERVATION", 195, 220], ["multiple", "OBSERVATION_MODIFIER", 227, 235], ["atrophy", "OBSERVATION", 243, 250], ["type", "OBSERVATION_MODIFIER", 251, 255], ["pathology", "OBSERVATION", 256, 265], ["some", "OBSERVATION_MODIFIER", 271, 275], ["progressive", "OBSERVATION_MODIFIER", 276, 287], ["supranuclear palsy", "OBSERVATION", 288, 306], ["human tissues", "ANATOMY", 426, 439], ["brain", "ANATOMY", 474, 479], ["putamen", "ANATOMY", 522, 529]]], ["In rodent brain, in situ hybridization studies showed LRRK2 mRNA to be widely expressed in motor and nonmotor areas (16, 17) with a preference for dopamine-receptive areas (17, 18) with little or no expression in the SN.", [["brain", "ANATOMY", 10, 15], ["nonmotor areas", "ANATOMY", 101, 115], ["SN", "ANATOMY", 217, 219], ["dopamine", "CHEMICAL", 147, 155], ["dopamine", "CHEMICAL", 147, 155], ["brain", "ORGAN", 10, 15], ["LRRK2", "GENE_OR_GENE_PRODUCT", 54, 59], ["dopamine", "SIMPLE_CHEMICAL", 147, 155], ["LRRK2 mRNA", "RNA", 54, 64], ["rodent", "SPECIES", 3, 9], ["situ hybridization studies", "TEST", 20, 46], ["LRRK2 mRNA", "PROBLEM", 54, 64], ["dopamine", "TREATMENT", 147, 155], ["brain", "ANATOMY", 10, 15], ["LRRK2 mRNA", "OBSERVATION", 54, 64], ["no", "UNCERTAINTY", 196, 198], ["expression", "OBSERVATION", 199, 209], ["SN", "ANATOMY", 217, 219]]], ["Human embryonic kidney cells transfected with human recombinant Lrrk2 showed a diffuse cytoplasmic localization and an association with the outer mitochondrial membrane (9, 11) .INTRODUCTIONThe distribution of Lrrk2 in the brain of PD and other neurodegenerative disorders is not known.", [["embryonic kidney cells", "ANATOMY", 6, 28], ["cytoplasmic", "ANATOMY", 87, 98], ["outer mitochondrial membrane", "ANATOMY", 140, 168], ["brain", "ANATOMY", 223, 228], ["PD", "DISEASE", 232, 234], ["neurodegenerative disorders", "DISEASE", 245, 272], ["Human", "ORGANISM", 0, 5], ["embryonic kidney cells", "CELL", 6, 28], ["human", "ORGANISM", 46, 51], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 64, 69], ["cytoplasmic", "ORGANISM_SUBSTANCE", 87, 98], ["outer", "CELLULAR_COMPONENT", 140, 145], ["mitochondrial membrane", "CELLULAR_COMPONENT", 146, 168], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 210, 215], ["brain", "ORGAN", 223, 228], ["Human embryonic kidney cells", "CELL_TYPE", 0, 28], ["human recombinant Lrrk2", "PROTEIN", 46, 69], ["Lrrk2", "PROTEIN", 210, 215], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 46, 51], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 46, 51], ["Human embryonic kidney cells", "PROBLEM", 0, 28], ["human recombinant Lrrk2", "TEST", 46, 69], ["a diffuse cytoplasmic localization", "PROBLEM", 77, 111], ["Lrrk2", "PROBLEM", 210, 215], ["PD", "PROBLEM", 232, 234], ["other neurodegenerative disorders", "PROBLEM", 239, 272], ["kidney", "ANATOMY", 16, 22], ["diffuse", "OBSERVATION_MODIFIER", 79, 86], ["cytoplasmic localization", "OBSERVATION", 87, 111], ["outer", "ANATOMY_MODIFIER", 140, 145], ["mitochondrial membrane", "OBSERVATION", 146, 168], ["distribution", "OBSERVATION_MODIFIER", 194, 206], ["Lrrk2", "OBSERVATION", 210, 215], ["brain", "ANATOMY", 223, 228], ["neurodegenerative disorders", "OBSERVATION", 245, 272], ["not known", "UNCERTAINTY", 276, 285]]], ["In the present study, we analyzed for the presence of LRRK2 mRNA in human astrocytes, oligodendroglia, and microglia; in the human neuronal cell lines SH-SY5Y and LA-N-2 and in whole brain, liver, and heart.", [["astrocytes", "ANATOMY", 74, 84], ["oligodendroglia", "ANATOMY", 86, 101], ["microglia", "ANATOMY", 107, 116], ["neuronal cell lines SH-SY5Y", "ANATOMY", 131, 158], ["LA-N-2", "ANATOMY", 163, 169], ["brain", "ANATOMY", 183, 188], ["liver", "ANATOMY", 190, 195], ["heart", "ANATOMY", 201, 206], ["LRRK2", "GENE_OR_GENE_PRODUCT", 54, 59], ["human", "ORGANISM", 68, 73], ["astrocytes", "CELL", 74, 84], ["oligodendroglia", "CELL", 86, 101], ["microglia", "CELL", 107, 116], ["human", "ORGANISM", 125, 130], ["neuronal cell lines SH-SY5Y", "CELL", 131, 158], ["LA-N-2", "CELL", 163, 169], ["brain", "ORGAN", 183, 188], ["liver", "ORGAN", 190, 195], ["heart", "ORGAN", 201, 206], ["LRRK2 mRNA", "RNA", 54, 64], ["human astrocytes", "CELL_TYPE", 68, 84], ["oligodendroglia", "CELL_TYPE", 86, 101], ["microglia", "CELL_TYPE", 107, 116], ["human neuronal cell lines", "CELL_LINE", 125, 150], ["SH-SY5Y", "CELL_LINE", 151, 158], ["LA-N-2", "CELL_LINE", 163, 169], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 125, 130], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 125, 130], ["the present study", "TEST", 3, 20], ["LRRK2 mRNA in human astrocytes", "PROBLEM", 54, 84], ["oligodendroglia", "PROBLEM", 86, 101], ["microglia", "PROBLEM", 107, 116], ["LA", "TEST", 163, 165], ["LRRK2 mRNA", "OBSERVATION", 54, 64], ["human astrocytes", "ANATOMY", 68, 84], ["oligodendroglia", "OBSERVATION", 86, 101], ["human neuronal", "ANATOMY", 125, 139], ["cell lines", "OBSERVATION", 140, 150], ["LA", "ANATOMY", 163, 165], ["whole", "ANATOMY_MODIFIER", 177, 182], ["brain", "ANATOMY", 183, 188], ["liver", "ANATOMY", 190, 195], ["heart", "ANATOMY", 201, 206]]], ["Using membrane-bound overlapping peptides covering the full Lrrk2 sequence, we identified the C-terminal binding site of a polyclonal anti-Lrrk2 antibody and performed an immunohistochemical analysis of a series of brains of patients with PD, including one member of a family with autosomal-dominant late-onset parkinsonism (family B) (19) as well as patients with diffuse Lewy body disease (DLBD), Alzheimer disease (AD), amyotrophic lateral sclerosis (ALS), Pick disease, the parkinsonismYdementia complex of Guam (PDCG), and Huntington disease.", [["membrane", "ANATOMY", 6, 14], ["brains", "ANATOMY", 215, 221], ["body", "ANATOMY", 378, 382], ["PD", "DISEASE", 239, 241], ["parkinsonism", "DISEASE", 311, 323], ["Lewy body disease", "DISEASE", 373, 390], ["DLBD", "DISEASE", 392, 396], ["Alzheimer disease", "DISEASE", 399, 416], ["AD", "DISEASE", 418, 420], ["amyotrophic lateral sclerosis", "DISEASE", 423, 452], ["ALS", "DISEASE", 454, 457], ["Pick disease", "DISEASE", 460, 472], ["Huntington disease", "DISEASE", 528, 546], ["C", "CHEMICAL", 94, 95], ["membrane", "CELLULAR_COMPONENT", 6, 14], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 60, 65], ["anti-Lrrk2", "GENE_OR_GENE_PRODUCT", 134, 144], ["brains", "ORGAN", 215, 221], ["patients", "ORGANISM", 225, 233], ["patients", "ORGANISM", 351, 359], ["diffuse Lewy body disease", "CANCER", 365, 390], ["amyotrophic lateral sclerosis", "CANCER", 423, 452], ["Lrrk2 sequence", "DNA", 60, 74], ["C-terminal binding site", "PROTEIN", 94, 117], ["polyclonal anti-Lrrk2 antibody", "PROTEIN", 123, 153], ["patients", "SPECIES", 225, 233], ["patients", "SPECIES", 351, 359], ["membrane-bound overlapping peptides", "TREATMENT", 6, 41], ["the full Lrrk2 sequence", "TEST", 51, 74], ["the C-terminal binding site", "PROBLEM", 90, 117], ["a polyclonal anti-Lrrk2 antibody", "TREATMENT", 121, 153], ["an immunohistochemical analysis", "TEST", 168, 199], ["PD", "PROBLEM", 239, 241], ["autosomal-dominant late-onset parkinsonism", "PROBLEM", 281, 323], ["diffuse Lewy body disease (DLBD)", "PROBLEM", 365, 397], ["Alzheimer disease (AD)", "PROBLEM", 399, 421], ["amyotrophic lateral sclerosis (ALS)", "PROBLEM", 423, 458], ["Pick disease", "PROBLEM", 460, 472], ["Huntington disease", "PROBLEM", 528, 546], ["dominant", "OBSERVATION_MODIFIER", 291, 299], ["late-onset", "OBSERVATION_MODIFIER", 300, 310], ["parkinsonism", "OBSERVATION", 311, 323], ["diffuse", "OBSERVATION_MODIFIER", 365, 372], ["Lewy body disease", "OBSERVATION", 373, 390], ["Alzheimer disease", "OBSERVATION", 399, 416], ["amyotrophic", "OBSERVATION_MODIFIER", 423, 434], ["lateral", "OBSERVATION_MODIFIER", 435, 442], ["sclerosis", "OBSERVATION", 443, 452], ["Huntington disease", "OBSERVATION", 528, 546]]], ["We find that the LRRK2 gene is expressed in all cell types and organs studied; that the Lrrk2 protein occurs in the soluble state in normal brain; and that such pathologic entities as Lewy bodies, neurofibrillary tangles, and Pick bodies are recognized by a polyclonal antibody to Lrrk2.Postmortem Human TissuesTissue from brain, heart, and liver from 2 controls (male aged 78 and a female aged 93) were selected from our Kinsmen Laboratory Brain Bank for Western blot analysis.", [["cell", "ANATOMY", 48, 52], ["organs", "ANATOMY", 63, 69], ["brain", "ANATOMY", 140, 145], ["neurofibrillary tangles", "ANATOMY", 197, 220], ["Pick bodies", "ANATOMY", 226, 237], ["Tissue", "ANATOMY", 311, 317], ["brain", "ANATOMY", 323, 328], ["heart", "ANATOMY", 330, 335], ["liver", "ANATOMY", 341, 346], ["neurofibrillary tangles", "DISEASE", 197, 220], ["LRRK2", "GENE_OR_GENE_PRODUCT", 17, 22], ["cell", "CELL", 48, 52], ["organs", "ORGAN", 63, 69], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 88, 93], ["brain", "ORGAN", 140, 145], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 281, 286], ["Human", "ORGANISM", 298, 303], ["TissuesTissue", "TISSUE", 304, 317], ["brain", "ORGAN", 323, 328], ["heart", "ORGAN", 330, 335], ["liver", "ORGAN", 341, 346], ["LRRK2 gene", "DNA", 17, 27], ["Lrrk2 protein", "PROTEIN", 88, 101], ["polyclonal antibody", "PROTEIN", 258, 277], ["Lrrk2", "PROTEIN", 281, 286], ["Human", "SPECIES", 298, 303], ["Human", "SPECIES", 298, 303], ["the Lrrk2 protein", "TEST", 84, 101], ["Lewy bodies", "PROBLEM", 184, 195], ["neurofibrillary tangles", "PROBLEM", 197, 220], ["Pick bodies", "PROBLEM", 226, 237], ["a polyclonal antibody to Lrrk2", "TREATMENT", 256, 286], ["Western blot analysis", "TEST", 456, 477], ["all cell", "OBSERVATION_MODIFIER", 44, 52], ["normal", "OBSERVATION", 133, 139], ["brain", "ANATOMY", 140, 145], ["Lewy bodies", "OBSERVATION", 184, 195], ["neurofibrillary tangles", "OBSERVATION", 197, 220], ["Human TissuesTissue", "OBSERVATION", 298, 317], ["brain", "ANATOMY", 323, 328], ["heart", "ANATOMY", 330, 335], ["liver", "ANATOMY", 341, 346]]], ["For immunohistochemistry, brain tissues from 5 sporadic PD cases, one familial PD case, one DLBD case, 5 AD cases (one with associated PD), one Pick disease case, 2 ALS cases, 6 PDCG cases, 2 Huntington disease, and 4 control cases, including one from Guam, were selected.", [["brain tissues", "ANATOMY", 26, 39], ["PD", "DISEASE", 56, 58], ["familial PD", "DISEASE", 70, 81], ["DLBD", "DISEASE", 92, 96], ["AD", "DISEASE", 105, 107], ["PD", "DISEASE", 135, 137], ["Pick disease", "DISEASE", 144, 156], ["ALS", "DISEASE", 165, 168], ["PDCG", "DISEASE", 178, 182], ["Huntington disease", "DISEASE", 192, 210], ["brain tissues", "TISSUE", 26, 39], ["DLBD", "CANCER", 92, 96], ["PDCG", "CANCER", 178, 182], ["immunohistochemistry", "TEST", 4, 24], ["2 Huntington disease", "PROBLEM", 190, 210], ["brain", "ANATOMY", 26, 31]]], ["In each case, the diagnosis had been confirmed by standard neuropathologic examination.", [["standard neuropathologic examination", "TEST", 50, 86]]], ["The familial PD case was from family B in which a susceptibility locus on chromosome 2p13 had been identified (16) .", [["chromosome 2p13", "ANATOMY", 74, 89], ["PD", "DISEASE", 13, 15], ["chromosome 2p13", "CELLULAR_COMPONENT", 74, 89], ["susceptibility locus", "DNA", 50, 70], ["chromosome 2p13", "DNA", 74, 89], ["a susceptibility locus on chromosome", "PROBLEM", 48, 84]]], ["Details of the cases and a summary of the pathologic findings are given in the Table.", [["the pathologic findings", "TEST", 38, 61]]], ["Cell LinesPostmortem Human TissuesThe human neuroblastoma SH-SY5Y cell line was a gift from Dr. R. Ross, Fordham University, New York, NY, and the LA-N-2 cells were obtained from Dr. R. C. Seeger, Children's Hospital, Los Angeles, California.", [["Cell", "ANATOMY", 0, 4], ["Tissues", "ANATOMY", 27, 34], ["neuroblastoma SH-SY5Y cell line", "ANATOMY", 44, 75], ["LA-N-2 cells", "ANATOMY", 147, 159], ["Cell", "CELL", 0, 4], ["human", "ORGANISM", 38, 43], ["neuroblastoma SH-SY5Y cell line", "CELL", 44, 75], ["LA-N-2 cells", "CELL", 147, 159], ["human neuroblastoma SH-SY5Y cell line", "CELL_LINE", 38, 75], ["Human", "SPECIES", 21, 26], ["human", "SPECIES", 38, 43], ["Children", "SPECIES", 197, 205], ["human", "SPECIES", 38, 43], ["The human neuroblastoma SH", "TEST", 34, 60], ["the LA", "TEST", 143, 149], ["Human Tissues", "OBSERVATION", 21, 34], ["neuroblastoma", "OBSERVATION", 44, 57], ["cell line", "OBSERVATION", 66, 75], ["LA", "ANATOMY", 147, 149]]], ["The human astrocytic U-373 MG, human monocytic U937, and human monocytic THP-1 cell lines were obtained from the American Type Culture Collection (ATCC).", [["astrocytic U-373 MG", "ANATOMY", 10, 29], ["monocytic U937", "ANATOMY", 37, 51], ["monocytic THP-1 cell lines", "ANATOMY", 63, 89], ["U-373", "CHEMICAL", 21, 26], ["human", "ORGANISM", 4, 9], ["astrocytic U-373 MG", "CELL", 10, 29], ["human", "ORGANISM", 31, 36], ["monocytic U937", "CELL", 37, 51], ["human", "ORGANISM", 57, 62], ["monocytic THP-1 cell lines", "CELL", 63, 89], ["human astrocytic U-373 MG", "CELL_LINE", 4, 29], ["human monocytic U937", "CELL_LINE", 31, 51], ["human monocytic THP-1 cell lines", "CELL_LINE", 57, 89], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 4, 9], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 57, 62], ["The human astrocytic U", "TEST", 0, 22], ["human monocytic U937", "TEST", 31, 51], ["human monocytic THP", "TEST", 57, 76], ["cell lines", "TEST", 79, 89]]], ["These cells were grown in Dulbecco modified Eagle mediumYnutrient mixture F12 Ham (DMEM-F12) supplemented with 10% fetal bovine serum (FBS; GIBCO BRL, Life Technologies, Burlington, ON, Canada) containing gentamicin (50 Kg/mL).", [["cells", "ANATOMY", 6, 11], ["fetal bovine serum", "ANATOMY", 115, 133], ["FBS", "ANATOMY", 135, 138], ["DMEM-F12", "CHEMICAL", 83, 91], ["gentamicin", "CHEMICAL", 205, 215], ["gentamicin", "CHEMICAL", 205, 215], ["cells", "CELL", 6, 11], ["F12 Ham", "CELL", 74, 81], ["DMEM-F12", "CELL", 83, 91], ["bovine", "ORGANISM", 121, 127], ["serum", "ORGANISM_SUBSTANCE", 128, 133], ["FBS", "ORGANISM_SUBSTANCE", 135, 138], ["gentamicin", "SIMPLE_CHEMICAL", 205, 215], ["bovine", "SPECIES", 121, 127], ["bovine", "SPECIES", 121, 127], ["These cells", "PROBLEM", 0, 11], ["Dulbecco modified Eagle mediumYnutrient mixture", "TREATMENT", 26, 73], ["10% fetal bovine serum (FBS", "TREATMENT", 111, 138], ["Life Technologies", "TREATMENT", 151, 168], ["gentamicin", "TREATMENT", 205, 215]]], ["Incubation was carried out in a humidified 5% CO 2 /95% air atmosphere at 37-C.", [["CO", "CHEMICAL", 46, 48], ["a humidified", "TREATMENT", 30, 42]]], ["Retinoic acid-differentiated SH-SY5Y cultures were prepared as previously described (20, 21) .", [["SH-SY5Y cultures", "ANATOMY", 29, 45], ["Retinoic acid-differentiated SH-SY5Y cultures", "CELL_LINE", 0, 45], ["Retinoic acid-differentiated SH-SY5Y cultures", "TEST", 0, 45]]], ["THP-1 cells were stimulated for 4 hours and 24 hours by a combination of LPS (0.5 Kg/mL) plus IFN-F (150 U/mL) after being seeded into 10-cm tissue culture plates at a concentration of 5 \u00c2 10 5 cells/ mL in 15 mL of DMEM-F12 medium containing 5% FBS.Postmortem Human TissuesHuman microglial, astrocytic, and oligodendroglial cells were isolated from surgically resected temporal lobe tissues and isolation protocols described by De Groot et al (22) were used with minor modifications (23) .", [["THP-1 cells", "ANATOMY", 0, 11], ["tissue", "ANATOMY", 141, 147], ["cells", "ANATOMY", 194, 199], ["FBS", "ANATOMY", 246, 249], ["TissuesHuman microglial", "ANATOMY", 267, 290], ["astrocytic", "ANATOMY", 292, 302], ["oligodendroglial cells", "ANATOMY", 308, 330], ["temporal lobe tissues", "ANATOMY", 370, 391], ["LPS", "CHEMICAL", 73, 76], ["IFN-F", "CHEMICAL", 94, 99], ["THP-1 cells", "CELL", 0, 11], ["LPS", "SIMPLE_CHEMICAL", 73, 76], ["IFN-F", "GENE_OR_GENE_PRODUCT", 94, 99], ["cells", "CELL", 194, 199], ["FBS", "ORGANISM_SUBSTANCE", 246, 249], ["Human", "ORGANISM", 261, 266], ["TissuesHuman microglial", "CELL", 267, 290], ["astrocytic", "CELL", 292, 302], ["oligodendroglial cells", "CELL", 308, 330], ["temporal lobe tissues", "TISSUE", 370, 391], ["THP-1 cells", "CELL_LINE", 0, 11], ["IFN", "PROTEIN", 94, 97], ["Human TissuesHuman microglial, astrocytic, and oligodendroglial cells", "CELL_TYPE", 261, 330], ["Human", "SPECIES", 261, 266], ["LPS", "TREATMENT", 73, 76], ["IFN", "TREATMENT", 94, 97], ["tissue culture plates", "TEST", 141, 162], ["DMEM", "TREATMENT", 216, 220], ["oligodendroglial cells", "TREATMENT", 308, 330], ["isolation protocols", "TREATMENT", 396, 415], ["De Groot et al (22)", "TREATMENT", 429, 448], ["10-cm tissue", "OBSERVATION_MODIFIER", 135, 147], ["TissuesHuman microglial", "ANATOMY", 267, 290], ["oligodendroglial cells", "OBSERVATION", 308, 330], ["temporal lobe", "ANATOMY", 370, 383]]], ["Before their mRNA was extracted, microglial and astrocytic cells were grown for 7 days, whereas oligodendroglial cells were grown for 1 to 7 days as previously described (23) .RNA Isolation and cDNA Synthesis by Reverse TranscriptionTotal RNA was isolated from cultured cells by using the Trizol reagent (GIBCO BRL; Life Technologies) according to the manufacturer's instructions.", [["microglial", "ANATOMY", 33, 43], ["astrocytic cells", "ANATOMY", 48, 64], ["oligodendroglial cells", "ANATOMY", 96, 118], ["cells", "ANATOMY", 270, 275], ["microglial", "CELL", 33, 43], ["astrocytic cells", "CELL", 48, 64], ["oligodendroglial cells", "CELL", 96, 118], ["cells", "CELL", 270, 275], ["mRNA", "RNA", 13, 17], ["microglial and astrocytic cells", "CELL_TYPE", 33, 64], ["oligodendroglial cells", "CELL_TYPE", 96, 118], ["Reverse TranscriptionTotal RNA", "RNA", 212, 242], ["cultured cells", "CELL_LINE", 261, 275], ["microglial and astrocytic cells", "PROBLEM", 33, 64], ["oligodendroglial cells", "PROBLEM", 96, 118], ["cDNA Synthesis", "TREATMENT", 194, 208], ["Reverse TranscriptionTotal RNA", "TREATMENT", 212, 242], ["the Trizol reagent", "TREATMENT", 285, 303], ["Life Technologies", "TREATMENT", 316, 333], ["astrocytic cells", "OBSERVATION", 48, 64], ["oligodendroglial cells", "OBSERVATION", 96, 118]]], ["Two micrograms of the resultant RNA extract was then used to prepare cDNA.", [["cDNA", "DNA", 69, 73], ["the resultant RNA extract", "TREATMENT", 18, 43]]], ["RNA was treated with 10 U of DNase I (Invitrogen Life Technologies, Burlington, ON, Canada) for 60 minutes at 37-C in 25Polymerase Chain ReactionOne microliter of the transcription reaction was amplified for LRRK2.", [["DNase I", "GENE_OR_GENE_PRODUCT", 29, 36], ["LRRK2", "GENE_OR_GENE_PRODUCT", 208, 213], ["RNA", "RNA", 0, 3], ["DNase I", "PROTEIN", 29, 36], ["LRRK2", "PROTEIN", 208, 213], ["DNase I (Invitrogen Life Technologies", "TREATMENT", 29, 66], ["Burlington", "TREATMENT", 68, 78], ["the transcription reaction", "PROBLEM", 163, 189], ["LRRK2", "PROBLEM", 208, 213]]], ["The polymerase chain reaction (PCR) was carried out in a 25-KL mixture containing 1 \u00c2 GeneAmp PCR buffer II, 1.25 U of AmpliTaq Gold DNA polymerase, 2 mM MgCl 2 (all from Applied Biosystems, Streetsville, ON, Canada), 200 KM dNTPs (Invitrogen Life Technologies), and 0.5 KM of each primer.", [["dNTPs", "CHEMICAL", 225, 230], ["MgCl 2", "CHEMICAL", 154, 160], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["The polymerase chain reaction", "PROBLEM", 0, 29], ["PCR", "TEST", 31, 34], ["AmpliTaq Gold DNA polymerase", "TEST", 119, 147], ["KM dNTPs", "TREATMENT", 222, 230]]], ["The amplification program consisted of an initial denaturation step at 94-C, which was extended to 9 minutes to activate AmpliTaq Gold enzyme.", [["AmpliTaq Gold enzyme", "GENE_OR_GENE_PRODUCT", 121, 141], ["AmpliTaq Gold enzyme", "PROTEIN", 121, 141], ["an initial denaturation step", "TREATMENT", 39, 67]]], ["This was followed by an annealing step at 55-C for 1 minute and an initial synthesis step at 72-C for 3 minutes.", [["an annealing step", "TREATMENT", 21, 38], ["an initial synthesis step", "TEST", 64, 89]]], ["Two sets of primers were used.", [["primers", "TREATMENT", 12, 19]]], ["The primer sequences (5 \u00b6 to 3 \u00b6) were as follows: LRRK315F, 5 \u00b6-AGCTTATTGTCTGGTAGGATCTG; LRRK315R, 5 \u00b6-ATGGTGAGCCTTGGTTGATC; LRRK260F, TGAATGC CACCGAGGAATCTG; LRRK260R, GTGAACTGCGT GAGGAAGCT.", [["primer sequences", "DNA", 4, 20], ["The primer sequences", "TEST", 0, 20]]], ["After amplification, PCR products were separated on a 6% polyacrylamide gel and visualized by incubation for 10 minutes in a solution containing 10 ng/mL of ethidium bromide.", [["ethidium bromide", "CHEMICAL", 157, 173], ["polyacrylamide", "CHEMICAL", 57, 71], ["ethidium bromide", "CHEMICAL", 157, 173], ["ethidium bromide", "SIMPLE_CHEMICAL", 157, 173], ["PCR products", "DNA", 21, 33], ["PCR products", "TREATMENT", 21, 33], ["a 6% polyacrylamide gel", "TREATMENT", 52, 75], ["a solution", "TREATMENT", 123, 133], ["ethidium bromide", "TREATMENT", 157, 173]]], ["Polaroid photographs of the gels were taken.", [["Polaroid photographs of the gels", "TEST", 0, 32]]], ["The predicted sizes of the PCR product were 315 and 260 bp, respectively.", [["the PCR product", "TEST", 23, 38], ["bp", "TEST", 56, 58], ["sizes", "OBSERVATION_MODIFIER", 14, 19]]], ["Restriction digest analysis of the 315 bp product by Dde I and that of the 260 bp product by Mbo I (GIBCO BRL; Life Technologies, Burlington, ON, Canada) resulted in 2 fragments corresponding to the predicted sizes of 255 and 32 bp and those of 180 and 73 bp, respectively (data not shown).Western BlottingFrozen brain tissue was homogenized in 5 volumes of ice-cold TS buffer (50 mM Tris-HCl, pH 7.6, 150 mM NaCl).", [["brain tissue", "ANATOMY", 313, 325], ["Tris-HCl", "CHEMICAL", 384, 392], ["NaCl", "CHEMICAL", 409, 413], ["Tris-HCl", "CHEMICAL", 384, 392], ["NaCl", "CHEMICAL", 409, 413], ["Dde I", "GENE_OR_GENE_PRODUCT", 53, 58], ["BlottingFrozen brain tissue", "TISSUE", 298, 325], ["Tris-HCl", "SIMPLE_CHEMICAL", 384, 392], ["315 bp product", "PROTEIN", 35, 49], ["Dde I", "PROTEIN", 53, 58], ["Mbo I", "PROTEIN", 93, 98], ["Life Technologies", "TREATMENT", 111, 128], ["2 fragments", "PROBLEM", 166, 177], ["bp", "TEST", 229, 231], ["bp", "TEST", 256, 258], ["cold TS buffer", "TREATMENT", 362, 376], ["Tris", "TEST", 384, 388], ["pH", "TEST", 394, 396], ["sizes", "OBSERVATION_MODIFIER", 209, 214], ["brain tissue", "ANATOMY", 313, 325]]], ["The homogenates were centrifuged at 100,000 \u00c2 g for 1 hour at 4-C.", [["homogenates", "ANATOMY", 4, 15], ["The homogenates", "TREATMENT", 0, 15]]], ["The supernatant was taken and separated by 7.5% sodium dodecyl sulfateYpolyacrylamide gel electrophoresis (SDS-PAGE).", [["supernatant", "ANATOMY", 4, 15], ["sodium dodecyl sulfate", "CHEMICAL", 48, 70], ["Ypolyacrylamide gel", "CHEMICAL", 70, 89], ["sodium dodecyl sulfate", "CHEMICAL", 48, 70], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 48, 70], ["Ypolyacrylamide", "SIMPLE_CHEMICAL", 70, 85], ["The supernatant", "TREATMENT", 0, 15], ["7.5% sodium dodecyl sulfate", "TREATMENT", 43, 70], ["Ypolyacrylamide gel electrophoresis", "TREATMENT", 70, 105]]], ["Proteins in the gel were electrotransferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore Co., Bedford, MA).", [["polyvinylidene fluoride", "CHEMICAL", 51, 74], ["polyvinylidene fluoride", "CHEMICAL", 51, 74], ["PVDF", "CHEMICAL", 76, 80], ["polyvinylidene fluoride", "SIMPLE_CHEMICAL", 51, 74], ["Proteins in the gel", "PROBLEM", 0, 19], ["a polyvinylidene fluoride (PVDF) membrane", "TREATMENT", 49, 90]]], ["After blocking with 5% skim milk and 0.1% Tween 20 in TS buffer, the membrane was incubated with the rabbit polyclonal antibody to Lrrk2 (NB 300-268; Novus Biologicals, Littleton, CO).", [["milk", "ANATOMY", 28, 32], ["membrane", "ANATOMY", 69, 77], ["Tween 20", "CHEMICAL", 42, 50], ["NB 300-268", "CHEMICAL", 138, 148], ["Tween 20", "CHEMICAL", 42, 50], ["milk", "ORGANISM_SUBSTANCE", 28, 32], ["Tween 20", "SIMPLE_CHEMICAL", 42, 50], ["TS", "SIMPLE_CHEMICAL", 54, 56], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["rabbit", "ORGANISM", 101, 107], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 131, 136], ["rabbit polyclonal antibody", "PROTEIN", 101, 127], ["Lrrk2", "PROTEIN", 131, 136], ["CO", "PROTEIN", 180, 182], ["rabbit", "SPECIES", 101, 107], ["rabbit", "SPECIES", 101, 107], ["5% skim milk", "TREATMENT", 20, 32], ["the rabbit polyclonal antibody", "TREATMENT", 97, 127], ["NB", "TEST", 138, 140]]], ["After incubation with horseradish peroxidase (HRP)-conjugated anti-rabbit IgG, immunoreactivity was visualized by the chemiluminescence method using the ECL Western blotting system (Amersham Pharmacia Biotech, Uppsala, Sweden).Preparation of 12-mer Lrrk2 Peptide MembranesFull-length human Lrrk2 contains 2527 amino acids.", [["amino acids", "CHEMICAL", 310, 321], ["amino acids", "CHEMICAL", 310, 321], ["horseradish peroxidase", "SIMPLE_CHEMICAL", 22, 44], ["HRP", "SIMPLE_CHEMICAL", 46, 49], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 249, 254], ["human", "ORGANISM", 284, 289], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 290, 295], ["amino acids", "AMINO_ACID", 310, 321], ["horseradish peroxidase", "PROTEIN", 22, 44], ["HRP", "PROTEIN", 46, 49], ["anti-rabbit IgG", "PROTEIN", 62, 77], ["12-mer Lrrk2 Peptide MembranesFull-length human Lrrk2", "PROTEIN", 242, 295], ["horseradish", "SPECIES", 22, 33], ["anti-rabbit", "SPECIES", 62, 73], ["human", "SPECIES", 284, 289], ["anti-rabbit", "SPECIES", 62, 73], ["human", "SPECIES", 284, 289], ["horseradish peroxidase", "TEST", 22, 44], ["conjugated anti-rabbit IgG", "TREATMENT", 51, 77], ["immunoreactivity", "PROBLEM", 79, 95], ["the chemiluminescence method", "TEST", 114, 142], ["Preparation of 12-mer Lrrk2 Peptide MembranesFull-length human Lrrk2", "TREATMENT", 227, 295], ["amino acids", "TREATMENT", 310, 321]]], ["Twelve-mer overlapping peptides were synthesized as arrays on cellulose membranes as previously described (25) .", [["cellulose membranes", "ANATOMY", 62, 81], ["arrays on cellulose membranes", "TREATMENT", 52, 81]]], ["A total of 1259 Lrrk2 peptides were programmed for robotic synthesis by shifting each peptide by 2 amino acids from its N-terminal to its C-terminal.", [["amino acids", "CHEMICAL", 99, 110], ["amino acids", "CHEMICAL", 99, 110], ["N", "CHEMICAL", 120, 121], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 16, 21], ["amino acids", "AMINO_ACID", 99, 110], ["N-terminal", "PROTEIN", 120, 130], ["A total of 1259 Lrrk2 peptides", "TREATMENT", 0, 30], ["robotic synthesis", "TREATMENT", 51, 68], ["shifting each peptide", "TREATMENT", 72, 93], ["2 amino acids", "TREATMENT", 97, 110]]], ["The spots were arranged in rows of 12 with 34 rows per membrane.", [["membrane", "ANATOMY", 55, 63], ["membrane", "CELLULAR_COMPONENT", 55, 63]]], ["A total of 3 full membranes (panels A, B, and C) and 3 rows of a fourth membrane (panel D) were required to cover the full sequence.", [["membranes", "ANATOMY", 18, 27], ["membrane", "ANATOMY", 72, 80], ["membranes", "CELLULAR_COMPONENT", 18, 27], ["membrane", "CELLULAR_COMPONENT", 72, 80], ["B", "PROTEIN", 39, 40], ["the full sequence", "TEST", 114, 131]]], ["After preparation, the membranes were dried and stored in the cold.", [["membranes", "ANATOMY", 23, 32], ["membranes", "CELLULAR_COMPONENT", 23, 32]]], ["Used membranes were regenerated by washing twice with dimethyl formamide for 15 minutes followed by soaking at 37-C overnight in a buffer containing 8 M urea, 1% SDS, and 0.1% 2mercaptoethanol.", [["membranes", "ANATOMY", 5, 14], ["dimethyl formamide", "CHEMICAL", 54, 72], ["urea", "CHEMICAL", 153, 157], ["2mercaptoethanol", "CHEMICAL", 176, 192], ["dimethyl formamide", "CHEMICAL", 54, 72], ["urea", "CHEMICAL", 153, 157], ["SDS", "CHEMICAL", 162, 165], ["2mercaptoethanol", "CHEMICAL", 176, 192], ["membranes", "CELLULAR_COMPONENT", 5, 14], ["dimethyl formamide", "SIMPLE_CHEMICAL", 54, 72], ["urea", "SIMPLE_CHEMICAL", 153, 157], ["2mercaptoethanol", "SIMPLE_CHEMICAL", 176, 192], ["membranes", "TREATMENT", 5, 14], ["dimethyl formamide", "TREATMENT", 54, 72], ["a buffer containing 8 M urea", "TREATMENT", 129, 157]]], ["After washing twice with a solution of 40% methanol, 10% glacial acetic acid in H 2 O, v/v for 20 minutes, and then 3 times with methanol for 2 minutes, the membranes were dried in air and stored in the cold for future use.Epitope Probing of Rabbit Anti-Human Lrrk2Polyclonal Antibody NB 300-268Epitope Probing of Rabbit Anti-Human Lrrk2Two sets of Lrrk2 12-mer peptide array membranes were presoaked in methanol for 1 minute and washed with TBST0.2 (10M Tris-HCl, pH 7.4, 150M NaCl, 0.2% Tween-20).", [["membranes", "ANATOMY", 157, 166], ["membranes", "ANATOMY", 376, 385], ["methanol", "CHEMICAL", 43, 51], ["glacial acetic acid", "CHEMICAL", 57, 76], ["methanol", "CHEMICAL", 129, 137], ["10M Tris-HCl", "CHEMICAL", 451, 463], ["NaCl", "CHEMICAL", 478, 482], ["methanol", "CHEMICAL", 43, 51], ["acetic acid", "CHEMICAL", 65, 76], ["H 2 O", "CHEMICAL", 80, 85], ["methanol", "CHEMICAL", 129, 137], ["methanol", "CHEMICAL", 404, 412], ["TBST0.2", "CHEMICAL", 442, 449], ["Tris-HCl", "CHEMICAL", 455, 463], ["NaCl", "CHEMICAL", 478, 482], ["Tween-20", "CHEMICAL", 489, 497], ["methanol", "SIMPLE_CHEMICAL", 43, 51], ["acetic acid", "SIMPLE_CHEMICAL", 65, 76], ["H 2 O", "SIMPLE_CHEMICAL", 80, 85], ["methanol", "SIMPLE_CHEMICAL", 129, 137], ["membranes", "CELLULAR_COMPONENT", 157, 166], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 349, 354], ["methanol", "SIMPLE_CHEMICAL", 404, 412], ["TBST0.2", "SIMPLE_CHEMICAL", 442, 449], ["Tris-HCl", "SIMPLE_CHEMICAL", 455, 463], ["Rabbit Anti-Human Lrrk2Two sets", "DNA", 314, 345], ["Rabbit", "SPECIES", 242, 248], ["Rabbit", "SPECIES", 314, 320], ["Rabbit", "SPECIES", 242, 248], ["Rabbit", "SPECIES", 314, 320], ["a solution of 40% methanol", "TREATMENT", 25, 51], ["10% glacial acetic acid", "TREATMENT", 53, 76], ["methanol", "TREATMENT", 129, 137], ["Epitope Probing", "TEST", 223, 238], ["Rabbit Anti-Human Lrrk2Polyclonal Antibody", "TEST", 242, 284], ["NB", "TEST", 285, 287], ["Rabbit Anti-Human Lrrk2Two sets of Lrrk2", "TREATMENT", 314, 354], ["mer peptide array membranes", "TREATMENT", 358, 385], ["TBST0.2", "TEST", 442, 449], ["Tris", "TEST", 455, 459], ["pH", "TEST", 465, 467], ["NaCl", "TEST", 478, 482]]], ["One set was probed with buffer (1% bovine serum albumin [BSA] in TBST0.05) and the other with antibody NB300-268 (1:1,000 dilution with 3% BSA in TBST0.05).", [["serum", "ANATOMY", 42, 47], ["NB300-268", "CHEMICAL", 103, 112], ["bovine", "ORGANISM", 35, 41], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["albumin", "GENE_OR_GENE_PRODUCT", 48, 55], ["BSA", "SIMPLE_CHEMICAL", 57, 60], ["TBST0.05", "SIMPLE_CHEMICAL", 65, 73], ["NB300-268", "SIMPLE_CHEMICAL", 103, 112], ["BSA", "SIMPLE_CHEMICAL", 139, 142], ["bovine", "SPECIES", 35, 41], ["buffer (1% bovine serum albumin", "TREATMENT", 24, 55], ["BSA", "TEST", 57, 60], ["antibody NB300", "TEST", 94, 108]]], ["After 2 hours of incubation at 37-C, the membranes were washed 5 times with TBST0.2, blocked with 5% BSA for 1 hour, then incubated with goat anti-rabbit IgG-HRP conjugate (1: 6,000 in 1% BSA-TBST0.05) for 1 hour at 37-C.", [["membranes", "ANATOMY", 41, 50], ["TBST0.2", "CHEMICAL", 76, 83], ["BSA", "CHEMICAL", 101, 104], ["membranes", "CELLULAR_COMPONENT", 41, 50], ["TBST0.2", "SIMPLE_CHEMICAL", 76, 83], ["BSA", "SIMPLE_CHEMICAL", 101, 104], ["goat", "ORGANISM", 137, 141], ["HRP conjugate", "SIMPLE_CHEMICAL", 158, 171], ["BSA-TBST0.05", "SIMPLE_CHEMICAL", 188, 200], ["goat anti-rabbit IgG", "PROTEIN", 137, 157], ["HRP conjugate", "PROTEIN", 158, 171], ["goat", "SPECIES", 137, 141], ["anti-rabbit", "SPECIES", 142, 153], ["goat", "SPECIES", 137, 141], ["incubation", "TREATMENT", 17, 27], ["5% BSA", "TREATMENT", 98, 104], ["goat anti-rabbit IgG", "TEST", 137, 157]]], ["Finally, the membranes were washed with TBST0.2, developed with ECL Western blotting detection reagents, and scanned under an imager (Bio-Rad Fluorescent Imager, Hercules, CA).Interaction of >-Synuclein on Lrrk2 Peptide Array MembranesTwo sets of Lrrk2 peptide array membranes were pretreated as described previously.", [["membranes", "ANATOMY", 13, 22], ["membranes", "ANATOMY", 267, 276], ["membranes", "CELLULAR_COMPONENT", 13, 22], ["TBST0.2", "SIMPLE_CHEMICAL", 40, 47], [">-Synuclein", "GENE_OR_GENE_PRODUCT", 191, 202], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 206, 211], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 247, 252], [">-Synuclein", "PROTEIN", 191, 202], ["an imager", "TEST", 123, 132], ["Lrrk2 Peptide Array Membranes", "TREATMENT", 206, 235], ["Lrrk2 peptide array membranes", "TREATMENT", 247, 276], ["Lrrk2 peptide", "OBSERVATION", 247, 260], ["array membranes", "OBSERVATION", 261, 276]]], ["One set was incubated with recombinant >-synuclein (gift of Dr. Benoit Giasson), 10 Kg/mL in 10 mmol phosphate-buffered saline (PBS), pH 7.4 plus proteinase inhibitor cocktail at 37-C overnight; the other with buffer as a control.", [["phosphate", "CHEMICAL", 101, 110], ["phosphate", "CHEMICAL", 101, 110], [">-synuclein", "SIMPLE_CHEMICAL", 39, 50], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 101, 126], ["buffered saline (PBS", "TREATMENT", 111, 131], ["pH", "TEST", 134, 136], ["proteinase inhibitor cocktail", "TREATMENT", 146, 175], ["buffer", "TREATMENT", 210, 216]]], ["After blocking with 5% BSA at 37-C for 2 hours, the membranes were incubated with the anti->-synuclein monoclonal antibody LB509 (Synuclein Clone LB509; Zymed Lab, San Francisco, CA; 1:100, in 3% BSA-TBST0.05) at 37-C for 2 hours.", [["membranes", "ANATOMY", 52, 61], ["BSA", "CHEMICAL", 23, 26], ["BSA", "SIMPLE_CHEMICAL", 23, 26], ["37-C", "SIMPLE_CHEMICAL", 30, 34], ["membranes", "CELLULAR_COMPONENT", 52, 61], ["BSA-TBST0.05", "SIMPLE_CHEMICAL", 196, 208], ["anti->-synuclein monoclonal antibody LB509", "PROTEIN", 86, 128], ["5% BSA", "TREATMENT", 20, 26], ["the anti->-synuclein monoclonal antibody", "TEST", 82, 122], ["CA", "TEST", 179, 181], ["BSA", "TEST", 196, 199]]], ["Then, after washing 5 times with TBST0.2, the membranes were incubated with rabbit anti-mouse IgG-HRP conjugate (Sigma-Aldrich, Oakville, ON, Canada; 1: 4,000, in 3% BSA-TBST0.05) at 37-C for 1 hour.", [["membranes", "ANATOMY", 46, 55], ["TBST0.2", "SIMPLE_CHEMICAL", 33, 40], ["membranes", "CELLULAR_COMPONENT", 46, 55], ["rabbit", "ORGANISM", 76, 82], ["HRP conjugate", "SIMPLE_CHEMICAL", 98, 111], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 113, 126], ["BSA-TBST0.05", "SIMPLE_CHEMICAL", 166, 178], ["rabbit anti-mouse IgG", "PROTEIN", 76, 97], ["HRP conjugate", "PROTEIN", 98, 111], ["rabbit", "SPECIES", 76, 82], ["rabbit", "SPECIES", 76, 82], ["rabbit anti-mouse IgG", "TEST", 76, 97]]], ["Finally, the membranes were washed with TBST0.2, developed with ECL Western blotting detection reagents (Amersham Biosciences, Baie d'Urf\u00e9, PQ, Canada), and scanned under the imager as described previously.ImmunohistochemistryApproximately 7-mm-thick transverse tissue blocks from representative levels of the cerebral hemispheres, including hippocampus, frontal, temporal, parietal, primary motor and occipital cortices, the amygdala, basal ganglia and thalamus, mesencephalon, pons, medulla oblongata, and cerebellum were analyzed.", [["membranes", "ANATOMY", 13, 22], ["tissue", "ANATOMY", 262, 268], ["cerebral hemispheres", "ANATOMY", 310, 330], ["hippocampus", "ANATOMY", 342, 353], ["frontal", "ANATOMY", 355, 362], ["temporal", "ANATOMY", 364, 372], ["parietal", "ANATOMY", 374, 382], ["primary motor", "ANATOMY", 384, 397], ["occipital cortices", "ANATOMY", 402, 420], ["amygdala", "ANATOMY", 426, 434], ["basal ganglia", "ANATOMY", 436, 449], ["thalamus", "ANATOMY", 454, 462], ["mesencephalon", "ANATOMY", 464, 477], ["pons", "ANATOMY", 479, 483], ["medulla oblongata", "ANATOMY", 485, 502], ["cerebellum", "ANATOMY", 508, 518], ["membranes", "CELLULAR_COMPONENT", 13, 22], ["TBST0.2", "SIMPLE_CHEMICAL", 40, 47], ["tissue", "TISSUE", 262, 268], ["cerebral hemispheres", "MULTI-TISSUE_STRUCTURE", 310, 330], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 342, 353], ["frontal", "MULTI-TISSUE_STRUCTURE", 355, 362], ["temporal", "MULTI-TISSUE_STRUCTURE", 364, 372], ["parietal", "MULTI-TISSUE_STRUCTURE", 374, 382], ["occipital cortices", "MULTI-TISSUE_STRUCTURE", 402, 420], ["amygdala", "MULTI-TISSUE_STRUCTURE", 426, 434], ["basal ganglia", "MULTI-TISSUE_STRUCTURE", 436, 449], ["thalamus", "MULTI-TISSUE_STRUCTURE", 454, 462], ["mesencephalon", "MULTI-TISSUE_STRUCTURE", 464, 477], ["pons", "MULTI-TISSUE_STRUCTURE", 479, 483], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 485, 502], ["cerebellum", "ORGAN", 508, 518], ["ImmunohistochemistryApproximately", "TEST", 206, 239], ["thick transverse tissue blocks", "PROBLEM", 245, 275], ["hippocampus, frontal, temporal, parietal, primary motor and occipital cortices, the amygdala, basal ganglia and thalamus, mesencephalon, pons, medulla oblongata, and cerebellum", "PROBLEM", 342, 518], ["7-mm", "OBSERVATION_MODIFIER", 240, 244], ["transverse tissue", "OBSERVATION_MODIFIER", 251, 268], ["representative levels", "OBSERVATION", 281, 302], ["cerebral hemispheres", "ANATOMY", 310, 330], ["hippocampus", "ANATOMY", 342, 353], ["frontal", "ANATOMY_MODIFIER", 355, 362], ["temporal", "ANATOMY_MODIFIER", 364, 372], ["parietal", "ANATOMY_MODIFIER", 374, 382], ["primary", "ANATOMY_MODIFIER", 384, 391], ["motor", "ANATOMY_MODIFIER", 392, 397], ["occipital cortices", "ANATOMY", 402, 420], ["amygdala", "ANATOMY_MODIFIER", 426, 434], ["basal ganglia", "ANATOMY", 436, 449], ["thalamus", "ANATOMY_MODIFIER", 454, 462], ["mesencephalon", "ANATOMY_MODIFIER", 464, 477], ["pons", "ANATOMY", 479, 483], ["medulla oblongata", "ANATOMY", 485, 502], ["cerebellum", "ANATOMY", 508, 518]]], ["In the ALS cases, spinal cords at the cervical and thoracic levels were analyzed.", [["spinal cords", "ANATOMY", 18, 30], ["cervical", "ANATOMY", 38, 46], ["thoracic", "ANATOMY", 51, 59], ["ALS", "DISEASE", 7, 10], ["spinal cords", "MULTI-TISSUE_STRUCTURE", 18, 30], ["cervical", "ORGAN", 38, 46], ["thoracic", "ORGAN", 51, 59], ["spinal cords", "ANATOMY", 18, 30], ["cervical", "ANATOMY", 38, 46], ["thoracic levels", "ANATOMY", 51, 66]]], ["These samples were fixed in 4% paraformaldehyde in 0.1 M phosphate buffer pH 7.4 for 2 days and were maintained in 15% sucrose in 0.01 M PBS, pH 7.4, until processed.ImmunohistochemistrySections 30-Km thick were cut on a freezing microtome from all specimens and were investigated immunohistochemically as free-floating sections.", [["samples", "ANATOMY", 6, 13], ["specimens", "ANATOMY", 249, 258], ["sections", "ANATOMY", 320, 328], ["phosphate", "CHEMICAL", 57, 66], ["sucrose", "CHEMICAL", 119, 126], ["paraformaldehyde", "CHEMICAL", 31, 47], ["phosphate", "CHEMICAL", 57, 66], ["sucrose", "CHEMICAL", 119, 126], ["paraformaldehyde", "SIMPLE_CHEMICAL", 31, 47], ["sucrose", "SIMPLE_CHEMICAL", 119, 126], ["These samples", "TEST", 0, 13], ["4% paraformaldehyde", "TREATMENT", 28, 47], ["phosphate buffer pH", "TEST", 57, 76], ["pH", "TEST", 142, 144], ["ImmunohistochemistrySections", "TEST", 166, 194], ["a freezing microtome", "TREATMENT", 219, 239], ["all specimens", "TEST", 245, 258]]], ["A rabbit polyclonal anti-Lrrk2 antibody (NB 300-268) was used to detect Lrrk2.", [["NB 300-268", "CHEMICAL", 41, 51], ["rabbit", "ORGANISM", 2, 8], ["anti-Lrrk2", "GENE_OR_GENE_PRODUCT", 20, 30], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 72, 77], ["rabbit polyclonal anti-Lrrk2 antibody", "PROTEIN", 2, 39], ["Lrrk2", "PROTEIN", 72, 77], ["rabbit", "SPECIES", 2, 8], ["rabbit", "SPECIES", 2, 8], ["A rabbit polyclonal anti-Lrrk2 antibody", "TEST", 0, 39], ["NB", "TEST", 41, 43], ["Lrrk2", "PROBLEM", 72, 77]]], ["Two monoclonal antibodies to >-synuclein (Synuclein Clone LB509, 1:1,000 and Synuclein VP-A106; Vector Labs, Burlingame, CA; 1:1,000) and a polyclonal antibody to ubiquitin (Z0458; DakoCytomation, Carpinteria, CA; 1:1,000) were used to detect Lewy bodies.", [[">-synuclein", "GENE_OR_GENE_PRODUCT", 29, 40], ["Synuclein Clone LB509", "GENE_OR_GENE_PRODUCT", 42, 63], ["Synuclein VP-A106", "GENE_OR_GENE_PRODUCT", 77, 94], ["Vector Labs", "GENE_OR_GENE_PRODUCT", 96, 107], ["Burlingame", "GENE_OR_GENE_PRODUCT", 109, 119], ["CA", "GENE_OR_GENE_PRODUCT", 121, 123], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 163, 172], ["monoclonal antibodies", "PROTEIN", 4, 25], [">-synuclein", "PROTEIN", 29, 40], ["Synuclein Clone LB509, 1:1,000 and Synuclein VP", "PROTEIN", 42, 89], ["A106", "PROTEIN", 90, 94], ["Vector Labs", "PROTEIN", 96, 107], ["Burlingame", "PROTEIN", 109, 119], ["CA", "PROTEIN", 121, 123], ["1:1,000", "PROTEIN", 125, 132], ["polyclonal antibody", "PROTEIN", 140, 159], ["ubiquitin", "PROTEIN", 163, 172], ["Z0458", "PROTEIN", 174, 179], ["CA", "PROTEIN", 210, 212], ["Two monoclonal antibodies", "TEST", 0, 25], [">-synuclein", "TEST", 29, 40], ["Synuclein Clone LB509", "TEST", 42, 63], ["Synuclein VP", "TEST", 77, 89], ["Vector Labs", "TEST", 96, 107], ["Burlingame", "TEST", 109, 119], ["CA", "TEST", 121, 123], ["a polyclonal antibody", "TEST", 138, 159], ["ubiquitin", "TEST", 163, 172], ["Z0458", "TEST", 174, 179], ["DakoCytomation", "TEST", 181, 195], ["Carpinteria", "TEST", 197, 208], ["CA", "TEST", 210, 212], ["Lewy bodies", "PROBLEM", 243, 254], ["Lewy bodies", "OBSERVATION", 243, 254]]], ["To immunostain sections with AD-type changes and tau pathologies, a monoclonal anti-beta amyloid (AA) antibody (6F/3D, M 0872; DakoCytomation; 1:1,000) was used.", [["sections", "ANATOMY", 15, 23], ["tau", "GENE_OR_GENE_PRODUCT", 49, 52], ["anti-beta amyloid", "GENE_OR_GENE_PRODUCT", 79, 96], ["AA", "SIMPLE_CHEMICAL", 98, 100], ["monoclonal anti-beta amyloid (AA) antibody", "PROTEIN", 68, 110], ["6F", "PROTEIN", 112, 114], ["immunostain sections", "TEST", 3, 23], ["tau pathologies", "PROBLEM", 49, 64], ["a monoclonal anti-beta amyloid (AA) antibody", "TEST", 66, 110], ["DakoCytomation", "TEST", 127, 141]]], ["The anti-tau antibodies used were: anti-tau A0024 (C-243-441; DakoCytomation; rabbit IgG, 1:1,000), which recognizes phosphorylated and nonphosphorylated tau; monoclonal anti-PHF antibody (AT8; Innogenetics, Ghent, Belgium; 1:500); and Tau-C3 (gift of Dr. L. I. Binder), which recognizes the D421 truncated site of tau (26) .ImmunohistochemistryFor immunostaining, the avidinYbiotinYperoxidase technique was used.", [["anti-tau antibodies", "GENE_OR_GENE_PRODUCT", 4, 23], ["anti-tau A0024", "SIMPLE_CHEMICAL", 35, 49], ["DakoCytomation", "GENE_OR_GENE_PRODUCT", 62, 76], ["rabbit", "ORGANISM", 78, 84], ["IgG", "GENE_OR_GENE_PRODUCT", 85, 88], ["1:1,000", "GENE_OR_GENE_PRODUCT", 90, 97], ["tau", "GENE_OR_GENE_PRODUCT", 154, 157], ["Tau-C3", "GENE_OR_GENE_PRODUCT", 236, 242], ["tau (26)", "GENE_OR_GENE_PRODUCT", 315, 323], ["anti-tau antibodies", "PROTEIN", 4, 23], ["anti-tau A0024", "PROTEIN", 35, 49], ["C-243-441", "PROTEIN", 51, 60], ["rabbit IgG", "PROTEIN", 78, 88], ["1:1,000", "PROTEIN", 90, 97], ["nonphosphorylated tau", "PROTEIN", 136, 157], ["monoclonal anti-PHF antibody", "PROTEIN", 159, 187], ["AT8", "PROTEIN", 189, 192], ["Tau", "PROTEIN", 236, 239], ["C3", "PROTEIN", 240, 242], ["D421 truncated site", "PROTEIN", 292, 311], ["tau", "PROTEIN", 315, 318], ["avidinYbiotinYperoxidase", "PROTEIN", 369, 393], ["rabbit", "SPECIES", 78, 84], ["rabbit", "SPECIES", 78, 84], ["The anti-tau antibodies", "TEST", 0, 23], ["DakoCytomation", "TEST", 62, 76], ["rabbit IgG", "TEST", 78, 88], ["nonphosphorylated tau", "TEST", 136, 157], ["monoclonal anti-PHF antibody", "TEST", 159, 187], ["Innogenetics", "TEST", 194, 206], ["Immunohistochemistry", "TEST", 325, 345], ["immunostaining", "TEST", 349, 363], ["the avidinYbiotinYperoxidase technique", "TREATMENT", 365, 403]]], ["To remove endogenous peroxidase activity, the sections were first incubated in 0.3% hydrogen peroxide for 30 minutes.", [["sections", "ANATOMY", 46, 54], ["hydrogen peroxide", "CHEMICAL", 84, 101], ["hydrogen peroxide", "CHEMICAL", 84, 101], ["peroxidase", "GENE_OR_GENE_PRODUCT", 21, 31], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 84, 101], ["endogenous peroxidase", "PROTEIN", 10, 31], ["endogenous peroxidase activity", "TREATMENT", 10, 40], ["0.3% hydrogen peroxide", "TREATMENT", 79, 101], ["peroxidase activity", "OBSERVATION", 21, 40]]], ["The sections were next preincubated with 5% skim milk for 1 hour.", [["sections", "ANATOMY", 4, 12], ["milk", "ANATOMY", 49, 53], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["5% skim milk", "TREATMENT", 41, 53]]], ["They were then incubated with the Lrrk2 primary antibody diluted 1:1,000 in PBST containing 1% normal swine serum overnight at room temperature, for 48 to 72 hours at 4-C, or at room temperature overnight.", [["serum", "ANATOMY", 108, 113], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 34, 39], ["swine", "ORGANISM", 102, 107], ["serum", "ORGANISM_SUBSTANCE", 108, 113], ["4-C", "SIMPLE_CHEMICAL", 167, 170], ["Lrrk2 primary antibody", "PROTEIN", 34, 56], ["swine", "SPECIES", 102, 107], ["swine", "SPECIES", 102, 107], ["the Lrrk2 primary antibody", "TEST", 30, 56]]], ["After washing 3 \u00c2 5 minutes with PBST, the sections were incubated for 30 minutes at room temperature with swineanti-rabbit biotinylated secondary antibody diluted at 1:300 in PBST.", [["sections", "ANATOMY", 43, 51], ["swineanti-rabbit biotinylated secondary antibody", "PROTEIN", 107, 155], ["PBST", "TREATMENT", 33, 37], ["swineanti-rabbit biotinylated secondary antibody", "PROBLEM", 107, 155]]], ["The sections were washed in PBST (3 \u00c2 5 minutes) and incubated with a mixture of avidin and biotinylated HRP (DakoCytomation; ABComplex/HRP-Kit, K0355) following the recommendation of the manufacturer.", [["sections", "ANATOMY", 4, 12], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["avidin", "GENE_OR_GENE_PRODUCT", 81, 87], ["HRP", "SIMPLE_CHEMICAL", 105, 108], ["biotinylated HRP", "PROTEIN", 92, 108], ["HRP", "PROTEIN", 136, 139], ["The sections", "TEST", 0, 12], ["PBST", "TEST", 28, 32], ["a mixture of avidin", "TREATMENT", 68, 87], ["biotinylated HRP", "TREATMENT", 92, 108], ["DakoCytomation", "TREATMENT", 110, 124], ["ABComplex/HRP", "TREATMENT", 126, 139], ["the manufacturer", "TREATMENT", 184, 200]]], ["The stock solution of the avidinYbiotin complex was prepared by adding 10 KL of solution A and 10 KL of solution B to 1 mL PBST.", [["avidinYbiotin", "CHEMICAL", 26, 39], ["avidinYbiotin", "CHEMICAL", 26, 39], ["avidinYbiotin", "SIMPLE_CHEMICAL", 26, 39], ["avidinYbiotin complex", "PROTEIN", 26, 47], ["The stock solution of the avidinYbiotin complex", "TREATMENT", 0, 47]]], ["The stock solution was used at a dilution of 1:100 to incubate sections for 1 hour at room temperature, which was followed by a wash of 3 \u00c2 5 minutes in PBST.", [["sections", "ANATOMY", 63, 71], ["The stock solution", "TREATMENT", 0, 18]]], ["Finally, the sections were incubated with 3, 3-diaminobenzidine (DAB), which produced a brown reaction product, or a combination of DAB and nickel ammonium sulfate that produced a dark purple reaction product.", [["sections", "ANATOMY", 13, 21], ["3, 3-diaminobenzidine", "CHEMICAL", 42, 63], ["DAB", "CHEMICAL", 65, 68], ["DAB", "CHEMICAL", 132, 135], ["nickel ammonium", "CHEMICAL", 140, 155], ["3, 3-diaminobenzidine", "CHEMICAL", 42, 63], ["DAB", "CHEMICAL", 65, 68], ["DAB", "CHEMICAL", 132, 135], ["nickel ammonium sulfate", "CHEMICAL", 140, 163], ["3, 3-diaminobenzidine", "SIMPLE_CHEMICAL", 42, 63], ["DAB", "SIMPLE_CHEMICAL", 65, 68], ["DAB", "SIMPLE_CHEMICAL", 132, 135], ["nickel ammonium sulfate", "SIMPLE_CHEMICAL", 140, 163], ["the sections", "TEST", 9, 21], ["a brown reaction product", "PROBLEM", 86, 110], ["DAB and nickel ammonium sulfate", "TREATMENT", 132, 163], ["a dark purple reaction product", "PROBLEM", 178, 208], ["brown", "OBSERVATION", 88, 93], ["reaction product", "OBSERVATION", 94, 110], ["dark purple", "OBSERVATION_MODIFIER", 180, 191], ["reaction product", "OBSERVATION", 192, 208]]], ["For this combined DABYnickel ammonium sulfate reaction, the sections were incubated in 0.2% nickel ammonium sulfate (Fluka, Buchs, Switzerland, 09885) diluted in Tris buffer at pH 7.4 for 10 minutes and then were transferred to a 0.2% nickel ammonium sulfate solution that contained DAB (50 mg for 100 mL Tris).", [["sections", "ANATOMY", 60, 68], ["DABYnickel", "CHEMICAL", 18, 28], ["ammonium sulfate", "CHEMICAL", 29, 45], ["nickel ammonium sulfate", "CHEMICAL", 92, 115], ["Fluka, Buchs, Switzerland, 09885", "CHEMICAL", 117, 149], ["nickel ammonium sulfate", "CHEMICAL", 235, 258], ["DAB", "CHEMICAL", 283, 286], ["DABYnickel ammonium sulfate", "CHEMICAL", 18, 45], ["nickel ammonium sulfate", "CHEMICAL", 92, 115], ["Fluka", "CHEMICAL", 117, 122], ["nickel ammonium sulfate", "CHEMICAL", 235, 258], ["DAB", "CHEMICAL", 283, 286], ["DABYnickel ammonium sulfate", "SIMPLE_CHEMICAL", 18, 45], ["nickel ammonium sulfate", "SIMPLE_CHEMICAL", 92, 115], ["Fluka", "SIMPLE_CHEMICAL", 117, 122], ["nickel ammonium sulfate", "SIMPLE_CHEMICAL", 235, 258], ["DAB", "SIMPLE_CHEMICAL", 283, 286], ["this combined DABYnickel ammonium sulfate reaction", "TREATMENT", 4, 54], ["the sections", "TEST", 56, 68], ["nickel ammonium sulfate", "TREATMENT", 92, 115], ["a 0.2% nickel ammonium sulfate solution", "TREATMENT", 228, 267]]], ["Finally, the sections were incubated in the same mixture of nickel ammonium sulfate and DAB to which 30% H 2 O 2 (10 KL to 200 mL) was added.", [["sections", "ANATOMY", 13, 21], ["nickel ammonium sulfate", "CHEMICAL", 60, 83], ["DAB", "CHEMICAL", 88, 91], ["H 2 O", "CHEMICAL", 105, 110], ["nickel ammonium sulfate", "CHEMICAL", 60, 83], ["DAB", "CHEMICAL", 88, 91], ["H 2 O 2", "CHEMICAL", 105, 112], ["nickel ammonium sulfate", "SIMPLE_CHEMICAL", 60, 83], ["DAB", "SIMPLE_CHEMICAL", 88, 91], ["H 2 O 2", "SIMPLE_CHEMICAL", 105, 112], ["the sections", "TEST", 9, 21], ["nickel ammonium sulfate", "TREATMENT", 60, 83], ["DAB", "TREATMENT", 88, 91]]], ["During this last step of incubation, positive control sections were monitored by microscopic analysis for efficiency of the immunoreaction.", [["sections", "ANATOMY", 54, 62], ["microscopic analysis", "TEST", 81, 101], ["the immunoreaction", "PROBLEM", 120, 138]]], ["The sections were rinsed in distilled water, dehydrated in graded ethanol, passed 2 \u00c2 5 minutes in xylene, and were mounted in Entellan (VWR Canlab, Mississauga, ON, Canada, UN 1866).", [["sections", "ANATOMY", 4, 12], ["ethanol", "CHEMICAL", 66, 73], ["ethanol", "CHEMICAL", 66, 73], ["xylene", "CHEMICAL", 99, 105], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["ethanol", "SIMPLE_CHEMICAL", 66, 73], ["xylene", "SIMPLE_CHEMICAL", 99, 105], ["The sections", "TREATMENT", 0, 12], ["xylene", "TREATMENT", 99, 105]]], ["Control sections, in which the primary antibody was replaced by normal serum, were immunostained in parallel with the Lrrk2-immunostained sections.", [["sections", "ANATOMY", 8, 16], ["serum", "ANATOMY", 71, 76], ["sections", "ANATOMY", 138, 146], ["Control sections", "MULTI-TISSUE_STRUCTURE", 0, 16], ["serum", "ORGANISM_SUBSTANCE", 71, 76], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 118, 123], ["primary antibody", "PROTEIN", 31, 47], ["Lrrk2", "PROTEIN", 118, 123], ["Control sections", "TEST", 0, 16], ["the primary antibody", "TEST", 27, 47], ["the Lrrk2", "TEST", 114, 123]]], ["Sections were pretreated with 80% formic acid for 15 minutes before immunostaining for >-synuclein.ImmunohistochemistryDouble immunofluorescence staining to detect overlapping expression of Lrrk2 and >-synuclein in Lewy bodies was also performed on SN sections of patients with PD in whom the presence of Lewy bodies had previously been confirmed by ubiquitin and >-synuclein staining.", [["SN sections", "ANATOMY", 249, 260], ["formic acid", "CHEMICAL", 34, 45], ["PD", "DISEASE", 278, 280], ["formic acid", "CHEMICAL", 34, 45], ["formic acid", "SIMPLE_CHEMICAL", 34, 45], [">-synuclein", "GENE_OR_GENE_PRODUCT", 87, 98], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 190, 195], [">-synuclein", "GENE_OR_GENE_PRODUCT", 200, 211], ["SN sections", "MULTI-TISSUE_STRUCTURE", 249, 260], ["patients", "ORGANISM", 264, 272], ["ubiquitin", "GENE_OR_GENE_PRODUCT", 350, 359], [">-synuclein", "GENE_OR_GENE_PRODUCT", 364, 375], [">-synuclein", "PROTEIN", 87, 98], ["Lrrk2", "PROTEIN", 190, 195], [">-synuclein", "PROTEIN", 200, 211], ["ubiquitin", "PROTEIN", 350, 359], ["patients", "SPECIES", 264, 272], ["80% formic acid", "TREATMENT", 30, 45], ["immunostaining", "TEST", 68, 82], [">-synuclein", "TREATMENT", 87, 98], ["ImmunohistochemistryDouble immunofluorescence staining", "TEST", 99, 153], ["overlapping expression of Lrrk2 and >-synuclein in Lewy bodies", "PROBLEM", 164, 226], ["PD", "TREATMENT", 278, 280], ["Lewy bodies", "PROBLEM", 305, 316], [">-synuclein staining", "PROBLEM", 364, 384], ["Lrrk2", "OBSERVATION", 190, 195], ["Lewy bodies", "OBSERVATION", 305, 316], ["synuclein staining", "OBSERVATION", 366, 384]]], ["The SN sections were simultaneously incubated with a mixture of polyclonal anti-Lrrk2 (1:300) and monoclonal anti->synuclein (clone LB509, 1:200) antibodies overnight at room temperature.", [["SN sections", "ANATOMY", 4, 15], ["SN sections", "CANCER", 4, 15], ["anti-Lrrk2", "GENE_OR_GENE_PRODUCT", 75, 85], ["anti->synuclein", "SIMPLE_CHEMICAL", 109, 124], ["clone", "ORGANISM", 126, 131], ["polyclonal anti-Lrrk2", "PROTEIN", 64, 85], ["1:300", "PROTEIN", 87, 92], ["monoclonal anti->synuclein", "PROTEIN", 98, 124], ["clone LB509, 1:200) antibodies", "PROTEIN", 126, 156], ["polyclonal anti-Lrrk2", "TREATMENT", 64, 85], ["monoclonal anti->synuclein (clone LB509", "TREATMENT", 98, 137]]], ["The sections were rinsed in PBST (3 \u00c2 5 minutes) and then incubated for 1 hour at room temperature with FITC-conjugated swine anti-rabbit antibody (DakoCytomation; F0205, 1:30) to yield a green fluorescence for Lrrk2.", [["sections", "ANATOMY", 4, 12], ["FITC", "CHEMICAL", 104, 108], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["FITC", "SIMPLE_CHEMICAL", 104, 108], ["swine", "ORGANISM", 120, 125], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 211, 216], ["FITC-conjugated swine anti-rabbit antibody", "PROTEIN", 104, 146], ["F0205", "PROTEIN", 164, 169], ["1:30", "PROTEIN", 171, 175], ["Lrrk2", "PROTEIN", 211, 216], ["swine", "SPECIES", 120, 125], ["anti-rabbit", "SPECIES", 126, 137], ["swine", "SPECIES", 120, 125], ["The sections", "TEST", 0, 12], ["PBST", "TEST", 28, 32], ["FITC", "TEST", 104, 108], ["Lrrk2", "PROBLEM", 211, 216]]], ["The sections were washed in PBST (3 \u00c2 5 minutes).", [["sections", "ANATOMY", 4, 12], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["The sections", "TEST", 0, 12]]], ["Some were incubated with 1% normal rabbit serum for 1 hour at room temperature to quench any crossreaction between the secondary antibodies.", [["serum", "ANATOMY", 42, 47], ["rabbit", "ORGANISM", 35, 41], ["serum", "ORGANISM_SUBSTANCE", 42, 47], ["secondary antibodies", "PROTEIN", 119, 139], ["rabbit", "SPECIES", 35, 41], ["rabbit", "SPECIES", 35, 41], ["secondary antibodies", "OBSERVATION", 119, 139]]], ["Other sections were incubated directly with TRITC-labeled rabbit anti-mouse antibody (DakoCytomation; R0270, 1:30) to yield a red fluorescence for >-synuclein.", [["sections", "ANATOMY", 6, 14], [">-synuclein", "CHEMICAL", 147, 158], ["TRITC", "SIMPLE_CHEMICAL", 44, 49], ["rabbit", "ORGANISM", 58, 64], [">-synuclein", "SIMPLE_CHEMICAL", 147, 158], ["TRITC-labeled rabbit anti-mouse antibody", "PROTEIN", 44, 84], ["DakoCytomation; R0270, 1:30", "PROTEIN", 86, 113], [">-synuclein", "PROTEIN", 147, 158], ["rabbit", "SPECIES", 58, 64], ["rabbit", "SPECIES", 58, 64], ["Other sections", "TEST", 0, 14], ["TRITC", "TEST", 44, 49], ["a red fluorescence", "PROBLEM", 124, 142], [">-synuclein", "TREATMENT", 147, 158]]], ["No differences were observed between these 2 treatments.", [["these 2 treatments", "TREATMENT", 37, 55]]], ["SN sections were similarly incubated with the Lrrk2 polyclonal antibody and monoclonal antibodies either to Tau-C3, glial fibrillary acidic protein (GFAP, clone F2; DakoCytomation) to detect astrocytes or HLA-DR (CR3/ 43; DakoCytomation; R0270) to detect microglia.", [["SN sections", "ANATOMY", 0, 11], ["astrocytes", "ANATOMY", 191, 201], ["microglia", "ANATOMY", 255, 264], ["SN sections", "CANCER", 0, 11], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 46, 51], ["Tau-C3", "GENE_OR_GENE_PRODUCT", 108, 114], ["glial fibrillary acidic protein", "GENE_OR_GENE_PRODUCT", 116, 147], ["GFAP", "GENE_OR_GENE_PRODUCT", 149, 153], ["DakoCytomation", "GENE_OR_GENE_PRODUCT", 165, 179], ["astrocytes", "CELL", 191, 201], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 205, 211], ["CR3", "GENE_OR_GENE_PRODUCT", 213, 216], ["microglia", "CELL", 255, 264], ["Lrrk2 polyclonal antibody", "PROTEIN", 46, 71], ["monoclonal antibodies", "PROTEIN", 76, 97], ["Tau", "PROTEIN", 108, 111], ["C3", "PROTEIN", 112, 114], ["glial fibrillary acidic protein", "PROTEIN", 116, 147], ["GFAP", "PROTEIN", 149, 153], ["clone F2", "PROTEIN", 155, 163], ["DakoCytomation", "PROTEIN", 165, 179], ["astrocytes", "CELL_TYPE", 191, 201], ["HLA-DR", "PROTEIN", 205, 211], ["CR3", "PROTEIN", 213, 216], ["R0270", "PROTEIN", 238, 243], ["microglia", "CELL_TYPE", 255, 264], ["SN sections", "TEST", 0, 11], ["the Lrrk2 polyclonal antibody", "TEST", 42, 71], ["monoclonal antibodies", "TEST", 76, 97], ["Tau", "TEST", 108, 111], ["glial fibrillary acidic protein", "TEST", 116, 147], ["GFAP", "TEST", 149, 153], ["clone F2", "TEST", 155, 163], ["DakoCytomation", "TEST", 165, 179], ["astrocytes", "TEST", 191, 201], ["HLA", "TEST", 205, 208], ["CR3", "TEST", 213, 216], ["DakoCytomation", "TEST", 222, 236], ["microglia", "PROBLEM", 255, 264], ["microglia", "ANATOMY", 255, 264]]], ["The primary antibodies were identified using the same combination of fluorescent secondary antibodies.", [["primary antibodies", "PROTEIN", 4, 22], ["fluorescent secondary antibodies", "PROTEIN", 69, 101], ["The primary antibodies", "TEST", 0, 22], ["fluorescent secondary antibodies", "PROBLEM", 69, 101], ["secondary antibodies", "OBSERVATION", 81, 101]]], ["The sections were coverslipped with Fluoromount-G (Southern Biotechnology Associates, Birmingham, AL) and examined with a Carl Zeiss Axi-overt-200 fluorescence microscope.", [["sections", "ANATOMY", 4, 12], ["Fluoromount-G", "CHEMICAL", 36, 49], ["sections", "MULTI-TISSUE_STRUCTURE", 4, 12], ["Fluoromount-G", "SIMPLE_CHEMICAL", 36, 49]]], ["The capture of the green Lrrk2 fluorescence and the red fluorescence of >synuclein, tau, GFAP, or HLA-DR as well as the merged images were performed using the Northern Elite program.", [["Lrrk2", "GENE_OR_GENE_PRODUCT", 25, 30], ["synuclein", "GENE_OR_GENE_PRODUCT", 73, 82], ["tau", "GENE_OR_GENE_PRODUCT", 84, 87], ["GFAP", "GENE_OR_GENE_PRODUCT", 89, 93], ["HLA-DR", "GENE_OR_GENE_PRODUCT", 98, 104], ["green Lrrk2", "PROTEIN", 19, 30], ["synuclein", "PROTEIN", 73, 82], ["tau", "PROTEIN", 84, 87], ["GFAP", "PROTEIN", 89, 93], ["HLA", "PROTEIN", 98, 101], ["DR", "PROTEIN", 102, 104], ["the green Lrrk2 fluorescence", "TEST", 15, 43], ["the red fluorescence", "TEST", 48, 68], ["GFAP", "TEST", 89, 93], ["the merged images", "TEST", 116, 133], ["green Lrrk2", "OBSERVATION", 19, 30]]], ["Staining of cell nuclei with Hoechst dye 3258 (1 Kg/mL) produced a white fluorescence in ultraviolet light that changed to a blue color in the merged fluorescent images.", [["cell nuclei", "ANATOMY", 12, 23], ["Hoechst dye 3258", "CHEMICAL", 29, 45], ["Hoechst dye 3258", "CHEMICAL", 29, 45], ["cell", "CELL", 12, 16], ["Hoechst dye 3258", "SIMPLE_CHEMICAL", 29, 45], ["Hoechst dye", "TREATMENT", 29, 40], ["a white fluorescence in ultraviolet light", "PROBLEM", 65, 106], ["a blue color", "TEST", 123, 135], ["cell nuclei", "OBSERVATION", 12, 23]]], ["Recombinant >-synuclein binds to at least 3 regions of adjacent 12-mer peptides on panel A of the membrane (arrows).", [["membrane", "ANATOMY", 98, 106], [">-synuclein", "GENE_OR_GENE_PRODUCT", 12, 23], ["membrane", "CELLULAR_COMPONENT", 98, 106], ["Recombinant >-synuclein", "PROTEIN", 0, 23], ["Recombinant >-synuclein binds", "PROBLEM", 0, 29], ["synuclein binds", "OBSERVATION", 14, 29], ["at least", "OBSERVATION_MODIFIER", 33, 41]]], ["Their sequences are STLLEQNVNFR-KILLSKGIH, DIHKLVLAALNRFIGN, and KGDSQIISLLLRRLALDV, respectively.", [["STLLEQNVNFR", "DNA", 20, 31], ["KILLSKGIH", "DNA", 32, 41], ["KGDSQIISLLLRRLALDV", "DNA", 65, 83], ["Their sequences", "TEST", 0, 15], ["STLLEQNVNFR", "TEST", 20, 31], ["DIHKLVLAALNRFIGN", "TEST", 43, 59]]], ["The control membrane, which was exposed only to the synuclein antibody, was blank (data not shown).", [["membrane", "ANATOMY", 12, 20], ["membrane", "CELLULAR_COMPONENT", 12, 20], ["synuclein antibody", "PROTEIN", 52, 70], ["the synuclein antibody", "TEST", 48, 70]]], ["To analyze the coexpression of Lrrk2 and tau in hippocampal sections of patients with AD and Pick disease, double immunostaining with the polyclonal anti-Lrrk2 antibody (1:300) and the monoclonal AT8 anti-tau antibody (1:200) was carried out.Immunoabsorption AssayAn immunoabsorption assay was done using the synthetic peptide that had been used as the antigen in generating the Lrrk2 antibody.", [["hippocampal sections", "ANATOMY", 48, 68], ["AD", "DISEASE", 86, 88], ["Pick disease", "DISEASE", 93, 105], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 31, 36], ["tau", "GENE_OR_GENE_PRODUCT", 41, 44], ["hippocampal sections", "MULTI-TISSUE_STRUCTURE", 48, 68], ["patients", "ORGANISM", 72, 80], ["anti-Lrrk2", "GENE_OR_GENE_PRODUCT", 149, 159], ["AT8", "GENE_OR_GENE_PRODUCT", 196, 199], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 379, 384], ["Lrrk2", "PROTEIN", 31, 36], ["tau", "PROTEIN", 41, 44], ["polyclonal anti-Lrrk2 antibody", "PROTEIN", 138, 168], ["1:300", "PROTEIN", 170, 175], ["monoclonal AT8 anti-tau antibody", "PROTEIN", 185, 217], ["1:200", "PROTEIN", 219, 224], ["Lrrk2 antibody", "PROTEIN", 379, 393], ["patients", "SPECIES", 72, 80], ["Lrrk2", "PROBLEM", 31, 36], ["AD and Pick disease", "PROBLEM", 86, 105], ["double immunostaining", "TEST", 107, 128], ["the polyclonal anti-Lrrk2 antibody", "TEST", 134, 168], ["the monoclonal AT8 anti-tau antibody", "TEST", 181, 217], ["Immunoabsorption AssayAn immunoabsorption assay", "TEST", 242, 289], ["the synthetic peptide", "TREATMENT", 305, 326], ["the antigen", "TEST", 349, 360], ["the Lrrk2 antibody", "TEST", 375, 393], ["Lrrk2 antibody", "OBSERVATION", 379, 393]]], ["This peptide spanned residues 2500Y2527 of Lrrk2 (Novus Biologicals, Inc.; NB-300-268).", [["Lrrk2", "GENE_OR_GENE_PRODUCT", 43, 48], ["Lrrk2", "PROTEIN", 43, 48], ["Lrrk2", "TEST", 43, 48], ["NB", "TEST", 75, 77]]], ["Five micrograms per milliliter Lrrk2 268 peptide in PBS was mixed with 1 Kg/mL anti Lrrk2 antibody in continuous rotation at 4-C for 4 hours.", [["PBS", "SIMPLE_CHEMICAL", 52, 55], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 84, 89], ["anti Lrrk2 antibody", "PROTEIN", 79, 98], ["peptide in PBS", "TREATMENT", 41, 55], ["anti Lrrk2 antibody", "TREATMENT", 79, 98]]], ["In parallel, 1 Kg/mL anti-Lrrk2 268 antibody was incubated in PBS under the same conditions.", [["anti-Lrrk2 268 antibody", "PROTEIN", 21, 44]]], ["Parallel immunostaining of adjacent sections of the hippocampus of patients with DLBD, AD, and Pick disease was carried out with the immunoabsorbed and nonimmunoabsorbed anti-Lrrk2 antibodies as described previously.LRRK2 mRNA ExpressionAll tissues and cell lines tested by reverse transcriptaseY polymerase chain reaction demonstrated expression of LRRK2.", [["sections", "ANATOMY", 36, 44], ["hippocampus", "ANATOMY", 52, 63], ["DLBD", "ANATOMY", 81, 85], ["tissues", "ANATOMY", 241, 248], ["cell lines", "ANATOMY", 253, 263], ["DLBD", "DISEASE", 81, 85], ["AD", "DISEASE", 87, 89], ["Pick disease", "DISEASE", 95, 107], ["sections", "MULTI-TISSUE_STRUCTURE", 36, 44], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 52, 63], ["patients", "ORGANISM", 67, 75], ["DLBD", "CANCER", 81, 85], ["anti-Lrrk2", "GENE_OR_GENE_PRODUCT", 170, 180], ["LRRK2", "GENE_OR_GENE_PRODUCT", 216, 221], ["tissues", "TISSUE", 241, 248], ["cell lines", "CELL", 253, 263], ["LRRK2", "GENE_OR_GENE_PRODUCT", 350, 355], ["immunoabsorbed and nonimmunoabsorbed anti-Lrrk2 antibodies", "PROTEIN", 133, 191], ["LRRK2 mRNA", "RNA", 216, 226], ["cell lines", "CELL_LINE", 253, 263], ["LRRK2", "PROTEIN", 350, 355], ["patients", "SPECIES", 67, 75], ["DLBD", "PROBLEM", 81, 85], ["AD", "PROBLEM", 87, 89], ["Pick disease", "PROBLEM", 95, 107], ["the immunoabsorbed and nonimmunoabsorbed anti-Lrrk2 antibodies", "PROBLEM", 129, 191], ["cell lines", "TEST", 253, 263], ["LRRK2", "PROBLEM", 350, 355], ["immunostaining", "OBSERVATION", 9, 23], ["hippocampus", "ANATOMY", 52, 63], ["All tissues", "OBSERVATION_MODIFIER", 237, 248], ["cell lines", "OBSERVATION", 253, 263], ["LRRK2", "OBSERVATION", 350, 355]]], ["This is illustrated in Figure 1 Figure 2 A shows a typical Western blot of human brain supernatant.", [["brain supernatant", "ANATOMY", 81, 98], ["human", "ORGANISM", 75, 80], ["brain", "ORGAN", 81, 86], ["human", "SPECIES", 75, 80], ["human", "SPECIES", 75, 80], ["brain", "ANATOMY", 81, 86]]], ["The antibody to Lrrk2 stained a close doublet of higher molecular weight than 250 kDa, which roughly corresponds to the predicted value of full-length Lrrk2 with possible posttranslational modifications.", [["Lrrk2", "GENE_OR_GENE_PRODUCT", 16, 21], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 151, 156], ["Lrrk2", "PROTEIN", 16, 21], ["Lrrk2", "PROTEIN", 151, 156], ["The antibody", "TEST", 0, 12], ["Lrrk2", "TEST", 16, 21], ["posttranslational modifications", "PROBLEM", 171, 202], ["possible", "UNCERTAINTY", 162, 170], ["posttranslational modifications", "OBSERVATION", 171, 202]]], ["Several other positive bands from 28 to 145 kDa may represent C-terminal fragments of Lrrk2.", [["C", "CHEMICAL", 62, 63], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 86, 91], ["C-terminal fragments", "DNA", 62, 82], ["Lrrk2", "PROTEIN", 86, 91], ["Several other positive bands", "PROBLEM", 0, 28], ["C-terminal fragments of Lrrk2", "PROBLEM", 62, 91], ["positive bands", "OBSERVATION_MODIFIER", 14, 28], ["may represent", "UNCERTAINTY", 48, 61], ["terminal", "OBSERVATION_MODIFIER", 64, 72], ["fragments", "OBSERVATION", 73, 82], ["Lrrk2", "OBSERVATION", 86, 91]]], ["Strong bands were observed at approximately 62 and 32.5 kDa, suggesting major cleavages in the MAPKKK and WD 40 domains.", [["MAPKKK", "GENE_OR_GENE_PRODUCT", 95, 101], ["MAPKKK", "PROTEIN", 95, 101], ["WD 40 domains", "PROTEIN", 106, 119], ["Strong bands", "PROBLEM", 0, 12], ["major cleavages", "PROBLEM", 72, 87], ["bands", "OBSERVATION", 7, 12], ["major", "OBSERVATION_MODIFIER", 72, 77], ["cleavages", "OBSERVATION", 78, 87]]], ["This indicates that significant amounts of Lrrk2 C-terminal fragments are produced in brain, which, if retained in an insoluble state, would be recognized immunohistochemically.", [["brain", "ANATOMY", 86, 91], ["Lrrk2", "CHEMICAL", 43, 48], ["C", "CHEMICAL", 49, 50], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 43, 48], ["brain", "ORGAN", 86, 91], ["Lrrk2 C-terminal fragments", "DNA", 43, 69], ["significant amounts of Lrrk2 C-terminal fragments", "PROBLEM", 20, 69], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["amounts", "OBSERVATION_MODIFIER", 32, 39], ["Lrrk2", "OBSERVATION", 43, 48], ["terminal", "OBSERVATION_MODIFIER", 51, 59], ["fragments", "OBSERVATION", 60, 69], ["brain", "ANATOMY", 86, 91]]], ["Figure 2B shows the results of probing Lrrk2 peptide membranes with the Lrrk2 polyclonal antibody NB 300-268.", [["NB 300-268", "CHEMICAL", 98, 108], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 39, 44], ["Lrrk2", "PROTEIN", 39, 44], ["Lrrk2 polyclonal antibody NB 300-268", "PROTEIN", 72, 108], ["Figure 2B", "TEST", 0, 9], ["probing Lrrk2 peptide membranes", "PROBLEM", 31, 62], ["the Lrrk2 polyclonal antibody NB", "TEST", 68, 100]]], ["The figure shows that the region of the molecule recognized by the antibody is included in the sequence IEVRKE-LAEKMRRTSVE spanning residues 2511 to 2527 of the far C-terminal region of Lrrk2.", [["C", "CHEMICAL", 165, 166], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 186, 191], ["IEVRKE", "PROTEIN", 104, 110], ["LAEKMRRTSVE", "DNA", 111, 122], ["C-terminal region", "PROTEIN", 165, 182], ["Lrrk2", "PROTEIN", 186, 191], ["the antibody", "TEST", 63, 75], ["the sequence IEVRKE", "TEST", 91, 110], ["molecule", "OBSERVATION", 40, 48], ["Lrrk2", "OBSERVATION", 186, 191]]], ["Figure 3 shows panels A, B, C, and D of the Lrrk2 peptide membranes.", [["Lrrk2 peptide membranes", "ANATOMY", 44, 67], ["B", "GENE_OR_GENE_PRODUCT", 25, 26], ["C", "GENE_OR_GENE_PRODUCT", 28, 29], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 44, 49], ["B", "PROTEIN", 25, 26], ["Figure", "TEST", 0, 6], ["panels", "TEST", 15, 21], ["Lrrk2", "OBSERVATION", 44, 49], ["peptide membranes", "OBSERVATION", 50, 67]]], ["It shows that recombinant >-synuclein binds to at least 3 regions in panel A (arrows) encompassing residues 423 to 442, 541 to 556, and 781 to 798.", [["recombinant >-synuclein", "GENE_OR_GENE_PRODUCT", 14, 37], ["recombinant >-synuclein", "PROTEIN", 14, 37], ["recombinant >-synuclein binds", "PROBLEM", 14, 43]]], ["Figure 4A illustrates positive cytoplasmic Lrrk2 immunostaining in pyramidal neurons of the hippocampus in a patient without neurologic symptoms and without identifiable brain pathology.", [["cytoplasmic", "ANATOMY", 31, 42], ["pyramidal neurons", "ANATOMY", 67, 84], ["hippocampus", "ANATOMY", 92, 103], ["neurologic", "ANATOMY", 125, 135], ["brain", "ANATOMY", 170, 175], ["neurologic symptoms", "DISEASE", 125, 144], ["cytoplasmic", "ORGANISM_SUBSTANCE", 31, 42], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 43, 48], ["pyramidal neurons", "CELL", 67, 84], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 92, 103], ["patient", "ORGANISM", 109, 116], ["brain", "ORGAN", 170, 175], ["Lrrk2", "PROTEIN", 43, 48], ["pyramidal neurons", "CELL_TYPE", 67, 84], ["patient", "SPECIES", 109, 116], ["positive cytoplasmic Lrrk2 immunostaining in pyramidal neurons of the hippocampus", "PROBLEM", 22, 103], ["neurologic symptoms", "PROBLEM", 125, 144], ["identifiable brain pathology", "PROBLEM", 157, 185], ["cytoplasmic Lrrk2 immunostaining", "OBSERVATION", 31, 63], ["pyramidal neurons", "OBSERVATION", 67, 84], ["hippocampus", "ANATOMY", 92, 103], ["brain", "ANATOMY", 170, 175], ["pathology", "OBSERVATION", 176, 185]]], ["Such positive neuronal staining was observed in all other brain areas examined, including the temporal, parietal, primary motor, and occipital cortices.", [["neuronal", "ANATOMY", 14, 22], ["brain areas", "ANATOMY", 58, 69], ["temporal", "ANATOMY", 94, 102], ["parietal", "ANATOMY", 104, 112], ["primary motor", "ANATOMY", 114, 127], ["occipital cortices", "ANATOMY", 133, 151], ["neuronal", "CELL", 14, 22], ["brain", "ORGAN", 58, 63], ["temporal", "MULTI-TISSUE_STRUCTURE", 94, 102], ["parietal", "MULTI-TISSUE_STRUCTURE", 104, 112], ["occipital cortices", "MULTI-TISSUE_STRUCTURE", 133, 151], ["Such positive neuronal staining", "PROBLEM", 0, 31], ["positive", "OBSERVATION_MODIFIER", 5, 13], ["neuronal staining", "OBSERVATION", 14, 31], ["brain", "ANATOMY", 58, 63], ["areas", "ANATOMY_MODIFIER", 64, 69], ["temporal", "ANATOMY_MODIFIER", 94, 102], ["parietal", "ANATOMY_MODIFIER", 104, 112], ["primary motor", "ANATOMY", 114, 127], ["occipital cortices", "ANATOMY", 133, 151]]], ["Dopaminergic neurons of the SN also showed similar staining.", [["Dopaminergic neurons", "ANATOMY", 0, 20], ["SN", "ANATOMY", 28, 30], ["Dopaminergic neurons", "CELL", 0, 20], ["SN", "MULTI-TISSUE_STRUCTURE", 28, 30], ["Dopaminergic neurons", "CELL_TYPE", 0, 20], ["similar staining", "PROBLEM", 43, 59], ["similar", "OBSERVATION_MODIFIER", 43, 50], ["staining", "OBSERVATION", 51, 59]]], ["Some Lrrk2-positive glial cells compatible with astrocytes ( Fig. 4B ) and reactive microglia (Fig. 4C) were also observed.", [["Lrrk2-positive glial cells", "ANATOMY", 5, 31], ["astrocytes", "ANATOMY", 48, 58], ["microglia", "ANATOMY", 84, 93], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 5, 10], ["astrocytes", "CELL", 48, 58], ["Fig. 4B", "CELL", 61, 68], ["microglia", "CELL", 84, 93], ["Lrrk2-positive glial cells", "CELL_LINE", 5, 31], ["astrocytes", "CELL_TYPE", 48, 58], ["reactive microglia", "CELL_TYPE", 75, 93], ["Some Lrrk2-positive glial cells", "PROBLEM", 0, 31], ["astrocytes", "PROBLEM", 48, 58], ["reactive microglia", "PROBLEM", 75, 93], ["Lrrk2", "OBSERVATION", 5, 10], ["positive glial cells", "OBSERVATION", 11, 31], ["astrocytes", "ANATOMY", 48, 58], ["reactive microglia", "OBSERVATION", 75, 93]]], ["No immunoreactivity was observed with control serum (Fig. 4D) .", [["serum", "ANATOMY", 46, 51], ["serum", "ORGANISM_SUBSTANCE", 46, 51], ["immunoreactivity", "PROBLEM", 3, 19], ["immunoreactivity", "OBSERVATION", 3, 19]]], ["Figure 5 illustrates immunostaining of pathologic tissue in PD and DLBD.", [["tissue", "ANATOMY", 50, 56], ["PD", "DISEASE", 60, 62], ["DLBD", "DISEASE", 67, 71], ["tissue", "TISSUE", 50, 56], ["DLBD", "CANCER", 67, 71], ["pathologic tissue in PD and DLBD", "PROBLEM", 39, 71], ["pathologic tissue", "OBSERVATION", 39, 56], ["PD", "OBSERVATION", 60, 62]]], ["The anti-Lrrk2 antibody identified Lewy bodies in the SN in all sporadic PD cases and also in the familial PD case from family B (Fig. 5A, B) .", [["SN", "ANATOMY", 54, 56], ["PD", "DISEASE", 73, 75], ["PD", "DISEASE", 107, 109], ["anti-Lrrk2 antibody", "GENE_OR_GENE_PRODUCT", 4, 23], ["SN", "CANCER", 54, 56], ["B", "CANCER", 139, 140], ["anti-Lrrk2 antibody", "PROTEIN", 4, 23], ["The anti-Lrrk2 antibody", "TEST", 0, 23], ["Lewy bodies", "PROBLEM", 35, 46], ["Lewy bodies", "OBSERVATION", 35, 46]]], ["A few Lrrk2-positive Lewy neurites were observed (Fig. 5C ).", [["neurites", "ANATOMY", 26, 34], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 6, 11], ["Lrrk2", "PROTEIN", 6, 11], ["A few Lrrk2-positive Lewy neurites", "PROBLEM", 0, 34], ["few", "OBSERVATION_MODIFIER", 2, 5], ["Lrrk2", "OBSERVATION", 6, 11], ["positive", "OBSERVATION_MODIFIER", 12, 20], ["Lewy neurites", "OBSERVATION", 21, 34]]], ["Lrrk2-immunoreactive Lewy bodies were also observed in the locus ceruleus and raphe nuclei in the pons and in the tegmentum of the medulla oblongata.", [["Lewy bodies", "ANATOMY", 21, 32], ["locus ceruleus", "ANATOMY", 59, 73], ["raphe nuclei", "ANATOMY", 78, 90], ["pons", "ANATOMY", 98, 102], ["tegmentum", "ANATOMY", 114, 123], ["medulla oblongata", "ANATOMY", 131, 148], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 0, 5], ["locus ceruleus", "CELLULAR_COMPONENT", 59, 73], ["raphe nuclei", "CELLULAR_COMPONENT", 78, 90], ["pons", "ORGAN", 98, 102], ["tegmentum", "ORGAN", 114, 123], ["medulla oblongata", "MULTI-TISSUE_STRUCTURE", 131, 148], ["Lrrk2", "PROTEIN", 0, 5], ["Lrrk2", "TEST", 0, 5], ["Lewy bodies", "PROBLEM", 21, 32], ["immunoreactive", "OBSERVATION_MODIFIER", 6, 20], ["locus", "ANATOMY_MODIFIER", 59, 64], ["ceruleus", "ANATOMY", 65, 73], ["raphe", "ANATOMY_MODIFIER", 78, 83], ["nuclei", "ANATOMY_MODIFIER", 84, 90], ["pons", "ANATOMY", 98, 102], ["tegmentum", "ANATOMY_MODIFIER", 114, 123], ["medulla oblongata", "ANATOMY", 131, 148]]], ["A similar strong Lrrk2 immunoreactivity of Lewy bodies was observed in the SN, brainstem, parahippocampal, and neocortical areas in DLBD.", [["SN", "ANATOMY", 75, 77], ["brainstem", "ANATOMY", 79, 88], ["parahippocampal", "ANATOMY", 90, 105], ["neocortical areas", "ANATOMY", 111, 128], ["DLBD", "ANATOMY", 132, 136], ["DLBD", "DISEASE", 132, 136], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 17, 22], ["brainstem", "MULTI-TISSUE_STRUCTURE", 79, 88], ["parahippocampal", "MULTI-TISSUE_STRUCTURE", 90, 105], ["neocortical areas", "MULTI-TISSUE_STRUCTURE", 111, 128], ["DLBD", "CANCER", 132, 136], ["Lrrk2", "PROTEIN", 17, 22], ["A similar strong Lrrk2 immunoreactivity of Lewy bodies", "PROBLEM", 0, 54], ["the SN, brainstem, parahippocampal, and neocortical areas in DLBD", "PROBLEM", 71, 136], ["strong", "OBSERVATION_MODIFIER", 10, 16], ["Lrrk2 immunoreactivity", "OBSERVATION", 17, 39], ["Lewy bodies", "OBSERVATION", 43, 54], ["SN", "ANATOMY", 75, 77], ["brainstem", "ANATOMY", 79, 88], ["parahippocampal", "ANATOMY_MODIFIER", 90, 105], ["neocortical", "ANATOMY_MODIFIER", 111, 122]]], ["It was also observed in the AD case in which the AD-type cortical changes were combined with Lewy body pathology.", [["cortical", "ANATOMY", 57, 65], ["body", "ANATOMY", 98, 102], ["AD", "DISEASE", 28, 30], ["AD", "DISEASE", 49, 51], ["cortical", "MULTI-TISSUE_STRUCTURE", 57, 65], ["the AD-type cortical changes", "PROBLEM", 45, 73], ["Lewy body pathology", "PROBLEM", 93, 112], ["cortical changes", "OBSERVATION", 57, 73]]], ["Lrrk2-immunoreactive Lewy bodies in the middle temporal gyrus in a patient with DLBD are illustrated in Figure 5D .", [["Lewy bodies", "ANATOMY", 21, 32], ["middle temporal gyrus", "ANATOMY", 40, 61], ["DLBD", "DISEASE", 80, 84], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 0, 5], ["temporal gyrus", "MULTI-TISSUE_STRUCTURE", 47, 61], ["patient", "ORGANISM", 67, 74], ["DLBD", "CANCER", 80, 84], ["Lrrk2", "PROTEIN", 0, 5], ["patient", "SPECIES", 67, 74], ["Lrrk2", "TEST", 0, 5], ["Lewy bodies in the middle temporal gyrus", "PROBLEM", 21, 61], ["immunoreactive", "OBSERVATION_MODIFIER", 6, 20], ["middle temporal gyrus", "ANATOMY", 40, 61]]], ["An example of Lewy bodies in a pyramidal neuron in the precentral cortex with slightly stained processes from the same DLBD case is shown in Figure 5E .", [["pyramidal neuron", "ANATOMY", 31, 47], ["precentral cortex", "ANATOMY", 55, 72], ["pyramidal neuron", "CANCER", 31, 47], ["precentral cortex", "CANCER", 55, 72], ["DLBD", "CANCER", 119, 123], ["Lewy bodies", "PROBLEM", 14, 25], ["slightly stained processes", "PROBLEM", 78, 104], ["Lewy bodies", "OBSERVATION", 14, 25], ["pyramidal neuron", "OBSERVATION", 31, 47], ["precentral", "ANATOMY_MODIFIER", 55, 65], ["cortex", "ANATOMY_MODIFIER", 66, 72], ["slightly", "OBSERVATION_MODIFIER", 78, 86], ["stained", "OBSERVATION", 87, 94]]], ["When the SN of a patient with PD known to exhibit Lewy body pathology was doubly immunostained for Lrrk2 and >synuclein by immunofluorescence technique, the green Lrrk2 fluorescence (Fig. 5F ) and red >-synuclein fluorescence (Fig. 5G) of Lewy bodies overlapped and on merged fluorescent images yielded a yellowYorange fluorescence with a typical central core (Fig. 5H) .ImmunohistochemistryFigures 5I and J show Lrrk2 compared with tau immunoreactivity in the hippocampus of a patient with AD.", [["body", "ANATOMY", 55, 59], ["hippocampus", "ANATOMY", 461, 472], ["PD", "DISEASE", 30, 32], ["AD", "DISEASE", 491, 493], ["patient", "ORGANISM", 17, 24], ["Lewy body pathology", "CANCER", 50, 69], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 99, 104], ["synuclein", "GENE_OR_GENE_PRODUCT", 110, 119], ["red >-synuclein", "GENE_OR_GENE_PRODUCT", 197, 212], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 413, 418], ["tau", "GENE_OR_GENE_PRODUCT", 433, 436], ["hippocampus", "ORGAN", 461, 472], ["patient", "ORGANISM", 478, 485], ["Lrrk2", "PROTEIN", 99, 104], ["synuclein", "PROTEIN", 110, 119], ["green Lrrk2", "PROTEIN", 157, 168], ["Lrrk2", "PROTEIN", 413, 418], ["tau", "PROTEIN", 433, 436], ["patient", "SPECIES", 17, 24], ["patient", "SPECIES", 478, 485], ["PD", "TREATMENT", 30, 32], ["Lewy body pathology", "PROBLEM", 50, 69], ["Lrrk2", "PROBLEM", 99, 104], ["immunofluorescence technique", "TEST", 123, 151], ["the green Lrrk2 fluorescence", "TEST", 153, 181], ["red >-synuclein fluorescence", "TREATMENT", 197, 225], ["Lewy bodies", "PROBLEM", 239, 250], ["fluorescent images", "TEST", 276, 294], ["ImmunohistochemistryFigures", "TEST", 371, 398], ["Lrrk2", "PROBLEM", 413, 418], ["tau immunoreactivity", "TEST", 433, 453], ["AD", "PROBLEM", 491, 493], ["hippocampus", "ANATOMY", 461, 472]]], ["On doubly immunostained sections, in which Lrrk2 immunoreactivity was revealed in black and that of Tau C3-positive neurofibrillary tangles in brown, a subset only of neurofibrillary tangles exhibited a black Lrrk2 immunoreaction, whereas the remaining tangles showed only tau immunostaining.", [["sections", "ANATOMY", 24, 32], ["neurofibrillary tangles", "ANATOMY", 167, 190], ["sections", "MULTI-TISSUE_STRUCTURE", 24, 32], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 43, 48], ["Tau C3", "GENE_OR_GENE_PRODUCT", 100, 106], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 209, 214], ["tau", "GENE_OR_GENE_PRODUCT", 273, 276], ["Lrrk2", "PROTEIN", 43, 48], ["Tau C3", "PROTEIN", 100, 106], ["Lrrk2", "PROTEIN", 209, 214], ["tau", "PROTEIN", 273, 276], ["doubly immunostained sections", "TEST", 3, 32], ["Lrrk2 immunoreactivity", "TEST", 43, 65], ["Tau C3", "TEST", 100, 106], ["positive neurofibrillary tangles in brown", "PROBLEM", 107, 148], ["neurofibrillary tangles", "PROBLEM", 167, 190], ["a black Lrrk2 immunoreaction", "PROBLEM", 201, 229], ["tau immunostaining", "PROBLEM", 273, 291], ["neurofibrillary tangles", "OBSERVATION", 116, 139], ["neurofibrillary tangles", "OBSERVATION", 167, 190], ["black Lrrk2 immunoreaction", "OBSERVATION", 203, 229], ["tau immunostaining", "OBSERVATION", 273, 291]]], ["Figure 6 illustrates Lrrk2-immunoreactive pathology in PDCG.", [["PDCG", "ANATOMY", 55, 59], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 21, 26], ["PDCG", "CANCER", 55, 59], ["Lrrk2", "PROTEIN", 21, 26], ["Figure", "TEST", 0, 6], ["Lrrk2", "TEST", 21, 26], ["immunoreactive pathology in PDCG", "PROBLEM", 27, 59], ["immunoreactive pathology", "OBSERVATION", 27, 51]]], ["The anti-Lrrk2 antibody labeled neurofibrillary tangles (Fig. 6A ) and Lewy bodies (not shown here), which were observed in 4 of 6 PDCG cases in the brainstem and amygdala.", [["brainstem", "ANATOMY", 149, 158], ["amygdala", "ANATOMY", 163, 171], ["anti-Lrrk2 antibody", "GENE_OR_GENE_PRODUCT", 4, 23], ["PDCG", "CANCER", 131, 135], ["brainstem", "CANCER", 149, 158], ["amygdala", "CANCER", 163, 171], ["anti-Lrrk2 antibody", "PROTEIN", 4, 23], ["The anti-Lrrk2 antibody", "TEST", 0, 23], ["neurofibrillary tangles", "TEST", 32, 55], ["Lewy bodies", "TEST", 71, 82], ["neurofibrillary tangles", "OBSERVATION", 32, 55], ["Lewy bodies", "OBSERVATION", 71, 82], ["brainstem", "ANATOMY", 149, 158], ["amygdala", "ANATOMY", 163, 171]]], ["In one case, Lewy bodies were also present in the neocortex.", [["neocortex", "ANATOMY", 50, 59], ["neocortex", "CANCER", 50, 59], ["Lewy bodies", "PROBLEM", 13, 24], ["Lewy bodies", "OBSERVATION", 13, 24], ["neocortex", "ANATOMY", 50, 59]]], ["In addition, glial pathology, including astrocytic plaques (Fig. 6B) , Bhazy[ granules (Fig. 6C) , thorn-shaped astrocytes (Fig. 6D) , and oligodendroglial coiled bodies (Fig. 6E , F) all showed strong Lrrk2 immunostaining.", [["glial", "ANATOMY", 13, 18], ["astrocytic plaques", "ANATOMY", 40, 58], ["Bhazy[ granules", "ANATOMY", 71, 86], ["astrocytes", "ANATOMY", 112, 122], ["oligodendroglial coiled bodies", "ANATOMY", 139, 169], ["glial pathology", "CANCER", 13, 28], ["astrocytic plaques", "CELLULAR_COMPONENT", 40, 58], ["granules", "CELLULAR_COMPONENT", 78, 86], ["astrocytes", "CELL", 112, 122], ["oligodendroglial coiled bodies", "CELLULAR_COMPONENT", 139, 169], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 202, 207], ["thorn-shaped astrocytes", "CELL_TYPE", 99, 122], ["oligodendroglial coiled bodies", "CELL_TYPE", 139, 169], ["Lrrk2", "PROTEIN", 202, 207], ["glial pathology", "TEST", 13, 28], ["astrocytic plaques", "PROBLEM", 40, 58], ["Bhazy[ granules (Fig. 6C", "PROBLEM", 71, 95], ["thorn-shaped astrocytes", "PROBLEM", 99, 122], ["oligodendroglial coiled bodies", "PROBLEM", 139, 169], ["strong Lrrk2 immunostaining", "PROBLEM", 195, 222], ["glial", "ANATOMY", 13, 18], ["pathology", "OBSERVATION", 19, 28], ["astrocytic plaques", "OBSERVATION", 40, 58], ["astrocytes", "ANATOMY", 112, 122], ["oligodendroglial", "ANATOMY", 139, 155], ["strong", "OBSERVATION_MODIFIER", 195, 201], ["Lrrk2 immunostaining", "OBSERVATION", 202, 222]]], ["Figure 7 illustrates Lrrk2 immunoreactivity in some other pathologies.", [["Lrrk2", "GENE_OR_GENE_PRODUCT", 21, 26], ["Lrrk2", "PROTEIN", 21, 26], ["Lrrk2 immunoreactivity", "TEST", 21, 43], ["some other pathologies", "PROBLEM", 47, 69], ["pathologies", "OBSERVATION", 58, 69]]], ["Pick bodies show strong immunoreaction with anti-Lrrk2 antibody where it colocalizes with phosphorylated tau (Fig. 7AYE ).", [["anti-Lrrk2 antibody", "GENE_OR_GENE_PRODUCT", 44, 63], ["tau", "GENE_OR_GENE_PRODUCT", 105, 108], ["Fig. 7AYE", "GENE_OR_GENE_PRODUCT", 110, 119], ["anti-Lrrk2 antibody", "PROTEIN", 44, 63], ["phosphorylated tau", "PROTEIN", 90, 108], ["Fig. 7AYE", "PROTEIN", 110, 119], ["strong immunoreaction", "PROBLEM", 17, 38], ["anti-Lrrk2 antibody", "PROBLEM", 44, 63], ["strong", "OBSERVATION_MODIFIER", 17, 23], ["immunoreaction", "OBSERVATION", 24, 38]]], ["Lrrk2-positive intraneuronal inclusions were observed in motor neurons of the anterior horn of the spinal cord (Fig. 7F ) and glial inclusions in the degenerating corticospinal tracts (Fig. 7G) in the ALS cases.", [["intraneuronal inclusions", "ANATOMY", 15, 39], ["motor neurons", "ANATOMY", 57, 70], ["anterior horn", "ANATOMY", 78, 91], ["spinal cord", "ANATOMY", 99, 110], ["glial inclusions", "ANATOMY", 126, 142], ["corticospinal tracts", "ANATOMY", 163, 183], ["ALS", "DISEASE", 201, 204], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 0, 5], ["motor neurons", "CELL", 57, 70], ["anterior horn", "MULTI-TISSUE_STRUCTURE", 78, 91], ["spinal cord", "ORGAN", 99, 110], ["glial inclusions", "CELLULAR_COMPONENT", 126, 142], ["corticospinal tracts", "MULTI-TISSUE_STRUCTURE", 163, 183], ["Lrrk2", "PROTEIN", 0, 5], ["motor neurons", "CELL_TYPE", 57, 70], ["Lrrk2", "TEST", 0, 5], ["positive intraneuronal inclusions", "PROBLEM", 6, 39], ["glial inclusions in the degenerating corticospinal tracts", "PROBLEM", 126, 183], ["positive", "OBSERVATION_MODIFIER", 6, 14], ["intraneuronal inclusions", "OBSERVATION", 15, 39], ["motor neurons", "OBSERVATION", 57, 70], ["anterior", "ANATOMY_MODIFIER", 78, 86], ["horn", "ANATOMY_MODIFIER", 87, 91], ["spinal cord", "ANATOMY", 99, 110], ["glial inclusions", "OBSERVATION", 126, 142], ["degenerating", "OBSERVATION_MODIFIER", 150, 162], ["corticospinal tracts", "ANATOMY", 163, 183]]], ["Intranuclear (Fig. 7H ) and some intracytoplasmic Lrrk2-positive inclusions were also observed in the brain of the 2 patients with Huntington disease.", [["brain", "ANATOMY", 102, 107], ["Huntington disease", "DISEASE", 131, 149], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 50, 55], ["brain", "ORGAN", 102, 107], ["patients", "ORGANISM", 117, 125], ["Lrrk2", "PROTEIN", 50, 55], ["patients", "SPECIES", 117, 125], ["Intranuclear (Fig. 7H", "TEST", 0, 21], ["some intracytoplasmic Lrrk2", "TEST", 28, 55], ["positive inclusions", "PROBLEM", 56, 75], ["Huntington disease", "PROBLEM", 131, 149], ["intracytoplasmic Lrrk2", "OBSERVATION", 33, 55], ["positive inclusions", "OBSERVATION", 56, 75], ["brain", "ANATOMY", 102, 107], ["Huntington disease", "OBSERVATION", 131, 149]]], ["Figure 8 illustrates Lrrk2-positive reactive microglia and reactive astrocytes in the temporal white matter of a case with DLBD.", [["microglia", "ANATOMY", 45, 54], ["astrocytes", "ANATOMY", 68, 78], ["temporal white matter", "ANATOMY", 86, 107], ["DLBD", "DISEASE", 123, 127], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 21, 26], ["microglia", "CELL", 45, 54], ["astrocytes", "CELL", 68, 78], ["DLBD", "CANCER", 123, 127], ["Lrrk2", "PROTEIN", 21, 26], ["positive reactive microglia", "CELL_TYPE", 27, 54], ["reactive astrocytes", "CELL_TYPE", 59, 78], ["Figure", "TEST", 0, 6], ["Lrrk2", "TEST", 21, 26], ["positive reactive microglia", "PROBLEM", 27, 54], ["reactive astrocytes", "PROBLEM", 59, 78], ["DLBD", "PROBLEM", 123, 127], ["positive", "OBSERVATION_MODIFIER", 27, 35], ["reactive microglia", "OBSERVATION", 36, 54], ["reactive astrocytes", "OBSERVATION", 59, 78], ["temporal", "OBSERVATION_MODIFIER", 86, 94], ["white matter", "OBSERVATION_MODIFIER", 95, 107]]], ["Adjacent sections were used for double immunofluorescence staining.", [["sections", "ANATOMY", 9, 17], ["Adjacent sections", "CANCER", 0, 17], ["Adjacent sections", "TEST", 0, 17], ["double immunofluorescence staining", "PROBLEM", 32, 66]]], ["On the section doubly immunostained for Lrrk2 (green fluorescence, Fig. 8C ) and CR3/43, which recognizes activated microglia (red fluorescence, Fig. 8D ), the orange merged image (Fig. 8E) indicates that the cell is an activated microglia.", [["microglia", "ANATOMY", 116, 125], ["cell", "ANATOMY", 209, 213], ["microglia", "ANATOMY", 230, 239], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 40, 45], ["green fluorescence, Fig. 8C", "GENE_OR_GENE_PRODUCT", 47, 74], ["CR3/43", "GENE_OR_GENE_PRODUCT", 81, 87], ["microglia", "CELL", 116, 125], ["cell", "CELL", 209, 213], ["microglia", "CELL", 230, 239], ["Lrrk2", "PROTEIN", 40, 45], ["CR3", "PROTEIN", 81, 84], ["43", "PROTEIN", 85, 87], ["activated microglia", "CELL_TYPE", 106, 125], ["activated microglia", "CELL_TYPE", 220, 239], ["Lrrk2", "TEST", 40, 45], ["green fluorescence", "TEST", 47, 65], ["Fig. 8C", "TEST", 67, 74], ["CR3", "TEST", 81, 84], ["red fluorescence", "TEST", 127, 143], ["an activated microglia", "PROBLEM", 217, 239], ["activated microglia", "OBSERVATION", 220, 239]]], ["Similarly, a section was double immunostained with anti-Lrrk2 antibody (green fluorescence, Fig. 8F ) and anti-GFAP (red fluorescence, Fig. 8G ).", [["anti-Lrrk2", "GENE_OR_GENE_PRODUCT", 51, 61], ["anti-GFAP", "GENE_OR_GENE_PRODUCT", 106, 115], ["anti-Lrrk2 antibody", "PROTEIN", 51, 70], ["anti-GFAP", "PROTEIN", 106, 115], ["a section", "TEST", 11, 20], ["anti-Lrrk2 antibody", "TREATMENT", 51, 70], ["green fluorescence", "TEST", 72, 90], ["anti-GFAP (red fluorescence", "TREATMENT", 106, 133]]], ["The orange merged image (Fig. 8H ) demonstrates the colocalization of Lrrk2 and GFAP in the same astrocytes.", [["astrocytes", "ANATOMY", 97, 107], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 70, 75], ["GFAP", "GENE_OR_GENE_PRODUCT", 80, 84], ["astrocytes", "CELL", 97, 107], ["Lrrk2", "PROTEIN", 70, 75], ["GFAP", "PROTEIN", 80, 84], ["astrocytes", "CELL_TYPE", 97, 107], ["the colocalization of Lrrk2 and GFAP", "TEST", 48, 84], ["Lrrk2", "OBSERVATION", 70, 75]]], ["Some Lrrk2-positive reactive microglia and a few astrocytes were also seen, particularly in the white matter in some PD, AD, DLBD, and PDCG cases.Immunoabsorption AssayTo verify the specificity of the Lrrk2 antibody, an immunoabsorption test was carried out using the synthetic peptide that was used for rabbit immunization (residues 2500Y2527; Novus Biologicals, Inc.; NB-300-268).", [["microglia", "ANATOMY", 29, 38], ["astrocytes", "ANATOMY", 49, 59], ["white matter", "ANATOMY", 96, 108], ["PD", "DISEASE", 117, 119], ["AD", "DISEASE", 121, 123], ["DLBD", "DISEASE", 125, 129], ["PDCG", "DISEASE", 135, 139], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 5, 10], ["microglia", "CELL", 29, 38], ["astrocytes", "CELL", 49, 59], ["DLBD", "CANCER", 125, 129], ["PDCG", "CANCER", 135, 139], ["Lrrk2 antibody", "GENE_OR_GENE_PRODUCT", 201, 215], ["rabbit", "ORGANISM", 304, 310], ["Lrrk2", "PROTEIN", 5, 10], ["microglia", "CELL_TYPE", 29, 38], ["astrocytes", "CELL_TYPE", 49, 59], ["Lrrk2 antibody", "PROTEIN", 201, 215], ["rabbit", "SPECIES", 304, 310], ["rabbit", "SPECIES", 304, 310], ["Some Lrrk2-positive reactive microglia", "PROBLEM", 0, 38], ["a few astrocytes", "PROBLEM", 43, 59], ["the white matter", "PROBLEM", 92, 108], ["DLBD", "TEST", 125, 129], ["the Lrrk2 antibody", "TEST", 197, 215], ["an immunoabsorption test", "TEST", 217, 241], ["the synthetic peptide", "TREATMENT", 264, 285], ["rabbit immunization", "TREATMENT", 304, 323], ["NB", "TEST", 370, 372], ["Lrrk2", "OBSERVATION", 5, 10], ["positive", "OBSERVATION_MODIFIER", 11, 19], ["reactive microglia", "OBSERVATION", 20, 38], ["few", "OBSERVATION_MODIFIER", 45, 48], ["astrocytes", "OBSERVATION", 49, 59], ["white matter", "OBSERVATION_MODIFIER", 96, 108], ["some PD", "OBSERVATION_MODIFIER", 112, 119]]], ["Figure 9 illustrates parallel immunostaining of adjacent sections with the Lrrk2 antibody demonstrating positive staining of neurofibrillary tangles (Fig. 9A ) and Pick bodies (Fig. 9C ) that were abolished with the immunoabsorbed Lrrk2 antibody ( Fig. 9B and D, respectively) .DISCUSSIONThe present results indicate that the LRRK2 gene and the Lrrk2 protein are constitutively expressed in all central nervous system cell types.", [["sections", "ANATOMY", 57, 65], ["central nervous system cell", "ANATOMY", 395, 422], ["sections", "MULTI-TISSUE_STRUCTURE", 57, 65], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 75, 80], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 231, 236], ["D", "GENE_OR_GENE_PRODUCT", 260, 261], ["LRRK2", "GENE_OR_GENE_PRODUCT", 326, 331], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 345, 350], ["central nervous system cell", "CELL", 395, 422], ["Lrrk2 antibody", "PROTEIN", 75, 89], ["immunoabsorbed Lrrk2 antibody", "PROTEIN", 216, 245], ["Fig. 9B and D", "PROTEIN", 248, 261], ["LRRK2 gene", "DNA", 326, 336], ["Lrrk2 protein", "PROTEIN", 345, 358], ["central nervous system cell types", "CELL_TYPE", 395, 428], ["adjacent sections", "TEST", 48, 65], ["the Lrrk2 antibody", "TEST", 71, 89], ["positive staining of neurofibrillary tangles", "PROBLEM", 104, 148], ["Pick bodies", "TEST", 164, 175], ["the immunoabsorbed Lrrk2 antibody", "TEST", 212, 245], ["the LRRK2 gene", "TEST", 322, 336], ["the Lrrk2 protein", "TEST", 341, 358], ["neurofibrillary tangles", "OBSERVATION", 125, 148], ["Lrrk2 protein", "OBSERVATION", 345, 358], ["central nervous system cell types", "OBSERVATION", 395, 428]]], ["LRRK2 has previously been reported to be expressed in human lung (9) , heart, and liver (8) .", [["lung", "ANATOMY", 60, 64], ["heart", "ANATOMY", 71, 76], ["liver", "ANATOMY", 82, 87], ["LRRK2", "GENE_OR_GENE_PRODUCT", 0, 5], ["human", "ORGANISM", 54, 59], ["lung", "ORGAN", 60, 64], ["heart", "ORGAN", 71, 76], ["liver", "ORGAN", 82, 87], ["LRRK2", "PROTEIN", 0, 5], ["human", "SPECIES", 54, 59], ["human", "SPECIES", 54, 59], ["LRRK2", "PROBLEM", 0, 5], ["human", "ANATOMY_MODIFIER", 54, 59], ["lung", "ANATOMY", 60, 64], ["heart", "ANATOMY", 71, 76], ["liver", "ANATOMY", 82, 87]]], ["We found Lrrk2 to be expressed in the soluble fraction of human brain, liver, and heart indicating that the gene is translated and the product must have physiological functions in widespread tissues of the body.", [["brain", "ANATOMY", 64, 69], ["liver", "ANATOMY", 71, 76], ["heart", "ANATOMY", 82, 87], ["tissues", "ANATOMY", 191, 198], ["body", "ANATOMY", 206, 210], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 9, 14], ["human", "ORGANISM", 58, 63], ["brain", "ORGAN", 64, 69], ["liver", "ORGAN", 71, 76], ["heart", "ORGAN", 82, 87], ["tissues", "TISSUE", 191, 198], ["body", "ORGANISM_SUBDIVISION", 206, 210], ["Lrrk2", "PROTEIN", 9, 14], ["human", "SPECIES", 58, 63], ["human", "SPECIES", 58, 63], ["Lrrk2", "PROBLEM", 9, 14], ["Lrrk2", "OBSERVATION", 9, 14], ["human brain", "ANATOMY", 58, 69], ["liver", "ANATOMY", 71, 76], ["heart", "ANATOMY", 82, 87], ["widespread", "OBSERVATION_MODIFIER", 180, 190], ["body", "ANATOMY", 206, 210]]], ["This is consistent with the report of Giasson et al (27) who, in addition to human brain, detected the protein in multiple mouse organs.DISCUSSIONHowever, it is not understood why it is the brain, and especially the SN, which is primarily affected by mutations that alter the functional state of the protein.", [["brain", "ANATOMY", 83, 88], ["organs", "ANATOMY", 129, 135], ["brain", "ANATOMY", 190, 195], ["human", "ORGANISM", 77, 82], ["brain", "ORGAN", 83, 88], ["mouse", "ORGANISM", 123, 128], ["organs", "ORGAN", 129, 135], ["brain", "ORGAN", 190, 195], ["human", "SPECIES", 77, 82], ["mouse", "SPECIES", 123, 128], ["human", "SPECIES", 77, 82], ["mouse", "SPECIES", 123, 128], ["consistent with", "UNCERTAINTY", 8, 23], ["brain", "ANATOMY", 83, 88], ["brain", "ANATOMY", 190, 195]]], ["We found that the anti-Lrrk2 antibody we used, which recognizes the far Cterminal sequence in the molecule, colocalized with Lewy bodies in the SN of sporadic and familial PD cases.", [["SN", "ANATOMY", 144, 146], ["PD", "DISEASE", 172, 174], ["anti-Lrrk2 antibody", "GENE_OR_GENE_PRODUCT", 18, 37], ["anti-Lrrk2 antibody", "PROTEIN", 18, 37], ["Cterminal sequence", "PROTEIN", 72, 90], ["the anti-Lrrk2 antibody", "TEST", 14, 37], ["Lewy bodies", "OBSERVATION", 125, 136]]], ["It also identified cortical Lewy bodies in cases with DLBD.", [["cortical Lewy bodies", "ANATOMY", 19, 39], ["cortical Lewy bodies", "DISEASE", 19, 39], ["DLBD", "DISEASE", 54, 58], ["cortical", "OBSERVATION_MODIFIER", 19, 27], ["Lewy bodies", "OBSERVATION", 28, 39]]], ["Double immunofluorescence staining clearly showed the overlap of Lrrk2 and >-synuclein immunoreactions in Lewy bodies in the SN of PD cases.", [["Lewy bodies", "ANATOMY", 106, 117], ["SN", "ANATOMY", 125, 127], ["PD", "DISEASE", 131, 133], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 65, 70], [">-synuclein", "GENE_OR_GENE_PRODUCT", 75, 86], ["Lrrk2", "PROTEIN", 65, 70], ["Double immunofluorescence staining", "TEST", 0, 34], ["Lrrk2", "PROBLEM", 65, 70], [">-synuclein immunoreactions in Lewy bodies", "PROBLEM", 75, 117], ["synuclein immunoreactions", "OBSERVATION", 77, 102], ["Lewy bodies", "OBSERVATION", 106, 117]]], ["In PDCG, which is known to be associated with parkinsonian features, Lrrk2 labeled not only a subset of neurofibrillary tangles, but in 4 of the 6 cases identified Lewy bodies in the brainstem and in one case cortical Lewy bodies.DISCUSSIONThe astrocytic and oligodendroglial tau aggregations, which are typical of this disorder, all showed a distinctive Lrrk2-positive immunoreaction.", [["brainstem", "ANATOMY", 183, 192], ["cortical Lewy bodies", "ANATOMY", 209, 229], ["astrocytic", "ANATOMY", 244, 254], ["oligodendroglial", "ANATOMY", 259, 275], ["parkinsonian", "DISEASE", 46, 58], ["PDCG", "CANCER", 3, 7], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 69, 74], ["brainstem", "ORGAN", 183, 192], ["astrocytic", "CELL", 244, 254], ["oligodendroglial tau", "GENE_OR_GENE_PRODUCT", 259, 279], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 355, 360], ["PDCG", "PROTEIN", 3, 7], ["Lrrk2", "PROTEIN", 69, 74], ["Lrrk2", "PROTEIN", 355, 360], ["parkinsonian features", "PROBLEM", 46, 67], ["neurofibrillary tangles", "PROBLEM", 104, 127], ["Lewy bodies in the brainstem", "PROBLEM", 164, 192], ["The astrocytic and oligodendroglial tau aggregations", "PROBLEM", 240, 292], ["this disorder", "PROBLEM", 315, 328], ["a distinctive Lrrk2-positive immunoreaction", "PROBLEM", 341, 384], ["known to be associated with", "UNCERTAINTY", 18, 45], ["parkinsonian", "OBSERVATION", 46, 58], ["neurofibrillary tangles", "OBSERVATION", 104, 127], ["Lewy bodies", "OBSERVATION", 164, 175], ["brainstem", "ANATOMY", 183, 192], ["cortical", "ANATOMY_MODIFIER", 209, 217], ["Lewy bodies", "OBSERVATION", 218, 229], ["astrocytic", "OBSERVATION_MODIFIER", 244, 254], ["oligodendroglial tau aggregations", "OBSERVATION", 259, 292], ["distinctive", "OBSERVATION_MODIFIER", 343, 354], ["Lrrk2", "OBSERVATION", 355, 360], ["positive immunoreaction", "OBSERVATION", 361, 384]]], ["These included astrocytic plaques, thorn-shaped astrocytes, and coiled bodies of oligodendrocytes.", [["astrocytic plaques", "ANATOMY", 15, 33], ["astrocytes", "ANATOMY", 48, 58], ["coiled bodies", "ANATOMY", 64, 77], ["oligodendrocytes", "ANATOMY", 81, 97], ["astrocytic plaques", "PATHOLOGICAL_FORMATION", 15, 33], ["astrocytes", "CELL", 48, 58], ["oligodendrocytes", "CELL", 81, 97], ["thorn-shaped astrocytes", "CELL_TYPE", 35, 58], ["oligodendrocytes", "CELL_TYPE", 81, 97], ["astrocytic plaques", "PROBLEM", 15, 33], ["thorn-shaped astrocytes", "PROBLEM", 35, 58], ["coiled bodies of oligodendrocytes", "PROBLEM", 64, 97], ["astrocytic plaques", "OBSERVATION", 15, 33], ["thorn", "OBSERVATION_MODIFIER", 35, 40], ["shaped astrocytes", "OBSERVATION", 41, 58], ["oligodendrocytes", "OBSERVATION", 81, 97]]], ["Such glial pathologic changes are known to occur in other tauopathies such as progressive supranuclear palsy and corticobasal degeneration.", [["glial", "ANATOMY", 5, 10], ["supranuclear", "ANATOMY", 90, 102], ["corticobasal", "ANATOMY", 113, 125], ["tauopathies", "DISEASE", 58, 69], ["supranuclear palsy", "DISEASE", 90, 108], ["corticobasal degeneration", "DISEASE", 113, 138], ["glial", "CELL", 5, 10], ["Such glial pathologic changes", "PROBLEM", 0, 29], ["other tauopathies", "PROBLEM", 52, 69], ["progressive supranuclear palsy", "PROBLEM", 78, 108], ["corticobasal degeneration", "PROBLEM", 113, 138], ["glial", "OBSERVATION_MODIFIER", 5, 10], ["pathologic", "OBSERVATION", 11, 21], ["progressive", "OBSERVATION_MODIFIER", 78, 89], ["supranuclear palsy", "OBSERVATION", 90, 108], ["corticobasal degeneration", "OBSERVATION", 113, 138]]], ["Coiled bodies are also known to occur in ALS and multiple system atrophy.", [["Coiled bodies", "ANATOMY", 0, 13], ["ALS", "DISEASE", 41, 44], ["multiple system atrophy", "DISEASE", 49, 72], ["Coiled bodies", "PROBLEM", 0, 13], ["ALS", "PROBLEM", 41, 44], ["multiple system atrophy", "PROBLEM", 49, 72], ["bodies", "ANATOMY_MODIFIER", 7, 13], ["multiple", "OBSERVATION_MODIFIER", 49, 57], ["system", "OBSERVATION_MODIFIER", 58, 64], ["atrophy", "OBSERVATION", 65, 72]]], ["It is intriguing that Pick bodies, which are tau-positive but >synuclein negative, are strongly immunoreactive for Lrrk2.DISCUSSIONThese immunohistochemical results differ from the report of Giasson et al, who used an antibody raised against residues 1246Y1265 of Lrrk2 (24) .", [["Pick bodies", "ANATOMY", 22, 33], ["synuclein", "GENE_OR_GENE_PRODUCT", 63, 72], ["Lrrk2.DISCUSSIONThese", "PROTEIN", 115, 136], ["Lrrk2", "PROTEIN", 264, 269], ["an antibody", "TEST", 215, 226], ["Lrrk2", "TEST", 264, 269]]], ["Their antibody demonstrated cytoplasmic staining of normal neurons, but failed to detect >-synuclein inclusions, neurofibrillary tangles, and glial inclusions.", [["cytoplasmic", "ANATOMY", 28, 39], ["neurons", "ANATOMY", 59, 66], ["neurofibrillary tangles", "ANATOMY", 113, 136], ["glial inclusions", "ANATOMY", 142, 158], ["cytoplasmic", "ORGANISM_SUBSTANCE", 28, 39], ["neurons", "CELL", 59, 66], ["synuclein", "GENE_OR_GENE_PRODUCT", 91, 100], ["glial inclusions", "CELLULAR_COMPONENT", 142, 158], ["normal neurons", "CELL_TYPE", 52, 66], ["Their antibody", "TEST", 0, 14], ["cytoplasmic staining of normal neurons", "PROBLEM", 28, 66], ["synuclein inclusions", "PROBLEM", 91, 111], ["neurofibrillary tangles", "PROBLEM", 113, 136], ["glial inclusions", "PROBLEM", 142, 158], ["cytoplasmic staining", "OBSERVATION", 28, 48], ["normal neurons", "OBSERVATION", 52, 66], ["neurofibrillary tangles", "OBSERVATION", 113, 136], ["glial inclusions", "OBSERVATION", 142, 158]]], ["It is possible that the midregion sequence against which this antibody was raised is not as exposed in pathologic lesions as the far C-terminal sequence.", [["lesions", "ANATOMY", 114, 121], ["C", "CHEMICAL", 133, 134], ["pathologic lesions", "CANCER", 103, 121], ["midregion sequence", "DNA", 24, 42], ["C-terminal sequence", "DNA", 133, 152], ["the midregion sequence", "PROBLEM", 20, 42], ["this antibody", "TEST", 57, 70], ["pathologic lesions", "PROBLEM", 103, 121], ["pathologic", "OBSERVATION_MODIFIER", 103, 113], ["lesions", "OBSERVATION", 114, 121]]], ["It may also be that the antibody used in our experiments detects Cterminal fragments that are retained in an insoluble state and possibly bound to the pathologic deposits.", [["Cterminal fragments", "ANATOMY", 65, 84], ["Cterminal fragments", "DNA", 65, 84], ["the antibody", "TREATMENT", 20, 32], ["Cterminal fragments", "PROBLEM", 65, 84], ["the pathologic deposits", "PROBLEM", 147, 170], ["may also be", "UNCERTAINTY", 3, 14], ["Cterminal fragments", "OBSERVATION", 65, 84], ["retained", "OBSERVATION_MODIFIER", 94, 102], ["pathologic", "OBSERVATION_MODIFIER", 151, 161], ["deposits", "OBSERVATION", 162, 170]]], ["The fact that >synuclein strongly binds to Lrrk2 sequences on Lrrk2 peptide membranes is evidence in favor of an in vivo interaction between Lrrk2 and >-synuclein.DISCUSSIONThe fact that Lrrk2 appears to be present in neuronal and glial inclusions in several neurodegenerative disorders may indicate that a common link may exist in the pathogenesis of these disorders.", [["Lrrk2 peptide membranes", "ANATOMY", 62, 85], ["neuronal", "ANATOMY", 218, 226], ["glial inclusions", "ANATOMY", 231, 247], ["neurodegenerative disorders", "DISEASE", 259, 286], ["synuclein", "GENE_OR_GENE_PRODUCT", 15, 24], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 43, 48], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 62, 67], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 141, 146], ["Lrrk2", "GENE_OR_GENE_PRODUCT", 187, 192], ["neuronal", "CELL", 218, 226], ["glial inclusions", "CELLULAR_COMPONENT", 231, 247], ["Lrrk2 sequences", "DNA", 43, 58], ["Lrrk2", "PROTEIN", 141, 146], ["Lrrk2", "PROTEIN", 187, 192], ["Lrrk2 sequences", "TEST", 43, 58], ["Lrrk2 peptide membranes", "TREATMENT", 62, 85], ["Lrrk2", "PROBLEM", 187, 192], ["neuronal and glial inclusions", "PROBLEM", 218, 247], ["several neurodegenerative disorders", "PROBLEM", 251, 286], ["these disorders", "PROBLEM", 352, 367], ["Lrrk2", "OBSERVATION", 187, 192], ["appears to be", "UNCERTAINTY", 193, 206], ["neuronal", "ANATOMY", 218, 226], ["glial inclusions", "OBSERVATION", 231, 247], ["several", "OBSERVATION_MODIFIER", 251, 258], ["neurodegenerative disorders", "OBSERVATION", 259, 286]]], ["It must be emphasized, however, that these are preliminary observations on a limited number of cases using a single antibody.", [["a single antibody", "TREATMENT", 107, 124]]], ["The findings will need to be confirmed using multiple antibodies on a much larger series of cases.", [["multiple antibodies", "PROTEIN", 45, 64], ["multiple antibodies", "TREATMENT", 45, 64], ["a much larger series of cases", "TREATMENT", 68, 97]]], ["The finding that LRRK2 mutations were also found in a few cases with AD also reinforces this possibility.", [["AD", "DISEASE", 69, 71], ["LRRK2", "GENE_OR_GENE_PRODUCT", 17, 22], ["LRRK2", "PROTEIN", 17, 22], ["LRRK2 mutations", "PROBLEM", 17, 32], ["LRRK2 mutations", "OBSERVATION", 17, 32]]], ["This is in harmony with previous findings showing that in familial PD cases with LRRK2 mutations, heterogenic pathologic changes were observed at autopsy.", [["PD", "DISEASE", 67, 69], ["LRRK2", "GENE_OR_GENE_PRODUCT", 81, 86], ["LRRK2", "PROTEIN", 81, 86], ["LRRK2 mutations", "PROBLEM", 81, 96], ["heterogenic pathologic changes", "PROBLEM", 98, 128], ["heterogenic", "OBSERVATION_MODIFIER", 98, 109], ["pathologic", "OBSERVATION", 110, 120]]], ["Further histologic, biochemical, and molecular analyses studies may reveal that a common thread exists, possibly in protein phosphorylations carried out by its MAPKKK domain.", [["MAPKKK", "GENE_OR_GENE_PRODUCT", 160, 166], ["MAPKKK domain", "PROTEIN", 160, 173], ["Further histologic", "TEST", 0, 18], ["molecular analyses studies", "TEST", 37, 63], ["protein phosphorylations", "TEST", 116, 140]]]], "PMC7294299": [["IntroductionCurrently, the pandemic that has developed has some antecedents related to the SARS-CoV 2002 outbreak, of which several works have been carried out to develop new drugs directed to specific regions of the coronavirus (SARS-CoV 2002).", [["SARS", "DISEASE", 91, 95], ["coronavirus", "ORGANISM", 217, 228], ["SARS-CoV 2002", "ORGANISM", 230, 243], ["SARS-CoV", "SPECIES", 91, 99], ["the SARS", "PROBLEM", 87, 95], ["new drugs", "TREATMENT", 171, 180], ["the coronavirus", "PROBLEM", 213, 228]]], ["The disease caused by SARS-CoV-2 generates a wide range of signs and symptoms, causing respiratory, gastrointestinal and even death diseases [1,2].", [["respiratory", "ANATOMY", 87, 98], ["gastrointestinal", "ANATOMY", 100, 116], ["SARS", "DISEASE", 22, 26], ["respiratory, gastrointestinal and even death", "DISEASE", 87, 131], ["SARS-CoV-2", "ORGANISM", 22, 32], ["SARS-CoV", "SPECIES", 22, 30], ["The disease", "PROBLEM", 0, 11], ["SARS", "PROBLEM", 22, 26], ["signs and symptoms", "PROBLEM", 59, 77], ["respiratory, gastrointestinal and even death diseases", "PROBLEM", 87, 140], ["disease", "OBSERVATION", 4, 11], ["gastrointestinal", "ANATOMY", 100, 116]]], ["In the first reports on the SARS-CoV-2 (COVID-19) outbreak in China reported that the average age was 47 years, with an incubation period of 4 days, 41.9% were women, with fever 88.7% and cough the 67.8% of the patients in the study, accompanied by lymphocytopenia in 83.2%.", [["SARS", "DISEASE", 28, 32], ["fever", "DISEASE", 172, 177], ["cough", "DISEASE", 188, 193], ["lymphocytopenia", "DISEASE", 249, 264], ["women", "ORGANISM", 160, 165], ["patients", "ORGANISM", 211, 219], ["women", "SPECIES", 160, 165], ["patients", "SPECIES", 211, 219], ["SARS-CoV", "SPECIES", 28, 36], ["the SARS", "TEST", 24, 32], ["CoV", "TEST", 33, 36], ["COVID", "TEST", 40, 45], ["fever", "PROBLEM", 172, 177], ["cough", "TEST", 188, 193], ["the study", "TEST", 223, 232], ["lymphocytopenia", "PROBLEM", 249, 264], ["lymphocytopenia", "OBSERVATION", 249, 264]]], ["It should be noted that there was no specific treatment for SARS-CoV-2, the treatment was based on antibiotics in 58.0% and antivirals (Oseltamivir) in 36.2% [2].", [["SARS", "DISEASE", 60, 64], ["Oseltamivir", "CHEMICAL", 136, 147], ["Oseltamivir", "CHEMICAL", 136, 147], ["Oseltamivir", "SIMPLE_CHEMICAL", 136, 147], ["SARS-CoV", "SPECIES", 60, 68], ["SARS", "PROBLEM", 60, 64], ["CoV", "TEST", 65, 68], ["the treatment", "TREATMENT", 72, 85], ["antibiotics", "TREATMENT", 99, 110], ["antivirals (Oseltamivir)", "TREATMENT", 124, 148]]], ["Recently, new antivirals have been developed, focusing on RNA-Dependent RNA Polymerase (RdRp), Polyproteins (3CLpro and PLpro), Spike Protein (S-Protein) [3,4] and membrane fusion inhibitors (HR1 and HR2 of S-Protein) [[5], [6], [7]] from SARS-CoV-2.", [["membrane", "ANATOMY", 164, 172], ["Polymerase", "GENE_OR_GENE_PRODUCT", 76, 86], ["RdRp", "GENE_OR_GENE_PRODUCT", 88, 92], ["Polyproteins", "GENE_OR_GENE_PRODUCT", 95, 107], ["3CLpro", "GENE_OR_GENE_PRODUCT", 109, 115], ["PLpro", "GENE_OR_GENE_PRODUCT", 120, 125], ["Spike Protein", "GENE_OR_GENE_PRODUCT", 128, 141], ["S-Protein) [3,4]", "GENE_OR_GENE_PRODUCT", 143, 159], ["membrane", "CELLULAR_COMPONENT", 164, 172], ["[7]", "SIMPLE_CHEMICAL", 229, 232], ["SARS-CoV-2", "ORGANISM", 239, 249], ["RNA-Dependent RNA Polymerase", "PROTEIN", 58, 86], ["RdRp", "PROTEIN", 88, 92], ["Polyproteins", "PROTEIN", 95, 107], ["3CLpro", "PROTEIN", 109, 115], ["PLpro", "PROTEIN", 120, 125], ["Spike Protein", "PROTEIN", 128, 141], ["S-Protein) [3,4] and membrane fusion inhibitors", "PROTEIN", 143, 190], ["HR1", "PROTEIN", 192, 195], ["HR2", "PROTEIN", 200, 203], ["new antivirals", "TREATMENT", 10, 24], ["RNA", "TEST", 58, 61], ["Dependent RNA Polymerase", "PROBLEM", 62, 86], ["RdRp", "TEST", 88, 92], ["Polyproteins (3CLpro and PLpro", "TREATMENT", 95, 125], ["Spike Protein", "TEST", 128, 141], ["Protein", "TEST", 145, 152], ["membrane fusion inhibitors", "TREATMENT", 164, 190], ["HR1", "TEST", 192, 195], ["HR2", "TEST", 200, 203], ["S-Protein", "TEST", 207, 216], ["SARS", "TEST", 239, 243], ["CoV", "TEST", 244, 247]]], ["Without a treatment that demonstrating an advantage therapeutic, which demonstrates the urgent need for the development of specific drugs against a selective target that alters the evolution of this disease.IntroductionThere are works related to SARS-CoV, for the development of a specific drug, which have reported the development of peptides related to the key protein for the interaction between the SARS-CoV and the host cell; the angiotensin-converting enzyme 2 (ACE2), reporting amino acids sequence that was essential for drug development (Glu22, Glu23, Lys26, Asp30, Lys31, His34, Glu35, Glu37, Asp38, Glu56 and Glu57) [8].", [["cell", "ANATOMY", 425, 429], ["SARS", "DISEASE", 246, 250], ["angiotensin", "CHEMICAL", 435, 446], ["amino acids", "CHEMICAL", 485, 496], ["amino acids", "CHEMICAL", 485, 496], ["Glu22", "CHEMICAL", 547, 552], ["Glu23", "CHEMICAL", 554, 559], ["Lys26", "CHEMICAL", 561, 566], ["Asp30", "CHEMICAL", 568, 573], ["Lys31", "CHEMICAL", 575, 580], ["His34", "CHEMICAL", 582, 587], ["Glu35", "CHEMICAL", 589, 594], ["Glu37", "CHEMICAL", 596, 601], ["Asp38", "CHEMICAL", 603, 608], ["Glu56", "CHEMICAL", 610, 615], ["Glu57", "CHEMICAL", 620, 625], ["SARS-CoV", "ORGANISM", 246, 254], ["SARS-CoV", "ORGANISM", 403, 411], ["host cell", "CELL", 420, 429], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 435, 466], ["ACE2", "GENE_OR_GENE_PRODUCT", 468, 472], ["amino acids", "AMINO_ACID", 485, 496], ["Glu22", "GENE_OR_GENE_PRODUCT", 547, 552], ["Glu23", "GENE_OR_GENE_PRODUCT", 554, 559], ["Lys26", "GENE_OR_GENE_PRODUCT", 561, 566], ["Asp30", "GENE_OR_GENE_PRODUCT", 568, 573], ["Lys31", "GENE_OR_GENE_PRODUCT", 575, 580], ["His34", "GENE_OR_GENE_PRODUCT", 582, 587], ["Glu35", "GENE_OR_GENE_PRODUCT", 589, 594], ["Glu37", "GENE_OR_GENE_PRODUCT", 596, 601], ["Asp38", "GENE_OR_GENE_PRODUCT", 603, 608], ["Glu56", "GENE_OR_GENE_PRODUCT", 610, 615], ["Glu57", "AMINO_ACID", 620, 625], ["SARS-CoV", "PROTEIN", 403, 411], ["angiotensin-converting enzyme 2", "PROTEIN", 435, 466], ["ACE2", "PROTEIN", 468, 472], ["amino acids sequence", "PROTEIN", 485, 505], ["SARS-CoV", "SPECIES", 246, 254], ["SARS-CoV", "SPECIES", 403, 411], ["a treatment", "TREATMENT", 8, 19], ["specific drugs", "TREATMENT", 123, 137], ["this disease", "PROBLEM", 194, 206], ["SARS", "PROBLEM", 246, 250], ["peptides", "PROBLEM", 335, 343], ["the SARS", "TEST", 399, 407], ["the host cell", "PROBLEM", 416, 429], ["the angiotensin", "TEST", 431, 446], ["converting enzyme", "TEST", 447, 464], ["amino acids sequence", "TEST", 485, 505], ["drug development", "TEST", 529, 545], ["Glu22", "TEST", 547, 552], ["Glu23", "TEST", 554, 559], ["Lys26", "TEST", 561, 566], ["Asp30", "TEST", 568, 573], ["Lys31", "TEST", 575, 580], ["His34", "TEST", 582, 587], ["Glu35", "TEST", 589, 594], ["Glu37", "TEST", 596, 601], ["Asp38", "TEST", 603, 608], ["Glu56", "TEST", 610, 615], ["host cell", "OBSERVATION", 420, 429]]], ["As well as another work that reported the important amino acids between the region binding domain (RBD) of the S-Protein SARS-CoV with the ACE2 (Gln24, Thr27, Lys31, His34, Glu37, Asp38, Tyr41, Gln42, Leu45, Leu79, Met82, Tyr83, Asn90, Gln325, Glu329, Asn330, Lys353 and Gly354 in ACE2) [9].", [["amino acids", "CHEMICAL", 52, 63], ["amino acids", "CHEMICAL", 52, 63], ["Gln24", "CHEMICAL", 145, 150], ["Thr27", "CHEMICAL", 152, 157], ["Lys31", "CHEMICAL", 159, 164], ["His34", "CHEMICAL", 166, 171], ["Glu37", "CHEMICAL", 173, 178], ["Asp38", "CHEMICAL", 180, 185], ["Tyr41", "CHEMICAL", 187, 192], ["Gln42", "CHEMICAL", 194, 199], ["Leu45", "CHEMICAL", 201, 206], ["Leu79", "CHEMICAL", 208, 213], ["Met82", "CHEMICAL", 215, 220], ["Tyr83", "CHEMICAL", 222, 227], ["Asn90", "CHEMICAL", 229, 234], ["Gln325", "CHEMICAL", 236, 242], ["Glu329", "CHEMICAL", 244, 250], ["Asn330", "CHEMICAL", 252, 258], ["Lys353", "CHEMICAL", 260, 266], ["Gly354", "CHEMICAL", 271, 277], ["amino acids", "AMINO_ACID", 52, 63], ["S-Protein SARS-CoV", "GENE_OR_GENE_PRODUCT", 111, 129], ["ACE2", "GENE_OR_GENE_PRODUCT", 139, 143], ["Gln24", "GENE_OR_GENE_PRODUCT", 145, 150], ["Thr27", "GENE_OR_GENE_PRODUCT", 152, 157], ["Lys31", "GENE_OR_GENE_PRODUCT", 159, 164], ["His34", "GENE_OR_GENE_PRODUCT", 166, 171], ["Glu37", "GENE_OR_GENE_PRODUCT", 173, 178], ["Asp38", "GENE_OR_GENE_PRODUCT", 180, 185], ["Tyr41", "GENE_OR_GENE_PRODUCT", 187, 192], ["Gln42", "GENE_OR_GENE_PRODUCT", 194, 199], ["Leu45", "GENE_OR_GENE_PRODUCT", 201, 206], ["Leu79", "GENE_OR_GENE_PRODUCT", 208, 213], ["Met82", "GENE_OR_GENE_PRODUCT", 215, 220], ["Tyr83", "GENE_OR_GENE_PRODUCT", 222, 227], ["Asn90", "GENE_OR_GENE_PRODUCT", 229, 234], ["Gln325", "GENE_OR_GENE_PRODUCT", 236, 242], ["Glu329", "GENE_OR_GENE_PRODUCT", 244, 250], ["Asn330", "GENE_OR_GENE_PRODUCT", 252, 258], ["Lys353", "GENE_OR_GENE_PRODUCT", 260, 266], ["Gly354 in ACE2", "GENE_OR_GENE_PRODUCT", 271, 285], ["region binding domain", "PROTEIN", 76, 97], ["RBD", "PROTEIN", 99, 102], ["S-Protein SARS-CoV", "PROTEIN", 111, 129], ["ACE2", "PROTEIN", 139, 143], ["Gln24", "PROTEIN", 145, 150], ["Thr27", "PROTEIN", 152, 157], ["Lys31", "PROTEIN", 159, 164], ["His34", "PROTEIN", 166, 171], ["Glu37", "PROTEIN", 173, 178], ["Asp38", "PROTEIN", 180, 185], ["Tyr41", "PROTEIN", 187, 192], ["Gln42", "PROTEIN", 194, 199], ["Leu45", "PROTEIN", 201, 206], ["Leu79", "PROTEIN", 208, 213], ["Met82", "PROTEIN", 215, 220], ["Tyr83", "PROTEIN", 222, 227], ["Asn90", "PROTEIN", 229, 234], ["Gln325", "PROTEIN", 236, 242], ["Glu329", "PROTEIN", 244, 250], ["Asn330", "PROTEIN", 252, 258], ["Lys353", "PROTEIN", 260, 266], ["Gly354", "PROTEIN", 271, 277], ["ACE2", "PROTEIN", 281, 285], ["SARS-CoV", "SPECIES", 121, 129], ["the important amino acids", "PROBLEM", 38, 63], ["the S-Protein SARS", "TEST", 107, 125], ["the ACE2", "TEST", 135, 143], ["Thr27", "TEST", 152, 157], ["Lys31", "TEST", 159, 164], ["His34", "TEST", 166, 171], ["Glu37", "TEST", 173, 178], ["Asp38", "TEST", 180, 185], ["Tyr41", "TEST", 187, 192], ["Gln42", "TEST", 194, 199], ["Leu45", "TEST", 201, 206], ["Leu79", "TEST", 208, 213], ["Met82", "TEST", 215, 220], ["Tyr83", "TEST", 222, 227], ["Asn90", "TEST", 229, 234], ["Gln325", "TEST", 236, 242], ["Glu329", "TEST", 244, 250], ["Asn330", "TEST", 252, 258]]], ["Currently, has been reported the crystallographic structure of the interaction between SARS-CoV2-RBD and ACE2 (Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353, and Arg357 in ACE2) [10], which we used in this study.IntroductionThere are reports of the development of pharmacological compounds that have an effect on the interaction of SARS-CoV and ACE2 [11,12], as well as focused on important proteins in the SARS-CoV such as the Main protease (Mpro), which propose synthesized aromatic compounds [13].IntroductionAlthough there is a great similarity between SARS-CoV and SARS-CoV-2 sequence (sequence identity of almost 80%) [14], the same results of compounds or antibodies that were tested in SARS-CoV are not presented in SARS-CoV-2; the differences in the residues found in SARS-CoV-2 explain the resistance generates against compounds and antibodies (S230) [15] [16].IntroductionThe affinity of SARS-CoV-2 with ACE2 has been determined to be up to 20 times higher than that reported in SARS-CoV in 2002, which may help explain why the complications that develop are more serious, and the probability of contagion is greater, having a great impact on the health of the population [17].", [["SARS", "DISEASE", 335, 339], ["SARS", "DISEASE", 560, 564], ["SARS", "DISEASE", 902, 906], ["SARS", "DISEASE", 993, 997], ["Asp30", "CHEMICAL", 118, 123], ["His34", "CHEMICAL", 125, 130], ["Tyr41", "CHEMICAL", 132, 137], ["Gln42", "CHEMICAL", 139, 144], ["Met82", "CHEMICAL", 146, 151], ["Lys353", "CHEMICAL", 153, 159], ["Arg357", "CHEMICAL", 165, 171], ["SARS-CoV2-RBD", "GENE_OR_GENE_PRODUCT", 87, 100], ["ACE2", "GENE_OR_GENE_PRODUCT", 105, 109], ["Gln24", "GENE_OR_GENE_PRODUCT", 111, 116], ["Asp30", "GENE_OR_GENE_PRODUCT", 118, 123], ["His34", "GENE_OR_GENE_PRODUCT", 125, 130], ["Tyr41", "GENE_OR_GENE_PRODUCT", 132, 137], ["Gln42", "GENE_OR_GENE_PRODUCT", 139, 144], ["Met82", "GENE_OR_GENE_PRODUCT", 146, 151], ["Lys353", "GENE_OR_GENE_PRODUCT", 153, 159], ["Arg357 in ACE2", "GENE_OR_GENE_PRODUCT", 165, 179], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 335, 343], ["ACE2", "GENE_OR_GENE_PRODUCT", 348, 352], ["SARS-CoV", "ORGANISM", 410, 418], ["Main protease", "GENE_OR_GENE_PRODUCT", 431, 444], ["Mpro", "GENE_OR_GENE_PRODUCT", 446, 450], ["SARS-CoV", "ORGANISM", 560, 568], ["SARS-CoV-2", "ORGANISM", 573, 583], ["SARS-CoV", "ORGANISM", 697, 705], ["SARS-CoV-2", "ORGANISM", 727, 737], ["SARS-CoV-2", "ORGANISM", 780, 790], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 902, 912], ["ACE2", "GENE_OR_GENE_PRODUCT", 918, 922], ["SARS-CoV", "ORGANISM", 993, 1001], ["CoV2", "PROTEIN", 92, 96], ["RBD", "PROTEIN", 97, 100], ["ACE2", "PROTEIN", 105, 109], ["Gln24", "PROTEIN", 111, 116], ["Asp30", "PROTEIN", 118, 123], ["His34", "PROTEIN", 125, 130], ["Tyr41", "PROTEIN", 132, 137], ["Gln42", "PROTEIN", 139, 144], ["Met82", "PROTEIN", 146, 151], ["Lys353", "PROTEIN", 153, 159], ["Arg357", "PROTEIN", 165, 171], ["ACE2", "PROTEIN", 175, 179], ["ACE2", "PROTEIN", 348, 352], ["Main protease", "PROTEIN", 431, 444], ["Mpro", "PROTEIN", 446, 450], ["SARS-CoV and SARS-CoV-2 sequence", "DNA", 560, 592], ["antibodies", "PROTEIN", 666, 676], ["ACE2", "PROTEIN", 918, 922], ["SARS-CoV", "SPECIES", 335, 343], ["SARS-CoV", "SPECIES", 410, 418], ["SARS-CoV", "SPECIES", 560, 568], ["SARS-CoV", "SPECIES", 573, 581], ["SARS-CoV", "SPECIES", 697, 705], ["SARS-CoV", "SPECIES", 727, 735], ["SARS-CoV", "SPECIES", 780, 788], ["SARS-CoV", "SPECIES", 902, 910], ["SARS-CoV", "SPECIES", 993, 1001], ["SARS", "TEST", 87, 91], ["CoV2", "TEST", 92, 96], ["ACE2", "TEST", 105, 109], ["Asp30", "TEST", 118, 123], ["His34", "TEST", 125, 130], ["Tyr41", "TEST", 132, 137], ["Gln42", "TEST", 139, 144], ["Met82", "TEST", 146, 151], ["this study", "TEST", 204, 214], ["pharmacological compounds", "PROBLEM", 267, 292], ["the Main protease (Mpro)", "TREATMENT", 427, 451], ["SARS", "TEST", 560, 564], ["SARS", "TEST", 573, 577], ["CoV-2 sequence", "TEST", 578, 592], ["sequence identity", "TEST", 594, 611], ["antibodies", "PROBLEM", 666, 676], ["the residues", "PROBLEM", 758, 770], ["SARS", "PROBLEM", 780, 784], ["CoV", "TEST", 785, 788], ["SARS", "PROBLEM", 902, 906], ["CoV", "TEST", 907, 910], ["ACE2", "TREATMENT", 918, 922], ["the complications", "PROBLEM", 1038, 1055], ["greater", "OBSERVATION_MODIFIER", 1123, 1130]]], ["It was determined that in SARS-CoV, ACE2 plays a very important role so that it can cross the cell membrane and be able to replicate the SARS-CoV; taking into account that SARS-CoV-2 also interacts with ACE2.", [["cell membrane", "ANATOMY", 94, 107], ["SARS", "DISEASE", 26, 30], ["SARS", "DISEASE", 137, 141], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 26, 34], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["cell membrane", "CELLULAR_COMPONENT", 94, 107], ["SARS-CoV", "ORGANISM", 137, 145], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 172, 182], ["ACE2", "GENE_OR_GENE_PRODUCT", 203, 207], ["ACE2", "PROTEIN", 36, 40], ["ACE2", "PROTEIN", 203, 207], ["SARS-CoV", "SPECIES", 26, 34], ["SARS-CoV", "SPECIES", 137, 145]]], ["Recently, an important protein for the interaction of ACE2 with SARS-CoV2, TMPRSS2, was identified, where it is demonstrated that if it is limited to this protein, the interaction of the virus with the cell can be affected [18].IntroductionSome works for the development of new drugs against SARS-CoV-2, propose epitopes as potential sites of interaction [19], as well as using Docking and compound libraries, as well as looking for a repositioning of drugs [5], to search for compounds that interact with some SARS-CoV-2 region and thus be able to prevent interaction with ACE2 [20].", [["cell", "ANATOMY", 202, 206], ["SARS", "DISEASE", 292, 296], ["ACE2", "GENE_OR_GENE_PRODUCT", 54, 58], ["SARS-CoV2", "GENE_OR_GENE_PRODUCT", 64, 73], ["TMPRSS2", "GENE_OR_GENE_PRODUCT", 75, 82], ["cell", "CELL", 202, 206], ["SARS-CoV-2", "ORGANISM", 292, 302], ["ACE2", "GENE_OR_GENE_PRODUCT", 574, 578], ["ACE2", "PROTEIN", 54, 58], ["CoV2", "PROTEIN", 69, 73], ["TMPRSS2", "PROTEIN", 75, 82], ["epitopes", "PROTEIN", 312, 320], ["SARS-CoV-2 region", "DNA", 511, 528], ["ACE2", "PROTEIN", 574, 578], ["SARS-CoV", "SPECIES", 292, 300], ["SARS", "TEST", 64, 68], ["TMPRSS2", "TEST", 75, 82], ["this protein", "PROBLEM", 150, 162], ["the virus", "PROBLEM", 183, 192], ["new drugs", "TREATMENT", 274, 283], ["SARS", "PROBLEM", 292, 296], ["Docking and compound libraries", "TREATMENT", 378, 408], ["a repositioning of drugs", "TREATMENT", 433, 457]]], ["A drug that was proposed to interact in ACE2, is Arbidol, which recently reported the crystallographic structure, demonstrating that Arbidol interacts in S-protein (domain S2) from SARS-CoV-2 [21], which demonstrates the low existence of drugs that are directly interacting with ACE2.IntroductionWe use the amino acids reported in the crystallographic structure of the interaction between the S-protein-RBD of SARS-CoV-2 and ACE2 (Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353 and Arg357 in ACE2) [10,22], therefore, using the crystallographic structure of ACE2 (PDB 1R42), we carried out a Docking directed to these mentioned residues using a library of compounds (EXPRESS-pick Collection from Chembridge Corp.) to select the best compounds, and that these can affect the interaction between ACE2 and SARS-CoV-2, making these results an important contribution to establishing the foundations that allow the development of a drug that optimizes the resolution of this pandemic.Preparation of receptor protein and definition of binding sites ::: Method detailsAtomic coordinates of Angiotensin converting enzyme 2 (ACE2) were obtained from the Protein Data Bank (PDB: 1R42).", [["Arbidol", "CHEMICAL", 49, 56], ["Arbidol", "CHEMICAL", 133, 140], ["amino acids", "CHEMICAL", 307, 318], ["Angiotensin", "CHEMICAL", 1084, 1095], ["Arbidol", "CHEMICAL", 49, 56], ["Arbidol", "CHEMICAL", 133, 140], ["amino acids", "CHEMICAL", 307, 318], ["Asp30", "CHEMICAL", 438, 443], ["His34", "CHEMICAL", 445, 450], ["Tyr41", "CHEMICAL", 452, 457], ["Gln42", "CHEMICAL", 459, 464], ["Met82", "CHEMICAL", 466, 471], ["Lys353", "CHEMICAL", 473, 479], ["Arg357", "CHEMICAL", 484, 490], ["ACE2", "GENE_OR_GENE_PRODUCT", 40, 44], ["Arbidol", "SIMPLE_CHEMICAL", 49, 56], ["Arbidol", "SIMPLE_CHEMICAL", 133, 140], ["ACE2", "GENE_OR_GENE_PRODUCT", 279, 283], ["amino acids", "AMINO_ACID", 307, 318], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 410, 420], ["ACE2", "GENE_OR_GENE_PRODUCT", 425, 429], ["Gln24", "GENE_OR_GENE_PRODUCT", 431, 436], ["Asp30", "GENE_OR_GENE_PRODUCT", 438, 443], ["His34", "GENE_OR_GENE_PRODUCT", 445, 450], ["Tyr41", "GENE_OR_GENE_PRODUCT", 452, 457], ["Gln42", "GENE_OR_GENE_PRODUCT", 459, 464], ["Met82", "GENE_OR_GENE_PRODUCT", 466, 471], ["Lys353", "GENE_OR_GENE_PRODUCT", 473, 479], ["Arg357", "GENE_OR_GENE_PRODUCT", 484, 490], ["ACE2", "GENE_OR_GENE_PRODUCT", 494, 498], ["ACE2", "GENE_OR_GENE_PRODUCT", 560, 564], ["PDB 1R42", "GENE_OR_GENE_PRODUCT", 566, 574], ["ACE2", "GENE_OR_GENE_PRODUCT", 796, 800], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 805, 815], ["Angiotensin converting enzyme 2", "GENE_OR_GENE_PRODUCT", 1084, 1115], ["ACE2", "GENE_OR_GENE_PRODUCT", 1117, 1121], ["ACE2", "PROTEIN", 40, 44], ["Arbidol", "PROTEIN", 133, 140], ["S-protein", "PROTEIN", 154, 163], ["domain S2", "PROTEIN", 165, 174], ["ACE2", "PROTEIN", 279, 283], ["S-protein", "PROTEIN", 393, 402], ["RBD", "PROTEIN", 403, 406], ["SARS-CoV-2", "PROTEIN", 410, 420], ["ACE2", "PROTEIN", 425, 429], ["Gln24", "PROTEIN", 431, 436], ["Asp30", "PROTEIN", 438, 443], ["His34", "PROTEIN", 445, 450], ["Tyr41", "PROTEIN", 452, 457], ["Gln42", "PROTEIN", 459, 464], ["Met82", "PROTEIN", 466, 471], ["Lys353", "PROTEIN", 473, 479], ["Arg357", "PROTEIN", 484, 490], ["ACE2", "PROTEIN", 494, 498], ["ACE2", "PROTEIN", 560, 564], ["PDB 1R42", "PROTEIN", 566, 574], ["ACE2", "PROTEIN", 796, 800], ["receptor protein", "PROTEIN", 995, 1011], ["binding sites", "PROTEIN", 1030, 1043], ["Angiotensin converting enzyme 2", "PROTEIN", 1084, 1115], ["ACE2", "PROTEIN", 1117, 1121], ["SARS-CoV", "SPECIES", 805, 813], ["Arbidol", "TREATMENT", 49, 56], ["Arbidol interacts in S-protein (domain S2", "PROBLEM", 133, 174], ["SARS", "TEST", 181, 185], ["CoV", "TEST", 186, 189], ["the amino acids", "TREATMENT", 303, 318], ["the S-protein", "TEST", 389, 402], ["SARS", "TEST", 410, 414], ["CoV", "TEST", 415, 418], ["ACE2", "TEST", 425, 429], ["Gln24", "TEST", 431, 436], ["Asp30", "TEST", 438, 443], ["His34", "TEST", 445, 450], ["Tyr41", "TEST", 452, 457], ["a Docking", "TREATMENT", 592, 601], ["a library of compounds", "TREATMENT", 645, 667], ["ACE2", "TEST", 796, 800], ["this pandemic", "PROBLEM", 966, 979], ["receptor protein", "TREATMENT", 995, 1011], ["Angiotensin converting enzyme", "TEST", 1084, 1113], ["low existence", "OBSERVATION_MODIFIER", 221, 234]]], ["The structure was used as protein targets for docking procedures.", [["docking procedures", "TREATMENT", 46, 64]]], ["The protonation and energy minimization of PDB file was performed using Molecular Operating Environment (MOE) software with the default parameters and the CHARMM27 force field [23,24].", [["PDB file", "TEST", 43, 51]]], ["We select one region to interaction in ACE2 (Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353 and Arg357) [10].Screening library ::: Method detailsThe EXPRESS-pick Collection Stock of the small molecule screening library from Chembridge Corp. was used for docking [25].", [["Gln24", "CHEMICAL", 45, 50], ["Asp30", "CHEMICAL", 52, 57], ["His34", "CHEMICAL", 59, 64], ["Tyr41", "CHEMICAL", 66, 71], ["Gln42", "CHEMICAL", 73, 78], ["Met82", "CHEMICAL", 80, 85], ["Lys353", "CHEMICAL", 87, 93], ["Arg357", "CHEMICAL", 98, 104], ["ACE2", "GENE_OR_GENE_PRODUCT", 39, 43], ["Gln24", "GENE_OR_GENE_PRODUCT", 45, 50], ["Asp30", "GENE_OR_GENE_PRODUCT", 52, 57], ["His34", "GENE_OR_GENE_PRODUCT", 59, 64], ["Tyr41", "GENE_OR_GENE_PRODUCT", 66, 71], ["Gln42", "GENE_OR_GENE_PRODUCT", 73, 78], ["Met82", "GENE_OR_GENE_PRODUCT", 80, 85], ["Lys353", "GENE_OR_GENE_PRODUCT", 87, 93], ["ACE2", "PROTEIN", 39, 43], ["Gln24", "PROTEIN", 45, 50], ["Asp30", "PROTEIN", 52, 57], ["His34", "PROTEIN", 59, 64], ["Tyr41", "PROTEIN", 66, 71], ["Gln42", "PROTEIN", 73, 78], ["Met82", "PROTEIN", 80, 85], ["ACE2", "TEST", 39, 43], ["Asp30", "TEST", 52, 57], ["His34", "TEST", 59, 64], ["Tyr41", "TEST", 66, 71], ["small", "OBSERVATION_MODIFIER", 188, 193]]], ["This collection of small molecule screening compounds contains over 500,000 chemical compounds that fulfill the druggable properties of Lipinski's rules [26,27] and cover a broad area of chemical space.Molecular docking ::: Method detailsFor docking, the receptors were kept rigid, while the ligand atoms were released to move to a maximal number of rotatable bonds.", [["small molecule screening compounds", "PROBLEM", 19, 53], ["Lipinski's rules", "TEST", 136, 152], ["a broad area of chemical space", "PROBLEM", 171, 201], ["rigid", "PROBLEM", 275, 280], ["small", "OBSERVATION_MODIFIER", 19, 24], ["molecule", "OBSERVATION_MODIFIER", 25, 33], ["broad", "OBSERVATION_MODIFIER", 173, 178], ["chemical space", "OBSERVATION", 187, 201], ["rotatable bonds", "OBSERVATION", 350, 365]]], ["All crystallographic water molecules were deleted from the initial structures.", [["crystallographic water molecules", "PROTEIN", 4, 36], ["All crystallographic water molecules", "TREATMENT", 0, 36]]], ["High-throughput virtual molecular docking was carried out [25,28] by means of the software AutoDock and MOE, using default parameters (Placement: Triangle Matcher, Rescoring 1: London \u0394G, Refinement: Forcefield, Rescoring 2: London \u0394G, for each ligand up to 20 conformations were generated and saved).Calculation of the free binding energy (\u0394Gbinding) ::: Method detailsThe binding affinity of each complex (Ligand-protein) was estimated with the ratio of General Born vs Volume Integral (GB/VI), using parameters in MOE [29,30].", [["Ligand-protein", "PROTEIN", 408, 422]]], ["General Born or non-bonded interaction energies comprise Van der Waals, Coulomb electrostatic interactions and implied solvent interaction energies [30].Selection of compounds ::: Method detailsEach compound was simulated with up to 50 conformations, to select the best compounds, the average of the \u0394Gbinding interaction value of up to 20 conformers, the description of chemical properties by PhysChem - ACD/Labs [31], the theoretical toxicity [32], carcinogenicity and mutagenicity [33] were considered.", [["toxicity", "DISEASE", 436, 444], ["PhysChem", "SIMPLE_CHEMICAL", 394, 402], ["Labs", "TEST", 409, 413], ["the theoretical toxicity", "PROBLEM", 420, 444], ["mutagenicity", "TEST", 471, 483]]], ["The calculated interactions between ACE2 and compounds were visualized with Ligand-interaction interactions implemented in MOE.Selection of compounds by docking ::: ResultsAmong the interactions in ACE2 (Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353 and Arg357) with compounds (Fig. 1), the selection criteria of the top poses, out of almost 500,000 compounds from Chembridge library, were the frequency of the conformers of each compound and the \u0394Gbinding values between \u22126.0 to \u22127.3 kcal/mol\u22121.", [["Gln24", "CHEMICAL", 204, 209], ["Asp30", "CHEMICAL", 211, 216], ["His34", "CHEMICAL", 218, 223], ["Tyr41", "CHEMICAL", 225, 230], ["Gln42", "CHEMICAL", 232, 237], ["Met82", "CHEMICAL", 239, 244], ["Lys353", "CHEMICAL", 246, 252], ["Arg357", "CHEMICAL", 257, 263], ["ACE2", "GENE_OR_GENE_PRODUCT", 36, 40], ["ACE2", "GENE_OR_GENE_PRODUCT", 198, 202], ["Gln24", "GENE_OR_GENE_PRODUCT", 204, 209], ["Asp30", "GENE_OR_GENE_PRODUCT", 211, 216], ["His34", "GENE_OR_GENE_PRODUCT", 218, 223], ["Tyr41", "GENE_OR_GENE_PRODUCT", 225, 230], ["Gln42", "GENE_OR_GENE_PRODUCT", 232, 237], ["Met82", "GENE_OR_GENE_PRODUCT", 239, 244], ["Lys353", "GENE_OR_GENE_PRODUCT", 246, 252], ["Arg357", "AMINO_ACID", 257, 263], ["ACE2", "PROTEIN", 36, 40], ["ACE2", "PROTEIN", 198, 202], ["Gln24", "PROTEIN", 204, 209], ["Asp30", "PROTEIN", 211, 216], ["His34", "PROTEIN", 218, 223], ["Tyr41", "PROTEIN", 225, 230], ["Gln42", "PROTEIN", 232, 237], ["Met82", "PROTEIN", 239, 244], ["Lys353", "PROTEIN", 246, 252], ["Arg357", "PROTEIN", 257, 263], ["ACE2", "TEST", 36, 40], ["ACE2", "TEST", 198, 202], ["Gln24", "TEST", 204, 209], ["Asp30", "TEST", 211, 216], ["His34", "TEST", 218, 223], ["Tyr41", "TEST", 225, 230], ["Gln42", "TEST", 232, 237], ["Met82", "TEST", 239, 244], ["Arg", "TEST", 257, 260], ["the selection criteria", "TEST", 290, 312], ["the \u0394Gbinding values", "TEST", 446, 466]]], ["We made the choice of compounds based on the average of the score from up to 20 conformers per compound and better probability to be safe in humans.", [["humans", "ORGANISM", 141, 147], ["humans", "SPECIES", 141, 147], ["humans", "SPECIES", 141, 147]]], ["We selected 20 compounds depicted here as C1 to C20 (Table 1) from the Express-pick Collection Stock of the small molecule screening Chembridge library (ChemBridge Corporation) and the analysis of the interaction of each compound chosen with ACE2, was carried out with the interaction report (in Supplementary material Tables S1\u2013S20).Best values of interaction of compounds C1\u2013C20 with ACE2 ::: ResultsFor selection of the best compounds, the analysis from Docking's results was carried out, taking into account the average of the interaction \u0394Gbinding (15 to 20 conformers) was determined, as well as the standard deviation for each compound.", [["C1\u2013C20", "CHEMICAL", 374, 380], ["ACE2", "GENE_OR_GENE_PRODUCT", 242, 246], ["C1\u2013C20", "SIMPLE_CHEMICAL", 374, 380], ["ACE2", "GENE_OR_GENE_PRODUCT", 386, 390], ["ACE2", "PROTEIN", 242, 246], ["ACE2", "PROTEIN", 386, 390], ["the analysis", "TEST", 181, 193], ["ACE2", "TREATMENT", 242, 246], ["the analysis", "TEST", 439, 451], ["Docking's results", "TEST", 457, 474], ["small", "OBSERVATION_MODIFIER", 108, 113]]], ["Subsequently, the theoretical toxicity was evaluated with two website (ProTox-II - Prediction of TOXicity and PreADMET web server, prediction of carcinogenicity and mutagenicity, Table 2).", [["toxicity", "DISEASE", 30, 38], ["the theoretical toxicity", "PROBLEM", 14, 38], ["TOXicity", "PROBLEM", 97, 105]]], ["Besides, we determined 30 compounds with good results, but with significant theoretical toxicity effects, we show them in Table S21.Best values of interaction of compounds C1\u2013C20 with ACE2 ::: ResultsThe description of the chemical properties of each compound (C1\u2013C20, Table S22), ADME (Table S23) and theoretical toxicity (Table S24), are shown in the supplemental material.Interaction of compounds C1\u2013C20 with ACE2 ::: ResultsTo propose the probable interaction sites between each compound (C1\u2013C20) with ACE2 we analyzed up to 20 conformers of each compound that showed the better \u0394Gbinding values of interaction in amino acids Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353 and Arg357 (Fig. 1).", [["toxicity", "DISEASE", 88, 96], ["toxicity", "DISEASE", 314, 322], ["amino acids", "CHEMICAL", 618, 629], ["C1\u2013C20", "CHEMICAL", 172, 178], ["C1\u2013C20", "CHEMICAL", 261, 267], ["C1\u2013C20", "CHEMICAL", 400, 406], ["amino acids", "CHEMICAL", 618, 629], ["Gln24", "CHEMICAL", 630, 635], ["Asp30", "CHEMICAL", 637, 642], ["His34", "CHEMICAL", 644, 649], ["Tyr41", "CHEMICAL", 651, 656], ["Gln42", "CHEMICAL", 658, 663], ["Met82", "CHEMICAL", 665, 670], ["Lys353", "CHEMICAL", 672, 678], ["Arg357", "CHEMICAL", 683, 689], ["C1\u2013C20", "SIMPLE_CHEMICAL", 172, 178], ["ACE2", "GENE_OR_GENE_PRODUCT", 184, 188], ["C1\u2013C20", "SIMPLE_CHEMICAL", 261, 267], ["Table S22", "SIMPLE_CHEMICAL", 269, 278], ["ADME", "SIMPLE_CHEMICAL", 281, 285], ["C1\u2013C20", "SIMPLE_CHEMICAL", 400, 406], ["ACE2", "GENE_OR_GENE_PRODUCT", 412, 416], ["C1\u2013C20", "SIMPLE_CHEMICAL", 493, 499], ["ACE2", "GENE_OR_GENE_PRODUCT", 506, 510], ["amino acids", "AMINO_ACID", 618, 629], ["Gln24", "GENE_OR_GENE_PRODUCT", 630, 635], ["Asp30", "GENE_OR_GENE_PRODUCT", 637, 642], ["His34", "GENE_OR_GENE_PRODUCT", 644, 649], ["Tyr41", "GENE_OR_GENE_PRODUCT", 651, 656], ["Gln42", "GENE_OR_GENE_PRODUCT", 658, 663], ["Met82", "GENE_OR_GENE_PRODUCT", 665, 670], ["Lys353", "GENE_OR_GENE_PRODUCT", 672, 678], ["Arg357", "AMINO_ACID", 683, 689], ["ACE2", "PROTEIN", 184, 188], ["ACE2", "PROTEIN", 412, 416], ["ACE2", "PROTEIN", 506, 510], ["Asp30", "PROTEIN", 637, 642], ["Tyr41", "PROTEIN", 651, 656], ["Gln42", "PROTEIN", 658, 663], ["Met82", "PROTEIN", 665, 670], ["significant theoretical toxicity effects", "PROBLEM", 64, 104], ["ADME (Table S23)", "TREATMENT", 281, 297], ["theoretical toxicity", "PROBLEM", 302, 322], ["interaction sites", "PROBLEM", 452, 469], ["ACE2", "TEST", 506, 510], ["amino acids", "TEST", 618, 629], ["Asp30", "TEST", 637, 642], ["His34", "TEST", 644, 649], ["Tyr41", "TEST", 651, 656], ["Gln42", "TEST", 658, 663], ["Met82", "TEST", 665, 670]]], ["From docking's result (Tables S1\u2013S20), we determined the main amino acids in ACE2 to interact with the 20 compounds, these are Lys26, His34, Glu37, Asp38, Tyr41, Gln96, Gln325, Asn330, Lys353, Arg357, Ala386, Ala387, Pro389 and Arg393 (Table 2).", [["amino acids", "CHEMICAL", 62, 73], ["amino acids", "CHEMICAL", 62, 73], ["Lys26", "CHEMICAL", 127, 132], ["His34", "CHEMICAL", 134, 139], ["Glu37", "CHEMICAL", 141, 146], ["Asp38", "CHEMICAL", 148, 153], ["Tyr41", "CHEMICAL", 155, 160], ["Gln96", "CHEMICAL", 162, 167], ["Gln325", "CHEMICAL", 169, 175], ["Asn330", "CHEMICAL", 177, 183], ["Lys353", "CHEMICAL", 185, 191], ["Arg", "CHEMICAL", 193, 196], ["Ala386", "CHEMICAL", 201, 207], ["Ala387", "CHEMICAL", 209, 215], ["Pro389", "CHEMICAL", 217, 223], ["Arg393", "CHEMICAL", 228, 234], ["amino acids", "AMINO_ACID", 62, 73], ["ACE2", "GENE_OR_GENE_PRODUCT", 77, 81], ["Lys26", "GENE_OR_GENE_PRODUCT", 127, 132], ["His34", "GENE_OR_GENE_PRODUCT", 134, 139], ["Glu37", "GENE_OR_GENE_PRODUCT", 141, 146], ["Asp38", "GENE_OR_GENE_PRODUCT", 148, 153], ["Tyr41", "GENE_OR_GENE_PRODUCT", 155, 160], ["Gln96", "GENE_OR_GENE_PRODUCT", 162, 167], ["Gln325", "GENE_OR_GENE_PRODUCT", 169, 175], ["Asn330", "GENE_OR_GENE_PRODUCT", 177, 183], ["Lys353", "GENE_OR_GENE_PRODUCT", 185, 191], ["Arg357", "AMINO_ACID", 193, 199], ["Ala386", "GENE_OR_GENE_PRODUCT", 201, 207], ["Ala387", "GENE_OR_GENE_PRODUCT", 209, 215], ["Pro389", "AMINO_ACID", 217, 223], ["Arg393", "AMINO_ACID", 228, 234], ["ACE2", "PROTEIN", 77, 81], ["Lys26", "TEST", 127, 132], ["His34", "TEST", 134, 139], ["Glu37", "TEST", 141, 146], ["Asp38", "TEST", 148, 153], ["Tyr41", "TEST", 155, 160], ["Gln96", "TEST", 162, 167], ["Gln325", "TEST", 169, 175], ["Arg", "TEST", 193, 196], ["Ala386", "TEST", 201, 207], ["Ala387", "TEST", 209, 215], ["Pro389", "TEST", 217, 223], ["Arg", "TEST", 228, 231]]], ["The interaction of each compound and its conformers in ACE2 are shown in the supplementary material (Figs.", [["ACE2", "GENE_OR_GENE_PRODUCT", 55, 59], ["ACE2", "PROTEIN", 55, 59]]], ["S1\u2013S20).DiscussionSeveral works have been done to develop new drugs against SARS-CoV-2 [[5], [6], [7],19,20,34], testing antibodies or compounds that affect SARS-CoV 2002 [17], also characterizing and proposing potential targets for the interaction between SARS-CoV-2 and ACE2 [18,19], to determine the effectiveness of some therapeutic options that can contribute/favor the resolution of the pandemic that is developing worldwide.", [["SARS", "DISEASE", 76, 80], ["S1\u2013S20", "GENE_OR_GENE_PRODUCT", 0, 6], ["SARS-CoV", "ORGANISM", 76, 84], ["[5], [6], [7],19,20,34]", "SIMPLE_CHEMICAL", 88, 111], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 257, 267], ["ACE2", "GENE_OR_GENE_PRODUCT", 272, 276], ["S1", "PROTEIN", 0, 2], ["ACE2", "PROTEIN", 272, 276], ["SARS-CoV", "SPECIES", 76, 84], ["SARS-CoV", "SPECIES", 257, 265], ["new drugs", "TREATMENT", 58, 67], ["SARS", "TEST", 76, 80], ["CoV", "TEST", 81, 84], ["testing antibodies", "TEST", 113, 131], ["SARS", "TEST", 157, 161], ["SARS", "TEST", 257, 261], ["CoV", "TEST", 262, 265], ["ACE2", "TEST", 272, 276], ["the pandemic", "PROBLEM", 389, 401], ["pandemic", "OBSERVATION", 393, 401]]], ["In this study we carried out a Docking aimed at the reported residues that are important for the SARS-CoV-2 RBD/spike protein, to interact with ACE2 [10,22], we determined that residues Lys26, His34, Glu37, Asp38, Tyr41, Gln96, Gln325, Asn330, Lys353, Arg357, Ala386, Ala387, Pro389 and Arg393 are important for the majority of the compounds that we propose to interact in ACE2 (Table 1).", [["Lys26", "CHEMICAL", 186, 191], ["His34", "CHEMICAL", 193, 198], ["Glu37", "CHEMICAL", 200, 205], ["Asp38", "CHEMICAL", 207, 212], ["Tyr41", "CHEMICAL", 214, 219], ["Gln96", "CHEMICAL", 221, 226], ["Gln325", "CHEMICAL", 228, 234], ["Asn330", "CHEMICAL", 236, 242], ["Lys353", "CHEMICAL", 244, 250], ["Arg", "CHEMICAL", 252, 255], ["Ala386", "CHEMICAL", 260, 266], ["Ala387", "CHEMICAL", 268, 274], ["Pro389", "CHEMICAL", 276, 282], ["Arg393", "CHEMICAL", 287, 293], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 97, 107], ["ACE2", "GENE_OR_GENE_PRODUCT", 144, 148], ["Lys26", "GENE_OR_GENE_PRODUCT", 186, 191], ["His34", "GENE_OR_GENE_PRODUCT", 193, 198], ["Glu37", "GENE_OR_GENE_PRODUCT", 200, 205], ["Asp38", "GENE_OR_GENE_PRODUCT", 207, 212], ["Tyr41", "GENE_OR_GENE_PRODUCT", 214, 219], ["Gln96", "GENE_OR_GENE_PRODUCT", 221, 226], ["Gln325", "GENE_OR_GENE_PRODUCT", 228, 234], ["Asn330", "GENE_OR_GENE_PRODUCT", 236, 242], ["Lys353", "GENE_OR_GENE_PRODUCT", 244, 250], ["Arg357", "AMINO_ACID", 252, 258], ["Ala386", "GENE_OR_GENE_PRODUCT", 260, 266], ["Ala387", "GENE_OR_GENE_PRODUCT", 268, 274], ["Pro389", "GENE_OR_GENE_PRODUCT", 276, 282], ["Arg393", "GENE_OR_GENE_PRODUCT", 287, 293], ["ACE2 (Table 1", "GENE_OR_GENE_PRODUCT", 373, 386], ["SARS-CoV-2 RBD", "PROTEIN", 97, 111], ["spike protein", "PROTEIN", 112, 125], ["ACE2", "PROTEIN", 144, 148], ["ACE2", "PROTEIN", 373, 377], ["Table 1", "PROTEIN", 379, 386], ["this study", "TEST", 3, 13], ["the SARS", "TEST", 93, 101], ["spike protein", "PROBLEM", 112, 125], ["ACE2", "TEST", 144, 148], ["residues", "TEST", 177, 185], ["Lys26", "TEST", 186, 191], ["His34", "TEST", 193, 198], ["Glu37", "TEST", 200, 205], ["Asp38", "TEST", 207, 212], ["Tyr41", "TEST", 214, 219], ["Gln96", "TEST", 221, 226], ["Arg", "TEST", 252, 255]]], ["Furthermore, we propose that the interaction site in ACE2 presents little change in the structural conformation when the S-protein-RBD is present, since we perform an alignment and superposition of the three-dimensional structures, of the apo-ACE2 (PDB: 1R42) and the ACE2 with RBD (PDB: 6M17) and there is an RMSD between them of 2.4 \u00c5 (Fig. S21), which shows that the interaction of ACE2 with RBD does not affect the three-dimensional conformation, moreover, the amino acids that we take into account to do the Docking (amino acids Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353 and Arg357), they are in similar positions in both structures, it helps us to propose that the interaction site is maintained, and this could facilitate competition for the site of interaction in ACE2 for the compounds that we propose.", [["amino acids", "CHEMICAL", 465, 476], ["amino acids", "CHEMICAL", 522, 533], ["amino acids", "CHEMICAL", 465, 476], ["amino acids", "CHEMICAL", 522, 533], ["Gln24", "CHEMICAL", 534, 539], ["Asp30", "CHEMICAL", 541, 546], ["His34", "CHEMICAL", 548, 553], ["Tyr41", "CHEMICAL", 555, 560], ["Gln42", "CHEMICAL", 562, 567], ["Met82", "CHEMICAL", 569, 574], ["Lys353", "CHEMICAL", 576, 582], ["Arg357", "CHEMICAL", 587, 593], ["ACE2", "GENE_OR_GENE_PRODUCT", 53, 57], ["apo-ACE2", "GENE_OR_GENE_PRODUCT", 239, 247], ["ACE2", "GENE_OR_GENE_PRODUCT", 268, 272], ["ACE2", "GENE_OR_GENE_PRODUCT", 385, 389], ["amino acids", "AMINO_ACID", 465, 476], ["amino acids", "AMINO_ACID", 522, 533], ["Gln24", "GENE_OR_GENE_PRODUCT", 534, 539], ["Asp30", "GENE_OR_GENE_PRODUCT", 541, 546], ["His34", "GENE_OR_GENE_PRODUCT", 548, 553], ["Tyr41", "GENE_OR_GENE_PRODUCT", 555, 560], ["Gln42", "GENE_OR_GENE_PRODUCT", 562, 567], ["Met82", "GENE_OR_GENE_PRODUCT", 569, 574], ["Lys353", "GENE_OR_GENE_PRODUCT", 576, 582], ["Arg357", "GENE_OR_GENE_PRODUCT", 587, 593], ["ACE2", "GENE_OR_GENE_PRODUCT", 779, 783], ["ACE2", "PROTEIN", 53, 57], ["S-protein", "PROTEIN", 121, 130], ["RBD", "PROTEIN", 131, 134], ["apo-ACE2", "PROTEIN", 239, 247], ["PDB: 1R42", "PROTEIN", 249, 258], ["ACE2", "PROTEIN", 268, 272], ["RBD", "PROTEIN", 278, 281], ["6M17", "PROTEIN", 288, 292], ["ACE2", "PROTEIN", 385, 389], ["RBD", "PROTEIN", 395, 398], ["Asp30", "PROTEIN", 541, 546], ["His34", "PROTEIN", 548, 553], ["Tyr41", "PROTEIN", 555, 560], ["Gln42", "PROTEIN", 562, 567], ["Met82", "PROTEIN", 569, 574], ["Arg357", "PROTEIN", 587, 593], ["ACE2", "PROTEIN", 779, 783], ["the interaction site", "PROBLEM", 29, 49], ["the S-protein-RBD", "PROBLEM", 117, 134], ["PDB", "TEST", 283, 286], ["RBD", "PROBLEM", 395, 398], ["the amino acids", "TREATMENT", 461, 476], ["amino acids", "TEST", 522, 533], ["Asp30", "TEST", 541, 546], ["His34", "TEST", 548, 553], ["little", "OBSERVATION_MODIFIER", 67, 73], ["change", "OBSERVATION_MODIFIER", 74, 80], ["RBD", "OBSERVATION", 131, 134], ["RMSD", "OBSERVATION", 310, 314]]], ["Also, it has been reported that these amino acids are very important for the interaction of this type of virus with ACE2 [8,9,11], based on this results, we propose these 20 compounds (C1\u2013C20) could be tested by some working group that has performed in vitro assays with ACE2 and SARS-CoV-2 [[15], [16], [17], [18],22].DiscussionWhat advantages could the approach of directing drug development to the region of interaction in ACE2 with RBD have in S-Protein?", [["amino acids", "CHEMICAL", 38, 49], ["RBD", "DISEASE", 436, 439], ["amino acids", "CHEMICAL", 38, 49], ["amino acids", "AMINO_ACID", 38, 49], ["ACE2", "GENE_OR_GENE_PRODUCT", 116, 120], ["C1\u2013C20", "SIMPLE_CHEMICAL", 185, 191], ["ACE2", "GENE_OR_GENE_PRODUCT", 271, 275], ["[15], [16], [17], [18],22]", "SIMPLE_CHEMICAL", 292, 318], ["ACE2", "GENE_OR_GENE_PRODUCT", 426, 430], ["ACE2", "PROTEIN", 116, 120], ["ACE2", "PROTEIN", 271, 275], ["ACE2", "PROTEIN", 426, 430], ["RBD", "PROTEIN", 436, 439], ["S-Protein", "PROTEIN", 448, 457], ["these amino acids", "TREATMENT", 32, 49], ["C1\u2013C20", "TREATMENT", 185, 191], ["vitro assays", "TEST", 253, 265], ["ACE2", "TEST", 271, 275], ["SARS", "TEST", 280, 284], ["CoV", "TEST", 285, 288], ["RBD", "PROBLEM", 436, 439]]], ["Proposing a different way to attack COVID-19 could help the treatments that are currently being investigated.", [["COVID-19", "CHEMICAL", 36, 44], ["COVID-19", "CHEMICAL", 36, 44], ["COVID", "TREATMENT", 36, 41], ["the treatments", "TREATMENT", 56, 70]]], ["Despite the large number of works reported on new antivirals and compounds targeting SARS-CoV-2, there is still no 100% effective treatment.", [["SARS-CoV-2", "ORGANISM", 85, 95], ["SARS-CoV", "SPECIES", 85, 93], ["new antivirals", "TREATMENT", 46, 60], ["SARS-CoV", "TEST", 85, 93], ["large", "OBSERVATION_MODIFIER", 12, 17], ["no", "UNCERTAINTY", 112, 114]]], ["Research directed towards the RNA chain, which interact in the RdRp region (Remdesivir, Ribavirin and Favipiravir) [35] and polyproteins (PLpro and 3CLpro, Lopinavir and Darunavir) [4,36,37], they are constantly developing a protocol to determine their effectiveness, but something characteristic of these antiviral potentials is that these drugs carry out their mechanism of action in the intracellular space, interacting with the viral RNA sequence and/or encoded protein important for the process of viral replication within the host cell.", [["intracellular space", "ANATOMY", 390, 409], ["cell", "ANATOMY", 537, 541], ["Ribavirin", "CHEMICAL", 88, 97], ["Favipiravir", "CHEMICAL", 102, 113], ["Lopinavir", "CHEMICAL", 156, 165], ["Darunavir", "CHEMICAL", 170, 179], ["Ribavirin", "CHEMICAL", 88, 97], ["Favipiravir", "CHEMICAL", 102, 113], ["Lopinavir", "CHEMICAL", 156, 165], ["Darunavir", "CHEMICAL", 170, 179], ["Ribavirin", "SIMPLE_CHEMICAL", 88, 97], ["Favipiravir", "SIMPLE_CHEMICAL", 102, 113], ["PLpro", "SIMPLE_CHEMICAL", 138, 143], ["3CLpro", "SIMPLE_CHEMICAL", 148, 154], ["Lopinavir", "SIMPLE_CHEMICAL", 156, 165], ["Darunavir", "SIMPLE_CHEMICAL", 170, 179], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 390, 403], ["host cell", "CELL", 532, 541], ["RNA chain", "PROTEIN", 30, 39], ["RdRp region", "PROTEIN", 63, 74], ["viral RNA sequence", "DNA", 432, 450], ["host cell", "CELL_TYPE", 532, 541], ["Remdesivir", "TREATMENT", 76, 86], ["Ribavirin and Favipiravir)", "TREATMENT", 88, 114], ["polyproteins", "TREATMENT", 124, 136], ["PLpro", "TREATMENT", 138, 143], ["3CLpro", "TREATMENT", 148, 154], ["Lopinavir", "TREATMENT", 156, 165], ["Darunavir", "TREATMENT", 170, 179], ["a protocol", "TREATMENT", 223, 233], ["these drugs", "TREATMENT", 335, 346], ["the viral RNA sequence", "TEST", 428, 450], ["viral replication", "PROBLEM", 503, 520], ["RNA chain", "OBSERVATION_MODIFIER", 30, 39], ["intracellular space", "ANATOMY", 390, 409], ["viral replication", "OBSERVATION", 503, 520], ["host cell", "OBSERVATION", 532, 541]]], ["Another way to attack SARS-CoV-2 is to develop membrane fusion inhibitors (EK1 and EK1C4) [[5], [6], [7]], in which they seek to prevent the HR1 region of S-Protein (Fig. S22) from interacting with HR2 and its ligand in the ACE2 membrane, hindering the process of fusing the viral membrane and blocking the introduction of viral genetic material, there are currently very promising results of this type of drug, with evaluated doses with an IC50s between 1.3 and 15.8 nM against SARS-CoV-2 [7], it shows that its development is viable.DiscussionWe determined that there are very few studies of new drugs against ACE2, previously Arbidol was thought to have ACE2 as a selective target, but the description of the interaction of Arbidol with S2-Domain in S-Protein of SARS-CoV-2 was made [21].DiscussionTherefore, the development of antivirals against COVID-19, still in development, shows that there are no specific drugs against SARS-CoV-2, since several of the drugs that are using, they have been developed against other diseases, such as Ebola (Remdesivir) [4], influenza (Arbidol) [21], SARS and MERS [13,14], searching a drug repurposing [38].", [["membrane", "ANATOMY", 47, 55], ["membrane", "ANATOMY", 229, 237], ["membrane", "ANATOMY", 281, 289], ["SARS", "DISEASE", 22, 26], ["Arbidol", "CHEMICAL", 629, 636], ["Arbidol", "CHEMICAL", 727, 734], ["COVID-19", "CHEMICAL", 850, 858], ["SARS", "DISEASE", 929, 933], ["Ebola", "DISEASE", 1041, 1046], ["influenza", "DISEASE", 1065, 1074], ["Arbidol", "CHEMICAL", 1076, 1083], ["SARS", "DISEASE", 1091, 1095], ["Arbidol", "CHEMICAL", 629, 636], ["Arbidol", "CHEMICAL", 727, 734], ["membrane", "CELLULAR_COMPONENT", 47, 55], ["EK1", "SIMPLE_CHEMICAL", 75, 78], ["EK1C4) [[5], [6], [7]]", "SIMPLE_CHEMICAL", 83, 105], ["S-Protein", "GENE_OR_GENE_PRODUCT", 155, 164], ["HR2", "GENE_OR_GENE_PRODUCT", 198, 201], ["ACE2", "GENE_OR_GENE_PRODUCT", 224, 228], ["membrane", "CELLULAR_COMPONENT", 229, 237], ["membrane", "CELLULAR_COMPONENT", 281, 289], ["ACE2", "GENE_OR_GENE_PRODUCT", 612, 616], ["Arbidol", "SIMPLE_CHEMICAL", 629, 636], ["ACE2", "GENE_OR_GENE_PRODUCT", 657, 661], ["Arbidol", "SIMPLE_CHEMICAL", 727, 734], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 766, 776], ["COVID-19", "ORGANISM", 850, 858], ["SARS-CoV-2", "ORGANISM", 929, 939], ["Ebola", "ORGANISM", 1041, 1046], ["Arbidol", "SIMPLE_CHEMICAL", 1076, 1083], ["HR1 region", "PROTEIN", 141, 151], ["S-Protein", "PROTEIN", 155, 164], ["Fig. S22", "PROTEIN", 166, 174], ["HR2", "PROTEIN", 198, 201], ["ACE2", "PROTEIN", 224, 228], ["ACE2", "PROTEIN", 612, 616], ["ACE2", "PROTEIN", 657, 661], ["S2", "PROTEIN", 740, 742], ["SARS-CoV", "SPECIES", 479, 487], ["SARS-CoV", "SPECIES", 929, 937], ["SARS", "PROBLEM", 22, 26], ["CoV", "TEST", 27, 30], ["membrane fusion inhibitors", "TREATMENT", 47, 73], ["the viral membrane", "TREATMENT", 271, 289], ["viral genetic material", "PROBLEM", 323, 345], ["an IC50s", "TEST", 438, 446], ["SARS", "TEST", 479, 483], ["CoV", "TEST", 484, 487], ["new drugs", "TREATMENT", 594, 603], ["ACE2", "PROBLEM", 657, 661], ["SARS", "TEST", 766, 770], ["CoV", "TEST", 771, 774], ["antivirals", "TREATMENT", 831, 841], ["COVID", "TEST", 850, 855], ["SARS", "PROBLEM", 929, 933], ["the drugs", "TREATMENT", 958, 967], ["other diseases", "PROBLEM", 1017, 1031], ["Ebola (Remdesivir)", "TREATMENT", 1041, 1059], ["influenza (Arbidol)", "TREATMENT", 1065, 1084], ["SARS", "PROBLEM", 1091, 1095], ["ACE2 membrane", "ANATOMY", 224, 237], ["viral membrane", "OBSERVATION", 275, 289], ["viable", "OBSERVATION_MODIFIER", 528, 534]]], ["Besides, proposing combinations of drugs, with different mechanisms of action (such as those mentioned), will be used for the pandemic that is occurring, in addition, will be necessary to develop selective drugs against ACE2 (Fig. S23), which may be able to prevent interaction with SARS-CoV-2.DiscussionCarrying out the selection of the compounds, taking into account the results of between 15 and 20 conformers of each compound, gives us a greater probability of choosing the compounds that could be selective in the amino acids sequence Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353 and Arg357 in ACE2 (Fig. 1), subsequently validate them by two toxicity prediction web servers (Tables 2 and S22), obtaining important characteristics such as a lethal dose 50 (LD50) within acceptable values as well as a very low probability of toxicity; which must be fulfilled by each compound for its selection.", [["amino acids", "CHEMICAL", 519, 530], ["toxicity", "DISEASE", 652, 660], ["toxicity", "DISEASE", 834, 842], ["amino acids", "CHEMICAL", 519, 530], ["Gln24", "CHEMICAL", 540, 545], ["Asp30", "CHEMICAL", 547, 552], ["His34", "CHEMICAL", 554, 559], ["Tyr41", "CHEMICAL", 561, 566], ["Gln42", "CHEMICAL", 568, 573], ["Met82", "CHEMICAL", 575, 580], ["Lys353", "CHEMICAL", 582, 588], ["Arg357", "CHEMICAL", 593, 599], ["ACE2", "GENE_OR_GENE_PRODUCT", 220, 224], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 283, 293], ["amino acids", "AMINO_ACID", 519, 530], ["Gln24", "GENE_OR_GENE_PRODUCT", 540, 545], ["Asp30", "GENE_OR_GENE_PRODUCT", 547, 552], ["His34", "GENE_OR_GENE_PRODUCT", 554, 559], ["Tyr41", "GENE_OR_GENE_PRODUCT", 561, 566], ["Gln42", "GENE_OR_GENE_PRODUCT", 568, 573], ["Met82", "GENE_OR_GENE_PRODUCT", 575, 580], ["Lys353", "GENE_OR_GENE_PRODUCT", 582, 588], ["Arg357", "AMINO_ACID", 593, 599], ["ACE2", "GENE_OR_GENE_PRODUCT", 603, 607], ["ACE2", "PROTEIN", 220, 224], ["Fig. S23", "PROTEIN", 226, 234], ["amino acids sequence", "PROTEIN", 519, 539], ["Asp30", "PROTEIN", 547, 552], ["Tyr41", "PROTEIN", 561, 566], ["Gln42", "PROTEIN", 568, 573], ["Met82", "PROTEIN", 575, 580], ["Arg357", "PROTEIN", 593, 599], ["ACE2", "PROTEIN", 603, 607], ["SARS-CoV", "SPECIES", 283, 291], ["drugs", "TREATMENT", 35, 40], ["selective drugs", "TREATMENT", 196, 211], ["ACE2 (Fig. S23)", "TREATMENT", 220, 235], ["the amino acids sequence", "TEST", 515, 539], ["Gln24", "TEST", 540, 545], ["Asp30", "TEST", 547, 552], ["His34", "TEST", 554, 559], ["Tyr41", "TEST", 561, 566], ["Met82", "TEST", 575, 580], ["ACE2", "TEST", 603, 607], ["a lethal dose", "TREATMENT", 748, 761], ["a very low probability of toxicity", "PROBLEM", 808, 842]]], ["Thus, this could reduce the time that must be waited for to be used in humans, therefore we propose compounds (C1\u2013C20), with a high probability to be safe in humans.", [["humans", "ORGANISM", 71, 77], ["C1\u2013C20", "SIMPLE_CHEMICAL", 111, 117], ["humans", "ORGANISM", 158, 164], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 158, 164], ["humans", "SPECIES", 71, 77], ["humans", "SPECIES", 158, 164]]], ["In addition, we show the next 30 compounds, which have some probability of generating side effects, such as carcinogenicity, hepatotoxicity and immunotoxicity mainly; these compounds are on the supplementary material (Table S21) which could be tested in in vitro tests with ACE2 - SARS-CoV-2 interaction.DiscussionIt will be necessary to evaluate by in vivo tests, the effect of these compounds could to generate when interacting with ACE2 in humans, since the ACE2 functions on angiotensin and its effects at the cardiovascular system level [[39], [40], [41], [42], [43]], they would have to be considered to determine the therapeutic effect and the degree of impact that they could have on the health-disease process of COVID-19 and/or some alteration in the functions of ACE2.DiscussionMost of these proposed compounds do not have any specific use registered, nor a scientific article or registered patent, all the compounds are available to purchase or systematize them, to carry out in vitro assays for the interaction of SARS-CoV-2 with ACE2, and in this way, be able to develop a new drug that helps combat this pandemic.", [["cardiovascular", "ANATOMY", 514, 528], ["hepatotoxicity", "DISEASE", 125, 139], ["immunotoxicity", "DISEASE", 144, 158], ["angiotensin", "CHEMICAL", 479, 490], ["SARS", "DISEASE", 1027, 1031], ["COVID-19", "CHEMICAL", 722, 730], ["ACE2", "GENE_OR_GENE_PRODUCT", 274, 278], ["CoV-2", "GENE_OR_GENE_PRODUCT", 286, 291], ["ACE2", "GENE_OR_GENE_PRODUCT", 435, 439], ["humans", "ORGANISM", 443, 449], ["ACE2", "GENE_OR_GENE_PRODUCT", 461, 465], ["angiotensin", "GENE_OR_GENE_PRODUCT", 479, 490], ["[40], [41], [42], [43]]", "SIMPLE_CHEMICAL", 549, 572], ["COVID-19", "CELL", 722, 730], ["ACE2", "GENE_OR_GENE_PRODUCT", 774, 778], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 1027, 1037], ["ACE2", "GENE_OR_GENE_PRODUCT", 1043, 1047], ["ACE2", "PROTEIN", 274, 278], ["ACE2", "PROTEIN", 435, 439], ["ACE2", "PROTEIN", 461, 465], ["ACE2", "PROTEIN", 774, 778], ["ACE2", "PROTEIN", 1043, 1047], ["humans", "SPECIES", 443, 449], ["humans", "SPECIES", 443, 449], ["SARS-CoV", "SPECIES", 1027, 1035], ["generating side effects", "PROBLEM", 75, 98], ["carcinogenicity", "PROBLEM", 108, 123], ["hepatotoxicity", "PROBLEM", 125, 139], ["immunotoxicity", "PROBLEM", 144, 158], ["vitro tests", "TEST", 257, 268], ["ACE2", "TEST", 274, 278], ["vivo tests", "TEST", 353, 363], ["these compounds", "TREATMENT", 379, 394], ["the ACE2 functions", "PROBLEM", 457, 475], ["angiotensin", "TREATMENT", 479, 490], ["the cardiovascular system level", "TEST", 510, 541], ["COVID", "TEST", 722, 727], ["vitro assays", "TEST", 991, 1003], ["ACE2", "TREATMENT", 1043, 1047], ["side effects", "OBSERVATION_MODIFIER", 86, 98], ["hepatotoxicity", "OBSERVATION", 125, 139], ["patent", "OBSERVATION", 902, 908]]], ["Furthermore, as already reported, SARS-CoV have an affinity for the same ACE2 region, which could help in the future to prevent new viruses that have an affinity for this region of interaction in ACE2.ConclusionsWe propose 20 compounds that have a high probability of interacting in a specific region in ACE2 (Gln24, Asp30, His34, Tyr41, Gln42, Met82, Lys353 and Arg357), and thus hinder interaction with the RBD of SARS-CoV-2.", [["SARS", "DISEASE", 416, 420], ["Asp30", "CHEMICAL", 317, 322], ["His34", "CHEMICAL", 324, 329], ["Tyr41", "CHEMICAL", 331, 336], ["Gln42", "CHEMICAL", 338, 343], ["Met82", "CHEMICAL", 345, 350], ["Lys353", "CHEMICAL", 352, 358], ["Arg357", "CHEMICAL", 363, 369], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["ACE2", "GENE_OR_GENE_PRODUCT", 73, 77], ["ACE2", "GENE_OR_GENE_PRODUCT", 196, 200], ["ACE2", "GENE_OR_GENE_PRODUCT", 304, 308], ["Gln24", "GENE_OR_GENE_PRODUCT", 310, 315], ["Asp30", "GENE_OR_GENE_PRODUCT", 317, 322], ["His34", "GENE_OR_GENE_PRODUCT", 324, 329], ["Tyr41", "GENE_OR_GENE_PRODUCT", 331, 336], ["Gln42", "GENE_OR_GENE_PRODUCT", 338, 343], ["Met82", "GENE_OR_GENE_PRODUCT", 345, 350], ["Lys353", "GENE_OR_GENE_PRODUCT", 352, 358], ["Arg357", "GENE_OR_GENE_PRODUCT", 363, 369], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 416, 426], ["ACE2 region", "PROTEIN", 73, 84], ["ACE2", "PROTEIN", 196, 200], ["ACE2", "PROTEIN", 304, 308], ["Gln24", "PROTEIN", 310, 315], ["Asp30", "PROTEIN", 317, 322], ["His34", "PROTEIN", 324, 329], ["Tyr41", "PROTEIN", 331, 336], ["Gln42", "PROTEIN", 338, 343], ["Met82", "PROTEIN", 345, 350], ["Lys353", "PROTEIN", 352, 358], ["Arg357", "PROTEIN", 363, 369], ["RBD", "PROTEIN", 409, 412], ["SARS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 416, 424], ["SARS-CoV", "PROBLEM", 34, 42], ["an affinity", "PROBLEM", 48, 59], ["new viruses", "PROBLEM", 128, 139], ["ACE2", "TEST", 304, 308], ["Asp30", "TEST", 317, 322], ["His34", "TEST", 324, 329], ["Tyr41", "TEST", 331, 336], ["SARS", "TEST", 416, 420], ["CoV", "TEST", 421, 424], ["new", "OBSERVATION_MODIFIER", 128, 131], ["viruses", "OBSERVATION", 132, 139], ["20 compounds", "OBSERVATION_MODIFIER", 223, 235]]], ["Furthermore, these 20 compounds have a high probability to be safe in humans, since they were validated by the ProTox-II and PreADMET server (ADME and Toxicity Predictor).", [["humans", "ORGANISM", 70, 76], ["humans", "SPECIES", 70, 76], ["humans", "SPECIES", 70, 76]]], ["This could facilitate in vitro assays to determine the effectiveness of new drugs with a mechanism of action in ACE2 and thus, propose a new treatment against COVID-19.Funding sourceAll sources of funding should also be acknowledged and you should declare any involvement of study sponsors in the study design; collection, analysis and interpretation of data; the writing of the manuscript; the decision to submit the manuscript for publication.", [["ACE2", "GENE_OR_GENE_PRODUCT", 112, 116], ["ACE2", "PROTEIN", 112, 116], ["vitro assays", "TEST", 25, 37], ["new drugs", "TREATMENT", 72, 81], ["a new treatment", "TREATMENT", 135, 150], ["COVID", "TEST", 159, 164], ["the study", "TEST", 293, 302], ["collection, analysis", "TEST", 311, 331], ["interpretation of data", "TEST", 336, 358]]], ["If the study sponsors had no such involvement, this should be stated.Funding sourceThe authors are very grateful for the financial support from 10.13039/100013183SIP-10.13039/501100003069IPN M\u00e9xico (20196821, 20200919), 10.13039/501100007177COFAA-10.13039/501100003069IPN2, PRODEP-10.13039/100010096SEP, 10.13039/501100013395SNI-10.13039/501100003141CONACyT and UABC.Declaration of competing interestThe authors declare that they have no conflict of interest.", [["10.13039/100013183SIP-10.13039/501100003069IPN", "CHEMICAL", 144, 190], ["20196821, 20200919), 10.13039/501100007177COFAA-10.13039/501100003069IPN2", "CHEMICAL", 199, 272], ["PRODEP-10.13039/100010096SEP", "CHEMICAL", 274, 302], ["the study", "TEST", 3, 12], ["PRODEP", "TEST", 274, 280], ["SNI", "TEST", 325, 328], ["UABC", "TEST", 362, 366]]]], "5f244f5b17f06ac8e1055dfe488c50f7d9ab2e5e": [["INTRODUCTIONSince the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, significant attention has been focused on the relationship between Bacillus Calmette-Guerin (BCG) vaccination and COVID-19 mortality.", [["coronavirus disease", "DISEASE", 38, 57], ["COVID-19", "CHEMICAL", 64, 72], ["Bacillus Calmette-Guerin", "CHEMICAL", 151, 175], ["coronavirus", "ORGANISM", 38, 49], ["Bacillus Calmette-Guerin", "ORGANISM", 151, 175], ["BCG", "ORGANISM", 177, 180], ["Bacillus Calmette-Guerin", "SPECIES", 151, 175], ["the coronavirus disease", "PROBLEM", 34, 57], ["COVID", "TEST", 64, 69], ["pandemic", "PROBLEM", 74, 82], ["Bacillus Calmette", "TREATMENT", 151, 168], ["Guerin (BCG) vaccination", "TREATMENT", 169, 193], ["COVID", "TEST", 198, 203], ["coronavirus disease", "OBSERVATION", 38, 57]]], ["In particular, there is interest in whether BCG vaccination is associated with a reduction in COVID-19-associated mortality.", [["BCG vaccination", "PROBLEM", 44, 59], ["COVID", "TEST", 94, 99], ["reduction", "OBSERVATION_MODIFIER", 81, 90]]], ["BCG is the most widespread vaccine against tuberculosis (TB) and also elicits non-specific effects and innate immune memory against non-mycobacterial diseases.", [["tuberculosis", "DISEASE", 43, 55], ["TB", "DISEASE", 57, 59], ["non-mycobacterial diseases", "DISEASE", 132, 158], ["BCG", "PROBLEM", 0, 3], ["tuberculosis", "PROBLEM", 43, 55], ["non-specific effects", "PROBLEM", 78, 98], ["non-mycobacterial diseases", "PROBLEM", 132, 158], ["most widespread", "OBSERVATION_MODIFIER", 11, 26], ["tuberculosis", "OBSERVATION", 43, 55], ["non-specific", "OBSERVATION_MODIFIER", 78, 90]]], ["A survey of key unpublished and published data regarding the association between BCG vaccination and COVID-19 mortality was conducted, and concluded that there was a lack of evidence to support a protective effect of BCG against COVID-19 [1] .", [["COVID-19", "CHEMICAL", 229, 237], ["COVID-19", "CHEMICAL", 229, 237], ["BCG vaccination", "TREATMENT", 81, 96], ["COVID", "TEST", 101, 106], ["a protective effect of BCG", "TREATMENT", 194, 220], ["COVID", "TEST", 229, 234]]], ["However, such studies ignore the important fact that about one-quarter of the world's population may have latent TB infection (LTBI), a condition in which there is no evidence of clinically active TB but persistent immune responses are stimulated by Mycobacterium tuberculosis antigens.", [["latent TB infection", "DISEASE", 106, 125], ["LTBI", "DISEASE", 127, 131], ["TB", "DISEASE", 197, 199], ["Mycobacterium tuberculosis antigens", "GENE_OR_GENE_PRODUCT", 250, 285], ["Mycobacterium tuberculosis antigens", "PROTEIN", 250, 285], ["Mycobacterium tuberculosis", "SPECIES", 250, 276], ["Mycobacterium tuberculosis", "SPECIES", 250, 276], ["such studies", "TEST", 9, 21], ["latent TB infection", "PROBLEM", 106, 125], ["clinically active TB", "PROBLEM", 179, 199], ["persistent immune responses", "PROBLEM", 204, 231], ["Mycobacterium tuberculosis antigens", "PROBLEM", 250, 285], ["latent", "OBSERVATION_MODIFIER", 106, 112], ["TB", "OBSERVATION_MODIFIER", 113, 115], ["infection", "OBSERVATION", 116, 125], ["no evidence of", "UNCERTAINTY", 164, 178], ["active", "OBSERVATION_MODIFIER", 190, 196], ["TB", "OBSERVATION", 197, 199], ["Mycobacterium tuberculosis", "OBSERVATION", 250, 276]]], ["The regional data shown in Table 1 illustrate that the number of LTBIs far surpasses the number of active TB infections.", [["LTBIs", "DISEASE", 65, 70], ["TB infections", "DISEASE", 106, 119], ["The regional data", "TEST", 0, 17], ["active TB infections", "PROBLEM", 99, 119], ["active", "OBSERVATION_MODIFIER", 99, 105], ["TB infections", "OBSERVATION", 106, 119]]], ["The number of LBT infections clearly surpasses that of TB infections.", [["infections", "DISEASE", 18, 28], ["TB", "DISEASE", 55, 57], ["infections", "DISEASE", 58, 68], ["LBT", "CANCER", 14, 17], ["LBT infections", "PROBLEM", 14, 28], ["TB infections", "PROBLEM", 55, 68], ["LBT", "OBSERVATION_MODIFIER", 14, 17], ["infections", "OBSERVATION", 18, 28], ["TB", "OBSERVATION_MODIFIER", 55, 57], ["infections", "OBSERVATION", 58, 68]]], ["LTBI also induces lifelong innate immune immunity [2] , [3] and may confer an immunological protective effect against COVID-19.STATEMENT OF HYPOTHESISMany countries with a relatively high incidence of TB infection, including Japan, require BCG vaccination during early childhood.", [["LTBI", "DISEASE", 0, 4], ["TB infection", "DISEASE", 201, 213], ["LTBI", "PROBLEM", 0, 4], ["COVID", "TEST", 118, 123], ["TB infection", "PROBLEM", 201, 213], ["BCG vaccination", "TREATMENT", 240, 255], ["TB", "OBSERVATION_MODIFIER", 201, 203], ["infection", "OBSERVATION", 204, 213]]], ["Most citizens of these countries also have LTBI, which is highly immunoprotective because of elicited innate immune responses.", [["LTBI", "DISEASE", 43, 47], ["LTBI", "PROBLEM", 43, 47], ["LTBI", "OBSERVATION", 43, 47]]], ["In fact, TB infection leads to LTBI in 90%-95% of cases, while 5%-10% of individuals develop active TB disease [5] .", [["TB infection", "DISEASE", 9, 21], ["LTBI", "DISEASE", 31, 35], ["TB disease", "DISEASE", 100, 110], ["individuals", "ORGANISM", 73, 84], ["TB infection", "PROBLEM", 9, 21], ["LTBI", "TEST", 31, 35], ["cases", "TEST", 50, 55], ["active TB disease", "PROBLEM", 93, 110], ["TB", "OBSERVATION_MODIFIER", 9, 11], ["infection", "OBSERVATION", 12, 21], ["active", "OBSERVATION_MODIFIER", 93, 99], ["TB disease", "OBSERVATION", 100, 110]]], ["Therefore, the number of TB infections per hundred thousand individuals can be used as a proxy for the number of LTBIs.", [["TB", "DISEASE", 25, 27], ["infections", "DISEASE", 28, 38], ["LTBIs", "DISEASE", 113, 118], ["LTBIs", "PATHOLOGICAL_FORMATION", 113, 118], ["TB infections", "PROBLEM", 25, 38], ["LTBIs", "TREATMENT", 113, 118], ["TB", "OBSERVATION_MODIFIER", 25, 27], ["infections", "OBSERVATION", 28, 38]]], ["Furthermore, M. tuberculosis infection via BCG vaccination can enhance innate immunity.", [["tuberculosis infection", "DISEASE", 16, 38], ["M. tuberculosis", "ORGANISM", 13, 28], ["M. tuberculosis", "SPECIES", 13, 28], ["M. tuberculosis", "SPECIES", 13, 28], ["M. tuberculosis infection", "PROBLEM", 13, 38], ["BCG vaccination", "TREATMENT", 43, 58], ["tuberculosis", "OBSERVATION_MODIFIER", 16, 28], ["infection", "OBSERVATION", 29, 38]]], ["Therefore, citizens of countries with high prevalence of TB infection (high TB burden countries) together with high BCG vaccination rates are considered to have enhanced innate immunity compared with the citizens of lower TB burden countries.", [["TB infection", "DISEASE", 57, 69], ["TB", "DISEASE", 76, 78], ["TB", "DISEASE", 222, 224], ["TB infection", "PROBLEM", 57, 69], ["high BCG vaccination rates", "TREATMENT", 111, 137], ["TB", "OBSERVATION_MODIFIER", 57, 59], ["infection", "OBSERVATION", 60, 69]]], ["This high level of natural immunity is thought to be responsible for the lower COVID-19 mortality rate.STATEMENT OF HYPOTHESISThe aim of this study was to test the hypothesis that LTBI is associated with reduced COVID-19 mortality.TESTING THE HYPOSESISThe instrumental variable (IV) method was used to assess causality.", [["LTBI", "DISEASE", 180, 184], ["the lower COVID", "TEST", 69, 84], ["mortality rate", "TEST", 88, 102], ["this study", "TEST", 137, 147], ["LTBI", "PROBLEM", 180, 184], ["reduced COVID", "PROBLEM", 204, 217], ["THE HYPOSESISThe instrumental variable (IV) method", "TREATMENT", 239, 289], ["natural immunity", "OBSERVATION", 19, 35], ["LTBI", "OBSERVATION", 180, 184]]], ["All data used in the analysis are publicly available and are described in the appendix.", [["appendix", "ORGAN", 78, 86], ["All data", "TEST", 0, 8], ["the analysis", "TEST", 17, 29], ["appendix", "ANATOMY", 78, 86]]], ["Much discussion has centered around the strong correlation between BCG and COVID-19 mortality.", [["BCG", "TEST", 67, 70], ["COVID", "TEST", 75, 80]]], ["Regression analysis, particularly the IV method, is a statistical method that addresses this problem to assess causality.TESTING THE HYPOSESISCare must be taken in using COVID-19 mortality as a dependent variable [6] .", [["Regression analysis", "TEST", 0, 19], ["the IV method", "TREATMENT", 34, 47], ["COVID", "TEST", 170, 175]]], ["This is because COVID-19 mortality is conditionally observed in potentially infected individuals, and can only be detected by testing of symptomatic or asymptomatic individuals.", [["COVID", "TEST", 16, 21], ["symptomatic or asymptomatic individuals", "PROBLEM", 137, 176], ["infected", "OBSERVATION", 76, 84]]], ["Therefore, the case fatality rate (CFR), defined as the ratio of the number of COVID-19 deaths per million people to the number of COVID-19 infections per million people, is typically used.", [["deaths", "DISEASE", 88, 94], ["infections", "DISEASE", 140, 150], ["people", "ORGANISM", 163, 169], ["people", "SPECIES", 107, 113], ["people", "SPECIES", 163, 169], ["COVID", "TEST", 131, 136]]], ["As explained above, the logarithm of the number of TB infections per 100,000 individuals (lntb10) can be used as a proxy variable for LTBIs.", [["TB", "DISEASE", 51, 53], ["infections", "DISEASE", 54, 64], ["TB infections", "PROBLEM", 51, 64], ["LTBIs", "TREATMENT", 134, 139], ["TB", "OBSERVATION_MODIFIER", 51, 53], ["infections", "OBSERVATION", 54, 64]]], ["For this regression analysis to be statistically accurate, the explanatory variable X must first be correlated with the error term u (i.e., the covariance of X and u must be zero).", [["this regression analysis", "TEST", 4, 28]]], ["This condition clearly does not hold in general: besides LTBI, many other co-occurring factors, such as cultural norms, mitigation efforts, health infrastructure, and urban concentration, may influence this relationship [8] .", [["LTBI", "DISEASE", 57, 61], ["LTBI", "PROBLEM", 57, 61], ["LTBI", "OBSERVATION", 57, 61]]], ["This would be an example of a \"spurious regression\".TESTING THE HYPOSESISTo overcome such a problem, the IV method can be used.", [["a \"spurious regression\"", "PROBLEM", 28, 51], ["the IV method", "TREATMENT", 101, 114]]], ["An IV is a variable that is strongly correlated with the explanatory variable X but is not correlated or only weakly correlated with the error term.", [["An IV", "TREATMENT", 0, 5]]], ["The IVs used here were as follows.", [["IVs", "DNA", 4, 7], ["The IVs", "TREATMENT", 0, 7]]], ["Four diagnostic tests were performed to assess whether the estimates were statistically relevant.", [["Four diagnostic tests", "TEST", 0, 21]]], ["One test was concerned with the explanatory variables and the other three were concerned with the IVs.", [["the IVs", "TREATMENT", 94, 101]]], ["The Wu-Hausman test assesses the endogeneity of the explanatory variables.", [["The Wu-Hausman test", "TEST", 0, 19]]], ["If the null hypothesis is rejected, one can simply use the standard ordinary least squares regression instead of using the IV.", [["the null hypothesis", "PROBLEM", 3, 22], ["the IV", "TREATMENT", 119, 125], ["rejected", "OBSERVATION", 26, 34]]], ["The first test of an instrument is Sargan's exogenous test, which assesses whether the right number of IVs are selected and confirms that they are sufficiently uncorrelated with the error term.", [["IVs", "PROTEIN", 103, 106], ["Sargan's exogenous test", "TEST", 35, 58], ["IVs", "TREATMENT", 103, 106], ["right", "ANATOMY_MODIFIER", 87, 92], ["IVs", "OBSERVATION", 103, 106]]], ["Finally, it is necessary to perform a \"weak IV test\" to check if the selected IVs are strongly correlated with the explanatory variables.TESTING THE HYPOSESISThe instrumental variables used here were bcgindex, region and pop65.", [["pop65", "GENE_OR_GENE_PRODUCT", 221, 226], ["bcgindex", "PROTEIN", 200, 208], ["pop65", "PROTEIN", 221, 226], ["a \"weak IV test", "TEST", 36, 51]]], ["Two models were estimated using the IV method: one with three instruments and the other with two instrument (bcgindex and region).", [["the IV method", "TREATMENT", 32, 45], ["three instruments", "TREATMENT", 56, 73], ["two instrument (bcgindex and region", "TREATMENT", 93, 128]]], ["Most of the countries with low income levels (annual per capita income less than $825 USD) reported zero deaths attributed to COVID-19 [7] .TESTING THE HYPOSESISTo avoid underreporting bias in these countries, they were excluded.", [["deaths", "DISEASE", 105, 111], ["COVID-19", "CHEMICAL", 126, 134], ["zero deaths", "PROBLEM", 100, 111], ["COVID", "TEST", 126, 131]]], ["The total number of countries analyzed was thus 104.CONCLUSIONThe results are shown in Table 2 .", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["The estimates of the Generalized Moment Method (GMM), which is often used as an alternative to the IV method, are also reported.CONCLUSIONFor the diagnostic tests of the two estimation models, Sargan's exogenous test indicated that the selected IVs met the exogenous property.", [["the IV method", "TREATMENT", 95, 108], ["the diagnostic tests", "TEST", 142, 162], ["the two estimation models", "TEST", 166, 191], ["Sargan's exogenous test", "TEST", 193, 216], ["the selected IVs", "TREATMENT", 232, 248], ["Generalized", "OBSERVATION_MODIFIER", 21, 32], ["exogenous property", "OBSERVATION", 257, 275]]], ["The results of the weak IV test indicated that the IVs were sufficiently and strongly correlated with the explanatory variables.", [["the weak IV test", "TEST", 15, 31], ["the IVs", "TREATMENT", 47, 54]]], ["All the coefficients of lntb10 were approximately -0.02, indicating a negative association between LTBI and COVID-19 mortality.", [["LTBI", "DISEASE", 99, 103], ["lntb10", "GENE_OR_GENE_PRODUCT", 24, 30], ["lntb10", "DNA", 24, 30], ["LTBI", "TEST", 99, 103], ["COVID", "TEST", 108, 113], ["negative", "OBSERVATION", 70, 78]]], ["Thus, these results lend statistical support to the hypothesis that LTBI can protect against COVID-19 mortality.CONCLUSIONBecause these estimation models were linear-log type, the estimated coefficient of -", [["LTBI", "DISEASE", 68, 72], ["LTBI", "PROBLEM", 68, 72], ["COVID", "TEST", 93, 98], ["these estimation models", "TEST", 130, 153]]]], "d310762b53b4c9a86a30f5ae5c04a0fff9385bf0": [["The 2019-2020 novel coronavirus disease (COVID-19) pandemic, caused by the worldwide spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has changed healthcare systems across the globe.", [["coronavirus disease", "DISEASE", 20, 39], ["COVID-19) pandemic", "DISEASE", 41, 59], ["acute respiratory syndrome coronavirus", "DISEASE", 102, 140], ["coronavirus", "ORGANISM", 20, 31], ["SARS-CoV-2", "ORGANISM", 144, 154], ["severe acute respiratory syndrome coronavirus", "SPECIES", 95, 140], ["SARS-CoV-2", "SPECIES", 144, 154], ["novel coronavirus disease", "PROBLEM", 14, 39], ["COVID", "TEST", 41, 46], ["pandemic", "PROBLEM", 51, 59], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 95, 140], ["coronavirus disease", "OBSERVATION", 20, 39], ["severe", "OBSERVATION_MODIFIER", 95, 101], ["acute", "OBSERVATION_MODIFIER", 102, 107], ["respiratory syndrome", "OBSERVATION", 108, 128], ["globe", "ANATOMY", 199, 204]]], ["In the global North, this development has introduced frontline workers to vulnerability at a national level for the first time.", [["global", "OBSERVATION_MODIFIER", 7, 13], ["North", "OBSERVATION_MODIFIER", 14, 19]]], ["Critical supply shortages of personal protective equipment (PPE) and ventilators have left healthcare workers (HCWs) with feelings of anxiety, guilt, and helplessness.", [["anxiety", "DISEASE", 134, 141], ["helplessness", "DISEASE", 154, 166], ["personal protective equipment", "TREATMENT", 29, 58], ["ventilators", "TREATMENT", 69, 80], ["anxiety", "PROBLEM", 134, 141], ["guilt", "PROBLEM", 143, 148], ["helplessness", "PROBLEM", 154, 166]]], ["In the following text, we discuss collective lessons from global health work in resource-limited settings that inform our current experience with COVID-19.LESSON 1.", [["COVID-19", "CHEMICAL", 146, 154], ["COVID", "TEST", 146, 151]]], ["WHAT FLEXIBILITY REALLY MEANSGlobal health practitioners are taught that when working in a resource-constrained setting, effective approaches need to use locally driven solutions, informed by evidence that is context-specific.", [["locally driven solutions", "TREATMENT", 154, 178]]], ["For example, it may not be ethical to perform cardiopulmonary resuscitation in settings where ventilators and circulatory supports are not available to support the patient in the post-resuscitation period.", [["circulatory", "ANATOMY", 110, 121], ["patient", "ORGANISM", 164, 171], ["patient", "SPECIES", 164, 171], ["cardiopulmonary resuscitation", "TREATMENT", 46, 75], ["ventilators", "TREATMENT", 94, 105], ["circulatory supports", "TREATMENT", 110, 130], ["may not be", "UNCERTAINTY", 16, 26]]], ["Identifying resourcespecific solutions focused on equity, efficiency, and sustainability of the health system thus becomes essential in.LESSON 1.", [["resourcespecific solutions", "TREATMENT", 12, 38]]], ["However, this routine reliance to inform best practice has been dismantled in the setting of COVID-19 because in a novel situation, no one knows with certainty how best to proceed-at every level of every organization.", [["COVID", "TEST", 93, 98]]], ["Our inability to perform this kind of informed decision-making contributes to new feelings of anxiety, both within the medical community and amongst the lay public.LESSON 2.", [["anxiety", "DISEASE", 94, 101], ["anxiety", "PROBLEM", 94, 101]]], ["FIND EXPERTISE IN PLACES YOU MAY NOT HAVE THOUGHT TO LOOK BEFOREIn this time of uncertainty, we have found ourselves drawing on lessons learned from our colleagues in the global South: creative ways to reuse and make PPE, new methods for sterilizing limited resources, and new treatment modalities that bypass high-cost medications.", [["PPE", "TREATMENT", 217, 220], ["sterilizing limited resources", "TREATMENT", 238, 267], ["new treatment modalities", "TREATMENT", 273, 297], ["bypass high-cost medications", "TREATMENT", 303, 331]]], ["When clinically applicable, minimize hierarchy to facilitate engagement of all stakeholders-patients, HCWs, and community members-in bidirectional learning and creative problem-solving.", [["patients", "ORGANISM", 92, 100], ["patients", "SPECIES", 92, 100]]], ["Many of the most ingenious solutions to difficult problems come from colleagues who regularly think outside the box to overcome resource limitations and drive context-specific solutions.", [["most ingenious", "OBSERVATION_MODIFIER", 12, 26]]], ["As the line between individual sub-specialties begins to blur and hierarchy is flattened-as chiefs of surgery are now being asked to practice as internal medicine interns on COVID-19 wards-new experts are quickly emerging.", [["surgery", "TREATMENT", 102, 109], ["line", "OBSERVATION_MODIFIER", 7, 11], ["hierarchy", "OBSERVATION_MODIFIER", 66, 75], ["flattened", "OBSERVATION_MODIFIER", 79, 88]]], ["When demands on time are high, the ability to manage ever-increasing patient loads and academic requirements is viewed as a productive skill; however, this approach limits our engagement in any one area.LESSON 3: BLEND INTERPERSONAL RELATIONSHIPS AND WORK; ADAPT YOUR PERCEPTION OF TIMEVariation in this conception of time can cause stress for first-time global health practitioners.", [["patient", "ORGANISM", 69, 76], ["patient", "SPECIES", 69, 76], ["increasing patient loads", "PROBLEM", 58, 82], ["academic requirements", "TREATMENT", 87, 108], ["this approach", "TREATMENT", 151, 164], ["TIMEVariation", "TREATMENT", 282, 295]]], ["Many cultures in the global South are polychronic, 2 where time is viewed as infinite.", [["Many cultures", "TEST", 0, 13]]], ["Like a stream, polychronic time adjusts its shape to fill the available space.", [["stream", "OBSERVATION_MODIFIER", 7, 13]]], ["It allows for meetings to seamlessly flow in and out of personal connection, and is often embraced in cultures where uncertainty is commonplace, allowing the unexpected to be expected.", [["cultures", "TEST", 102, 110]]], ["Deadlines are fluid, and empathy for understanding how life's struggles influence these deadlines is recognized collectively.", [["fluid", "PROBLEM", 14, 19], ["fluid", "OBSERVATION", 14, 19]]], ["USE CHALLENGING SITUATIONS AS OPPORTUNITIES TO ADVOCATELike many disasters before it, the COVID-19 pandemic is bringing to light long-standing structural oppression, embedded racism, and widespread class inequity.", [["the COVID", "TEST", 86, 95], ["oppression", "OBSERVATION", 154, 164], ["racism", "OBSERVATION_MODIFIER", 175, 181], ["widespread", "OBSERVATION_MODIFIER", 187, 197], ["class", "OBSERVATION_MODIFIER", 198, 203], ["inequity", "OBSERVATION_MODIFIER", 204, 212]]], ["Recent CDC data show that black Americans were more likely to require hospitalization for COVID-19 than white Americans in the same catchment area, and early data suggest they may also have higher rates of death.", [["death", "DISEASE", 206, 211], ["Recent CDC data", "TEST", 0, 15], ["black Americans", "PROBLEM", 26, 41], ["COVID", "TEST", 90, 95], ["death", "PROBLEM", 206, 211]]], ["3, 4 Although freedom of social mobility caused resource-replete countries to be the first to be affected by the novel virus's spread, they will hardly have the worst experience if communities with fewer resources are left to deal with the fallout on their own.LESSON 4.", [["the novel virus's spread", "PROBLEM", 109, 133]]], ["USE CHALLENGING SITUATIONS AS OPPORTUNITIES TO ADVOCATEAs social medicine advocates, we have consistently seen that those who are most vulnerable require increased, not equal, support in times of crisis to achieve equity.", [["crisis", "PROBLEM", 196, 202]]], ["This advocacy feels particularly uncomfortable during uncertain times, but remember that uncertainty exists because the system is broken.", [["broken", "OBSERVATION", 130, 136]]], ["BEING A HCW WHEN RESOURCES ARE SCARCE IS TRAUMATIC\"Trauma-Informed Care\" 1,5 has never been more critical.", [["Trauma", "DISEASE", 51, 57], ["Trauma", "PROBLEM", 51, 57]]], ["The existing literature largely focuses on coping strategies for HCWs outside of work, but what about during work, in the face of extraordinary demands?", [["coping strategies", "TREATMENT", 43, 60]]], ["What about when friends and family call during \"off hours\" to ask a litany of questions about severe acute respiratory syndrome coronavirus 2 and its implications?LESSON 5.", [["acute respiratory syndrome coronavirus", "DISEASE", 101, 139], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 94, 139], ["acute", "OBSERVATION_MODIFIER", 101, 106], ["respiratory syndrome", "OBSERVATION", 107, 127]]], ["Novel coronavirus disease feels no different, but this time, we were stripped from the ability to pre-prepare.", [["coronavirus disease", "DISEASE", 6, 25], ["coronavirus", "ORGANISM", 6, 17], ["Novel coronavirus disease", "PROBLEM", 0, 25], ["coronavirus disease", "OBSERVATION", 6, 25]]], ["Now, it is more important than ever to recognize your own trauma and to tell your coworkers when you are nearing burnout, not sleeping, or emotionally exhausted.", [["trauma", "DISEASE", 58, 64], ["burnout", "DISEASE", 113, 120]]], ["In this era, assume that everyone comes from a place of trauma; listen from that place and share in that same vulnerability.", [["trauma", "DISEASE", 56, 62], ["trauma", "PROBLEM", 56, 62]]], ["DO LOOK BACK-THE RIGHT WAY No one denies that the COVID-19 pandemic has placed us in an unprecedented and terrifying situation.", [["RIGHT", "ANATOMY_MODIFIER", 17, 22]]], ["Without learning from individual and systemic failures, we would never improve.", [["individual and systemic failures", "PROBLEM", 22, 54], ["systemic", "OBSERVATION_MODIFIER", 37, 45], ["failures", "OBSERVATION", 46, 54]]], ["How will recognition of our own embedded trauma allow us to better take care of others?", [["trauma", "DISEASE", 41, 47]]]], "PMC7361840": [["BackgroundIn the rapidly changing landscape following the emergence of COVID\u201019, a constant has been the request from governments across the globe for citizens to practice physical distancing and to isolate themselves at home.", [["rapidly", "OBSERVATION_MODIFIER", 17, 24], ["globe", "ANATOMY", 141, 146]]], ["Following these guidelines, billions of people have dramatically changed their daily routines and restricted their movements and interactions, potentially with significant welfare effects (Brooks et al., 2020; Lima et al., 2020).", [["people", "ORGANISM", 40, 46], ["people", "SPECIES", 40, 46]]], ["Currently, little systematic evidence exists on how people are experiencing daily life during the pandemic.", [["people", "ORGANISM", 52, 58], ["people", "SPECIES", 52, 58], ["the pandemic", "PROBLEM", 94, 106]]], ["In this study, we therefore asked a sample of the Irish population to reconstruct the activities, interactions, and emotional experiences of the previous day.", [["this study", "TEST", 3, 13]]], ["Polling during the same week indicated widespread support for the restrictions that had been put in place (Delaney & Lunn, 2020).BackgroundSet against this backdrop, the existing subjective well\u2010being literature offers some insight into the effects of the dramatic changes in people\u2019s daily lives on their emotional well\u2010being.", [["people", "ORGANISM", 276, 282], ["people", "SPECIES", 276, 282]]], ["Activities affected by movement restrictions such as spending time in nature (MacKerron & Mourato, 2013), exercising (Reed & Ones, 2006), walking (Hanson & Jones, 2015), and supportive interpersonal interactions (Gonza & Burger, 2017; Kahneman, Krueger, Schkade, Schwarz, & Stone, 2004) have been associated with enhanced well\u2010being.BackgroundIn contrast, time spent alone, engaged in social media use, and caring for children have been associated with reduced emotional well\u2010being (Allcott, Braghieri, Eichmeyer, & Gentzkow, 2020; Kahneman et al., 2004; White & Dolan, 2009).", [["reduced emotional well\u2010being", "DISEASE", 453, 481], ["children", "ORGANISM", 418, 426], ["children", "SPECIES", 418, 426]]], ["While these findings offer suggestive evidence, their applicability to the current situation \u2013 daily life during the COVID\u201019 pandemic \u2013 is unclear.BackgroundA small set of studies have shown that self\u2010isolation and quarantine following previous virus outbreaks (e.g., SARS, H1N1) may produce negative psychological effects (Brooks et al., 2020).", [["SARS", "DISEASE", 269, 273], ["H1N1", "DISEASE", 275, 279], ["BackgroundA small set of studies", "PROBLEM", 148, 180], ["self\u2010isolation", "PROBLEM", 197, 211], ["quarantine", "TREATMENT", 216, 226], ["previous virus outbreaks", "PROBLEM", 237, 261], ["SARS", "PROBLEM", 269, 273], ["H1N1", "PROBLEM", 275, 279], ["small", "OBSERVATION_MODIFIER", 160, 165]]], ["Such studies of well\u2010being during virus outbreaks have chiefly relied on global reports of past \u2018usual\u2019 feelings, and the dynamics of daily experience have been neglected.BackgroundIn the current study, we therefore generated a snapshot of the experiences of people living through the COVID\u201019 outbreak in Ireland using the Day Reconstruction Method (DRM).", [["people", "ORGANISM", 259, 265], ["people", "SPECIES", 259, 265], ["Such studies", "TEST", 0, 12], ["the current study", "TEST", 184, 201]]], ["The DRM is a diary\u2010based tool designed to collect data on the experiences a person has on a given day, through a systematic reconstruction conducted on the following day (Kahneman et al., 2004).", [["person", "SPECIES", 76, 82], ["a diary\u2010based tool", "PROBLEM", 11, 29], ["a systematic reconstruction", "TREATMENT", 111, 138], ["DRM", "OBSERVATION", 4, 7]]], ["Drawing on the DRM, we estimated how affective experiences are associated with daily activities, time spent indoors/outdoors, and social interaction during the pandemic with a view to providing evidence to inform academic and policy debates on how the emotional consequences of self\u2010isolation measures may be mitigated or exacerbated.Participants ::: MethodWe asked a large Irish market research company to distribute the survey link to their access panel on Wednesday, March 25th.", [["Participants", "SPECIES", 334, 346], ["self\u2010isolation measures", "TREATMENT", 278, 301]]], ["To be eligible for the study, participants needed to be aged 18 or above and live in the Republic of Ireland.", [["participants", "ORGANISM", 30, 42], ["participants", "SPECIES", 30, 42], ["the study", "TEST", 19, 28]]], ["Eligible participants received an email from the research company that invited them to complete our survey before 8 pm that day.", [["participants", "SPECIES", 9, 21]]], ["The company offered a prize draw for one prize of \u20ac250 and five prizes of \u20ac50 additional to other draws they run for regular survey participants.", [["participants", "SPECIES", 132, 144]]], ["The panel contained 3,500\u20104,000 active members, most of them recruited face\u2010to\u2010face to obtain a quota\u2010controlled basis to be representative of the adult population.", [["The panel", "TEST", 0, 9]]], ["Additionally, some participants were invited to join the panel at the end of other surveys or using snowball recruitment.", [["participants", "SPECIES", 19, 31], ["snowball recruitment", "TREATMENT", 100, 120]]], ["A total of 604 participants completed our survey.", [["participants", "ORGANISM", 15, 27], ["participants", "SPECIES", 15, 27]]], ["The sample consisted of 191 men and 413 women, with a mean age of 47 (SD = 12).", [["men", "ORGANISM", 28, 31], ["women", "ORGANISM", 40, 45], ["men", "SPECIES", 28, 31], ["women", "SPECIES", 40, 45], ["The sample", "TEST", 0, 10]]], ["The sample was drawn from across Irish regions (Dublin = 31.1%, rest of Leinster = 25.8%, Muster = 23.7%, and Connaught/Ulster = 19.4%).", [["The sample", "TEST", 0, 10], ["Leinster", "TEST", 72, 80], ["Muster", "TEST", 90, 96], ["Connaught", "TEST", 110, 119], ["Ulster", "TEST", 120, 126]]], ["The majority of the sample (54.8%) had an ordinary bachelor degree or national diploma, just under half of the sample (47.02%) were in full\u2010time employment, and the median household income was \u20ac50,000\u2010\u20ac59,999.", [["the sample", "TEST", 16, 26], ["majority", "OBSERVATION_MODIFIER", 4, 12]]], ["Full details of the sample demographic characteristics can be found in Table S1.Day reconstruction method ::: Measures ::: MethodWe utilized a short version of the DRM (Kahneman et al., 2004) where participants completed a diary documenting what they did and how they felt during a set of up to 5 sequential \u2018episodes\u2019 from a randomly allocated section of their day.", [["participants", "SPECIES", 198, 210]]], ["Participants were prompted to think of episodes as scenes in a movie demarcated by transitions such as going to a different location, or ending one activity and starting another.", [["Participants", "SPECIES", 0, 12]]], ["Participants could describe less than 5 episodes if an earlier episode was the last episode of their day.", [["Participants", "SPECIES", 0, 12], ["an earlier episode", "PROBLEM", 52, 70]]], ["Participants described 4.63 episodes on average so that we recorded 2795 episodes of March 24th in total.Day reconstruction method ::: Measures ::: MethodPositive affect scores were calculated as the average rating of three items, that is, how happy, how calm/relaxed, and how energetic participants reported feeling during each episode (Cronbach\u2019s alpha = 0.84).", [["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 287, 299], ["MethodPositive affect scores", "PROBLEM", 148, 176], ["Cronbach\u2019s alpha", "TEST", 338, 354]]], ["We selected these items to ensure positive feelings associated with different levels of arousal were assessed (Posner, Russell, & Peterson, 2005).", [["positive feelings", "PROBLEM", 34, 51]]], ["Negative affect was calculated using six items as the average of how sad, bored, frustrated/annoyed, lonely, worried/anxious, and overwhelmed participants were (Cronbach\u2019s alpha = 0.87).", [["participants", "SPECIES", 142, 154], ["anxious", "PROBLEM", 117, 124], ["alpha", "TEST", 172, 177], ["affect", "OBSERVATION_MODIFIER", 9, 15]]], ["Once again, we picked items to ensure negative feelings associated with a range of arousal levels were included (e.g., bored, worried/anxious) and to capture feelings likely to be impacted by the pandemic (e.g., overwhelmed, lonely).", [["anxious", "PROBLEM", 134, 141]]], ["Emotions were rated on a numerical scale ranging from 1 = not at all to 7 = very much.Statistical analysis ::: MethodWe first examined descriptive statistics of affect levels measured while participants were in specific locations or engaged in specific activities.", [["participants", "SPECIES", 190, 202], ["a numerical scale", "TEST", 23, 40], ["affect levels", "PROBLEM", 161, 174]]], ["Next, we focused on how affect ratings varied within individuals using individual fixed effect specifications that control for fixed observable and unobservable differences across individuals using the following regression model:Affectit=\u03b1i+\u03b2aait+\u03f5itwhereAffectis the affect rating of individualiin episodet;ais a vector representing all activities undertaken in episodetby individuali, and the\u03b2parameters are to be estimated;\u03b1iis the individual fixed effect; and\u03f5itis the robust error term.", [["individual fixed effect specifications", "TREATMENT", 71, 109], ["fixed observable", "PROBLEM", 127, 143], ["Affectit", "PROBLEM", 229, 237], ["individualiin episodet", "PROBLEM", 285, 307]]], ["To ease comparison with other studies, we standardized affect levels to have a mean of zero and standard deviation of one.", [["other studies", "TEST", 24, 37]]], ["We applied this basic model to the whole sample and conducted separate fixed effects regressions examining the associations between activities, locations, and social interactions on the one hand and affect levels on the other hand.", [["hand", "ORGANISM_SUBDIVISION", 190, 194], ["hand", "ORGANISM_SUBDIVISION", 226, 230], ["this basic model", "TREATMENT", 11, 27], ["the whole sample", "TREATMENT", 31, 47]]], ["To manage the risk of finding false associations in our multiple testing approach, we used the Benjamini\u2013Hochberg method, identifying significant associations at a false discovery rate of 0.05 (see Supplementary Materials).Location ::: ResultsIndividual fixed effect regression models of the relationship between the location of the individual and affect levels at the same time showed that being outdoors or in nature is the location with highest positive (b = .59, SE = .05, p < .01) and lowest negative affect (b = \u2212.25, SE = .05, p < .01).", [["the Benjamini\u2013Hochberg method", "TREATMENT", 91, 120], ["SE", "TEST", 467, 469], ["p", "TEST", 477, 478], ["b", "TEST", 514, 515], ["SE", "TEST", 524, 526], ["p", "TEST", 534, 535]]], ["See Table S2 for the accompanying regression coefficients.Everyday activities ::: ResultsExercising (b = .46, SE = .07, p < .01), going for a walk (b = .33, SE = .06, p < .01), gardening (b = .29, SE = .09, p < .01), and pursuing a hobby (b = .23, SE = .09, p < .05) were ranked as the most enjoyable activities (see Table 1) and associated with the largest increase in positive affect in our within\u2010person analyses (see Figure 1).", [["SE", "TEST", 110, 112], ["a walk (b", "TEST", 140, 149], ["SE", "TEST", 157, 159], ["SE", "TEST", 197, 199], ["p", "TEST", 207, 208], ["SE", "TEST", 248, 250], ["positive affect", "PROBLEM", 370, 385], ["largest", "OBSERVATION_MODIFIER", 350, 357], ["increase", "OBSERVATION_MODIFIER", 358, 366], ["positive affect", "OBSERVATION", 370, 385]]], ["Taking care of children was also linked to raised positive affect (b = .21, SE = .06, p < .01) and reduced negative feelings (b = \u2212.19, SE = .05, p < .01).", [["children", "ORGANISM", 15, 23], ["children", "SPECIES", 15, 23], ["positive affect", "PROBLEM", 50, 65], ["SE", "TEST", 76, 78], ["reduced negative feelings", "PROBLEM", 99, 124], ["b", "TEST", 126, 127], ["SE", "TEST", 136, 138]]], ["In contrast, levels of negative affect were notably higher when participants were using social media (b = .11, SE = .04, p < .05), home\u2010schooling children (b = .30, SE = .07, p < .01), and informing themselves about COVID\u201019 (b = .27, SE = .04, p < .01).", [["participants", "SPECIES", 64, 76], ["children", "SPECIES", 146, 154], ["COVID", "TEST", 216, 221], ["SE", "TEST", 235, 237], ["negative", "OBSERVATION", 23, 31]]], ["Within\u2010person effects of all daily activities on affect levels are shown in Figure 1 and presented in Table S2.Social interaction ::: ResultsEngaging in in\u2010person social interactions with friends was associated with raised positive affect ratings (b = .34, SE = .10, p < .05).", [["affect levels", "TEST", 49, 62], ["raised positive affect ratings", "PROBLEM", 216, 246], ["SE", "TEST", 257, 259]]], ["In line with prior research (Bryson & MacKerron, 2017), time spent in work\u2010related personal or remote interactions was linked to reduced positive and increased negative affect (see Figure 1 and Table S2).", [["reduced positive", "PROBLEM", 129, 145], ["increased negative affect", "PROBLEM", 150, 175]]], ["Surprisingly, interactions with one\u2019s spouse or significant other were linked to significantly lower positive affect (b = \u2212.17, SE = .05, p < .01).Additional analyses ::: ResultsSensitivity tests indicated that the study findings did not differ markedly when fixed effects regressions included activity dummies, location, and interaction dummies simultaneously (see Figure S1) or when random effects regressions were employed (see Figures S2 and S3).", [["significantly lower positive affect", "PROBLEM", 81, 116], ["ResultsSensitivity tests", "TEST", 171, 195], ["the study", "TEST", 211, 220], ["fixed effects regressions", "PROBLEM", 259, 284], ["activity dummies", "PROBLEM", 294, 310], ["random effects regressions", "PROBLEM", 385, 411]]], ["We did not find evidence of systematic differences between males and females in the relationship between activities, interactions, locations, and affect levels.DiscussionWe present a rich snapshot of how people are experiencing the activities and settings of their daily lives during the COVID\u201019 pandemic on a day when the government had announced strict restrictions such as the closure of all non\u2010essential businesses.", [["people", "ORGANISM", 204, 210], ["people", "SPECIES", 204, 210], ["systematic differences between males", "PROBLEM", 28, 64], ["not find evidence of", "UNCERTAINTY", 7, 27]]], ["Average positive and negative affect ratings on this day were 4.47 and 2.76, respectively.", [["positive", "OBSERVATION", 8, 16], ["negative affect", "OBSERVATION_MODIFIER", 21, 36]]], ["Our analyses provide the first available estimates of how within\u2010person variation in emotional well\u2010being is linked to the ways people are spending their time during the outbreak.", [["people", "ORGANISM", 128, 134], ["people", "SPECIES", 128, 134]]], ["The findings also provide important information from a population health perspective by highlighting key issues related to everyday activities and experiences that may require policy consideration and inform the mental health guidelines of governments and international bodies during the crisis.DiscussionFirst, in line with prior research (e.g., Hanson & Jones, 2015; MacKerron & Mourato, 2013; Reed & Ones, 2006), we find that positive affect is greatest when outdoors and that engaging in hobbies and physically active pursuits such as exercising, walking, and gardening are particularly positive activities.", [["the crisis", "PROBLEM", 284, 294]]], ["The well\u2010being during outdoor activities is an important public policy consideration and needs to be viewed in light of the trade\u2010off between population well\u2010being and compliance with physical distance guidance that form part of virus mitigation efforts.", [["physical distance guidance", "TREATMENT", 184, 210], ["virus mitigation efforts", "TREATMENT", 229, 253]]], ["However, it is not possible to infer from the current data that elevated well\u2010being observed in outdoor pursuits could not be attained by substitute indoor activities.", [["not possible", "UNCERTAINTY", 15, 27]]], ["Second, our results suggest that spending time with children following the closure of schools and childcare facilities may benefit rather than reduce parents\u2019 emotional well\u2010being, as suggested by prior research (White & Dolan 2009; Kahneman et al., 2004).", [["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60]]], ["Third, we find that social media use and informing oneself about COVID\u201019 are both associated with elevated levels of negative affect.", [["elevated levels of negative affect", "PROBLEM", 99, 133], ["negative affect", "OBSERVATION", 118, 133]]], ["These results suggest that setting personal limits for news and social media consumption, as recommended by recent research (Garfin, Silver, & Holman, 2020) and World Health Organization guidelines (WHO, 2020), may help to safeguard people\u2019s emotional well\u2010being at this difficult time.", [["people", "ORGANISM", 233, 239], ["people", "SPECIES", 233, 239]]], ["Fourth, we observed reduced emotional well\u2010being levels during interactions with one\u2019s spouse or partner, which is an atypical finding (Kahneman et al., 2004) and may reflect difficulties in adapting to major changes in household routines and responsibilities following the outbreak.DiscussionThe current study is not without limitations.", [["The current study", "TEST", 293, 310], ["reduced", "OBSERVATION_MODIFIER", 20, 27], ["not without", "UNCERTAINTY", 314, 325]]], ["While our sample included a diverse range of age and socioeconomic groups, it likely differs in observable and unobservable variables from the overall population: all participants had agreed to be part of a survey panel of a market research company, they were contacted via email and hence were Internet savvy, and they were incentivized by various lottery prizes.", [["participants", "SPECIES", 167, 179]]], ["While the survey company recruited the panel on a quota\u2010controlled basis to be representative of the adult population, our study sample was predominantly female indicating some selection effects.", [["our study sample", "TEST", 119, 135]]], ["Hence, it is important to work with larger probability\u2010based samples to build up a full profile of everyday life during the crisis, and the current study should not be seen as a substitute for such work (Lehdonvirta, Oksanen, R\u00e4s\u00e4nen, & Blank, 2020).", [["the current study", "TEST", 136, 153]]], ["Some of our results (e.g., related to exercising and home\u2010schooling) rely on a small percentage (e.g., \u2264 5%) of episodes.", [["episodes", "PROBLEM", 112, 120]]], ["While these findings remain significant after controlling the false discovery rate, follow\u2010up studies are needed to verify these associations.", [["follow\u2010up studies", "TEST", 84, 101], ["significant", "OBSERVATION_MODIFIER", 28, 39]]], ["Our results capture a snapshot of one point in time, precluding an understanding of whether and how people\u2019s routines and emotional well\u2010being are adapting during the crisis.", [["people", "ORGANISM", 100, 106], ["people", "SPECIES", 100, 106]]], ["For instance, as people become more accustomed to virtual interactions, well\u2010being benefits may follow.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23]]], ["Multi\u2010wave data from a range of countries are needed to provide insight into the effects of crisis trajectories and isolation measures on well\u2010being on a global scale.DiscussionIn conclusion, distancing people from others to limit infection is a crucial public health measure but may also pose significant mental health risks.", [["infection", "DISEASE", 231, 240], ["people", "ORGANISM", 203, 209], ["people", "SPECIES", 203, 209], ["Multi\u2010wave data", "TEST", 0, 15], ["crisis trajectories", "PROBLEM", 92, 111], ["isolation measures", "TREATMENT", 116, 134], ["a global scale", "TREATMENT", 152, 166], ["infection", "OBSERVATION", 231, 240]]], ["Our findings point to everyday activities that may mitigate (e.g., outdoor activities, gardening, exercise, pursuing hobbies) or exacerbate (e.g., social media use, home\u2010schooling, listening to COVID\u201019 news) the welfare effects of isolation.", [["isolation", "TREATMENT", 232, 241]]], ["The current study also highlights the value in monitoring people\u2019s daily emotional well\u2010being during the pandemic to understand how people are faring and to inform actions that may promote well\u2010being and enhance the sustainability of self\u2010isolation measures.Conflicts of interestAll authors declare no conflict of interest.Author contributionsLeonhard Lades (Conceptualization; Data curation; Formal analysis; Investigation; Methodology; Validation; Visualization; Writing \u2013 original draft; Writing \u2013 review & editing) Kate Laffan (Conceptualization; Investigation; Methodology; Writing \u2013 original draft; Writing \u2013 review & editing) Michael Daly (Conceptualization; Investigation; Methodology; Writing \u2013 original draft; Writing \u2013 review & editing) Liam Delaney (Conceptualization; Funding acquisition; Investigation; Methodology; Writing \u2013 original draft; Writing \u2013 review & editing).", [["people", "ORGANISM", 58, 64], ["people", "ORGANISM", 132, 138], ["people", "SPECIES", 58, 64], ["people", "SPECIES", 132, 138], ["The current study", "TEST", 0, 17], ["self\u2010isolation measures", "TREATMENT", 234, 257], ["Data curation", "TEST", 378, 391], ["Formal analysis", "TEST", 393, 408]]]]}